

Table of Contents

Actimmune .....17

Adalimumab.....20

Adbry .....40

ADHD Products .....46

Aemcolo .....49

Afinitor .....51

Afrezza .....75

Agamree .....78

Akeega .....80

Alecensa .....83

Alfa Interferons .....89

Alinia.....93

Alunbrig .....95

Ampyra ..... 100

Anthelmintics .....101

Anticonvulsants .....108

Antipsoriatic Agents.....123

Antipsychotics.....128

Apokyn.....133

Aqneursa .....136

Aqneursa .....139

Arcalyst.....142

Arikayce .....145

Attruby .....149

Augtyro .....153

Austedo .....157

Austedo .....161

Ayvakit .....165

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Azole Antifungals .....	170
Balversa .....	184
Baxdela .....	188
Belbuca_Butrans .....	194
Benefit Determination Mifeprex .....	204
Benlysta .....	205
Benznidazole .....	209
Berinert .....	210
Besremi .....	214
Biltricide .....	216
Bimzelx .....	218
Bonjesta and Diclegis .....	231
Bosulif .....	233
Braftovi .....	237
Brexafemme .....	246
Brilinta and Effient .....	249
Bronchitol .....	251
Brukinsa .....	253
Buphenyl .....	258
Buprenorphine for Opioid Dependence .....	260
Bylvay .....	264
Cablivi .....	268
Cabometyx .....	270
Calquence .....	278
Camzyos .....	282
Caprelsa .....	285
Carbaglu .....	289
Cayston .....	291
Cerdelga and Zavesca .....	293

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

CGRP .....	296
Cholbam .....	303
Cialis and Chewtadzy for BPH .....	306
Cibinqo .....	308
Cimzia .....	314
Cinryze.....	334
Ciprodex .....	338
Colony Stimulating Factors .....	340
Combination Basal Insulin/GLP-1 Receptor Agonist .....	365
Cometriq.....	368
Compounds and Bulk Powders.....	372
Constipation Agents .....	382
Continuous Glucose Monitors .....	401
Copiktra .....	404
Copper Chelating Agents .....	408
Corlanor.....	414
Cosentyx.....	420
Cotellic .....	432
Cuvrior .....	437
Cystaran, Cystadrops .....	440
Daliresp .....	442
Danziten .....	444
Daraprim.....	448
Daurismo .....	452
Daybue .....	456
DEKAs Plus.....	458
Descovy .....	459
Dificid .....	464
Dojolvi .....	466

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Donepezil 23mg.....	469
Doptelet.....	471
DPP-4 Inhibitors.....	475
Dry Eye Disease.....	480
Duexis and Vimovo .....	484
Duopa.....	488
Dupixent .....	490
Duvyzat.....	511
Egrifta .....	515
Elmiron .....	516
Emflaza.....	517
Empaveli .....	519
Enbrel .....	522
Endari .....	533
Enspryng.....	535
Entocort.....	538
Entresto .....	539
Entyvio SC.....	543
Eohilia.....	547
Epaned .....	550
Erivedge .....	552
Erleada .....	555
Erythropoietic Agents .....	558
Esbriet, Ofev.....	571
Eucrisa.....	577
Evrysdi .....	579
Exkivity.....	585
Fabhalta.....	588
Fasenra.....	594

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Febuxostat .....	600
Fentanyl IR .....	602
Filspari .....	606
Filsuvez .....	610
Firazyr, Sajazir.....	613
Firdapse .....	616
Firdapse .....	619
Fortamet, Glumetza.....	622
Forteo .....	625
Fotivda .....	630
Fruzaqla .....	633
Furoscix .....	636
Galafold .....	638
Gattex .....	640
Gavreto .....	642
Gilotrif.....	648
Gleevec.....	652
GLP-1 & Dual GIP/GLP-1 Receptor Agonists .....	659
Gonadotropin-Releasing Hormone Agonists .....	664
Growth Hormone, Growth Stimulating Agents - Managed Medicaid.....	680
Haegarda .....	726
HCG.....	730
Hemangeol .....	731
Hemlibra .....	733
Hepatitis C Criteria .....	738
Hetlioz .....	748
HIV .....	751
Hycamtin .....	756
Hyftor.....	759

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Ibrance.....	762
Iclusig.....	765
ICS.LABA Combination Products.....	770
Idhifa.....	782
Ilaris.....	785
Ilumya.....	795
Imbruvica.....	800
Impavido.....	806
Inbrija.....	808
Ingrezza.....	811
Inhaled Corticosteroids.....	814
Inlyta.....	816
Inqovi.....	821
Inrebic.....	824
Insulin Pen Needles and Syringes.....	828
Insulins.....	830
Iqirvo.....	853
Iressa.....	856
Iron Chelators.....	860
Irritable Bowel Syndrome - Diarrhea.....	864
Isotretinoin.....	868
Isturisa.....	872
Itovebi.....	874
Iwilfin.....	878
Jakafi.....	881
Jaypirca.....	892
Jesduvroq.....	896
Joenja.....	899
Juxtapid.....	902

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Jynarque.....	906
Kalydeco .....	908
Kerendia.....	912
Keveyis.....	915
Kevzara .....	917
Kineret .....	924
Kisqali .....	931
Kisqali Femara Co-Pack .....	935
Korlym .....	939
Koselugo .....	941
Krazati.....	945
Kuvan.....	951
Kynmobi.....	952
Lampit .....	955
Lazcluze.....	957
Lenvima .....	960
Lidoderm .....	968
Litfulo .....	971
Litfulo .....	974
Livdelzi.....	977
Livmarli.....	981
Livtency .....	985
Lokelma, Veltassa .....	987
Long-Acting Opioid Products.....	989
Lonhala and Yupelri .....	1014
Lonsurf .....	1017
Lorbrena .....	1021
Lovenox.....	1026
Lumakras .....	1030

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Lupkynis .....	1036
Lynparza .....	1040
Lyrica .....	1050
Lysteda .....	1055
Lytgobi .....	1056
Marinol, Syndros.....	1059
Mavenclad .....	1066
Mekinist .....	1070
Mektovi .....	1085
Mepron .....	1094
Migranal, Trudhesa .....	1096
Miplyffa .....	1100
Mozobil .....	1103
MS Agents .....	1106
Mulpleta.....	1111
Multaq .....	1113
Myalept.....	1115
Mycapssa .....	1118
Mytesi .....	1121
Namzaric .....	1122
Nasonex, Xhance.....	1124
Nayzilam and Valtoco .....	1127
Nerlynx .....	1131
Nexavar.....	1137
Nexletol, Nexlizet.....	1148
Ninlaro .....	1153
Nityr.....	1157
Nocdurna.....	1158
Non-Preferred Drugs .....	1161

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Northera.....	1165
Nourianz .....	1169
Nourianz .....	1172
Nubeqa.....	1175
Nucala .....	1179
Nuedexta .....	1198
Nuplazid .....	1199
Nurtec, Qulipta, Ubrelvy, Zavzpret .....	1201
Nuzyra .....	1215
OAB Agents .....	1220
Ocaliva.....	1228
Odomzo .....	1232
Ogsiveo.....	1235
Ohtuvayre .....	1238
Ojemda.....	1243
Ojjaara .....	1246
Olumiant.....	1250
Omega .....	1255
Omnipod 5 .....	1261
Omvox .....	1265
Onureg.....	1268
Opfolda.....	1272
Ophthalmic Antihistamine .....	1275
Opzelura - CO, MD, NJ, NM, PA CHIP, WA .....	1278
Opzelura - CO, MD, NJ, NM, PA CHIP, WA .....	1283
Orencia.....	1288
Orfadin.....	1298
Orgovyx.....	1300
Oriahnn_MyFembree .....	1303

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Orilissa .....	1308
Orkambi .....	1313
Orladeyo .....	1315
Orserdu.....	1319
Osphena .....	1323
Otezla .....	1326
Oxbryta .....	1335
Oxervate .....	1339
PAH.....	1341
Palforzia .....	1349
Palynziq .....	1352
Panretin .....	1355
Pemazyre .....	1358
Piqray.....	1362
Pomalyst .....	1366
PPI (Proton Pump Inhibitors).....	1371
Praluent .....	1376
Preferred Non-Solid Dosage Forms.....	1386
Pretomanid .....	1389
Prevymis .....	1391
Procysbi .....	1393
Progesterone - Non-Oral .....	1395
Progesterone - Oral.....	1396
Promacta, Alvaiz.....	1398
Provigil, Nuvigil .....	1405
Pulmozyme .....	1407
Pyrukynd .....	1408
Qbrexza.....	1411
Qinlock .....	1413

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Qlosi, Vuity .....	1418
Quantity Limits .....	1422
Radicava ORS.....	1426
Ravicti.....	1430
Rayos.....	1433
Rectiv.....	1436
Regranex .....	1438
Relistor .....	1439
Relyvrio .....	1444
Repatha .....	1447
Repository Corticotropins .....	1456
Retevmo .....	1459
Revlimid.....	1465
Revuforj .....	1477
Reyvow .....	1480
Rezdiffra.....	1485
Rezlidhia .....	1488
Rezurock.....	1491
Rinvoq.....	1493
Rivfloza .....	1518
Rozerem.....	1523
Rozlytrek .....	1525
Rubraca .....	1529
Ruconest .....	1535
Rukobia.....	1538
Rydapt .....	1540
Samsca.....	1544
Sandostatin.....	1546
Savaysa.....	1554

Scemblix.....	1558
Sensipar.....	1562
Sevelamer carbonate.....	1565
SGLT2 Inhibitors .....	1567
Short-Acting Opioid Products .....	1578
Signifor.....	1592
Siliq .....	1594
Simponi .....	1599
Sivextro .....	1609
Skyclarys.....	1614
Skyrizi .....	1616
Sohonos.....	1626
Somavert .....	1629
Soriatane .....	1632
Sotyktu .....	1635
Spevigo .....	1641
Spravato.....	1644
Sprycel.....	1649
Stivarga.....	1655
Strensiq .....	1662
Stromectol .....	1667
Sublingual Immunotherapy (SLIT) .....	1669
Sucraid .....	1678
Sunosi.....	1682
Sutent .....	1688
Symdeko .....	1697
Synagis .....	1701
Tabrecta.....	1717
Tafinlar .....	1720

Tagrisso.....	1735
Takhzyro.....	1739
Taltz.....	1745
Talzenna.....	1759
Tarceva.....	1763
Targretin (bexarotene).....	1769
Tarpeyo.....	1772
Tasigna.....	1775
Tasmar.....	1780
Tavalisse.....	1783
Tavneos.....	1786
Tazverik.....	1789
Tegsedi.....	1793
Temodar.....	1796
Tepmetko.....	1803
Test Strips.....	1806
Testosterone.....	1809
Tezspire.....	1819
Thalomid.....	1827
Therapeutic Duplication (Subtype A).....	1833
Therapeutic Duplication (Subtype B).....	1837
Tibsovo.....	1839
Tobramycin Inhalation.....	1846
Tocilizumab.....	1849
Topical NSAIDs.....	1859
Topical Retinoid Products.....	1864
Trelegy Ellipta, Breztri.....	1870
Tremfya.....	1873
Trikafta.....	1882

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Triptans.....	1886
Truqap.....	1896
Tryvio .....	1900
Tukysa.....	1904
Turalio.....	1909
Tykerb .....	1912
Tymlos .....	1921
Upneeq.....	1923
Ustekinumab.....	1926
Vafseo.....	1944
Valchlor .....	1948
Vanflyta.....	1951
Vecamyl.....	1954
Velsipity .....	1956
Vemlidy.....	1960
Venclexta .....	1963
Veozah .....	1972
Verkazia .....	1975
Verquvo.....	1977
Verzenio .....	1981
Verzenio .....	1986
Vijoice.....	1990
Vitrakvi .....	1993
Vivjoa.....	1996
Vizimpro.....	1998
Vonjo .....	2001
Voranigo.....	2005
Votrient.....	2008
Vowst.....	2017

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Voxzogo.....	2020
Voydeya .....	2024
Vtama .....	2027
Vyalev .....	2030
Vyalev .....	2032
Vyndaqel and Vyndamax.....	2034
Wainua.....	2038
Wakix .....	2041
Wegovy .....	2046
Welireg.....	2051
Winrevair.....	2055
Xalkori.....	2059
Xarelto .....	2065
Xdemvy .....	2073
Xeljanz, Xeljanz XR, Xeljanz Oral Solution.....	2075
Xenazine .....	2092
Xenleta.....	2095
Xermelo .....	2098
Xifaxan .....	2100
Xolair .....	2105
Xolremdi .....	2122
Xopenex Respules .....	2125
Xospata.....	2127
Xphozah .....	2131
Xpovio.....	2134
Xtandi .....	2139
Xuriden .....	2145
Xyrem, Xywav, Lumryz.....	2147
Yonsa .....	2155

Yorvipath .....	2159
Zejula .....	2162
Zejula .....	2167
Zelboraf .....	2172
Zepbound.....	2179
Zeposia .....	2184
Zilbrysq .....	2190
Zokinvy .....	2194
Zolinza .....	2196
Zoryve .....	2199
Zoryve .....	2207
Zurzuvae .....	2213
Zydelig .....	2215
Zykadia .....	2218
Zymfentra.....	2223
Zytiga .....	2228
Zytiga .....	2233
Zyvox.....	2237

Actimmune



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146461
<b>Guideline Name</b>	Actimmune
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Actimmune	
Diagnosis	Chronic Granulomatous Disease (CGD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic granulomatous disease</p>	

Product Name:Actimmune	
Diagnosis	Osteopetrosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe, malignant osteopetrosis</p>	

Product Name:Actimmune	
Diagnosis	Primary Cutaneous Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Mycosis fungoides (MF)</li> <li>• Sézary syndrome (SS)</li> </ul>	

Product Name:Actimmune	
Diagnosis	Chronic Granulomatous Disease (CGD), Osteopetrosis, Primary Cutaneous Lymphomas
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Patient does not show evidence of progressive disease while on Actimmune

**Product Name:Actimmune**

Diagnosis	NCCN Recommended Regimens
-----------	---------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

**Product Name:Actimmune**

Diagnosis	NCCN Recommended Regimens
-----------	---------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Documentation of positive clinical response to Actimmune therapy

Adalimumab



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-173221
<b>Guideline Name</b>	Adalimumab
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderately to severely active rheumatoid arthritis

**AND**

2 - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**AND**

4 - ONE of the following:

4.1 Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

4.2 BOTH of the following:

4.2.1 ONE of the following:

- Failure to a 3 month trial of ONE non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses confirmed by claims history or submission of medical records
- History of intolerance or contraindication to one non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Simponi (golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**4.2.2** If the request is for a non-preferred adalimumab product, ONE of the following:

- Failure of Tyenne (tocilizumab-aazg) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Tyenne (tocilizumab-aazg) [please specify intolerance or contraindication]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes	<p>*If approving a non-preferred adalimumab, please enter                  1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)                  2) An authorization for the non-preferred adalimumab at GPI-12 level</p> <p>See PDL links in Background</p>
-------	---

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis

**AND**

**1.2** Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.3** Prescribed by or in consultation with a rheumatologist

**AND**

**1.4** If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

**AND**

**1.5** If the request is for a non-preferred adalimumab product, ONE of the following:

- Failure of Tyenne (tocilizumab-aazg) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Tyenne (tocilizumab-aazg) [please specify intolerance or contraindication]

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis

**AND**

**2.3** Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

**AND**

**2.5** If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes	<p>*If approving a non-preferred adalimumab, please enter                  1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)                  2) An authorization for the non-preferred adalimumab at GPI-12 level</p> <p>See PDL links in Background</p>
-------	---

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of active psoriatic arthritis

**AND**

**2** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab),

Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab-rzaa)]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes

\*If approving a non-preferred adalimumab, please enter  
1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)

	2) An authorization for the non-preferred adalimumab at GPI-12 level  See PDL links in Background
--	---

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe chronic plaque psoriasis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a dermatologist</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - ONE of the following:</p> <p><b>4.1</b> Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**4.2 ONE of the following:**

**4.2.1 ALL of the following:**

**4.2.1.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**4.2.1.2 ONE of the following:**

**4.2.1.2.1** Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

**4.2.1.2.2** History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**4.2.1.3 ONE of the following:**

**4.2.1.3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records

**OR**

**4.2.1.3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**4.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes	<p>*If approving a non-preferred adalimumab, please enter</p> <p>1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)</p> <p>2) An authorization for the non-preferred adalimumab at GPI-12 level</p> <p>See PDL links in Background</p>
-------	---

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis	Ankylosing Spondylitis (AS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of active ankylosing spondylitis

**AND**

**2** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

**4.2.1** Failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records

**OR**

**4.2.2** History of intolerance or contraindication to TWO NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**4.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes

\*If approving a non-preferred adalimumab, please enter  
 1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)  
 2) An authorization for the non-preferred adalimumab at GPI-12 level  
  
 See PDL links in Background

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis Crohn's Disease (CD)

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active Crohn's disease

**AND**

**2** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

**4.2.1** Failure to ONE of the following conventional drugs or classes at maximally indicated doses, as confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (generic Imuran)
- 6-mercaptopurine (generic Purinethol)
- Methotrexate

**OR**

**4.2.2** History of intolerance or contraindication to ALL of the following conventional drugs or classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (generic Imuran)
- 6-mercaptopurine (generic Purinethol)
- Methotrexate

**OR**

**4.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of Crohn's disease as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), ustekinumab]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical

reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)*	
Notes	<p>*If approving a non-preferred adalimumab, please enter</p> <p>1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)</p> <p>2) An authorization for the non-preferred adalimumab at GPI-12 level</p> <p>See PDL links in Background</p>

Product Name:Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active ulcerative colitis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a gastroenterologist</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - ONE of the following:</p>	

**4.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

**4.2.1** Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine) as confirmed by claims history or submitted medical records

**OR**

**4.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission medical records [e.g., Simponi (golimumab), ustekinumab, Xeljanz (tofacitinib)]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes	<p>*If approving a non-preferred adalimumab, please enter                  1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)                  2) An authorization for the non-preferred adalimumab at GPI-12 level</p> <p>See PDL links in Background</p>
-------	---

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis	Hidradenitis Suppurativa (HS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III)

**AND**

**2** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

**4.2.1** Failure to at least ONE oral antibiotic (e.g., doxycycline, clindamycin, rifampin) at maximally indicated doses, as confirmed by claims history or submission of medical records

**OR**

**4.2.2** History of intolerance or contraindication to at least ONE oral antibiotic (e.g., doxycycline, clindamycin, rifampin) (please specify intolerance or contraindication)

**OR**

**4.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of hidradenitis suppurativa as confirmed by claims history or submitted medical records [e.g., Bimzelx (bimekizumab-bkzx), Cosentyx (secukinumab)]

**AND**

**5** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes

\*If approving a non-preferred adalimumab, please enter  
 1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)  
 2) An authorization for the non-preferred adalimumab at GPI-12 level  
  
 See PDL links in Background

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)

Diagnosis	Uveitis (UV)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of non-infectious uveitis

**AND**

**2** - Uveitis is classified as ONE of the following:

- Intermediate
- Posterior
- Panuveitis

**AND**

**3** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**4** - Prescribed by or in consultation with **ONE** of the following:

- Rheumatologist
- Ophthalmologist

**AND**

**5** - **ONE** of the following:

**5.1** Patient is currently on Adalimumab therapy as confirmed by claims history or submission of medical records

**OR**

**5.2** **BOTH** of the following:

**5.2.1** **ONE** of the following:

**5.2.1.1** Failure to at least **ONE** corticosteroid (e.g., prednisolone, prednisone) at maximally indicated dose, as confirmed by claims history or submission of medical records

**OR**

**5.2.1.2** History of intolerance or contraindication to at least **ONE** corticosteroid (e.g., prednisolone, prednisone) (please specify intolerance or contraindication)

**AND**

**5.2.2** **ONE** of the following:

**5.2.2.1** Failure to at least ONE systemic non-biologic immunosuppressant (e.g., methotrexate, cyclosporine, azathioprine, mycophenolate) at maximally indicated dose, as confirmed by claims history or submission of medical records

**OR**

**5.2.2.2** History of intolerance or contraindication to at least ONE systemic non-biologic immunosuppressant (e.g., methotrexate, cyclosporine, azathioprine, mycophenolate) (please specify intolerance or contraindication)

**AND**

**6** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes	<p>*If approving a non-preferred adalimumab, please enter                  1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)                  2) An authorization for the non-preferred adalimumab at GPI-12 level                   See PDL links in Background</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, Adalimumab (all products)	
Diagnosis	RA, PJIA, PsA, Plaque Psoriasis, AS, CD, Ulcerative Colitis, HS, UV
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Adalimumab therapy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is not receiving adalimumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]^

**AND**

**3** - If the request is for a non-preferred adalimumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred adalimumab products (please document reason/special circumstances)\*

Notes

\*If approving a non-preferred adalimumab, please enter  
 1) The group authorization CSPREFADAL (for NY EPP and NY use: CSNYADAL)  
 2) An authorization for the non-preferred adalimumab at GPI-12 level  
  
 See PDL links in Background  
 ^ Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>

NY/NY EPP: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA CHIP: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
2/19/2025	Updated formularies. Replaced Stelara with ustekinumab. Added step therapy bypass in HS section

Adbry



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161236
<b>Guideline Name</b>	Adbry
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Adbry	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate-to severe chronic atopic dermatitis</p>	

**AND**

**2 - ONE** of the following:

**2.1** Failure to TWO of the following therapeutic classes of topical therapies, confirmed by claims history or submission of medical records:

- One medium, high or very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following therapeutic classes of topical therapies (please specify intolerance or contraindication):

- One medium, high or very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**OR**

**2.3** Patient is currently on Adbry therapy as confirmed by claims history or submission of medical records

**AND**

**3 - ONE** of the following:

**3.1** Failure to Dupixent confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to Dupixent (please specify intolerance or contraindication)

**OR**

**3.3** Patient is currently on Adbry therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is NOT receiving Adbry in combination with EITHER of the following:

- Biologic immunomodulator [e.g., Dupixent (dupilumab)]
- Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

**AND**

**5** - Prescribed by ONE of the following:

- Dermatologist
- Allergist
- Immunologist

Product Name:Adbry	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Adbry therapy	

**AND**

**2** - Patient is NOT receiving Adbry in combination with either of the following:

- Biologic immunomodulator [e.g., Dupixent (dupilumab)]
- Janus kinas inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

**AND**

**3** - Prescribed by ONE of the following:

- Dermatologist
- Allergist
- Immunologist

## 2 . Background

Benefit/Coverage/Program Information			
Table 1. Relative potencies of topical corticosteroids			
Class	Drug	Dosage Form	Strength (%)
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
High Potency	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream, lotion	0.05

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
	Triamcinolone acetonide	Cream, ointment, lotion	0.1
Lower-medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinolone acetonide	Cream, solution	0.01
	Dexamethasone	Cream	0.1

Lowest potency	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

ADHD Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-206555
<b>Guideline Name</b>	ADHD Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:(All) Brand Adderall, generic amphetamine/dextroamphetamine, Brand Adderall XR, generic amphetamine/dextroamphetamine ER, Adhansia XR, Adzenys XR-ODT, Brand Aptensio XR, generic methylphenidate ER cap, Azstarys, Brand Concerta, generic methylphenidate ER OSM (generic Concerta), Cotempla XR-ODT, Brand Daytrana, generic methylphenidate patch, Brand Desoxyn, generic methamphetamine, Brand Dexedrine, generic dextroamphetamine ER, Dyanavel XR, Brand Evekeo, generic amphetamine, Evekeo ODT, Brand Focalin, generic dexmethylphenidate, Brand Focalin XR, generic dexmethylphenidate ER, Brand Intuniv, generic guanfacine ER, Jornay PM, Brand Kapvay, generic clonidine ER, Brand Methylin, generic methylphenidate soln, generic methylphenidate chew tabs, Brand Metadate CD, generic methylphenidate ER (CD), generic methylphenidate ER tab, Brand Mydayis, generic amphetamine/dextroamphetamine ER (generic Mydayis), Brand Procentra, generic dextroamphetamine soln, Qelbree, Quillichew ER, Quillivant XR, Brand Relexxii, Brand Methylphenidate ER OSM, generic methylphenidate ER OSM (generic Relexxii), Brand Ritalin, generic methylphenidate tablet, Brand Ritalin LA, generic methylphenidate ER (LA), Brand Strattera, generic atomoxetine, Brand Vyvanse chewable tablets, generic lisdexamfetamine chewable tablets, Brand Vyvanse capsules, generic

lisdexamfetamine capsules, Xelstrym, Brand Zenzedi, generic dextroamphetamine, Onyda XR	
Diagnosis	Members Less than the FDA Approved Minimum Age*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Diagnosis of Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:</p> <ul style="list-style-type: none"> <li>• American Hospital Formulary Service Drug Information</li> <li>• National Comprehensive Cancer Network Drugs and Biologics Compendium</li> <li>• Thomson Micromedex DrugDex</li> <li>• Clinical Pharmacology</li> <li>• United States Pharmacopoeia-National Formulary (USP-NF)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - The child is unresponsive to, or has had an inadequate response to behavioral therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - The child is experiencing moderate-severe continuing disturbance in function despite behavioral therapy</p>	
Notes	*See Table 1 in background section for FDA approved min ages.

## 2 . Background

<b>Benefit/Coverage/Program Information</b>	
<b>Table 1: FDA Approved Minimum Age Table</b>	
<b>Product name</b>	<b>FDA Approved Minimum Age</b>
All products NOT listed below	6 years of age
Adderall (amphetamine/dextroamphetamine salts)	3 years of age
Dexedrine (dextroamphetamine)	3 years of age
Evekeo ODT/Evekeo (amphetamine) tablet	3 years of age
Mydayis (mixed amphetamine salts) ER capsule	13 years of age
ProCentra (dextroamphetamine) solution	3 years of age
Zenzedi (dextroamphetamine) tablet	3 years of age

### 3 . Revision History

<b>Date</b>	<b>Notes</b>
3/3/2025	Updated GPIs. Added Onyda XR

Aemcolo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146288
<b>Guideline Name</b>	Aemcolo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Aemcolo	
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of travelers' diarrhea</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

**2.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- Azithromycin (generic Zithromax)
- Ciprofloxacin (generic Cipro)
- Levofloxacin (generic Levaquin)
- Ofloxacin (generic Floxin)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Azithromycin (generic Zithromax)
- Ciprofloxacin (generic Cipro)
- Levofloxacin (generic Levaquin)
- Ofloxacin (generic Floxin)

Afinitor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155816
<b>Guideline Name</b>	Afinitor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Neuroendocrine tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of ONE of the following:</p>	

- Neuroendocrine tumors of gastrointestinal origin
- Neuroendocrine tumors of lung origin
- Neuroendocrine tumors of thymic origin

**AND**

**1.2** Disease is progressive

**AND**

**1.3** ONE of the following:

- Disease is unresectable
- Disease is locally advanced
- Disease is metastatic

**AND**

**1.4** If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of neuroendocrine tumors of pancreatic origin

**AND**

**2.2** ONE of the following:

- Used for the management of recurrent, locoregional advanced disease and/or metastatic disease

- Used as preoperative therapy of locoregional insulinoma with or without diazoxide

**AND**

**2.3** If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Neuroendocrine Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Renal cell cancer, Kidney Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced renal cell cancer/kidney cancer</p>	

**AND**

**2** - Disease is ONE of the following:

- Relapsed
- Stage IV disease

**AND**

**3** - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Renal cell cancer, Kidney Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on therapy	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of tuberous sclerosis complex (TSC)-associated renal cell carcinoma

**AND**

2 - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Subependymal Giant Cell Astrocytoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of subependymal giant cell astrocytoma (SEGA)

**AND**

2 - Used as adjuvant treatment

**AND**

3 - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Subependymal Giant Cell Astrocytoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Waldenströms Macroglobulinemia or Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of one of the following:</b></p> <ul style="list-style-type: none"> <li>• Waldenströms macroglobulinemia</li> <li>• Lymphoplasmacytic lymphoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - One of the following:</b></p> <ul style="list-style-type: none"> <li>• Disease is non-responsive to primary treatment</li> <li>• Disease is progressive</li> <li>• Disease has relapsed</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - If the request is for Torpenz, ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)</li> </ul>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Waldenströms Macroglobulinemia or Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of breast cancer

**AND**

2 - One of the following:

2.1 Disease is recurrent

**OR**

2.2 Disease is metastatic

**AND**

3 - Disease is hormone receptor positive (HR+) [i.e., estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+)]

**AND**

4 - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**5** - One of the following:

**5.1** Patient is a postmenopausal woman

**OR**

**5.2** BOTH of the following:

- Patient is a premenopausal woman
- Patient is being treated with ovarian ablation/suppression

**OR**

**5.3** Patient is male

**AND**

**6** - Used in combination with one of the following:

**6.1** Exemestane if progressed within 12 months or on a non-steroidal aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole)]

**OR**

**6.2** Fulvestrant

**OR**

**6.3** Tamoxifen

**AND**

7 - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Hodgkin Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of classic Hodgkin lymphoma

**AND**

2 - Disease is refractory to at least 3 prior lines of therapy

**AND**

**3** - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Hodgkin Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	PEComa (perivascular epithelioid cell tumor), recurrent angiomyolipoma, or lymphangiomyomatosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of one of the following soft tissue sarcoma subtypes:

**1.1** Locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

**OR**

**1.2** Recurrent angiomyolipoma

**OR**

**1.3** Lymphangiomyomatosis

**AND**

**2** - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	PEComa (perivascular epithelioid cell tumor), recurrent angiomyolipoma, or lymphangiomyomatosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on therapy	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Thymic Carcinoma or Thymoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <ul style="list-style-type: none"> <li>• Diagnosis of thymic carcinoma</li> <li>• Diagnosis of thymoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 First-line therapy as a single agent for those who cannot tolerate first-line combination regimens</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Second-line therapy as a single agent</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for Torpenz, ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)</li> </ul>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO
--

Diagnosis	Thymic Carcinoma or Thymoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Follicular carcinoma, Oncocytic carcinoma, or papillary carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Follicular carcinoma</li> <li>• Oncocytic carcinoma</li> <li>• Papillary carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable locoregional recurrent disease</li> <li>• Persistent disease</li> <li>• Metastatic disease</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**3 - ONE of the following:**

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**4 - Disease is refractory to radioactive iodine treatment**

**AND**

**5 - If the request is for Torpenz, ONE of the following:**

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

**Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO**

Diagnosis	Follicular carcinoma, Oncocytic carcinoma, or papillary carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - Patient does not show evidence of progressive disease while on therapy**

**Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO**

Diagnosis	Meningioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of meningioma</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Disease is recurrent or progressive</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Surgery and/or radiation is not possible</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - One of the following:</b></p> <ul style="list-style-type: none"> <li>• Used in combination with bevacizumab (Avastin, Mvasi, etc.)</li> <li>• Used in combination with octreotide acetate LAR</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>5 - If the request is for Torpenz, ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)</li> </ul>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Meningioma
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name:Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endometrial carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with letrozole</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for Torpenz, ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)</li> </ul>	

Product Name:Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO
---

Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Tuberous Sclerosis Complex associated Partial-Onset Seizures
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of tuberous sclerosis complex associated partial-onset seizures</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as adjunctive therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for Torpenz, ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)</li> </ul>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Tuberous Sclerosis Complex associated Partial-Onset Seizures
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Osteosarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of osteosarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Relapsed/Refractory</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Used as second-line therapy</p>	

**AND**

**4** - Used in combination with Nexavar (sorafenib)

**AND**

**5** - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Osteosarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following

- Rosai-Dorfman Disease
- Langerhans Cell Histiocytosis
- Erdheim-Chester Disease

**AND**

2 - Presence of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation

**AND**

3 - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on therapy</p>	

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Gastrointestinal Stromal Tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable</li> <li>• Progressive</li> <li>• Metastatic</li> <li>• Gross residual (R2 resection)</li> <li>• Tumor rupture</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease has progressed after single agent therapy with ALL of the following:</p> <ul style="list-style-type: none"> <li>• imatinib (generic Gleevec)</li> <li>• sunitinib (generic Sutent)</li> <li>• Stivarga (regorafenib)</li> <li>• Qinlock (ripretinib)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Used in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• imatinib (generic Gleevec)</li> <li>• sunitinib (generic Sutent)</li> <li>• Stivarga (regorafenib)</li> </ul>	

**AND**

**5** - If the request is for Torpenz, ONE of the following:

- Failure to everolimus (generic Afinitor) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to everolimus (generic Afinitor) (please specify contraindication or intolerance)

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient does not show evidence of progressive disease while on therapy

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Brand Afinitor, generic everolimus, Torpenz, Brand Afinitor Disperz, generic everolimus TBSO	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

## 2 . Revision History

Date	Notes
9/24/2024	Added step thru everolimus for Torpenz

Afrezza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146289
<b>Guideline Name</b>	Afrezza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Afrezza	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 Diagnosis of type 1 diabetes mellitus and used in combination with a basal insulin or continuous insulin pump</p>	

**OR**

**1.2** Diagnosis of type 2 diabetes mellitus

**AND**

**2** - Patient is unable to self-inject medications (e.g. Humalog, Lantus, Levemir) due to ONE of the following:

- Physical impairment
- Visual impairment
- Lipohypertrophy
- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-5 for specific phobia diagnostic criteria)

**AND**

**3** - Forced Expiratory Volume (FEV1) within the last 60 days is greater than or equal to 70% of expected normal as determined by the physician

**AND**

**4** - Afrezza will not be approved in patients with ONE of the following:

- Who smoke cigarettes
- Who recently quit smoking (within the past 6 months)
- With chronic lung disease (e.g. asthma, chronic obstructive pulmonary disease)

Product Name: Afrezza	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Repeat pulmonary function test confirms that patient has NOT experienced a decline of 20% or more in Forced Expiratory Volume (FEV1)

**AND**

**2** - Patient continues to be unable to self-inject short-acting insulin due to ONE of the following:

- Physical impairment
- Visual impairment
- Lipohypertrophy
- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-5 for specific phobia diagnostic criteria)

**AND**

**3** - Patient continues to not smoke cigarettes

Agamree



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155765
<b>Guideline Name</b>	Agamree
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Agamree	
Diagnosis	Duchenne Muscular Dystrophy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Published clinical evidence shows Agamree is likely to produce equivalent therapeutic results as other available corticosteroids (e.g., prednisone); therefore, Agamree is not medically necessary for treatment of Duchenne muscular dystrophy</p>	
Notes	All requests for authorization will be denied by OptumRx and must be submitted through the appeals process to the UnitedHealthcare Community Plan Pharmacy Appeals team for consideration.



Akeega



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164692
<b>Guideline Name</b>	Akeega
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Indiana</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Akeega	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Deleterious or suspected deleterious BRCA-mutated (BRCAm)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Used in combination with prednisone</p>	

Product Name:Akeega	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Akeega therapy</p>	

Product Name:Akeega	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Akeega	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Akeega therapy</p>	

**2 . Revision History**

Date	Notes
2/4/2025	Added IN formulary. No change to clinical criteria.

Alecensa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151762
<b>Guideline Name</b>	Alecensa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Alecensa	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

<b>AND</b>
<b>2</b> - Disease is anaplastic lymphoma kinase (ALK)-positive
<b>AND</b>
<b>3</b> - One of the following:
<b>3.1</b> Disease is one of the following:
<ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul>
<b>OR</b>
<b>3.2</b> Used as adjuvant treatment following tumor resection

<b>Product Name:Alecensa</b>	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of symptomatic Erdheim-Chester Disease</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used as targeted therapy anaplastic lymphoma kinase (ALK)-fusion</p>	

**AND**

**3** - Disease is ONE of the following:

- Relapsed
- Refractory

Product Name:Alecensa

Diagnosis	T-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of anaplastic large cell lymphoma (ALCL)

**AND**

**2** - Used as second-line or initial palliative intent therapy and subsequent therapy

**AND**

**3** - Disease is ONE of the following:

- Relapsed
- Refractory

**AND**

**4** - Anaplastic lymphoma kinase (ALK)-positive

Product Name:Alecensa	
Diagnosis	B-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of large B-Cell lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Relapsed</li> <li>• Refractory</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Anaplastic lymphoma kinase (ALK)-positive</p>	

Product Name:Alecensa	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic brain cancer from NSCLC</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Tumor is anaplastic lymphoma kinase (ALK)-positive

Product Name:Alecensa	
Diagnosis	Soft Tissue Sarcoma/Uterine Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of inflammatory myofibroblastic tumor (IMT)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Presence of anaplastic lymphoma kinase (ALK) translocation</p>	

Product Name:Alecensa	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Histiocytic Neoplasms, T-Cell Lymphomas, B-Cell Lymphomas, Central Nervous System (CNS) Cancers, Soft Tissue Sarcoma/Uterine Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Alecensa therapy</p>	

Product Name:Alecensa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Alecensa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Alecensa therapy</p>	

## 2 . Revision History

Date	Notes
8/14/2024	Added criteria for adjuvant treatment following tumor resection of AL K-positive NSCLC per FDA label. Updated references.

Alfa Interferons



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159206
<b>Guideline Name</b>	Alfa Interferons
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Pegasys	
Diagnosis	Chronic Hepatitis B
Approval Length	48 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis B infection</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - Patient does not have decompensated liver disease (defined as Child-Pugh Class B or C)**

Product Name:Pegasys	
Diagnosis	Chronic Hepatitis C
Approval Length	48 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient does not have decompensated liver disease (defined as Child-Pugh Class B or C)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Will be used as part of a combination antiviral treatment regimen</p>	

Product Name:Pegasys	
Diagnosis	Diagnoses Other Than Hepatitis
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Chronic myeloid leukemia (CML)</li> <li>• Hairy cell leukemia</li> <li>• Erdheim-Chester disease (ECD)</li> </ul>	

- Myeloproliferative neoplasms (MPNs) such as essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF)
- Mycosis fungoides/Sezary syndrome
- Primary cutaneous CD30+ T-cell lymphoproliferative disorders
- Systemic mastocytosis
- Adult T-cell leukemia/lymphoma

Product Name:Pegasys	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Pegasys	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Pegasys therapy</p>	

**2 . Revision History**

Date	Notes
11/4/2024	Removed Intron A



Alinia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146290
<b>Guideline Name</b>	Alinia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic nitazoxanide, Brand Alinia	
Diagnosis	Diarrhea caused by Giardia lamblia
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of giardiasis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Failure to metronidazole, as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to metronidazole (please specify contraindication or intolerance)

Product Name:generic nitazoxanide, Brand Alinia	
Diagnosis	Diarrhea caused by Cryptosporidium parvum
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of cryptosporidiosis</p>	

Alunbrig



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158241
<b>Guideline Name</b>	Alunbrig
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Alunbrig	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is ONE of the following:

- Metastatic
- Recurrent
- Advanced

**AND**

**3** - Tumor is anaplastic lymphoma kinase (ALK)-positive

Product Name:Alunbrig	
Diagnosis	Soft Tissue Sarcoma/Uterine Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of inflammatory myofibroblastic tumor (IMT)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Presence of ALK (anaplastic lymphoma kinase) translocation</p>	

Product Name:Alunbrig	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of symptomatic Erdheim-Chester Disease

**AND**

2 - Used as targeted therapy (anaplastic lymphoma kinase) ALK-fusion

**AND**

3 - Disease is ONE of the following:

- Relapsed
- Refractory

Product Name:Alunbrig	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of metastatic brain cancer from NSCLC

**AND**

2 - Tumor is anaplastic lymphoma kinase (ALK)-positive

Product Name:Alunbrig
-----------------------

Diagnosis	Anaplastic Large Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of anaplastic large cell lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tumor is anaplastic lymphoma kinase (ALK)-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is relapsed or refractory</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Used as palliative intent therapy or second-line and subsequent therapy</p>	

Product Name:Alunbrig	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma/Uterine Neoplasms, Histiocytic Neoplasms, Central Nervous System (CNS) Cancers, Anaplastic Large Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Alunbrig therapy</p>	

Product Name:Alunbrig	
Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Alunbrig	
Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Alunbrig therapy</p>	

## 2 . Revision History

Date	Notes
10/30/2024	Added Anaplastic Large Cell Lymphoma

Ampyra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146469
<b>Guideline Name</b>	Ampyra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Ampyra, generic dalfampridine ER	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple sclerosis</p>	

Anthelmintics



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155832
<b>Guideline Name</b>	Anthelmintics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Generic albendazole, Emverm	
Diagnosis	Enterobius vermicularis (pinworm)
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Enterobius vermicularis (pinworm)</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure of over-the-counter pyrantel pamoate confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to over-the-counter pyrantel pamoate (please specify intolerance or contraindication)

Product Name:Generic albendazole	
Diagnosis	Taenia solium and Taenia saginata (Taeniasis or Cysticercosis/Neurocysticercosis)
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 -</b> Diagnosis of Taeniasis or Cysticercosis/Neurocysticercosis</p>	

Product Name:Generic albendazole, Emverm	
Diagnosis	Echinococcosis (Tapeworm)
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 -</b> Diagnosis of Hydatid Disease [Echinococcosis (Tapeworm)]</p>	

Product Name:Emverm	
Diagnosis	Ancylostoma/Necatoriasis (Hookworm)
Approval Length	1 month(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Ancylostoma/Necatoriasis (Hookworm)</p>	

Product Name:Generic albendazole	
Diagnosis	Ancylostoma/Necatoriasis (Hookworm)
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Ancylostoma/Necatoriasis (Hookworm)</p>	

Product Name:Generic albendazole, Emverm	
Diagnosis	Ascariasis (Roundworm)
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Ascariasis (Roundworm)</p>	

Product Name:Generic albendazole, Emverm	
Diagnosis	Toxocariasis (Roundworm)
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Diagnosis of Toxocariasis (Roundworm)

Product Name:Generic albendazole, Emverm

Diagnosis	Trichinellosis
-----------	----------------

Approval Length	1 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of Trichinellosis

Product Name:Generic albendazole, Emverm

Diagnosis	Trichuriasis (Whipworm)
-----------	-------------------------

Approval Length	1 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of Trichuriasis (Whipworm)

Product Name:Generic albendazole, Emverm

Diagnosis	Capillariasis
-----------	---------------

Approval Length	1 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of Capillariasis

Product Name:Generic albendazole, Emverm	
Diagnosis	Baylisascaris
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Baylisascaris</p>	

Product Name:Generic albendazole	
Diagnosis	Clonorchiasis (Liver flukes)
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Clonorchiasis (Liver flukes)</p>	

Product Name:Generic albendazole	
Diagnosis	Gnathostomiasis
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Gnathostomiasis</p>	

Product Name:Generic albendazole	
Diagnosis	Strongyloidiasis
Approval Length	1 month(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Strongyloidiasis</p>	

Product Name:Generic albendazole	
Diagnosis	Loiasis
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Loiasis</p>	

Product Name:Generic albendazole	
Diagnosis	Opisthorchiasis
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Opisthorchiasis</p>	

Product Name:Generic albendazole	
Diagnosis	Anisakiasis
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Diagnosis of Anisakiasis

Product Name:Generic albendazole

Diagnosis	Microsporidiosis
-----------	------------------

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of Microsporidiosis not caused by Enterocytozoon bienersi or Vittaforma corneae

**2 . Revision History**

Date	Notes
9/24/2024	Clarified spelling of Opisthorchiasis

Anticonvulsants



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161699
<b>Guideline Name</b>	Anticonvulsants
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Aptiom, Briviact tabs/oral soln, Xcopri	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p>	

**2.1** Diagnosis of partial-onset seizures

**AND**

**2.2** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies) confirmed by claims history or submitted medical records:

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name:Fycompa	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p> <p>    <b>2.1</b> ONE of the following:</p> <p>        <b>2.1.1</b> Diagnosis of partial-onset seizures with or without secondarily generalized seizures</p> <p style="text-align: center;"><b>OR</b></p>	

**2.1.2 ALL of the following:**

- Diagnosis of primary generalized tonic-clonic seizures
- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**2.2 History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies) confirmed by claims history or submitted medical records:**

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name:generic lacosamide tabs/oral soln, Brand Vimpat tabs/oral soln

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - For continuation of prior therapy for a seizure disorder

**OR**

**2** - ALL of the following:

**2.1 ONE of the following:**

**2.1.1** Diagnosis of partial onset seizures

**OR**

**2.1.2** ALL of the following:

- Diagnosis of primary generalized tonic-clonic seizures
- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**2.2** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies) confirmed by claims history or submitted medical records:

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name:Epidiolex	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p>	

**OR**

**2** - Diagnosis of seizures associated with Dravet syndrome or tuberous sclerosis complex

**OR**

**3** - BOTH of the following:

**3.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome

**AND**

**3.2** History of greater than or equal to 8 week trial of at least TWO generic anticonvulsants (e.g., divalproex, lamotrigine, topiramate, valproic acid)

Product Name: Brand Onfi, generic clobazam

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - For continuation of prior therapy for a seizure disorder

**OR**

**2** - BOTH of the following:

**2.1** ONE of the following:

- Diagnosis of seizures associated with Lennox-Gastaut syndrome
- Diagnosis of refractory partial onset seizures (four or more uncontrolled seizures per month after an adequate trial of at least two antiepileptic drugs)
- Diagnosis of Dravet syndrome

**AND**

**2.2 BOTH** of the following:

- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

Product Name:generic rufinamide, Brand Banzel	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of seizures associated with Lennox-Gastaut syndrome</p>	

Product Name:generic tiagabine, Brand Gabitril	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p>	

**2.1** Diagnosis of partial-onset seizures

**AND**

**2.2** Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)

**AND**

**2.3** Not used as primary treatment

**AND**

**2.4** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name: Sympazan	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - For continuation of prior therapy for a seizure disorder	

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS)

**AND**

**2.2** BOTH of the following:

- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**2.3** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Divalproex (e.g., generic Depakote)
- Lamotrigine (e.g., generic Lamictal)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Felbamate (generic Felbatol)
- Rufinamide (generic Banzel)

**AND**

**2.4** Prescriber provides a reason or special circumstance the patient cannot use clobazam (generic Onfi) tablets or suspension

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of refractory partial onset seizures (four or more uncontrolled seizures per month after an adequate trial of at least two antiepileptic drugs)

**AND**

**3.2 BOTH** of the following:

- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**3.3** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

**AND**

**3.4** Prescriber provides a reason or special circumstance the patient cannot use generic clobazam tablets or suspension

**OR**

**4 - ALL** of the following:

- Diagnosis of Dravet syndrome
- Patient is currently taking Diacomit
- Prescriber provides a reason or special circumstance the patient cannot use generic clobazam tablets or suspension

Product Name: Brand Sabril powd pack, Vigadrone powd pack, generic vigabatrin powd pack	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of infantile spasms</p> <p style="text-align: center;"><b>OR</b></p> <p>3 - ALL of the following:</p> <p>3.1 Diagnosis of complex partial seizures</p> <p style="text-align: center;"><b>AND</b></p> <p>3.2 Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)</p> <p style="text-align: center;"><b>AND</b></p> <p>3.3 Not used as primary treatment</p> <p style="text-align: center;"><b>AND</b></p> <p>3.4 History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>• Carbamazepine (e.g., generic Tegretol)</li> <li>• Divalproex (e.g., generic Depakote)</li> <li>• Gabapentin (e.g., generic Neurontin)</li> </ul>	

- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name: Brand Sabril tablets, Vigadrone tablets, generic vigabatrin tablets	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p> <p>2.1 Diagnosis of complex partial seizures</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2 Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)</p> <p style="text-align: center;"><b>AND</b></p> <p>2.3 Not used as primary treatment</p> <p style="text-align: center;"><b>AND</b></p>	

**2.4** History of greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Carbamazepine (e.g., generic Tegretol)
- Divalproex (e.g., generic Depakote)
- Gabapentin (e.g., generic Neurontin)
- Lamotrigine (e.g., generic Lamictal)
- Levetiracetam (e.g., generic Keppra)
- Oxcarbazepine (e.g., generic Trileptal)
- Phenytoin (e.g., generic Dilantin)
- Pregabalin (e.g., generic Lyrica)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

Product Name:Diacomit	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of Dravet syndrome and currently taking clobazam</p>	

Product Name:Fintepla	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p>	

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of seizures associated with Dravet syndrome

**AND**

**2.2** History of greater than or equal to 8-week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Divalproex (e.g., generic Depakote)
- Levetiracetam (e.g., generic Keppra)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome

**AND**

**3.2** ONE of the following:

**3.2.1** Failure of a greater than or equal to 8 week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:

- Divalproex (e.g., generic Depakote)
- Lamotrigine (e.g., generic Lamictal)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)

**OR**

**3.2.2** History of intolerance or contraindication to ALL of the following (any release formulation qualifies) (please specify intolerance or contraindication):

- Divalproex (e.g., generic Depakote)
- Lamotrigine (e.g., generic Lamictal)
- Topiramate (e.g., generic Topamax)
- Valproic acid (e.g., generic Depakene)

Product Name: Ztalmy	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of prior therapy for a seizure disorder</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p> <p><b>2.1</b> Diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder confirmed with genetic testing</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2</b> History of greater than or equal to 8-week trial of at least TWO of the following (any release formulation qualifies), confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>• Carbamazepine (e.g., generic Tegretol)</li> <li>• Divalproex (e.g., generic Depakote)</li> <li>• Gabapentin (e.g., generic Neurontin)</li> <li>• Lamotrigine (e.g., generic Lamictal)</li> <li>• Levetiracetam (e.g., generic Keppra)</li> <li>• Oxcarbazepine (e.g., generic Trileptal)</li> <li>• Phenytoin (e.g., generic Dilantin)</li> <li>• Pregabalin (e.g., generic Lyrica)</li> <li>• Topiramate (e.g., generic Topamax)</li> <li>• Valproic acid (e.g., generic Depakene)</li> </ul>	

- Zonisamide (generic Zonegran)

## 2 . Revision History

Date	Notes
12/5/2024	Updated GPs

Antipsoriatic Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-173218
<b>Guideline Name</b>	Antipsoriatic Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic calcitriol ointment	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of psoriasis**

**AND**

**2 - ONE of the following:**

**2.1** Failure to TWO medium to high potency corticosteroid topical treatments (see Background) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance or contraindication to TWO medium to high potency corticosteroid topical treatments (see Background) (please specify intolerance or contraindication)

**AND**

**3 - ONE of the following:**

**3.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Calcipotriene cream
- Calcipotriene ointment

**OR**

**3.2** History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication):

- Calcipotriene cream
- Calcipotriene ointment

## **2 . Background**

**Benefit/Coverage/Program Information**

**Table 1. Relative Potency of Selected Topical Corticosteroid Products**

<b>Drug</b>	<b>Dosage Form</b>	<b>Strength</b>
<b>Super-High Potency (group 1)</b>		
Augmented betamethasone dipropionate (Diprolene)	Gel, Ointment, lotion	0.05%
Clobetasol propionate (Clobex, Olux, Temovate, Temovate E)	Cream, Ointment, Gel, Solution, Lotion, Shampoo, Spray Aerosol, Foam Aerosol	0.05%
Fluocinonide (Vanos)	Cream	0.1%
Flurandrenolide (Cordran)	Tape (roll)	4 mcg/cm <sup>2</sup>
Halobetasol propionate (Ultravate, Lexette)	Lotion, Cream, Ointment, Foam	0.05%
<b>High Potency (group 2)</b>		
Amcinonide (Amcort)	Ointment	0.1%
Augmented betamethasone dipropionate (Diprolene, Diprolene AF)	Cream, Lotion, Ointment	0.05%
Betamethasone dipropionate	Lotion, Ointment	0.05%
Clobetasol propionate (Impoyz)	Cream	0.025%
Desoximetasone (Topicort)	Cream, Ointment, Spray	0.25%,
	Gel	0.05%
Diflorasone diacetate (Psorcon)	Cream, Ointment	0.05%
Fluocinonide (Lidex, Lidex E)	Cream, Gel, Ointment, Solution	0.05%
Halcinonide (Halog)	Cream, Ointment, Solution	0.1%

Halobetasol propionate (Bryhali)	Lotion	0.01%
<b>High Potency (group 3)</b>		
Amcinonide (Amcort)	Cream, Lotion	0.1%
Betamethasone valerate (Valisone)	Ointment	0.1%
Desoximetasone (Topicort)	Cream, ointment	0.05%
Diflorasone diacetate (Florone, Psorcon)	Cream	0.05%
Fluocinonide (Lidex-E)	Cream	0.05%
Fluticasone propionate (Cutivate)	Ointment	0.005%
Mometasone furoate (Elocon)	Ointment	0.1%
Triamcinolone acetonide (Aristocort HP, Kenalog, Triderm)	Cream, ointment	0.5%
<b>Medium Potency (group 4)</b>		
Betamethasone dipropionate (sernivo)	Spray	0.05%
Clocortolone pivalate (Cloderm)	Cream	0.1%
Fluocinolone acetonide (Synalar)	Cream, Ointment	0.025%
Flurandrenolide (Cordran)	Ointment	0.05%
Fluticasone propionate (Cutivate)	Cream, Lotion	0.05%
Hydrocortisone valerate (Westcort)	Ointment	0.2%
Mometasone furoate (Elocon)	Cream, lotion, Solution	0.1%
Triamcinolone acetonide (Aristocort, Kenalog)	Cream, Lotion Ointment	0.1%
	Ointment	0.05%

### 3 . Revision History

Date	Notes
2/18/2025	Removed calcipotriene cream and ointment as targets for guideline. Added a step through either calcipotriene cream or ointment.

Antipsychotics



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164589
<b>Guideline Name</b>	Antipsychotics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name: aripiprazole ODT, aripiprazole oral soln, Abilify Maintena, Abilify MyCite, Brand Abilify, generic aripiprazole tabs, Abilify Asimtufii, Aristada, Aristada Initio, Caplyta, Brand Clozaril, generic clozapine tabs, clozapine ODT, Cobenfy, Erzofri, Fanapt, Fanapt Titration Pack, Brand Geodon caps, generic ziprasidone caps, Brand Invega, generic paliperidone ER, Invega Sustenna, Invega Trinza, Invega Hafyera, Brand Latuda, generic lurasidone, Lybalvi, molindone, Perseris, Rexulti, Brand Risperdal, generic risperidone tabs/oral soln, risperidone ODT, Brand Risperdal Consta, generic risperidone ER inj, Rykindo, Brand Saphris, generic asenapine, Secuado, Brand Seroquel, generic quetiapine, Brand Seroquel XR, generic quetiapine ER, Uzedy, Versacloz, Vraylar, Brand Zyprexa tabs, generic olanzapine tabs, Brand Zyprexa Zydis, generic olanzapine ODT	
Diagnosis	Atypical Antipsychotics: Prior Authorization for Minimum Age Edit*
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 The patient is unresponsive to other treatment modalities, unless contraindication (i.e., other medications or behavioral modification attempted)

**AND**

1.2 The patient has tried and failed all available preferred\*\* atypical antipsychotics that are Food and Drug Administration (FDA) approved for the patient's age

**AND**

1.3 ONE of the following:

1.3.1 Patient has ONE of the following diagnoses:

- Schizophrenia or schizoaffective disorder
- Autism
- Bipolar disorder

**OR**

1.3.2 Patient displays symptoms of aggression as a symptom of developmental delay, Tourette's syndrome or chronic tics, oppositional defiant disorder, or conduct disorder

Notes	*See Table 1 in the Background section for UHC C&S Plan Minimum Age Edits **PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

Product Name: Caplyta	
Diagnosis	Caplyta Requests Exceeding Quantity Limit
Approval Length	12 month(s)
Guideline Type	Quantity Limit

**Approval Criteria**

1 - ONE of the following:

1.1 The requested drug must be used for a Food and Drug Administration (FDA)-approved indication

**OR**

1.2 The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical Pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

2 - ONE of the following:

2.1 The drug is being prescribed within the manufacturer's published dosing guidelines

**OR**

2.2 The requested dose falls within dosing guidelines found in ONE of the following compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical Pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**3** - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation

**AND**

**4** - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

**AND**

**5** - Physician has provided rationale for needing to exceed the quantity limit of one capsule per day, at a maximum dose of 42 mg (NOTE: The treatment effect of Caplyta at doses higher than 42 mg daily versus placebo was NOT statistically significant in clinical trials)

## 2 . Background

### Benefit/Coverage/Program Information

**Table 1: UHC C&S Plan Minimum Age Edits: Based on FDA-approved uses, prior authorization is required for antipsychotic medications for members less than the following ages:**

- Abilify Discmelt, Abilify oral solution – 6 years of age
- Abilify Maintena – 18 years of age
- Abilify MyCite – 18 years of age
- Abilify oral tablets – 6 years of age
- Abilify Asimtufii – 18 years of age
- Aristada – 18 years of age
- Caplyta – 18 years of age
- Clozaril – 18 years of age
- Cobenfy – 18 years of age
- Erzofri - 18 years of age
- Fanapt – 18 years of age
- Geodon – 18 years of age
- Invega – 12 years of age
- Invega Sustenna – 18 years of age
- Invega Trinza – 18 years of age
- Invega Hafyera – 18 years of age
- Latuda – 10 years of age
- Lybalvi – 18 years of age

- Molindone – 12 years of age
- Perseris – 18 years of age
- Rexulti – 18 years of age
- Risperdal – 5 years of age
- Risperdal Consta – 18 years of age
- Rykindo – 18 years of age
- Saphris – 10 years of age
- Secuado – 18 years of age
- Seroquel, Seroquel XR – 10 years of age
- Uzedy – 18 years of age
- Vraylar – 18 years of age
- Zyprexa – 13 years of age
- Zyprexa Zydys – 6 years of age

### 3 . Revision History

Date	Notes
1/31/2025	Added Erzofri

Apokyn



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146471
<b>Guideline Name</b>	Apokyn
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Apokyn, generic apomorphine hcl	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Apokyn will be used as intermittent treatment for OFF episodes

**AND**

**3** - Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**4** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**5** - Patient continues to experience greater than or equal to 2 hours of OFF time per day despite optimal management of carbidopa/levodopa therapy including BOTH of the following:

- Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more before or one hour after a meal or avoidance of high protein diet
- Dose and dosing interval optimization

**AND**

**6** - ONE of the following:

**6.1** Failure to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes) confirmed by claims history or submitted medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

**OR**

**6.2** History of contraindication or intolerance to TWO anti-Parkinson's disease therapies from

the following adjunctive pharmacotherapy classes (contraindication/intolerance must be from two different classes; please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Product Name: Brand Apokyn, generic apomorphine hcl	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to the requested therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication</p>	

Aqneursa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-165150
<b>Guideline Name</b>	Aqneursa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Aqneursa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Niemann-Pick disease type C (NPC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis has been genetically confirmed by mutation analysis of NPC1 and NPC2 genes</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Medication is being used to treat neurological manifestations of NPC</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Medication is not being used in combination with Miplyffa (arimoclomol)</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Medication is prescribed by or in consultation with a provider with expertise in the treatment of NPC</p>	

Product Name:Aqneursa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Aqneursa therapy (e.g., slowed disease progression from baseline based on assessment with NPC–specific scales)</p>	

**AND**

**2** - Medication is not being used in combination with Miplyffa (arimoclomol)

**AND**

**3** - Medication is prescribed by or in consultation with a provider with expertise in the treatment of Niemann-Pick disease type C (NPC)

## 2 . Revision History

Date	Notes
2/13/2025	Updated formularies. Added criteria that Aqneursa is not taken in combination with Miplyffa

Aqneursa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-165150
<b>Guideline Name</b>	Aqneursa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Aqneursa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Niemann-Pick disease type C (NPC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis has been genetically confirmed by mutation analysis of NPC1 and NPC2 genes</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Medication is being used to treat neurological manifestations of NPC</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Medication is not being used in combination with Miplyffa (arimoclomol)</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Medication is prescribed by or in consultation with a provider with expertise in the treatment of NPC</p>	

Product Name:Aqneursa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Aqneursa therapy (e.g., slowed disease progression from baseline based on assessment with NPC–specific scales)</p>	

**AND**

**2** - Medication is not being used in combination with Miplyffa (arimoclomol)

**AND**

**3** - Medication is prescribed by or in consultation with a provider with expertise in the treatment of Niemann-Pick disease type C (NPC)

## 2 . Revision History

Date	Notes
2/13/2025	Updated formularies. Added criteria that Aqneursa is not taken in combination with Miplyffa

Arcalyst



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146472
<b>Guideline Name</b>	Arcalyst
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Arcalyst	
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)</p>	

Product Name:Arcalyst	
Diagnosis	Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is in remission (e.g., diary score of less than 0.5 [reflecting no fever, skin rash and bone pain], acute phase reactants [less than 0.5 mg/dL CRP (milligrams per deciliter C-Reactive protein)], absence of objective skin rash, no radiological evidence of active bone lesions)</p>	

Product Name:Arcalyst	
Diagnosis	Pericarditis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent pericarditis (RP)</p>	

Product Name:Arcalyst	
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency of Interleukin-1 Receptor Antagonist (DIRA), Pericarditis
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p data-bbox="196 365 440 401"><b>Approval Criteria</b></p> <p data-bbox="196 432 1052 468">1 - Documentation of positive clinical response to Arcalyst therapy</p>	

Arikayce



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146473
<b>Guideline Name</b>	Arikayce
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Arikayce	
Diagnosis	Refractory Mycobacterium avium complex (MAC) lung disease
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of refractory Mycobacterium avium complex (MAC) lung disease</p>	

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting respiratory cultures positive for MAC within the previous 6 months

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) or prescription claims history documenting the patient has been receiving a multidrug background regimen containing at least TWO of the following agents for a minimum of 6 consecutive months within the past 12 months:

- Macrolide antibiotic (e.g., azithromycin, clarithromycin)
- Ethambutol
- Rifamycin antibiotic (e.g., rifampin, rifabutin)

**AND**

**4** - Patient will continue to receive a multidrug background regimen

**AND**

**5** - Documentation that the patient has not achieved negative sputum cultures after receipt of a multidrug background regimen for a minimum of 6 consecutive months

**AND**

**6** - In vitro susceptibility testing of recent (within 6 months) positive culture documents that the MAC isolate is susceptible to amikacin with a minimum inhibitory concentration (MIC) of less than or equal to 64 micrograms per milliliter (mcg/mL)

**AND**

**7** - Prescribed by or in consultation with one of the following:

- Infectious disease specialist

- Pulmonologist

Product Name:Arikayce	
Diagnosis	Refractory Mycobacterium avium complex (MAC) lung disease
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 Documentation that the patient has achieved negative respiratory cultures

**OR**

1.2 ALL of the following:

1.2.1 Patient has not achieved negative respiratory cultures while on Arikayce

**AND**

1.2.2 Physician attestation that patient has demonstrated clinical benefit while on Arikayce

**AND**

1.2.3 In vitro susceptibility testing of most recent (within 6 months) positive culture with available susceptibility testing documents that the Mycobacterium avium complex (MAC) isolate is susceptible to amikacin with a minimum inhibitory concentration (MIC) of less than 64 micrograms per milliliter (mcg/mL)

**AND**

**1.2.4** Patient has NOT received greater than 12 months of Arikayce therapy with continued positive respiratory cultures

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) or prescription claims history documenting that the patient continues to receive a multidrug background regimen containing at least TWO of the following agents:

- Macrolide antibiotic (e.g., azithromycin, clarithromycin)
- Ethambutol
- Rifamycin antibiotic (e.g., rifampin, rifabutin)

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Infectious disease specialist
- Pulmonologist

Attruby



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-199189
<b>Guideline Name</b>	Attruby
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Attruby	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - One of the following:</b></p> <p><b>2.1 Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2 Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of ATTR amyloid deposits</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.3 All of the following:</b></p> <ul style="list-style-type: none"> <li>• Echocardiogram or cardiac magnetic resonance imaging suggestive of amyloidosis</li> <li>• Radionuclide imaging (99mTc-DPD, 99mTc-PYP, or 99m Tc-HMDP) showing grade 2 or 3 cardiac uptake*</li> <li>• Absence of light chain amyloidosis</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Physician attests that the patient has an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level that, when combined with signs and symptoms, is considered definitive for a diagnosis of ATTR-CM</b></p>	

**AND**

**5** - One of the following:

- History of heart failure, with at least one prior hospitalization for heart failure
- Presence of signs and symptoms of heart failure (e.g., dyspnea, edema)

**AND**

**6** - Prescribed by or in consultation with a cardiologist

**AND**

**7** - Patient is not receiving Attruby in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi (inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]

Notes

\*May require prior authorization and notification

Product Name:Attruby

Approval Length

12 month(s)

Therapy Stage

Reauthorization

Guideline Type

Prior Authorization

**Approval Criteria**

**1** - Documentation that the patient has experienced a positive clinical response to Attruby (e.g., improved symptoms, quality of life, slowing of disease progression, decreased hospitalizations, etc.)

**AND**

**2** - Documentation that patient continues to have New York Heart Association (NYHA) Functional Class I, II, or III heart failure

**AND**

**3** - Prescribed by or in consultation with a cardiologist

**AND**

**4** - Patient is not receiving Attruby in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi (inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]

## 2 . Revision History

Date	Notes
2/25/2025	Updated formularies in scope. No change to clinical criteria.

Augtyro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155867
<b>Guideline Name</b>	Augtyro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Augtyro	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

<b>AND</b>
<p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Advanced</li> <li>• Metastatic</li> </ul>
<b>AND</b>
<p><b>3</b> - Disease is ROS1-positive</p>

Product Name: Augtyro	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Presence of solid tumor(s)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusion (e.g., ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Locally advanced</li> <li>• Metastatic</li> </ul>	

- Unresectable

Product Name:Augtyro	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Augtyro therapy</p>	

Product Name:Augtyro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Augtyro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Documentation of positive clinical response to Augtyro therapy

**2 . Revision History**

Date	Notes
9/24/2024	Added criteria for Solid Tumors.

Austedo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180196
<b>Guideline Name</b>	Austedo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Austedo*	
Diagnosis	Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate to severe tardive dyskinesia

**AND**

2 - ONE of the following:

**2.1** Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication

**OR**

**2.2** Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist

Notes

\*Austedo XR not applicable to this guideline

Product Name:Austedo*	
Diagnosis	Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Documentation of positive clinical response to Austedo therapy	
Notes	*Austedo XR not applicable to this guideline

Product Name:Austedo*	
Diagnosis	Chorea associated with Huntington's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chorea associated with Huntington's Disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Psychiatrist</li> </ul>	
Notes	*Austedo XR not applicable to this guideline

Product Name:Austedo*	
Diagnosis	Chorea associated with Huntington's Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Austedo therapy</p>	
Notes	*Austedo XR not applicable to this guideline

## 2 . Revision History

Date	Notes
2/19/2025	Updated formularies

Austedo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-159281
<b>Guideline Name</b>	Austedo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Austedo*	
Diagnosis	Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe tardive dyskinesia</p>	

**AND**

**2** - ONE of the following:

**2.1** Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication

**OR**

**2.2** Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist

Notes	*Austedo XR not applicable to this guideline
-------	--

Product Name:Austedo*	
Diagnosis	Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Austedo therapy	
Notes	*Austedo XR not applicable to this guideline

Product Name:Austedo*
-----------------------

Diagnosis	Chorea associated with Huntington’s Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chorea associated with Huntington’s Disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Psychiatrist</li> </ul>	
Notes	*Austedo XR not applicable to this guideline

Product Name:Austedo*	
Diagnosis	Chorea associated with Huntington’s Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Austedo therapy</p>	
Notes	*Austedo XR not applicable to this guideline

## 2 . Revision History

Date	Notes
------	-------

11/5/2024	For Huntington's disease: Removed step through tetrabenazine and updated prescriber requirement to allow psychiatrist. Clarified that Au stedo XR is not applicable to this guideline
-----------	---

Ayvakit



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154695
<b>Guideline Name</b>	Ayvakit
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Ayvakit	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of gastrointestinal stromal tumor (GIST)</p>	

**AND**

**2 - ONE of the following:**

**2.1** Submission of medical records or claims history confirming patient has unresectable, recurrent, or metastatic disease after failure on approved therapies (e.g., imatinib, sunitinib, dasatinib, regorafenib, ripretinib)

**OR**

**2.2 BOTH of the following:**

**2.2.1** Disease is ONE of the following:

- Unresectable
- Resectable with significant morbidity
- Metastatic
- Recurrent
- Limited progression
- Gross residual disease (R2 resection)
- Residual disease with significant morbidity

**AND**

**2.2.2** Presence of a platelet-derived growth factor receptor alpha (PDGFRA) exon mutation, including 18 D842V mutation

Product Name:Ayvakit	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of myeloid/lymphoid neoplasms with eosinophilia	

<b>AND</b>
<b>2</b> - Presence of a FIP1L1-PDGFR $\alpha$ (platelet-derived growth factor receptor $\alpha$ ) rearrangement
<b>AND</b>
<b>3</b> - Presence of a PDGFR $\alpha$ D842V mutation

Product Name:Ayvakit	
Diagnosis	Systemic Mastocytosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Advanced systemic mastocytosis</li> <li>• Aggressive systemic mastocytosis</li> <li>• Systemic mastocytosis with an associated hematological neoplasm</li> <li>• Mast cell leukemia</li> <li>• Indolent systemic mastocytosis</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Platelet count is greater than or equal to <math>50 \times 10^9</math>/liter</p>	

Product Name:Ayvakit	
Diagnosis	Gastrointestinal Stromal Tumor (GIST), Myeloid/Lymphoid Neoplasms, Systemic Mastocytosis
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Ayvakit therapy</p>	

Product Name:Ayvakit	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Ayvakit	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ayvakit therapy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
9/10/2024	Updated wording of systemic mastocytosis criteria per NCCN without change to clinical intent.

Azole Antifungals



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147444
<b>Guideline Name</b>	Azole Antifungals
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Sporanox capsules, generic itraconazole capsules	
Diagnosis	Systemic Fungal Infections
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Blastomycosis</li> <li>Histoplasmosis</li> </ul>	

<ul style="list-style-type: none"> <li>Aspergillosis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2 - BOTH of the following:</b></p> <p><b>2.1</b> Diagnosis of coccidioidomycosis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2 ONE of the following:</b></p> <p><b>2.2.1</b> Failure to fluconazole (generic Diflucan) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2.2</b> History of contraindication, intolerance, or resistance to fluconazole (generic Diflucan) (please specify intolerance, contraindication, or resistance)</p>
--

Product Name: Brand Sporanox capsules, generic itraconazole capsules	
Diagnosis	Onychomycosis Fingernails
Approval Length	2 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 -</b> Diagnosis of fingernail onychomycosis confirmed by <b>ONE</b> of the following:</p> <ul style="list-style-type: none"> <li>KOH (potassium hydroxide) test</li> <li>Fungal culture</li> <li>Nail biopsy</li> </ul>	

Product Name: Brand Sporanox capsules, generic itraconazole capsules	
Diagnosis	Onychomycosis Fingernails
Approval Length	2 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Three months have elapsed since completion of initial therapy for fingernail onychomycosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to therapy</p>	

Product Name: Brand Sporanox capsules, generic itraconazole capsules	
Diagnosis	Onychomycosis Toenails
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of toenail onychomycosis confirmed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• KOH (potassium hydroxide) test</li> <li>• Fungal culture</li> <li>• Nail biopsy</li> </ul>	

Product Name: Brand Sporanox capsules, generic itraconazole capsules	
Diagnosis	Onychomycosis Toenails
Approval Length	3 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Nine months have elapsed since completion of initial therapy for toenail onychomycosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to therapy</p>	

Product Name:Brand Sporanox oral solution, generic itraconazole oral solution	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Oropharyngeal candidiasis</li> <li>• Esophageal candidiasis</li> </ul>	

Product Name:Brand Vfend tablets, generic voriconazole tablets	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of invasive aspergillosis including Aspergillus fumigatus</p>	

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of candidemia

**AND**

**2.2** Patient is non-neutropenic

**AND**

**2.3** ONE of the following:

**2.3.1** Failure to fluconazole (generic Diflucan) as confirmed by claims history or submission of medical records

**OR**

**2.3.2** History of contraindication, intolerance, or resistance to fluconazole (generic Diflucan) (please specify intolerance, contraindication, or resistance)

**OR**

**3** - BOTH of the following:

**3.1** ONE of the following diagnoses:

- Candida infection in the abdomen
- Candida infection in the kidney
- Candida infection in the bladder wall
- Candida infection in wounds
- Disseminated Candida infections in skin
- Esophageal candidiasis

**AND**

**3.2 ONE of the following:**

**3.2.1** Failure to fluconazole (generic Diflucan) as confirmed by claims history or submission of medical records

**OR**

**3.2.2** History of contraindication, intolerance, or resistance to fluconazole (generic Diflucan) (please specify intolerance, contraindication, or resistance)

**OR**

**4** - Diagnosis of *Scedosporium apiospermum* infection (asexual form of *Pseudallescheria boydii*)

**OR**

**5** - Diagnosis of *Fusarium* spp. infection including *Fusarium solani*

**OR**

**6** - Diagnosis of *Exserohilum* species infection

Product Name:Brand Vfend susp, generic voriconazole susp	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Diagnosis of invasive aspergillosis including <i>Aspergillus fumigatus</i></p>	

**OR**

**1.2** ALL of the following:

**1.2.1** Diagnosis of Candidemia

**AND**

**1.2.2** Patient is non-neutropenic

**AND**

**1.2.3** ONE of the following:

**1.2.3.1** Failure to fluconazole (generic Diflucan) as confirmed by claims history or submission of medical records

**OR**

**1.2.3.2** History of contraindication, intolerance, or resistance to fluconazole (generic Diflucan) (please specify intolerance, contraindication, or resistance)

**OR**

**1.3** BOTH of the following:

**1.3.1** ONE of the following diagnoses:

- Candida infection in the abdomen
- Candida infection in the kidney
- Candida infection in the bladder wall
- Candida infection in wounds
- Disseminated Candida infections in skin
- Esophageal candidiasis

**AND**

**1.3.2** ONE of the following:

**1.3.2.1** Failure to fluconazole (generic Diflucan) as confirmed by claims history or submission of medical records

**OR**

**1.3.2.2** History of contraindication, intolerance, or resistance to fluconazole (generic Diflucan) (please specify intolerance, contraindication, or resistance)

**OR**

**1.4** Diagnosis of *Scedosporium apiospermum* infection (asexual form of *Pseudallescheria boydii*)

**OR**

**1.5** Diagnosis of *Fusarium* spp. infection including *Fusarium solani*

**OR**

**1.6** Diagnosis of *Exserohilum* species infection

**AND**

**2** - Physician has provided rationale for the patient needing to use voriconazole oral suspension instead of voriconazole tablets

Product Name: Brand Noxafil tablets, generic posaconazole tablets	
Diagnosis	Prophylaxis of Aspergillus or Candida Infections
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Used as prophylaxis of invasive fungal infections caused by ONE of the following:

- Aspergillus
- Candida

**AND**

2 - ONE of the following conditions:

2.1 Patient is at high risk of infections due to severe immunosuppression from ONE of the following conditions:

2.1.1 Hematopoietic stem cell transplant (HSCT) with graft-versus-host disease (GVHD)

**OR**

2.1.2 Hematologic malignancies with prolonged neutropenia from chemotherapy [e.g., acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)]

**OR**

2.2 Patient has a prior fungal infection requiring secondary prophylaxis

Product Name: Brand Noxafil tablets, generic posaconazole tablets	
Diagnosis	Treatment of Invasive Aspergillosis
Approval Length	84 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of invasive aspergillosis</p>	

**AND**

**2** - ONE of the following:

**2.1** Failure to voriconazole (generic Vfend) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication, intolerance, or resistance to voriconazole (generic Vfend) (please specify intolerance, contraindication, or resistance)

Product Name: Brand Noxafil suspension, generic posaconazole suspension, Noxafil delayed release suspension packets

Diagnosis	Prophylaxis of Aspergillus or Candida Infections
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Used as prophylaxis of invasive fungal infections caused by ONE of the following:

- Aspergillus
- Candida

**AND**

**2** - ONE of the following conditions:

**2.1** Patient is at high risk of infections due to severe immunosuppression from ONE of the following conditions:

**2.1.1** Hematopoietic stem cell transplant (HSCT) with graft-versus-host disease (GVHD)

**OR**

**2.1.2** Hematologic malignancies with prolonged neutropenia from chemotherapy [e.g., acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)]

**OR**

**2.2** Patient has a prior fungal infection requiring secondary prophylaxis

Product Name: Brand Noxafil suspension, generic posaconazole suspension

Diagnosis	Oropharyngeal Candidiasis (OPC)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of oropharyngeal candidiasis (OPC)

**AND**

**2** - ONE of the following:

**2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Fluconazole (generic Diflucan)
- Itraconazole (generic Sporanox)

**OR**

**2.2** History of contraindication, intolerance, or resistance to BOTH of the following (please specify intolerance, contraindication, or resistance):

- Fluconazole (generic Diflucan)

- Itraconazole (generic Sporanox)

Product Name:Cresemba	
Approval Length	3 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of invasive aspergillosis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to voriconazole (generic Vfend) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of contraindication, intolerance, or resistance to voriconazole (generic Vfend) (please specify intolerance, contraindication, or resistance)</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of invasive mucormycosis</p>	

Product Name:Tolsura	
Approval Length	3 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following fungal infections:

- Blastomycosis
- Histoplasmosis
- Aspergillosis

**AND**

2 - ONE of the following:

2.1 Failure to itraconazole capsules (generic Sporanox) as confirmed by claims history or submission of medical records

**OR**

2.2 History of contraindication or intolerance to itraconazole capsules (generic Sporanox) (please specify intolerance or contraindication)

Product Name: Brand Sporanox capsules, generic itraconazole capsules, Brand Sporanox oral solution, generic itraconazole oral solution, Brand Vfend tablets, generic voriconazole tablets, Brand Vfend suspension, generic voriconazole suspension, Brand Noxafil tablets, generic posaconazole tablets, Brand Noxafil oral suspension, generic posaconazole oral suspension, Noxafil delayed release suspension packets, Cresemba, Tolsura

Diagnosis	Infectious Diseases Society of America (IDSA) Recommended Regimens
Approval Length	Based on provider and IDSA recommended treatment durations, up to 12 months
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is recognized for treatment of the diagnosis by the Infectious Diseases Society of America (IDSA)

## 2 . Revision History

Date	Notes
5/16/2024	Updated GPIs (removed obsolete posaconazole tab; added new Cresemba 74.5mg)

Balversa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150796
<b>Guideline Name</b>	Balversa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/2/2024
-----------------	----------

### 1 . Criteria

Product Name:Balversa	
Diagnosis	Urothelial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of urothelial carcinoma</p>	

**AND**

**2** - ONE of the following:

- Locally advanced
- Metastatic

**AND**

**3** - Presence of FGFR3 genetic alterations

**AND**

**4** - Disease has progressed on or after at least one line of prior systemic therapy [e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin), immune checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)]

**AND**

**5** - One of the following:

**5.1** Patient has received prior systemic therapy containing an immune checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)

**OR**

**5.2** Patient is not eligible for immune checkpoint inhibitor therapy (e.g., pembrolizumab, nivolumab, avelumab)

Product Name:Balversa	
Diagnosis	Urothelial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Balversa therapy

Product Name:Balversa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Balversa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Balversa therapy</p>	

**2 . Revision History**

Date	Notes
8/1/2024	Copy of core



Baxdela



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146295
<b>Guideline Name</b>	Baxdela
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Baxdela	
Diagnosis	Community-Acquired Bacterial Pneumonia
Approval Length	10 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**3** - All of the following:

**3.1** Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

**3.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Baxdela

**AND**

**3.3** One of the following:

**3.3.1** Failure to three of the following antibiotics or antibiotic regimens as confirmed by claims history or submission of medical records:

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

**OR**

**3.3.2** History of intolerance or contraindication to all of the following antibiotics or antibiotic regimens (please specify intolerance or contraindication)

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

Product Name: Baxdela	
Diagnosis	Acute Bacterial Skin and Skin Structure Infections
Approval Length	14 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p> <p style="text-align: center;"><b>OR</b></p> <p>3 - All of the following:</p> <p>3.1 One of the following diagnoses:</p> <p>3.1.1 Both of the following</p> <p>3.1.1.1 Acute bacterial skin and skin structure infections</p> <p style="text-align: center;"><b>AND</b></p> <p>3.1.1.2 Infection caused by methicillin-resistant Staphylococcus aureus (MRSA) documented by culture and sensitivity report</p> <p style="text-align: center;"><b>OR</b></p> <p>3.1.2 Both of the following:</p> <p>3.1.2.1 Empirical treatment of patients with acute bacterial skin and skin structure infections</p>	

**AND**

**3.1.2.2** Presence of MRSA infection is likely

**AND**

**3.2** ONE of the following:

**3.2.1** Failure of linezolid (generic Zyvox) confirmed by claims history or submitted medical records

**OR**

**3.2.2** History of intolerance or contraindication to linezolid (generic Zyvox) (please specify intolerance or contraindication)

**AND**

**3.3** One of the following:

**3.3.1** Failure to one of the following antibiotics as confirmed by claims history or submitted medical records:

- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- A tetracycline
- Clindamycin

**OR**

**3.3.2** History of intolerance or contraindication to all of the following (please specify intolerance or contraindication):

- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- A tetracycline
- Clindamycin

**OR**

**4** - All of the following:

**4.1** Diagnosis of acute bacterial skin and skin structure infections

**AND**

**4.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Baxdela

**AND**

**4.3** One of the following:

**4.3.1** Failure to three of the following antibiotics as confirmed by claims history or submitted medical records:

- A penicillin
- A cephalosporin
- A tetracycline
- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- Clindamycin

**OR**

**4.3.2** History of intolerance or contraindication to all of the following antibiotics (please specify intolerance or contraindication):

- A penicillin
- A cephalosporin
- A tetracycline
- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- Clindamycin

Product Name: Baxdela

Diagnosis

Off-Label Uses

Approval Length	Based on provider and IDSA recommended treatment durations, up to 6 months.
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3</b> - The drug has been recognized for treatment of the indication by the Infectious Diseases Society of America (IDSA)</p>	

Belbuca\_Butrans



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161157
<b>Guideline Name</b>	Belbuca_Butrans
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	DUR: Opioid Naïve (Not having filled an opioid in the past 60 days) exceeding the 7 day supply limit*
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient meets ONE of the following:</p> <ul style="list-style-type: none"> <li>Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</li> <li>End of life care, including hospice care</li> </ul>	

<ul style="list-style-type: none"> <li>• Palliative care</li> <li>• Sickle cell anemia</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - Prescriber attests that the patient has received an opioid within the past 60 days</p>	
Notes	*Approval length for cancer related pain, end of life, palliative care, or sickle cell pain will be issued for 12 months. All other approvals will be issued for the requested duration, not to exceed one month.

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	Cancer-related pain/Hospice/Sickle Cell Anemia/End of Life related pain
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - The patient is being treated for one of the following:</p> <ul style="list-style-type: none"> <li>• Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</li> <li>• Hospice</li> <li>• Sickle cell anemia</li> <li>• End of life related pain</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for Belbuca or Brand Butrans, the prescriber provides a reason or special circumstance the patient cannot use generic buprenorphine patches</p>	
Notes	If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

	If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried generic buprenorphine patches, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 12-month authorization should be entered for generic buprenorphine patches.
--	--

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia pain/Non-end of life care pain
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Prescriber attests to BOTH of the following:</p> <p>1.1 Patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Pain is moderate to severe and expected to persist for an extended period of time (chronic)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - BOTH of the following:</p> <p>3.1 Patient has been screened for underlying depression and/or anxiety</p>	

**AND**

**3.2** If applicable, any underlying conditions have been or will be addressed

**AND**

**4** - ONE of the following:

**4.1** The patient has a history of failure to a trial of tramadol IR (immediate release) as confirmed by claims history or submission of medical records

**OR**

**4.2** The patient has a contraindication or intolerance to tramadol IR (please specify contraindication or intolerance)

**OR**

**4.3** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time

**OR**

**4.4** Patient is new to plan and currently established on Belbuca or Butrans for at least the past 30 days

**AND**

**5** - If the request is for neuropathic pain (examples of neuropathic pain include neuralgias and neuropathies), BOTH of the following:

**5.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (document date of trial) (if contraindicated, document contraindication)

**AND**

**5.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (document drug and date of trial) (if contraindicated, document contraindication)

**AND**

**6** - If the request is for Belbuca or Brand Butrans, the prescriber provides a reason or special circumstance the patient cannot use generic buprenorphine patches

Notes	<p>If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried generic buprenorphine patches, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for generic buprenorphine patches.</p>
-------	---

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia pain/Non-end of life care pain
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)</p>	

**AND**

**2** - Documented rationale for not tapering and discontinuing opioid if treatment goals are not being met

**AND**

**3** - Prescriber attests to BOTH of the following:

**3.1** Patient has been screened for substance abuse/opioid dependence

**AND**

**3.2** Pain is moderate to severe and expected to persist for an extended period of time (chronic)

**AND**

**4** - If the request is for Belbuca or Brand Butrans, the prescriber provides a reason or special circumstance the patient cannot use generic buprenorphine patches

Notes	<p>If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried generic buprenorphine patches, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for generic buprenorphine patches.</p>
-------	---

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
Guideline Type	Quantity Limit

**Approval Criteria**

1 - The requested dose cannot be achieved by moving to a higher strength of the product

**AND**

2 - The requested dose is within the FDA (Food and Drug Administration) maximum dose per day, where an FDA maximum dose per day exists

Notes	Approval durations: 12 months for cancer related pain/hospice/sickle cell anemia related pain/end of life related pain. 6 months for non-cancer related pain/non-hospice/non-sickle cell anemia related pain/non-end of life related pain.
-------	--

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	Cancer-related pain/Hospice/End of Life Related Pain/Sickle Cell Anemia Related Pain
Approval Length	12 month(s)
Guideline Type	Morphine Milligram Equivalents (MME)
<p><b>Approval Criteria</b></p> <p>1 - Patient has one of the following:</p> <ul style="list-style-type: none"> <li>• Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</li> <li>• Hospice pain</li> <li>• An end of life diagnosis</li> <li>• Sickle cell anemia related pain</li> </ul>	
Notes	The authorization should be entered for an MME of 9999 so as to prevent future disruptions in therapy if the patient's dose is increased.

Product Name: Belbuca, generic buprenorphine patches, Brand Butrans	
---	--

Diagnosis	Non-cancer related pain/Non-hospice/Non-End of Life Related Pain/Non-Sickle Cell Anemia Related Pain
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Morphine Milligram Equivalents (MME)
<p><b>Approval Criteria</b></p> <p>1 - Prescriber attests that the patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - BOTH of the following:</p> <p>3.1 Patient has been screened for underlying depression and/or anxiety</p> <p style="text-align: center;"><b>AND</b></p> <p>3.2 If applicable, any underlying conditions have been or will be addressed</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - ONE of the following:</p> <p>4.1 Opioid medication doses of less than 90 MME (Morphine Milligram Equivalents) have been tried and did not adequately control pain (document drug regimen or MME and dates of therapy)</p> <p style="text-align: center;"><b>OR</b></p>	

<b>4.2</b> Patient is new to plan and currently established on the requested MME for at least the past 30 days	
Notes	<p>Authorization will be issued for 6 months for non-cancer related pain/n on-hospice/non-sickle cell anemia related pain/non-end of life related pain up to the current requested MME plus 90 MME.</p> <p>If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization c riteria requirements, a denial should be issued and a maximum 60-da y authorization may be authorized one time for the requested MME do se.</p>

Product Name:Belbuca, generic buprenorphine patches, Brand Butrans	
Diagnosis	Non-cancer related/Non-hospice/Non-End of Life Related Pain/Non-Sickle Cell Anemia Related Pain
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Morphine Milligram Equivalentents (MME)
<p><b>Approval Criteria</b></p> <p><b>1</b> - Prescriber attests that the patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Documented rationale for not tapering and discontinuing opioid if treatment goals are not being met</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)</p>	
Notes	Authorization will be issued for 6 months for non-cancer related pain/n on-hospice/non-sickle cell anemia related pain/non-end of life related pain up to the current requested MME plus 90 MME

	<p>If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested MME dose.</p>
--	--

## 2 . Revision History

Date	Notes
11/21/2024	Updated language to clarify "cancer" is Cancer-related pain

Benefit Determination Mifeprex



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146297
<b>Guideline Name</b>	Benefit Determination Mifeprex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Mifeprex, generic mifepristone	
Approval Length	1 month(s)
Guideline Type	Benefit Determination
<p><b>Approval Criteria</b></p> <p>1 - Provider attests patient requires treatment for purposes identified in the Hyde amendment and any applicable state laws and regulations.</p>	

Benlysta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146478
<b>Guideline Name</b>	Benlysta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Benlysta SQ	
Diagnosis	Systemic Lupus Erythematosus
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of systemic lupus erythematosus</p>	

**AND**

**2** - Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]

**AND**

**3** - Patient does NOT have severe active central nervous system lupus

**AND**

**4** - Patient is NOT receiving Benlysta in combination with any of the following:

- Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
- Lupkynis (voclosporin)
- Saphnelo (anifrolumab-fnia)

Product Name: Benlysta SQ	
Diagnosis	Active Lupus Nephritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of active lupus nephritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is currently receiving standard immunosuppressive therapy for systemic lupus</p>	

erythematosus [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]

**AND**

**3** - Patient does NOT have severe active central nervous system lupus

**AND**

**4** - Patient is NOT receiving Benlysta in combination with any of the following:

- Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
- Lupkynis (voclosporin)
- Saphnelo (anifrolumab-fnia)

Product Name: Benlysta SQ

Diagnosis	Systemic Lupus Erythematosus, Active Lupus Nephritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Benlysta therapy

**AND**

**2** - Patient is NOT receiving Benlysta in combination with any of the following:

- Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]
- Lupkynis (voclosporin)
- Saphnelo (anifrolumab-fnia)



Benznidazole



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146298
<b>Guideline Name</b>	Benznidazole
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Benznidazole	
Approval Length	60 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Chagas disease (American trypanosomiasis) due to Trypanosoma cruzi</p>	

Berinert



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147728
<b>Guideline Name</b>	Berinert
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Berinert	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p>1.1 C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-converting enzyme-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosaminase 3-O-sulfotransferase 6
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - Prescribed for the acute treatment of HAE attacks

**AND**

**3** - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Firazyr, Ruconest)

**AND**

**4** - ONE of the following:

**4.1** Failure of Ruconest as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to Ruconest (please specify intolerance or contraindication)

**OR**

**4.3** Patient is currently on Berinert therapy as confirmed by claims history or submission of medical records

**AND**

**5** - Prescribed by ONE of the following:

- Immunologist
- Allergist

Product Name: Berinert	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Berinert therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed for the acute treatment of HAE (hereditary angioedema) attacks</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Firazyr, Ruconest)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Immunologist</li> </ul>	

- Allergist

## 2 . Revision History

Date	Notes
5/23/2024	Update to types of genetic variant(s) and diagnostic criteria with normal C1 inhibitor levels in initial auth section and minor update in reauth section.

Besremi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-159223
<b>Guideline Name</b>	Besremi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Besremi	
Diagnosis	Polycythemia Vera
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of polycythemia vera</p>	

Product Name:Besremi
----------------------

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Besremi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Besremi therapy</p>	

## 2 . Revision History

Date	Notes
11/4/2024	New program

Biltricide



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146300
<b>Guideline Name</b>	Biltricide
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Biltricide, generic praziquantel	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Infections due to schistosoma</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2** Infections due to the liver trematodes (flukes), *Clonorchis sinensis*/*Opisthorchis viverrini* (i.e., clonorchiasis or opisthorchiasis)

Bimzelx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-173201
<b>Guideline Name</b>	Bimzelx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Bimzelx	
Diagnosis	Plaque Psoriasis (PsO)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of moderate to severe plaque psoriasis

**AND**

1.2 ONE of the following:

1.2.1 ALL of the following:

1.2.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, genital involvement, or severe scalp psoriasis

**AND**

1.2.1.2 ONE of the following:

1.2.1.2.1 Failure of ONE of the following topical therapy classes confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

1.2.1.2.2 History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin

- Coal tar

**AND**

**1.2.1.3** ONE of the following:

- Failure of a 3 month trial of methotrexate, at the maximally indicated doses, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Orencia (abatacept), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Otezla (apremilast), ustekinumab]

**AND**

**1.3** Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast), ustekinumab]

**AND**

**1.4** ONE of the following:

**1.4.1** Failure to two of the following preferred products confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**1.4.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**1.5** ONE of the following:

- Failure to Cosentyx (secukinumab) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**AND**

**1.6** Prescribed by or in consultation with a dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Bimzelx therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderate to severe plaque psoriasis

**AND**

**2.3** Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept),

adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast), ustekinumab]

**AND**

**2.4 Prescribed by or in consultation with a dermatologist**

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Bimzelx	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of active psoriatic arthritis

**AND**

2 - One of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Cosentyx (secukinumab), adalimumab, Simponi (golimumab), Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab), Rinvoq (upadacitinib), Enbrel (etanercept), ustekinumab]

**AND**

**3** - One of the following:

**3.1** BOTH of the following:

**3.1.1** ONE of the following:

**3.1.1.1** Failure to two of the following as confirmed by claims history or submitted medical records

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**3.1.1.2** History of intolerance or contraindication to all of the following (please specify intolerance or contraindication)

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**3.1.2** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**OR**

**3.2** Patient is currently on Bimzelx therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept),

adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast), ustekinumab]

**AND**

**5** - Prescribed by or in consultation with a rheumatologist or dermatologist

Notes

\*See PDL links in Background

Product Name: Bimzelx

Diagnosis Ankylosing Spondylitis (AS)

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of active ankylosing spondylitis

**AND**

**2** - One of the following:

- Failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), Enbrel (etanercept)]

**AND**

**3** - One of the following:

**3.1** One of the following:

**3.1.1** Failure of ALL of the following as confirmed by claims history or submitted medical records

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Cosentyx (secukinumab)

**OR**

**3.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Cosentyx (secukinumab)

**OR**

**3.2** Patient is currently on Bimzelx therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**5** - Prescribed by or in consultation with a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Bimzelx	
Diagnosis	Non-radiographic Axial Spondyloarthritis

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of active non-radiographic axial spondyloarthritis</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - One of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records</li> <li>• History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)</li> <li>• Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of non-radiographic axial spondyloarthritis as confirmed by claims history or submission of medical records [e.g. Cimzia (certolizumab), Cosentyx (secukinumab), Rinvoq (upadacitinib)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - One of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records</li> <li>• History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)</li> <li>• Patient is currently on Bimzelx therapy as confirmed by claims history or submission of medical records</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</b></p>	

**AND**

**5** - Prescribed by or in consultation with a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Bimzelx

Diagnosis	Hidradenitis Suppurativa (HS)
-----------	-------------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III)

**AND**

**2** - ONE of the following:

- Failure to at least one oral antibiotic (e.g., doxycycline, clindamycin, rifampin) at maximally indicated doses, as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to at least one oral antibiotic (e.g., doxycycline, clindamycin, rifampin) (please specify contraindication or intolerance)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of hidradenitis suppurativa as confirmed by claims history or submitted medical records [e.g., adalimumab, Cosentyx (secukinumab)]

**AND**

**3** - ONE of the following:

**3.1** ONE of the following:

**3.1.1** Failure to both of the following preferred products confirmed by claims history or submission of medical records

- One of the preferred adalimumab products\*
- Cosentyx (secukinumab)

**OR**

**3.1.2** History of contraindication or intolerance to both of the following preferred products (please specify contraindication or intolerance)

- One of the preferred adalimumab products\*
- Cosentyx (secukinumab)

**OR**

**3.2** Patient is currently on Bimzelx therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orenzia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]

**AND**

**5** - Prescribed by or in consultation with a dermatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Bimzelx	
Diagnosis	Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Non-radiographic Axial Spondyloarthritis, Hidradenitis Suppurativa (HS)
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Bimzelx therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]*</p>	
Notes	*Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL links:</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA CHIP: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
2/17/2025	Updated Cosentyx step in PsO section. Removed requirement that one of the steps in PsO must be adalimumab. Changed references of brand Stelara to generic ustekinumab. Removed Ilumya step in PsO section and added preferred ustekinumab as step therapy option. Added criteria for hidradenitis suppurativa.

Bonjesta and Diclegis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146301
<b>Guideline Name</b>	Bonjesta and Diclegis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic doxylamine/pyridoxine, Brand Diclegis, Bonjesta	
Approval Length	9 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nausea and vomiting associated with pregnancy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Documented failure or contraindication to lifestyle modifications (e.g., diet, avoidance of triggers)

**AND**

**3** - ONE of the following:

**3.1** Failure to a five day trial of over-the-counter doxylamine taken together with pyridoxine (i.e., not a combined dosage form, but separate formulations taken concomitantly), as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to over-the-counter doxylamine taken together with pyridoxine (i.e., not a combined dosage form, but separate formulations taken concomitantly) (please specify contraindication or intolerance)

Bosulif



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146480
<b>Guideline Name</b>	Bosulif
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Bosulif	
Diagnosis	Chronic Myelogenous/Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient must have a diagnosis of chronic myeloid leukemia</p>	

**AND**

**2** - One of the following:

**2.1** Patient is not a candidate for imatinib as attested by physician

**OR**

**2.2** Patient is currently on Bosulif therapy

Product Name: Bosulif	
Diagnosis	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient must have a diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia</p>	

Product Name: Bosulif	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient must have a diagnosis of myeloid/lymphoid neoplasms with eosinophilia</p>	

**AND**

**2** - Presence of ABL1 (gene) rearrangement

Product Name: Bosulif	
Diagnosis	Chronic Myelogenous/Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Bosulif therapy</p>	

Product Name: Bosulif	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Bosulif will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Bosulif	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Bosulif therapy	

Braftovi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156254
<b>Guideline Name</b>	Braftovi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Braftovi	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of melanoma</p>	

**AND**

**2** - Presence of BRAF V600E mutation

**AND**

**3** - Disease is one of the following:

- Unresectable
- Metastatic

**AND**

**4** - Used in combination with Mektovi (binimetinib)

**AND**

**5** - ONE of the following:

**5.1** Patient has a contraindication or history of intolerance to ONE of the following regimens (please specify contraindication or intolerance)

- Tafinlar (dabrafenib) plus Mekinist (trametinib)
- Zelboraf (vemurafenib) plus Cotellic (cobimetinib)

**OR**

**5.2** Provider attests that the patient is not an appropriate candidate for either of the following regimens

- Tafinlar (dabrafenib) plus Mekinist (trametinib)
- Zelboraf (vemurafenib) plus Cotellic (cobimetinib)

**OR**

**5.3** For continuation of prior Braftovi therapy

Product Name: Braftovi	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Braftovi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with Mektovi (binimetinib)</p>	

Product Name: Braftovi	
Diagnosis	Colon Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of colon cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Presence of BRAF V600E mutation</p>	

**AND**

**3** - Disease is one of the following:

- Advanced
- Metastatic

**AND**

**4** - Patient has received prior therapy

**AND**

**5** - Used in combination with ONE of the following:

- Erbitux (cetuximab)
- Vectibix (panitumumab)

Product Name: Braftovi	
Diagnosis	Colon Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Braftovi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used in combination with ONE of the following:</p>	

- Erbitux (cetuximab)
- Vectibix (panitumumab)

Product Name: Braftovi	
Diagnosis	Rectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of rectal cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Presence of BRAF V600E mutation</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient has received prior therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Used in combination with ONE of the following:</p>	

- Erbitux (cetuximab)
- Vectibix (panitumumab)

Product Name: Braftovi	
Diagnosis	Rectal Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Braftovi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Erbitux (cetuximab)</li> <li>• Vectibix (panitumumab)</li> </ul>	

Product Name: Braftovi	
Diagnosis	Non-Small Cell Lung Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Presence of BRAF V600E mutation

**AND**

**3** - Disease is one of the following:

- Advanced
- Recurrent
- Metastatic

**AND**

**4** - Used in combination with Mektovi (binimetinib)

**AND**

**5** - ONE of the following:

**5.1** Patient has a contraindication or history of intolerance to the following regimen (please specify contraindication or intolerance):

- Tafinlar (dabrafenib) plus Mekinist (trametinib)

**OR**

**5.2** Provider attests that the patient is not an appropriate candidate for the following regimen:

- Tafinlar (dabrafenib) plus Mekinist (trametinib)

**OR**

**5.3** For continuation of prior Braftovi therapy

Product Name: Braftovi	
Diagnosis	Non-Small Cell Lung Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Braftovi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with Mektovi (binimetinib)</p>	

Product Name: Braftovi	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Braftovi	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Braftovi therapy

**2 . Revision History**

Date	Notes
9/25/2024	Add step thru section for melanoma and NSCLC

Brexafemme



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146302
<b>Guideline Name</b>	Brexafemme
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brexafemme	
Diagnosis	Vulvovaginal candidiasis
Approval Length	3 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of vulvovaginal candidiasis (VVC)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Confirmed azole resistance demonstrated by culture and susceptibility testing

**OR**

**2.2** BOTH of the following:

**2.2.1** Other causes (including but not limited to bacterial vaginosis or trichomoniasis) have been ruled out

**AND**

**2.2.2** Failure of a 7-day course of oral fluconazole therapy defined as 100 mg (milligrams), 150 mg, or 200 mg taken orally every third day for a total of 3 doses (days 1,4, and 7), confirmed by claims history or submission of medical records, for the current episode of VVC

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Infectious disease physician
- Obstetrician/Gynecologist

Product Name: Brexafemme	
Diagnosis	Recurrent vulvovaginal candidiasis
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of recurrent vulvovaginal candidiasis (RVVC)	

**AND**

**2** - ONE of the following:

**2.1** Confirmed azole resistance demonstrated by culture and susceptibility testing

**OR**

**2.2** BOTH of the following:

**2.2.1** Other causes (including but not limited to bacterial vaginosis or trichomoniasis) have been ruled out

**AND**

**2.2.2** Failure of a maintenance course of oral fluconazole confirmed by claims history or submission of medical records defined as 100-mg, 150-mg, or 200-mg taken weekly for 6 months

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Infectious disease physician
- Obstetrician/Gynecologist

Brilinta and Effient



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146303
<b>Guideline Name</b>	Brilinta and Effient
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Brilinta	
Diagnosis	Acute coronary syndrome (ACS)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute coronary syndrome (ACS) [e.g., unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI)]</p>	

**OR**

**2** - The medication is being used to reduce the risk of a first myocardial infarction (MI) or stroke in a patient with coronary artery disease (CAD) at high risk for such events [e.g., type 2 diabetes mellitus, hypertension, dyslipidemia, multi-vessel CAD, obesity, heart failure, current smoker or chronic kidney disease]

**OR**

**3** - The medication is being used to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score less than or equal to 5) or high-risk transient ischemic attack (TIA)

Product Name: Brand Effient, generic prasugrel	
Diagnosis	Acute coronary syndrome (ACS)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of acute coronary syndrome (ACS) [e.g., unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The patient must be managed with percutaneous coronary intervention (PCI)</p>	

Bronchitol



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146304
<b>Guideline Name</b>	Bronchitol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Bronchitol	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Used in conjunction with standard CF therapies [e.g., chest physiotherapy, bronchodilators, antibiotics, anti-inflammatory therapy (e.g., ibuprofen, oral/inhaled corticosteroids)]

**AND**

**3** - Patient has passed the Bronchitol Tolerance Test

Product Name:Bronchitol	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Bronchitol therapy</p>	

Brukinsa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154623
<b>Guideline Name</b>	Brukinsa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brukinsa	
Diagnosis	B-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <ul style="list-style-type: none"> <li>Diagnosis of follicular lymphoma (FL)</li> <li>Disease is relapsed or refractory</li> </ul>	

- Patient has received at least two or more lines of systemic therapy
- Brukinsa will be used in combination with obinutuzumab

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of ONE of the following:

- Extranodal marginal zone lymphoma (EMZL) of the stomach
- Extranodal marginal zone lymphoma of nongastric sites (noncutaneous)
- Nodal marginal zone lymphoma

**AND**

**2.2** Disease is relapsed, refractory, or progressive

**AND**

**2.3** Patient has received at least one anti-CD20-based regimen (e.g., rituximab, obinutuzumab)

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of splenic marginal zone lymphoma

**AND**

**3.2** Disease is relapsed or refractory

**AND**

**3.3** Patient has received at least one anti-CD20-based regimen (e.g., rituximab, obinutuzumab)

**OR**

**4** - Diagnosis of mantle cell lymphoma (MCL)

Product Name:Brukinsa	
Diagnosis	Waldenström's Macroglobulinemia (WM)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of Waldenström's macroglobulinemia (WM)</p>	

Product Name:Brukinsa	
Diagnosis	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)</p>	

Product Name:Brukinsa	
Diagnosis	B-Cell Lymphomas, Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Brukinsa therapy</p>	

Product Name:Brukinsa	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hairy cell leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is relapsed, refractory, or progressive</p>	

Product Name:Brukinsa	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Brukinsa therapy</p>	

Product Name:Brukinsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brukinsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Brukinsa therapy</p>	

## 2 . Revision History

Date	Notes
9/9/2024	Annual review. Clinical coverage criteria added for follicular lymphoma and hairy cell leukemia. Updated B-cell lymphoma formatting. Updated background and reference.

Buphenyl



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146483
<b>Guideline Name</b>	Buphenyl
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Buphenyl oral powder, generic sodium phenylbutyrate oral powder	
Diagnosis	Urea Cycle Disorders (UCDs)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of urea cycle disorders (UCDs)</p>	

Product Name:Brand Buphenyl tablets, generic sodium phenylbutyrate tablets
--

Diagnosis	Urea Cycle Disorders (UCDs)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of urea cycle disorders (UCDs)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescriber provides a reason or special circumstance the patient cannot use sodium phenylbutyrate (generic Buphenyl) powder for oral solution</p>	

Product Name: Brand Buphenyl tablets, generic sodium phenylbutyrate tablets	
Diagnosis	Urea Cycle Disorders (UCDs)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Buphenyl (sodium phenylbutyrate) tablets</p>	

Buprenorphine for Opioid Dependence



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146305
<b>Guideline Name</b>	Buprenorphine for Opioid Dependence
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic buprenorphine/naloxone SL film, buprenorphine/naloxone SL tabs, buprenorphine SL tabs	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient has a DSM-V-TR (diagnostic and statistical manual, fifth edition, text revision) diagnosis of opioid use disorder</p>	
Notes	*Up to 24 mg per day of buprenorphine, or equivalent dosing of an alternative medication, will be authorized.

Product Name: Brand Suboxone, Zubsolv, Bunavail	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - The patient has a DSM-V-TR (diagnostic and statistical manual, fifth edition, text revision) diagnosis of opioid use disorder</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The patient must have a reason or special circumstance that they cannot use BOTH of the following (please specify reason or special circumstance):</p> <ul style="list-style-type: none"> <li>• Buprenorphine/naloxone sublingual film (generic Suboxone sublingual film)</li> <li>• Buprenorphine/naloxone sublingual tablet</li> </ul>	
Notes	*Up to 24 mg per day of buprenorphine, or equivalent dosing of an alternative medication, will be authorized.

Product Name: Brand Suboxone, Zubsolv, Bunavail	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - The patient has been prescribed a buprenorphine product for the purpose of opioid use disorder maintenance therapy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - The patient must have a reason or special circumstance that they cannot use BOTH of the following (please specify reason or special circumstance):

- Buprenorphine/naloxone sublingual film (generic Suboxone sublingual film)
- Buprenorphine/naloxone sublingual tablet

Notes

\*Up to 24 mg per day of buprenorphine, or equivalent dosing of an alternative medication, will be authorized.

Product Name:generic buprenorphine/naloxone SL film, Brand Suboxone, buprenorphine/naloxone SL tabs, Zubsolv, buprenorphine SL tabs, Bunavail

Diagnosis	Exceeding 24 mg of buprenorphine or Equivalent
Approval Length	Authorization length will be issued for requested duration of therapy, not to exceed 12 months
Guideline Type	Drug Utilization Review

**Approval Criteria**

**1** - Physician has provided rationale for needing to exceed the 24 mg (milligrams) buprenorphine daily limit

Product Name:generic buprenorphine/naloxone SL film, Brand Suboxone, buprenorphine/naloxone SL tabs, Zubsolv, buprenorphine SL tabs, Bunavail

Approval Length	Authorization length will be issued for requested duration of therapy, not to exceed 12 months
Guideline Type	Quantity Limit

**Approval Criteria**

**1** - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation

**OR**

**2** - Physician has provided rationale for requiring the specific quantity requested



Bylvay



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156302
<b>Guideline Name</b>	Bylvay
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Bylvay	
Diagnosis	Progressive Familial Intrahepatic Cholestasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Confirmed molecular diagnosis of progressive familial intrahepatic cholestasis (PFIC)</p>	

**AND**

**2** - Patient does not have a ABCB11 variant resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3)

**AND**

**3** - Patient is experiencing moderate to severe pruritus associated with PFIC

**AND**

**4** - Patient has a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory

**AND**

**5** - Patient has had an inadequate response to at least TWO other conventional treatments for the symptomatic relief of pruritus (e.g., ursodeoxycholic acid, diphenhydramine, cholestyramine, rifampin, naltrexone, sertraline)

**AND**

**6** - Prescribed by a gastroenterologist or hepatologist

Product Name:Bylvay

Diagnosis	Progressive Familial Intrahepatic Cholestasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Bylvay therapy (e.g., reduced serum bile acids, improved pruritis, and less sleep disturbance)

**AND**

**2** - Prescribed by a gastroenterologist or hepatologist

Product Name:Bylvay

Diagnosis	Alagille Syndrome
-----------	-------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis Alagille syndrome (ALGS)

**AND**

**2** - Confirmation of diagnosis by presence of the JAG1 or Notch2 gene mutation

**AND**

**3** - Patient has a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory

**AND**

**4** - Patient is experiencing moderate to severe pruritis associated with ALGS

**AND**

**5** - Patient has had an inadequate response to at least TWO other conventional treatments for the symptomatic relief of pruritus (e.g., ursodeoxycholic acid, diphenhydramine, cholestyramine, rifampin, naltrexone, sertraline).

**AND**

**6** - Prescribed by a gastroenterologist or hepatologist

Product Name:Bylvay	
Diagnosis	Alagille Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Bylvay therapy (e.g., reduced serum bile acids, improved pruritis)</p> <p><b>AND</b></p> <p><b>2</b> - Prescribed by a gastroenterologist or hepatologist</p>	

## 2 . Revision History

Date	Notes
9/25/2024	Updated examples of conventional treatment and initial authorization durations

Cablivi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146485
<b>Guideline Name</b>	Cablivi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Cablivi	
Diagnosis	Acquired thrombotic thrombocytopenic purpura (aTTP)
Approval Length	2 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP)</p>	

**AND**

**2** - Cablivi was initiated as a bolus intravenous injection administered by a healthcare provider in combination with plasma exchange therapy

**AND**

**3** - Cablivi will be used in combination with immunosuppressive therapy (e.g., corticosteroids)

**AND**

**4** - Total treatment duration will be limited to 58 days beyond the last therapeutic plasma exchange

Product Name: Cablivi	
Diagnosis	Acquired thrombotic thrombocytopenic purpura (aTTP)
Approval Length	2 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Request is for a new (different) episode requiring the re-initiation of plasma exchange for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) (Documentation of date of prior episode and documentation date of new episode required)</p>	

Cabometyx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163727
<b>Guideline Name</b>	Cabometyx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Cabometyx	
Diagnosis	Kidney cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following:</p> <ul style="list-style-type: none"> <li>Stage IV or relapsed renal cell carcinoma (RCC)</li> </ul>	

- Hereditary leiomyomatosis and RCC (HLRCC)

Product Name: Cabometyx	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Positive for RET gene rearrangements</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul>	

Product Name: Cabometyx	
Diagnosis	Hepatocellular Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of hepatocellular carcinoma

**AND**

2 - Used as subsequent-line systemic therapy

**AND**

3 - ONE of the following:

- Patient has liver-confined, unresectable disease and is not a transplant candidate
- Patient has extrahepatic/metastatic disease and deemed ineligible for resection, transplant, or locoregional therapy

Product Name: Cabometyx	
Diagnosis	Bone cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following:</p> <ul style="list-style-type: none"> <li>• Osteosarcoma</li> <li>• Ewing Sarcoma (including mesenchymal chondrosarcoma)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Relapsed/refractory</li> </ul>	

<ul style="list-style-type: none"> <li>Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used as second line therapy</p>
--

Product Name: Cabometyx	
Diagnosis	Gastrointestinal Stromal Tumors (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of gastrointestinal stromal tumors (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has ONE of the following:</p> <ul style="list-style-type: none"> <li>Gross residual disease (R2 resection)</li> <li>Unresectable primary disease</li> <li>Tumor rupture</li> <li>Recurrent/metastatic disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease has progressed on ALL of the following:</p> <ul style="list-style-type: none"> <li>imatinib (generic Gleevec)</li> <li>sunitinib (generic Sutent)</li> <li>Stivarga (regorafenib)</li> <li>Standard dose Qinlock (ripretinib)</li> </ul>	

Product Name: Cabometyx	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endometrial carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as second-line or subsequent treatment</p>	

Product Name: Cabometyx	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of differentiated thyroid cancer (DTC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is locally advanced or metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease has progressed following prior VEGFR-targeted therapy</p>	

**AND**

**4** - Disease is radioactive iodine-refractory or ineligible

Product Name: Cabometyx	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of one of the following soft tissue sarcoma subtypes:</p> <ul style="list-style-type: none"> <li>• Alveolar soft part sarcoma (ASPS)</li> <li>• Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS)</li> <li>• Clear cell sarcoma</li> <li>• Extraskeletal myxoid chondrosarcoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used as subsequent line of therapy for advanced/metastatic disease</p>	

Product Name: Cabometyx	
Diagnosis	Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma, Osteosarcoma, Ewing Sarcoma, Gastrointestinal Stromal Tumors (GIST), Kidney Cancer, Endometrial Carcinoma, Thyroid Cancer, Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Cabometyx therapy

Product Name: Cabometyx	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Cabometyx	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Cabometyx therapy</p>	

**2 . Revision History**

Date	Notes
1/14/2025	Consolidated sections and updated coverage criteria for kidney cancer and renal cell carcinoma into kidney cancer. Consolidated sections

	<p>and updated coverage criteria for ewing sarcoma and osteosarcoma into bone cancer. Added criteria for soft tissue sarcoma per NCCN guideline. Updated coverage criteria for hepatocellular carcinoma and endometrial carcinoma.</p>
--	--

Calquence



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146487
<b>Guideline Name</b>	Calquence
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Calquence	
Diagnosis	Mantle cell lymphoma (MCL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of mantle cell lymphoma (MCL)</p>	

**AND**

**2** - Patient has received at least one prior therapy for MCL [e.g., Rituxan (rituximab)]

Product Name: Calquence	
Diagnosis	Chronic lymphocytic leukemia/small lymphocytic lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma</p>	

Product Name: Calquence	
Diagnosis	B-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Nodal Marginal Zone Lymphoma</li> <li>• Extranodal Marginal Zone Lymphoma (EMZL) of the stomach</li> <li>• Splenic Marginal Zone Lymphoma</li> <li>• Extranodal Marginal Zone Lymphoma of Nongastric Sites (Non-cutaneous)</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**2** - Disease is recurrent, relapsed, refractory, or progressive

Product Name: Calquence	
Diagnosis	Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Patient did not respond to primary therapy</li> <li>• Disease is relapsed or progressive</li> </ul>	

Product Name: Calquence	
Diagnosis	Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia/small lymphocytic lymphoma, B-Cell Lymphomas, Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Calquence therapy</p>	

Product Name: Calquence	
Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Calquence	
Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Calquence therapy</p>	

Camzyos



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146488
<b>Guideline Name</b>	Camzyos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Camzyos	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of obstructive hypertrophic cardiomyopathy (HCM)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Heart failure is classified as ONE of the following:

- New York Heart Association (NYHA) class II heart failure
- NYHA class III heart failure

**AND**

**3** - Patient has a left ventricular ejection fraction of greater than or equal to 55%

**AND**

**4** - Patient has a Valsalva left ventricular outflow tract (LVOT) peak gradient greater than or equal to 50 mmHg at rest or with provocation

**AND**

**5** - One of the following:

**5.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- Non-vasodilating beta blocker (e.g., atenolol, bisoprolol, metoprolol, propranolol)
- Nondihydropyridine calcium channel blocker (i.e., diltiazem, verapamil)
- Disopyramide

**OR**

**5.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Non-vasodilating beta blocker (e.g., atenolol, bisoprolol, metoprolol, propranolol)
- Nondihydropyridine calcium channel blocker (i.e., diltiazem, verapamil)
- Disopyramide

**AND**

**6** - Camzyos is prescribed by, or in consultation with, a cardiologist

Product Name: Camzyos	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy as supported by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Reduction in NYHA (New York Heart Association) class</li> <li>• No worsening in NYHA class</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has a left ventricular ejection fraction of greater than or equal to 50%</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Camzyos is prescribed by, or in consultation with, a cardiologist</p>	

Caprelsa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-159297
<b>Guideline Name</b>	Caprelsa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Caprelsa	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of medullary thyroid cancer (MTC)</p>	

**AND**

**1.2 ONE** of the following:

- Unresectable locoregional disease that is symptomatic or progressing
- Asymptomatic recurrent or persistent distant metastatic disease if unresectable and progressing
- Recurrent or persistent distant metastases if symptomatic disease or progression

**OR**

**2 - ALL** of the following:

**2.1 ONE** of the following diagnoses:

- Follicular carcinoma
- Oncocytic carcinoma
- Papillary carcinoma

**AND**

**2.2 ONE** of the following:

- Unresectable recurrent disease
- Persistent locoregional disease
- Metastatic disease

**AND**

**2.3 ONE** of the following:

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**2.4** Disease is refractory to radioactive iodine treatment

Product Name: Caprelsa	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Caprelsa therapy</p>	

Product Name: Caprelsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Caprelsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Caprelsa therapy</p>	

## 2 . Revision History

Date	Notes
11/5/2024	Updated criteria for medullary thyroid carcinoma

Carbaglu



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146490
<b>Guideline Name</b>	Carbaglu
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Carbaglu, generic carglumic acid	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hyperammonemia due to ONE of the following:</p> <ul style="list-style-type: none"> <li>N-acetylglutamate synthase (NAGS) deficiency</li> <li>Propionic acidemia (PA)</li> </ul>	

- Methylmalonic acidemia (MMA)

Product Name: Brand Carbaglu, generic carglumic acid	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to the requested therapy	

Cayston



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146491
<b>Guideline Name</b>	Cayston
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Cayston	
Diagnosis	Cystic Fibrosis (CF)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Failure to tobramycin solution for inhalation (generic Bethkis) confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance or contraindication to tobramycin solution for inhalation (generic Bethkis) (please specify intolerance or contraindication)

Cerdelga and Zavesca



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146492
<b>Guideline Name</b>	Cerdelga and Zavesca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Cerdelga	
Diagnosis	Gaucher Disease Type 1
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Gaucher disease type 1</p>	

**AND**

**2** - Patient is ONE of the following as detected by a Food and Drug Administration (FDA)-cleared test:

- CYP2D6 extensive metabolizer
- CYP2D6 intermediate metabolizer
- CYP2D6 poor metabolizer

Product Name:Cerdelga	
Diagnosis	Gaucher Disease Type 1
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p>	

Product Name:Brand Zavesca, generic miglustat, Yargesa	
Diagnosis	Mild to Moderate Type 1 Gaucher Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of mild to moderate type 1 Gaucher disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is unable to receive enzyme replacement therapy due to ONE of the following conditions:

**2.1** Allergy or hypersensitivity to enzyme replacement therapy

**OR**

**2.2** Poor venous access

**OR**

**2.3** Unavailability of enzyme replacement therapy (e.g., Cerezyme, VPRIV)

Product Name: Brand Zavesca, generic miglustat, Yargesa	
Diagnosis	Mild to Moderate Type 1 Gaucher Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p>	

CGRP



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180190
<b>Guideline Name</b>	CGRP
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Ajovy, Emgality 120mg	
Diagnosis	Migraines
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of migraine consistent with The International Classification of Headache Disorders, 3rd edition

**AND**

**2** - ONE of the following:

**2.1** 4 to 7 migraine days per month and at least ONE of the following:

- Less than 15 headache days per month
- Provider attests this is the patient's predominant headache diagnosis (i.e., primary driver of headaches is not a different, non-migrainous condition)

**OR**

**2.2** Greater than or equal to 8 migraine days per month

**AND**

**3** - ONE of the following:

**3.1** Failure (after a trial of at least two months), to TWO of the following prophylactic therapies or classes as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan (generic Atacand)\*
- Divalproex sodium [generic Depakote/Depakote ER (extended-release)]
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** History of intolerance or contraindication to TWO of the following prophylactic therapies or classes (please specify intolerance or contraindication):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*

- Candesartan (generic Atacand)\*
- Divalproex sodium [generic Depakote/Depakote ER (extended-release)]
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4** - Medication will NOT be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines [e.g., Aimovig, Nurtec ODT (orally disintegrating tablet), Qulipta, Vyepti (eptinezumab-jjmr)]

Notes

\*Timolol and candesartan are non-preferred and should not be included in denial to provider.

\*\*OnabotulinumtoxinA (generic Botox) is a medical benefit and should not be included in denial to provider.

Product Name:Aimovig

Diagnosis Migraines

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of migraine consistent with The International Classification of Headache Disorders, 3rd edition

**AND**

**2** - ONE of the following:

**2.1** 4 to 7 migraine days per month and at least ONE of the following:

- Less than 15 headache days per month

- Provider attests this is the patient's predominant headache diagnosis (i.e., primary driver of headaches is not a different, non-migrainous condition)

**OR**

**2.2** Greater than or equal to 8 migraine days per month

**AND**

**3** - ONE of the following:

**3.1** Failure (after a trial of at least two months), to TWO of the following prophylactic therapies or classes as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan (generic Atacand)\*
- Divalproex sodium [generic Depakote/Depakote ER (extended-release)]
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** History of intolerance or contraindication to TWO of the following prophylactic therapies or classes (please specify intolerance or contraindication):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan (generic Atacand)\*
- Divalproex sodium [generic Depakote/Depakote ER (extended-release)]
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4** - ONE of the following:

**4.1** Failure (after a trial of at least three months), to BOTH of the following as documented by claims history or submission of medical records:

- Ajoovy
- Emgality [120 mg (milligram) strength]

**OR**

**4.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Ajoovy
- Emgality (120 mg strength)

**AND**

**5** - Medication will not be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines [e.g., Ajoovy, Emgality, Nurtec ODT (orally disintegrating tablet), Qulipta, Vyepti]

Notes	<p>*Timolol and candesartan are non-preferred and should not be included in denial to provider.</p> <p>**OnabotulinumtoxinA (generic Botox) is a medical benefit and should not be included in denial to provider.</p>
-------	--

Product Name:Aimovig, Ajoovy, Emgality 120mg	
Diagnosis	Migraines
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity</p>	

**AND**

**2** - Medication will NOT be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines [e.g., Nurtec ODT (orally disintegrating tablet), Qulipta, Vyepti]

Product Name:Emgality 100mg	
Diagnosis	Episodic Cluster Headache
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of episodic cluster headache</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Medication will NOT be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines [e.g., Aimovig, Ajovy, Nurtec ODT (orally disintegrating tablet), Qulipta, Vyepti]</p>	

Product Name:Emgality 100mg	
Diagnosis	Episodic Cluster Headache
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity

**AND**

2 - Medication will NOT be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines [e.g., Aimovig, Ajovy, Nurtec ODT (orally disintegrating tablet), Qulipta, Vyepti]

**2 . Revision History**

Date	Notes
2/19/2025	Updated formularies. Updated prophylactic therapy drug list and requirement contraindication/intolerance count from all to two. Updated Botox note

Cholbam



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146493
<b>Guideline Name</b>	Cholbam
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Cholbam	
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of a bile acid synthesis disorder</p>	

**AND**

**1.2** Bile acid synthesis disorder is due to single enzyme defects (SEDs)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of a peroxisomal disorder including Zellweger spectrum disorders

**AND**

**2.2** Patient exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption

**AND**

**2.3** Cholbam is being used as adjunctive treatment

Product Name:Cholbam	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Cholbam therapy as evidenced by BOTH of the following:</p> <p><b>1.1</b> Improvement in liver function (e.g., aspartate aminotransferase [AST], alanine aminotransferase [ALT])</p>	

**AND**

**1.2** Absence of complete biliary obstruction

Cialis and Chewtadzy for BPH



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156306
<b>Guideline Name</b>	Cialis and Chewtadzy for BPH
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Chewtadzy 5mg, Brand Cialis 5 mg, generic tadalafil 5 mg	
Diagnosis	Benign prostatic hyperplasia (BPH)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient has a diagnosis of benign prostatic hyperplasia (BPH)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- Alpha Blockers: (e.g., tamsulosin, alfuzosin ER, doxazosin, or terazosin)
- 5-alpha reductase inhibitors (e.g., finasteride)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Alpha Blockers: (e.g., tamsulosin, alfuzosin ER, doxazosin, or terazosin)
- 5-alpha reductase inhibitors (e.g., finasteride)

**AND**

**3** - Dose does not exceed 5 mg (milligrams) once daily

**AND**

**4** - If the request is for Chewtadzy, ONE of the following:

- Failure to tadalafil 5 mg (generic Cialis 5 mg) confirmed by claims history or submission of medical records
- History of intolerance or contraindication to tadalafil 5 mg (generic Cialis 5 mg) (please specify intolerance or contraindication)

## 2 . Revision History

Date	Notes
9/26/2024	Added Chewtadzy

Cibinqo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147335
<b>Guideline Name</b>	Cibinqo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Cibinqo	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate-to-severe chronic atopic dermatitis</p>	

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** ONE of the following:

**2.1.1.1** Failure to TWO of the following therapeutic classes of topical therapies as confirmed by claims history or submission of medical records:

- One medium, high, or very-high potency topical corticosteroid\* [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)]
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**OR**

**2.1.1.2** History of intolerance or contraindication to ALL of the following therapeutic classes of topical therapies (please specify intolerance or contraindication):

- One medium, high, or very-high potency topical corticosteroid\* [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)]
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** BOTH of the following:

**2.1.2.1.1** Submission of medical records (e.g., chart notes, laboratory values) documenting a 3 month trial of a systemic drug product for the treatment of atopic dermatitis [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab), cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, etc.]

**AND**

**2.1.2.1.2** Physician attests that the patient was not adequately controlled with the documented systemic drug product

**OR**

**2.1.2.2** Physician attests that systemic treatment with BOTH of the following FDA (Food and Drug Administration)-approved chronic atopic dermatitis therapies is inadvisable (document drug and contraindication rationale):

- Adbry (tralokinumab-ldrm)
- Dupixent (dupilumab)

**OR**

**2.1.2.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure [refer to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-V-TR) 300.29 for specific phobia diagnostic criteria]

**OR**

**2.2** Patient is currently on Cibinqo therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Cibinqo in combination with any of the following:

- Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab)]
- Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura (topical ruxolitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

<p><b>4 - Prescribed by or in consultation with ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Allergist</li> <li>• Immunologist</li> </ul>	
Notes	*See list of "Relative Potencies of Topical Corticosteroids" in Table 1 of the Background.

Product Name:Cibinqo	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Documentation of positive clinical response to Cibinqo therapy</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Patient is NOT receiving Cibinqo in combination with any of the following:</b></p> <ul style="list-style-type: none"> <li>• Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab)]</li> <li>• Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura (topical ruxolitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Prescribed by or in consultation with ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Allergist</li> <li>• Immunologist</li> </ul>	

## 2 . Background

Benefit/Coverage/Program Information			
Table 1: Relative potencies of topical corticosteroids			
Class	Drug	Dosage Form	Strength (%)
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
High Potency	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
Triamcinolone acetonide	Cream, ointment	0.5	
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05

	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
	Triamcinolone acetonide	Cream, ointment, lotion	0.1
Lower-medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

### 3 . Revision History

Date	Notes
5/13/2024	Copy NY

Cimzia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180187
<b>Guideline Name</b>	Cimzia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Cimzia	
Diagnosis	Crohn's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of moderately to severely active Crohn's disease

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to ONE of the following confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (Imuran)
- 6-mercaptopurine (Purinethol)
- Methotrexate (Rheumatrex, Trexall)

**OR**

**1.2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (Imuran)
- 6-mercaptopurine (Purinethol)
- Methotrexate (Rheumatrex, Trexall)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of Crohn's disease as confirmed by claims history or submission of medical records [e.g., adalimumab, ustekinumab, Skyrizi (risankizumab)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to ONE of the following as confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**1.3.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]

**AND**

**1.5** Prescribed by or in consultation with a gastroenterologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active Crohn's disease

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]

**AND**

**2.4** Prescribed by or in consultation with a gastroenterologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Cimzia	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)</p> <p><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine], at the maximally indicated doses, confirmed by claims history or submitted medical records</p> <p><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to ONE non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)</p>	

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to ALL of the following as confirmed by claims history or submitted medical records:

- Enbrel (etanercept)
- One of the preferred adalimumab products\*
- Tyenne (tocilizumab-aazg)

**OR**

**1.3.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Enbrel (etanercept)
- One of the preferred adalimumab products\*
- Tyenne (tocilizumab-aazg)

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

<b>Product Name:Cimzia</b>	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1 - ALL of the following:</b>	
<b>1.1</b> Diagnosis of active psoriatic arthritis	

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to a 3 month trial of methotrexate, at the maximally indicated dose, confirmed by claims history or submitted medical records

**OR**

**1.2.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to TWO of the following as confirmed by claims history or submitted medical records:

- Enbrel (etanercept)
- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**1.3.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Enbrel (etanercept)

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes

\*See PDL links in Background

Product Name:Cimzia	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of active ankylosing spondylitis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure of TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to TWO NSAIDs (please specify intolerance or contraindication)</p>	

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to BOTH of the following as confirmed by claims history or submitted medical records:

- Enbrel (etanercept)
- One of the preferred adalimumab products\*

**OR**

**1.3.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Enbrel (etanercept)
- One of the preferred adalimumab products\*

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active ankylosing spondylitis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Cimzia	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - ALL of the following:**

**1.1** Diagnosis of moderate to severe plaque psoriasis

**AND**

**1.2 ONE of the following:**

**1.2.1 ALL of the following:**

**1.2.1.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.2.1.2 ONE of the following:**

**1.2.1.2.1** Failure to ONE of the following topical therapies, confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

**1.2.1.2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.2.1.3 ONE of the following:**

**1.2.1.3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose, confirmed by claims history or submitted medical records

**OR**

**1.2.1.3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to TWO of the following preferred products, confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**1.3.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication)

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz

(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.5** Prescribed by or in consultation with a dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderate to severe plaque psoriasis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a dermatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Cimzia	
Diagnosis	Non-Radiographic Axial Spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ALL of the following:</b></p> <p><b>1.1</b> Diagnosis of non-radiographic axial spondyloarthritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2 ONE of the following:</b></p> <p><b>1.2.1</b> Failure of TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2.2</b> History of intolerance or contraindication to TWO NSAIDs (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2.3</b> Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of non-radiographic axial spondyloarthritis as confirmed by claims history or submission of medical records [e.g., Cosentyx (secukinumab), Rinvoq (upadacitinib), Taltz (ixekizumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3 ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records</li> <li>• History of contraindication or intolerance to Cosentyx (please specify contraindication or intolerance)</li> </ul>	

**AND**

**1.4** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Cosentyx (secukinumab), Rinvoq (upadacitinib), Taltz (ixekizumab)]

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of non-radiographic axial spondyloarthritis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Cosentyx (secukinumab), Rinvoq (upadacitinib), Taltz (ixekizumab)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Product Name:Cimzia	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ALL of the following:</b></p> <p><b>1.1</b> Diagnosis of active polyarticular juvenile idiopathic arthritis (pJIA)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2 ONE of the following:</b></p> <p><b>1.2.1</b> Failure to ALL of the following as confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>• Enbrel (etanercept)</li> <li>• One of the preferred adalimumab products*</li> <li>• Tyenne (tocilizumab-aazg)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2.2</b> History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):</p> <ul style="list-style-type: none"> <li>• Enbrel (etanercept)</li> <li>• One of the preferred adalimumab products*</li> <li>• Tyenne (tocilizumab-aazg)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.4</b> Prescribed by or in consultation with a rheumatologist</p>	

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active polyarticular juvenile idiopathic arthritis (pJIA)

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

<b>Product Name:</b> Cimzia	
Diagnosis	Crohn's Disease, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Cimzia therapy	

**AND**

**2** - Patient is NOT receiving Cimzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Siliq (brodalumab), Ilumya (tildrakizumab), Otezla (apremilast)]\*

Notes

\* Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

### Benefit/Coverage/Program Information

#### PDL Links

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
2/19/2025	Updated formularies. Replaced Ilumya with ustekinumab as a step therapy option in PsO and added ustekinumab as ST option in CD and PsA. Replaced Stelara with ustekinumab throughout

Cinryze



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147161
<b>Guideline Name</b>	Cinryze
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Cinryze	
Diagnosis	Hereditary angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by one of the following:</p> <p><b>1.1</b> C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-converting enzyme-1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosaminase 3-O-sulfotransferase 6
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - Prescribed for the prophylaxis of HAE attacks

**AND**

**3** - Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Haegarda, Orladeyo, Takhzyro)

**AND**

**4** - Prescriber attests that the patient has experienced attacks of a severity and/or frequency such that they would clinically benefit from prophylactic therapy with Cinryze

**AND**

**5** - One of the following:

**5.1** Failure to Haegarda confirmed by claims history or submitted medical records

**OR**

**5.2** History of intolerance or contraindication to Haegarda (please specify intolerance or contraindication)

**OR**

**5.3** Patient is currently on Cinryze therapy confirmed by claims history or submitted medical records

**AND**

**6** - Prescribed by ONE of the following:

- Immunologist
- Allergist

Product Name:Cinryze	
Diagnosis	Hereditary angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Cinryze therapy

**AND**

**2** - Reduction in the utilization of on-demand therapies used for acute attacks (e.g., Berinert, Firazyr, Ruconest) as determined by claims information, while on Cinryze therapy

**AND**

**3** - Prescribed for the prophylaxis of HAE attacks

**AND**

**4** - Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Haegarda, Orladeyo, Takhzyro)

**AND**

**5** - Prescribed by ONE of the following:

- Immunologist
- Allergist

## 2 . Revision History

Date	Notes
5/8/2024	Update to diagnostic criteria for HAE with normal C1 inhibitor levels. Simplified reauthorization criteria.

Ciprodex



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146308
<b>Guideline Name</b>	Ciprodex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Ciprodex, generic ciprofloxacin/dexamethasone	
Approval Length	1 Month
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 The patient has a perforated tympanic membrane or tympanostomy tubes</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2** The patient has had an inadequate response, intolerance or contraindication to ONE preferred alternative confirmed by claims history or submission of medical records (please specify intolerance or contraindication if applicable).

Colony Stimulating Factors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-180198
<b>Guideline Name</b>	Colony Stimulating Factors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Leukine, Zarxio	
Diagnosis	Bone Marrow/Stem Cell Transplant
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 Patient has non-myeloid malignancies and is undergoing myeloablative chemotherapy followed by autologous or allogeneic bone marrow transplant (BMT)

**OR**

1.2 Used for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

**OR**

1.3 Patient has had a peripheral stem cell transplant (PSCT) and has received myeloablative chemotherapy

**AND**

2 - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Neupogen, Nivestym, Nypozi, Releuko	
Diagnosis	Bone Marrow/Stem Cell Transplant
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Patient has non-myeloid malignancies and is undergoing myeloablative chemotherapy followed by autologous or allogeneic bone marrow transplant (BMT)</p>	

**OR**

**1.2** Used for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

**OR**

**1.3** Patient has had a peripheral stem cell transplant (PSCT) and has received myeloablative chemotherapy

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**3** - ONE of the following:

**3.1** The request is for Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**3.2** Both of the following:

**3.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**3.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records

- History of contraindication, intolerance or adverse event to Zarxio (please specify contraindication, intolerance, or adverse event)

Product Name:Leukine, Zarxio

Diagnosis	AML Induction or Consolidation Therapy
-----------	--

Approval Length	3 months or duration of therapy
-----------------	---------------------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of acute myeloid leukemia (AML)

**AND**

2 - ONE of the following:

2.1 Patient achieved complete remission after induction therapy

**OR**

2.2 Patient is receiving consolidation chemotherapy

**OR**

2.3 Patient is receiving fludarabine, cytarabine with or without idarubicin for relapsed or refractory disease

**OR**

2.4 Patient is receiving cladribine, cytarabine with or without mitoxantrone or idarubicin for relapsed or refractory disease

**AND**

**3** - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Neupogen, Nivestym, Nypozi, Releuko

Diagnosis	AML Induction or Consolidation Therapy
-----------	--

Approval Length	3 months or duration of therapy
-----------------	---------------------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of acute myeloid leukemia (AML)

**AND**

**2** - One of the following:

**2.1** Patient achieved complete remission after induction therapy

**OR**

**2.2** Patient is receiving consolidation chemotherapy

**OR**

**2.3** Patient is receiving fludarabine, cytarabine with or without idarubicin for relapsed or refractory disease

**OR**

**2.4** Patient is receiving cladribine, cytarabine with or without mitoxantrone or idarubicin for relapsed or refractory disease

**AND**

**3** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**4** - ONE of the following:

**4.1** The request is for Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**4.2** Both of the following:

**4.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**4.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of contraindication, intolerance or adverse effect to Zarxio (please specify contraindication, intolerance, or adverse effect)

Product Name:Leukine, Neulasta, Neulasta Onpro, Zarxio, Udenyca, Udenyca Onbody	
Diagnosis	Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia (FN)
Approval Length	3 months or duration of therapy.
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** One of the following:

- Patient is receiving dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) for bladder cancer
- Patient is receiving dose dense AC (doxorubicin, cyclophosphamide) followed by dose-dense paclitaxel for breast cancer
- Patient is receiving chemotherapy regimen(s) associated with greater than 20% incidence of febrile neutropenia (FN)

**OR**

**1.2** Both of the following:

**1.2.1** Patient is receiving chemotherapy regimen(s) associated with 10-20% incidence of FN

**AND**

**1.2.2** Patient has one or more risk factors for chemotherapy-induced febrile neutropenia such as:

- Persistent neutropenia due to prior chemotherapy, radiation therapy, or bone marrow involvement by tumor (< 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to ≤ 500 neutrophils/mcL over the next 48 hours)
- Liver dysfunction (bilirubin > 2.0)
- Renal dysfunction (creatinine clearance < 50)
- Age greater than 65 years receiving full chemotherapy dose intensity

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Granix, Neupogen, Nivestym, Nypozi, Releuko	
Diagnosis	Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia (FN)
Approval Length	3 months or duration of therapy.
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - ONE of the following:**

**1.1 One of the following:**

- Patient is receiving dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) for bladder cancer
- Patient is receiving dose dense AC (doxorubicin, cyclophosphamide) followed by dose-dense paclitaxel for breast cancer
- Patient is receiving chemotherapy regimen(s) associated with greater than 20% incidence of febrile neutropenia (FN)

**OR**

**1.2 Both of the following:**

**1.2.1 Patient is receiving chemotherapy regimen(s) associated with 10-20% incidence of FN**

**AND**

**1.2.2 Patient has one or more risk factors for chemotherapy-induced febrile neutropenia such as:**

- Persistent neutropenia due to prior chemotherapy, radiation therapy, or bone marrow involvement by tumor (< 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to ≤ 500 neutrophils/mcL over the next 48 hours)
- Liver dysfunction (bilirubin > 2.0)
- Renal dysfunction (creatinine clearance < 50)
- Age greater than 65 years receiving full chemotherapy dose intensity

**AND**

**2 - Prescribed by or in consultation with a hematologist or oncologist**

**AND**

**3 - ONE of the following:**

**3.1** The request is for Granix vial, Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**3.2** Both of the following:

**3.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Granix, Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**3.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of contraindication, intolerance, or adverse effect to Zarxio (please specify contraindication, intolerance, or adverse effect)

Product Name:Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend, Ziextenzo	
Diagnosis	Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia (FN)
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> One of the following:</p> <ul style="list-style-type: none"> <li>• Patient is receiving dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) for bladder cancer</li> <li>• Patient is receiving dose dense AC (doxorubicin, cyclophosphamide) followed by dose-dense paclitaxel for breast cancer</li> </ul>	

- Patient is receiving chemotherapy regimen(s) associated with greater than 20% incidence of febrile neutropenia (FN)

**OR**

**1.2** Both of the following:

**1.2.1** Patient is receiving chemotherapy regimen(s) associated with 10-20% incidence of FN

**AND**

**1.2.2** Patient has one or more risk factors for chemotherapy-induced febrile neutropenia:

- Persistent neutropenia due to prior chemotherapy, radiation therapy or bone marrow involvement by tumor (< 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to ≤ 500 neutrophils/mcL over the next 48 hours)
- Liver dysfunction (bilirubin > 2.0)
- Renal dysfunction (creatinine clearance < 50)
- Age greater than 65 years receiving full chemotherapy dose intensity

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**3** - BOTH of the following:

**3.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend or Ziextenzo than experienced with Neulasta or Udenyca/Udenyca Onbody

**AND**

**3.2** One of the following:

- Failure to Neulasta or Udenyca/Udenyca Onbody as confirmed by claims history or submission of medical records

- History of intolerance, contraindication, or adverse effect to Neulasta or Udenyca/Udenyca Onbody (please specify intolerance, contraindication or adverse effect)

Product Name:Leukine, Neulasta, Neulasta Onpro, Zarxio, Udenyca, Udenyca Onbody

Diagnosis	Secondary Prophylaxis of Febrile Neutropenia (FN)
-----------	---

Approval Length	3 months or duration of therapy
-----------------	---------------------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 ONE of the following:

1.1.1.1 Patient is receiving myelosuppressive anticancer drug(s) given with a curative intent (curative chemotherapy, chemotherapy in curative adjuvant/neoadjuvant setting)

**OR**

1.1.1.2 Patient is receiving myelosuppressive anticancer drug(s) with a non-curative intent and use of secondary prophylaxis is in accordance with the United States Food and Drug Administration approved labeling

**OR**

1.1.1.3 Patient is receiving myelosuppressive anticancer drug(s) for definitive therapy (bridge to stem cell transplant, organ transplant, definitive surgery for oligometastatic disease)

**AND**

1.1.2 ONE of the following:

1.1.2.1 Patient has a documented history of a neutropenic event (febrile neutropenia or low

neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen at full dose for which primary prophylaxis was not received

**OR**

**1.1.2.2** Patient has a documented history of neutropenic event from a previous course of chemotherapy

**OR**

**1.2** ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** Patient is receiving myelosuppressive anticancer drug(s) given with non-curative intent

**AND**

**1.2.1.2** Patient has a documented history of neutropenic event (febrile neutropenia or low neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen after a trial of dose reduction

**OR**

**1.2.2** Patient is receiving myelosuppressive anticancer drug(s) where primary prophylaxis is indicated

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Granix, Neupogen, Nivestym, Nypozi, Releuko	
Diagnosis	Secondary Prophylaxis of Febrile Neutropenia (FN)
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** BOTH of the following:

**1.1.1** ONE of the following:

**1.1.1.1** Patient is receiving myelosuppressive anticancer drug(s) given with a curative intent (curative chemotherapy, chemotherapy in curative adjuvant/neoadjuvant setting)

**OR**

**1.1.1.2** Patient is receiving myelosuppressive anticancer drug(s) with a non-curative intent and use of secondary prophylaxis is in accordance with the United States Food and Drug Administration approved labeling

**OR**

**1.1.1.3** Patient is receiving myelosuppressive anticancer drug(s) for definitive therapy (bridge to stem cell transplant, organ transplant, definitive surgery for oligometastatic disease)

**AND**

**1.1.2** ONE of the following:

**1.1.2.1** Patient has a documented history of a neutropenic event (febrile neutropenia or low neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen at full dose for which primary prophylaxis was not received

**OR**

**1.1.2.2** Patient has a documented history of neutropenic event from a previous course of chemotherapy

**OR**

**1.2** ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** Patient is receiving myelosuppressive anticancer drug(s) given with non-curative intent

**AND**

**1.2.1.2** Patient has a documented history of neutropenic event (febrile neutropenia or low neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen after a trial of dose reduction

**OR**

**1.2.2** Patient is receiving myelosuppressive anticancer drug(s) where primary prophylaxis is indicated

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**3** - ONE of the following:

**3.1** The request is for Granix vial, Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**3.2** Both of the following:

**3.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Granix, Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**3.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Zarxio (please specify intolerance, contraindication or adverse effect)

Product Name:Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend, Ziextenzo	
Diagnosis	Secondary Prophylaxis of Febrile Neutropenia (FN)
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p> <p>1.1.1 ONE of the following:</p> <p>1.1.1.1 Patient is receiving myelosuppressive anticancer drug(s) given with a curative intent (curative chemotherapy, chemotherapy in curative adjuvant/neoadjuvant setting)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.1.1.2 Patient is receiving myelosuppressive anticancer drug(s) with a non-curative intent and use of secondary prophylaxis is in accordance with the United States Food and Drug Administration approved labeling</p> <p style="text-align: center;"><b>OR</b></p> <p>1.1.1.3 Patient is receiving myelosuppressive anticancer drug(s) for definitive therapy (bridge to stem cell transplant, organ transplant, definitive surgery for oligometastatic disease)</p>	

**AND**

**1.1.2** One of the following:

**1.1.2.1** Patient has a documented history of a neutropenic event (febrile neutropenia or low neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen at full dose for which primary prophylaxis was not received

**OR**

**1.1.2.2** Patient has a documented history of neutropenic event from a previous course of chemotherapy

**OR**

**1.2** One of the following:

**1.2.1** Both of the following:

**1.2.1.1** Patient is receiving myelosuppressive anticancer drug(s) given with non-curative intent

**AND**

**1.2.1.2** Patient has a documented history of neutropenic event (febrile neutropenia or low neutrophil count leading to delay of subsequent cycle) during a previous cycle of the same chemotherapy regimen after a trial of dose reduction

**OR**

**1.2.2** Patient is receiving myelosuppressive anticancer drug(s) where primary prophylaxis is indicated

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**3 - BOTH** of the following:

**3.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Fulphila, Fynetra, Nyvepria, Rolvedon, Stimufend or Ziextenzo than experienced with Neulasta or Udenyca/Udenyca Onbody

**AND**

**3.2** One of the following:

- Failure to Neulasta or Udenyca/Udenyca Onbody as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Neulasta or Udenyca/Udenyca Onbody (please specify intolerance, contraindication or adverse effect)

Product Name:Leukine, Neulasta, Neulasta Onpro, Zarxio, Udenyca, Udenyca Onbody	
Diagnosis	Treatment of Febrile Neutropenia (FN)
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 -</b> Diagnosis of febrile neutropenia (FN)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 -</b> Patient has not received long-acting prophylactic pegfilgrastim in the last 14 days</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Patient has one or more risk factors for an infection-associated complication such as:

- Sepsis syndrome
- Greater than 65 years or age
- Absolute Neutrophil Count (ANC) less than 100/mcL
- Neutropenia expected to be greater than 10 days in duration
- Pneumonia
- Clinically documented infections including invasive fungal infection
- Hospitalization at the time of fever
- Prior episode(s) of FN

**AND**

**4** - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Neupogen, Nivestym, Nypozi, Releuko

Diagnosis	Treatment of Febrile Neutropenia (FN)
-----------	---------------------------------------

Approval Length	1 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of febrile neutropenia (FN)

**AND**

**2** - Patient has not received long-acting prophylactic pegfilgrastim in the last 14 days

**AND**

**3** - Patient has one or more risk factors for an infection-associated complication such as:

- Sepsis syndrome
- Greater than 65 years of age
- Absolute Neutrophil Count (ANC) less than 100/mcL
- Neutropenia expected to be greater than 10 days in duration

- Pneumonia
- Clinically documented infections including invasive fungal infection
- Hospitalization at the time of fever
- Prior episode(s) of FN

**AND**

**4** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**5** - One of the following:

**5.1** The request is for Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**5.2** Both of the following:

**5.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Nivestym, Nypozi or Releuko than experienced with Zarxio

**AND**

**5.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Zarxio (please specify intolerance, contraindication or adverse effect)

Product Name: Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend, Ziextenzo	
Diagnosis	Treatment of Febrile Neutropenia (FN)
Approval Length	1 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of febrile neutropenia (FN)

**AND**

2 - Patient has not received long-acting prophylactic pegfilgrastim in the last 14 days

**AND**

3 - Patient has one or more risk factors for an infection-associated complication such as:

- Sepsis syndrome
- Greater than 65 years of age
- Absolute Neutrophil Count (ANC) less than 100/mcL
- Neutropenia expected to be greater than 10 days in duration
- Pneumonia
- Clinically documented infections including invasive fungal infection
- Hospitalization at the time of fever
- Prior episode(s) of FN

**AND**

4 - Prescribed by or in consultation with a hematologist or oncologist

**AND**

5 - Both of the following:

**5.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Fulphila, Fynetra, Nyvepria, Rolvedon, Stimufend or Ziextenzo than experienced with Neulasta or Udenyca/Udenyca Onbody

**AND**

**5.2** One of the following:

- Failure to Neulasta or Udenyca/Udenyca Onbody as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Neulasta or Udenyca/Udenyca Onbody (please specify intolerance, contraindication or adverse effect)

Product Name:Zarxio	
Diagnosis	Severe Chronic Neutropenia (SCN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe chronic neutropenia (SCN) [i.e., congenital, cyclic, and idiopathic neutropenias with chronic absolute neutrophil count (ANC) less than or equal to 500 neutrophils/microliter]</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a hematologist or oncologist</p>	

Product Name:Neupogen, Nivestym, Nypozi, Releuko	
Diagnosis	Severe Chronic Neutropenia (SCN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe chronic neutropenia (SCN) [i.e., congenital, cyclic, and idiopathic neutropenias with chronic absolute neutrophil count (ANC) less than or equal to 500 neutrophils/microliter]</p>	

**AND**

**2** - Prescribed by or in consultation with a hematologist or oncologist

**AND**

**3** - ONE of the following:

**3.1** The request is for Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

**3.2** Both of the following:

**3.2.1** Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**3.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Zarxio (please specify intolerance, contraindication or adverse effect)

Product Name:Leukine, Neulasta, Zarxio, Udenyca, Udenyca Onbody	
Diagnosis	Hematopoietic Syndrome of Acute Radiation Syndrome
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient has been acutely exposed to myelosuppressive doses of radiation

**AND**

2 - Prescribed by or in consultation with a hematologist or oncologist

Product Name: Neupogen, Nivestym, Nypozi, Releuko

Diagnosis	Hematopoietic Syndrome of Acute Radiation Syndrome
-----------	--

Approval Length	3 months or duration of therapy
-----------------	---------------------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Patient has been acutely exposed to myelosuppressive doses of radiation

**AND**

2 - Prescribed by or in consultation with a hematologist or oncologist

**AND**

3 - ONE of the following:

3.1 The request is for Neupogen vial, Nivestym vial, or Releuko vial AND the requested dose is less than 0.3 milliliters

**OR**

3.2 Both of the following:

3.2.1 Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Nivestym, Nypozi, or Releuko than experienced with Zarxio

**AND**

**3.2.2** One of the following:

- Failure to Zarxio as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Zarxio (please specify intolerance, contraindication or adverse effect)

Product Name:Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend, Ziextenzo	
Diagnosis	Hematopoietic Syndrome of Acute Radiation Syndrome
Approval Length	3 months or duration of therapy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been acutely exposed to myelosuppressive doses of radiation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a hematologist or oncologist</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - BOTH of the following:</p> <p><b>3.1</b> Physician attestation that in their clinical opinion the clinical response would be expected to be superior with Fulphila, Fylnetra, Nyvepria, Rolvedon, Stimufend or Ziextenzo than experienced with Neulasta or Udenyca/Udenyca Onbody</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3.2</b> One of the following:</p>	

- Failure to Neulasta or Udenyca/Udenyca Onbody as confirmed by claims history or submission of medical records
- History of intolerance, contraindication or adverse effect to Neulasta or Udenyca/Udenyca Onbody (please specify intolerance, contraindication or adverse effect)

## 2 . Revision History

Date	Notes
2/20/2025	Updated formularies. Added Nypozi

Combination Basal Insulin/GLP-1 Receptor Agonist



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147277
<b>Guideline Name</b>	Combination Basal Insulin/GLP-1 Receptor Agonist
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Soliqua	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Inadequately controlled on ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>GLP-1 (glucagon-like peptide-1) receptor agonist [e.g. Trulicity (dulaglutide), Victoza (liraglutide), Bydureon BCise (exenatide extended-release), Byetta (exenatide), Ozempic (semaglutide), Rybelsus (semaglutide)]</li> </ul>	

- Basal insulin (e.g. insulin glargine, insulin degludec, insulin detemir)

Product Name:Xultophy	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Inadequately controlled on ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• GLP-1 (glucagon-like peptide-1) receptor agonist [e.g. Victoza (liraglutide injection), Ozempic (semaglutide), Rybelsus (semaglutide)]</li> <li>• Basal insulin (e.g. insulin glargine, insulin degludec, insulin detemir)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - One of the following:</p> <p><b>3.1</b> Failure to Soliqua as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> History of contraindication or intolerance to Soliqua (please specify contraindication or intolerance)</p>	

Product Name:Xultophy	
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xultophy therapy</p>	

## 2 . Revision History

Date	Notes
5/13/2024	New; copy core

Cometriq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146498
<b>Guideline Name</b>	Cometriq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Cometriq	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of medullary carcinoma</p>	

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of ONE of the following:

- Follicular carcinoma
- Oncocytic cell carcinoma
- Papillary carcinoma

**AND**

**2.2** Disease is progressive after treatment with ONE of the following as confirmed by claims history or submission of medical records:

- Lenvima (lenvatinib)
- Nexavar (sorafenib)

**AND**

**2.3** Disease is at least ONE of the following:

- Symptomatic iodine-refractory
- Unresectable locoregional recurrent or persistent disease
- Distant metastatic disease

Product Name:Cometriq	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient does not show evidence of progressive disease while on Cometriq therapy

Product Name:Cometriq	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Positive for RET gene rearrangements</p>	

Product Name:Cometriq	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Cometriq therapy</p>	

Product Name:Cometriq	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Cometriq	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Cometriq therapy</p>	

Compounds and Bulk Powders



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146311
<b>Guideline Name</b>	Compounds and Bulk Powders
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Compounds or Bulk Powders	
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - The requested drug component is a covered medication</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

**2.1** The requested drug component is to be administered for an FDA (Food and Drug Administration)-approved indication

**OR**

**2.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**3** - If a drug included in the compound requires prior authorization and/or step therapy, all drug specific clinical criteria must also be met

**AND**

**4** - If the drug component is no longer available commercially, it must not have been withdrawn for safety reasons

**AND**

**5** - ONE of the following:

**5.1** A unique vehicle is required

**OR**

**5.2** A unique dosage form is required for a commercially available product due to patient's age, weight, or inability to take a solid dosage form

**OR**

**5.3** A unique formulation is required for a commercially available product due to an allergy or intolerance to an inactive ingredient in the commercially available product

**OR**

**5.4** There is a shortage of the commercially available product per the FDA Drug Shortage database or the ASHP (American Society of Health-System Pharmacists) Current Drug Shortages tracking log

**AND**

**6** - Coverage for compounds and bulk powders will NOT be approved for any of the following:

**6.1** For topical compound preparations (e.g., creams, ointments, lotions, or gels to be applied to the skin for transdermal, transcutaneous, or any other topical route), if the requested compound contains any FDA approved ingredient that is not FDA approved for TOPICAL use (see Table 1 in Background section)

**OR**

**6.2** If the requested compound contains topical fluticasone, topical fluticasone will NOT be approved unless both of the following are met:

**6.2.1** Topical fluticasone is intended to treat a dermatologic condition (scar treatments are considered cosmetic and will not be covered)

**AND**

**6.2.2** Patient has a contraindication to all commercially available topical fluticasone formulations

**OR**

**6.3** Requested compound contains any ingredients when used for cosmetic purposes (see Table 2 in Background section)

**OR**

**6.4** Requested compound contains any ingredient(s) which are on the FDA's Do Not Compound List (see Table 3 in Background section)

## 2 . Background

### Benefit/Coverage/Program Information

**Table 1: Example topical compound preparations that contain any FDA approved ingredient that are not FDA approved for TOPICAL use, including but NOT LIMITED TO the following:**

- (1) Ketamine
- (2) Gabapentin
- (3) Flurbiprofen (topical ophthalmic use not included)
- (4) Ketoprofen
- (5) Morphine
- (6) Nabumetone
- (7) Oxycodone
- (8) Cyclobenzaprine
- (9) Baclofen
- (10) Tramadol
- (11) Hydrocodone
- (12) Meloxicam
- (13) Amitriptyline

- (14) Pentoxifylline
- (15) Orphenadrine
- (16) Piroxicam
- (17) Levocetirizine
- (18) Amantadine
- (19) Oxytocin
- (20) Sumatriptan
- (21) Chorionic gonadotropin (human)
- (22) Clomipramine
- (23) Dexamethasone
- (24) Hydromorphone
- (25) Methadone
- (26) Papaverine
- (27) Mefenamic acid
- (28) Promethazine
- (29) Succimer DMSA
- (30) Tizanidine
- (31) Apomorphine
- (32) Carbamazepine
- (33) Ketorolac
- (34) Dimercaptopropane-sulfonate
- (35) Dimercaptosuccinic acid

- (36) Duloxetine
- (37) Fluoxetine
- (38) Bromfenac (topical ophthalmic use not included)
- (39) Nepafenac (topical ophthalmic use not included)

**Table 2: Example compounds that contain ingredients for cosmetic purposes:**

- (1) Hydroquinone
- (2) Acetyl hexapeptide-8
- (3) Tocopheryl Acid Succinate
- (4) PracaSil TM-Plus
- (5) Chrysaderm Day Cream
- (6) Chrysaderm Night Cream
- (7) PCCA Spira-Wash
- (8) Lipopen Ultra
- (9) Versapro
- (10) Fluticasone
- (11) Mometasone
- (12) Halobetasol
- (13) Betamethasone
- (14) Clobetasol
- (15) Triamcinolone
- (16) Minoxidil

- (17) Tretinoin
- (18) Dexamethasone
- (19) Spironolactone
- (20) Cycloserine
- (21) Tamoxifen
- (22) Sermorelin
- (23) Mederma Cream
- (24) PCCA Cosmetic HRT Base
- (25) Sanare Scar Therapy Cream
- (26) Scarcin Cream
- (27) Apothederm
- (28) Stera Cream
- (29) Copasil
- (30) Collagenase
- (31) Arbutin Alpha
- (32) Nourisil
- (33) Freedom Cepapro
- (34) Freedom Silomac Anhydrous
- (35) Retinaldehyde
- (36) Apothederm

**Table 3: Example ingredients on the FDA's Do Not Compound List:**

- (1) 3,3',4',5-tetrachlorosalicylanilide
- (2) Adenosine phosphate
- (3) Adrenal cortex
- (4) Alatrofloxacin mesylate
- (5) Aminopyrine
- (6) Astemizole
- (7) Azaribine
- (8) Benoxaprofen
- (9) Bithionol
- (10) Camphorated oil
- (11) Carbetapentane citrate
- (12) Casein, iodinated
- (13) Cerivastatin sodium
- (14) Chlormadinone acetate
- (15) Chloroform
- (16) Cisapride
- (17) Defenfluramine hydrochloride
- (18) Diamthazole dihydrochloride
- (19) Dibromsalan
- (20) Dihydrostreptomycin sulfate
- (21) Dipyrone
- (22) Encainide hydrochloride

- (23) Etreinate
- (24) Fenfluramine hydrochloride
- (25) Flosequinan
- (26) Glycerol, iodinated
- (27) Grepafloxacin
- (28) Mepazine
- (29) Metabromsalan
- (30) Methapyrilene
- (31) Methopholine
- (32) Methoxyflurane
- (33) Mibefradil dihydrochloride
- (34) Nomifensine maleate
- (35) Novobiocin sodium
- (36) Oxyphenisatin acetate
- (37) Oxyphenisatin
- (38) Pemoline
- (39) Pergolide mesylate
- (40) Phenacetin
- (41) Phenformin hydrochloride
- (42) Phenylpropanolamine
- (43) Pipamazine
- (44) Potassium arsenite

- (45) Propoxyphene
- (46) Rapacuronium bromide
- (47) Rofecoxib
- (48) Sibutramine hydrochloride
- (49) Sparteine sulfate
- (50) Sulfadimethoxine
- (51) Sweet spirits of nitre
- (52) Tegaserod maleate
- (53) Temafloxacin hydrochloride
- (54) Terfenadine
- (55) Ticrynafen
- (56) Tribromsalan
- (57) Trichloroethane
- (58) Troglitazone
- (59) Trovafloxacin mesylate:
- (60) Urethane
- (61) Valdecoxib
- (62) Zomepirac sodium

Constipation Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146312
<b>Guideline Name</b>	Constipation Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic lubiprostone	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 ONE of the following:</p> <p>1.1.1 Diagnosis of opioid-induced constipation in an adult with chronic, non-cancer pain</p>	

**OR**

**1.1.2** Diagnosis of opioid-induced constipation in a patient with chronic pain related to prior cancer diagnosis or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**1.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2** - BOTH of the following:

**2.1** Diagnosis of chronic idiopathic constipation

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose

- Polyethylene glycol (Miralax)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of irritable bowel syndrome with constipation

**AND**

**3.2** Patient was female at birth

**AND**

**3.3** ONE of the following:

**3.3.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**3.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

Product Name: Brand Amitiza	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 ONE of the following:</p> <p>1.1.1 Diagnosis of opioid-induced constipation in an adult with chronic, non-cancer pain</p> <p style="text-align: center;"><b>OR</b></p> <p>1.1.2 Diagnosis of opioid-induced constipation in a patient with chronic pain related to prior cancer diagnosis or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul>	

**AND**

**1.3** ONE of the following:

**1.3.1** Failure to Movantik as confirmed by claims history or submission of medical records

**OR**

**1.3.2** History of intolerance or contraindication to Movantik (please specify intolerance or contraindication)

**AND**

**1.4** ONE of the following:

**1.4.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**1.4.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of chronic idiopathic constipation

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose

- Polyethylene glycol (Miralax)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure to Motegrity as confirmed by claims history or submission of medical records

**OR**

**2.3.2** History of intolerance or contraindication to Motegrity (please specify intolerance or contraindication)

**AND**

**2.4** ONE of the following:

**2.4.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**2.4.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of irritable bowel syndrome with constipation

**AND**

**3.2** Patient was female at birth

**AND**

**3.3** ONE of the following:

**3.3.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**3.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3.4** ONE of the following:

**3.4.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**3.4.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name: Linzess	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of chronic idiopathic constipation</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.3 ONE of the following:</p> <p>1.3.1 Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**1.3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**AND**

**1.4** ONE of the following:

**1.4.1** Failure to Motegrity as confirmed by claims history or submission of medical records

**OR**

**1.4.2** History of intolerance or contraindication to Motegrity (please specify intolerance or contraindication)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of irritable bowel syndrome with constipation

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**2.3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**OR**

**3** - BOTH of the following:

**3.1** Diagnosis of functional constipation

**AND**

**3.2** ONE of the following:

**3.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**3.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

Product Name:Trulance	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of chronic idiopathic constipation</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.3 ONE of the following:</p> <p>1.3.1 Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**1.3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**AND**

**1.4** ONE of the following:

**1.4.1** Failure to Motegrity as confirmed by claims history or submission of medical records

**OR**

**1.4.2** History of intolerance or contraindication to Motegrity (please specify intolerance or contraindication)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of irritable bowel syndrome with constipation

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**2.3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name: Motegrity	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic idiopathic constipation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p>	

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3** - ONE of the following:

**3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name: Movantik	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Diagnosis of opioid-induced constipation in a patient being treated for chronic, non-cancer pain</p> <p><b>OR</b></p> <p><b>1.2</b> Diagnosis of opioid-induced constipation in a patient with chronic pain related to prior cancer diagnosis or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation</p> <p><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3 - ONE of the following:**

**3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name: Symproic	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following:</b></p>	

**1.1** Diagnosis of opioid-induced constipation in a patient being treated for chronic, non-cancer pain

**OR**

**1.2** Diagnosis of opioid-induced constipation in a patient with chronic pain related to prior cancer diagnosis or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation

**AND**

**2** - ONE of the following:

**2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3** - ONE of the following:

**3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**AND**

**4** - ONE of the following:

**4.1** Failure to Movantik as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to Movantik (please specify intolerance or contraindication)

Product Name:Zelnorm	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of irritable bowel syndrome with constipation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient was female at birth</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <p><b>3.1</b> Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul>	

**OR**

**3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**4** - ONE of the following:

**4.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name:lbsrela	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of irritable bowel syndrome with constipation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> Failure to ONE of the following as confirmed by claims history or submission of medical records:</p>	

- Lactulose
- Polyethylene glycol (Miralax)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3** - ONE of the following:

**3.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

Product Name: Brand Amitiza, generic lubiprostone, Ibsrela, Linzess, Motegrity, Movantik, Symproic, Trulance, Zelnorm	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	

Continuous Glucose Monitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-156368
<b>Guideline Name</b>	Continuous Glucose Monitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Continuous Glucose Monitors, sensors, and transmitters (all brands)	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of diabetes</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - One of the following:**

**2.1** Patient is on an intensive insulin regimen (3 or more insulin injections per day or uses continuous subcutaneous insulin infusion pump)

**OR**

**2.2** One of the following:

- Patient has a history of a level 3 hypoglycemic event
- Patient has a history of more than one level 2 hypoglycemia events that persist despite multiple attempts to adjust medication(s) or modify diabetes treatment plan

**AND**

**3 - Patient regularly monitors blood glucose 4 or more times per day**

**AND**

**4 - If the request is for a Guardian Connect (all components), Guardian 3 (all components), Guardian 4 (all components), or Freestyle Libre 3 (all components), ONE of the following:**

**4.1** BOTH of the following:

**4.1.1** Patient has a physical or mental limitation that makes utilization of Dexcom G6 and Dexcom G7 unsafe, inaccurate, or otherwise not feasible (e.g., manual dexterity; document limitation)

**AND**

**4.1.2** Patient has a physical or mental limitation that makes utilization of the preferred Freestyle Libre product unsafe, inaccurate, or otherwise not feasible (e.g., manual dexterity; document limitation)

**OR**

**4.2** Provider submits documentation why the patient requires use of the Guardian Connect, Guardian 3, Guardian 4, or Freestyle Libre 3 for treatment of diabetes

Product Name:Continuous Glucose Monitors, sensors, and transmitters (all brands)	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response</p>	

## 2 . Revision History

Date	Notes
9/26/2024	Clarified nonpreferred CGM criteria

Copiktra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146499
<b>Guideline Name</b>	Copiktra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Copiktra	
Diagnosis	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</p>	

**AND**

**2** - Disease is relapsed or refractory

**AND**

**3** - ONE of the following:

**3.1** Failure to at least TWO prior therapies for CLL/SLL confirmed by claims history or submitted medical records. Examples include, but not limited to, regimens consisting of: [Leukeran (chlorambucil), Gazyva (obinutuzumab), Arzerra (ofatumumab), Bendeka (bendamustine), Imbruvica (ibrutinib), Calquence (acalabrutinib), Venclexta (venetoclax), etc.]

**OR**

**3.2** History of intolerance or contraindication to at least TWO prior therapies for CLL/SLL. Examples include, but not limited to, regimens consisting of: [Leukeran (chlorambucil), Gazyva (obinutuzumab), Arzerra (ofatumumab), Bendeka (bendamustine), Imbruvica (ibrutinib), Calquence (acalabrutinib), Venclexta (venetoclax), etc.] (please specify intolerance or contraindication)

Product Name:Copiktra	
Diagnosis	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Copiktra therapy	

Product Name:Copiktra	
Diagnosis	T-cell Lymphomas

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hepatosplenic T-cell lymphoma</li> <li>• Breast implant-associated anaplastic large cell lymphoma</li> <li>• Peripheral T-cell lymphomas</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is relapsed or refractory</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <p><b>3.1</b> Failure to at least TWO prior systemic therapies confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> History of intolerance or contraindication to at least TWO prior systemic therapies (please specify intolerance or contraindication)</p>	

Product Name: Copiktra	
Diagnosis	T-cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Copiktra therapy

Product Name: Copiktra	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Copiktra	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Copiktra therapy</p>	

Copper Chelating Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-149088
<b>Guideline Name</b>	Copper Chelating Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Depen Titratabs, generic penicillamine tablets	
Diagnosis	Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe active rheumatoid arthritis</p>	

Product Name: Brand Depen Titratabs, generic penicillamine tablets	
Diagnosis	Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name: Brand Depen Titratabs, generic penicillamine tablets	
Diagnosis	Wilson's disease, Cystinuria
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Wilson's disease (i.e., hepatolenticular degeneration)</li> <li>• Cystinuria</li> </ul>	

Product Name: Brand Cuprimine, generic penicillamine capsules	
Diagnosis	Wilson's disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration)</p>	

**AND**

**2** - ONE of the following:

**2.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- penicillamine tablets (generic Depen Titratabs)
- trientine 250 mg capsules (generic Syprine)

**OR**

**2.2** History of intolerance to BOTH of the following (please specify intolerance):

- penicillamine tablets (generic Depen Titratabs)
- trientine 250 mg capsules (generic Syprine)

Product Name: Brand Cuprimine, generic penicillamine capsules	
Diagnosis	Cystinuria, Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Cystinuria</li> <li>• Severe active rheumatoid arthritis</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p>	

**2.1** Failure to penicillamine tablets (generic Depen Titratabs) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance to penicillamine tablets (generic Depen Titratabs) (please specify intolerance)

Product Name: Brand Cuprimine, generic penicillamine capsules

Diagnosis	Wilson's disease, Cystinuria, Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

Product Name: Brand Syprine, generic trientine hcl 250 mg capsules

Diagnosis	Wilson's disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration)

Product Name: Brand Syprine, generic trientine hcl 250 mg capsules

Diagnosis	Wilson's disease
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name:trientine hcl 500 mg capsules	
Diagnosis	Wilson's disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure to BOTH of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• penicillamine tablets (generic Depen Titratabs)</li> <li>• trientine 250 mg capsules (generic Syprine)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• penicillamine tablets (generic Depen Titratabs)</li> <li>• trientine 250 mg capsules (generic Syprine)</li> </ul>	

Product Name:trientine hcl 500 mg capsules	
Diagnosis	Wilson's disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

## 2 . Revision History

Date	Notes
6/28/2024	Updated trial/failure requirements for Cuprimine, Syprine, and trientine 500 mg capsules.

Corlanor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158165
<b>Guideline Name</b>	Corlanor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brand Corlanor, generic ivabradine	
Diagnosis	Symptomatic Chronic Heart Failure
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p><b>1.1</b> Worsening heart failure in a diagnosis of stable, symptomatic, chronic [e.g., New York Heart Association (NYHA) class II, III, or IV] heart failure</p>	

**AND**

**1.2** Patient has a left ventricular ejection fraction (EF) less than or equal to 35%

**AND**

**1.3** The patient is in sinus rhythm

**AND**

**1.4** Patient has a resting heart rate greater than or equal to 70 beats per minute

**AND**

**1.5** ONE of the following:

**1.5.1** Patient is on a stabilized dose and receiving concomitant therapy with maximum tolerated beta blocker (e.g., carvedilol, metoprolol succinate, bisoprolol) as confirmed by claims history or submission of medical records

**OR**

**1.5.2** Patient has a contraindication or intolerance to beta-blocker therapy (please specify contraindication or intolerance)

**AND**

**1.6** ONE of the following:

**1.6.1** Patient is on a stabilized dose and receiving concomitant therapy with Farxiga (includes combination products containing dapagliflozin) as confirmed by claims history or submission of medical records

**OR**

**1.6.2** Patient has a contraindication or intolerance to SGLT2 (sodium-glucose co-transporter 2) inhibitor therapy (please specify contraindication or intolerance)

**AND**

**1.7** ONE of the following:

**1.7.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following, as confirmed by claims history or submission of medical records:

**1.7.1.1** Angiotensin-converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)

**OR**

**1.7.1.2** Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**OR**

**1.7.1.3** Angiotensin receptor-neprilysin inhibitor (ARNI) (e.g., Entresto)

**OR**

**1.7.2** Patient has a contraindication or intolerance to ACE inhibitors, ARBs, and ARNIs (please specify contraindication or intolerance)

**AND**

**1.8** ONE of the following:

**1.8.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated aldosterone antagonist (e.g., eplerenone, spironolactone) as confirmed by claims history or submission of medical records

**OR**

**1.8.2** Patient has a contraindication or intolerance to aldosterone antagonist therapy (please specify contraindication or intolerance)

**AND**

**1.9** Prescribed by or in consultation with a cardiologist

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of stable symptomatic heart failure due to dilated cardiomyopathy (DCM)

**AND**

**2.2** Patient is in sinus rhythm

**AND**

**2.3** Patient has an elevated heart rate

**AND**

**2.4** Prescribed by or in consultation with a cardiologist

**OR**

**3** - Patient is currently established on Corlanor therapy

Product Name:Brand Corlanor, generic ivabradine	
Diagnosis	Inappropriate Sinus Tachycardia (IST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - All of the following</p> <p><b>1.1</b> Diagnosis of inappropriate sinus tachycardia (IST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Patient is in sinus rhythm</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> One of the following:</p> <ul style="list-style-type: none"> <li>• Patient has tried and failed or had an inadequate response to a beta blocker (e.g., carvedilol, metoprolol succinate, bisoprolol) as confirmed by claims history or submission of medical records</li> <li>• Patient has a contraindication or intolerance to beta-blocker therapy (please specify contraindication or intolerance)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.4</b> Prescribed by or in consultation with a cardiologist</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - Patient is currently established on Corlanor therapy</p>	

Product Name: Brand Corlanor, generic ivabradine	
Diagnosis	Symptomatic Chronic Heart Failure, Inappropriate Sinus Tachycardia (IST)
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Corlanor therapy</p>	

## 2 . Revision History

Date	Notes
10/29/2024	Added generic ivabradine. Updated product names.

Cosentyx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180202
<b>Guideline Name</b>	Cosentyx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Cosentyx	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate to severe plaque psoriasis

**AND**

2 - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**AND**

4 - ONE of the following:

4.1 Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records

**OR**

4.2 BOTH of the following:

4.2.1 ONE of the following:

4.2.1.1 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab), Enbrel (etanercept)]

**OR**

**4.2.1.2** ALL of the following:

**4.2.1.2.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**4.2.1.2.2** ONE of the following:

- Failure of ONE of the following confirmed by claims history or submitted medical records: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar
- History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication): Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar

**AND**

**4.2.1.2.3** ONE of the following:

- Failure of a 3 month trial of methotrexate, at the maximally indicated doses, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**AND**

**4.2.2** ONE of the following:

**4.2.2.1** Failure to TWO of the following preferred products as confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

Notes

\*See PDL links in Background

Product Name: Cosentyx

Diagnosis Ankylosing Spondylitis

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of active ankylosing spondylitis

**AND**

**2** - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** BOTH of the following:

**4.2.1** ONE of the following:

**4.2.1.1** Failure to TWO NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks confirmed by claims history or submitted medical records

**OR**

**4.2.1.2** History of intolerance or contraindication to TWO NSAIDs (please specify intolerance or contraindication)

**OR**

**4.2.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib), Rinvoq (upadacitinib), Enbrel (etanercept)]

**AND**

**4.2.2** ONE of the following:

- Failure of BOTH of the following confirmed by claims history or submitted medical records: One of the preferred adalimumab products\*, Enbrel (etanercept)
- History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication): One of the preferred adalimumab products\*, Enbrel (etanercept)

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Cosentyx	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a rheumatologist OR dermatologist</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - ONE of the following:</p> <p>4.1 Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>4.2 BOTH of the following:</p> <p>4.2.1 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure of a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submitted medical records</li> <li>• History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)</li> <li>• Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab),</li> </ul>	

ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Enbrel (etanercept)]

**AND**

**4.2.2 ONE of the following:**

**4.2.2.1 Failure to TWO of the following confirmed by claims history or submitted medical records:**

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2 History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):**

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

Notes

\*See PDL links in Background

Product Name: Cosentyx

Diagnosis	Non-radiographic axial spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of active non-radiographic axial spondyloarthritis

**AND**

**2** - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ONE of the following:

**4.2.1** Failure to TWO NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks confirmed by claims history or submitted medical records

**OR**

**4.2.2** History of intolerance or contraindication to TWO NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**4.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of non-radiographic axial spondyloarthritis as confirmed by claims history or submission of medical records [e.g., adalimumab, Cimzia (certolizumab), Simponi (golimumab)]

Product Name: Cosentyx

Diagnosis

Enthesitis-Related Arthritis

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of active enthesitis-related arthritis</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - ONE of the following:</b></p> <p><b>2.1</b> Failure to TWO NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to TWO NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.3</b> Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), adalimumab, Cimzia (certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Prescribed by or in consultation with a rheumatologist</b></p>	

Product Name: Cosentyx	
Diagnosis	Hidradenitis Suppurativa (HS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to at least ONE oral antibiotic (e.g., doxycycline, clindamycin, rifampin) at maximally indicated doses, as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to at least ONE oral antibiotic (e.g., doxycycline, clindamycin, rifampin) (please specify contraindication or intolerance)</li> <li>• Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of hidradenitis suppurativa as confirmed by claims history or submitted medical records [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)].</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to at least one of the preferred adalimumab products* as confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to one of the preferred adalimumab products* (please specify contraindication or intolerance)</li> <li>• Patient is currently on Cosentyx therapy as confirmed by claims history or submission of medical records</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator</p>	

[e.g., adalimumab, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**5** - Prescribed by or in consultation with a dermatologist

Notes

\*See PDL links in Background

**Product Name: Cosentyx**

Diagnosis	Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis (PsA), Non-radiographic Axial Spondyloarthritis, Enthesitis-Related Arthritis, Hidradenitis Suppurativa (HS)
-----------	--

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Documentation of positive clinical response to Cosentyx therapy

**AND**

2 - Patient is NOT receiving Cosentyx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\*

Notes

\* Examples of drug(s) may not be applicable based on the requested indication.

**2 . Background**

**Benefit/Coverage/Program Information**

**PDL Links:**

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
2/20/2025	Updated formularies. Removed reference to brand Stelara. Removed Ilumya step in PsO section – and added preferred ustekinumab as step therapy option in PsO and PsA. Removed requirement that one of the steps in PsO must be adalimumab. Updated step therapy bypass in HS section to bypass oral antibiotic therapy for patients with a history of targeted immunomodulator therapy and bypass for adalimumab section for current utilizers.

Cotellic



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163877
<b>Guideline Name</b>	Cotellic
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Cotellic	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of melanoma</p>	

**AND**

**2** - ONE of the following:

**2.1** Patient has unacceptable toxicities to Tafinlar (dabrafenib)/Mekinist (trametinib) on the basis of agent side-effect profile

**OR**

**2.2** Disease is one of the following:

- Relapsed greater than 3 months after treatment discontinuation
- Unresectable
- Metastatic

**AND**

**3** - Disease is positive for ONE of the following mutations:

- BRAF V600E
- BRAF V600K

**AND**

**4** - Used in combination with Zelboraf (vemurafenib)

<b>Product Name:Cotellic</b>	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - One of the following:**

- Circumscribed glioma
- Glioblastoma
- Limited brain metastases
- Extensive brain metastases

**AND**

**2 - Disease is BRAF V600E positive**

**AND**

**3 - Used in combination with Zelboraf (vemurafenib)**

Product Name:Cotellic	
Diagnosis	Melanoma, Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Patient does not show evidence of progressive disease while on Cotellic therapy</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Used in combination with Zelboraf (vemurafenib)</b></p>	

Product Name:Cotellic	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following histiocytic neoplasms:</p> <ul style="list-style-type: none"> <li>• Langerhans cell histiocytosis</li> <li>• Erdheim-Chester disease</li> </ul>	

Product Name:Cotellic	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Cotellic therapy</p>	

Product Name:Cotellic	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Cotellic
-----------------------

Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Cotellic therapy</p>	

## 2 . Revision History

Date	Notes
1/16/2025	Updated melanoma, central nervous system cancers, and histiocytic neoplasms criteria

Cuvrior



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148965
<b>Guideline Name</b>	Cuvrior
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Cuvrior	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Wilson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is de-coppered [i.e., serum non-ceruloplasmin copper (NCC) level greater than or equal to 25 and less than or equal to 150 mcg/L (micrograms/liter)]

**AND**

**3** - Patient is tolerant to penicillamine

**AND**

**4** - Prescriber provides a reason or special circumstance why the patient cannot use penicillamine tablets (generic Depen Titratabs)

**AND**

**5** - ONE of the following:

**5.1** Failure to trientine 250 mg capsules (generic Syprine) as confirmed by claims history or submission of medical records

**OR**

**5.2** History of intolerance to trientine 250 mg capsules (generic Syprine) (please specify intolerance)

**AND**

**6** - Prescribed by a hepatologist

Product Name:Cuvrior	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Cuvrior therapy (e.g., increased 24-hour urinary copper excretion from baseline, normalization of serum free copper, prevention of or improvement in symptoms)

**AND**

2 - Prescribed by a hepatologist

**2 . Revision History**

Date	Notes
6/26/2024	Updated language on why pt must switch from preferred penicillamine agent, added step through trientine 250 mg capsules, added prescriber requirement, and updated initial/reauth durations to 12 months.

Cystaran, Cystadrops



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164695
<b>Guideline Name</b>	Cystaran, Cystadrops
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Cystaran, Cystadrops	
Diagnosis	Cystinosis
Approval Length	12 month(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystinosis</p>	

## 2 . Revision History

Date	Notes
2/4/2025	Adding Indiana and PA Medicaid formularies. No change to clinical criteria.

Daliresp



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-165155
<b>Guideline Name</b>	Daliresp
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Daliresp, generic roflumilast	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of chronic obstructive pulmonary disease (COPD)

## 2 . Revision History

Date	Notes
2/13/2025	Updated formularies. Removed all criteria except diagnosis check

Danziten



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-173219
<b>Guideline Name</b>	Danziten
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Danziten	
Diagnosis	Chronic Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic myeloid leukemia

Product Name:Danziten

Diagnosis	Acute Lymphoblastic Leukemia (Ph+B-ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL)

Product Name:Danziten

Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor

Product Name:Danziten

Diagnosis	Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia (Ph+B-ALL), Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Danziten therapy</p>	

Product Name:Danziten	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Danziten	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Danziten therapy</p>	

## 2 . Revision History

Date	Notes
------	-------

2/18/2025	New program
-----------	-------------

Daraprim



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146505
<b>Guideline Name</b>	Daraprim
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Daraprim, generic pyrimethamine	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ONE of the following:</p> <p>1.1 Treatment of severe acquired toxoplasmosis, including toxoplasmic encephalitis</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2 Treatment of congenital toxoplasmosis**

**OR**

**1.3 Secondary prophylaxis of toxoplasmic encephalitis**

**OR**

**1.4 ALL of the following:**

**1.4.1** Primary pneumocystis pneumonia (PCP) prophylaxis in human immunodeficiency virus (HIV)-infected patients or as secondary prophylaxis in HIV-infected patients who have been treated for an acute episode of pneumocystis pneumonia

**AND**

**1.4.2** Patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX)

**AND**

**1.4.3** One of the following:

**1.4.3.1** Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX) using a desensitization protocol and is still unable to tolerate

**OR**

**1.4.3.2** Evidence of moderately severe or life threatening-reaction to trimethoprim-sulfamethoxazole (TMP-SMX) in the past [e.g., toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome]

**OR**

**1.5 ALL of the following:**

**1.5.1** Primary prophylaxis of toxoplasmic encephalitis

**AND**

**1.5.2** Toxoplasma immunoglobulin G (IgG) positive

**AND**

**1.5.3** CD4 (cluster of differentiation 4) less than or equal to 100 cells per mm<sup>3</sup> if initiating prophylaxis or CD4 100-200 cells per mm<sup>3</sup> if reinstating prophylaxis\*

**AND**

**1.5.4** Will be used in combination with dapsone or atovaquone

**AND**

**1.5.5** Patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX)

**AND**

**1.5.6** ONE of the following:

**1.5.6.1** Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX) using a desensitization protocol and is still unable to tolerate

**OR**

**1.5.6.2** Evidence of moderately severe or life threatening-reaction to trimethoprim-sulfamethoxazole (TMP-SMX) in the past [e.g., toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome]

Notes

\*Consider discontinuation of primary prophylaxis if CD4 > 200 cells/mm<sup>3</sup> for > 3 months after institution of combination antiretroviral therapy.

Product Name: Brand Daraprim*, generic pyrimethamine*	
Guideline Type	Reject 88 - Therapeutic Duplication
<p><b>Approval Criteria</b></p> <p>1 - There is a reason or special circumstances why the patient must be on Daraprim (pyrimethamine) commercial tablets and a compound containing pyrimethamine at the same time</p>	
Notes	*Approval Length: 2 months (if deemed medically necessary for long-term use by the prescriber, authorization will be issued for 12 months)

Daurismo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-181191
<b>Guideline Name</b>	Daurismo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Daurismo	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - ONE of the following:**

**1.1** Diagnosis of newly-diagnosed acute myeloid leukemia (AML)

**OR**

**1.2** Relapsed/refractory disease with ALL of the following:

**1.2.1** Given as a component of repeating the initial successful induction regimen

**AND**

**1.2.2** Late relapse (greater than or equal to 12 months since induction regimen)

**AND**

**1.2.3** Initial therapy was not administered continuously

**AND**

**1.2.4** Initial therapy was not stopped due to development of clinical resistance

**AND**

**2 -** Daurismo therapy to be given in combination with low-dose cytarabine

**AND**

**3 - ONE of the following:**

**3.1** Patient is at least 75 years old

**OR**

**3.2** Patient has significant comorbidities that preclude the use of intensive induction chemotherapy [e.g., severe cardiac disease, Eastern Cooperative Oncology Group (ECOG) performance status greater than or equal to 2, baseline creatinine greater than 1.3 milligrams/deciliter]

Product Name:Daurismo	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Daurismo therapy</p>	

Product Name:Daurismo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Daurismo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Daurismo therapy</p>	

## 2 . Revision History

Date	Notes
2/20/2025	Combined formularies. No changes to clinical criteria.

Daybue



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150913
<b>Guideline Name</b>	Daybue
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/3/2024
-----------------	----------

## 1 . Criteria

Product Name:Daybue	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Rett Syndrome (RTT) confirmed by ONE of the following:</p> <p>1.1 ALL of the following clinical signs and symptoms:</p> <ul style="list-style-type: none"> <li>A pattern of development, regression, then recovery or stabilization</li> </ul>	

- Partial or complete loss of purposeful hand skills such as grasping with fingers, reaching for things, or touching things on purpose
- Partial or complete loss of spoken language
- Repetitive hand movements, such as wringing the hands, washing, squeezing, clapping, or rubbing
- Gait abnormalities, including walking on toes or with an unsteady, wide-based, stiff-legged gait

**OR**

**1.2** Confirmed genetic mutation in the MECP2 gene

**AND**

**2** - Prescribed by, or in consultation with, **ONE** of the following:

- Geneticist
- Pediatrician who specializes in childhood neurological or developmental disorders
- Neurologist

Product Name:Daybue	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Daybue therapy	

## 2 . Revision History

Date	Notes
8/2/2024	Updated initial approval duration from 6 months to 12 months.

DEKAs Plus



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146316
<b>Guideline Name</b>	DEKAs Plus
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:DEKAs Plus Ocean, DEKAs Plus	
Diagnosis	Cystic Fibrosis
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis</p>	

Descovy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-202203
<b>Guideline Name</b>	Descovy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Descovy	
Diagnosis	Human Immunodeficiency Virus-1 (HIV-1)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of human immunodeficiency virus-1 (HIV-1)**

**AND**

**2 - ONE of the following:**

**2.1** Submission of medical records documenting a history of adverse event or intolerance to prior use of emtricitabine/tenofovir disoproxil fumarate (generic Truvada)

**OR**

**2.2** Patient is currently on Descovy therapy

**OR**

**2.3** Submission of medical records documenting an estimated GFR (glomerular filtration rate) below 90 mL/min (milliliters/minute)

**OR**

**2.4** Submission of medical records documenting a diagnosis of osteoporosis as defined by a BMD (bone mineral density) T-score less than or equal to -2.5 based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) [Provider must submit patient specific BMD T-score]

**OR**

**2.5** Submission of medical records documenting a prior low-trauma or non-traumatic fracture

**OR**

**2.6** Patient is less than 20 years of age

**OR**

**2.7** Submission of medical records documenting a diagnosis of osteopenia as defined by a BMD T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) [Provider must submit patient specific BMD T-scores] with evidence of progressive bone loss on serial DEXA (dual-energy X-ray absorptiometry) scan

Product Name:Descovy	
Diagnosis	Post-Exposure Prophylaxis (PEP)
Approval Length	4 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of post-exposure prophylaxis (PEP)</p>	

Product Name:Descovy 200/25 mg	
Diagnosis	HIV-1 Pre-Exposure Prophylaxis (PrEP)
Approval Length	Authorization will be issued for 12 months at GPI-14 level to approve only the 200/25mg strength
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Request is for 200/25 mg strength</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used for HIV-1 pre-exposure prophylaxis (PrEP)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p>	

**3.1** Submission of medical records documenting a history of adverse event or intolerance to prior use of emtricitabine/tenofovir disoproxil fumarate (generic Truvada)

**OR**

**3.2** Submission of medical records documenting an estimated GFR (glomerular filtration rate) below 90 mL/min (milliliters/minute)

**OR**

**3.3** Submission of medical records documenting a diagnosis of osteoporosis as defined by a BMD (bone mineral density) T-score less than or equal to -2.5 based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) [Provider must submit patient specific BMD T-score]

**OR**

**3.4** Submission of medical records documenting a prior low-trauma or non-traumatic fracture

**OR**

**3.5** Patient is less than 20 years of age

**OR**

**3.6** Submission of medical records documenting a diagnosis of osteopenia as defined by a BMD T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) [Provider must submit patient specific BMD T-scores] with evidence of progressive bone loss on serial DEXA (dual-energy X-ray absorptiometry) scan

## 2 . Revision History

Date	Notes
------	-------

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

2/27/2025	Combined formularies, but removed NY and NY EPP from markets in scope as Descovy moving to open access for these markets. No changes to criteria.
-----------	---

Dificid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154718
<b>Guideline Name</b>	Dificid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Dificid	
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Clostridioides difficile-associated diarrhea (CDAD) [previously known as Clostridium difficile-associated diarrhea]</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Failure to one of the following:

- Firvanq (vancomycin) oral solution
- vancomycin 125 mg or 250 mg capsules
- vancomycin 25 mg/ml or 50 mg/ml oral solution

**OR**

**2.2** History of intolerance or contraindication to all of the following: (please specify intolerance or contraindication)

- Firvanq (vancomycin) oral solution
- vancomycin 125 mg or 250 mg capsules
- vancomycin 25 mg/ml or 50 mg/ml oral solution

**OR**

**2.3** For continuation of prior Difucid therapy

Dojolvi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149530
<b>Guideline Name</b>	Dojolvi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/3/2024
-----------------	----------

## 1 . Criteria

Product Name:Dojolvi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records confirming the diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD) with at least two of the following diagnostic criteria:</p> <ul style="list-style-type: none"> <li>Disease specific elevation of acyl-carnitines on a newborn blood spot or in plasma</li> <li>Low enzyme activity in cultured fibroblasts</li> </ul>	

- Genetic testing demonstrating one or more pathogenic mutations in a gene associated with long-chain fatty acid oxidation disorders (e.g., CPT2, ACADVL, HADHA, or HADHB)

**AND**

**2** - Patient is not receiving Dojolvi in combination with any other medium-chain triglyceride (MCT) products

**AND**

**3** - Prescribed by a board certified medical geneticist experienced in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD)

**AND**

**4** - Target recommended daily dosage does not exceed 35% of the patient's total prescribed daily caloric intake (DCI)

**AND**

**5** - Patient is receiving disease related dietary management

**AND**

**6** - If not diagnosed by newborn screening, patient has a history of clinical manifestations of long-chain fatty acid oxidation disorders LC-FAOD (e.g., rhabdomyolysis)

Product Name:Dojolvi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Dojolvi therapy (e.g., increased cardiac efficiency, decreased left ventricular wall mass, decreased incidence of rhabdomyolysis, etc.)

**AND**

**2** - Patient is not receiving Dojolvi in combination with any other medium-chain triglyceride (MCT) product

**AND**

**3** - Prescribed by a board certified medical geneticist experienced in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD)

**AND**

**4** - Target recommended daily dosage does not exceed 35% of the patient's total prescribed daily caloric intake (DCI)

**AND**

**5** - Patient is receiving disease related dietary management

**2 . Revision History**

Date	Notes
7/3/2024	New guideline.

Donepezil 23mg



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146319
<b>Guideline Name</b>	Donepezil 23mg
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic donepezil 23 mg	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Failure to donepezil at a minimum dose of 10 mg (milligrams) daily for 90 days, as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - History of contraindication or intolerance to donepezil 10 mg (please specify contraindication or intolerance)

Doptelet



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180207
<b>Guideline Name</b>	Doptelet
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Doptelet	
Diagnosis	Thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure
Approval Length	1 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of thrombocytopenia

**AND**

2 - Patient has chronic liver disease

**AND**

3 - Patient is scheduled to undergo a procedure

**AND**

4 - ONE of the following:

4.1 Failure to Mulpleta (lusutrombopag) as confirmed by claims history or submission of medical records

**OR**

4.2 History of contraindication or intolerance to Mulpleta (lusutrombopag) (please specify contraindication or intolerance)

<b>Product Name:Doptelet</b>	
Diagnosis	Chronic Immune Thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of chronic immune thrombocytopenia (ITP)

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 ONE of the following:

2.1.1.1 Failure to at least ONE of the following as confirmed by claims history or submission of medical records:

- Corticosteroids
- Immunoglobulins

**OR**

2.1.1.2 History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Corticosteroids
- Immunoglobulins

**AND**

2.1.2 ONE of the following:

2.1.2.1 Failure to Promacta (eltrombopag) as confirmed by claims history or submission of medical records

**OR**

2.1.2.2 History of contraindication or intolerance to Promacta (eltrombopag) (please specify contraindication or intolerance)

**OR**

**2.2** Patient is currently on Doptelet therapy

Product Name:Doptelet	
Diagnosis	Chronic Immune Thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Doptelet therapy</p>	

## 2 . Revision History

Date	Notes
2/20/2025	Updated formularies

DPP-4 Inhibitors



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-197189
<b>Guideline Name</b>	DPP-4 Inhibitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Alogliptin, Alogliptin/metformin, Alogliptin/pioglitazone, Brand Onglyza, generic saxagliptin	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values:

- A1C greater than or equal to 6.5%
- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**2** - For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

Product Name:Nesina, Kazano, Oseni	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values:</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed</p>	

greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**2** - The prescriber has given a clinical reason or special circumstance why the patient is unable to use ONE of the following (please document reason/special circumstance):

- Alogliptin (authorized generic of Nesina)
- Alogliptin/metformin (authorized generic of Kazano)
- Alogliptin/pioglitazone (authorized generic of Oseni)

Product Name:Nesina, Kazano, Oseni	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy (e.g., improved A1C)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The prescriber has given a clinical reason or special circumstance why the patient is unable to use ONE of the following (please document reason/special circumstance):</p> <ul style="list-style-type: none"> <li>• Alogliptin (authorized generic of Nesina)</li> <li>• Alogliptin/metformin (authorized generic of Kazano)</li> <li>• Alogliptin/pioglitazone (authorized generic of Oseni)</li> </ul>	

Product Name:Januvia, Janumet, Janumet XR, Brand Kombiglyze XR, generic saxagliptin/metformin ER, Tradjenta, Jentadueto, Jentadueto XR, Zituvimet, Zituvimet XR, Zituvio, Sitagliptin, Sitagliptin/metformin	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following:</b></p> <p><b>1.1</b> Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values:</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - ONE of the following:</b></p> <p><b>2.1</b> Failure to a 90 day trial with ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Alogliptin (authorized generic of Nesina)</li> <li>• Alogliptin/metformin (authorized generic of Kazano)</li> <li>• Alogliptin/pioglitazone (authorized generic of Oseni)</li> <li>• Saxagliptin (generic Onglyza)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication)</p> <ul style="list-style-type: none"> <li>• Alogliptin (authorized generic of Nesina)</li> </ul>	

- Alogliptin/metformin (authorized generic of Kazano)
- Alogliptin/pioglitazone (authorized generic of Oseni)
- Saxagliptin (generic Onglyza)

Product Name: Januvia, Janumet, Janumet XR, Brand Kombiglyze XR, generic saxagliptin/metformin ER, Tradjenta, Jentadueto, Jentadueto XR, Zituvimet, Zituvimet XR, Zituvio, Sitagliptin, Sitagliptin/metformin	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy (e.g., improved A1C)</p>	

## 2 . Revision History

Date	Notes
2/25/2025	Moved Onglyza to diagnosis only and added generic Onglyza to list of step therapy options. Updated criteria to remove step through metformin therapy throughout. Added reauthorization criteria to all sections that are not automated with DX2RX. Updated diabetes diagnosis check in alignment with other diabetic classes. Separated preferred authorized generic with branded versions to ensure appropriate MSC M review would occur

Dry Eye Disease



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154758
<b>Guideline Name</b>	Dry Eye Disease
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Restasis Multidose, Brand Restasis, Cequa, Tyrvaya, Vevye, Miebo, Xiidra	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Tear deficiency associated with ocular inflammation due to ONE of the following:</p> <ul style="list-style-type: none"> <li>Moderate to severe keratoconjunctivitis sicca</li> <li>Moderate to severe dry eye disease</li> </ul>	

**AND**

**2** - Not prescribed to manage dry eyes peri-operative elective eye surgery [e.g., LASIK (laser-assisted in situ keratomileusis)]

**AND**

**3** - Failure to at least one OTC (over-the-counter) artificial tear product (e.g., Systane Ultra, Akwa Tears, Refresh Optive, Soothe XP) as confirmed by claims history or submission of medical records

**AND**

**4** - One of the following:

**4.1** Failure to cyclosporine emulsion 0.05% (generic Restasis) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to cyclosporine emulsion 0.05% (generic Restasis) (please specify contraindication or intolerance)

**AND**

**5** - Medication will not be used in combination with another prescription product for dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single dose-vials, Tyrvaya, Xiidra)

**AND**

**6** - Prescribed by or in consultation with one of the following:

- Ophthalmologist
- Optometrist
- Rheumatologist

Product Name:generic cyclosporine	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Tear deficiency associated with ocular inflammation due to ONE of the following:</p> <ul style="list-style-type: none"> <li>• Moderate to severe keratoconjunctivitis sicca</li> <li>• Moderate to severe dry eye disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Not prescribed to manage dry eyes peri-operative elective eye surgery [e.g., LASIK (laser-assisted in situ keratomileusis)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Failure to at least one OTC (over-the-counter) artificial tear product (e.g., Systane Ultra, Akwa Tears, Refresh Optive, Soothe XP) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Medication will not be used in combination with another prescription product for dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single dose-vials, Tyrvaya, Xiidra)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed by or in consultation with one of the following:</p> <ul style="list-style-type: none"> <li>• Ophthalmologist</li> <li>• Optometrist</li> <li>• Rheumatologist</li> </ul>	

Product Name: Restasis Multidose, Brand Restasis, generic cyclosporine, Xiidra, Cequa, Tyrvaya, Vevye, Miebo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has demonstrated clinically significant improvement with therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Medication will not be used in combination with another prescription product for dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single dose-vials, Tyrvaya, Xiidra)</p>	

Duexis and Vimovo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146887
<b>Guideline Name</b>	Duexis and Vimovo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Duexis, generic ibuprofen/famotidine	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following risk factors for NSAID (non-steroidal anti-inflammatory drug)-induced adverse GI (gastrointestinal) events:</p> <ul style="list-style-type: none"> <li>Patient is greater than or equal to 65 years of age</li> <li>Prior history of peptic, gastric, or duodenal ulcer</li> <li>History of NSAID-related ulcer</li> <li>History of clinically significant GI bleeding</li> </ul>	

- Untreated or active H. Pylori (helicobacter pylori) gastritis
- Concurrent use of oral corticosteroids (e.g., prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (e.g., warfarin, heparin)
- Concurrent use of antiplatelets (e.g., aspirin including low-dose, clopidogrel)

**AND**

**2** - ONE of the following:

**2.1** Failure to THREE combinations of preferred\* NSAIDS, one of which must be celecoxib (generic Celebrex), taken concomitantly with preferred\* H2-receptor antagonists, as confirmed by claims history or submitted medical records

**OR**

**2.2** History of contraindication or intolerance to ALL preferred\* NSAIDs and ALL preferred\* H2-receptor antagonists (please specify contraindication or intolerance)

**AND**

**3** - Physician has provided rationale for needing to use fixed-dose combination therapy with Duexis instead of taking individual products in combination

Notes	*PDL links in Background
-------	--------------------------

Product Name:Brand Vimovo, generic naproxen/esomeprazole	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following risk factors for NSAID (non-steroidal anti-inflammatory drug)-induced adverse GI (gastrointestinal) events:</p> <ul style="list-style-type: none"> <li>• Patient is greater than or equal to 65 years of age</li> <li>• Prior history of peptic, gastric, or duodenal ulcer</li> <li>• History of NSAID-related ulcer</li> </ul>	

- History of clinically significant GI bleeding
- Untreated or active H. Pylori (helicobacter pylori) gastritis
- Concurrent use of oral corticosteroids (e.g., prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (e.g., warfarin, heparin)
- Concurrent use of antiplatelets (e.g., aspirin including low-dose, clopidogrel)

**AND**

**2** - ONE of the following:

**2.1** Failure to THREE combinations of preferred\* NSAIDS, one of which must be celecoxib (generic Celebrex), taken concomitantly with preferred\* proton pump inhibitors, as confirmed by claims history or submitted medical records

**OR**

**2.2** History of contraindication or intolerance to ALL preferred\* NSAIDs and ALL preferred\* proton pump inhibitors (please specify contraindication or intolerance)

**AND**

**3** - Physician has provided rationale for needing to use fixed-dose combination therapy with Vimovo instead of taking individual products in combination

Notes	*PDL links in Background
-------	--------------------------

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL links</b></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>

## 3 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
4/30/2024	Updated PDL link

Duopa



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164345
<b>Guideline Name</b>	Duopa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Duopa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient experiences a wearing “off” phenomenon that cannot be managed by increasing the dose of oral levodopa

**AND**

**3** - Has undergone or has planned placement of a procedurally-placed tube

**AND**

**4** - Prescribed by or in consultation with a neurologist

Product Name:Duopa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Duopa therapy</p>	

## 2 . Revision History

Date	Notes
1/27/2025	Updated initial auth criteria

Dupixent



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164416
<b>Guideline Name</b>	Dupixent
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Dupixent	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate-to-severe chronic atopic dermatitis</p>	

**AND**

**2** - ONE of the following:

**2.1** Failure to TWO of the following therapeutic classes of topical therapies as confirmed by claims history or submission of medical records:

- One medium, high, or very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**OR**

**2.2** History of contraindication or intolerance to ALL of the following therapeutic classes of topical therapies (please specify contraindication or intolerance):

- One medium, high, or very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**OR**

**2.3** Patient is currently on Dupixent therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Dupixent in combination with either of the following:

- Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]
- Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist
- Immunologist

Product Name: Dupixent	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Dupixent therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Dupixent in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]</li> <li>• Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Allergist</li> <li>• Immunologist</li> </ul>	

Product Name: Dupixent	
Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate-to-severe asthma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 ALL of the following:</p> <p>2.1.1 Classification of asthma as uncontrolled or inadequately controlled as defined by at least ONE of the following:</p> <ul style="list-style-type: none"> <li>• Poor symptom control [e.g., Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20]</li> <li>• Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months</li> <li>• Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)</li> <li>• Airflow limitation [e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second (FEV1) less than 80% predicted (in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal)]</li> <li>• Patient is currently dependent on oral corticosteroids for the treatment of asthma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2.1.2 Dupixent will be used in combination with ONE of the following:</p> <p>2.1.2.1 ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)] (see Table 2 in Background)</p>	

**OR**

**2.1.2.2** Combination therapy including BOTH of the following:

- ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)] (see Table 2 in Background)
- ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist - montelukast (Singulair); theophylline]

**AND**

**2.1.3** ONE of the following:

- Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting that asthma is an eosinophilic phenotype as defined by a baseline (pre-dupilumab treatment) peripheral blood eosinophil level greater than or equal to 150 cells/microliter
- Patient is currently dependent on oral corticosteroids for the treatment of asthma

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is currently on Dupixent therapy as confirmed by claims history or submission of medical records

**AND**

**2.2.2** Dupixent will be used in combination with ONE of the following:

**2.2.2.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**OR**

**2.2.2.2** Combination therapy including BOTH of the following:

- ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]
- ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist – montelukast (Singulair); theophylline]

**AND**

**3** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name: Dupixent	
Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Dupixent therapy as demonstrated by at least ONE of the following:</p> <ul style="list-style-type: none"> <li>• Reduction in the frequency of exacerbations</li> </ul>	

- Decreased utilization of rescue medications
- Increase in percent predicted forced expiratory volume in 1 second (FEV1) from pretreatment baseline
- Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- Reduction in oral corticosteroid requirements

**AND**

**2** - Dupixent will be used in combination with ONE of the following:

**2.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**OR**

**2.2** Combination therapy including BOTH of the following:

- ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]
- ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist – montelukast (Singulair); theophylline]

**AND**

**3** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist

- Pulmonologist

Product Name: Dupixent	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyposis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) defined by ALL of the following:</p> <p>1.1.1 TWO or more of the following symptoms for longer than 12 weeks duration:</p> <ul style="list-style-type: none"> <li>• Nasal mucopurulent discharge</li> <li>• Nasal obstruction, blockage, or congestion</li> <li>• Facial pain, pressure, and/or fullness</li> <li>• Reduction or loss of sense of smell</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 ONE of the following findings using nasal endoscopy and/or sinus computed tomography (CT):</p> <ul style="list-style-type: none"> <li>• Purulent mucus or edema in the middle meatus or ethmoid regions</li> <li>• Polyps in the nasal cavity or the middle meatus</li> <li>• Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of paranasal sinuses</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.1.3 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Presence of bilateral nasal polyposis</li> </ul>	

- Patient has previously required surgical removal of bilateral nasal polyps

**AND**

**1.1.4** ONE of the following:

**1.1.4.1** Patient has required prior sinus surgery

**OR**

**1.1.4.2** Patient has required systemic corticosteroids (e.g., prednisone, methylprednisolone) for CRSwNP in the previous 2 years

**OR**

**1.1.4.3** Patient has been unable to obtain symptom relief after trial of TWO of the following classes of agents:

- Nasal saline irrigations
- Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)
- Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)

**OR**

**1.2** BOTH of the following:

- Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Patient is currently on Dupixent therapy as confirmed by claims history or submission of medical records

**AND**

**2** - Patient will receive Dupixent as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)

**AND**

**3** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist
- Otolaryngologist
- Pulmonologist

Product Name: Dupixent	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyposis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Dupixent therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient will continue to receive Dupixent as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone), as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is NOT receiving Dupixent in combination with any of the following:</p>	

- Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist
- Otolaryngologist
- Pulmonologist

Product Name: Dupixent	
Diagnosis	Eosinophilic Esophagitis
Approval Length	6 month(s)*
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of eosinophilic esophagitis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is experiencing symptoms related to esophageal dysfunction (e.g., dysphagia, food impaction, chest pain that is often centrally located and may not respond to antacids, gastroesophageal reflux disease-like symptoms/refractory heartburn, upper abdominal pain)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting eosinophil-predominant inflammation on esophageal biopsy, consisting of a peak value of 15</p>	

or more intraepithelial eosinophils per high power field (HPF) [or 60 eosinophils per mm<sup>2</sup> (square millimeters)]

**AND**

**4** - Secondary causes of esophageal eosinophilia have been ruled out

**AND**

**5** - Mucosal eosinophilia is isolated to the esophagus and symptoms have persisted after an 8-week trial of at least ONE of the following, as confirmed by claims history or submission of medical records:

- Proton pump inhibitors (e.g., pantoprazole, omeprazole)
- Topical (esophageal) corticosteroids (e.g., budesonide, fluticasone)

**AND**

**6** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**7** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Gastroenterologist

Notes	*If clinical criteria is met, enter a GPI-10 authorization with a MDD of 0.3 mL.
-------	--

Product Name: Dupixent	
Diagnosis	Eosinophilic Esophagitis
Approval Length	6 month(s)*

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Dupixent therapy as evidenced by improvement of at least ONE of the following from baseline:</p> <ul style="list-style-type: none"> <li>• Symptoms (e.g., dysphagia, chest pain, heartburn)</li> <li>• Histologic measures (e.g., esophageal intraepithelial eosinophil count)</li> <li>• Endoscopic measures (e.g., edema, furrows, exudates, rings, strictures)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Dupixent in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab), Nucala (mepolizumab)]</li> <li>• Anti-IgE therapy [e.g., Xolair (omalizumab)]</li> <li>• Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a gastroenterologist or allergist</p>	
Notes	*If clinical criteria is met, enter a GPI-10 authorization with a MDD of 0 .3 mL.

Product Name: Dupixent	
Diagnosis	Prurigo Nodularis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1 - Diagnosis of prurigo nodularis**

**AND**

**2 - Patient has greater than or equal to 20 nodular lesions**

**AND**

**3 - ONE of the following:**

**3.1** Failure to at least one previous prurigo nodularis treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors, topical capsaicin) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to all other prurigo nodularis treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors, topical capsaicin) (please specify contraindication or intolerance)

**AND**

**4 - Patient is NOT receiving Dupixent in combination with either of the following:**

- Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]
- Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

**AND**

**5 - Prescribed by or in consultation with ONE of the following:**

- Dermatologist
- Allergist
- Immunologist

Product Name: Dupixent	
Diagnosis	Prurigo Nodularis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Dupixent therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Dupixent in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]</li> <li>• Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Allergist</li> <li>• Immunologist</li> </ul>	

Product Name: Dupixent	
Diagnosis	Chronic Obstructive Pulmonary Disorder (COPD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1 - Diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)**

**AND**

**2 - Submission of documentation (e.g., medical records, chart notes) of ALL of the following:**

- Post-bronchodilator forced expiratory volume (FEV1) / forced vital capacity (FVC) ratio less than 0.7
- Post-bronchodilator FEV1 % predicted greater than or equal to 30% and less than or equal to 70%
- Patient has an eosinophilic phenotype defined by a baseline (pre-dupilumab treatment) peripheral blood eosinophil level greater than or equal to 300 cells/ $\mu$ L

**AND**

**3 - Uncontrolled or inadequately controlled COPD demonstrated by both of the following:**

**3.1 One of the following:**

- Two or more COPD exacerbations in the previous year requiring treatment with systemic corticosteroids and/or antibiotics
- One or more COPD exacerbation(s) that resulted in hospitalization or observation for over 24 hours in an emergency department or urgent care facility in the past year

**AND**

**3.2 COPD exacerbation(s) occurred while receiving maintenance therapy with one of the following:**

- Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
- Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

**AND**

**4 - Symptoms of chronic productive cough for at least 3 months in the past year**

**AND**

**5** - Dupixent will be used as add-on maintenance therapy with one of the following:

- Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
- Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

**AND**

**6** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**7** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name: Dupixent	
Diagnosis	Chronic Obstructive Pulmonary Disorder (COPD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

## Approval Criteria

**1** - Documentation of a positive clinical response to Dupixent therapy as demonstrated by at least one of the following:

- Reduction in the frequency of COPD exacerbations
- Increase in percent predicted FEV1 from pretreatment baseline
- Reduction in severity or frequency of COPD-related symptoms (e.g., dyspnea, wheezing, cough, sputum volume, decrease in sputum purulence)
- Reduction in oral corticosteroid requirements

**AND**

**2** - Dupixent will be used as add-on maintenance therapy with one of the following:

- Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
- Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

**AND**

**3** - Patient is NOT receiving Dupixent in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenna (benralizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

## 2 . Background

Benefit/Coverage/Program Information			
Table 1: Relative potencies of topical corticosteroids			
Class	Drug	Dosage Form	Strength (%)
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
High Potency	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	tridifloronide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
Triamcinolone acetonide	Cream, ointment	0.5	
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025

	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
	Triamcinolone acetonide	Cream, ointment, lotion	0.1
Lower-medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

**Table 2: Low, medium, and high daily doses of inhaled corticosteroids. Adults and adolescents (12 years of age and older)**

Drug	Daily dose (mcg)		
	Low	Medium	High
Beclomethasone dipropionate (CFC)	200-500	>500-1000	>1000
Beclomethasone dipropionate (HFA)	100-200	>200-400	>400
Budesonide DPI	200-400	>400-800	>800
Ciclesonide (HFA)	80-160	>160-320	>320
Fluticasone furoate (DPI)	100	N/A	200
Fluticasone propionate (DPI)	100-250	>250-500	>500

Fluticasone propionate (HFA)	100-250	>250-500	>500
Mometasone furoate	110-220	>220-440	>440
Triamcinolone acetonide	400-1000	>1000-2000	>2000

### 3 . Revision History

Date	Notes
1/28/2025	Updated prescriber check language throughout to be consistent and allow for consultation

Duvyzat



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155733
<b>Guideline Name</b>	Duvyzat
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Duvyzat	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Duchenne muscular dystrophy (DMD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Diagnosis confirmed by the presence of a mutation in the DMD gene

**AND**

**3** - Patient is 6 years of age or older

**AND**

**4** - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**5** - Patient has been or will be established on a stable corticosteroid regimen

**AND**

**6** - Prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD

**AND**

**7** - Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene moxparvovec-rokl)]

**AND**

**8** - Patient will not receive Duvyzat in combination with exon-skipping therapies for DMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltespo (viltolarsen), Vyondys 53 (golodirsen)]

Product Name:Duvyzat

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Physician attestation that patient would benefit from continued administration</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient continues to receive concomitant corticosteroid regimen</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene moxparvovec-rokl)]</p> <p style="text-align: center;"><b>AND</b></p> <p>6 - Patient will not receive Duvyzat in combination with exon-skipping therapies for DMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), Vyondys 53 (golodirsen)]</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
9/23/2024	New guideline.

Egrifta



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146510
<b>Guideline Name</b>	Egrifta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Egrifta SV	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of human immunodeficiency virus (HIV)-associated lipodystrophy</p>	

Elmiron



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146325
<b>Guideline Name</b>	Elmiron
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Elmiron	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a documented diagnosis of bladder pain or discomfort associated with interstitial cystitis</p>	

Emflaza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161235
<b>Guideline Name</b>	Emflaza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brand Emflaza, generic deflazacort	
Diagnosis	Duchenne Muscular Dystrophy
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Published clinical evidence shows Emflaza is likely to produce equivalent therapeutic results as other available corticosteroids (e.g., prednisone); therefore, Emflaza is not medically necessary for treatment of Duchenne muscular dystrophy</p>	
Notes	All requests for authorization will be denied by OptumRx and must be submitted through the appeals process to the UnitedHealthcare Community Plan Pharmacy Appeals team for consideration.

## 2 . Revision History

Date	Notes
11/25/2024	Updated GPs and product list to add generic

Empaveli



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148077
<b>Guideline Name</b>	Empaveli
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Empaveli	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as confirmed by BOTH of the following:</p> <p>1.1 Flow cytometry analysis confirming presence of PNH clones</p>	

**AND**

**1.2** Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia, unexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease, pulmonary hypertension, etc.)

**AND**

**2** - ONE of the following:

**2.1** Patient will not be prescribed Empaveli in combination with another complement inhibitor used for the treatment of PNH (e.g., Fabhalta, Soliris, Ultomiris)

**OR**

**2.2** Patient is currently receiving another complement inhibitor (e.g., Fabhalta, Soliris, Ultomiris) which will be discontinued and Empaveli will be initiated in accordance with the United States Food and Drug Administration approved labeling

**AND**

**3** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

Product Name:Empaveli	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Documentation of positive clinical response to Empaveli therapy [e.g., increased or stabilization of hemoglobin levels, reduction in transfusions, improvement in hemolysis, decrease in LDH (lactate dehydrogenase), increased reticulocyte count, etc.]

**AND**

**2** - Patient is not receiving Empaveli in combination with another complement inhibitor used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) (e.g., Fabhalta, Soliris, Ultomiris)

**AND**

**3** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

## 2 . Revision History

Date	Notes
6/4/2024	In initial auth section, simplified criteria language for converting to new complement inhibitor therapy.

Enbrel



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180212
<b>Guideline Name</b>	Enbrel
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Enbrel	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - All of the following:

1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

1.2 ONE of the following:

1.2.1 Failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses, confirmed by claims history or submission of medical records

**OR**

1.2.2 History of intolerance or contraindication to one non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of rheumatoid arthritis confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

1.3 Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

1.4 Prescribed by or in consultation with a rheumatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Enbrel therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active rheumatoid arthritis

**AND**

**2.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Product Name:Enbrel	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis	

**AND**

**2** - Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Product Name:Enbrel	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - All of the following:</p> <p><b>1.1</b> Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> ONE of the following:</p> <p><b>1.2.1</b> Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2.2</b> History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)</p>	

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab-rzaa)]

**AND**

**1.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Enbrel therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name:Enbrel	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - All of the following:</p> <p>1.1 Diagnosis of moderate to severe chronic plaque psoriasis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 ALL of the following:</p> <p>1.2.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis</p> <p style="text-align: center;"><b>AND</b></p>	

**1.2.1.2 ONE of the following:**

**1.2.1.2.1** Failure to one of the following topical therapy classes confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

**1.2.1.2.2** History of intolerance or contraindication to all of the following topical therapy classes (please specify intolerance or contraindication)

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.2.1.3 ONE of the following:**

**1.2.1.3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records

**OR**

**1.2.1.3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of plaque psoriasis as confirmed by claims

history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**1.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.4** Prescribed by or in consultation with a dermatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Enbrel therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderate to severe chronic plaque psoriasis

**AND**

**2.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a dermatologist

Product Name:Enbrel	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - All of the following:</p> <p>1.1 Diagnosis of active ankylosing spondylitis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to two non-steroidal anti-inflammatory drugs (NSAIDs: e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.3 Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 Patient is NOT receiving Enbrel in combination with another targeted immunomodulator</p>	

[e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.4** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Enbrel therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active ankylosing spondylitis

**AND**

**2.3** Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Product Name:Enbrel	
Diagnosis	Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Enbrel therapy

**AND**

2 - Patient is NOT receiving Enbrel in combination with another targeted immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\*

Notes	* Examples of drug(s) may not be applicable based on the requested indication.
-------	--

**2 . Revision History**

Date	Notes
2/20/2025	Updated formularies. Replaced Stelara with ustekinumab throughout

Endari



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146326
<b>Guideline Name</b>	Endari
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Endari	
Diagnosis	Sickle cell disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <ul style="list-style-type: none"> <li>Diagnosis of sickle cell disease</li> </ul>	

<ul style="list-style-type: none"> <li>Used to reduce acute complications of sickle cell disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <ul style="list-style-type: none"> <li>Patient is using Endari with concurrent hydroxyurea therapy</li> <li>Patient is unable to take hydroxyurea due to a contraindication or intolerance (please specify contraindication or intolerance)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has had 2 or more painful sickle cell crises within the past 12 months</p>
---

Product Name:Endari	
Diagnosis	Sickle cell disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Endari therapy</p>	

Enspryng



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160437
<b>Guideline Name</b>	Enspryng
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Enspryng	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies

**AND**

**3** - History of failure, contraindication, or intolerance to rituximab therapy

**AND**

**4** - One of the following:

- History of one or more relapses that required rescue therapy during the previous 12 months
- History of two or more relapses that required rescue therapy during the previous 24 months

**AND**

**5** - Prescribed by, or in consultation with, a neurologist

**AND**

**6** - Patient is NOT receiving Enspryng in combination with any of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
- Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc]
- Anti-IL6 (anti-interleukin-6) therapy [e.g., Actemra (tocilizumab)]
- B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumab)]

Product Name:Enspryng	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Enspryng therapy

**AND**

2 - Prescribed by, or in consultation with, a neurologist

**AND**

3 - Patient is NOT receiving Enspryng in combination with any of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
- Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc]
- Anti-IL6 (anti-interleukin-6) therapy [e.g., Actemra (tocilizumab)]
- B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumab)]

**2 . Revision History**

Date	Notes
11/11/2024	Updated examples of complement inhibitors

Entocort



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146327
<b>Guideline Name</b>	Entocort
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:budesonide caps	
Diagnosis	Crohn's Disease
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Used for the treatment of Crohn's disease</p>	

Entresto



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156316
<b>Guideline Name</b>	Entresto
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Entresto, Entresto Sprinkles	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Request is for continuation of therapy initiated during an inpatient stay</p> <p style="text-align: center;"><b>OR</b></p>	

**2 - ALL of the following:**

**2.1** Diagnosis of pediatric heart failure with systemic left ventricular systolic dysfunction which is symptomatic

**AND**

**2.2** Prescribed by or in consultation with a cardiologist

**AND**

**2.3** If the request is for Entresto Sprinkles, the prescriber has given a clinical reason or special circumstance why the patient is unable to use regular Entresto tablets

**OR**

**3 - ALL of the following:**

**3.1** Diagnosis of heart failure (with or without hypertension)

**AND**

**3.2** ONE of the following:

**3.2.1** Ejection fraction is less than or equal to 40 percent

**OR**

**3.2.2** BOTH of the following:

**3.2.2.1** Ejection fraction is greater than 40 percent

**AND**

**3.2.2.2** Patient has structural heart disease [i.e., left atrial enlargement (LAE) or left ventricular hypertrophy (LVH)]

**AND**

**3.3** Heart failure is classified as ONE of the following:

- New York Heart Association Class II
- New York Heart Association Class III
- New York Heart Association Class IV

**AND**

**3.4** Patient does not have a history of angioedema

**AND**

**3.5** Patient will discontinue any use of concomitant ACE (angiotensin converting enzyme) Inhibitor or ARB (angiotensin II receptor blocker) before initiating treatment with Entresto\*

**AND**

**3.6** Patient is not concomitantly on aliskiren therapy

**AND**

**3.7** Entresto is prescribed by, or in consultation with, a cardiologist

Notes	*ACE inhibitors must be discontinued at least 36 hours prior to initiation of Entresto.
-------	---

Product Name:Entresto, Entresto Sprinkles	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - The Entresto dose has been titrated to a dose of 97 mg (milligrams)/103 mg twice daily or the maximum labeled dose for pediatric patients, or to a maximum dose as tolerated by the patient

**AND**

2 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
9/26/2024	Added Entresto sprinkles

Entyvio SC



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-180216
<b>Guideline Name</b>	Entyvio SC
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Entyvio SC	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records documenting clinical rationale for need of subcutaneous Entyvio in place of Entyvio administered intravenously (covered under the medical benefit)

**AND**

**2** - Diagnosis of moderately to severely active ulcerative colitis (UC)

**AND**

**3** - ONE of the following:

**3.1** Patient has been established on therapy with Entyvio under an active UnitedHealthcare medical benefit prior authorization for the treatment of moderately to severely active ulcerative colitis

**OR**

**3.2** Patient is currently on Entyvio for subcutaneous use therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is NOT receiving Entyvio for subcutaneous use in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab, Xeljanz (tofacitinib)]

**AND**

**5** - Prescribed by or in consultation with a gastroenterologist

Product Name:Entyvio SC

Diagnosis	Crohn's disease (CD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records documenting clinical rationale for need of subcutaneous Entyvio in place of Entyvio administered intravenously (covered under the medical benefit)

**AND**

**2** - Diagnosis of moderately to severely active Crohn's disease (CD)

**AND**

**3** - ONE of the following:

**3.1** Patient has been established on therapy with Entyvio under an active UnitedHealthcare medical benefit prior authorization for the treatment of moderately to severely active Crohn's disease

**OR**

**3.2** Patient is currently on Entyvio for subcutaneous use therapy as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is NOT receiving Entyvio in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab, Xeljanz (tofacitinib)]

**AND**

**5** - Prescribed by or in consultation with a gastroenterologist

<b>Product Name:Entyvio SC</b>	
Diagnosis	Ulcerative Colitis (UC), Crohn's disease (CD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Entyvio for subcutaneous use therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Entyvio in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab, Xeljanz (tofacitinib)]</p>	

## 2 . Revision History

Date	Notes
2/20/2025	Updated formularies. Replaced Stelara with ustekinumab throughout program. Updated bypass language for current users

Eohilia



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-151000
<b>Guideline Name</b>	Eohilia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	8/6/2024
-----------------	----------

### 1 . Criteria

Product Name:Eohilia	
Approval Length	12 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of eosinophilic esophagitis (EoE)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is experiencing symptoms related to esophageal dysfunction (e.g., dysphagia, food</p>	

impaction, chest pain that is often centrally located and may not respond to antacids, gastroesophageal reflux disease-like symptoms/refractory heartburn, upper abdominal pain)

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting eosinophil-predominant inflammation on esophageal biopsy, consisting of a peak value of  $\geq 15$  intraepithelial eosinophils per high power field (HPF)

**AND**

**4** - Secondary causes of esophageal eosinophilia have been ruled out

**AND**

**5** - One of the following:

**5.1** Failure to an 8 week trial of both of the following as confirmed by claims history or submission of medical records:

- Proton pump inhibitor (e.g., pantoprazole, omeprazole)
- Inhalational corticosteroid administered orally [e.g., budesonide inhalation suspension (generic Pulmicort Respules), Fluticasone HFA (Flovent HFA authorized generic)]

**OR**

**5.2** History of contraindication or intolerance to both of the following (please specify intolerance or contraindication):

- Proton pump inhibitor (e.g., pantoprazole, omeprazole)
- Inhalational corticosteroid administered orally [e.g., budesonide inhalation suspension (generic Pulmicort Respules), Fluticasone HFA (Flovent HFA authorized generic)]

**AND**

**6** - Prescribed by or in consultation with one of the following:

- Allergist/Immunologist

- Gastroenterologist

Epaned



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146329
<b>Guideline Name</b>	Epaned
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic enalapril oral soln, Brand Epaned	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is less than 8 years of age</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p>	

**2.1 ONE of the following diagnoses:**

- Hypertension
- Heart failure
- Asymptomatic left ventricular dysfunction, defined as left ventricular ejection fraction less than or equal to 35%

**AND**

**2.2 ONE of the following:**

**2.2.1** Failure to TWO formulary oral anti-hypertensives [e.g., angiotensin-converting enzyme (ACE) inhibitor, ACE inhibitor combination, angiotensin-receptor blocker (ARB), ARB combination, thiazide diuretic] as confirmed by claims history or submission of medical records

**OR**

**2.2.2** History of contraindication or intolerance to ALL formulary oral anti-hypertensives (e.g., ACE inhibitor, ACE inhibitor combination, ARB, ARB combination, thiazide diuretic) (please specify contraindication or intolerance)

**OR**

**2.2.3** Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to ONE of the following:

- Oral/motor difficulties
- Dysphagia

Erivedge



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146515
<b>Guideline Name</b>	Erivedge
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Erivedge	
Diagnosis	Basal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic basal cell carcinoma</p>	

**OR**

**2** - BOTH of the following:

**2.1** Diagnosis of locally advanced basal cell carcinoma

**AND**

**2.2** ONE of the following:

- Cancer has recurred following surgery
- Patient is not a candidate for surgery
- Patient is not a candidate for radiation

Product Name:Erivedge	
Diagnosis	Medulloblastoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of medulloblastoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has mutations in the sonic hedgehog pathway</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has failed prior chemotherapy</p>	

Product Name:Erivedge	
Diagnosis	Basal Cell Carcinoma, Medulloblastoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Erivedge therapy</p>	

Product Name:Erivedge	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Erivedge	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Erivedge therapy</p>	

Erleada



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146516
<b>Guideline Name</b>	Erleada
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Erleada	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2 - ONE of the following:**

**2.1 BOTH of the following:**

- Disease is castration-resistant or recurrent
- Disease is non-metastatic

**OR**

**2.2 BOTH of the following:**

- Disease is castration-sensitive or naïve
- Disease is metastatic

**AND**

**3 - ONE of the following:**

**3.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**3.2** Patient has had bilateral orchiectomy

Product Name:Erleada	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Erleada therapy

Product Name:Erleada

Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Erleada

Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Erleada therapy

Erythropoietic Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146517
<b>Guideline Name</b>	Erythropoietic Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia Due to Chronic Kidney Disease (CKD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic kidney disease (CKD)</p>	

**AND**

**2** - Hematocrit is less than 30 percent at initiation of therapy

**AND**

**3** - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)

**AND**

**4** - ONE of the following:

**4.1** Patient is on dialysis

**OR**

**4.2** ALL of the following:

**4.2.1** Patient is NOT on dialysis

**AND**

**4.2.2** The rate of hematocrit decline indicates the likelihood of requiring a red blood cell (RBC) transfusion

**AND**

**4.2.3** Therapeutic goal is reducing the risk of alloimmunization and/or other RBC transfusion-related risks

Product Name: Aranesp, Epogen, Procrit, Retacrit

Diagnosis

Anemia Due to Chronic Kidney Disease (CKD)

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 BOTH of the following:</p> <p>2.1.1 Patient is on dialysis</p> <p style="text-align: center;"><b>AND</b></p> <p>2.1.2 Hematocrit remains less than 33 percent</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 ALL of the following:</p> <p>2.2.1 Patient is NOT on dialysis</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2.2 Hematocrit remains less than 30 percent</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2.3 Therapeutic goal is reducing the risk of alloimmunization and/or other RBC transfusion</p>	

Product Name:Epogen, Procrit, Retacrit	
Diagnosis	Anemia Associated with Zidovudine Treatment in HIV-Infected Patients
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is receiving zidovudine administered at less than or equal to 4200 milligrams per week</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Endogenous serum erythropoietin level is less than or equal to 500 milliunits per milliliter</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Hematocrit is less than 30 percent at initiation of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)</p>	

Product Name:Epogen, Procrit, Retacrit	
Diagnosis	Anemia Associated with Zidovudine Treatment in HIV-Infected Patients
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy

**AND**

2 - Patient is receiving zidovudine administered at less than or equal to 4200 milligrams per week

**AND**

3 - Endogenous serum erythropoietin level less than or equal to 500 milliunits per milliliter

**AND**

4 - Hematocrit remains less than or equal to 36 percent for continuation of therapy

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia Due to Cancer Chemotherapy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Hematocrit less than or equal to 30 percent at initiation of therapy

**AND**

2 - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency) and there is documentation of normal iron stores

**AND**

**3** - One of the following:

**3.1** Patient has moderate to severe chronic kidney disease (CKD)

**OR**

**3.2** Undergoing palliative treatment

**OR**

**3.3** Receiving myelosuppressive chemotherapy not given with curative intent

**OR**

**3.4** Both of the following:

- Receiving myelosuppressive chemotherapy with curative intent
- Patient is refusing blood transfusion(s)

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia Due to Cancer Chemotherapy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy</p>	

<b>AND</b>
<b>2</b> - Chemotherapy is given as palliative treatment
<b>AND</b>
<b>3</b> - Hematocrit remains less than 30 percent for continuation of therapy

Product Name: Epogen, Procrit, Retacrit	
Diagnosis	Preoperative Use for Reduction of Allogeneic Blood Transfusions in Surgery Patients
Approval Length	3 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Perioperative hematocrit is greater than 30 percent and less than or equal to 39 percent</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is expected to require at least 2 units of blood during the surgical procedure</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is at high risk for blood loss during surgery</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is unable or unwilling to donate autologous blood</p>	

**AND**

**5** - Surgery procedure is elective, non-cardiac, and non-vascular

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia Associated with Myelodysplastic Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of myelodysplastic syndrome (MDS)

**AND**

**2** - Serum erythropoietin level less than or equal to 500 milliunits per milliliter

**AND**

**3** - Hematocrit is less than or equal to 30 percent at the initiation of therapy

**AND**

**4** - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)

**AND**

**5** - Treatment of lower risk [defined as IPSS-R (Very Low, Low, Intermediate)] disease with symptomatic anemia

**AND**

**6** - One of the following:

**6.1** Patient is with del(5q) chromosomal abnormality

**OR**

**6.2** Both of the following:

- Patient is without del(5q) chromosomal abnormality
- Ring sideroblasts less than 15% (or ring sideroblasts less than 5% with an SF3B1 mutation)

**OR**

**6.3** All of the following:

- Patient is without del(5q) chromosomal abnormality
- Ring sideroblasts greater than or equal to 15% (or ring sideroblasts greater than or equal to 5% with an SF3B1 mutation)
- Following no response to Reblozyl (luspatercept-aamt)

Product Name: Aranesp, Epogen, Procrit, or Retacrit	
Diagnosis	Anemia Associated with Myelodysplastic syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Hematocrit remains less than or equal to 36 percent for continuation of therapy	

<b>AND</b>
<b>2</b> - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy
<b>AND</b>
<b>3</b> - Serum erythropoietin level less than or equal to 500 milliunits per milliliter

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia associated with Myeloproliferative Neoplasms – Myelofibrosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Serum erythropoietin level less than or equal to 500 mUnits/mL</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Hematocrit is less than or equal to 30 percent at the initiation of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)</p>	

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Anemia associated with Myeloproliferative Neoplasms – Myelofibrosis
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Serum erythropoietin level less than or equal to 500 mUnits/mL</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Hematocrit remains less than or equal to 36 percent for continuation of therapy</p>	

Product Name: Epogen, Procrit, Retacrit	
Diagnosis	Anemia in Patients with Hepatitis C with Ribavirin and Interferon Therapy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hepatitis C virus (HCV) infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is receiving ribavirin and interferon therapy</p>	

<b>AND</b>
<b>3</b> - Hematocrit is less than or equal to 30 percent at initiation of therapy
<b>AND</b>
<b>4</b> - Patient does not have evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)

Product Name: Epogen, Procrit, Retacrit	
Diagnosis	Anemia in Patients with Hepatitis C with Ribavirin and Interferon Therapy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Hematocrit remains less than or equal to 36 percent for continuation of care</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Documentation of positive clinical response to erythropoietin stimulating agent (ESA) therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is receiving ribavirin and interferon therapy</p>	

Product Name: Aranesp, Epogen, Procrit, Retacrit	
Diagnosis	Erythropoietin Stimulating Agents -Off-Label Uses

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Off-label requests will be evaluated on a case-by-case basis by a clinical pharmacist</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Requests for coverage in patients with hemoglobin (Hgb) greater than 10 grams per deciliter or hematocrit (Hct) greater than 30 percent will not be approved</p>	

Esbriet, Ofev



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146518
<b>Guideline Name</b>	Esbriet, Ofev
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Esbriet, generic pirfenidone, Ofev	
Diagnosis	Idiopathic Pulmonary Fibrosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of idiopathic pulmonary fibrosis (IPF) as documented by ALL of the following:</p> <p>1.1 Exclusion of other known causes of interstitial lung disease (e.g., domestic and</p>	

occupational environmental exposures, connective tissue disease, and drug toxicity), as documented by an ICD-10 Code of J84.112 (idiopathic pulmonary fibrosis)

**AND**

**1.2 ONE** of the following:

**1.2.1** If the patient was NOT subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF

**OR**

**1.2.2** If the patient was subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern reveal IPF or probable IPF

**AND**

**2 - ONE** of the following:

**2.1** If the request is for Esbriet (pirfenidone), it is not being used in combination with Ofev

**OR**

**2.2** If the request is for Ofev, it is not being used in combination with Esbriet (pirfenidone)

**AND**

**3 - The prescriber is a pulmonologist**

Product Name: Brand Esbriet, generic pirfenidone, Ofev	
Diagnosis	Idiopathic Pulmonary Fibrosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - ONE of the following:

2.1 If the request is for Esbriet (pirfenidone), it is not being used in combination with Ofev

**OR**

2.2 If the request is for Ofev, it is not being used in combination with Esbriet (pirfenidone)

**AND**

3 - The prescriber is a pulmonologist

Product Name:Ofev	
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) as documented by ALL of the following:

1.1 ONE of the following:

1.1.1 Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints

**OR**

**1.1.2** At least TWO of the following:

- Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of the fingers)
- Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)
- Telangiectasia
- Abnormal nailfold capillaries
- Pulmonary arterial hypertension
- Raynaud’s phenomenon
- SSc-related autoantibodies [e.g., anticentromere, anti-topoisomerase I, anti-RNA (ribonucleic acid) polymerase III]

**AND**

**1.2** Presence of interstitial lung disease as determined by finding evidence of pulmonary fibrosis on high-resolution computed tomography (HRCT), involving at least 10% of the lungs

**AND**

**2** - Ofev is not being used in combination with Esbriet (pirfenidone)

**AND**

**3** - The prescriber is a pulmonologist

Product Name:Ofev	
Diagnosis	Chronic Fibrosing Interstitial Lung Disease with a Progressive Phenotype
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype as documented by BOTH of the following:

**1.1** Presence of fibrotic ILD as determined by finding evidence of pulmonary fibrosis on HRCT (high-resolution computed tomography), involving at least 10% of the lungs

**AND**

**1.2** Patient is presenting with clinical signs of progression as defined by ONE of the following in the previous 24 months:

**1.2.1** Forced vital capacity (FVC) decline of greater than 10%

**OR**

**1.2.2** TWO of the following:

- FVC decline of greater than or equal to 5%, but less than 10%
- Patient is experiencing worsening respiratory symptoms
- Patient is exhibiting increasing extent of fibrotic changes on chest imaging

**AND**

**2** - Ofev is not being used in combination with Esbriet (pirfenidone)

**AND**

**3** - The prescriber is a pulmonologist

Product Name:Ofev	
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease, Chronic Fibrosing Interstitial Lung Disease with a Progressive Phenotype
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Ofev therapy

**AND**

**2** - Ofev is not being used in combination with Esbriet (pirfenidone)

**AND**

**3** - The prescriber is a pulmonologist

Eucrisa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146330
<b>Guideline Name</b>	Eucrisa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Eucrisa	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 ONE of the following:</p> <p>1.1.1 Failure to ONE topical corticosteroid [e.g., mometasone furoate, flucinolone acetonide (generic Synalar), flucinonide] as confirmed by claims history or submission of medical records</p>	

**OR**

**1.1.2** History of contraindication or intolerance ONE topical corticosteroid [e.g., mometasone furoate, fluocinolone acetonide (generic Synalar), fluocinonide] (please specify contraindication or intolerance)

**AND**

**1.2** ONE of the following:

**1.2.1** Patient is less than 2 years of age

**OR**

**1.2.2** Patient is greater than or equal to 2 years of age and ONE of the following:

- Failure to ONE topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)] as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to ONE topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)] (Please specify contraindication or intolerance)

**OR**

**2** - Patient is currently on Eucrisa therapy as confirmed by claims history or submission of medical records

Evrysdi



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164405
<b>Guideline Name</b>	Evrysdi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Evrysdi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of spinal muscular atrophy (SMA)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation or deletion of genes in chromosome 5q resulting in ONE of the following:

**2.1** Homozygous gene deletion or mutation of SMN1 gene (e.g., homozygous deletion of exon 7 at locus 5q13)

**OR**

**2.2** Compound heterozygous mutation of SMN1 gene [e.g., deletion of SMN1 exon 7 (allele 1) and mutation of SMN1 (allele 2)]

**AND**

**3** - Patient is not dependent on invasive ventilation or tracheostomy

**AND**

**4** - Patient is not dependent on the use of non-invasive ventilation beyond use for naps and nighttime sleep

**AND**

**5** - Patient is not receiving concomitant chronic survival motor neuron (SMN)-modifying therapy [e.g., Spinraza (nusinersen)]

**AND**

**6** - One of the following:

**6.1** Patient has not previously received gene replacement therapy for the treatment of SMA [e.g., Zolgensma (onasemnogene abeparvovec-xioi)]

**OR**

**6.2** Both of the following:

**6.2.1** Patient has previously received gene replacement therapy [e.g., Zolgensma (onasemnogene abeparvovec-xioi)] for the treatment of SMA

**AND**

**6.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting a decline from pretreatment baseline status following gene replacement therapy [e.g., Zolgensma (onasemnogene abeparvovec-xioi)] as demonstrated by a decline in one of the following exams:

- Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
- Hammersmith Infant Neurological Exam Part 2 (HINE-2)
- Hammersmith Functional Motor Scale Expanded (HF MSE)
- Revised Upper Limb Module (RULM) Test
- Motor Function Measure 32 (MFM-32) Scale

**AND**

**7** - Submission of medical records (e.g., chart notes, laboratory values) documenting the baseline assessment of at least ONE of the following exams (based on patient age and motor ability) to establish baseline motor ability (baseline motor function analysis could include assessments evaluated prior to receipt of previous chronic SMN-modifying therapy if transitioning therapy)\*:

- Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
- Hammersmith Infant Neurological Exam Part 2 (HINE-2)
- Hammersmith Functional Motor Scale Expanded (HF MSE)
- Revised Upper Limb Module (RULM) Test
- Motor Function Measure 32 (MFM-32) Scale

**AND**

**8** - Prescribed by or in consultation with a neurologist with expertise in the treatment of SMA

Notes

\*Baseline assessments for patients less than 2 months of age requesting Evrysdi are not necessary in order not to delay access to initial therapy in recently diagnosed infants. Initial assessments shortly post-therapy can serve as baseline with respect to efficacy reauthorization assessment.

Product Name: Evrysdi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes, laboratory values) with the most recent results documenting a positive clinical response to Evrysdi compared to pretreatment baseline status [inclusive of baseline assessments prior to receipt of previous chronic survival motor neuron (SMN)-modifying therapy] as demonstrated by at least ONE of the following exams:</p> <p><b>1.1</b> Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Improvement or maintenance of previous improvement of at least a 4-point increase in score from pretreatment baseline</li> <li>• Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Hammersmith Infant Neurological Exam Part 2 (HINE-2) with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Improvement or maintenance of previous improvement of at least a 2-point (or maximal score) increase in ability to kick</li> <li>• Improvement or maintenance of previous improvement of at least a 1-point increase in any other HINE-2 milestone (e.g., head control, rolling, sitting, crawling, etc.), excluding voluntary grasp</li> <li>• The patient exhibited improvement, or maintenance of previous improvement, in more HINE motor milestones than worsening, from pretreatment baseline (net positive improvement)</li> <li>• Patient has achieved and maintained any new motor milestones when they would otherwise be unexpected to do so</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.3</b> Hammersmith Functional Motor Scale Expanded (HFMSE) with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Improvement or maintenance of previous improvement of at least a 3-point increase in score from pretreatment baseline</li> </ul>	

- Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**1.4 Revised Upper Limb Module (RULM) with ONE of the following:**

- Improvement or maintenance of previous improvement of at least a 2-point increase in score from pretreatment baseline
- Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**1.5 Motor Function Measure 32 (MFM-32) with ONE of the following:**

- Improvement or maintenance of previous improvement of at least a 3-point increase in score from pretreatment baseline
- Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**AND**

**2 - Patient is not dependent on invasive ventilation or tracheostomy**

**AND**

**3 - Patient is not dependent on the use of non-invasive ventilation beyond use for naps and nighttime sleep**

**AND**

**4 - Patient is not receiving concomitant chronic SMN-modifying therapy [e.g., Spinraza (nusinersen)]**

**AND**

**5** - Prescribed by or in consultation with a neurologist with expertise in the treatment of spinal muscular atrophy (SMA)

## 2 . Revision History

Date	Notes
1/28/2025	Added criteria for patients that have documented decline from pretreatment baseline status following administration of gene replacement therapy

Exkivity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146520
<b>Guideline Name</b>	Exkivity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Exkivity	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

<b>AND</b>
<b>2</b> - Disease is locally advanced or metastatic
<b>AND</b>
<b>3</b> - Disease is epidermal growth factor receptor (EGFR) exon 20 insertion mutation positive
<b>AND</b>
<b>4</b> - Subsequent therapy for disease that has progressed on or after platinum-based chemotherapy

<b>Product Name:Exkivity</b>	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Patient does not show evidence of progressive disease while on Exkivity therapy	

<b>Product Name:Exkivity</b>	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Exkivity	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Exkivity therapy</p>	

Fabhalta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160516
<b>Guideline Name</b>	Fabhalta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Fabhalta	
Diagnosis	Paroxysmal nocturnal hemoglobinuria (PNH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as confirmed by BOTH of the following:</p>	

**1.1** Flow cytometry analysis confirming presence of PNH clones

**AND**

**1.2** Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia, unexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease, pulmonary hypertension, etc.)

**AND**

**2** - ONE of the following:

**2.1** Patient will not be prescribed Fabhalta in combination with another complement inhibitor used for the treatment of PNH (e.g., Empaveli, PiaSky, Soliris, Ultomiris)

**OR**

**2.2** Patient is currently receiving another complement inhibitor (e.g., Empaveli, PiaSky, Soliris, Ultomiris) which will be discontinued and Fabhalta will be initiated in accordance with the United States Food and Drug Administration approved labeling

**AND**

**3** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

Product Name:Fabhalta	
Diagnosis	Paroxysmal nocturnal hemoglobinuria (PNH)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Fabhalta therapy (e.g., increased or stabilization of hemoglobin levels, reduction in transfusions, improvement in hemolysis, decrease in LDH, increased reticulocyte count, etc.)

**AND**

2 - Patient is not receiving Fabhalta in combination with another complement inhibitor used for the treatment of PNH (e.g., Empaveli, PiaSky, Soliris, Ultomiris)

**AND**

3 - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

Product Name:Fabhalta	
Diagnosis	Primary immunoglobulin A nephropathy (IgAN)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal biopsy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine</p>	

ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool]

**AND**

**3** - Used to reduce proteinuria

**AND**

**4** - Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m<sup>2</sup>

**AND**

**5** - ONE of the following:

**5.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following as confirmed by claims history or submission of medical records:

- Maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Maximally tolerated angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**OR**

**5.2** Patient has an allergy, contraindication, or intolerance to ACE inhibitors and ARBs (please specify allergy, contraindication, or intolerance)

**AND**

**6** - ONE of the following:

**6.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated sodium-glucose cotransporter-2 (SGLT2) inhibitor [e.g., Jardiance (empagliflozin)] as confirmed by claims history or submission of medical records

**OR**

**6.2** Patient has an allergy, contraindication, or intolerance to SGLT2 inhibitors (please specify allergy, contraindication, or intolerance)

**AND**

**7** - ONE of the following:

**7.1** Failure to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) as confirmed by claims history or submission of medical records

**OR**

**7.2** History of intolerance or contraindication to a glucocorticoid (please specify intolerance or contraindication)

**AND**

**8** - Prescribed by or in consultation with a nephrologist

Product Name:Fabhalta	
Diagnosis	Primary immunoglobulin A nephropathy (IgAN)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Fabhalta therapy demonstrated by a reduction in proteinuria</p>	

## 2 . Revision History

Date	Notes
------	-------

11/12/2024	Added criteria for IgAN. Updated examples for combination use requirement for PNH.
------------	--

Fasenra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154990
<b>Guideline Name</b>	Fasenra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Fasenra Pen	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Fasenra under an active UnitedHealthcare medical benefit prior authorization for the treatment of severe asthma</p>	

**AND**

**2** - Documentation of positive clinical response to Fasenra therapy as demonstrated by ONE of the following:

**2.1** Reduction in the frequency of exacerbations

**OR**

**2.2** Decreased utilization of rescue medications

**OR**

**2.3** Increase in percent predicted forced expiratory volume in 1 second (FEV1) from pretreatment baseline

**OR**

**2.4** Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

**OR**

**2.5** Reduction in oral corticosteroid requirements

**AND**

**3** - Fasenra is being used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**4** - Patient is NOT receiving Fasenra in combination with any of the following:

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Nucala (mepolizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name:Fasenra Pen	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization – Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of severe asthma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Classification of asthma as uncontrolled or inadequately controlled as defined by ONE of the following:</p> <p><b>2.1</b> Poor symptom control [e.g., Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20]</p> <p style="text-align: center;"><b>OR</b></p>	

**2.2** Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months

**OR**

**2.3** Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)

**OR**

**2.4** Airflow limitation [e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second (FEV1) less than 80% predicted (in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal)]

**OR**

**2.5** Patient is currently dependent on oral corticosteroids for the treatment of asthma

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming asthma is an eosinophilic phenotype as defined by a baseline (pre-treatment) peripheral blood eosinophil level greater than or equal to 150 cells per microliter

**AND**

**4** - Fasentra will be used in combination with ONE of the following:

**4.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., fluticasone/salmeterol (authorized generic of AirDuo), fluticasone propionate/salmeterol diskus (generic for Advair Diskus), Wixela Inhub (generic for Advair Diskus), Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol), Dulera (mometasone/formoterol)]

**OR**

**4.2** Combination therapy including BOTH of the following:

**4.2.1** ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR), Arnuity Ellipta (fluticasone furoate)]

**AND**

**4.2.2** ONE additional asthma controller medication [e.g., LABA - Striverdi (olodaterol) or Arcapta (indacaterol); leukotriene receptor antagonist - montelukast (Singulair); theophylline]

**AND**

**5** - Patient is NOT receiving Fasentra in combination with any of the following:

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Nucala (mepolizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**6** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name:Fasentra Pen	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Documentation of positive clinical response as demonstrated by at least ONE of the following:

- Reduction in the frequency of exacerbations
- Decreased utilization of rescue medications
- Increase in percent predicted FEV1 (forced expiratory volume in 1 second) from pretreatment baseline
- Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- Reduction in oral corticosteroid requirements

**AND**

**2** - Used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**3** - Patient is NOT receiving Fasentra in combination with any of the following:

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Nucala (mepolizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

## 2 . Revision History

Date	Notes
9/16/2024	Modified criteria for existing prior authorization for under the medical benefit.

Febuxostat



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146331
<b>Guideline Name</b>	Febuxostat
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic febuxostat	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Failure to allopurinol (generic Zyloprim) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - History of contraindication or intolerance to allopurinol (generic Zyloprim) (please specify contraindication or intolerance)

Fentanyl IR



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155738
<b>Guideline Name</b>	Fentanyl IR
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Fentanyl citrate lozenges (generic Actiq)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records demonstrating use is for the management of breakthrough pain associated with a cancer diagnosis (cancer diagnosis must be documented)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids (Document drug and date of trial):

- Oral morphine sulfate at a doses of greater than or equal to 60 milligrams per day
- Fentanyl transdermal patch at a dose of greater than or equal to 25 micrograms per hour
- Oral oxycodone at a dose of greater than or equal to 30 milligrams per day
- Oral hydromorphone at a dose of greater than or equal to 8 milligrams per day
- Oral oxymorphone at a dose of greater than or equal to 25 milligrams per day
- Oral hydrocodone at a dose of greater than or equal to 60 mg/day
- An alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 milligrams per day)

**AND**

**3** - The patient is currently taking a long-acting opioid around the clock for cancer pain (Document drug)

**AND**

**4** - ONE of the following:

**4.1** The patient is not concurrently receiving an alternative fentanyl transmucosal product

**OR**

**4.2** BOTH of the following:

**4.2.1** The patient is currently receiving an alternative transmucosal fentanyl product

**AND**

**4.2.2** The prescriber is requesting the termination of all current authorizations for alternative transmucosal fentanyl products in order to begin treatment with the requested medication (Only one transmucosal fentanyl product will be approved at a time. If previous authorizations cannot be terminated, the PA request will be denied)

Product Name: Brand Actiq, Brand Fentora, fentanyl citrate buccal tablet (authorized generic of Fentora)

Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records demonstrating use is for the management of breakthrough pain associated with a cancer diagnosis (cancer diagnosis must be documented)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids (Document drug and date of trial):</p> <ul style="list-style-type: none"> <li>• Oral morphine sulfate at a doses of greater than or equal to 60 milligrams per day</li> <li>• Fentanyl transdermal patch at a dose of greater than or equal to 25 micrograms per hour</li> <li>• Oral oxycodone at a dose of greater than or equal to 30 milligrams per day</li> <li>• Oral hydromorphone at a dose of greater than or equal to 8 milligrams per day</li> <li>• Oral oxymorphone at a dose of greater than or equal to 25 milligrams per day</li> <li>• Oral hydrocodone at a dose of greater than or equal to 60 mg/day</li> <li>• An alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 milligrams per day)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - The patient is currently taking a long-acting opioid around the clock for cancer pain (Document drug)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - ONE of the following:</p> <p><b>4.1</b> The patient is not concurrently receiving an alternative fentanyl transmucosal product</p> <p style="text-align: center;"><b>OR</b></p> <p><b>4.2</b> BOTH of the following:</p>	

**4.2.1** The patient is currently receiving an alternative transmucosal fentanyl product

**AND**

**4.2.2** The prescriber is requesting the termination of all current authorizations for alternative transmucosal fentanyl products in order to begin treatment with the requested medication (Only one transmucosal fentanyl product will be approved at a time. If previous authorizations cannot be terminated, the PA request will be denied)

**AND**

**5** - One of the following:

- Failure to fentanyl citrate lozenges (generic Actiq) confirmed by claims history or submission of medical records
- History of intolerance or contraindication to fentanyl citrate lozenges (generic Actiq) (document intolerance or contraindication)

## 2 . Revision History

Date	Notes
9/23/2024	Removed Lazanda and Subsys as they are no longer on the market.

Filspari



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206573
<b>Guideline Name</b>	Filspari
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Filspari	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
	<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal biopsy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is at risk of disease progression</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used to slow kidney function decline</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Used to reduce proteinuria</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m<sup>2</sup></p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - BOTH of the following:</p> <p><b>6.1</b> Patient is on a maximized stable dose with ONE of the following prior to initiating therapy confirmed by claims history or submitted medical records</p> <ul style="list-style-type: none"> <li>• Maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)</li> <li>• Maximally tolerated angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)</li> </ul>

**AND**

**6.2** Use of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE inhibitors, ARBs), endothelin receptor antagonists [(ERAs) e.g., Letairis, Opsumit, Tracleer)], and Tekturna will be discontinued prior to initiating treatment

**AND**

**7** - ONE of the following:

**7.1** Failure to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) confirmed by claims history or submitted medical records.

**OR**

**7.2** History of contraindication or intolerance to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) (please specify intolerance or contraindication)

**AND**

**8** - Prescribed by or in consultation with a nephrologist

Product Name:Filspari	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response demonstrated by a reduction in proteinuria	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
3/4/2025	Updated formularies

Filsuvez



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147343
<b>Guideline Name</b>	Filsuvez
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Filsuvez	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is at least 6 months of age or older</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - One of the following diagnoses:

- Dystrophic epidermolysis bullosa (DEB)
- Junctional epidermolysis bullosa (JEB)

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) confirming a genetic mutation associated with DEB or JEB (i.e., COL7A1, LAMA3, LAMB3, LAMC2, COL17A1, ITGA6, ITGB4, ITGA3)

**AND**

**4** - Patient has at least one partial thickness wound that meets ALL of the following criteria:

- 10-50 cm<sup>2</sup> in size
- Present for at least 3 weeks
- Adequate granulation tissue
- Excellent vascularization
- No evidence of active wound infection
- No evidence or history of basal or squamous cell carcinomas (SCC)

**AND**

**5** - Prescribed by, or in consultation with, a dermatologist with expertise in the treatment of epidermolysis bullosa (EB)

**AND**

**6** - Patient is NOT receiving Filsuvez in combination with Vyjuvek on the same wound(s)

Product Name:Filsuvez	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Filsuvez therapy (e.g., complete wound closure, reduction in wound size, decrease in procedural pain, less frequent dressing changes, decreased total body wound burden)

**AND**

**2** - Wound(s) being treated meets ALL of the following criteria:

- Adequate granulation tissue
- Excellent vascularization
- No evidence of active wound infection
- No evidence or history of basal or squamous cell carcinomas (SCC)

**AND**

**3** - Filsuvez is prescribed by, or in consultation with, a dermatologist with expertise in the treatment of epidermolysis bullosa (EB)

**AND**

**4** - Patient is not receiving Filsuvez in combination with Vyjuvek on the same wound(s)

**2 . Revision History**

Date	Notes
5/13/2024	Copy core

Firazyr, Sajazir



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148035
<b>Guideline Name</b>	Firazyr, Sajazir
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Sajazir, Brand Firazyr, generic icatibant	
Diagnosis	Hereditary angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p>1.1 C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-converting enzyme 1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosaminase 3-O-sulfotransferase 6
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - Prescribed for the acute treatment of HAE attacks

**AND**

**3** - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Kalbitor, or Ruconest)

**AND**

**4** - Prescribed by ONE of the following:

- Immunologist
- Allergist

Product Name:Sajazir, Brand Firazyr, generic icatibant	
Diagnosis	Hereditary angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed for the acute treatment of hereditary angioedema (HAE) attacks</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Kalbitor, or Ruconest)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Immunologist</li> <li>• Allergist</li> </ul>	

## 2 . Revision History

Date	Notes
6/3/2024	Update to types of genetic variant(s) and diagnostic criteria with normal C1 inhibitor levels in initial auth section and minor language update in reauth section.

Firdapse



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164742
<b>Guideline Name</b>	Firdapse
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Firdapse	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a specialist in the treatment of LEMS (e.g., neurologist or oncologist)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine)]</p>	

Product Name:Firdapse	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Firdapse therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine)]</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
2/5/2025	Added Indiana and PA Medicaid formularies. No changes to clinical c riteria.

Firdapse



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164742
<b>Guideline Name</b>	Firdapse
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Firdapse	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a specialist in the treatment of LEMS (e.g., neurologist or oncologist)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine)]</p>	

Product Name:Firdapse	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Firdapse therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine)]</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
2/5/2025	Added Indiana and PA Medicaid formularies. No changes to clinical c riteria.

Fortamet, Glumetza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146333
<b>Guideline Name</b>	Fortamet, Glumetza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic metformin extended-release (generic Fortamet)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - History of greater than or equal to 12-week trial of metformin extended-release (generic Glucophage XR) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - One of the following:

**2.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Glucophage XR) as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**2.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Glucophage XR) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

Product Name: Brand Glumetza, generic metformin extended-release (generic Glumetza)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - History of greater than or equal to 12 week trial of metformin extended-release (generic Glucophage XR) as confirmed by claims history or submission of medical records</p> <p><b>AND</b></p> <p><b>2</b> - One of the following:</p> <p><b>2.1</b> Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Glucophage XR) as evidenced by the hemoglobin A1c level being above the patient's goal</p> <p><b>OR</b></p> <p><b>2.2</b> Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Glucophage XR) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)</p>	

**AND**

**3** - History of greater than or equal to 12 week trial of metformin extended-release (generic Fortamet) as confirmed by claims history or submission of medical records

**AND**

**4** - One of the following:

**4.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Fortamet) as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**4.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Fortamet) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

**AND**

**5** - Submission of article(s) published in the peer-reviewed medical literature showing that the requested drug is likely to be more efficacious to this patient than metformin extended-release (generic Glucophage XR AND generic Fortamet)

Forteo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161184
<b>Guideline Name</b>	Forteo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brand Forteo, generic teriparatide, brand Teriparatide	
Diagnosis	Osteoporosis
Approval Length	24 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p>	

- Patient is female
- Diagnosis of postmenopausal osteoporosis

**OR**

**1.2 BOTH of the following:**

- Patient is male
- Diagnosis of osteoporosis

**AND**

**2 - ONE of the following:**

**2.1** Patient is at high risk of fracture [e.g., recent fracture (e.g., within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids), very low T-score (e.g., less than -3.0), high risk for falls or history of injurious falls, and very high fracture probability by FRAX (fracture risk assessment tool) (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%)]

**OR**

**2.2** Patient has a history of failure to at least one other available osteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate) as confirmed by claims history or submission of medical records

**OR**

**2.3** Patient has contraindication or intolerance to at least one other available osteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate) (please specify contraindication or intolerance)

**AND**

**3 - ONE of the following:**

**3.1** Treatment duration has not exceeded a total of 24 months of cumulative use of

parathyroid hormone analogs (e.g., teriparatide injection, Forteo, Tymlos) during the patient's lifetime

**OR**

**3.2 BOTH of the following:**

**3.2.1** Patient is currently or has previously been treated with parathyroid hormone analogs (e.g., teriparatide injection, Forteo, Tymlos)

**AND**

**3.2.2** The prescriber attests that the patient remains at or has returned to having a high risk for fracture

**AND**

**4 - ONE of the following:**

- Failure to Tymlos as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to Tymlos (please specify contraindication or intolerance)

Product Name: Brand Forteo, generic teriparatide, brand Teriparatide	
Diagnosis	Osteoporosis Associated with Sustained Systemic Glucocorticoid Therapy
Approval Length	24 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of glucocorticoid-induced osteoporosis	

**AND**

**2** - History of prednisone or its equivalent at a dose greater than or equal to 5 mg (milligrams)/day as confirmed by claims history or submission of medical records

**AND**

**3** - ONE of the following:

**3.1** Patient is at high risk of fracture [e.g., recent fracture (e.g., within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids), very low T-score (e.g., less than -3.0), high risk for falls or history of injurious falls, and very high fracture probability by FRAX (fracture risk assessment tool) (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%)]

**OR**

**3.2** Patient has a history of failure to at least one other available osteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate) as confirmed by claims history or submission of medical records

**OR**

**3.3** Patient has contraindication or intolerance to at least one other available osteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate) (please specify contraindication or intolerance)

**AND**

**4** - ONE of the following:

**4.1** Treatment duration has not exceeded a total of 24 months of cumulative use of parathyroid hormone analogs (e.g., teriparatide injection, Forteo, Tymlos)

**OR**

**4.2 BOTH of the following:**

**4.2.1** Patient is currently or has previously been treated with parathyroid hormone analogs (e.g., teriparatide injection, Forteo, Tymlos)

**AND**

**4.2.2** The prescriber attests that the patient remains at or has returned to having a high risk for fracture

Product Name: Brand Forteo, generic teriparatide, brand Teriparatide	
Diagnosis	Osteoporosis, Osteoporosis Associated with Sustained Systemic Glucocorticoid Therapy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Treatment duration of parathyroid hormones (e.g., teriparatide injection, Forteo, Tymlos) has not exceeded a total of 24 months during the patient's lifetime</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - The patient remains at or has returned to having a high risk for fracture despite a total of 24 months of use of parathyroid hormones (e.g., teriparatide injection, Forteo, Tymlos)</p>	

Fotivda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146527
<b>Guideline Name</b>	Fotivda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Fotivda	
Diagnosis	Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced renal cell carcinoma (RCC)</p>	

**AND**

**2** - ONE of the following:

- Disease has relapsed
- Disease is refractory

**AND**

**3** - Patient has received two or more prior systemic therapies

Product Name:Fotivda	
Diagnosis	Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Fotivda therapy</p>	

Product Name:Fotivda	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Fotivda	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Fotivda therapy</p>	

Fruzaqla



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146528
<b>Guideline Name</b>	Fruzaqla
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Fruzaqla	
Diagnosis	Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of colorectal cancer</p>	

**AND**

**2** - Disease of ONE of the following:

- Advanced
- Metastatic

**AND**

**3** - Patient has been previously treated with ALL of the following:

- Fluoropyrimidine-based chemotherapy (e.g., capecitabine, 5-FU)
- Oxaliplatin-based chemotherapy (e.g., CAPEOX, FOLFOX)
- Irinotecan-based chemotherapy (e.g., FOLFIRI, FOLFIRINOX)
- Anti-VEGF therapy (e.g., aflibercept, bevacizumab, ramucirumab)

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Disease is RAS wild-type

**AND**

**4.1.2** Patient has been previously treated with an anti-EGFR therapy (e.g., cetuximab, panitumumab)

**OR**

**4.2** Disease is not RAS wild-type

Product Name:Fruzaqla

Diagnosis

Colorectal Cancer

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Fruzaqla therapy</p>	

Product Name:Fruzaqla	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Fruzaqla	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Fruzaqla therapy</p>	

Furoscix



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160541
<b>Guideline Name</b>	Furoscix
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Furoscix	
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic heart failure</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has signs or symptoms of congestion due to fluid overload</p>	

**AND**

**3** - Patient is established on background loop diuretic therapy (e.g., bumetanide, furosemide, torsemide)

**AND**

**4** - Both of the following:

**4.1** Patient does not require ongoing emergency care or hospitalization for heart failure, acute pulmonary edema, or other conditions

**AND**

**4.2** Patient is currently a candidate for parenteral diuresis outside of the hospital

**AND**

**5** - Patient has an estimated creatine clearance greater than 30ml/min

**AND**

**6** - Furoscix is prescribed by or in consultation with a cardiologist

## 2 . Revision History

Date	Notes
11/12/2024	Removed criteria requiring NYHA Class II or III HF

Galafold



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146529
<b>Guideline Name</b>	Galafold
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Galafold	
Diagnosis	Fabry Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Fabry disease</p>	

**AND**

**2** - Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data

**AND**

**3** - Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta) or Elfabrio (pegunigalsidase alfa-iwxj)

Product Name:Galafold	
Diagnosis	Fabry Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Galafold therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta) or Elfabrio (pegunigalsidase alfa-iwxj)</p>	

Gattex



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146530
<b>Guideline Name</b>	Gattex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Gattex	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Short Bowel Syndrome (SBS)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Dependent on parenteral support

Product Name:Gattex	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Gattex therapy	

Gavreto



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163849
<b>Guideline Name</b>	Gavreto
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Gavreto	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is ONE of the following:

- Recurrent
- Advanced
- Metastatic

**AND**

**3** - There is presence of RET rearrangement positive tumors

Product Name:Gavreto	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of ONE of the following:

- Follicular carcinoma
- Oncocytic carcinoma
- Papillary carcinoma

**AND**

**1.2** ONE of the following:

- Unresectable locoregional recurrent disease
- Persistent disease

- Metastatic disease

**AND**

**1.3** Disease is RET gene fusion positive

**AND**

**1.4** Disease is not amenable to radioactive iodine therapy

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of medullary carcinoma

**AND**

**2.2** ONE of the following:

- Disease is recurrent, persistent, or progressive
- Disease is symptomatic with distant metastases

**AND**

**2.3** Disease is RET-mutation positive

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of anaplastic carcinoma

**AND**

**3.2 ONE of the following:**

- Disease is stage IVA or IVB (locoregional)
- Disease is metastatic

**AND**

**3.3 Disease is RET gene fusion positive**

Product Name:Gavreto	
Diagnosis	Hepatobiliary Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p> <p>1.1.1 Diagnosis of gallbladder cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable</li> <li>• Resected gross residual (R2)</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2 BOTH of the following:</p> <p>1.2.1 Diagnosis of cholangiocarcinoma</p>	

**AND**

**1.2.2** Disease is one of the following:

- Unresectable
- Resected gross residual (R2)
- Metastatic
- Resectable locoregionally advanced

**AND**

**2** - Disease is positive for RET gene fusion mutation

Product Name:Gavreto	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Thyroid Carcinoma, Hepatobiliary Cancers
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Gavreto therapy	

Product Name:Gavreto	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Gavreto	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Gavreto therapy</p>	

## 2 . Revision History

Date	Notes
1/15/2025	Updated criteria for hepatobiliary cancers

Gilotrif



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146532
<b>Guideline Name</b>	Gilotrif
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Gilotrif	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - ONE of the following:

- Squamous disease progressing after previous platinum-based chemotherapy
- Tumors are positive for non-resistant epidermal growth factor receptor (EGFR) mutations

Product Name:Gilotrif	
Diagnosis	Advanced Non-Nasopharyngeal Head and Neck Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of advanced, non-nasopharyngeal head and neck cancer</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease has progressed on or after platinum-containing chemotherapy</p>	

Product Name:Gilotrif	
Diagnosis	Brain Metastases
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Diagnosis of brain metastasis due to EGFR (epidermal growth factor receptor)-sensitizing mutation positive non-small cell lung cancer

<b>Product Name:Gilotrif</b>	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Advanced Non-Nasopharyngeal Head and Neck Cancer, Brain Metastases
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Gilotrif therapy</p>	

<b>Product Name:Gilotrif</b>	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Gilotrif will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

<b>Product Name:Gilotrif</b>	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Gilotrif therapy

Gleevec



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146533
<b>Guideline Name</b>	Gleevec
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Gleevec, generic imatinib	
Diagnosis	Chronic Myelogenous/Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic myelogenous/myeloid leukemia (CML)</p>	

Product Name: Brand Gleevec, generic imatinib	
Diagnosis	Acute Lymphoblastic Leukemia (ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)</p>	

Product Name: Brand Gleevec, generic imatinib	
Diagnosis	Myelodysplastic Disease (MDS)/Myeloproliferative Disease (MPD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of myelodysplastic/myeloproliferative disease (MDS/MPD)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Platelet-derived growth factor receptor (PDGFR) gene re-arrangements</p>	

Product Name: Brand Gleevec, generic imatinib	
Diagnosis	Aggressive Systemic Mastocytosis (ASM)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of aggressive systemic mastocytosis (ASM)

**AND**

2 - ONE of the following:

- Kit D816V mutation negative or unknown
- Well-differentiated SM [WDSM]
- Eosinophilia is present with FIP1L1-PDGFRA fusion gene

**Product Name: Brand Gleevec, generic imatinib**

Diagnosis	Hypereosinophilic Syndrome (HES)/Chronic Eosinophilic Leukemia (CEL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of at least ONE of the following:

- Hypereosinophilic syndrome (HES)
- Chronic eosinophilic leukemia (CEL)

**Product Name: Brand Gleevec, generic imatinib**

Diagnosis	Dermatofibrosarcoma Protuberans (DFSP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of dermatofibrosarcoma protuberans (DFSP)

Product Name: Brand Gleevec, generic imatinib

Diagnosis	Soft Tissue Sarcoma
-----------	---------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Gastrointestinal stromal tumors (GIST)
- Desmoid tumors/aggressive fibromatosis
- Pigmented villonodular synovitis (PVNS)/tenosynovial giant cell tumor (TGCT)

Product Name: Brand Gleevec, generic imatinib

Diagnosis	Chordoma
-----------	----------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of chordoma

Product Name: Brand Gleevec, generic imatinib

Diagnosis	Melanoma
-----------	----------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of melanoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has C-KIT (gene) mutation</p>	

Product Name:Brand Gleevec, generic imatinib	
Diagnosis	AIDS-Related Kaposi Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of AIDS (acquired immunodeficiency syndrome)-related Kaposi Sarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Not used as first line therapy</p>	

Product Name:Brand Gleevec, generic imatinib	
Diagnosis	Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic graft-versus-host disease

**AND**

2 - Patient is being treated with systemic corticosteroids

**AND**

3 - Patient had no response to first-line therapy options

Product Name: Brand Gleevec, generic imatinib

Diagnosis	Myeloid/Lymphoid Neoplasms with Eosinophilia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia

**AND**

2 - ONE of the following:

- FIP1L1-PDGFRB rearrangement
- PDGFRB rearrangement
- ABL1 rearrangement

Product Name: Brand Gleevec, generic imatinib

Diagnosis	All Indications except NCCN
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Gleevec therapy</p>	

Product Name:Brand Gleevec, generic imatinib	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brand Gleevec, generic imatinib	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Gleevec therapy</p>	

GLP-1 & Dual GIP/GLP-1 Receptor Agonists



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-197199
<b>Guideline Name</b>	GLP-1 & Dual GIP/GLP-1 Receptor Agonists
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Victoza 1.2mg per day (2 Pen Pack), liraglutide 1.2mg per day (2 Pen Pack), Mounjaro, Ozempic, Rybelsus	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values:

- A1C greater than or equal to 6.5%
- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**2** - For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

Product Name:Victoza 1.8mg per day (3 Pen Pack), liraglutide 1.8mg per day (3 Pen Pack)	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values:</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed</p>	

greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**2** - History of failure to achieve acceptable glycemic control with Victoza 1.2mg per day for 90 days (2 Pen Pack), as confirmed by claims history or submission of medical records

Product Name:Victoza 1.8mg per day (3 Pen Pack), liraglutide 1.8mg per day (3 Pen Pack)

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy (e.g., improved A1C)

Product Name:Bydureon BCise, Byetta, Trulicity

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - ONE of the following:

**1.1** Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values:

- A1C greater than or equal to 6.5%
- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**1.2** For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**2** - ONE of the following:

**2.1** Suboptimal response (i.e., suboptimal glycemic control) to both of the following, each for a minimum of 90 days, as confirmed by claims history or submission of medical records:

- A commercially available semaglutide product indicated for type 2 diabetes mellitus (e.g., Ozempic, Rybelsus)
- Mounjaro

**OR**

**2.2** History of contraindication or intolerance to both of the following (please specify contraindication or intolerance)

- A commercially available semaglutide product indicated for type 2 diabetes mellitus (e.g., Ozempic, Rybelsus)
- Mounjaro

Product Name:Bydureon BCise, Byetta, Trulicity	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy (e.g., improved A1C)	

## 2 . Revision History

Date	Notes
2/26/2025	Updated preferred product criteria to only require a diagnosis check and added standard reauthorization language to the Victoza 3-pack, Iraglutide and NP sections. Removed step thru metformin

Gonadotropin-Releasing Hormone Agonists



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161334
<b>Guideline Name</b>	Gonadotropin-Releasing Hormone Agonists
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:leuprolide acetate inj kit 5 mg/mL, Lupron Depot-Ped, Triptodur, Fensolvi	
Diagnosis	Central Precocious Puberty (CPP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of central precocious puberty (idiopathic or neurogenic)</p>	

**AND**

**2** - Onset of secondary sexual characteristics in ONE of the following:

**2.1** Females less than or equal to 8 years of age

**OR**

**2.2** Males less than or equal to 9 years of age

**AND**

**3** - Confirmation of diagnosis as defined by ONE of the following:

**3.1** Pubertal basal level of luteinizing hormone (based on laboratory reference ranges)

**OR**

**3.2** A pubertal luteinizing hormone response to a gonadotropin releasing hormone (GnRH) stimulation test

**OR**

**3.3** Bone age advanced one year beyond the chronological age

**AND**

**4** - If the request is for Triptodur or Lupron-Depot Ped (6-month), ONE of the following:

**4.1** Failure to Fensolvi as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to Fensolvi (please specify intolerance or contraindication)

Product Name:leuprolide acetate inj kit 5 mg/mL, Lupron Depot-Ped, Triptodur, Fensolvi

Diagnosis	Central Precocious Puberty (CPP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient is currently receiving therapy for central precocious puberty

**AND**

**2** - Documentation of positive clinical response to therapy (e.g., decrease in height velocity, cessation of menses, arrest pubertal progression, reduction in bone age advancement)

**AND**

**3** - Patient is currently younger than the appropriate time point for the onset of puberty, as **ONE** of the following:

**3.1** Female younger than 11 years of age

**OR**

**3.2** Male younger than 12 years of age

Product Name:Lupron Depot 3.75 mg and 3-month 11.25 mg

Diagnosis	Endometriosis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endometriosis or endometriosis is suspected</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Failure to BOTH of the following classes as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Oral contraceptives or depot medroxyprogesterone (e.g., Depo-Provera)</li> <li>• Non-steroidal anti-inflammatory drugs (NSAIDs)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.2 History of intolerance or contraindication to BOTH of the following classes (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Oral contraceptives or depot medroxyprogesterone (e.g., Depo-Provera)</li> <li>• Non-steroidal anti-inflammatory drugs (NSAIDs)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.3 Patient has had surgical ablation to prevent recurrence</p>	

Product Name:Lupron Depot 3.75 mg and 3-month 11.25 mg	
Diagnosis	Endometriosis
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Diagnosis of endometriosis or endometriosis is suspected

**AND**

**2** - Recurrence of symptoms following an initial course of therapy

**AND**

**3** - Concurrently to be used with add-back therapy (e.g., progestin, estrogen, or bone sparing agents)

**AND**

**4** - Treatment duration has not exceeded a total of 12 months, as confirmed by claims history or submission of medical records

Notes

Approval Length - Authorization will be issued for 6 months. Duration of both the initial and recurrent course of therapies is no longer than 12 months total.

Product Name:Lupron Depot 3.75 mg and 3-month 11.25 mg

Diagnosis Uterine Leiomyomata (Fibroids)

Approval Length 3 month(s)

Guideline Type Prior Authorization

**Approval Criteria**

**1** - ALL of the following:

**1.1** For the treatment of uterine leiomyomata-related anemia

**AND**

**1.2** Patient did not respond to iron therapy of 1 month duration

<p><b>AND</b></p> <p><b>1.3</b> For use prior to surgery</p> <p><b>OR</b></p> <p><b>2</b> - For use prior to surgery to reduce the size of fibroids to facilitate a surgical procedure (e.g., myomectomy, hysterectomy)</p>
---

Product Name:Lupron Depot 7.5 mg, 22.5 mg, 30 mg, and 45 mg, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj	
Diagnosis	Prostate Cancer
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - For a diagnosis of advanced or metastatic prostate cancer, the requested medication is not delegated to OptumRx for review and should be processed as a medical benefit</p>	

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj	
Diagnosis	Gender Dysphoria in Adolescents*
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes, laboratory values) documenting a diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry</p>	

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting the medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting the patient has experienced puberty development to at least Tanner stage 2

**AND**

**4** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following laboratory tests, based upon the laboratory reference range, confirming:

- Pubertal levels of estradiol in a female
- Pubertal levels of testosterone in a male
- Pubertal basal level of luteinizing hormone (based on laboratory reference ranges)
- A pubertal luteinizing hormone response to a gonadotropin-releasing hormone (GnRH) stimulation test

**AND**

**5** - Submission of medical records (e.g., chart notes, laboratory values) documenting a letter from the prescriber and/or formal documentation stating ALL of the following:

**5.1** Patient has experienced pubertal changes that have resulted in an increase of their gender dysphoria that has significantly impaired psychological or social functioning

**AND**

**5.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed

**AND**

**5.3** BOTH of the following:

**5.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**5.3.2** Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment

**AND**

**5.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Notes

\*Please verify gender dysphoria is a coverable benefit for the patient.

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Gender Dysphoria in Adolescents*
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following within the last 6 months:

- LH (luteinizing hormone) suppression assessing for appropriate suppression
- Change in dosing

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of

Mental Disorders (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting the medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy

**AND**

**4** - Submission of medical records (e.g., chart notes, laboratory values) documenting a letter from the prescriber and/or formal documentation stating ALL of the following:

**4.1** Patient continues to meet their individual goals of therapy for gender dysphoria

**AND**

**4.2** Patient continues to have a strong affinity for the desired (opposite of natal) gender

**AND**

**4.3** Discontinuation of treatment and subsequent pubertal development would interfere with or impair psychological functioning and well-being

**AND**

**4.4** Coexisting psychiatric and medical comorbidities or social problems that may interfere with treatment continue to be addressed or removed

**AND**

**4.5** BOTH of the following:

**4.5.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**4.5.2** Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment

**AND**

**4.6** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Notes	*Please verify gender dysphoria is a coverable benefit for the patient.
-------	---

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Adjunct for Gender-Affirming Hormonal Therapy for Transgender Adults*
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting a diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting the medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting the gonads (i.e., testes, ovaries) have not been removed and are functional (e.g., hormone producing)

**AND**

**4** - Submission of medical records (e.g., chart notes, laboratory values) documenting the patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progesterones) to achieve the desired (e.g., non-natal) gender

**AND**

**5** - Submission of medical records (e.g., chart notes, laboratory values) documenting inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, luteinizing hormone (LH), or gonadotropins (e.g., menses, testosterone)

**AND**

**6** - Submission of medical records (e.g., chart notes, laboratory values) documenting a letter from the prescriber and/or formal documentation stating ALL of the following:

**6.1** Transgender patient has identified goals of gender-affirming hormone therapy

**AND**

**6.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed

**AND**

**6.3** BOTH of the following:

**6.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**6.3.2** Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment

**AND**

**6.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Notes

\*Please verify gender dysphoria is a coverable benefit for the patient

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Adjunct for Gender-Affirming Hormonal Therapy for Transgender Adults*
-----------	---

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following within the last 6 months:

- Luteinizing hormone (LH) suppression assessing for appropriate suppression
- Change in dosing

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting a diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting the

medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy

**AND**

**4** - Submission of medical records (e.g., chart notes, laboratory values) documenting the gonads (i.e., testes, ovaries) are intact

**AND**

**5** - Submission of medical records (e.g., chart notes, laboratory values) documenting the patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progesterones) to achieve the desired (e.g., non-natal) gender

**AND**

**6** - Submission of medical records (e.g., chart notes, laboratory values) documenting inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, luteinizing hormone (LH), or gonadotropins (e.g., menses, testosterone)

**AND**

**7** - Submission of medical records (e.g., chart notes, laboratory values) documenting a letter from the prescriber and/or formal documentation stating ALL of the following:

**7.1** Transgender patient continues to meet goals of gender-affirming hormone therapy

**AND**

**7.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment continue to be addressed or removed

**AND**

**7.3** BOTH of the following:

**7.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**7.3.2** Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment

**AND**

**7.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Notes	*Please verify gender dysphoria is a coverable benefit for the patient
-------	--

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Fertility Preservation
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - For use in pre-menopausal women

**AND**

**2** - Patient is receiving a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytoxan (cyclophosphamide), procarbazine, vinblastine, cisplatin]

Product Name:Lupron Depot, Lupron Depot-Ped, Fensolvi, Triptodur, leuprolide acetate inj kit 5 mg/mL, leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Fertility Preservation
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is currently receiving gonadotropin-releasing hormone (GnRH) analog therapy for the purpose of fertility preservation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient continues to receive a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytoxan (cyclophosphamide), procarbazine, vinblastine, cisplatin]</p>	

Product Name:leuprolide acetate inj kit 5 mg/mL	
Diagnosis	Salivary Gland Tumors
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For a diagnosis of salivary gland tumors, the requested medication is not delegated to OptumRx for review and should be processed as a medical benefit</p>	

Product Name:leuprolide acetate inj kit 5 mg/mL	
Diagnosis	Uterine Sarcoma
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - For a diagnosis of uterine sarcoma, the requested medication is not delegated to OptumRx for review and should be processed as a medical benefit

Product Name:Lupron Depot, Lupron Depot-Ped, leuprolide acetate inj kit 5 mg/mL	
Diagnosis	NCCN Recommended Regimens
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For uses supported by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, the requested medication is not delegated to OptumRx for review and should be processed as a medical benefit</p>	

## 2 . Revision History

Date	Notes
11/26/2024	Updated GPIs. Updated step therapy in CPP section as Fensolvi was moved to preferred and Lupron Depot Ped was moved to NP

Growth Hormone, Growth Stimulating Agents - Managed Medicaid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161799
<b>Guideline Name</b>	Growth Hormone, Growth Stimulating Agents - Managed Medicaid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)*
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p>	

**1.1.1 ONE of the following:**

**1.1.1.1 All of the following:**

- Infant is less than 4 months of age
- Infant has growth deficiency
- Prescribed by an endocrinologist

**OR**

**1.1.1.2 BOTH of the following:**

- History of neonatal hypoglycemia associated with pituitary disease
- Prescribed by an endocrinologist

**OR**

**1.1.1.3 BOTH of the following:**

- Diagnosis of panhypopituitarism
- Prescribed by an endocrinologist

**AND**

**1.1.2** If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

**OR**

**1.2 ALL of the following:**

**1.2.1** Diagnosis of pediatric growth hormone (GH) deficiency as confirmed by ONE of the following:

**1.2.1.1** Projected height (as determined by extrapolating pre-treatment growth trajectory along current channel to 18-20 year mark) is greater than 2.0 standard deviations [SD] below midparental height utilizing age and gender growth charts related to height

**OR**

**1.2.1.2** Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) utilizing age and gender growth charts related to height

**OR**

**1.2.1.3** Growth velocity is greater than 2 SD below mean for age and gender

**OR**

**1.2.1.4** Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed greater than 2 years compared with chronological age)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Patient is male and ONE of the following:

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**1.2.2.2** Patient is female and ONE of the following:

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**1.2.3** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

**1.2.3.1** BOTH of the following:

**1.2.3.1.1** Patient has undergone TWO of the following provocative GH stimulation tests:

- Arginine
- Clonidine
- Glucagon
- Insulin
- Levodopa
- Growth hormone releasing hormone

**AND**

**1.2.3.1.2** BOTH GH response values are less than 10 micrograms per liter

**OR**

**1.2.3.2** BOTH of the following:

**1.2.3.2.1** Patient is less than 1 year of age

**AND**

**1.2.3.2.2** ONE of the following is below the age and gender adjusted normal range as provided by the physician's lab:

- Insulin-like Growth Factor 1 (IGF-1/Somatomedin-C)
- Insulin Growth Factor Binding Protein-3 (IGFBP-3)

**AND**

**1.2.4** ONE of the following:

**1.2.4.1** Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**OR**

**1.2.4.2** BOTH of the following:

- Tanner Stage 3 or greater
- Request does not exceed a maximum supply limit of 0.7 milligrams per kilogram per week

**AND**

**1.2.5** Prescribed by an endocrinologist

**AND**

**1.2.6** If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

Notes	*Includes children who have undergone brain radiation. If patient is a Transition Phase Adolescent or Adult who had childhood onset GH deficiency, utilize criteria for Transition Phase Adolescent or Adult GH D efficiency.
-------	---

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Pediatric Growth Hormone Deficiency (GHD)*
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2 - BOTH of the following:\*\***

- Expected adult height not attained
- Documentation of expected adult height goal (e.g. genetic potential)

**AND**

**3 - Calculated height (growth) velocity over the past 12 months**

**AND**

**4 - ONE of the following:**

**4.1 Patient is a male and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**4.2 Patient is a female and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**5 - ONE of the following:**

**5.1 Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week**

**OR**

**5.2 BOTH of the following:**

- Tanner Stage 3 or greater

<ul style="list-style-type: none"> <li>Request does not exceed a maximum supply limit of 0.7 milligrams per kilogram per week</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>6 - Prescribed by an endocrinologist</b></p>	
Notes	<p>*Includes children who have undergone brain radiation. If patient is a Transition Phase Adolescent or Adult who had childhood onset GH deficiency, utilize criteria for Transition Phase Adolescent or Adult GH D efficiency.</p> <p>**Documentation of previous height, current height and goal expected adult height will be required for renewal.</p>

Product Name: Skytrofa	
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following:</b></p> <p><b>1.1 ALL of the following:</b></p> <p><b>1.1.1 ONE of the following:</b></p> <ul style="list-style-type: none"> <li>History of neonatal hypoglycemia associated with pituitary disease</li> <li>Diagnosis of panhypopituitarism</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.2 Prescribed by an endocrinologist</b></p> <p style="text-align: center;"><b>AND</b></p>	

**1.1.3 ONE of the following:**

**1.1.3.1** Failure to ONE of the following, confirmed by claims history or submission of medical records:

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

**1.1.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

**1.2 ALL of the following:**

**1.2.1** Diagnosis of pediatric GH (growth hormone) deficiency as confirmed by ONE of the following:

**1.2.1.1** Projected height (as determined by extrapolating pre-treatment growth trajectory along current channel to 18-20 year mark) is greater than 2.0 standard deviations [SD] below midparental height utilizing age and gender growth charts related to height

**OR**

**1.2.1.2** Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) utilizing age and gender growth charts related to height

**OR**

**1.2.1.3** Growth velocity is greater than 2 SD below mean for age and gender

**OR**

**1.2.1.4** Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed greater than 2 years compared with chronological age)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Patient is male and ONE of the following:

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**1.2.2.2** Patient is female and ONE of the following:

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**1.2.3** Submission of medical records (e.g., chart notes, laboratory values) documenting BOTH of the following:

**1.2.3.1** Patient has undergone TWO of the following provocative GH stimulation tests:

- Arginine
- Clonidine
- Glucagon
- Insulin
- Levodopa
- Growth hormone releasing hormone

**AND**

**1.2.3.2** Both GH response values are less than 10 micrograms per liter

**AND**

**1.2.4** One of the following:

**1.2.4.1** Failure to ONE of the following, confirmed by claims history or submission of medical records:

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

**1.2.4.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**AND**

**1.2.5** Prescribed by an endocrinologist

Product Name: Skytrofa	
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:*</p> <ul style="list-style-type: none"> <li>• Previous height and date obtained</li> <li>• Current height and date obtained</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**2 - BOTH of the following:\***

- Expected adult height not attained
- Documentation of expected adult height goal (e.g. genetic potential)

**AND**

**3 - Calculated height (growth) velocity over the past 12 months**

**AND**

**4 - ONE of the following:**

**4.1 Patient is a male and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**4.2 Patient is a female and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**5 - Prescribed by an endocrinologist**

Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.
-------	--

Product Name:Sogroya, Ngenla	
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 ALL of the following:

1.1.1 Diagnosis of panhypopituitarism

**AND**

1.1.2 Prescribed by an endocrinologist

**AND**

1.1.3 ONE of the following:

1.1.3.1 Failure to ONE of the following, confirmed by claims history or submission of medical records:

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

1.1.3.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

1.2 ALL of the following:

1.2.1 Diagnosis of pediatric GH (growth hormone) deficiency as confirmed by ONE of the following:

1.2.1.1 Projected height (as determined by extrapolating pre-treatment growth trajectory

along current channel to 18-20 year mark) is greater than 2.0 standard deviations [SD] below midparental height utilizing age and gender growth charts related to height

**OR**

**1.2.1.2** Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) utilizing age and gender growth charts related to height

**OR**

**1.2.1.3** Growth velocity is greater than 2 SD below mean for age and gender

**OR**

**1.2.1.4** Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed greater than 2 years compared with chronological age)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Patient is male and ONE of the following:

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**1.2.2.2** Patient is female and ONE of the following:

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**1.2.3** Submission of medical records (e.g., chart notes, laboratory values) documenting BOTH of the following:

**1.2.3.1** Patient has undergone TWO of the following provocative GH stimulation tests:

- Arginine
- Clonidine
- Glucagon
- Insulin
- Levodopa
- Growth hormone releasing hormone

**AND**

**1.2.3.2** Both GH response values are less than 10 micrograms per liter

**AND**

**1.2.4** ONE of the following:

**1.2.4.1** If the request is for Sogroya, the patient is 2.5 years of age or older

**OR**

**1.2.4.2** If the request is for Ngenla, the patient is 3 years of age or older

**AND**

**1.2.5** ONE of the following:

**1.2.5.1** Failure to ONE of the following, confirmed by claims history or submission of medical records:

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

**1.2.5.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**AND**

**1.2.6** Prescribed by an endocrinologist

Product Name: Sogroya, Ngenla	
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:*</p> <ul style="list-style-type: none"> <li>• Previous height and date obtained</li> <li>• Current height and date obtained</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - BOTH of the following:*</p> <ul style="list-style-type: none"> <li>• Expected adult height not attained</li> <li>• Documentation of expected adult height goal (e.g. genetic potential)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Calculated height (growth) velocity over the past 12 months</p> <p style="text-align: center;"><b>AND</b></p>	

**4 - ONE of the following:**

**4.1 Patient is a male and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**4.2 Patient is a female and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**5 - Prescribed by an endocrinologist**

Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.
-------	--

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Prader-Willi Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of Prader-Willi Syndrome</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Prescribed by an endocrinologist</b></p>	

**AND**

**3** - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Prader-Willi Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following criteria:

**1.1** BOTH of the following:

**1.1.1** Evidence of positive response to therapy (e.g., increase in total lean body mass, decrease in fat mass)

**AND**

**1.1.2** Prescribed by an endocrinologist

**OR**

**1.2** ALL of the following:

**1.2.1** Height increase of at least 2 centimeters per year over the previous year of treatment as documented by BOTH of the following:

- Previous height and date obtained

<ul style="list-style-type: none"> <li>• Current height and date obtained</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2 BOTH of the following:</b></p> <ul style="list-style-type: none"> <li>• Expected adult height not attained</li> <li>• Documentation of expected adult height goal</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.3 Prescribed by an endocrinologist</b></p>
--

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Growth Failure in Children Small for Gestational Age (SGA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of SGA (small for gestational age) based on demonstration of catch up growth failure in the first 24 months of life using a birth to 36 month growth chart as confirmed by BOTH of the following:</b></p> <p><b>1.1 Documentation that ONE of the following is below the third percentile for gestational age (greater than or equal to 2 standard deviations [SD] below population mean):</b></p> <ul style="list-style-type: none"> <li>• Birth weight</li> <li>• Birth length</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2 Patient has demonstrated failure of catch up growth in the first 24 months of life</b></p>	

**AND**

**2** - Documentation that height remains less than or equal to third percentile (greater than or equal to 2 SD below population mean)

**AND**

**3** - Prescribed by an endocrinologist

**AND**

**4** - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Growth Failure in Children Small for Gestational Age (SGA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - Documentation of BOTH of the following:\*

<ul style="list-style-type: none"> <li>• Expected adult height not attained</li> <li>• Expected adult height goal</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Prescribed by an endocrinologist</b></p>	
Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Turner Syndrome or Noonan Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of pediatric growth failure associated with ONE of the following:</b></p> <p><b>1.1 BOTH of the following:</b></p> <p><b>1.1.1 Turner Syndrome (Gonadal Dysgenesis)</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.2 Patient is female and ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Tanner stage less than 4</li> <li>• Bone age less than 14 years measured in the past 12 months</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2 BOTH of the following:</b></p>	

**1.2.1 Noonan Syndrome**

**AND**

**1.2.2 ONE of the following:**

**1.2.2.1 Patient is male and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**1.2.2.2 Patient is female and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**2 - Height is below the fifth percentile on growth charts for age and gender**

**AND**

**3 - Prescribed by an endocrinologist**

**AND**

**4 - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)**

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Turner Syndrome or Noonan Syndrome
-----------	------------------------------------

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:*</p> <ul style="list-style-type: none"> <li>• Previous height and date obtained</li> <li>• Current height and date obtained</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of BOTH of the following:*</p> <ul style="list-style-type: none"> <li>• Expected adult height not attained</li> <li>• Expected adult height goal</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by an endocrinologist</p>	
Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Short-Stature Homeobox (SHOX) Gene Deficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Diagnosis of pediatric growth failure with short-stature homeobox (SHOX) gene deficiency as confirmed by genetic testing

**AND**

**2** - ONE of the following:

**2.1** Patient is male and ONE of the following:

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**2.2** Patient is female and ONE of the following:

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**3** - Prescribed by an endocrinologist

**AND**

**4** - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Short-Stature Homeobox (SHOX) Gene Deficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

2 - Documentation of BOTH of the following:\*

- Expected adult height not attained
- Expected adult height goal

**AND**

3 - Prescribed by an endocrinologist

Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.
-------	--

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Growth Failure associated with Chronic Renal Insufficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pediatric growth failure associated with chronic renal insufficiency</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1 Patient is male and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 16 years measured in the past 12 months

**OR**

**2.2 Patient is female and ONE of the following:**

- Tanner stage less than 4
- Bone age less than 14 years measured in the past 12 months

**AND**

**3 - Prescribed by ONE of the following:**

- Endocrinologist
- Nephrologist

**AND**

**4 - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)**

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Growth Failure associated with Chronic Renal Insufficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - Documentation of BOTH of the following:\*

- Expected adult height not attained
- Expected adult height goal

**AND**

**3** - Prescribed by ONE of the following:

- Endocrinologist
- Nephrologist

Notes

\*Documentation of previous height, current height and goal expected adult height will be required for renewal.

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of adult growth hormone deficiency (GHD) as a result of ONE of the following:

**1.1** Clinical records supporting a diagnosis of childhood-onset GHD

**OR**

**1.2** BOTH of the following:

**1.2.1** Adult-onset GHD

**AND**

**1.2.2** Clinical records documenting that hormone deficiency is a result of hypothalamic-pituitary disease from organic or known causes (e.g., damage from surgery, cranial irradiation, head trauma, or subarachnoid hemorrhage)

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting **ONE** of the following:

**2.1** BOTH of the following:

**2.1.1** Patient has undergone **ONE** of the following GH (growth hormone) stimulation tests to confirm adult GH deficiency:

- Insulin tolerance test (ITT)
- ARG (Arginine) and GHRH (growth hormone releasing hormone)
- Glucagon
- ARG
- Macrilen (macimorelin)

**AND**

**2.1.2** **ONE** of the following peak GH values:

**2.1.2.1** ITT less than or equal to 5 micrograms per liter

**OR**

**2.1.2.2** GHRH and ARG of **ONE** of the following:

- Less than or equal to 11 micrograms per liter if body mass index [BMI] is less than 25 kilograms per meter squared
- Less than or equal to 8 micrograms per liter if BMI is greater than or equal to 25 and less than 30 kilograms per meter squared
- Less than or equal to 4 micrograms per liter if BMI is greater than or equal to 30 kilograms per meter squared

**OR**

**2.1.2.3** Glucagon less than or equal to 3 micrograms per liter

**OR**

**2.1.2.4** ARG less than or equal to 0.4 micrograms per liter

**OR**

**2.1.2.5** Macimorelin less than 2.8 nanograms per milliliter 30, 45, 60 and 90 minutes following macimorelin administration

**OR**

**2.2** BOTH of the following:

**2.2.1** Submission of medical records (e.g., chart notes, laboratory values) documenting deficiency of THREE of the following anterior pituitary hormones:

- Prolactin
- ACTH (adrenocorticotrophic hormone)
- TSH (thyroid stimulating hormone)
- FSH/LH (follicle-stimulating hormone/luteinizing hormone)

**AND**

**2.2.2** Insulin-like Growth Factor 1 (IGF-1)/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab

**AND**

**3 - ONE of the following:**

**3.1** Diagnosis of panhypopituitarism

**OR**

**3.2** Other diagnosis and not used in combination with the following:

- Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]
- Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]

**AND**

**4 - Prescribed by an endocrinologist**

**AND**

**5 - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)**

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Documentation of Insulin-like Growth Factor 1 (IGF-1)/Somatomedin C level within the past 12 months

**AND**

**2** - ONE of the following:

**2.1** Diagnosis of panhypopituitarism

**OR**

**2.2** Other diagnosis and not used in combination with the following:

- Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]
- Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]

**AND**

**3** - Prescribed by an endocrinologist

Product Name:Sogroya	
Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of adult growth hormone deficiency (GHD) as a result of ONE of the following:</p> <p><b>1.1</b> Clinical records supporting a diagnosis of childhood-onset GHD</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2 BOTH of the following:**

**1.2.1 Adult-onset GHD**

**AND**

**1.2.2 Clinical records documenting that hormone deficiency is a result of hypothalamic-pituitary disease from organic or known causes (e.g., damage from surgery, cranial irradiation, head trauma, or subarachnoid hemorrhage)**

**AND**

**2 - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:**

**2.1 BOTH of the following:**

**2.1.1 Patient has undergone ONE of the following GH (growth hormone) stimulation tests to confirm adult GH deficiency:**

- Insulin tolerance test (ITT)
- ARG (Arginine) and GHRH (growth hormone releasing hormone)
- Glucagon
- ARG
- Macrilen (macimorelin)

**AND**

**2.1.2 ONE of the following peak GH values:**

**2.1.2.1 ITT less than or equal to 5 micrograms per liter**

**OR**

**2.1.2.2 GHRH and ARG of ONE of the following:**

- Less than or equal to 11 micrograms per liter if body mass index [BMI] is less than 25 kilograms per meter squared
- Less than or equal to 8 micrograms per liter if BMI is greater than or equal to 25 and less than 30 kilograms per meter squared

- Less than or equal to 4 micrograms per liter if BMI is greater than or equal to 30 kilograms per meter squared

**OR**

**2.1.2.3** Glucagon less than or equal to 3 micrograms per liter

**OR**

**2.1.2.4** ARG less than or equal to 0.4 micrograms per liter

**OR**

**2.1.2.5** Macimorelin less than 2.8 nanograms per milliliter 30, 45, 60 and 90 minutes following macimorelin administration

**OR**

**2.2** BOTH of the following:

**2.2.1** Submission of medical records (e.g., chart notes, laboratory values) documenting deficiency of THREE of the following anterior pituitary hormones:

- Prolactin
- ACTH (adrenocorticotrophic hormone)
- TSH (thyroid stimulating hormone)
- FSH/LH (follicle-stimulating hormone/luteinizing hormone)

**AND**

**2.2.2** Insulin-like Growth Factor 1 (IGF-1)/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab

**AND**

**3** - ONE of the following:

**3.1** Diagnosis of panhypopituitarism

**OR**

**3.2** Other diagnosis and not used in combination with the following:

- Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]
- Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]

**AND**

**4** - Prescribed by an endocrinologist

**AND**

**5** - ONE of the following:

**5.1** Failure to ONE of the following, confirmed by claims history or submission of medical records:

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

**OR**

**5.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Somatropin (Norditropin)
- Somatropin (Omnitrope)

Product Name: Sogroya	
Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of Insulin-like Growth Factor 1 (IGF-1)/Somatomedin C level within the past 12 months</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Diagnosis of panhypopituitarism</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Other diagnosis and not used in combination with the following:</p> <ul style="list-style-type: none"> <li>• Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]</li> <li>• Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by an endocrinologist</p>	

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim	
Diagnosis	Transition Phase Adolescent Patients
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

**2** - Documentation of **ONE** of the following:

- Attained expected adult height
- Closed epiphyses on bone radiograph

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting **ONE** of the following:

**3.1** **BOTH** of the following:

**3.1.1** Documentation of high risk of growth hormone (GH) deficiency due to GH deficiency in childhood from **ONE** of the following:

**3.1.1.1** Embryopathic/congenital defects

**OR**

**3.1.1.2** Genetic mutations

**OR**

**3.1.1.3** Irreversible structural hypothalamic-pituitary disease

**OR**

**3.1.1.4** Panhypopituitarism

**OR**

**3.1.1.5** Deficiency of **THREE** of the following anterior pituitary hormones:

- ACTH (adrenocorticotrophic hormone)
- TSH (thyroid stimulating hormone)
- Prolactin
- FSH/LH (follicle-stimulating hormone/luteinizing hormone)

**AND**

**3.1.2 ONE** of the following:

**3.1.2.1** Insulin-like Growth Factor 1 (IGF-1)/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab

**OR**

**3.1.2.2 ALL** of the following:

**3.1.2.2.1** Patient does not have a low IGF-1/Somatomedin C level

**AND**

**3.1.2.2.2** Discontinued GH therapy for at least 1 month

**AND**

**3.1.2.2.3** Patient has undergone **ONE** of the following GH stimulation tests after discontinuation of therapy for at least 1 month:

- Insulin tolerance test (ITT)
- ARG (Arginine) and GHRH (growth hormone releasing hormone)
- ARG
- Glucagon

**AND**

**3.1.2.2.4 ONE** of the following peak GH values:

**3.1.2.2.4.1** ITT less than or equal to 5 micrograms per liter

**OR**

**3.1.2.2.4.2** GHRH and ARG of ONE of the following:

- Less than or equal to 11 micrograms per liter if body mass index [BMI] is less than 25 kilograms per meter squared
- Less than or equal to 8 micrograms per liter if BMI is greater than or equal to 25 and less than 30 kilograms per meter squared
- Less than or equal to 4 micrograms per liter if BMI is greater than or equal to 30 kilograms per meter squared

**OR**

**3.1.2.2.4.3** Glucagon less than or equal to 3 micrograms per liter

**OR**

**3.1.2.2.4.4** ARG less than or equal to 0.4 micrograms per liter

**OR**

**3.2** ALL of the following:

**3.2.1** At low risk of severe GH deficiency (e.g., due to isolated and/or idiopathic GH deficiency)

**AND**

**3.2.2** Discontinued GH therapy for at least 1 month

**AND**

**3.2.3** BOTH of the following:

**3.2.3.1** Patient has undergone ONE of the following GH stimulation tests after discontinuation of therapy for at least 1 month:

- ITT
- GHRH and ARG
- ARG
- Glucagon

**AND**

**3.2.3.2** ONE of the following peak GH values:

**3.2.3.2.1** ITT less than or equal to 5 micrograms per liter

**OR**

**3.2.3.2.2** GHRH and ARG of ONE of the following:

- Less than or equal to 11 micrograms per liter if body mass index [BMI] is less than 25 kilograms per meter squared
- Less than or equal to 8 micrograms per liter if BMI is greater than or equal to 25 and less than 30 kilograms per meter squared
- Less than or equal to 4 micrograms per liter if BMI is greater than or equal to 30 kilograms per meter squared

**OR**

**3.2.3.2.3** Glucagon less than or equal to 3 micrograms per liter

**OR**

**3.2.3.2.4** ARG less than or equal to 0.4 micrograms per liter

**AND**

**4** - Prescribed by an endocrinologist

**AND**

**5** - If the request is for a non-preferred medication, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (document reason or special circumstance) (See Table 1 in Background section for non-preferred products)

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Norditropin Flexpro, Nutropin AQ NuSpin, Omnitrope, Saizen, Zomacton, Zorbtive, Serostim

Diagnosis	Transition Phase Adolescent Patients
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive response to therapy (e.g., increase in total lean body mass, exercise capacity or IGF-1 [Insulin-like Growth Factor 1] and IGFBP-3 [Insulin-like growth factor binding protein 3] levels)

**AND**

**2** - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

**3** - Prescribed by an endocrinologist

Product Name: Serostim	
Diagnosis	Human Immunodeficiency Virus (HIV)-associated wasting syndrome or cachexia
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of human immunodeficiency virus (HIV)-associated wasting syndrome or cachexia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of ONE of the following:</p> <p>2.1 Unintentional weight loss of greater than 10 percent over the last 12 months</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Unintentional weight loss of greater than 7.5 percent over the last 6 months</p> <p style="text-align: center;"><b>OR</b></p> <p>2.3 Loss of 5 percent body cell mass (BCM) within 6 months</p> <p style="text-align: center;"><b>OR</b></p> <p>2.4 Body mass index (BMI) less than 20 kilograms per meter squared</p> <p style="text-align: center;"><b>OR</b></p> <p>2.5 ONE of the following:</p>	

**2.5.1** ALL of the following:

- Patient is male
- BCM less than 35 percent of total body weight
- BMI less than 27 kilograms per meter squared

**OR**

**2.5.2** ALL of the following:

- Patient is female
- BCM less than 23 percent of total body weight
- BMI less than 27 kilograms per meter squared

**AND**

**3** - A nutritional evaluation has been completed since onset of wasting first occurred

**AND**

**4** - Patient has not had weight loss as a result of other underlying treatable conditions (e.g., depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes)

**AND**

**5** - Patient's anti-retroviral therapy has been optimized to decrease the viral load

Product Name: Serostim	
Diagnosis	Human Immunodeficiency Virus (HIV)-associated wasting syndrome or cachexia
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Evidence of positive response to therapy (i.e., greater than or equal to 2 percent increase in body weight and/or body cell mass [BCM])

**AND**

2 - ONE of the following targets or goals has not been achieved:

- Weight
- BCM
- Body Mass Index (BMI)

Product Name:Zorbtive	
Diagnosis	Short Bowel Syndrome
Approval Length	*4 weeks
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Short Bowel Syndrome</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is currently receiving specialized nutritional support (e.g., intravenous parenteral nutrition, fluid, and micronutrient supplements)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient has not previously received 4 weeks of treatment with Zorbtive*</p>	
Notes	*Treatment with Zorbtive will not be authorized beyond 4 weeks. Administration for more than 4 weeks has not been adequately studied.

Product Name:Increlex	
Diagnosis	Severe Primary IGF-1 Deficiency / Growth Hormone Gene Deletion
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following criteria:</p> <p>1.1 Documentation of ALL of the following:</p> <p>1.1.1 Diagnosis of severe primary Insulin-like Growth Factor 1 (IGF-1) deficiency</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Height standard deviation score less than or equal to -3.0</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.3 Basal IGF-1 standard deviation score less than or equal to -3.0</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.4 Normal or elevated growth hormone levels</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.5 Documentation of open epiphyses on last bone radiograph</p> <p style="text-align: center;"><b>AND</b></p>	

<p><b>1.1.6</b> The patient will not be treated with concurrent growth hormone therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.7</b> Prescribed by an endocrinologist</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> ALL of the following:</p> <p><b>1.2.1</b> Diagnosis of growth hormone gene deletion and has developed neutralizing antibodies to growth hormone</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2</b> Documentation of open epiphyses on last bone radiograph</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.3</b> The patient will not be treated with concurrent growth hormone therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.4</b> Prescribed by an endocrinologist</p>
--

Product Name: Increlex	
Diagnosis	Severe Primary IGF-1 Deficiency / Growth Hormone Gene Deletion
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year of treatment as documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - Documentation of BOTH of the following:\*

- Expected adult height not obtained
- Expected adult height goal

**AND**

**3** - Patient is not treated with concurrent growth hormone therapy

**AND**

**4** - Prescribed by an endocrinologist

Notes	*Documentation of previous height, current height and goal expected adult height will be required for renewal.
-------	--

**2 . Background**

<b>Benefit/Coverage/Program Information</b>
<p><b>Table 1: Human Growth Hormone:</b></p> <p><b>Preferred Agents:</b></p>   <p>Somatropin (Norditropin®), Somatropin (Omnitrope®)</p>

**Nonpreferred Agents:**

Somatropin (Genotropin®, Humatrope®, NordiFlex®, Nutropin AQ® NuSpin™, Saizen®, Zorbtive®, Serostim®, and Zomacton®), Skytrofa™ (lonapegsomatropin-tcgd), Ngenla (somatrogen), Sogroya (somapacitan)

**Growth Stimulating Products** : Mecasermin (Increlex®)

**3 . Revision History**

Date	Notes
12/9/2024	Removed Nutropin from step thru agents

Haegarda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147287
<b>Guideline Name</b>	Haegarda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Haegarda	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p>1.1 C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

**1.2.1** Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosaminase 3-O-sulfotransferase 6

**OR**

**1.2.2** Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema

**OR**

**1.2.3** Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - Prescribed for the prophylaxis of HAE attacks

**AND**

**3** - Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Orladeyo, Takzyro)

**AND**

**4** - Prescriber attests that patient has experienced attacks of a severity and/or frequency such that they would clinically benefit from prophylactic therapy with Haegarda

**AND**

**5** - Prescribed by ONE of the following:

- Immunologist
- Allergist

Product Name: Haegarda

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response to Haegarda therapy

**AND**

**2** - Reduction in the utilization of on-demand therapies used for acute attacks (e.g., Berinert, Firazyr, Ruconest) as determined by claims information, while on Haegarda therapy

**AND**

**3** - Prescribed for the prophylaxis of HAE attacks

**AND**

**4** - Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Orladeyo, Takhzyro)

**AND**

**5** - Prescribed by ONE of the following:

- Immunologist
- Allergist

## 2 . Revision History

Date	Notes
5/13/2024	Copy core; New

HCG



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146536
<b>Guideline Name</b>	HCG
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Novarel, Chorionic Gonadotropin, Ovidrel, Pregnyl	
Diagnosis	Prepubertal Cryptorchidism
Approval Length	6 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prepubertal cryptorchidism not due to anatomical obstruction</p>	

Hemangeol



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164950
<b>Guideline Name</b>	Hemangeol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Hemangeol	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of proliferating infantile hemangioma

**AND**

2 - Prescriber provides a reason or special circumstance the patient cannot use generic propranolol oral solution

## 2 . Revision History

Date	Notes
2/10/2025	Updated formularies

Hemlibra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158193
<b>Guideline Name</b>	Hemlibra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Hemlibra	
Diagnosis	Hemophilia A with Inhibitors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hemophilia A</p>	

**AND**

**2** - Patient has developed high-titer factor VIII inhibitors [greater than 5 Bethesda units (BU)]

**AND**

**3** - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)

<b>Product Name:Hemlibra</b>	
Diagnosis	Hemophilia A with Inhibitors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Hemlibra therapy	

<b>Product Name:Hemlibra</b>	
Diagnosis	Hemophilia A without Inhibitors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - ONE of the following:	
1.1 BOTH of the following:	
1.1.1 Diagnosis of severe hemophilia A	

**AND**

**1.1.2** Documentation of endogenous factor VIII levels less than 1% of normal factor VIII [less than 0.01 international units/milliliter (IU/mL)]

**OR**

**1.2** BOTH of the following:

**1.2.1** ONE of the following:

**1.2.1.1** BOTH of the following:

**1.2.1.1.1** Diagnosis of moderate hemophilia A

**AND**

**1.2.1.1.2** Documentation of endogenous factor VIII level greater than or equal to 1% and less than 5% (greater than or equal to 0.01 IU/mL to less than 0.05 IU/mL)

**OR**

**1.2.1.2** BOTH of the following:

**1.2.1.2.1** Diagnosis of mild hemophilia A

**AND**

**1.2.1.2.2** Documentation of endogenous factor VIII level greater than or equal to 5% (greater than or equal to 0.05 IU/mL)

**AND**

**1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting a failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve

appropriate trough level, previous history of inhibitors) after a trial of prophylactic factor VIII replacement products

**OR**

**1.3 BOTH of the following:**

**1.3.1** Patient is currently on Hemlibra therapy as confirmed by claims history or submission of medical records

**AND**

**1.3.2** Diagnosis of hemophilia A

**AND**

**2** - Hemlibra is prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)

**AND**

**3** - Prescriber attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Adynovate, Afstyla, Altuviio, Eloctate, Jivi) for the treatment of breakthrough bleeding episodes

<b>Product Name:</b> Hemlibra	
Diagnosis	Hemophilia A without Inhibitors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Hemlibra therapy	

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting that the patient is not receiving Hemlibra in combination with an extended half-life factor VIII replacement product (e.g., Adynovate, Afstyla, Altuviio, Eloctate, Jivi) for the treatment of breakthrough bleeding episodes (Prescription claim history that does not show any concomitant extended half-life factor VIII replacement product claim within 60 days of reauthorization request may be used as documentation)

## **2 . Revision History**

Date	Notes
10/29/2024	Added new Hemlibra strengths. Updated list of examples of extended half-life factor VIII replacement products.

Hepatitis C Criteria



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148186
<b>Guideline Name</b>	Hepatitis C Criteria
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Harvoni, ledipasvir/sofosbuvir (authorized generic of Harvoni)	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C genotype 1, 4, 5, or 6 infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Physician/provider asserts patient demonstrates treatment readiness, including the ability to adhere to the treatment regimen</p>	

**AND**

**3 - ONE of the following:**

**3.1** Patient is genotype 1 or 4 and has a history of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Sofosbuvir/velpatasvir (authorized generic of Epclusa)
- Mavyret
- Zepatier

**OR**

**3.2** Patient is genotype 5 or 6 and has a history of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Sofosbuvir/velpatasvir (authorized generic of Epclusa)
- Mavyret

**OR**

**3.3** Patient is currently on Harvoni (ledipasvir/sofosbuvir) therapy

**AND**

**4 -** Patient is NOT receiving the requested medication in combination with another HCV (hepatitis C virus) direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Mavyret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]

**AND**

**5 -** The requested regimen is an approvable regimen based on patient genotype and characteristics (See Table 1 in Background section)

**AND**

<b>6</b> - If brand is requested, the provider must submit explanation of medical necessity for brand versus authorized generic	
Notes	Approval length is by regimen based on patient genotype and characteristics in Table 1.

Product Name: Sovaldi	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of chronic hepatitis C genotype 1, 2, 3, or 4 infection</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Physician/provider asserts patient demonstrates treatment readiness, including the ability to adhere to the treatment regimen</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <p><b>3.1</b> Patient is genotype 1 or 4 and has a history of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Sofosbuvir/velpatasvir (authorized generic of Epclusa)</li> <li>• Mavyret</li> <li>• Zepatier</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> Patient is genotype 2 or 3 and has a history of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Sofosbuvir/velpatasvir (authorized generic of Epclusa)</li> <li>• Mavyret</li> </ul>	

<b>OR</b>	
3.3 Patient is currently on Sovaldi therapy	
<b>AND</b>	
4 - Patient is NOT receiving the requested medication in combination with another HCV (hepatitis C virus) direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), Zepatier (elbasvir/grazoprevir)]	
<b>AND</b>	
5 - The requested regimen is an approvable regimen based on patient genotype and characteristics (see Table 2 in Background section)	
Notes	Approval length is by regimen based on patient genotype and characteristics in Table 2.

Product Name:Vosevi	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Physician/provider asserts patient demonstrates treatment readiness, including the ability to adhere to the treatment regimen</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - The patient is without cirrhosis or has compensated cirrhosis (Child-Pugh A)</p>	

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Patient is genotype 1, 2, 3, 4, 5, or 6 and had virologic failure after completing previous treatment of at least 4 weeks' duration with an HCV (hepatitis C virus) regimen containing an NS5A (nonstructural protein 5A) inhibitor as confirmed by claims history or submission of medical records

**AND**

**4.1.2** If the patient is genotype 1 and has NOT been previously treated with an NS3/4A (nonstructural protein 3/4A) inhibitor, history of intolerance or contraindication to Mavyret (please specify intolerance or contraindication)

**OR**

**4.2** ALL of the following:

**4.2.1** Patient is genotype 1a or 3 and had virologic failure after completing previous treatment of at least 4 weeks' duration with an HCV regimen containing sofosbuvir without an NS5A inhibitor as confirmed by claims history or submission of medical records

**AND**

**4.2.2** If patient is genotype 1a and has been treated with or without an NS3/4A inhibitor, history of intolerance or contraindication to Mavyret (please specify intolerance or contraindication)

**AND**

**4.2.3** If patient is genotype 3 and has NOT been treated with an NS3/4A inhibitor, history of intolerance or contraindication to Mavyret (please specify intolerance or contraindication)

<b>OR</b>	
4.3 Patient is currently on Vosevi therapy	
<b>AND</b>	
5 - Patient is NOT receiving the requested medication in combination with another HCV direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]	
<b>AND</b>	
6 - The requested regimen is an approvable regimen based on patient genotype and characteristics (See Table 3 in Background section)	
Notes	Approval length is by regimen based on patient genotype and characteristics in Table 3.

Product Name: Zepatier	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C genotype 1 or 4 infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Physician/provider asserts patient demonstrates treatment readiness, including the ability to adhere to the treatment regimen</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving the requested medication in combination with another HCV</p>	

(hepatitis C virus) direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir)]

**AND**

**4** - The requested regimen is an approvable regimen based on patient genotype and characteristics (See Table 4 in Background section)

Notes	Approval length is by regimen based on patient genotype and characteristics in Table 4.
-------	---

## 2 . Background

Benefit/Coverage/Program Information		
<b>Table 1. Harvoni or ledipasvir/sofosbuvir (authorized generic of Harvoni)</b>		
<b>Recommended treatment regimen and duration:</b>		
Genotype	Patient Population	Regimen and Duration
Genotype 1	Treatment-naïve without cirrhosis or with compensated cirrhosis (Child-Pugh A)	HARVONI 12 weeks*
	Treatment-experienced** without cirrhosis	HARVONI 12 weeks
	Treatment-experienced** with compensated cirrhosis (Child-Pugh A)	HARVONI 24 weeks <sup>+</sup>
	Treatment-naïve and treatment-experienced** with decompensated cirrhosis (Child-Pugh B or C)	HARVONI + ribavirin 12 weeks
Genotype 1 or 4	Treatment-naïve and treatment-experienced** liver transplant recipients without cirrhosis, or with compensated cirrhosis (Child-Pugh A)	HARVONI + ribavirin 12 weeks

Genotype 4, 5, or 6	Treatment-naïve and treatment-experienced** without cirrhosis or with compensated cirrhosis (Child-Pugh A)	HARVONI 12 weeks
---------------------	--	------------------

\*HARVONI for 8 weeks can be considered in treatment-naïve genotype 1 patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL

\*\*Treatment-experienced adult and pediatric patients have failed a peginterferon alfa +/- ribavirin based regimen with or without an HCV protease inhibitor

\*HARVONI + ribavirin for 12 weeks can be considered in treatment-experienced genotype 1 patients with cirrhosis who are eligible for ribavirin

**Table 2. Sovaldi**

**Recommended Adult Treatment Regimen and Duration**

	Adult Patient Population	Regimen and Duration
Genotype 1 or 4	Treatment naïve without cirrhosis or with compensated cirrhosis (Child-Pugh A)	SOVALDI + peginterferon alfa + ribavirin 12 weeks
Genotype 2	Treatment naïve and treatment experienced* without cirrhosis or with compensated cirrhosis (Child-Pugh A)	SOVALDI + ribavirin 12 weeks
Genotype 3	Treatment naïve and treatment experienced* without cirrhosis or with compensated cirrhosis (Child-Pugh A)	SOVALDI + ribavirin 24 weeks

SOVALDI in combination with ribavirin for 24 weeks can be considered for adult patients with genotype 1 infection who are interferon ineligible.

SOVALDI should be used in combination with ribavirin for treatment of HCV in adult patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation, whichever occurs first.

\*Treatment-experienced patients have failed an interferon based regimen with or without ribavirin

**Recommended Treatment Regimen and Duration for Pediatric Patients 3 Years of Age and Older**

	<b>Pediatric Patient Population 3 Years of Age and Older</b>	<b>Regimen and Duration</b>
Genotype 2	Treatment naïve and treatment experienced* without cirrhosis or with compensated cirrhosis (Child-Pugh A)	SOVALDI + ribavirin 12 weeks
Genotype 3	Treatment naïve and treatment experienced* without cirrhosis or with compensated cirrhosis (Child-Pugh A)	SOVALDI + ribavirin 24 weeks

\*Treatment experienced patients have failed an interferon based regimen with or without ribavirin

**Table 3. Vosevi**

<b>Genotype</b>	<b>Patients previously treated with an HCV regimen containing:</b>	<b>VOSEVI Duration</b>
1, 2, 3, 4, 5, or 6	An NS5A inhibitor <sup>1</sup>	12 weeks
1a or 3	Sofosbuvir without an NS5A inhibitor <sup>2</sup>	12 weeks

1. In clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir.

2. In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir or telaprevir).

**Table 4. Zepatier**

**Dosage Regimens and Durations for ZEPATIER in Patients with Genotype 1 or 4 HCV with or without Cirrhosis**

Patient Population	Treatment	Duration
Genotype 1a: treatment naïve or PegIFN/RBV experienced* <u>without</u> baseline NS5A polymorphisms <sup>+</sup>	ZEPATIER	12 weeks
Genotype 1a: treatment naïve or PegIFN/RBV experienced* <u>with</u> baseline NS5A polymorphisms <sup>+</sup>	ZEPATIER + ribavirin	16 weeks
Genotype 1b: treatment naïve or PegIFN/RBV experienced*	ZEPATIER	12 weeks
Genotype 1a or 1b: PegIFN/RBV/PI experienced <sup>++</sup>	ZEPATIER + ribavirin	12 weeks
Genotype 4: treatment naïve	ZEPATIER	12 weeks
Genotype 4: PegIFN/RBV experienced*	ZEPATIER + ribavirin	16 weeks

\*Peginterferon alfa + ribavirin

+Polymorphisms at amino acid positions 28, 30, 31, or 93

++Peginterferon alfa + ribavirin + HCV NS3/4 A protease inhibitor

### 3 . Revision History

Date	Notes
6/13/2024	New guideline specific to NM

Hetlioz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146538
<b>Guideline Name</b>	Hetlioz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Hetlioz, generic tasimelteon, Hetlioz LQ	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p> <p>1.1.1 Diagnosis of non-24-hour sleep wake disorder (also known as free-running disorder,</p>	

free-running or non-entrained type circadian rhythm sleep disorder, or hypnnycthemeral syndrome)

**AND**

**1.1.2** Patient is totally blind (has no light perception)

**OR**

**1.2** Diagnosis of nighttime sleep disturbances in Smith-Magenis-Syndrome (SMS)

**AND**

**2** - ONE of the following:

**2.1** History of contraindication or intolerance to melatonin therapy (please specify contraindication or intolerance)

**OR**

**2.2** BOTH of the following:

**2.2.1** Failure of at least 6 months of continuous therapy (i.e., uninterrupted daily treatment) with melatonin, as confirmed by claims history or submission of medical records

**AND**

**2.2.2** Continuous trial of melatonin was done under the guidance of a specialist in sleep disorders

**AND**

**3** - Prescribed by or in consultation with a specialist in sleep disorders

Product Name: Brand Hetlioz, generic tasimelteon, Hetlioz LQ

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to therapy	

HIV



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-203227
<b>Guideline Name</b>	HIV
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brand Viread, generic tenofovir disoproxil fumarate	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• HIV (human immunodeficiency virus)</li> <li>• Hepatitis B</li> </ul>	

<ul style="list-style-type: none"> <li>HIV post-exposure prophylaxis (PEP)</li> </ul>	
Notes	Approval Duration: 12 months for HIV and hepatitis B; 4 weeks for PEP.

Product Name: Brand Truvada, generic emtricitabine/tenofovir disoproxil fumarate*	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>HIV (human immunodeficiency virus)</li> <li>Pre-exposure prophylaxis (PrEP)</li> <li>HIV post-exposure prophylaxis (PEP)</li> </ul>	
Notes	Approval Duration: 12 months for HIV and PrEP; 4 weeks for PEP.  *This criteria does not apply to Maryland, the medication is open access.

Product Name: Aptivus, Viracept, nevirapine, nevirapine ER	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of HIV (human immunodeficiency virus)</p>	

Product Name: Stribild	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1 - ONE of the following:**

**1.1** Diagnosis of post-exposure prophylaxis (PEP)

**OR**

**1.2** BOTH of the following:

**1.2.1** Diagnosis of HIV (human immunodeficiency virus)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Provider gives a reason or special circumstance as to why the patient is not an appropriate candidate for three preferred\* products, one of which must be Genvoya (please specify why the patient is not a candidate)

**OR**

**1.2.2.2** Continuation of current therapy

Notes	Approval Duration: 12 months for HIV; 4 weeks for PEP.  *See Table 1 in Background for PDL links.
-------	---

Product Name:(All other HIV medications which do not have criteria above) Brand Selzentry, generic maraviroc, Fuzeon, Tivicay, Tivicay PD, Isentress, Isentress HD, Brand Reyataz, generic atazanavir, Brand Prezista, generic darunavir, Brand Lexiva, generic fosamprenavir, Brand Norvir, generic ritonavir, Brand Ziagen, generic abacavir, Brand Emtriva, generic emtricitabine, Brand Epivir, generic lamivudine, stavudine, Brand Retrovir, generic zidovudine, Pifeltro, Brand Sustiva, generic efavirenz, Brand Intelence, generic etravirine, Edurant, Tybost, Brand Epzicom, generic abacavir/lamivudine, Evotaz, Dovato, Prezcobix, Cimduo, Brand Combivir, generic lamivudine/zidovudine, Brand Kaletra, generic lopinavir/ritonavir, Triumeq, Triumeq PD, Trizivir, Delstrigo, efavirenz/emtricitabine/tenofovir, Brand Symfi Lo, Brand Symfi, generic efavirenz/lamivudine/tenofovir, Odefsey, Symtuza, Juluca, Biktarvy, Complera, Genvoya

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - ONE of the following:

1.1 If the request is for a preferred\* medication, ONE of the following diagnoses:

- HIV (human immunodeficiency virus)
- HIV post-exposure prophylaxis (PEP)

**OR**

1.2 If the request is for a non-preferred\* medication, ONE of the following:

1.2.1 Diagnosis of post-exposure prophylaxis (PEP)

**OR**

1.2.2 BOTH of the following:

1.2.2.1 Diagnosis of HIV (human immunodeficiency virus)

**AND**

1.2.2.2 ONE of the following:

1.2.2.2.1 Provider gives a reason or special circumstance as to why the patient is not an appropriate candidate for three preferred\* products (please specify why the patient is not a candidate)

**OR**

1.2.2.2.2 Continuation of current therapy

Notes	<p>This guideline does NOT include Descovy and Rukobia. These medications have drug specific guidelines.</p> <p>Approval Duration: 12 months for HIV; 4 weeks for PEP.</p>
-------	--

	*See Table 1 in Background for PDL links.
--	---

## 2 . Background

Benefit/Coverage/Program Information
<p><b>Table 1: PDL Links</b></p> <p><b>CO:</b> <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p><b>MD:</b> <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p><b>PA CHIP:</b> <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p><b>IN:</b> <a href="https://www.uhcprovider.com/en/health-plans-by-state/indiana-health-plans/in-comm-plan-home/in-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/indiana-health-plans/in-comm-plan-home/in-cp-pharmacy.html</a></p> <p><b>NM:</b> <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>

## 3 . Revision History

Date	Notes
3/4/2025	Combined formularies, but removed NY/NY EPP from markets in scope as HIV drugs are moving to open access for these markets. Removed Brand Atripla as a target (obsolete). Moved Biktarvy, Complera, Genvoya, and Stribild as targets to this guideline (previously all stand alone gls). Updated criteria for non-preferred requests. Updated list of PDL links in background section. Updated notes, where applicable. Minor cosmetic updates.

Hycamtin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146539
<b>Guideline Name</b>	Hycamtin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Hycamtin, generic topotecan	
Diagnosis	Small Cell Lung Cancer (SCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of small cell lung cancer (SCLC)</p>	

**AND**

**2** - Patient has experienced a relapse of disease after initial first-line chemotherapy (e.g., cisplatin with etoposide)

Product Name:Brand Hycamtin, generic topotecan	
Diagnosis	Merkel Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of Merkel cell carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is M1 disseminated</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has a contraindication to or disease has progressed on anti-PD-L1 or anti-PD-1 therapy</p>	

Product Name:Brand Hycamtin, generic topotecan	
Diagnosis	Small Cell Lung Cancer (SCLC), Merkel Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Hycamtin (topotecan) therapy

Product Name:Brand Hycamtin, generic topotecan

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Brand Hycamtin, generic topotecan

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Hycamtin (topotecan) therapy

Hyftor



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146338
<b>Guideline Name</b>	Hyftor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Hyftor	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of tuberous sclerosis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - One of the following:

**2.1** One or more of the following major features:

- Hypomelanotic macules (At least 3; at least 5 mm diameter)
- Angiofibroma (At least 3) or fibrous cephalic plaque
- Ungual fibromas (At least 2)
- Shagreen patch
- Multiple retinal hamartomas
- Multiple cortical tubers and/or radial migration lines
- Subependymal nodule (At least 2)
- Subependymal giant cell astrocytoma
- Cardiac rhabdomyoma
- Lymphangiomyomatosis (LAM)
- Angiomyolipomas (At least 2)

**OR**

**2.2** Two or more of the following minor features:

- “Confetti” skin lesions
- Dental enamel pits (At least 3)
- Intraoral fibromas (At least 2)
- Retinal achromic patch
- Multiple renal cysts
- Nonrenal hamartomas
- Sclerotic bone lesions

**OR**

**2.3** Confirmed presence of a mutation in the TSC1 or TSC2 gene

**AND**

**3** - Patient has facial angiofibroma associated with tuberous sclerosis

**AND**

**4** - Patient is not receiving Hyftor in combination with a systemic mTOR (mechanistic target of rapamycin) inhibitor [e.g., Rapamune (sirolimus), Afinitor (everolimus)]

**AND**

**5** - Hyftor is being prescribed by, or in consultation, with a dermatologist, neurologist, or oncologist

Product Name:Hyftor	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy (e.g., improvement in skin lesions)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Hyftor in combination with a systemic mTOR inhibitor [e.g., Rapamune (sirolimus), Afinitor (everolimus)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Hyftor is being prescribed by, or in consultation, with a dermatologist, neurologist, or oncologist</p>	

Ibrance



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146540
<b>Guideline Name</b>	Ibrance
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Ibrance	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced, recurrent, or metastatic breast cancer</p>	

<b>AND</b>
<b>2</b> - Disease is hormone-receptor (HR)-positive
<b>AND</b>
<b>3</b> - Disease is human epidermal growth factor receptor 2 (HER2)-negative
<b>AND</b>
<b>4</b> - ONE of the following:
<ul style="list-style-type: none"> <li>• Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane)</li> <li>• Used in combination with Faslodex (fulvestrant)</li> </ul>

<b>Product Name:</b> Ibrance	
Diagnosis	Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of unresectable retroperitoneal WD-DDLS (well-differentiated/dedifferentiated liposarcoma)	

<b>Product Name:</b> Ibrance	
Diagnosis	Breast Cancer, Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Ibrance therapy</p>	

Product Name:Ibrance	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Ibrance will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Ibrance	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ibrance therapy</p>	

Iclusig



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146541
<b>Guideline Name</b>	Iclusig
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Iclusig	
Diagnosis	Chronic Myelogenous / Myeloid Leukemia (CML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic myelogenous/ myeloid leukemia (CML)</p>	

**AND**

**2** - One of the following:

**2.1** BOTH of the following:

- Disease is in the chronic phase
- Patient has resistance or intolerance to two or more tyrosine kinase inhibitor (TKI) therapies [e.g., imatinib mesylate, Sprycel (dasatinib), or Tasisna (nilotinib)]

**OR**

**2.2** Confirmed documentation of T315I mutation

**OR**

**2.3** BOTH of the following:

- Disease is in the accelerated or blast phase
- No other kinase inhibitors are indicated

Product Name:Iclusig	
Diagnosis	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)	

Product Name:Iclusig

Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - One of the following:</p> <p>2.1 Patient has a FGFR1 (fibroblast growth factor receptor 1) rearrangement</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Patient has an ABL1 (gene) rearrangement</p>	

Product Name: Iclusig	
Diagnosis	Gastrointestinal Stromal Tumors (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p>	

- Gross residual disease (R2 resection)
- Unresectable primary disease
- Tumor rupture
- Recurrent/metastatic disease after progression on approved therapies (e.g. imatinib, sunitinib, regorafenib, and standard dose ripretinib)

Product Name:Iclusig	
Diagnosis	Chronic Myelogenous / Myeloid Leukemia (CML), Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL), Myeloid/Lymphoid Neoplasms, Gastrointestinal Stromal Tumors (GIST)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Iclusig therapy</p>	

Product Name:Iclusig	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Iclusig	
Diagnosis	NCCN Recommended Regimen

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Iclusig therapy	

ICS.LABA Combination Products



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158104
<b>Guideline Name</b>	ICS.LABA Combination Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:generic budesonide/formoterol, generic Breyna	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 BOTH of the following:</p> <p>1.1.1 Diagnosis of COPD</p>	

**AND**

**1.1.2 ONE of the following:**

**1.1.2.1 Failure of ONE of the following confirmed by claims history or submitted medical records**

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**1.1.2.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):**

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**1.2 BOTH of the following:**

**1.2.1 Diagnosis of asthma**

**AND**

**1.2.2 ONE of the following:**

**1.2.2.1 Patient is less than 12 years of age**

**OR**

**1.2.2.2 ONE of the following:**

**1.2.2.2.1 Failure of ONE of the following confirmed by claims history or submitted medical records:**

- fluticasone/salmeterol (authorized generic of AirDuo Resplick)

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**1.2.2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- fluticasone/salmeterol (authorized generic of AirDuo Resplick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

Product Name:fluticasone/vilanterol (authorized generic of Breo Ellipta)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of asthma</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 BOTH of the following:</p> <p>1.2.1 ONE of the following:</p> <p>1.2.1.1 Failure of ONE of the following confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>• fluticasone/salmeterol (authorized generic of AirDuo Resplick)</li> <li>• fluticasone propionate/salmeterol diskus (generic Advair Diskus)</li> <li>• Wixela Inhub (generic Advair Diskus)</li> </ul> <p style="text-align: center;"><b>OR</b></p>	

**1.2.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- fluticasone/salmeterol (authorized generic of AirDuo Respiclick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Failure of Breyna or budesonide/formoterol (generic of Symbicort) confirmed by claims history or submitted medical records

**OR**

**1.2.2.2** History of intolerance or contraindication to Breyna or budesonide/formoterol (generic of Symbicort) (please specify intolerance or contraindication)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of COPD

**AND**

**2.2** ONE of the following:

**2.2.1** Failure of ONE of the following confirmed by claims history or submitted medical records

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure of Breyna or budesonide/formoterol (generic of Symbicort) confirmed by claims history or submitted medical records

**OR**

**2.3.2** History of intolerance or contraindication to Breyna or budesonide/formoterol (generic of Symbicort) (please specify intolerance or contraindication)

Product Name: Advair HFA, fluticasone-salmeterol (authorized generic of Advair HFA), Dulera, AirDuo Digihaler, AirDuo Respiclick \*

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of asthma

**AND**

**2** - ONE of the following:

**2.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- fluticasone/salmeterol (authorized generic of AirDuo Respiclick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- fluticasone/salmeterol (authorized generic of AirDuo Resplick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**3** - ONE of the following:

**3.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

Notes

\*Policy applies to Brand Necessary requests

Product Name: Brand Symbicort, Brand Advair Diskus\*

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

**Approval Criteria**

**1** - All of the following:

**1.1** Diagnosis of asthma

**AND**

**1.2** ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** Patient is less than 12 years of age

**AND**

**1.2.1.2** ONE of the following:

**1.2.1.2.1** Failure of Breyna or budesonide/formoterol (generic of Symbicort) confirmed by claims history or submitted medical records

**OR**

**1.2.1.2.2** History of intolerance or contraindication to Breyna or budesonide/formoterol (generic of Symbicort) (please specify intolerance or contraindication)

**OR**

**1.2.2** BOTH of the following:

**1.2.2.1** ONE of the following:

**1.2.2.1.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- fluticasone/salmeterol (authorized generic of AirDuo Respiclick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**1.2.2.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- fluticasone/salmeterol (authorized generic of AirDuo Respiclick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**1.2.2.2** ONE of the following:

**1.2.2.2.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**1.2.2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**2** - All of the following:

**2.1** Diagnosis of chronic obstructive pulmonary disease (COPD)

**AND**

**2.2** ONE of the following:

**2.2.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)

- Wixela Inhub (generic Advair Diskus)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**2.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

Notes	*Policy applies to Brand Necessary requests
-------	---

Product Name: Breo Ellipta*	
-----------------------------	--

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - BOTH of the following:

**1.1** Diagnosis of asthma

**AND**

**1.2** BOTH of the following:

**1.2.1** ONE of the following:

**1.2.1.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- fluticasone/salmeterol (authorized generic of AirDuo Resplick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**1.2.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- fluticasone/salmeterol (authorized generic of AirDuo Resplick)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**1.2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Breyna or budesonide/formoterol (generic of Symbicort) )

- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of chronic obstructive pulmonary disease (COPD)

**AND**

**2.2** ONE of the following:

**2.2.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**2.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

**OR**

**2.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Breyna or budesonide/formoterol (generic of Symbicort)
- fluticasone/vilanterol (authorized generic of Breo Ellipta)

Notes

\*Policy applies to Brand Necessary requests

## 2 . Revision History

Date	Notes
10/28/2024	Added new Breo Ellipta strength. Clarified preferred Respiclick product in T/F language.

Idhifa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157998
<b>Guideline Name</b>	Idhifa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Idhifa	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia (AML)</p>	

**AND**

**2** - AML is IDH2 (isocitrate dehydrogenase 2) mutation-positive

**AND**

**3** - ONE of the following:

**3.1** Disease is relapsed or refractory

**OR**

**3.2** Used as low-intensity treatment induction when not a candidate for intensive induction therapy

**OR**

**3.3** Used for consolidation therapy as continuation of low-intensity regimen used for induction

**OR**

**3.4** Used as follow-up after induction therapy following response to previous lower intensity therapy with the same regimen

Product Name: Idhifa	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient does not show evidence of progressive disease while on Idhifa therapy

Product Name:Idhifa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Idhifa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Idhifa therapy</p>	

## 2 . Revision History

Date	Notes
10/24/2024	Updated initial auth criteria for AML based on NCCN recommendations; Minor cosmetic updates.

Ilaris



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164637
<b>Guideline Name</b>	Ilaris
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Ilaris	
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Familial cold autoinflammatory syndrome (FCAS)
- Muckle-Wells Syndrome (MWS)

**AND**

2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of FCAS and MWS

Product Name: Ilaris	
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient is currently on Ilaris therapy for ONE of the following:

- Familial cold autoinflammatory syndrome (FCAS)
- Muckle-Wells Syndrome (MWS)

**AND**

2 - Documentation of positive clinical response to Ilaris therapy

Product Name: Ilaris	
Diagnosis	Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS)
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of TRAPS</p>	

Product Name: Ilaris	
Diagnosis	Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is currently on Ilaris therapy for tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Ilaris therapy, defined as a decrease in frequency or severity of attacks</p>	

Product Name: Ilaris	
Diagnosis	Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following</p> <ul style="list-style-type: none"> <li>• Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)</li> <li>• Mevalonate Kinase Deficiency (MKD)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of HIDS or MKD</p>	

Product Name: Ilaris	
Diagnosis	Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is currently on Ilaris therapy for ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)</li> <li>• Mevalonate Kinase Deficiency (MKD)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Ilaris therapy, defined as a decrease in frequency or severity of attacks</p>	

Product Name: Ilaris	
Diagnosis	Familial Mediterranean Fever (FMF)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Familial Mediterranean Fever (FMF)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of FMF</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <p>3.1 Failure to colchicine as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>3.2 History of contraindication or intolerance to colchicine (please specify contraindication or intolerance)</p>	

Product Name: Ilaris	
Diagnosis	Familial Mediterranean Fever (FMF)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient is currently on Ilaris therapy for Familial Mediterranean Fever (FMF)

**AND**

2 - Documentation of positive clinical response to Ilaris therapy, defined by a decrease in index disease flare or normalization of CRP (C-reactive protein)

**Product Name:Ilaris**

Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of systemic juvenile idiopathic arthritis (SJIA)

**AND**

2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of SJIA

**AND**

3 - Patient is NOT receiving Ilaris in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]

**Product Name:Ilaris**

Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is currently on Ilaris therapy for systemic juvenile idiopathic arthritis (SJIA)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Ilaris therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Ilaris in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]</p>	

Product Name: Ilaris	
Diagnosis	Still's Disease [Adult-Onset Still's Disease (AOSD)]
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Adult Onset Still's Disease (AOSD)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Diagnosis is made by, or in consultation with, a rheumatologist or immunologist with expertise in the diagnosis of Still's Disease</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Patient is not receiving Ilaris in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]

Product Name:Ilaris	
Diagnosis	Still's Disease [Adult-Onset Still's Disease (AOSD)]
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is currently on Ilaris therapy for Adult Onset Still's Disease (AOSD)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Ilaris therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Ilaris in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]</p>	

Product Name:Ilaris	
Diagnosis	Gout Flare
Approval Length	12 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of a gout flare</p>	

**AND**

**2** - ONE of the following:

**2.1** History of failure to BOTH of the following confirmed by claims history or submission of medical records:

- Colchicine
- Non-steroidal anti-inflammatory drugs (NSAIDs)

**OR**

**2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Colchicine
- Non-steroidal anti-inflammatory drugs (NSAIDs)

**AND**

**3** - Provider attests that the patient is not an appropriate candidate for systemic corticosteroids

**AND**

**4** - Prescribed by one of the following:

- Rheumatologist
- Nephrologist

**AND**

**5** - The patient has not received Ilaris in the past 12 weeks

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
2/3/2025	Updated formularies. Updated concurrent use criteria

Ilumya



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-182195
<b>Guideline Name</b>	Ilumya
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Ilumya	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - Diagnosis of chronic moderate to severe plaque psoriasis**

**AND**

**2 - Patient is NOT receiving Ilumya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]**

**AND**

**3 - Prescribed by, or in consultation with, a dermatologist**

**AND**

**4 - One of the following:**

**4.1 Patient is currently on Ilumya therapy as confirmed by claims history or submission of medical records**

**OR**

**4.2 BOTH of the following:**

**4.2.1 ONE of the following:**

**4.2.1.1 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab), Enbrel (etanercept)]**

**OR**

**4.2.1.2 ALL of the following:**

**4.2.1.2.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, genital involvement, or severe scalp psoriasis

**AND**

**4.2.1.2.2** ONE of the following:

- Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar
- History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication): Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar

**AND**

**4.2.1.2.3** ONE of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**AND**

**4.2.2** ONE of the following:

**4.2.2.1** Failure to TWO of the following preferred products as confirmed by claims history or submitted medical records

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication)

<ul style="list-style-type: none"> <li>• One of the preferred adalimumab products*</li> <li>• Enbrel (etanercept)</li> <li>• One of the preferred ustekinumab products*</li> </ul>	
Notes	*See PDL links in Background

<b>Product Name:Ilumya</b>	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ilumya therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Ilumya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

## 2 . Background

<b>Benefit/Coverage/Program Information</b>
<p><b>PDL Links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
2/21/2025	Updated formularies. Updated criteria to add ST through two preferred targeted immunomodulators. Updated safety check language. Removed reference to brand Stelara - replaced with generic

Imbruvica



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161251
<b>Guideline Name</b>	Imbruvica
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Imbruvica	
Diagnosis	B-Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of mantle cell lymphoma (MCL)</p>	

**AND**

**1.2** ONE of the following:

**1.2.1** Patient has received at least one prior therapy for MCL

**OR**

**1.2.2** Used in pre-treatment therapy in combination with Rituxan (rituximab) to limit the number of cycles with RHyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen

**OR**

**2** - Diagnosis of ONE of the following:

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

**OR**

**3** - BOTH of the following:

**3.1** Diagnosis of ONE of the following:

- Diffuse large B-cell lymphoma [non-GCB DLBCL (non-germinal center B-cell diffuse large B-cell) and non-candidate for transplant]
- Human Immunodeficiency Virus (HIV)-related B-cell lymphoma
- Post-transplant lymphoproliferative disorders
- Histologic transformation to diffuse large B-cell lymphoma
- Hairy cell leukemia
- Nodal or splenic marginal zone lymphoma (MZL)
- Extranodal marginal zone lymphoma (EMZL) of the stomach
- Extranodal marginal zone lymphoma (EMZL) of nongastric sites (noncutaneous)
- High grade B-cell lymphoma

**AND**

**3.2** Used as second-line or a subsequent therapy

Product Name:Imbruvica	
Diagnosis	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma</p>	

Product Name:Imbruvica	
Diagnosis	Primary CNS Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary central nervous system (CNS) lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Used as second-line or a subsequent therapy</p> <p style="text-align: center;"><b>OR</b></p>	

**2.2** Used as induction therapy if the patient is unsuitable or intolerant to high-dose methotrexate

**Product Name: Imbruvica**

Diagnosis	B-Cell Lymphoma, Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Primary CNS Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Imbruvica therapy

**Product Name: Imbruvica**

Diagnosis	Chronic Graft Versus Host Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic graft versus host disease

**AND**

2 - History of failure of at least one other systemic therapy [e.g., corticosteroids, mycophenolate, etc.] as confirmed by claims history or submission of medical records

**Product Name: Imbruvica**

Diagnosis	Chronic Graft Versus Host Disease
-----------	-----------------------------------

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient shows evidence of positive clinical response while on Imbruvica therapy</p>	

Product Name:Imbruvica	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Imbruvica	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Imbruvica therapy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
11/25/2024	Added rituximab to RHyperCVAD and minor formatting changes

Impavido



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146340
<b>Guideline Name</b>	Impavido
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Impavido	
Approval Length	28 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Visceral leishmaniasis due to Leishmania donovani</li> <li>Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, or Leishmania panamensis</li> <li>Mucosal leishmaniasis due to Leishmania braziliensis</li> <li>Primary Amebic Meningoencephalitis (PAM)</li> </ul>	

- Keratitis due to *Acanthamoeba*
- Amebic encephalitis due to *Balamuthia mandrillaris*

Inbrija



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146342
<b>Guideline Name</b>	Inbrija
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Inbrija	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Inbrija will be used as intermittent treatment for OFF episodes

**AND**

**3** - Prescribed by, or in consultation with, a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**4** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**5** - Patient continues to experience greater than or equal to 2 hours of OFF time per day despite optimal management of carbidopa/levodopa therapy including BOTH of the following:

- Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more before or one hour after a meal or avoidance of high protein diet
- Dose and dosing interval optimization

**AND**

**6** - ONE of the following:

**6.1** Failure to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes confirmed by claims history or submission of medical records (trial must be from two different classes):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

**OR**

**6.2** History of contraindication or intolerance to ALL anti-Parkinson's disease therapies from

the following adjunctive pharmacotherapy classes (please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

Product Name: Inbrija	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Inbrija therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication</p>	

Ingrezza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164976
<b>Guideline Name</b>	Ingrezza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Ingrezza	
Diagnosis	Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate to severe tardive dyskinesia

**AND**

2 - ONE of the following:

2.1 Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication

**OR**

2.2 Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist

Product Name: Ingrezza	
Diagnosis	Chorea associated with Huntington's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chorea associated with Huntington's disease</p>	

**AND**

**2** - Prescribed by or in consultation with **ONE** of the following:

- Neurologist
- Psychiatrist

Product Name: Ingrezza	
Diagnosis	Tardive Dyskinesia, Chorea associated with Huntington's Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ingrezza therapy</p>	

## 2 . Revision History

Date	Notes
2/11/2025	Updated formularies. Updated GPIs

Inhaled Corticosteroids



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-149518
<b>Guideline Name</b>	Inhaled Corticosteroids
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/4/2024
-----------------	----------

### 1 . Criteria

Product Name:Asmanex HFA, Asmanex Twisthaler	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of asthma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

**2.1** Failure of Brand Fluticasone propionate HFA confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to Brand Fluticasone propionate HFA (please specify intolerance or contraindication)

Product Name: Alvesco, ArmonAir Digihaler, Arnuity Ellipta, Flovent Diskus, Brand Flovent HFA, Pulmicort Flexhaler, Qvar RediHaler

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of asthma

**AND**

**2** - ONE of the following:

**2.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Brand Fluticasone propionate HFA
- Asmanex HFA or Asmanex Twisthaler

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Brand Fluticasone propionate HFA
- Asmanex HFA or Asmanex Twisthaler

Inlyta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158209
<b>Guideline Name</b>	Inlyta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Inlyta	
Diagnosis	Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of advanced renal cell carcinoma</p>	

**AND**

**1.2 ONE of the following:**

- Patient has failed one prior systemic therapy
- The requested medication will be used in combination with Bavencio (avelumab) or Keytruda (pembrolizumab)

**OR**

**2 - Diagnosis of relapsed or stage IV renal cell carcinoma**

Product Name: Inlyta	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Follicular Carcinoma</li> <li>• Oncocytic Carcinoma</li> <li>• Papillary Carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Disease is ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Recurrent and unresectable</li> <li>• Persistent</li> <li>• Metastatic</li> </ul>	

**AND**

**3** - Disease is not amenable to radioactive iodine treatment

Product Name:Inlyta	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of salivary gland tumor</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent and unresectable</li> <li>• Metastatic</li> </ul>	

Product Name:Inlyta	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of alveolar soft part sarcoma (ASPS)</p>	

**AND**

**2** - The requested medication will be used in combination with Keytruda (pembrolizumab)

Product Name: Inlyta	
Diagnosis	Renal Cell Carcinoma, Thyroid Carcinoma, Salivary Gland Tumor, Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Inlyta therapy</p>	

Product Name: Inlyta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Inlyta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Inlyta therapy</p>	

## 2 . Revision History

Date	Notes
10/29/2024	Updated initial auth criteria for RCC. Updated diagnosis header for RCC in reauth section. Minor update to initial auth criteria for NCCN Recommended Regimens with no changes to clinical intent; Minor cosmetic updates.

Inqovi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146548
<b>Guideline Name</b>	Inqovi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Inqovi	
Diagnosis	Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of myelodysplastic syndrome (MDS)</p>	

**AND**

**1.2** Patient is intermediate-1, intermediate-2, or high-risk per the International Prognostic Scoring System (IPSS)

**OR**

**2** - Diagnosis of chronic myelomonocytic leukemia (CMML)

Product Name: Inqovi	
Diagnosis	Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Inqovi therapy</p>	

Product Name: Inqovi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Inqovi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Inqovi therapy</p>	

Inrebic



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146549
<b>Guideline Name</b>	Inrebic
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Inrebic	
Diagnosis	Myelofibrosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis</p>	

**AND**

**2** - One of the following:

**2.1** Failure to Jakafi (ruxolitinib) confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to Jakafi (ruxolitinib) (please specify intolerance or contraindication)

**OR**

**2.3** Patient is currently on Inrebic therapy

Product Name:Inrebic	
Diagnosis	Myelofibrosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation that the patient has evidence of symptom improvement or reduction in spleen volume while on Inrebic	

Product Name:Inrebic	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia

**AND**

2 - Patient has a JAK2 (Janus kinase 2) rearrangement

**AND**

3 - ONE of the following:

3.1 Failure to Jakafi (ruxolitinib) confirmed by claims history or submitted medical records

**OR**

3.2 History of intolerance or contraindication to Jakafi (ruxolitinib) (please specify intolerance or contraindication)

**OR**

3.3 Patient is currently on Inrebic therapy

Product Name: Inrebic	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient does not show evidence of progressive disease while on Inrebic therapy

Product Name:Inrebic	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Inrebic	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Inrebic therapy</p>	

Insulin Pen Needles and Syringes



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-158147
<b>Guideline Name</b>	Insulin Pen Needles and Syringes
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Non-preferred insulin pen needles and insulin syringes	
Diagnosis	Non-Preferred
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - If the request is non-preferred*, history of failure to a preferred* BD (Becton Dickinson) insulin pen needle or syringe as confirmed by claims history or submission of medical records</p>	

<b>OR</b>	
<b>2</b> - If the request is non-preferred*, physician has provided documentation as to why the patient is unable to use a preferred* BD product (document rationale)	
Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

<b>Product Name:</b> All insulin pen needles and insulin syringes	
Diagnosis	Requests exceeding 6 pen needles or syringes per day*
Approval Length	12 month(s)
Guideline Type	Quantity Limit
<b>Approval Criteria</b>	
<b>1</b> - Physician confirmation that the patient requires a greater quantity because of more frequent delivery of insulin	
Notes	*The quantity limit for both pen needles and syringes is 6 of each per day.

## 2 . Revision History

Date	Notes
10/29/2024	Updated GPIs and moved PDL link.

Insulins



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146815
<b>Guideline Name</b>	Insulins
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Admelog vial, Apidra vial, Humalog 100U/ml vial, Insulin Aspart vial, Lyumjev vial	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Failure to insulin lispro vial confirmed by claims history or submission of medical records</p>	

**OR**

**1.2** History of contraindication or intolerance to insulin lispro vial (please specify intolerance or contraindication)

Product Name:Novolog vial, Fiasp vial	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p><b>1.1</b> Failure to BOTH of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• insulin lispro vial</li> <li>• Insulin Aspart vial</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• insulin lispro vial</li> <li>• Insulin Aspart vial</li> </ul>	

Product Name:Novolog Mix 70/30 vial, Novolog Mix 70/30 Relion vial	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1 - ONE of the following:**

**1.1** Failure to Insulin Aspart mix vial confirmed by claims history or submission of medical records

**OR**

**1.2** History of contraindication or intolerance to Insulin Aspart mix vial (please specify intolerance or contraindication)

**Product Name:**Humalog Mix 75/25 vial

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1 - ONE of the following:**

**1.1** Failure to Insulin lispro protamine/insulin lispro Kwikpen 75/25 100U/ML confirmed by claims history or submission of medical records

**OR**

**1.2** History of contraindication or intolerance to Insulin lispro protamine/insulin lispro Kwikpen 75/25 100U/ML (please specify intolerance or contraindication)

**Product Name:**Humulin R U-500 vial

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1 - Patient requires more than 200 units of insulin per day**

Product Name:Insulin Lispro Kwikpen, Insulin Lispro Junior Kwikpen	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 History of failure to insulin lispro vial as demonstrated by poorly controlled diabetes based on hemoglobin A1c</p> <p style="text-align: center;"><b>OR</b></p> <p>1.4 The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c</p>	

Product Name:Apidra Solostar pen, Humalog cartridge, Humalog Kwikpen, Humalog Junior Kwikpen, Insulin Aspart Penfill, Insulin Aspart Flexpen, Admelog Solostar pen, Lyumjev Kwikpen	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - ONE of the following:

**1.1** One of the following:

**1.1.1** Failure to insulin lispro vial confirmed by claims history or submission of medical records

**OR**

**1.1.2** History of contraindication or intolerance to insulin lispro vial (please specify intolerance or contraindication)

**OR**

**1.2** ONE of the following:

**1.2.1** A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin

**OR**

**1.2.2** A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin

**OR**

**1.2.3** The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

**AND**

**2** - ONE of the following:

**2.1** Failure to insulin lispro Kwikpen confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to insulin lispro Kwikpen (please specify intolerance or contraindication)

Product Name:Humalog Tempo Pen, Lyumjev Tempo Pen	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 ONE of the following:</p> <p>1.1.1 Failure to insulin lispro Kwikpen confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.1.2 History of contraindication or intolerance to insulin lispro Kwikpen (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Prescriber provides a reason or special circumstance the patient has to use the Tempo product</p>	

Product Name:Novolog Penfill, Novolog Flexpen, Fiasp Penfill, Fiasp Pumpcart, Fiasp FlexTouch	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - One of the following:

**1.1** One of the following:

**1.1.1** Failure to insulin lispro vial confirmed by claims history or submission of medical records

**OR**

**1.1.2** History of contraindication or intolerance to insulin lispro vial (please specify intolerance or contraindication)

**OR**

**1.2** ONE of the following:

- A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin
- A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin
- The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

**AND**

**2** - One of the following:

**2.1** Failure to BOTH of the following confirmed by claims history or submission of medical records:

- Insulin lispro Kwikpen
- Insulin aspart pen or cartridge

**OR**

**2.2** History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication):

- Insulin lispro Kwikpen
- Insulin aspart pen or cartridge

Product Name:Novolin R Flexpen, Novolin R Flexpen Relion	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Failure to ONE of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Humulin R U-100 vial</li> <li>• Novolin R U-100 vial</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Humulin R U-100 vial</li> <li>• Novolin R U-100 vial</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin</p> <p style="text-align: center;"><b>OR</b></p>	

**2.2** A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin

**OR**

**2.3** The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

Product Name: Humulin R U-500 Kwikpen

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - BOTH of the following:

**1.1** Patient requires more than 200 units of insulin per day

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to Humulin R U-500 vial confirmed by claims history or submission of medical records

**OR**

**1.2.2** History of contraindication or intolerance to Humulin R U-500 vial (please specify intolerance or contraindication)

**OR**

**2** - BOTH of the following:

**2.1** Patient requires more than 200 units of insulin per day

**AND**

**2.2** ONE of the following:

**2.2.1** A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin

**OR**

**2.2.2** A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin

**OR**

**2.2.3** The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

Product Name:Humulin N Kwikpen, Novolin N Flexpen, Novolin N Flexpen Relion	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Failure to ONE of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Humulin N U-100 vial</li> <li>• Novolin N U-100 vial</li> </ul> <p><b>OR</b></p>	

**1.2** History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication):

- Humulin N U-100 vial
- Novolin N U-100 vial

**OR**

**2** - ONE of the following:

**2.1** A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin

**OR**

**2.2** A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin

**OR**

**2.3** The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

Product Name: Humalog Mix Kwikpen 50/50, Insulin Aspart Flexpen 70/30, Humulin Kwikpen 70/30, Novolin Flexpen 70/30, Novolin Flexpen Relion 70/30

Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** Failure to the corresponding preferred insulin mix vial confirmed by claims history or submission of medical records

**OR**

**1.2** History of contraindication or intolerance to the corresponding preferred insulin mix vial (please specify intolerance or contraindication)

**OR**

**2** - ONE of the following:

**2.1** A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin

**OR**

**2.2** A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin

**OR**

**2.3** The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

Product Name:Novolog Mix 70/30 Flexpen, Novolog Mix 70/30 Flexpen Relion	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to the corresponding preferred insulin mix vial confirmed by claims history or submission of medical records</li> </ul>	

- History of contraindication or intolerance to the corresponding preferred insulin mix vial (please specify intolerance or contraindication)

**OR**

**1.2 ONE of the following:**

- A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin
- A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin
- The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

**AND**

**2 - ONE of the following:**

- Failure to Insulin Aspart Flexpen 70/30 100U/ML confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Insulin Aspart Flexpen 70/30 100U/ML (please specify intolerance or contraindication)

Product Name:Humalog Mix Kwikpen 72/25	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - One of the following:</b></p> <p><b>1.1 ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Failure to the corresponding preferred insulin mix vial confirmed by claims history or submission of medical records</li> <li>• History of contraindication or intolerance to the corresponding preferred insulin mix vial (please specify intolerance or contraindication)</li> </ul>	

**OR**

**1.2 ONE** of the following:

- A visual impairment that prevents the patient from using a vial and syringe to accurately draw up the dose of insulin
- A physical disability or handicap that prevents the patient from using a vial and syringe to draw up the dose and administer the insulin
- The patient is unable to use the vial dosage form of the drug due to documented poor compliance with vials and syringes resulting in poorly controlled diabetes based on hemoglobin A1c

**AND**

**2 - One** of the following:

- Failure to insulin lispro protamine/insulin lispro Kwikpen 75/25 100U/ML confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Insulin lispro protamine/insulin lispro Kwikpen 75/25 100U/ML (please specify intolerance or contraindication)

Product Name: Basaglar Kwikpen, Insulin Glargine Solostar 100U/ml, Insulin glargine-yfgn Pen, Semglee yfgn Pen Injector	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - BOTH</b> of the following:</p> <p><b>1.1 ONE</b> of the following:</p> <p><b>1.1.1</b> Failure to BOTH of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul>	

**OR**

**1.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**AND**

**1.2** The provider has given clinical justification why the patient is unable to use the preferred insulin glargine products

Product Name: Basaglar Tempo Pen	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 ONE of the following:</p> <p>1.1.1 Failure to BOTH of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.1.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul>	

**AND**

**1.2** Prescriber provides a reason or special circumstance the patient has to use the Tempo product

Product Name: Toujeo Solostar, Insulin Glargine Solostar 300U/ml, Toujeo Max Solostar, Insulin Glargine Max Solostar 300U/ml

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - BOTH of the following:

**1.1** ONE of the following:

**1.1.1** Failure to BOTH of the following confirmed by claims history or submission of medical records:

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**1.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**1.1.3** The provider has given clinical justification why the patient needs a concentrated glargine formulation

**AND**

**1.2** If the request is for Toujeo Solostar or Toujeo Solostar Max, ONE of the following:

**1.2.1** Failure to ONE of the following confirmed by claims history or submission of medical records:

- Insulin glargine Solostar 300U/ml
- Insulin glargine Max Solostar 300U/ml

**OR**

**1.2.2** History of intolerance or contraindication to ONE of the following (please specify intolerance or contraindication):

- Insulin glargine Solostar 300U/ml
- Insulin glargine Max Solostar 300U/ml

Product Name:Levemir Flexpen, Insulin Degludec Flextouch 100U/mL

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Failure to ONE of the following confirmed by claims history or submission of medical records:

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**2** - History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Rezvoglar Kwikpen
- Lantus (pens or vials)

Product Name:Tresiba Flextouch 100U/mL	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 Failure to ONE of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - The provider has given clinical justification why the patient is unable to use the insulin degludec flextouch product</p>	

Product Name:Insulin Degludec Flextouch 200U/mL	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Failure to ONE of the following confirmed by claims history or submission of medical records:</p>	

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**2** - History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**3** - The provider has given clinical justification why the patient needs a concentrated formulation

Product Name:Tresiba Flextouch 200U/mL	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - One of the following:</p> <p><b>1.1</b> Failure to ONE of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> <li>• Lantus (pens or vials)</li> </ul> <p><b>OR</b></p> <p><b>1.2</b> History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Rezvoglar Kwikpen</li> </ul>	

<ul style="list-style-type: none"> <li>Lantus (pens or vials)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.3</b> The provider has given clinical justification why the patient needs a concentrated formulation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The provider has given clinical justification why the patient is unable to use the insulin degludec flextouch product</p>
--

Product Name: Insulin Glargine vial, Insulin glargine-yfgn vial, Semglee yfgn vial	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - BOTH of the following:</p> <p><b>1.1</b> ONE of the following:</p> <p><b>1.1.1</b> Failure to BOTH of the following confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>Rezvoglar Kwikpen</li> <li>Lantus (pens or vials)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.2</b> History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>Rezvoglar Kwikpen</li> <li>Lantus (pens or vials)</li> </ul>	

**AND**

**1.2** The provider has given clinical justification why the patient is unable to use the preferred insulin glargine products

Product Name:Levemir vial, Insulin Degludec vial

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - ONE of the following:

**1.1** Failure to ONE of the following confirmed by claims history or submission of medical records:

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Rezvoglar Kwikpen
- Lantus (pens or vials)

Product Name:Tresiba vial

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1 - One of the following:**

**1.1 Failure to ONE of the following confirmed by claims history or submission of medical records:**

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**OR**

**1.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):**

- Rezvoglar Kwikpen
- Lantus (pens or vials)

**AND**

**2 - The provider has given clinical justification why the patient is unable to use the insulin degludec product**

Product Name:Admelog Solostar, Apidra, Insulin Aspart vial, Insulin Lispro vial, Humalog vial, Novolog vial, Novolog Relion vial, Fiasp vial, Lyumjev vial, Novolog Mix 70/30 vial, Novolog Mix 70/30 Relion vial, Humulin R U-500 vial, Apidra Solostar, Insulin Aspart Flexpen, Insulin Aspart Penfill, Insulin Lispro Junior Kwikpen, Insulin Lispro Kwikpen, Humalog Junior Kwikpen, Humalog Kwikpen, Humalog Tempo Pen, Novolog Flexpen, Novolog Flexpen Relion, Novolog Penfill, Fiasp Flextouch, Fiasp Penfill, Fiasp Pumpcart, Lyumjev Kwikpen, Lyumjev Tempo Pen, Novolin R Flexpen Relion, Novolin R Flexpen, Humulin R U-500 Kwikpen, Humulin N Kwikpen, Novolin N Flexpen Relion, Novolin N Flexpen, Humalog Mix 75/25 Kwikpen, Insulin Lispro Mix Kwikpen 72/25, Humalog Mix 50/50 Kwikpen, Insulin Aspart Protamine/Insulin Aspart 70/30 Flexpen, Humulin 70/30 Kwikpen, Novolin 70/30 Flexpen, Novolin 70/30 Flexpen Relion, Novolog Mix 70/30 Flexpen, Novolog Mix 70/30 Flexpen Relion, Lantus Solostar, Basaglar Tempo Pen, Toujeo Solostar, Insulin Glargine Solostar 300U/ml, Toujeo Max Solostar, Insulin Glargine Max Solostar 300U/ml, Semglee yfgn Pen Injector, Semglee yfgn vial Levemir Flexpen, Tresiba Flextouch, Insulin Degludec Flextouch, Semglee vial, Lantus vial, Levemir vial, Tresiba vial, Insulin Degludec vial, Basaglar Kwikpen, Insulin Glargine vial, Insulin Glargine-YFGN pen and vial, Insulin Glargine Solostar 100U/ml, Humulin R vial, Novolin R vial, Novolin R Relion vial, Humulin N vial, Novolin N Relion vial, Novolin N vial, Insulin Aspart Protamine/Insulin Aspart 70/30 vial, Humalog Mix 75/25 vial, Humalog Mix 50/50 vial, Humulin 70/30 vial, Novolin 70/30 Relion vial, Novolin 70/30 vial, Admelog vial, Humalog Cartridge, Rezvoglar Kwikpen

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p>1 - Quantity requests exceeding the limited amount will be approved based on physician confirmation that the patient requires a greater quantity due to poorly controlled diabetes based on blood glucose and/or hemoglobin A1c</p>	

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL Link:</b></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>

## 3 . Revision History

Date	Notes
4/30/2024	Removed PDL links for CORE markets and added PDL link for NM in background section.

Iqirvo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158160
<b>Guideline Name</b>	Iqirvo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Iqirvo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary biliary cholangitis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient does not have decompensated cirrhosis

**AND**

**3** - One of the following:

**3.1** Both of the following:

**3.1.1** Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)

**AND**

**3.1.2** Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal after at least 12 consecutive months of treatment with ursodeoxycholic acid (e.g., Urso, ursodiol)

**OR**

**3.2** History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso, ursodiol)  
[please specify contraindication or intolerance]

**AND**

**4** - Patient is not receiving Iqirvo in combination with Livdelzi (seladelpar) or Ocaliva (obeticholic acid)

**AND**

**5** - Prescribed by one of the following:

- Hepatologist
- Gastroenterologist

Product Name: Iqirvo

Approval Length

12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., laboratory values) documenting a reduction in alkaline phosphatase (ALP) level from pre-treatment baseline (i.e., prior to Iqirvo therapy)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient does not have decompensated cirrhosis</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Iqirvo in combination with Livdelzi (seladelpar) or Ocaliva (obeticholic acid)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by one of the following:</p> <ul style="list-style-type: none"> <li>• Hepatologist</li> <li>• Gastroenterologist</li> </ul>	

## 2 . Revision History

Date	Notes
10/29/2024	New

Iressa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146550
<b>Guideline Name</b>	Iressa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Iressa, generic gefitinib	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic non-small cell lung cancer (NSCLC)</p>	

**AND**

**2 - ONE of the following:**

**2.1** Tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions

**OR**

**2.2** Tumors are positive for exon 21 (L858R) substitution mutations

**OR**

**2.3** Tumors are positive for a known sensitizing EGFR mutation (e.g, exon 20 S768I mutation, exon 18 G719X mutation, exon 21 L861Q mutation)

Product Name:Brand Iressa, generic gefitinib	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Iressa therapy	

Product Name:Brand Iressa, generic gefitinib	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of central nervous system (CNS) cancer with metastatic lesions

**AND**

2 - Iressa is active against primary (NSCLC) tumor with a known epidermal growth factor receptor (EGFR) sensitizing mutation

Product Name: Brand Iressa, generic gefitinib	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Iressa therapy</p>	

Product Name: Brand Iressa, generic gefitinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Brand Iressa, generic gefitinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Iressa therapy</p>	

Iron Chelators



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146551
<b>Guideline Name</b>	Iron Chelators
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox	
Diagnosis	Chronic Iron Overload due to Blood Transfusion
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic iron overload (e.g., sickle cell anemia, thalassemia, etc.) due to blood transfusion</p>	

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox	
Diagnosis	Chronic Iron Overload due to Blood Transfusion
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name: Brand Ferriprox, generic deferiprone	
Diagnosis	Chronic Iron Overload due to Blood Transfusion
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following</p> <p>1.1 Diagnosis of transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Ferriprox (deferiprone) will not be used for the treatment of transfusional iron overload due to myelodysplastic syndrome or Diamond Blackfan anemia</p>	

Product Name: Brand Ferriprox, generic deferiprone	
Diagnosis	Chronic Iron Overload due to Blood Transfusion
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox	
Diagnosis	Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of chronic iron overload in non-transfusion dependent thalassemia (NTDT) syndrome</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Patient has liver iron (Fe) concentration (LIC) levels consistently greater than or equal to 5 mg Fe per gram of dry weight prior to initiation of treatment with Exjade (deferasirox) or Jadenu (deferasirox)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 Patient has serum ferritin levels consistently greater than 300 micrograms per liter prior to initiation of treatment with Exjade (deferasirox) or Jadenu (deferasirox)</p>	

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox	
Diagnosis	Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndrome

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to therapy	

Irritable Bowel Syndrome - Diarrhea



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208216
<b>Guideline Name</b>	Irritable Bowel Syndrome - Diarrhea
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic alosetron, Brand Lotronex	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) with symptoms for at least six months

**AND**

2 - Patient was female at birth

**AND**

3 - ONE of the following:

3.1 Failure to a tricyclic antidepressant (e.g., amitriptyline) as confirmed by claims history or submitted medical records

**OR**

3.2 History of intolerance or contraindication to a tricyclic antidepressant (e.g., amitriptyline) (please specify intolerance or contraindication)

**AND**

4 - Anatomic or biochemical abnormalities of the GI (gastrointestinal) tract have been excluded

Product Name:generic alosetron, Brand Lotronex	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Documentation of positive clinical response to the requested therapy

Product Name:Viberzi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of irritable bowel syndrome with diarrhea (IBS-D)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Failure to a tricyclic antidepressant (e.g., amitriptyline) as confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 History of intolerance or contraindication to a tricyclic antidepressant (e.g., amitriptyline) (please specify intolerance or contraindication)</p>	

Product Name:Viberzi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Viberzi therapy</p>	

## 2 . Revision History

Date	Notes
3/5/2025	Updated formularies

Isotretinoin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146823
<b>Guideline Name</b>	Isotretinoin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Accutane, Myorisan, generic isotretinoin, Claravis, Amnesteem, Zenatane, Brand Absorica, Absorica LD	
Diagnosis	Oncology Uses (Off Label)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN)</p>	

**OR**

**2** - Use is supported by ONE of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

Product Name: Accutane, Myorisan, generic isotretinoin, Claravis, Amnesteem, Zenatane, Brand Absorica, Absorica LD

Diagnosis	Acne
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** Diagnosis of severe recalcitrant nodular acne unresponsive to conventional therapy

**OR**

**1.2** Diagnosis of treatment resistant acne

**AND**

**2** - ONE of the following:

**2.1** Failure to an adequate trial on TWO of the following conventional therapy regimens confirmed by claims history or submission of medical records:

- Topical retinoid or retinoid-like agent [e.g., Retin-A/Retin-A Micro (tretinoin)]

- Oral antibiotic [e.g., Ery-Tab (erythromycin), Biaxin (clarithromycin), Minocin (minocycline)]
- Topical antibiotic with or without benzoyl peroxide [e.g., Cleocin-T (clindamycin), erythromycin, BenzaClin (benzoyl peroxide/clindamycin), Benzamycin (benzoyl peroxide/erythromycin)]

**OR**

**2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Topical retinoid or retinoid-like agent [e.g., Retin-A/Retin-A Micro (tretinoin)]
- Oral antibiotic [e.g., Ery-Tab (erythromycin), Biaxin (clarithromycin), Minocin (minocycline)]
- Topical antibiotic with or without benzoyl peroxide [e.g., Cleocin-T (clindamycin), erythromycin, BenzaClin (benzoyl peroxide/clindamycin), Benzamycin (benzoyl peroxide/erythromycin)]

**AND**

**3** - If the request is non-preferred\*, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication (please specify reason or special circumstance)

Notes

\*PDL Link: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

Product Name: Accutane, Myorisan, generic isotretinoin, Claravis, Amnesteem, Zenatane, Brand Absorica, Absorica LD

Diagnosis

Acne

Approval Length

6 month(s)

Therapy Stage

Reauthorization

Guideline Type

Prior Authorization

**Approval Criteria**

**1** - After greater than or equal to 2 months OFF therapy, persistent or recurring severe recalcitrant nodular acne is still present

**OR**

**2** - Total cumulative dose for total duration of therapy is less than 150 milligrams/kilogram (mg/kg) (will be approved up to a total of 150 mg/kg)

## 2 . Revision History

Date	Notes
4/30/2024	Removed PDL links for CORE markets in background section and added PDL link for NM in notes section, where applicable.

Isturisa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146552
<b>Guideline Name</b>	Isturisa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Isturisa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Cushing's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

- Patient is not a candidate for pituitary surgery
- Pituitary surgery has not been curative

Product Name:Isturisa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive response to Isturisa therapy</p>	

Itovebi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164670
<b>Guideline Name</b>	Itovebi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Itovebi	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of breast cancer

**AND**

2 - Disease is one of the following:

- Locally advanced
- Metastatic

**AND**

3 - Disease is hormone receptor (HR)-positive

**AND**

4 - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

5 - Disease is PIK3CA-mutation positive

**AND**

6 - Used following recurrence on or after completing adjuvant endocrine therapy

**AND**

7 - Used in combination with both of the following:

- Ibrance (palbociclib)

- Fulvestrant

Product Name: Itovebi	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Itovebi therapy</p>	

Product Name: Itovebi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Itovebi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Documentation of positive clinical response to Itovebi therapy

**2 . Revision History**

Date	Notes
2/4/2025	New guideline

lwilfin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146553
<b>Guideline Name</b>	lwilfin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:lwilfin	
Diagnosis	High-Risk Neuroblastoma (HRNB)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of high-risk neuroblastoma (HRNB)</p>	

**AND**

**2** - Patient has shown at least a partial response to prior multiagent, multimodality therapy

**AND**

**3** - Prior therapy included anti-GD2 immunotherapy (e.g., Danyelza (naxitamab-gqqk), Unituxin (dinutuximab))

Product Name: Iwilfin	
Diagnosis	High-Risk Neuroblastoma (HRNB)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Iwilfin therapy	

Product Name: Iwilfin	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

Product Name: Iwilfin	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Iwilfin therapy</p>	

Jakafi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163800
<b>Guideline Name</b>	Jakafi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Jakafi	
Diagnosis	Myelofibrosis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <p>1.1 Symptomatic lower-risk myelofibrosis</p>	

<b>OR</b>
<b>1.2</b> Intermediate or higher-risk myelofibrosis
<b>OR</b>
<b>1.3</b> Post-polycythemia vera myelofibrosis
<b>OR</b>
<b>1.4</b> Post-essential thrombocythemia myelofibrosis
<b>OR</b>
<b>1.5</b> Both of the following:
<ul style="list-style-type: none"> <li>• Myelofibrosis-associated anemia</li> <li>• Presence of symptomatic splenomegaly and/or constitutional symptoms</li> </ul>

Product Name:Jakafi	
Diagnosis	Polycythemia Vera
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Both of the following:</p> <p><b>1.1</b> Diagnosis of low-risk polycythemia vera</p>	

**AND**

**1.2** One of the following:

**1.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Hydroxyurea
- Interferon therapy (e.g., Intron A, Pegasys)

**OR**

**1.2.2** History of contraindication or intolerance to both of the following (please specify contraindication or intolerance):

- Hydroxyurea
- Interferon therapy (e.g., Intron A, Pegasys)

**OR**

**2** - Diagnosis of high-risk polycythemia vera

Product Name: Jakafi	
Diagnosis	Essential Thrombocythemia
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of essential thrombocythemia</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Inadequate response or loss of response to ONE of the following:

- Hydroxyurea
- Pegasys (peginterferon alfa-2a)
- Agrylin (Anagrelide)

Product Name:Jakafi	
Diagnosis	Myeloproliferative Neoplasms
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of accelerated/blast phase myeloproliferative neoplasm</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used for splenomegaly or other disease-related symptoms</p>	

Product Name:Jakafi	
Diagnosis	Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Myeloproliferative Neoplasms
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation that patient has evidence of symptom improvement or reduction in spleen volume while on Jakafi*</p>	

Notes	*If documentation does not provide evidence of symptom improvement or reduction in spleen volume while on Jakafi, authorization will be issued for 2 months to allow for dose titration with discontinuation of the therapy.
-------	--

Product Name:Jakafi	
Diagnosis	Graft versus host disease (GVHD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of acute graft versus host disease (GVHD)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Disease is steroid refractory</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p> <p>2.1 Diagnosis of chronic GVHD</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2 Failure of one or two lines of systemic therapy</p>	

Product Name:Jakafi	
Diagnosis	Graft versus host disease (GVHD)
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of symptom improvement while on Jakafi</p>	

Product Name:Jakafi	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has a JAK2 rearrangement</p>	

Product Name:Jakafi	
Diagnosis	Myelodysplastic Syndromes
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p>	

**1.1** Diagnosis of chronic myelomonocytic leukemia (CMML)-2

**AND**

**1.2** Used in combination with a hypomethylating agent (e.g., azacitidine, decitabine)

**OR**

**2** - BOTH of the following:

**2.1** Diagnosis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia

**AND**

**2.2** Disease is positive for CSF3R or JAK2 mutation

Product Name: Jakafi	
Diagnosis	T-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Both of the following:</p> <p><b>1.1</b> Diagnosis of one of the following:</p> <ul style="list-style-type: none"> <li>Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)</li> <li>Enteropathy-associated T-cell lymphoma (EATL)</li> <li>Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)</li> <li>Angioimmunoblastic T-cell lymphoma (AITL)</li> <li>Nodal peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL, TFH)</li> <li>Follicular T-cell lymphoma (FTCL)</li> <li>Anaplastic large cell lymphoma (ALCL)</li> </ul>	

**AND**

**1.2** Used as initial palliative intent therapy or second-line and subsequent therapy for relapsed/refractory disease

**OR**

**2** - Both of the following:

**2.1** One of the following diagnoses:

- T-cell large granular lymphocytic leukemia
- T-cell prolymphocytic leukemia

**AND**

**2.2** Used as second-line or subsequent therapy

**OR**

**3** - Both of the following:

**3.1** Diagnosis of hepatosplenic T-cell lymphoma

**AND**

**3.2** Used for refractory disease after two first-line therapy regimens

Product Name:Jakafi	
Diagnosis	Myeloid/Lymphoid Neoplasms, Myelodysplastic Syndromes, T-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Jakafi therapy

Product Name:Jakafi	
Diagnosis	Pediatric Acute Lymphoblastic Leukemia
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pediatric acute lymphoblastic leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as a component of consolidation therapy</p>	

Product Name:Jakafi	
Diagnosis	Immunotherapy-Related Toxicities
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Both of the following:</p> <p>1.1 Diagnosis of CAR-T induced G4 cytokine release syndrome</p> <p style="text-align: center;"><b>AND</b></p>	

**1.2** Disease is refractory to high-dose corticosteroids and anti-IL-6 therapy (e.g., Actemra [tocilizumab])

**OR**

**2** - Both of the following:

**2.1** Diagnosis of immune checkpoint inhibitor-related toxicities

**AND**

**2.2** Used in combination with Orencia (abatacept) for the management of concomitant myositis and myocarditis

Product Name:Jakafi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Jakafi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Jakafi therapy

**2 . Revision History**

Date	Notes
1/14/2025	Copy core

Jaypirca



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146555
<b>Guideline Name</b>	Jaypirca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Jaypirca	
Diagnosis	Mantle Cell Lymphoma (MCL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of mantle cell lymphoma (MCL)</p>	

**AND**

**2** - Disease is relapsed or refractory

**AND**

**3** - Both of the following:

**3.1** Patient has received at least two prior systemic therapies for MCL [e.g., Rituxan (rituximab)]

**AND**

**3.2** Patient has received at least one Bruton Tyrosine Kinase (BTK) inhibitor therapy for MCL [e.g., Imbruvica (ibrutinib), Calquence (acalabrutinib), Brukinsa (zanubrutinib)]

Product Name: Jaypirca	
Diagnosis	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has been previously treated with both of the following:</p> <p><b>2.1</b> Bruton Tyrosine Kinase (BTK) inhibitor therapy [e.g., Imbruvica (ibrutinib), Calquence (acalabrutinib), Brukinsa (zanubrutinib)]</p>	

**AND**

**2.2** B-cell lymphoma 2 (BCL-2) inhibitor therapy [e.g., Venclexta (venetoclax)]

Product Name: Jaypirca	
Diagnosis	Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Jaypirca therapy</p>	

Product Name: Jaypirca	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Jaypirca	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Jaypirca therapy</p>	

Jesduvroq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146350
<b>Guideline Name</b>	Jesduvroq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Jesduvroq	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of anemia due to chronic kidney disease (CKD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has been receiving dialysis for at least four months

**AND**

**3** - BOTH of the following:

- Ferritin greater than 100 mcg/L (micrograms per liter)
- Transferrin saturation (TSAT) greater than 20%

**AND**

**4** - Hemoglobin level is less than 11 g/dL (grams per deciliter)

**AND**

**5** - ONE of the following:

**5.1** Failure to an erythropoietin stimulating agent (ESA) [e.g., Aranesp (darbepoetin), Epogen (epoetin alfa), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)] as confirmed by claims history or submission of medical records

**OR**

**5.2** History of contraindication or intolerance to an erythropoietin stimulating agent (ESA) (please specify contraindication or intolerance)

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Hematologist
- Nephrologist

Product Name: Jesduvroq

Approval Length

12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Jesduvroq therapy (e.g., clinically meaningful increase in hemoglobin level)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Adequate iron stores confirmed by both of the following:</p> <ul style="list-style-type: none"> <li>• Ferritin greater than 100 mcg/L (micrograms per liter)</li> <li>• Transferrin saturation (TSAT) greater than 20%</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Hemoglobin level does not exceed 12 g/dL (grams per deciliter)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is not on concurrent treatment with an erythropoietin stimulating agent (ESA) [e.g., Aranesp (darbepoetin), Epogen (epoetin alfa), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)]</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hematologist</li> <li>• Nephrologist</li> </ul>	

Joenja



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150145
<b>Guideline Name</b>	Joenja
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Joenja	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Diagnosis has been confirmed by the presence of an APDS-associated genetic variant in either PIK3CD or PIK3R1

**AND**

**3** - Documentation of other clinical findings and manifestations consistent with APDS (e.g., recurrent respiratory tract infections, recurrent herpesvirus infections, lymphadenopathy, hepatosplenomegaly, autoimmune cytopenia)

**AND**

**4** - ONE of the following:

**4.1** Failure to one current standard of care for APDS (e.g., antimicrobial prophylaxis, immunoglobulin replacement therapy, immunosuppressive therapy) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to one current standard of care for APDS (e.g., antimicrobial prophylaxis, immunoglobulin replacement therapy, immunosuppressive therapy) (please specify intolerance or contraindication)

**AND**

**5** - Prescribed by ONE of the following:

- Hematologist
- Immunologist

**AND**

**6** - BOTH of the following:

- Patient is 12 years of age or older
- Patient weighs greater than or equal to 45 kg (kilograms)

Product Name: Joenja	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Joenja therapy (e.g., reduced lymph node size, increased naïve B-cell percentage, decreased frequency or severity of infections, decreased frequency of hospitalizations)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hematologist</li> <li>• Immunologist</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient weighs greater than or equal to 45 kg</p>	

## 2 . Revision History

Date	Notes
7/23/2024	Updated initial authorization duration to 12 months.

Juxtapid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146557
<b>Guideline Name</b>	Juxtapid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Juxtapid	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by ONE of the following:</p> <p>1.1 Submission of medical records (e.g., chart notes, laboratory values) confirming genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus</p>	

**OR**

**1.2** BOTH of the following:

**1.2.1** Pre-treatment low density lipoprotein cholesterol (LDL-C) greater than 400 mg/dL (milligrams per deciliter)

**AND**

**1.2.2** ONE of the following:

- Xanthoma before 10 years of age
- Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

**AND**

**2** - Patient has received comprehensive counseling regarding appropriate diet

**AND**

**3** - Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis)

**AND**

**4** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - ONE of the following:

**5.1** Failure to Repatha (evolocumab) as confirmed by claims history or submission of medical records

**OR**

**5.2** History of intolerance or contraindication to Repatha (evolocumab) (please specify intolerance or contraindication)

**AND**

**6** - Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab), Repatha (evolocumab)]

Product Name:Juxtapid	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient continues to receive comprehensive counseling regarding appropriate diet</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient continues to receive other lipid-lowering therapy (e.g., statin, low density lipoprotein [LDL] apheresis)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Documentation of a positive clinical response to therapy from pre-treatment baseline</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by ONE of the following:</p>	

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab), Repatha (evolocumab)]

Jynarque



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146558
<b>Guideline Name</b>	Jynarque
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Jynarque, Jynarque Pak	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)</p>	

Product Name:Jynarque, Jynarque Pak
-------------------------------------

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Jynarque therapy	

Kalydeco



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151780
<b>Guideline Name</b>	Kalydeco
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Kalydeco	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Submission of laboratory results confirming that patient has at least ONE of the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco, listed in Table 1 (see Background)

**AND**

**3** - Prescribed by, or in consultation with a provider who specializes in the treatment of CF

Product Name:Kalydeco	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Kalydeco therapy (e.g., improved lung function, stable lung function)</p>	

## 2 . Background

Benefit/Coverage/Program Information				
<b>Table 1. CFTR Gene Mutations</b>				
711+3A→G *	F311del	I148T	R75Q	S589N
2789+5G→A *	F311L	I175V	R117C *	S737F
3272-26A→G *	F508C	I807M	R117G	S945L *
3849+10kbC→T *	F508C;S1251N †	I1027T	R117H *	S977F *

A120T	F1052V	I1139V	R117L	S1159F
A234D	F1074L	K1060T	R117P	S1159P
A349V	G178E	L206W *	R170H	S1251N *
A455E *	G178R *	L320V	R347H *	S1255P *
A1067T	G194R	L967S	R347L	T338I
D110E	G314E	L997F	R352Q *	T1053I
D110H	G551D *	L1480P	R553Q	V232D
D192G	G551S *	M152V	R668C	V562I
D579G *	G576A	M952I	R792G	V754M
D924N	G970D	M952T	R933G	V1293G
D1152H *	G1069R	P67L *	R1070Q	W1282R
D1270N	G1244E *	Q237E	R1070W *	Y1014C
E56K	G1249R	Q237H	R1162L	Y1032C
E193K	G1349D *	Q359R	R1283M	
E822K	H939R	Q1291R	S549N *	
E831X *	H1375P	R74W	S549R *	

\* Clinical data exist for these mutations.

† Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.

### 3 . Revision History

Date	Notes
8/14/2024	Annual review. Removed prescriber requirement from reauthorization criteria. Updated reference.

Kerendia



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160463
<b>Guideline Name</b>	Kerendia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Kerendia	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Both of the following:

**2.1** UACR (urinary albumin-to-creatinine ratio) greater than or equal to 30 mg/g

**AND**

**2.2** eGFR (estimated glomerular filtration rate) greater than or equal to 25 mL/min/1.73 m<sup>2</sup>

**AND**

**3** - Kerendia is being used to reduce the risk of at least ONE of the following:

- Sustained eGFR decline
- End-stage kidney disease
- Cardiovascular death
- Non-fatal myocardial infarction
- Hospitalization for heart failure

**AND**

**4** - Serum potassium level is less than or equal to 5 mEQ/L (milliequivalents/liter) prior to initiating treatment

**AND**

**5** - ONE of the following:

**5.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following as confirmed by claims history or submission of medical records:

- Maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Maximally tolerated angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**OR**

**5.2** Patient has an allergy, contraindication, or intolerance to ACE inhibitors and ARBs (please specify allergy, contraindication, or intolerance)

**AND**

**6** - ONE of the following:

- Patient is on a stabilized dose and receiving concomitant therapy with a SGLT2 inhibitor (e.g., Farxiga)
- Failure to a SGLT2 inhibitor (e.g., Farxiga) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to a SGLT2 inhibitor (e.g., Farxiga) (please specify intolerance or contraindication)

Product Name:Kerendia	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	

## 2 . Revision History

Date	Notes
11/11/2024	Updated auth durations. Updated diagnosis to CDK associated with T2D

Keveyis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146560
<b>Guideline Name</b>	Keveyis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Keveyis, generic dichlorphenamide	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary hyperkalemic periodic paralysis or related variant</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - Diagnosis of primary hypokalemic periodic paralysis or related variant

Product Name: Brand Keveyis, generic dichlorphenamide

Approval Length | 12 month(s)

Therapy Stage | Reauthorization

Guideline Type | Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to the requested therapy

Kevzara



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156350
<b>Guideline Name</b>	Kevzara
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Kevzara	
Diagnosis	Rheumatoid Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active rheumatoid arthritis (RA)</p>	

**AND**

**2** - One of the following:

**2.1** All of the following:

**2.1.1** One of the following:

**2.1.1.1** Failure to a 3-month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses as confirmed by claims history or submitted medical records

**OR**

**2.1.1.2** History of intolerance or contraindication to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**OR**

**2.1.1.3** Patient has been previously treated with a biologic or targeted synthetic DMARD FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**2.1.2** One of the following:

**2.1.2.1** Failure of one preferred adalimumab product\* confirmed by claims history or submitted medical records

**OR**

**2.1.2.2** History of intolerance or contraindication to all preferred adalimumab products\* (please specify intolerance or contraindication)

**AND**

**2.1.3** One of the following:

**2.1.3.1** Failure of Tyenne (tocilizumab-aazg) confirmed by claims history or submitted medical records

**OR**

**2.1.3.2** History of intolerance or contraindication to Tyenne (tocilizumab-aazg) (please specify intolerance or contraindication)

**OR**

**2.2** Patient is currently on Kevzara therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is not receiving Kevzara in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

Product Name:Kevzara	
Diagnosis	Rheumatoid Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Kevzara therapy

**AND**

2 - Patient is not receiving Kevzara in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

Product Name:Kevzara	
Diagnosis	Polymyalgia Rheumatica (PMR)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of polymyalgia rheumatica (PMR)</p> <p><b>AND</b></p> <p>2 - Patient has had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper</p> <p><b>AND</b></p> <p>3 - Patient is not receiving Kevzara in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]</p>	

Product Name:Kevzara

Diagnosis	Polymyalgia Rheumatica (PMR)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Kevzara therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Kevzara in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]</p>	

Product Name:Kevzara	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active polyarticular juvenile idiopathic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Kevzara in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - One of the following:

- Failure of one preferred adalimumab product\* confirmed by claims history or submitted medical records
- History of intolerance or contraindication to all preferred adalimumab products\* (please specify intolerance or contraindication)

**AND**

**4** - One of the following:

- Failure of Tyenne (tocilizumab-aazg) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Tyenne (tocilizumab-aazg) (please specify intolerance or contraindication)

**AND**

**5** - Prescribed by or in consultation with a rheumatologist

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

<b>Product Name:Kevzara</b>	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Documentation of positive clinical response to Kevzara therapy	
<b>AND</b>	
<b>2</b> - Patient is not receiving Kevzara in combination with another targeted immunomodulator	

[e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

## 2 . Revision History

Date	Notes
9/26/2024	Added criteria for pJIA. Updated safety language

Kineret



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160487
<b>Guideline Name</b>	Kineret
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Kineret	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active rheumatoid arthritis (RA)</p>	

**AND**

**2** - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - One of the following:

**4.1** Patient is currently on Kineret therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** Both of the following:

**4.2.1** One of the following:

**4.2.1.1** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]

**OR**

**4.2.1.2** Failure to a 3 month trial of one non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses confirmed by claims history or submission of medical records

**OR**

**4.2.1.3** History of intolerance or contraindication to one non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**AND**

**4.2.2** One of the following:

**4.2.2.1** Failure of THREE of the following confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Olumiant (baricitinib)
- Tyenne (tocilizumab-aazg)

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Olumiant (baricitinib)
- Tyenne (tocilizumab-aazg)

Notes	* For a list of preferred adalimumab products please reference drug coverage tools.
-------	---

Product Name:Kineret	
Diagnosis	Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Diagnosis of neonatal-onset multisystem inflammatory disease (NOMID)

**AND**

**2** - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Product Name:Kineret	
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of active systemic juvenile idiopathic arthritis (SJIA) (formerly Still's Disease)</p> <p><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p> <p><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with a rheumatologist</p>	

**AND**

**4** - One of the following:

**4.1** Patient is currently on Kineret therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** One of the following:

**4.2.1** Failure of Tyenne (tocilizumab-aazg) confirmed by claims history or submitted medical records

**OR**

**4.2.2** History of intolerance or contraindication to Tyenne (tocilizumab-aazg) (please specify intolerance or contraindication)

Product Name:Kineret	
Diagnosis	Adult Onset Still's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of adult onset Still's Disease</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p>	

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Product Name:Kineret	
Diagnosis	Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of deficiency of Interleukin-1 Receptor Antagonist (DIRA)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with a rheumatologist</p>	

Product Name:Kineret	
Diagnosis	Rheumatoid Arthritis (RA), Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA), Adult Onset Still's Disease, Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Kineret therapy

**AND**

2 - Patient is NOT receiving Kineret in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**2 . Revision History**

Date	Notes
11/12/2024	Removed Cimzia as an alternative in RA section

Kisqali



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163693
<b>Guideline Name</b>	Kisqali
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Kisqali	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following types of breast cancer</p> <ul style="list-style-type: none"> <li>Early stage (II or III) at high-risk of recurrence</li> <li>Advanced</li> </ul>	

- Recurrent
- Metastatic

**AND**

**2 - BOTH** of the following:

- Disease is hormone receptor (HR)-positive
- Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**3 - ONE** of the following:

- Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane)
- Used in combination with Faslodex (fulvestrant)

**AND**

**4 - ONE** of the following:

**4.1** One of the following:

**4.1.1** Failure to Verzenio (abemaciclib) confirmed by claims history or submission of medical records

**OR**

**4.1.2** History of contraindication or intolerance to Verzenio (abemaciclib) (please specify intolerance or contraindication)

**OR**

**4.2** Patient is currently on Kisqali therapy

Product Name:Kisqali

Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent or metastatic endometrial cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tumor is estrogen receptor (ER)-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Used in combination with letrozole</p>	

Product Name:Kisqali	
Diagnosis	Breast Cancer, Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Kisqali therapy</p>	

Product Name:Kisqali	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Kisqali	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Kisqali therapy</p>	

## 2 . Revision History

Date	Notes
1/13/2025	Copy core

Kisqali Femara Co-Pack



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163711
<b>Guideline Name</b>	Kisqali Femara Co-Pack
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Kisqali Femara Co-Pack	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following types of breast cancer:</p> <ul style="list-style-type: none"> <li>Early stage (II or III) at high-risk of recurrence</li> <li>Advanced</li> </ul>	

<ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Metastatic</li> </ul>
<b>AND</b>
2 - Disease is hormone receptor (HR)-positive
<b>AND</b>
3 - Disease is human epidermal growth factor receptor 2 (HER2)-negative
<b>AND</b>
4 - ONE of the following:
4.1 Failure to Verzenio (abemaciclib) plus an aromatase inhibitor (e.g., anastrozole, letrozole) confirmed by claims history or submission of medical records
<b>OR</b>
4.2 History of contraindication or intolerance to Verzenio (abemaciclib) plus an aromatase inhibitor (e.g., anastrozole, letrozole) (please specify intolerance or contraindication)
<b>OR</b>
4.3 Patient is currently on Kisqali Femara Co-Pack therapy

Product Name:Kisqali Femara Co-Pack	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of recurrent or metastatic endometrial cancer

**AND**

2 - Tumor is estrogen receptor (ER)-positive

Product Name:Kisqali Femara Co-Pack	
Diagnosis	Breast Cancer, Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Kisqali Femara Co-Pack therapy</p>	

Product Name:Kisqali Femara Co-Pack	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Kisqali Femara Co-Pack	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Kisqali Femara Co-Pack therapy</p>	

## 2 . Revision History

Date	Notes
1/13/2025	Copy Core

Korlym



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147303
<b>Guideline Name</b>	Korlym
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Korlym, generic mifepristone	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endogenous Cushing's syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)</p>	

**AND**

**2** - ONE of the following:

- Diagnosis of type 2 diabetes mellitus
- Diagnosis of glucose intolerance

**AND**

**3** - ONE of the following:

- Patient has failed surgery
- Patient is not a candidate for surgery

Product Name: Brand Korlym, generic mifepristone	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of a positive clinical response while on the requested therapy</p>	

## 2 . Revision History

Date	Notes
5/13/2024	Updated reauthorization criteria and added generic mifepristone as a target. Updated product name lists and GPI tables accordingly.

Koselugo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158111
<b>Guideline Name</b>	Koselugo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Koselugo	
Diagnosis	Neurofibromatosis Type 1
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of neurofibromatosis type 1</p>	

**AND**

**2** - Patient has plexiform neurofibromas that are BOTH of the following:

- Inoperable
- Causing significant morbidity (e.g., disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, bladder/bowel dysfunction)

Product Name:Koselugo	
Diagnosis	Glioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> Circumscribed glioma with presence of BRAF fusion or BRAF V600E activating mutations</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> NF-1 mutated glioma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is recurrent or progressive</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used as monotherapy</p>	

Product Name:Koselugo	
Diagnosis	Langerhans Cell Histiocytosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Langerhans cell histiocytosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Presence of MAP kinase pathway mutation</li> <li>• No detectable mutation</li> <li>• Genetic testing not available</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Used as monotherapy</p>	

Product Name:Koselugo	
Diagnosis	Neurofibromatosis Type 1, Glioma, Langerhans Cell Histiocytosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Koselugo therapy</p>	

Product Name:Koselugo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Koselugo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Koselugo therapy</p>	

## 2 . Revision History

Date	Notes
10/28/2024	Updated diagnosis header in reauth section to remove reference to pilocytic astrocytoma and added glioma.

Krazati



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156450
<b>Guideline Name</b>	Krazati
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Krazati	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

<b>AND</b>
<b>2</b> - Presence of KRAS G12C mutation
<b>AND</b>
<b>3</b> - Disease is ONE of the following:
<ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul>
<b>AND</b>
<b>4</b> - Patient has received at least one prior systemic therapy

<b>Product Name:Krazati</b>	
Diagnosis	Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Diagnosis of colorectal cancer	
<b>AND</b>	
<b>2</b> - Presence of KRAS G12C mutation	
<b>AND</b>	

**3** - Disease is ONE of the following:

- Recurrent
- Advanced
- Metastatic

**AND**

**4** - Patient has received at least one prior systemic therapy

Product Name:Krazati	
Diagnosis	Ampullary Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ampullary adenocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Presence of KRAS G12C mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**4** - Patient has received at least one prior systemic therapy

Product Name:Krazati	
Diagnosis	Pancreatic Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of pancreatic adenocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Presence of KRAS G12C mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient has received at least one prior systemic therapy</p>	

Product Name:Krazati	
Diagnosis	Biliary Tract Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Gallbladder Cancer</li> <li>• Intrahepatic cholangiocarcinoma</li> <li>• Extrahepatic cholangiocarcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Presence of KRAS G12C mutation</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Disease is ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Unresectable</li> <li>• Resected gross residual (R2)</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Patient has received at least one prior systemic therapy</b></p>	

Product Name:Krazati	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Ampullary Adenocarcinoma, Pancreatic Adenocarcinoma, Biliary Tract Cancers
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Patient does not show evidence of progressive disease while on Krazati therapy

Product Name:Krazati	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Krazati	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Krazati therapy</p>	

## 2 . Revision History

Date	Notes
9/30/2024	Combined criteria for colon and rectal cancer in one section – Colorectal Cancer. Added criteria for NCCN recommended use of Krazati in biliary tract cancer.

Kuvan



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146568
<b>Guideline Name</b>	Kuvan
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic sapropterin, Brand Kuvan	
Diagnosis	Phenylketonuria (PKU)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of phenylketonuria (PKU)</p>	

Kynmobi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146569
<b>Guideline Name</b>	Kynmobi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Kynmobi	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Kynmobi will be used as intermittent treatment for OFF episodes

**AND**

**3** - Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**4** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**5** - Patient continues to experience greater than or equal to 2 hours of OFF time per day despite optimal management of carbidopa-levodopa therapy including BOTH of the following:

**5.1** Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more before or one hour after a meal or avoidance of high protein diet

**AND**

**5.2** Dose and dosing interval optimization

**AND**

**6** - ONE of the following:

**6.1** Failure to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from TWO different classes) as confirmed by claims history or submission of medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

**OR**

**6.2** Contraindication or intolerance to ALL anti-Parkinson’s disease therapies from the following adjunctive pharmacotherapy classes (please specify contraindication or intolerance):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Product Name:Kynmobi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of a positive clinical response to Kynmobi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication</p>	

Lampit



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164745
<b>Guideline Name</b>	Lampit
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Lampit	
Approval Length	60 Day(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi

**2 . Revision History**

Date	Notes
2/5/2025	Added Indiana and PA Medicaid formularies. No changes to clinical c riteria.

Lazcluze



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160564
<b>Guideline Name</b>	Lazcluze
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Lazcluze	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is ONE of the following:

- Recurrent
- Advanced
- Metastatic

**AND**

**3** - Disease is positive for ONE of the following:

- Epidermal growth factor receptor (EGFR) exon 19 deletion
- EGFR exon 21 L858R mutation

**AND**

**4** - Used in combination with Rybrevant (amivantamab-vmjw)

Product Name:Lazcluze	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Lazcluze therapy	

Product Name:Lazcluze	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Lazcluze	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lazcluze therapy</p>	

## 2 . Revision History

Date	Notes
11/13/2024	New program

Lenvima



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146570
<b>Guideline Name</b>	Lenvima
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Lenvima	
Diagnosis	Renal Cell Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced renal cell carcinoma</p>	

**AND**

**2 - ONE of the following:**

**2.1 BOTH of the following:**

**2.1.1 ONE of the following:**

**2.1.1.1** Failure to one prior anti-angiogenic therapy as confirmed by claims history or submission of medical records [e.g., Avastin (bevacizumab), Votrient (pazopanib), Sutent (sunitinib), Nexavar (sorafenib)]

**OR**

**2.1.1.2** History of intolerance or contraindication to one prior anti-angiogenic therapy [e.g., Avastin (bevacizumab), Votrient (pazopanib), Sutent (sunitinib), Nexavar (sorafenib)] (please specify contraindication or intolerance)

**AND**

**2.1.2** Used in combination with Afinitor (everolimus)

**OR**

**2.2** Used in combination with Keytruda (pembrolizumab)

Product Name:Lenvima	
Diagnosis	Renal Cell Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient does not show evidence of progressive disease while on Lenvima therapy

**AND**

2 - Used in combination with Afinitor (everolimus) or Keytruda (pembrolizumab)

Product Name:Lenvima

Diagnosis	Thyroid Cancer
-----------	----------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of differentiated thyroid cancer (DTC)

**AND**

2 - Disease is locally recurrent, metastatic, progressive, or symptomatic

**AND**

3 - Disease is radioactive iodine-refractory or ineligible

Product Name:Lenvima

Diagnosis	Hepatobiliary Cancer
-----------	----------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 Diagnosis of hepatocellular carcinoma

**AND**

1.1.2 Disease is ONE of the following:

- Unresectable
- Metastatic

**OR**

1.2 ALL of the following:

1.2.1 Diagnosis of biliary tract cancer

**AND**

1.2.2 Disease is ONE of the following:

- Unresectable or resected gross residual (R2) disease
- Metastatic

**AND**

1.2.3 Disease has progressed on or after systemic treatment

**AND**

1.2.4 Used in combination with Keytruda (pembrolizumab)

Product Name:Lenvima	
Diagnosis	Adenoid Cystic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent adenoid cystic carcinoma</p>	

Product Name:Lenvima	
Diagnosis	Thymic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of thymic carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Used as a single agent for those who cannot tolerate first-line combination regimens</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Used as a second line therapy in unresectable locally advanced disease, solitary metastasis or ipsilateral pleural metastasis, or extrathoracic metastatic disease</p>	

Product Name:Lenvima	
Diagnosis	Thyroid Cancer, Hepatobiliary Cancer, Adenoid Cystic Carcinoma, Thymic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lenvima therapy</p>	

Product Name:Lenvima	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endometrial carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with Keytruda (pembrolizumab)</p>	

Product Name:Lenvima	
Diagnosis	Cutaneous Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of cutaneous melanoma

**AND**

2 - Disease is ONE of the following:

- Disease is unresectable
- Disease is metastatic

**AND**

3 - Used in combination with Keytruda (pembrolizumab)

Product Name:Lenvima	
Diagnosis	Endometrial Carcinoma, Cutaneous Melanoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lenvima therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with Keytruda (pembrolizumab)</p>	

Product Name:Lenvima	
Diagnosis	NCCN Recommended Regimens

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Lenvima will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Lenvima	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lenvima therapy</p>	

Lidoderm



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164150
<b>Guideline Name</b>	Lidoderm
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic lidocaine 5% patch, Brand Lidoderm	
Diagnosis	Post-Herpetic Neuralgia
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of post-herpetic neuralgia</p>	

Product Name:generic lidocaine 5% patch, Brand Lidoderm
---

Diagnosis	Neuropathic Pain
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of neuropathic pain</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Failure to ALL of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Tricyclic anti-depressant (e.g., amitriptyline)</li> <li>• SNRI (serotonin and norepinephrine reuptake inhibitor) anti-depressant (e.g., duloxetine, venlafaxine)</li> <li>• Anticonvulsant (e.g., gabapentin, pregabalin)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.2 History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Tricyclic anti-depressant (e.g., amitriptyline)</li> <li>• SNRI anti-depressant (e.g., duloxetine, venlafaxine)</li> <li>• Anticonvulsant (e.g., gabapentin, pregabalin)</li> </ul>	

Product Name:generic lidocaine 5% patch, Brand Lidoderm	
Diagnosis	Neuropathic Pain
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**2 . Revision History**

Date	Notes
1/23/2025	Updated formularies, updated GPI and product name lists

Litfulo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164653
<b>Guideline Name</b>	Litfulo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Litfulo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Diagnosis of severe alopecia areata

**AND**

**2** - Other causes of hair loss have been ruled out (e.g., androgenetic alopecia, cicatricial alopecia, secondary syphilis, tinea capitis, triangular alopecia, and trichotillomania)

**AND**

**3** - Patient has a current episode of alopecia areata with at least 50% scalp hair loss

**AND**

**4** - ONE of the following:

**4.1** Patient is less than 18 years of age

**OR**

**4.2** Failure to Olumiant confirmed by claims history or submission of medical records

**OR**

**4.3** History of intolerance or contraindication to Olumiant (please specify intolerance or contraindication)

**AND**

**5** - Patient is not receiving Litfulo in combination with either of the following:

- Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**6** - Prescribed by or in consultation with a dermatologist

Product Name:Litfulo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Litfulo therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Litfulo in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine or cyclosporine)</li> </ul>	

## 2 . Revision History

Date	Notes
2/3/2025	Updated safety check language

Litfulo



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164653
<b>Guideline Name</b>	Litfulo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Litfulo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Diagnosis of severe alopecia areata

**AND**

**2** - Other causes of hair loss have been ruled out (e.g., androgenetic alopecia, cicatricial alopecia, secondary syphilis, tinea capitis, triangular alopecia, and trichotillomania)

**AND**

**3** - Patient has a current episode of alopecia areata with at least 50% scalp hair loss

**AND**

**4** - ONE of the following:

**4.1** Patient is less than 18 years of age

**OR**

**4.2** Failure to Olumiant confirmed by claims history or submission of medical records

**OR**

**4.3** History of intolerance or contraindication to Olumiant (please specify intolerance or contraindication)

**AND**

**5** - Patient is not receiving Litfulo in combination with either of the following:

- Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**6** - Prescribed by or in consultation with a dermatologist

Product Name:Litfulo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Litfulo therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Litfulo in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine or cyclosporine)</li> </ul>	

## 2 . Revision History

Date	Notes
2/3/2025	Updated safety check language

Livdelzi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164659
<b>Guideline Name</b>	Livdelzi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Livdelzi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
	<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of primary biliary cholangitis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient does not have decompensated cirrhosis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - One of the following:</p> <p><b>3.1</b> Both of the following:</p> <ul style="list-style-type: none"> <li>• Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)</li> <li>• Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal after at least 12 consecutive months of treatment with ursodeoxycholic acid (e.g., Urso, ursodiol)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso, ursodiol) (please specify contraindication or intolerance)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is not receiving Livdelzi in combination with Iqirvo (elafibranor) or Ocaliva (obeticholic acid)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed by one of the following:</p> <ul style="list-style-type: none"> <li>• Hepatologist</li> </ul>

- Gastroenterologist

Product Name:Livdelzi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., laboratory values) documenting a reduction in alkaline phosphatase (ALP) level from pre-treatment baseline (i.e., prior to Livdelzi therapy)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient does not have decompensated cirrhosis</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Livdelzi in combination with Iqirvo (elafibranor) or Ocaliva (obeticholic acid)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by one of the following:</p> <ul style="list-style-type: none"> <li>• Hepatologist</li> <li>• Gastroenterologist</li> </ul>	

## 2 . Revision History

Date	Notes
------	-------

2/4/2025	New program
----------	-------------

Livmarli



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158235
<b>Guideline Name</b>	Livmarli
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Livmarli	
Diagnosis	Progressive Familial Intrahepatic Cholestasis (PFIC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of progressive familial intrahepatic cholestasis (PFIC)</p>	

**AND**

**2** - Patient does not have a ABCB11 variant resulting in non-functional or complete absence of bile salt export pump (BSEP) protein

**AND**

**3** - Patient is experiencing moderate to severe pruritus associated with PFIC.

**AND**

**4** - Patient has a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory.

**AND**

**5** - Patient has had an inadequate response to at least two conventional treatments for the symptomatic relief of pruritus (e.g., ursodeoxycholic acid, diphenhydramine, cholestyramine, rifampin, naltrexone, and sertraline)

**AND**

**6** - Prescribed by a gastroenterologist or hepatologist.

Product Name: Livmarli	
Diagnosis	Progressive Familial Intrahepatic Cholestasis (PFIC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Documentation of positive clinical response to Livmarli therapy (e.g., reduced serum bile acids, improved pruritis and less sleep disturbance)

**AND**

2 - Prescribed by a gastroenterologist or hepatologist

Product Name:Livmarli

Diagnosis	Alagille Syndrome (ALGS)
-----------	--------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of Alagille syndrome (ALGS)

**AND**

2 - Confirmation of diagnosis by presence of the JAG1 or Notch2 gene mutation

**AND**

3 - Patient has a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory.

**AND**

4 - Patient is experiencing moderate to severe pruritis associated with ALGS

**AND**

**5** - Patient has had an inadequate response to at least two conventional treatments for the symptomatic relief of pruritus (e.g., ursodeoxycholic acid, diphenhydramine, cholestyramine, rifampin, naltrexone, and sertraline)

**AND**

**6** - Prescribed by a gastroenterologist or hepatologist.

Product Name: Livmarli	
Diagnosis	Alagille Syndrome (ALGS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Livmarli therapy (e.g., reduced serum bile acids, improved pruritis)</p> <p><b>AND</b></p> <p><b>2</b> - Prescribed by a gastroenterologist or hepatologist.</p>	

## 2 . Revision History

Date	Notes
10/30/2024	Updated examples of conventional treatment within initial authorization criteria for both PFIC and ALGS. Corrected spelling of pruritus.

Livtency



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146572
<b>Guideline Name</b>	Livtency
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Livtency	
Approval Length	2 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of post-transplant cytomegalovirus (CMV) infection or CMV disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - CMV infection or disease is refractory to treatment (with or without genotypic resistance) to ONE of the following:

- Ganciclovir
- Valganciclovir
- Cidofovir
- Foscarnet

**AND**

**3** - Patient will not use the requested medication in combination with ganciclovir or valganciclovir

Lokelma, Veltassa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154650
<b>Guideline Name</b>	Lokelma, Veltassa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Lokelma, Veltassa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-life threatening hyperkalemia</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Where clinically appropriate, loop or thiazide diuretic therapy for potassium removal has failed

**AND**

**3** - Patient follows a low potassium diet (less than or equal to 3 grams per day)

Product Name:Lokelma, Veltassa

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Patient has a positive clinical response to Lokelma or Veltassa therapy

**AND**

**2** - Patient continues to require treatment for hyperkalemia

**AND**

**3** - Patient follows a low potassium diet (less than or equal to 3 grams per day)

**2 . Revision History**

Date	Notes
9/9/2024	Removed requirement to adjust medications.

Long-Acting Opioid Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-162060
<b>Guideline Name</b>	Long-Acting Opioid Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic morphine sulfate ER/CR tabs, fentanyl patches, hydrocodone bitartrate ER caps, oxymorphone ER, morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, methadone tabs/soln, generic methadone conc, Brand Methadose conc, tramadol ER, Conzip, Brand Zohydro ER	
Diagnosis	DUR: Opioid Naïve (Not having filled an opioid in the past 60 days) exceeding the 7 day supply limit*
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p>	

<ul style="list-style-type: none"> <li>• Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</li> <li>• End of life care, including hospice care</li> <li>• Palliative care</li> <li>• Sickle cell anemia</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - Prescriber attests that the patient has received an opioid within the past 60 days</p>	
Notes	*Approval length for cancer-related pain, end of life, palliative care, or sickle cell pain will be issued for 12 months. All other approvals will be issued for the requested duration, not to exceed one month.

Product Name:generic morphine sulfate ER/CR tabs, fentanyl 12, 25, 50, 75, 100 mcg/hr patches	
Diagnosis	Cancer-related pain/Hospice/Sickle Cell Anemia/End of Life Related Pain*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient is being treated for cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - Patient is in hospice or is receiving end of life care</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3</b> - Patient is being treated for sickle cell anemia related pain</p>	

Notes	*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.
-------	--

Product Name:hydrocodone bitartrate ER caps, oxymorphone ER	
Diagnosis	Cancer-related pain/Hospice/Sickle Cell Anemia/End of Life Related Pain*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Patient is being treated for cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 Patient is in hospice or is receiving end of life care</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 Patient is being treated for sickle cell anemia related pain</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 The patient has failed a trial of at least ONE of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):</p> <ul style="list-style-type: none"> <li>• morphine sulfate controlled release tablets (generic MS Contin)</li> </ul>	

- preferred fentanyl transdermal

**OR**

**2.2** The patient has a history of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal

**OR**

**2.3** BOTH of the following:

**2.3.1** Patient is established on pain therapy with the requested medication for hospice related pain, sickle cell anemia related pain, end of life care related pain, or cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)

**AND**

**2.3.2** The medication is not a new regimen for treatment of cancer-related pain, hospice, sickle cell anemia related pain, or end of life care pain (document date regimen was started)

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

If the request is for oxycodone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER) and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 12 month authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.

Product Name:morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, fentanyl 37.5, 62.5, 87.5 mcg/hr patches, methadone tabs/soln, generic methadone conc, Brand Methadose conc, Brand Zohydro ER

Diagnosis	Cancer-related pain /Hospice/Sickle Cell Anemia/End of Life Related Pain*
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 Patient is being treated for cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)

**OR**

1.2 Patient is in hospice or is receiving end of life care

**OR**

1.3 Patient is being treated for sickle cell anemia related pain

**AND**

2 - ONE of the following:

2.1 The patient has failed a trial of at least THREE of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

**OR**

**2.2** The patient has a history of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

**OR**

**2.3** BOTH of the following:

**2.3.1** Patient is established on pain therapy with the requested medication for hospice related pain, sickle cell anemia related pain, end of life care related pain, or cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)

**AND**

**2.3.2** The medication is not a new regimen for treatment of cancer-related pain, hospice, sickle cell anemia related pain, or end of life care pain (Document date regimen was started)

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 12 month authorization should be entered for preferred products, depending on what the patient has already tried:

- If the patient has tried morphine sulfate controlled release tablets (generic MS Contin) or preferred fentanyl transdermal, an authorization should be entered for oxymorphone ER-non crush resistant (generic) and hydrocodone extended-release capsules (generic Zohydro ER).

	<ul style="list-style-type: none"> <li>• If the patient has not tried any of the preferred products [morphine sulfate controlled release tablets (generic MS Contin), preferred fentanyl transdermal, oxycodone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER)], an authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.</li> </ul>
--	--

Product Name: generic morphine sulfate ER/CR tabs, fentanyl 12, 25, 50, 75, 100 mcg/hr patches	
Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain*
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Prescriber attests to BOTH of the following:</p> <p>1.1 Patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Pain is moderate to severe and expected to persist for an extended period of time (chronic)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - BOTH of the following:</p> <p>3.1 Patient has been screened for underlying depression and/or anxiety</p>	

**AND**

**3.2** If applicable, any underlying conditions have been or will be addressed

**AND**

**4** - ONE of the following:

**4.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [document drug(s) and date of trial]

**OR**

**4.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**4.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**OR**

**4.4** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

**AND**

**5** - If the request is for neuropathic pain (examples of neuropathic pain include neuralgias and neuropathies), ONE of the following:

**5.1** BOTH of the following:

**5.1.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8

weeks of treatment with gabapentin titrated to a therapeutic dose (document date of trial) (if contraindicated, document contraindication)

**AND**

**5.1.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (document drug and date of trial) (if contraindicated, document contraindication)

**OR**

**5.2** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

Notes	*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.
-------	--

Product Name:hydrocodone bitartrate ER caps, oxymorphone ER	
Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain*
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Prescriber attests to BOTH of the following:</p> <p>1.1 Patient has been screened for substance abuse/opioid dependence</p> <p><b>AND</b></p>	

**1.2** Pain is moderate to severe and expected to persist for an extended period of time (chronic)

**AND**

**2** - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)

**AND**

**3** - BOTH of the following:

**3.1** Patient has been screened for underlying depression and/or anxiety

**AND**

**3.2** If applicable, any underlying conditions have been or will be addressed

**AND**

**4** - ONE of the following:

**4.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [document drug(s) and date of trial]

**OR**

**4.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**4.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**OR**

**4.4** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

**AND**

**5** - If the request is for neuropathic pain (examples of neuropathic pain include neuralgias and neuropathies), **ONE** of the following:

**5.1** **BOTH** of the following:

**5.1.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (document date of trial) (if contraindicated, document contraindication)

**AND**

**5.1.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (document drug and date of trial) (if contraindicated, document contraindication)

**OR**

**5.2** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

**AND**

**6** - **ONE** of the following:

**6.1** Patient has failed a trial of at least **ONE** of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal

**OR**

**6.2** Patient has a history of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal

<b>Notes</b>	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>If the request is for oxycodone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER) and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.</p>
--------------	--

Product Name:morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, fentanyl 37.5, 62.5, 87.5 mcg/hr patches, methadone tabs/soln, generic methadone conc, Brand Methadose conc, Brand Zohydro ER	
<b>Diagnosis</b>	Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain*
<b>Approval Length</b>	6 month(s)
<b>Therapy Stage</b>	Initial Authorization
<b>Guideline Type</b>	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Prescriber attests to BOTH of the following:</p> <p><b>1.1</b> Patient has been screened for substance abuse/opioid dependence</p>	

**AND**

**1.2** Pain is moderate to severe and expected to persist for an extended period of time (chronic)

**AND**

**2** - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)

**AND**

**3** - BOTH of the following:

**3.1** Patient has been screened for underlying depression and/or anxiety

**AND**

**3.2** If applicable, any underlying conditions have been or will be addressed

**AND**

**4** - ONE of the following:

**4.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [document drug(s) and date of trial]

**OR**

**4.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**4.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**OR**

**4.4** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

**AND**

**5** - If the request is for neuropathic pain (examples of neuropathic pain include neuralgias and neuropathies), **ONE** of the following:

**5.1** **BOTH** of the following:

**5.1.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (document date of trial) (if contraindicated, document contraindication)

**AND**

**5.1.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (document drug and date of trial) (if contraindicated, document contraindication)

**OR**

**5.2** Patient is new to plan and currently established on long-acting opioid therapy for at least the past 30 days

**AND**

**6** - **ONE** of the following:

**6.1** Patient has failed a trial of at least **THREE** of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):

- morphine sulfate controlled release tablets (generic MS Contin)

- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

**OR**

**6.2** Patient has a history of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for preferred products, depending on what the patient has already tried:

- If the patient has tried morphine sulfate controlled release tablets (generic MS Contin) or preferred fentanyl transdermal, an authorization should be entered for oxymorphone ER-non crush resistant (generic) and hydrocodone extended-release capsules (generic Zohydro ER).
- If the patient has not tried any of the preferred products [morphine sulfate controlled release tablets (generic MS Contin), preferred fentanyl transdermal, oxymorphone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER)], an authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.

Product Name:generic morphine sulfate ER/CR tabs, fentanyl 12, 25, 50, 75, 100 mcg/hr patches

Diagnosis

Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain\*

Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Document rationale for not tapering or discontinuing opioid if treatment goals are not being met</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescriber attests to BOTH of the following:</p> <p><b>3.1</b> Patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3.2</b> Pain is moderate to severe and expected to persist for an extended period of time (chronic)</p>	
Notes	*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

Product Name:hydrocodone bitartrate ER caps, oxymorphone ER	
Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain*
Approval Length	6 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Document rationale for not tapering or discontinuing opioid if treatment goals are not being met</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescriber attests to BOTH of the following:</p> <p><b>3.1</b> Patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3.2</b> Pain is moderate to severe and expected to persist for an extended period of time (chronic)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - ONE of the following:</p> <p><b>4.1</b> Patient has failed a trial of at least ONE of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):</p> <ul style="list-style-type: none"><li>• morphine sulfate controlled release tablets (generic MS Contin)</li><li>• preferred fentanyl transdermal</li></ul> <p style="text-align: center;"><b>OR</b></p>	

**4.2** Patient has a history of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal

**Notes**

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

If the request is for oxymorphone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER) and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.

Product Name:morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, fentanyl 37.5, 62.5, 87.5 mcg/hr patches, methadone tabs/soln, generic methadone conc, Brand Methadose conc, Brand Zohydro ER

Diagnosis	Non-cancer related pain/Non-hospice/Non-sickle cell anemia/Non-end of life care pain*
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)

**AND**

**2** - Document rationale for not tapering or discontinuing opioid if treatment goals are not being met

**AND**

**3** - Prescriber attests to BOTH of the following:

**3.1** Patient has been screened for substance abuse/opioid dependence

**AND**

**3.2** Pain is moderate to severe and expected to persist for an extended period of time (chronic)

**AND**

**4** - ONE of the following:

**4.1** Patient has failed a trial of at least THREE of the following, as confirmed by claims history or submission of medical records (document drugs and date of trials):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

**OR**

**4.2** Patient has a history of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- morphine sulfate controlled release tablets (generic MS Contin)
- preferred fentanyl transdermal
- oxymorphone ER non-crush resistant (generic)
- hydrocodone extended-release capsules (generic Zohydro ER)

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be i

	<p>issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for preferred products, depending on what the patient has already tried:</p> <ul style="list-style-type: none"> <li>• If the patient has tried morphine sulfate controlled release tablets (generic MS Contin) or preferred fentanyl transdermal, an authorization should be entered for oxymorphone ER-non crush resistant (generic) and hydrocodone extended-release capsules (generic Zohydro ER).</li> <li>• If the patient has not tried any of the preferred products [morphine sulfate controlled release tablets (generic MS Contin), preferred fentanyl transdermal, oxymorphone ER-non crush resistant (generic) or hydrocodone extended-release capsules (generic Zohydro ER)], an authorization should be entered for morphine sulfate controlled release tablets (generic MS Contin) and preferred fentanyl transdermal.</li> </ul>
--	---

Product Name: tramadol ER, Conzip	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p><b>1.1</b> The patient has failed a trial of tramadol IR (immediate release) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> The patient has a history of contraindication or intolerance to tramadol IR (please specify contraindication or intolerance)</p> <p style="text-align: center;"><b>OR</b></p>	

**2 - BOTH of the following:**

**2.1 ONE of the following:**

**2.1.1** Patient is being treated for cancer related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)

**OR**

**2.1.2** Patient is in hospice or is receiving end of life care

**OR**

**2.1.3** Patient is being treated for sickle cell anemia related pain

**AND**

**2.2 BOTH of the following:**

**2.2.1** Patient is established on pain therapy with the requested medication for hospice related pain, sickle cell anemia related pain, end of life care related pain, or cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)

**AND**

**2.2.2** The medication is not a new regimen for treatment of cancer-related pain, hospice, sickle cell anemia related pain, or end of life care pain (document date regimen was started)

Product Name:generic morphine sulfate ER/CR tabs, fentanyl patches, hydrocodone bitartrate ER caps, oxymorphone ER, morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, methadone tabs/soln, generic methadone conc, Brand Methadose conc, tramadol ER, Conzip, Brand Zohydro ER

Guideline Type	Quantity Limit
----------------	----------------

**Approval Criteria**

1 - The requested dose cannot be achieved by moving to a higher strength of the product

**AND**

2 - The requested dose is within the Food and Drug Administration (FDA) maximum dose per day, where an FDA maximum dose per day exists

Notes	Authorization will be issued for: <ul style="list-style-type: none"> <li>• 12 months for cancer-related pain/hospice/sickle cell anemia related pain/end of life related pain.</li> <li>• 12 months for all Tramadol ER requests.</li> <li>• 6 months for non-cancer related pain/non-hospice/non-sickle cell anemia related pain/non-end of life related pain.</li> </ul>
-------	--

Product Name:generic morphine sulfate ER/CR tabs, fentanyl patches, hydrocodone bitartrate ER caps, oxymorphone ER, morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, methadone tabs/soln, generic methadone conc, Brand Methadose conc, tramadol ER, Conzip, Brand Zohydro ER

Diagnosis	Cancer-related pain/Hospice/Sickle Cell Anemia/End of Life Related Pain
Approval Length	12 Months*
Guideline Type	Morphine Milligram Equivalent (MME)

**Approval Criteria**

1 - Doses exceeding the cumulative morphine milligram equivalent (MME) of 90 milligrams (mg) will be approved up to the requested amount for ALL opioid products if the patient has one of the following:

- Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)
- Hospice pain
- End of life diagnosis
- Sickle cell anemia

Notes	*Authorization will be issued for 12 months for cancer-related pain pain/hospice/sickle cell anemia/end of life related pain. The authorization should be entered for an MME of 9999 so as to prevent future disruptions in therapy if the patient's dose is increased.
-------	---

Product Name:generic morphine sulfate ER/CR tabs, fentanyl patches, hydrocodone bitartrate ER caps, oxymorphone ER, morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, methadone tabs/soln, generic methadone conc, Brand Methadose conc, tramadol ER, Conzip, Brand Zohydro ER

Diagnosis	Non-cancer related pain/non-hospice/non-sickle cell anemia/non-end of life related pain
-----------	---

Approval Length	6 Months*
-----------------	-----------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Morphine Milligram Equivalent (MME)
----------------	-------------------------------------

**Approval Criteria**

1 - If the dose exceeds the maximum cumulative morphine milligram equivalent (MME) of 90 mg, ALL of the following:

1.1 Prescriber attests the patient has been screened for substance abuse/opioid dependence

**AND**

1.2 Treatment goals are defined and include estimated duration of treatment (must document treatment goals)

**AND**

1.3 BOTH of the following:

1.3.1 Patient has been screened for underlying depression and/or anxiety

**AND**

1.3.2 If applicable, any underlying conditions have been or will be addressed

**AND**

**1.4 ONE of the following:**

**1.4.1** Opioid medication doses of less than 90 MME have been tried and did not adequately control pain (document drug regimen or MME and dates of therapy)

**OR**

**1.4.2** Patient is new to plan and currently established on the requested MME for at least the past 30 days

Notes	<p>*Authorization will be issued for 6 months for non-cancer related pain/non-hospice/non-sickle cell anemia/non-end of life related pain up to the current requested MME plus 90 MME.</p> <p>If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested MME dose.</p>
-------	---

Product Name:generic morphine sulfate ER/CR tabs, fentanyl patches, hydrocodone bitartrate ER caps, oxymorphone ER, morphine sulfate ER caps, hydromorphone ER, generic hydrocodone bitartrate ER tabs, Brand Hysingla ER, Brand MS Contin, Nucynta ER, oxycodone ER, Oxycontin, Xtampza ER, methadone tabs/soln, generic methadone conc, Brand Methadose conc, tramadol ER, Conzip, Brand Zohydro ER

Diagnosis	Non-cancer related pain/non-hospice/non-sickle cell anemia/non-end of life related pain
Approval Length	6 Months*
Therapy Stage	Reauthorization
Guideline Type	Morphine Milligram Equivalent (MME)

**Approval Criteria**

**1** - If the dose exceeds the maximum cumulative morphine milligram equivalent (MME) of 90 milligrams, ALL of the following:

**1.1** Prescriber attests the patient has been screened for substance abuse/opioid dependence

**AND**

**1.2** Document rationale for not tapering or discontinuing opioid if treatment goals are not being met

**AND**

**1.3** Documented meaningful improvement in pain and function when assessed against treatment goals (document improvement in function or pain score improvement)

Notes	<p>*Authorization will be issued for 6 months for non-cancer related pain/ non-hospice/non-sickle cell anemia/non-end of life related pain up to the current requested MME plus 90 MME.</p> <p>If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested MME dose.</p>
-------	--

## 2 . Revision History

Date	Notes
12/13/2024	Copy

Lonhala and Yupelri



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146356
<b>Guideline Name</b>	Lonhala and Yupelri
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Lonhala Magnair (Starter Kit and Refill Kit), Yupelri	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1 One of the following:**

- Failure of Incruse Ellipta confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Incruse Ellipta (please specify intolerance or contraindication)

**OR**

**2.2 BOTH of the following:**

**2.2.1 Patient is unable to use a metered-dose, dry powder or slow mist inhaler (e.g. Incruse Ellipta) to control his/her COPD due to ONE of the following:**

- Cognitive or physical impairment limiting coordination of handheld devices (e.g., cognitive decline, arthritis in the hands) (Document impairment)
- Patient is unable to generate adequate inspiratory force (e.g., peak inspiratory flow rate (PIFR) resistance is less than 60 liters per minute)

**AND**

**2.2.2 One of the following:**

- Failure of ipratropium nebulized solution (generic Atrovent) confirmed by claims history or submitted medical records
- History of intolerance or contraindication to ipratropium nebulized solution (generic Atrovent) (please specify intolerance or contraindication)

Product Name:Lonhala Magnair (Starter Kit and Refill Kit), Yupelri	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	



Lonsurf



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148216
<b>Guideline Name</b>	Lonsurf
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Lonsurf	
Diagnosis	Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced or metastatic colorectal cancer (mCRC)</p>	

**AND**

**2** - History of failure, contraindication, or intolerance to treatment with ALL of the following:

- Fluoropyrimidine-based chemotherapy
- Oxaliplatin-based chemotherapy
- Irinotecan-based chemotherapy
- Anti-vascular endothelial growth factor (VEGF) biological therapy

**AND**

**3** - ONE of the following:

**3.1** Tumors is RAS mutant-type

**OR**

**3.2** BOTH of the following:

- Tumor is RAS wild-type
- History of failure, contraindication, or intolerance to anti-EGFR (epidermal growth factor receptor) therapy

Product Name:Lonsurf	
Diagnosis	Gastric/Gastroesophageal Junction Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable locally advanced, recurrent, or metastatic gastric cancer</li> </ul>	

- Unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma

**AND**

**2** - History of failure, contraindication, or intolerance to treatment with at least TWO prior lines of chemotherapy that consisted of the following agents:

- Fluoropyrimidine (e.g., fluorouracil)
- Platinum (e.g., carboplatin, cisplatin, oxaliplatin)
- Taxane (e.g., docetaxel, paclitaxel) or irinotecan
- Human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy (e.g., trastuzumab) (if HER2 overexpression)

Product Name:Lonsurf	
Diagnosis	Colorectal Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lonsurf therapy</p>	

Product Name:Lonsurf	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Lonsurf	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lonsurf therapy</p>	

## 2 . Revision History

Date	Notes
6/6/2024	Updated diagnostic criteria for colorectal cancer. Updated gastric/gastroesophageal junction adenocarcinoma diagnostic criteria.

Lorbrena



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146574
<b>Guideline Name</b>	Lorbrena
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Lorbrena	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2 - ONE of the following:**

**2.1 Disease is BOTH of the following:**

- Recurrent, advanced, or metastatic
- Anaplastic lymphoma kinase (ALK)-positive

**OR**

**2.2 BOTH of the following:**

**2.2.1 Disease is BOTH of the following:**

- Recurrent, advanced, or metastatic
- ROS proto-oncogene 1 (ROS1)-positive

**AND**

**2.2.2 Disease has progressed on at least ONE of the following therapies:**

- Rozlytrek (entrectinib)
- Xalkori (crizotinib)
- Zykadia (ceritinib)

Product Name:Lorbrena	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of Erdheim-Chester Disease (ECD)

**AND**

2 - Disease is BOTH of the following:

- Symptomatic, relapsed, or refractory
- ALK-positive

Product Name:Lorbrena

Diagnosis	Soft Tissue Sarcoma
-----------	---------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK translocation

Product Name:Lorbrena

Diagnosis	Uterine Sarcoma
-----------	-----------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of uterine sarcoma

**AND**

**2** - Disease is ONE of the following:

- Advanced
- Recurrent/metastatic
- Inoperable

**AND**

**3** - Disease is ALK - positive

Product Name:Lorbrena	
Diagnosis	Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Anaplastic large cell lymphoma (ALCL)</li> <li>• Large B-Cell lymphoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is relapsed or refractory</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is ALK - positive</p>	

Product Name:Lorbrena	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Histiocytic Neoplasms, Soft Tissue Sarcoma, Uterine Sarcoma, Lymphoma

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lorbrena therapy</p>	

Product Name:Lorbrena	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Lorbrena	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lorbrena therapy</p>	

Lovenox



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146357
<b>Guideline Name</b>	Lovenox
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Lovenox, generic enoxaparin	
Diagnosis	Continuation of Therapy Upon Hospital Discharge
Approval Length	35 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Will be approved as continuation of therapy upon hospital discharge</p>	

Product Name:Brand Lovenox, generic enoxaparin
--

Diagnosis	Prophylaxis of DVT - Orthopedic Surgery
Approval Length	35 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For deep vein thrombosis (DVT) prophylaxis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is undergoing ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hip fracture surgery</li> <li>• Hip replacement surgery</li> <li>• Knee replacement surgery</li> </ul>	

Product Name: Brand Lovenox, generic enoxaparin	
Diagnosis	Prophylaxis of DVT - Abdominal Surgery
Approval Length	2 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For deep vein thrombosis (DVT) prophylaxis following abdominal surgery</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is at risk for thromboembolic complications</p>	

Product Name: Brand Lovenox, generic enoxaparin	
Diagnosis	Prophylaxis of DVT - Restricted Mobility
Approval Length	2 Week(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For deep vein thrombosis (DVT) prophylaxis in patients at risk for thromboembolic complications due to severely restricted mobility during acute illness</p>	

Product Name:Brand Lovenox, generic enoxaparin	
Diagnosis	DVT Treatment
Approval Length	2 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For the treatment of acute deep vein thrombosis (DVT)</p>	

Product Name:Brand Lovenox, generic enoxaparin	
Diagnosis	Prophylaxis of Ischemic Complications
Approval Length	2 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For prophylaxis of ischemic complications in ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unstable angina</li> <li>• Non-Q-Wave myocardial infarction</li> </ul>	

Product Name:Brand Lovenox, generic enoxaparin	
Diagnosis	Acute ST-Segment Elevation Myocardial Infarction
Approval Length	2 Week(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For the treatment of acute ST-segment elevation myocardial infarction (STEMI)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Managed medically</li> <li>• Managed with subsequent percutaneous coronary intervention</li> </ul>	

Product Name: Brand Lovenox, generic enoxaparin	
Diagnosis	Off-Label Uses
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:</p> <ul style="list-style-type: none"> <li>• American Hospital Formulary Service Drug Information</li> <li>• National Comprehensive Cancer Network Drugs and Biologics Compendium</li> <li>• Thomson Micromedex DrugDex</li> <li>• Clinical pharmacology</li> <li>• United States Pharmacopoeia-National Formulary (USP-NF)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program</p>	
Notes	Authorization will be issued for the compendia recommended duration of therapy, not to exceed 12 months.

Lumakras



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155016
<b>Guideline Name</b>	Lumakras
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Lumakras	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is ONE of the following:

- Recurrent
- Advanced
- Metastatic

**AND**

**3** - Tumor is KRAS G12C (gene)-mutated

**AND**

**4** - Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

Product Name:Lumakras	
Diagnosis	Pancreatic Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of pancreatic adenocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> </ul>	

<ul style="list-style-type: none"> <li>• Metastatic</li> </ul>
<b>AND</b>
<b>3</b> - Tumor is KRAS G12C-mutated
<b>AND</b>
<b>4</b> - Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

Product Name:Lumakras	
Diagnosis	Ampullary Adenocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ampullary adenocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Tumor is KRAS G12C-mutation positive</p>	

**AND**

**4** - Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

Product Name:Lumakras	
Diagnosis	Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Colon Cancer</li> <li>• Rectal Cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Tumor is KRAS G12C-mutation positive</p> <p style="text-align: center;"><b>AND</b></p>	

**4** - Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

Product Name:Lumakras	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ampullary Adenocarcinoma, Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lumakras therapy</p>	

Product Name:Lumakras	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Lumakras	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Lumakras therapy

**2 . Revision History**

Date	Notes
9/16/2024	Added criteria for ampullary adenocarcinoma, colon cancer, and rectal cancer

Lupkynis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152724
<b>Guideline Name</b>	Lupkynis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Lupkynis	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active lupus nephritis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Provider attests to ONE of the following:

- Diagnosis is biopsy proven
- Biopsy is contraindicated in the patient

**AND**

**3** - Provider attests to ONE of the following:

**3.1** Clinical progression (e.g., worsening of proteinuria or serum creatinine) after 3 months of induction therapy with immunosuppressive agents (e.g., mycophenolate, cyclophosphamide, methylprednisolone), as confirmed by claims history or submission of medical records

**OR**

**3.2** Failure to respond after 6 months of induction therapy with immunosuppressive agents (e.g., mycophenolate, cyclophosphamide, methylprednisolone), as confirmed by claims history or submission of medical records

**AND**

**4** - Prescribed in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil and corticosteroids)

**AND**

**5** - Patient is NOT receiving Lupkynis in combination with either of the following:

- Cyclophosphamide
- Benlysta (belimumab)

**AND**

**6** - Prescribed by ONE of the following:

- Nephrologist
- Rheumatologist

Product Name:Lupkynis	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lupkynis therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil and corticosteroids)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving Lupkynis in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Cyclophosphamide</li> <li>• Benlysta (belimumab)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Nephrologist</li> <li>• Rheumatologist</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>5 - ONE of the following:</p> <p>5.1 Patient has been on Lupkynis therapy for less than 12 months</p>	

**OR**

**5.2** BOTH of the following:

**5.2.1** Patient has completed 12 or more months of Lupkynis therapy

**AND**

**5.2.2** The provider attests that the benefit of continuation of therapy exceeds the risk in light of the patient's treatment response and risk of worsening nephrotoxicity

## 2 . Revision History

Date	Notes
8/27/2024	Annual review. Updated authorization lengths to 12 months.

Lynparza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154725
<b>Guideline Name</b>	Lynparza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Lynparza	
Diagnosis	Breast Cancer (High Risk Early)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of high risk early breast cancer</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Presence of deleterious or suspected deleterious germline breast cancer (BRCA)-mutations (gBRCAm)

**AND**

**3** - Disease is human growth factor receptor 2 (HER2)-negative

**AND**

**4** - ONE of the following:

**4.1** Patient is hormone receptor (HR) negative

**OR**

**4.2** BOTH of the following:

**4.2.1** Patient is hormone receptor (HR) positive

**AND**

**4.2.2** Patient is continuing concurrent treatment with endocrine therapy

**AND**

**5** - Patient has been treated with neoadjuvant or adjuvant chemotherapy

**AND**

**6** - Treatment duration has not exceeded 12 months of therapy

Product Name:Lynparza

Diagnosis

Breast Cancer (Metastatic or Recurrent)

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of ONE of the following:</b></p> <p><b>1.1 Metastatic breast cancer</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2 Recurrent breast cancer</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Presence of deleterious or suspected deleterious germline breast cancer (BRCA)-mutations (gBRCAm)</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - ONE of the following:</b></p> <p><b>3.1 BOTH of the following:</b></p> <p><b>3.1.1 Disease is human epidermal growth factor receptor 2 (HER2)-negative</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3.1.2 ONE of the following:</b></p> <p><b>3.1.2.1 Disease is hormone receptor (HR) negative</b></p> <p style="text-align: center;"><b>OR</b></p>	

**3.1.2.2** BOTH of the following:

**3.1.2.2.1** Disease is hormone receptor (HR) positive

**AND**

**3.1.2.2.2** ONE of the following:

- Disease has progressed on previous endocrine therapy
- Provider attestation that treatment with endocrine therapy is inappropriate

**OR**

**3.2** Disease is human epidermal growth factor receptor 2 (HER2)-positive

Product Name:Lynparza	
Diagnosis	Ovarian Cancer (Maintenance Therapy)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Epithelial ovarian cancer</li> <li>• Fallopian tube cancer</li> <li>• Primary peritoneal cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Advanced</li> </ul>	

- Recurrent
- AND**
- 3 - ONE of the following:**
- 3.1** Presence of deleterious or suspected deleterious germline or somatic BRCA-mutations
- OR**
- 3.2** Both of the following:
- 3.2.1** Cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation or genomic instability
- AND**
- 3.2.2** Used in combination with bevacizumab (e.g., Avastin, Mvasi)
- AND**
- 4 - Patient has had a complete or partial response to platinum-based chemotherapy**
- AND**
- 5 - Request is for maintenance therapy**

Product Name:Lynparza	
Diagnosis	Ovarian Cancer (Treatment)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer

**AND**

2 - Disease is ONE of the following:

- Advanced
- Persistent
- Recurrent

**AND**

3 - Presence of deleterious or suspected deleterious germline BRCA (breast cancer gene)-mutation

**AND**

4 - Patient has been treated with two or more prior lines of chemotherapy

Product Name:Lynparza	
Diagnosis	Pancreatic Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Diagnosis of pancreatic adenocarcinoma

**AND**

**2** - Disease is metastatic

**AND**

**3** - Presence of deleterious or suspected deleterious germline BRCA1/2 (breast cancer gene)-mutation

**AND**

**4** - Disease has NOT progressed while receiving at least 16 weeks of a first-line platinum-based chemotherapy regimen

Product Name:Lynparza	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of metastatic castration-resistant prostate cancer</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> BOTH of the following:</p> <p><b>2.1.1</b> Presence of deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations</p>	

**AND**

**2.1.2** Disease has progressed following prior treatment with ONE of the following:

- Enzalutamide (Xtandi)
- Abiraterone (e.g., Zytiga, Yonsa)

**OR**

**2.2** ALL of the following:

**2.2.1** Presence of deleterious or suspected deleterious BRCA-mutation

**AND**

**2.2.2** Used in combination with abiraterone (e.g., Zytiga, Yonsa)

**AND**

**2.2.3** Used in combination with ONE of the following:

- Prednisone
- Prednisolone

**AND**

**3** - ONE of the following:

**3.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**3.2** Patient has had bilateral orchiectomy

Product Name:Lynparza	
Diagnosis	Uterine Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of uterine sarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - The requested medication is NOT used as first-line therapy</p>	

Product Name:Lynparza	
Diagnosis	Breast Cancer (Metastatic or Recurrent), Ovarian Cancer (Maintenance or Treatment), Pancreatic Cancer, Prostate Cancer, Uterine Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Lynparza therapy</p>	

Product Name:Lynparza	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Lynparza	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lynparza therapy</p>	

Lyrica



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164978
<b>Guideline Name</b>	Lyrica
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Lyrica	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Requested for the treatment of a seizure disorder

**OR**

2 - BOTH of the following:

2.1 Diagnosis of ONE of the following:

- Fibromyalgia
- Diabetic peripheral neuropathy (DPN)
- Post herpetic neuralgia (PHN)
- Neuropathic pain associated with spinal cord injury

**AND**

2.2 ONE of the following:

2.2.1 Failure to generic pregabalin at a minimum dose of 300 mg (milligrams) daily for 4 weeks as confirmed by claims history or submission of medical records

**OR**

2.2.2 History of intolerance or contraindication to generic pregabalin (please specify intolerance or contraindication)

Product Name: Brand Lyrica CR, generic pregabalin ER	
Diagnosis	Diabetic Peripheral Neuropathy (DPN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of diabetic peripheral neuropathy (DPN)	

**AND**

**2 - ONE of the following:**

**2.1** Failure to gabapentin (generic Neurontin) at a minimum dose of 1800 mg daily for 4 weeks as confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance or contraindication to gabapentin (generic Neurontin) (please specify intolerance or contraindication)

**AND**

**3 - ONE of the following:**

**3.1** Failure to treatment with **ONE** of the following classes of medications as confirmed by claims history or submission of medical records:

- Tricyclic antidepressant at the maximum tolerated dose for 6 to 8 weeks, or intolerance to a tricyclic antidepressant
- Serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant (e.g., duloxetine, venlafaxine)

**OR**

**3.2** History of intolerance or contraindication to treatment from **BOTH** classes of medications (please specify intolerance or contraindication)

- Tricyclic antidepressant at the maximum tolerated dose for 6 to 8 weeks, or intolerance to a tricyclic antidepressant
- SNRI antidepressant (e.g., duloxetine, venlafaxine)

**AND**

**4 - ONE of the following:**

**4.1** Failure to generic pregabalin immediate-release capsules or generic pregabalin suspension as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to generic pregabalin immediate-release capsules or generic pregabalin suspension (please specify intolerance or contraindication)

Product Name: Brand Lyrica CR, generic pregabalin ER

Diagnosis	Post Herpetic Neuralgia (PHN)
-----------	-------------------------------

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of post herpetic neuralgia (PHN)

**AND**

**2** - ONE of the following:

**2.1** Failure to gabapentin (generic Neurontin) at a minimum dose of 1800 mg daily for 4 weeks as confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance or contraindication to gabapentin (generic Neurontin) (please specify intolerance or contraindication)

**AND**

**3** - ONE of the following:

**3.1** Failure to a tricyclic antidepressant at the maximum tolerated dose for 6 to 8 weeks as confirmed by claims history of submission of medical records

**OR**

**3.2** History of intolerance or contraindication to a tricyclic antidepressant (please specify intolerance or contraindication)

**AND**

**4** - ONE of the following:

**4.1** Failure to generic pregabalin immediate-release capsules or generic pregabalin suspension as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to generic pregabalin immediate-release capsules or generic pregabalin suspension (please specify intolerance or contraindication)

## 2 . Revision History

Date	Notes
2/11/2025	Updated formularies

Lysteda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146359
<b>Guideline Name</b>	Lysteda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Lysteda, generic tranexamic acid	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cyclic heavy menstrual bleeding</p>	

Lytgobi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163894
<b>Guideline Name</b>	Lytgobi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Lytgobi	
Diagnosis	Cholangiocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cholangiocarcinoma (intrahepatic or extrahepatic)</p>	

**AND**

**2** - Disease is ONE of the following:

- Unresectable
- Resected gross residual (R2)
- Metastatic

**AND**

**3** - Positive for fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements

**AND**

**4** - Used as second line or subsequent treatment

Product Name:Lytgobi	
Diagnosis	Cholangiocarcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Lytgobi therapy	

Product Name:Lytgobi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Lytgobi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Lytgobi therapy</p>	

**2 . Revision History**

Date	Notes
1/16/2025	Updated cholangiocarcinoma initial criteria

Marinol, Syndros



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161401
<b>Guideline Name</b>	Marinol, Syndros
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Syndros	
Diagnosis	Chemotherapy-induced nausea and vomiting
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is receiving cancer chemotherapy</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure to formulary generic dronabinol as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to formulary generic dronabinol (please specify contraindication or intolerance)

**OR**

**2.3** Patient is unable to swallow capsules

**AND**

**3 - ONE of the following:**

**3.1** Failure to a 5HT-3 (5-hydroxytryptamine type 3) receptor antagonist [e.g., Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)] as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to a 5HT-3 receptor antagonist [e.g., Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)] (please specify contraindication or intolerance)

**AND**

**4 - ONE of the following:**

**4.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lorazepam (generic Ativan)
- Prochlorperazine (generic Compazine)
- Dexamethasone (generic Decadron)

- Haloperidol (generic Haldol)
- Promethazine (generic Phenergan)
- Metoclopramide (generic Reglan)
- Olanzapine (generic Zyprexa)

**OR**

**4.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Lorazepam (generic Ativan)
- Prochlorperazine (generic Compazine)
- Dexamethasone (generic Decadron)
- Haloperidol (generic Haldol)
- Promethazine (generic Phenergan)
- Metoclopramide (generic Reglan)
- Olanzapine (generic Zyprexa)

Product Name: Brand Marinol, generic dronabinol	
Diagnosis	Chemotherapy-induced nausea and vomiting
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is receiving cancer chemotherapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure to a 5HT-3 (5-hydroxytryptamine type 3) receptor antagonist [e.g., Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)] as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2.2** History of contraindication or intolerance to a 5HT-3 receptor antagonist [e.g., Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)] (please specify contraindication or intolerance)

**AND**

**3** - ONE of the following:

**3.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Lorazepam (generic Ativan)
- Prochlorperazine (generic Compazine)
- Dexamethasone (generic Decadron)
- Haloperidol (generic Haldol)
- Promethazine (generic Phenergan)
- Metoclopramide (generic Reglan)
- Olanzapine (generic Zyprexa)

**OR**

**3.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Lorazepam (generic Ativan)
- Prochlorperazine (generic Compazine)
- Dexamethasone (generic Decadron)
- Haloperidol (generic Haldol)
- Promethazine (generic Phenergan)
- Metoclopramide (generic Reglan)
- Olanzapine (generic Zyprexa)

Product Name: Syndros	
Diagnosis	Anorexia in a patient with AIDS
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of anorexia with weight loss in a patient with AIDS (acquired immunodeficiency syndrome)

**AND**

**2** - Patient is on antiretroviral therapy

**AND**

**3** - ONE of the following:

**3.1** Patient is 65 years of age or greater

**OR**

**3.2** BOTH of the following:

**3.2.1** Patient is less than 65 years of age

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Failure to megestrol (generic Megace) as confirmed by claims history or submission of medical records

**OR**

**3.2.2.2** History of intolerance or contraindication to megestrol (generic Megace) (please specify intolerance or contraindication)

**AND**

**4** - ONE of the following:

**4.1** Failure to formulary generic dronabinol as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to formulary generic dronabinol (please specify contraindication or intolerance)

**OR**

**4.3** Patient is unable to swallow capsules

Product Name: Brand Marinol, generic dronabinol	
Diagnosis	Anorexia in a patient with AIDS
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of anorexia with weight loss in a patient with AIDS (acquired immunodeficiency syndrome)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is on antiretroviral therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <p><b>3.1</b> Patient is 65 years of age or greater</p>	

**OR**

**3.2 BOTH** of the following:

**3.2.1** Patient is less than 65 years of age

**AND**

**3.2.2 ONE** of the following:

**3.2.2.1** Failure to megestrol (generic Megace) as confirmed by claims history or submission of medical records

**OR**

**3.2.2.2** History of intolerance or contraindication to megestrol (generic Megace) (please specify intolerance or contraindication)

## 2 . Revision History

Date	Notes
11/27/2024	Added GPIs for Brand Marinol capsules 5mg and 10mg strengths. Minor update to 5HT-3 definition, with no changes to clinical intent.

Mavenclad



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-192187
<b>Guideline Name</b>	Mavenclad
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Mavenclad	
Approval Length	2 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary progressive MS with relapses)

**AND**

2 - Prescribed by, or in consultation with, a specialist in the treatment of MS (e.g., neurologist)

**AND**

3 - ONE of the following:

3.1 Trial and failure (after trial of at least 4 weeks) to TWO of the following disease-modifying therapies for MS (one of which must be a preferred dimethyl fumarate product) as confirmed by claims history or submission of medical records:

- Interferon beta-1a (Avonex\*, Rebif\*, Plegridy)
- Interferon beta-1b (Betaseron\*, Extavia\*)
- Glatiramer acetate products (e.g., Copaxone, Glatopa)
- A preferred dimethyl fumarate product (e.g., Tecfidera)
- Teriflunomide (generic Aubagio)
- Fingolimod (generic Gilenya)
- Mayzent (siponimod)
- Tysabri (natalizumab)\*\*
- Ocrevus (ocrelizumab)\*\*
- Lemtrada (alemtuzumab)\*\*
- Zeposia (ozanimod)\*
- Kesimpta (ofatumumab)\*
- Bafiertam (monomethyl fumarate)\*
- Briumvi (ublituximab)\*\*

**OR**

3.2 History of contraindication or intolerance to TWO of the following disease-modifying therapies for MS (please specify contraindication or intolerance)

- Interferon beta-1a (Avonex\*, Rebif\*, Plegridy)
- Interferon beta-1b (Betaseron\*, Extavia\*)
- Glatiramer acetate products (e.g., Copaxone, Glatopa)

- A preferred dimethyl fumarate product (e.g., Tecfidera)
- Teriflunomide (generic Aubagio)
- Fingolimod (generic Gilenya)
- Mayzent (siponimod)
- Tysabri (natalizumab)\*\*
- Ocrevus (ocrelizumab)\*\*
- Lemtrada (alemtuzumab)\*\*
- Zeposia (ozanimod)\*
- Kesimpta (ofatumumab)\*
- Bafiertam (monomethyl fumarate)\*
- Briumvi (ublituximab)\*\*

**OR**

**3.3** Patient is currently on Mavenclad

**AND**

**4** - Patient is NOT receiving Mavenclad in combination with another disease modifying therapy [e.g., interferon beta preparations, glatiramer acetate products, Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Gilenya (fingolimod), Mayzent (siponimod), Ocrevus (ocrelizumab), Lemtrada (alemtuzumab), or Aubagio (teriflunomide)]

Notes	*Avonex, Rebif, Betaseron, Bafiertam, Kesimpta, Zeposia, and Extavia are non-preferred and should not be included in denial to provider. **Briumvi, Tysabri, Ocrevus, and Lemtrada are medical benefit and should not be included in denial to provider.
-------	---

Product Name:Mavenclad	
Approval Length	2 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Mavenclad treatment</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is NOT receiving Mavenclad in combination with another disease modifying therapy [e.g., interferon beta preparations, glatiramer acetate products, Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Gilenya (fingolimod), Mayzent (siponimod), Ocrevus (ocrelizumab), Lemtrada (alemtuzumab), or Aubagio (teriflunomide)]

**AND**

**3** - Patient has not exceeded the FDA (Food and Drug Administration)-recommended limit of 2 treatment courses (4 treatment cycles) of Mavenclad

Notes	Duration of coverage will be limited to 1 reauthorization to allow 2 cumulative treatment courses (4 treatment cycles) of Mavenclad therapy.
-------	--

## 2 . Revision History

Date	Notes
2/24/2025	Updated formularies. Updated step through language to reference generic product for Aubagio and Gilenya, added Briumvi as option for step

Mekinist



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151095
<b>Guideline Name</b>	Mekinist
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/7/2024
-----------------	----------

## 1 . Criteria

Product Name:Mekinist	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p>	

**1.1.1 ONE of the following:**

**1.1.1.1 Unresectable melanoma**

**OR**

**1.1.1.2 Metastatic melanoma**

**OR**

**1.1.1.3 BOTH of the following:**

**1.1.1.3.1 Prescribed as adjuvant therapy for melanoma involving the lymph node(s)**

**AND**

**1.1.1.3.2 Used in combination with Tafinlar (dabrafenib)**

**AND**

**1.1.2 Cancer is positive for BRAF V600 (gene) mutation**

**OR**

**1.2 Distant metastatic uveal melanoma**

**AND**

**2 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)**

Product Name:Mekinist

Diagnosis

Non-Small Cell Lung Cancer (NSCLC)

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Metastatic</li> <li>• Advanced</li> <li>• Recurrent</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Cancer is positive for BRAF V600E (gene) mutation</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Used in combination with Tafenlar (dabrafenib)</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)</p>	

Product Name: Mekinist	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following:</b></p> <p><b>1.1 ALL of the following:</b></p> <p><b>1.1.1</b> Diagnosis of anaplastic thyroid cancer (ATC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.2</b> Cancer is positive for BRAF V600E (gene) mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.3</b> Used in combination with Tafenlar (dabrafenib)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.4 ONE of the following:</b></p> <p><b>1.1.4.1</b> Disease is ONE of the following:</p> <ul style="list-style-type: none"><li>• Metastatic</li><li>• Locally advanced</li><li>• Unresectable</li></ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.4.2</b> Prescribed as adjuvant therapy following resection</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2 ALL of the following:</b></p>	

**1.2.1 ONE of the following diagnoses:**

- Follicular Carcinoma
- Oncocytic Carcinoma
- Papillary Carcinoma

**AND**

**1.2.2 ONE of the following:**

- Unresectable locoregional recurrent disease
- Persistent disease
- Metastatic disease

**AND**

**1.2.3 ONE of the following:**

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**1.2.4 Disease is refractory to radioactive iodine treatment**

**AND**

**1.2.5 Cancer is positive for BRAF V600 mutation**

**AND**

**1.2.6 Used in combination with Tafinlar (dabrafenib)**

**AND**

**2** - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

<b>Product Name:Mekinist</b>	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** BOTH of the following:

**1.1.1** Patient has metastatic brain lesions

**AND**

**1.1.2** Mekinist is active against the primary tumor (melanoma)

**OR**

**1.2** Patient has a glioma

**AND**

**2** - Cancer is positive for BRAF V600E (gene) mutation

**AND**

**3** - Used in combination with Tafinlar (dabrafenib)

**AND**

**4** - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Epithelial Ovarian Cancer</li> <li>• Fallopian Tube Cancer</li> <li>• Primary Peritoneal Cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Persistent disease</li> <li>• Recurrence in BRAF V600E positive tumors</li> <li>• Recurrence of low-grade serous carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)</p>	

Product Name:Mekinist

Diagnosis	Hepatobiliary Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Gallbladder cancer</li> <li>• Extrahepatic Cholangiocarcinoma</li> <li>• Intrahepatic Cholangiocarcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used as subsequent treatment after progression on or after systemic treatment</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is unresectable or metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Cancer is positive for BRAF V600E (gene) mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Used in combination with Tafinlar (dabrafenib)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)</p>	

Product Name:Mekinist	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Langerhans Cell Histiocytosis</li> <li>• Erdheim-Chester Disease</li> <li>• Rosai-Dorfman Disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Mitogen-activated protein (MAP) kinase pathway mutation</li> <li>• No detectable mutation</li> <li>• Testing not available</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)</p>	

Product Name:Mekinist	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Presence of solid tumor

**AND**

2 - Used as subsequent treatment after progression on or after systemic treatment

**AND**

3 - Disease is unresectable or metastatic

**AND**

4 - Cancer is positive for BRAF V600E (gene) mutation

**AND**

5 - Used in combination with Tafinlar (dabrafenib)

**AND**

6 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	Pancreatic Cancer, Ambullary Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of ONE of the following:**

- Pancreatic adenocarcinoma
- Ampullary adenocarcinoma

**AND**

**2 - Disease is ONE of the following:**

- Metastatic
- Locally advanced
- Unresectable

**AND**

**3 - Cancer is positive for BRAF V600E mutation**

**AND**

**4 - Used in combination with Tafenlar (dabrafenib)**

**AND**

**5 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)**

<b>Product Name:Mekinist</b>	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of hairy cell leukemia

**AND**

2 - Used in combination with Tafinlar (dabrafenib)

**AND**

3 - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of salivary gland tumor

**AND**

2 - Disease is one of the following:

- Recurrent and unresectable
- Metastatic

**AND**

3 - Cancer is positive for BRAF V600E mutation

**AND**

**4** - Used in combination with Tafenlar (dabrafenib)

**AND**

**5** - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of BRAF V600E-mutated gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Gross residual disease (R2 resection)</li> <li>• Unresectable primary disease</li> <li>• Tumor rupture</li> <li>• Progressive</li> <li>• Recurrent</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used in combination with Tafenlar (dabrafenib)</p>	

**AND**

**4** - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	Melanoma, NSCLC, Thyroid Cancer, CNS Cancers, Epithelial Ovarian /Fallopian Tube /Primary Peritoneal Cancers, Hepatobiliary Cancers, Histiocytic Neoplasms, Solid Tumors, Pancreatic /Ampullary Cancer , Hairy Cell Leukemia, Salivary Gland Tumor, GIST
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Mekinist therapy</p>	

Product Name:Mekinist	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - If the request is for Mekinist solution, there is a reason or special circumstance why the patient is unable to use Mekinist tablets (document reason or special circumstance)

Product Name:Mekinist	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Mekinist therapy</p>	

## 2 . Revision History

Date	Notes
8/6/2024	Copy core

Mektovi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164675
<b>Guideline Name</b>	Mektovi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Mektovi	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of melanoma

**AND**

1.2 Disease is one of the following:

- Unresectable
- Metastatic

**AND**

1.3 Patient is positive for BRAFV600 mutation

**AND**

1.4 Used in combination with Braftovi (encorafenib)

**AND**

1.5 ONE of the following:

1.5.1 Patient has a contraindication or history of intolerance to ONE of the following regimens (please specify intolerance or contraindication):

- Tafinlar (dabrafenib) plus Mekinist (trametinib)
- Zelboraf (vemurafenib) plus Cotellic (cobimetinib)

**OR**

1.5.2 Provider attests that the patient is not an appropriate candidate based on the patient's clinical status or comorbidities for either of the following regimens:

- Tafinlar (dabrafenib) plus Mekinist (trametinib)
- Zelboraf (vemurafenib) plus Cotellic (cobimetinib)

**OR**

**1.5.3** For continuation of prior Mektovi therapy

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of melanoma

**AND**

**2.2** Disease is one of the following:

- Unresectable
- Metastatic

**AND**

**2.3** Patient is positive for NRAS-mutation

**AND**

**2.4** Progression after prior immune checkpoint inhibitor therapy

Product Name:Mektovi	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Mektovi therapy

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

- BRAFV600 mutation positive
- Used in combination with Braftovi (encorafenib)

**OR**

2.2 NRAS-mutated tumor

Product Name:Mektovi	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Multisystem Langerhans Cell Histiocytosis
- Single-system lung Langerhans Cell Histiocytosis
- Langerhans Cell Histiocytosis with CNS (central nervous system) lesions

**AND**

**2** - ONE of the following:

- Disease is positive for mitogen-activated protein (MAP) kinase pathway mutation
- No other detectable/actionable mutation
- Testing is not available

Product Name:Mektovi	
Diagnosis	Serous Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of low-grade serous carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is recurrent</p>	

Product Name:Mektovi	
Diagnosis	Histiocytic Neoplasms, Serous Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Mektovi therapy</p>	

Product Name:Mektovi
----------------------

Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Gross residual disease (R2 resection)</li> <li>• Unresectable primary disease</li> <li>• Tumor rupture</li> <li>• Progressive</li> <li>• Recurrent</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used in combination with imatinib mesylate (generic Gleevec)</p>	

Product Name: Mektovi	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Mektovi therapy</p>	

**AND**

**2** - Used in combination with imatinib mesylate (Gleevec)

Product Name:Mektovi	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is positive for BRAFV600 mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Used in combination with Braftovi (encorafenib)</p> <p style="text-align: center;"><b>AND</b></p>	

**5 - ONE of the following:**

**5.1** Patient has a contraindication or history of intolerance to Tafinlar (dabrafenib) plus Mekinist (trametinib) (please specify intolerance or contraindication)

**OR**

**5.2** Provider attests that the patient is not an appropriate candidate based on the patient's clinical status or comorbidities for Tafinlar (dabrafenib) plus Mekinist (trametinib)

**OR**

**5.3** For continuation of prior Mektovi therapy

Product Name:Mektovi	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Mektovi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used in combination with Braftovi (encorafenib)</p>	

Product Name:Mektovi	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Mektovi	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Mektovi therapy</p>	

## 2 . Revision History

Date	Notes
2/4/2025	Updated formularies. Updated reauth criteria

Mepron



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146361
<b>Guideline Name</b>	Mepron
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Mepron, generic atovaquone	
Diagnosis	Pneumocystis Jirovecii Pneumonia (PCP) Prophylaxis
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient has a diagnosis [e.g., HIV (human immunodeficiency virus)] warranting PCP (pneumocystis jirovecii pneumonia) infection prophylaxis</p>	

**AND**

**2** - The patient has a documented intolerance or contraindication to trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone (please specify intolerance or contraindication)

Product Name: Brand Mepron, generic atovaquone	
Diagnosis	Pneumocystis Jirovecii Pneumonia (PCP) Treatment
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - The patient has a diagnosis of mild to moderate pneumonia caused by pneumocystis jirovecii</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> Failure of trimethoprim-sulfamethoxazole (TMP-SMX) confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to TMP-SMX (please specify intolerance or contraindication)</p>	

Migranal, Trudhesa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-192189
<b>Guideline Name</b>	Migranal, Trudhesa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brand Migranal, generic dihydroergotamine mesylate nasal spray, Trudhesa	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of migraine headaches with or without aura**

**AND**

**2 - ONE of the following:**

**2.1** Failure to THREE preferred 5-HT<sub>1</sub> receptor agonist (triptan) alternatives (e.g., sumatriptan, rizatriptan, or naratriptan), one of which must be sumatriptan nasal spray, confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to THREE preferred 5-HT<sub>1</sub> receptor agonist (triptan) alternatives (e.g., sumatriptan, rizatriptan, or naratriptan), one of which must be sumatriptan nasal spray (please specify intolerance or contraindication)

Product Name: Brand Migranal, generic dihydroergotamine mesylate nasal spray, Trudhesa

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Quantity Limit
----------------	----------------

**Approval Criteria**

**1 - Diagnosis of migraine headaches with or without aura**

**AND**

**2 - Prescribed by, or in consultation with, ONE of the following:**

- Neurologist
- Pain management specialist

**AND**

**3 - Currently receiving prophylactic therapy with at least ONE of the following:**

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan (generic Atacand)\*
- A calcitonin gene-related peptide receptor\*\*\* (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy\* (fremanezumab), Emgality (galcanezumab), Qulipta\* (atogepant), Vyepti\*\* (eptinezumab-jjmr)]
- Divalproex sodium (Depakote/Depakote ER)
- OnabotulinumtoxinA (Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4 - BOTH** of the following:

**4.1 ONE** of the following:

**4.1.1** Higher dose or quantity is supported by the manufacturer's prescribing information

**OR**

**4.1.2** Higher dose or quantity is supported by ONE of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**4.1.3** Physician provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the Food and Drug Administration (FDA) for the diagnosis indicated

**AND**

**4.2** Physician acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes	<p>*This is non-preferred and should not be included in denial to provider .</p> <p>**This is a medical benefit and should not be included in denial to provider.</p> <p>***Requires a prior authorization.</p>
-------	---

## 2 . Revision History

Date	Notes
2/24/2025	Updated formularies. Updated step therapy language, naratriptan step therapy removed. Updated list of prophylactic therapy

Miplyffa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-192193
<b>Guideline Name</b>	Miplyffa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Miplyffa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of Niemann-Pick disease type C (NPC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Diagnosis has been genetically confirmed by mutation analysis of NPC1 and NPC2 genes</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Miplyffa is being used to treat neurological manifestations of NPC</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Miplyffa is prescribed in combination with miglustat</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Patient is NOT receiving Miplyffa in combination with Aqneursa (levacetylleucine)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - Miplyffa is prescribed by or in consultation with a provider with expertise in the treatment of NPC</p>	

<b>Product Name: Miplyffa</b>	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Miplyffa therapy (e.g., slowed disease progression from baseline based on assessment with NPC–specific scales)

**AND**

2 - Miplyffa continues to be prescribed in combination with miglustat

**AND**

3 - Patient is NOT receiving Miplyffa in combination with Aqneursa (levacetylleucine)

**AND**

4 - Miplyffa is prescribed by or in consultation with a provider with expertise in the treatment of NPC

**2 . Revision History**

Date	Notes
2/24/2025	Updated formularies. Added criteria that Miplyffa not taken in combination with Aqneursa

Mozobil



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146582
<b>Guideline Name</b>	Mozobil
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Mozobil, generic plerixafor	
Diagnosis	Hematopoietic Stem Cell Mobilization
Approval Length	30 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <ul style="list-style-type: none"> <li>Patients with non-Hodgkin's lymphoma (NHL) who will be undergoing autologous hematopoietic stem cell (HSC) transplantation</li> </ul>	

<ul style="list-style-type: none"> <li>Patients with multiple myeloma (MM) who will be undergoing autologous HSC transplantation</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used in combination with granulocyte-colony stimulating factor (G-CSF) [e.g., Zarxio (filgrastim)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with a hematologist/oncologist</p>
--

Product Name: Brand Mozobil, generic plerixafor	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Brand Mozobil, generic plerixafor	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to the requested therapy</p>	



MS Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161407
<b>Guideline Name</b>	MS Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic glatiramer, Glatopa, Mayzent, Plegridy	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple sclerosis (MS)</p>	

Product Name:Avonex, Bafiertam, Betaseron, Extavia, Kesimpta, Ponvory, Rebif, Vumerity	
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple sclerosis (MS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure of at least two of the preferred* alternatives (one of which must be a preferred dimethyl fumarate product) confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to all of the preferred* alternatives (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.3</b> Patient is currently on the requested drug therapy as confirmed by claims history or submission of medical records</p>	
Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

Product Name:Tascenso ODT	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Diagnosis of multiple sclerosis (MS)

**AND**

2 - Patient is 10 years of age or older

**AND**

3 - ONE of the following:

3.1 Failure of fingolimod 0.5mg (generic Gilenya 0.5 mg) confirmed by claims history or submitted medical records

**OR**

3.2 History of intolerance or contraindication to fingolimod 0.5mg (generic Gilenya 0.5 mg) (please specify intolerance or contraindication)

**OR**

3.3 Patient is currently on Tascenso ODT therapy as documented by claims history or submission of medical records

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

Product Name: Brand Aubagio, Brand Copaxone, Brand Gilenya 0.5mg, Brand Tecfidera	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple sclerosis (MS)</p>	

**AND**

**2 - ONE of the following:**

**2.1** Failure of at least two of the preferred\* alternatives (one of which must be a preferred dimethyl fumarate product) confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to all of the preferred\* alternatives (please specify intolerance or contraindication)

**OR**

**2.3** Patient is currently on the requested drug therapy as confirmed by claims history or submission of medical records

**AND**

**3 - ONE of the following:**

**3.1** The brand is being requested because of an adverse reaction, allergy or sensitivity to a generic/authorized generic equivalent (specify the adverse reaction, allergy, or sensitivity)

**OR**

**3.2** The brand is being requested due to an incomplete response with a generic/authorized generic equivalent, as documented by submission of medical records

**OR**

**3.3** The brand is being requested because transition to a generic/authorized generic equivalent could result in destabilization of the patient.

**OR**

**3.4** Special clinical circumstances exist that preclude the use of a generic/authorized generic equivalent of the brand medication for the patient (document special clinical circumstances)

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

Product Name: Avonex, Bafiertam, Betaseron, Extavia, Kesimpta, Ponvory, Rebif, Brand Vumerity, Tascenso ODT, Brand Aubagio, Brand Copaxone, Brand Gilenya 0.5 mg, Brand Tecfidera

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

- 1 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
11/27/2024	Updated GPs. Removed dimethyl fumarate, teriflunomide and fingoli mod

Mulpleta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146584
<b>Guideline Name</b>	Mulpleta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Mulpleta	
Diagnosis	Thrombocytopenia
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of thrombocytopenia</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has chronic liver disease

**AND**

**3** - Patient is scheduled to undergo a procedure

Multaq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146364
<b>Guideline Name</b>	Multaq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Multaq	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Paroxysmal Atrial Fibrillation (AF)</li> <li>Persistent AF defined as AF less than 6 months duration</li> </ul>	

**AND**

**1.2** ONE of the following:

- Patient is in sinus rhythm
- Patient is planned to undergo cardioversion to sinus rhythm

**AND**

**1.3** Patient does NOT have New York Heart Association (NYHA) Class IV heart failure

**AND**

**1.4** Patient does NOT have symptomatic heart failure with recent decompensation requiring hospitalization

**OR**

**2** - For continuation of current therapy

Myalept



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146585
<b>Guideline Name</b>	Myalept
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Myalept	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of congenital or acquired generalized lipodystrophy associated with leptin deficiency</p>	

**AND**

**2** - Used as an adjunct to diet modification

**AND**

**3** - Prescribed by an endocrinologist

**AND**

**4** - Patient has at least ONE of the following:

**4.1** Diabetes mellitus or insulin resistance with persistent hyperglycemia (hemoglobin A1C greater than 7.0%) despite BOTH of the following:

- Dietary intervention
- Optimized insulin therapy at maximum tolerated doses

**OR**

**4.2** Persistent hypertriglyceridemia (triglycerides greater than 250 milligrams per deciliter) despite BOTH of the following:

- Dietary intervention
- Optimized therapy with at least two triglyceride-lowering agents from different classes (e.g., fibrates, statins) at maximum tolerated doses

Product Name: Myalept	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Documentation of positive clinical response to Myalept therapy

**AND**

**2** - Used as an adjunct to diet modification

**AND**

**3** - Prescribed by an endocrinologist

Mycapssa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-192203
<b>Guideline Name</b>	Mycapssa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Mycapssa	
Diagnosis	Acromegaly
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of acromegaly by ONE of the following:

- Serum GH (growth hormone) level > 1 ng/mL (nanogram/milliliter) after a 2-hour oral glucose tolerance test (OGTT) at time of diagnosis
- Elevated serum IGF-1 (insulin-like growth factor-1) levels (above the age and gender adjusted normal range as provided by the physician's lab) at time of diagnosis

**AND**

1.2 ONE of the following:

1.2.1 Inadequate response to ONE of the following:

- Surgical resection
- Pituitary irradiation
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**OR**

1.2.2 Not a candidate for ALL of the following:

- Surgical resection
- Pituitary irradiation
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**AND**

1.3 Patient has responded to and tolerated treatment with ONE of the following somatostatin analogs:

- Sandostatin (octreotide) or Sandostatin LAR
- Somatuline Depot (lanreotide) [Note: Somatuline Depot (lanreotide) might not be covered on your pharmacy prescription drug benefit. Coverage might be available on your medical benefit.]

<b>AND</b>	
1.4 The provider has submitted clinical justification why the patient is unable to be maintained on current octreotide or lanreotide therapy*	
<b>OR</b>	
2 - Patient is currently on Mycapssa therapy for acromegaly	
Notes	*UHC generally does not consider frequency of dosing and/or lack of compliance to dosing regimens, an indication of medical necessity.

Product Name: Mycapssa	
Diagnosis	Acromegaly
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of a positive clinical response to Mycapssa therapy	

## 2 . Revision History

Date	Notes
2/25/2025	Updated formularies. Updated initial auth criteria wording

Mytesi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146365
<b>Guideline Name</b>	Mytesi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Mytesi	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) associated diarrhea</p>	

Namzaric



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146367
<b>Guideline Name</b>	Namzaric
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Namzaric	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 History of BOTH of the following as confirmed by claims history or submission of medical records:</p> <p>1.1.1 Memantine (generic Namenda)</p>	

**AND**

**1.1.2** Donepezil (generic Aricept)

**AND**

**1.2** Patient is stabilized on 10mg of donepezil once daily as confirmed by claims history or submission of medical records

Nasonex, Xhance



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155837
<b>Guideline Name</b>	Nasonex, Xhance
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Brand Nasonex, generic mometasone (Rx version only), Allergy nasal spray	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Failure to ONE of the following as confirmed by claims history or submission of medical record</p> <ul style="list-style-type: none"> <li>Prescription fluticasone nasal spray (generic Flonase)</li> <li>Flonase allergy relief (fluticasone propionate) OTC brand or generic</li> </ul>	

**OR**

**2** - History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance)

- Prescription fluticasone nasal spray (generic Flonase)
- Flonase allergy relief (fluticasone propionate) OTC brand or generic

Product Name: Xhance	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - One of the following:</p> <p><b>1.1</b> Diagnosis of chronic rhinosinusitis with nasal polyps</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Diagnosis of chronic rhinosinusitis without nasal polyps</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - One of the following:</p> <p><b>2.1</b> Failure to BOTH of the following as confirmed by claims history or submission of medical records</p> <ul style="list-style-type: none"> <li>• Fluticasone nasal spray (generic Flonase, Flonase Allergy)</li> <li>• Mometasone nasal spray (generic Nasonex or Nasonex 24H Allergy)</li> </ul> <p style="text-align: center;"><b>OR</b></p>	

**2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance)

- Fluticasone nasal spray (generic Flonase, Flonase Allergy)
- Mometasone nasal spray (generic Nasonex or Nasonex 24H Allergy)

## 2 . Revision History

Date	Notes
9/24/2024	Copy Core

Nayzilam and Valtoco



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148227
<b>Guideline Name</b>	Nayzilam and Valtoco
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nayzilam	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of epilepsy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Nayzilam is being prescribed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern

**AND**

**3** - The prescriber provides a reason or special circumstance that precludes the use of diazepam rectal gel

Product Name:Nayzilam

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

Product Name:Valtoco

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of epilepsy

**AND**

**2** - Valtoco is being prescribed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern

**AND**

**3** - The prescriber provides a reason or special circumstance that precludes the use of diazepam rectal gel

**AND**

**4** - ONE of the following:

**4.1** Patient is less than 12 years of age

**OR**

**4.2** ONE of the following:

**4.2.1** Failure of Nayzilam confirmed by claims history or submitted medical records

**OR**

**4.2.2** History of contraindication or intolerance to Nayzilam (please specify contraindication or intolerance)

Product Name:Valtoco	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
6/10/2024	Revised drug table for Valtoco name change.

Nerlynx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155031
<b>Guideline Name</b>	Nerlynx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Nerlynx	
Diagnosis	Early-Stage or Node-Positive Breast Cancer
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of early-stage breast cancer</p>	

**AND**

**1.2** Disease is human epidermal growth factor receptor 2 (HER2)-positive

**AND**

**1.3** Used as extended adjuvant therapy following adjuvant trastuzumab containing therapy (e.g., Herceptin, Kanjinti)

**AND**

**1.4** Patient will not have more than 12 months of treatment per occurrence\*

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of node positive breast cancer

**AND**

**2.2** Disease is hormone receptor (HR)-positive and HER2-positive

**AND**

**2.3** Used as extended adjuvant therapy following adjuvant trastuzumab containing therapy (e.g., Herceptin, Kanjinti)

**AND**

**2.4** Patient has a perceived high risk of recurrence

**AND**

**2.5** Patient will not have more than 12 months of treatment per occurrence\*

Notes	*Duration of coverage is limited to 12 months per occurrence.
-------	---

Product Name:Nerlynx	
Diagnosis	Advanced or Metastatic Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of advanced or metastatic breast cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Disease is human epidermal growth factor receptor 2 (HER2)-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 Patient has received two or more prior anti-HER2 based regimens in metastatic setting</p> <p style="text-align: center;"><b>AND</b></p> <p>1.4 Will be used in combination with capecitabine (generic Xeloda)</p> <p style="text-align: center;"><b>OR</b></p>	

**2 - BOTH of the following:**

**2.1** Diagnosis of stage IV (M1) breast cancer

**AND**

**2.2** ONE of the following:

**2.2.1** Both of the following:

- Disease is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative disease
- Patient has already received a CDK4/6 inhibitor therapy

**OR**

**2.2.2** Triple negative disease

Product Name:Nerlynx	
Diagnosis	Breast Cancer with Brain Metastases
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 -</b> Diagnosis of breast cancer</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 -</b> Patient has brain metastases</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Disease is human epidermal growth factor receptor 2 (HER2)-positive

**AND**

**4** - Used in combination with ONE of the following:

- capecitabine (generic Xeloda)
- Paclitaxel

**Product Name:**Nerlynx

Diagnosis	Advanced or Metastatic Breast Cancer, Breast Cancer with Brain Metastases
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient does not show evidence of progressive disease while on Nerlynx therapy

**Product Name:**Nerlynx

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Nerlynx	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Nerlynx therapy</p>	

## 2 . Revision History

Date	Notes
9/16/2024	Updated formatting, no changes to criteria

Nexavar



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158294
<b>Guideline Name</b>	Nexavar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Renal Cell Carcinoma (RCC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of renal cell carcinoma (RCC)</p>	

<b>AND</b>
<b>2 - ONE of the following:</b>
<b>2.1 Disease has relapsed</b>
<b>OR</b>
<b>2.2 BOTH of the following:</b>
<ul style="list-style-type: none"> <li>• Medically or surgically unresectable tumor</li> <li>• Diagnosis of Stage IV disease</li> </ul>

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Hepatocellular Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of hepatocellular carcinoma</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - ONE of the following:</b></p> <p><b>2.1 Patient has metastatic disease</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2 Patient has extensive liver tumor burden</b></p>	

**OR**

**2.3** Patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only)

**OR**

**2.4** BOTH of the following:

- Patient is not a transplant candidate
- Disease is unresectable

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Follicular carcinoma</li> <li>• Oncocytic carcinoma</li> <li>• Papillary carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable recurrent disease</li> <li>• Persistent locoregional disease</li> </ul>	

- Metastatic disease

**AND**

**1.3 ONE of the following:**

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**1.4 Disease is refractory to radioactive iodine treatment**

**OR**

**2 - ALL of the following:**

**2.1 Diagnosis of medullary thyroid carcinoma**

**AND**

**2.2 ONE of the following:**

- Disease is progressive
- Disease is symptomatic with distant metastases

**AND**

**2.3 ONE of the following:**

**2.3.1 Failure to ONE of the following, as confirmed by claims history or submission of medical records:**

- Caprelsa (vandetanib)
- Cometriq (cabozantinib)

**OR**

**2.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Caprelsa (vandetanib)
- Cometriq (cabozantinib)

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of angiosarcoma</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of desmoid tumors/aggressive fibromatosis</p> <p style="text-align: center;"><b>OR</b></p> <p>3 - BOTH of the following:</p> <p><b>3.1</b> Diagnosis of progressive gastrointestinal stromal tumors (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3.2</b> ONE of the following:</p> <p><b>3.2.1</b> Failure to ONE of the following as confirmed by claims history or submission of medical records:</p>	

- imatinib (generic for Gleevec)
- sunitinib (generic for Sutent)
- Stivarga (regorafenib)
- Qinlock (ripretinib)

**OR**

**3.2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- imatinib (generic for Gleevec)
- sunitinib (generic for Sutent)
- Stivarga (regorafenib)
- Qinlock (ripretinib)

**OR**

**4** - Diagnosis of solitary fibrous tumor/hemangiopericytoma

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Bone Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of chordoma</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Disease is recurrent</p>	

**OR**

**2** - BOTH of the following:

**2.1** ONE of the following:

- Diagnosis of osteosarcoma
- Diagnosis of dedifferentiated chondrosarcoma
- Diagnosis of high-grade undifferentiated pleomorphic sarcoma (UPS)

**AND**

**2.2** Not used as first-line therapy

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of acute myeloid leukemia (AML)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has FLT3-ITD mutation-positive disease</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Patient has relapsed disease</li> </ul>	

<ul style="list-style-type: none"> <li>• Patient has refractory disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Used in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• azacytidine (generic for Vidaza)</li> <li>• decitabine (generic for Dacogen)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Patient is unable to tolerate more aggressive treatment regimens</p>
---

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Ovarian Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Ovarian cancer</li> <li>• Fallopian tube cancer</li> <li>• Primary peritoneal cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Patient has persistent disease</li> <li>• Patient has recurrent disease</li> </ul>	

<b>AND</b>
<b>3</b> - Disease is platinum-resistant
<b>AND</b>
<b>4</b> - Used in combination with topotecan

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of salivary gland tumor</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent and unresectable</li> <li>• Metastatic</li> </ul>	

Product Name: Brand Nexavar, generic sorafenib	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement

**Product Name:Brand Nexavar, generic sorafenib**

Diagnosis	Renal Cell Carcinoma (RCC), Hepatocellular Carcinoma, Thyroid Cancer, Soft Tissue Sarcoma, Bone Cancer, Acute Myeloid Leukemia, Ovarian Cancer, Salivary Gland Tumor, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on the requested therapy

**Product Name:Brand Nexavar, generic sorafenib**

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

**Product Name:Brand Nexavar, generic sorafenib**

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to the requested therapy</p>	

## 2 . Revision History

Date	Notes
10/30/2024	Updated product name lists throughout guideline. Minor update to reauth criteria sections, with no changes to clinical intent. Minor cosmetic update to diagnosis header for NCCN sections, with no changes to clinical intent.

Nexletol, Nexlizet



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152706
<b>Guideline Name</b>	Nexletol, Nexlizet
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Nexletol, Nexlizet	
Diagnosis	Hyperlipidemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <p>1.1 Primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)</p>	

**OR**

**1.2** Established cardiovascular disease (CVD) as documented by one of the following:

- coronary artery disease
- symptomatic peripheral arterial disease
- cerebrovascular atherosclerotic disease

**OR**

**1.3** High risk for cardiovascular disease (CVD) as documented by one of the following:

- Diabetes and over 60 years old
- Reynolds risk score greater than 30%
- Coronary artery calcium score greater than 400 Agatston units
- ASCVD risk score greater than or equal to 20% with the American College of Cardiology/American Heart Association (ACC/AHA) risk estimator

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming ONE of the following [prescription claims history may be used in conjunction as confirmation of medication use, dose, and duration]:

**2.1** Patient has been receiving at least 12 consecutive weeks of high intensity statin therapy [i.e., atorvastatin 40-80 mg (milligrams), rosuvastatin 20-40 mg] and will continue to receive a high intensity statin at maximally tolerated dose

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms:

- Myalgia [muscle symptoms without CK (creatine kinase) elevations]
- Myositis [muscle symptoms with CK elevations less than 10 times upper limit of normal (ULN)]

**AND**

**2.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity or moderate-intensity statin therapy [i.e., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 10 mg, pravastatin greater than or equal to 10 mg, lovastatin 20-40 mg, fluvastatin extended-release 80 mg, fluvastatin 20-40 mg up to 40mg twice daily or Livalo (pitavastatin) greater than or equal to 1 mg] and will continue to receive a low-intensity or moderate-intensity statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low or moderate-, and high-intensity statins as evidenced by ONE of the following:

**2.3.1** ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms for low or moderate-, and high-intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times ULN)

**OR**

**2.3.2** Patient has a labeled contraindication to all statins as documented in medical records

**OR**

**2.3.3** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., laboratory values) confirming ONE of the following LDL-C (low-density lipoprotein cholesterol) values while on maximally tolerated lipid lowering therapy within the last 120 days:

- LDL-C greater than or equal to 100 mg/dL (milligrams/deciliter) with ASCVD

- LDL-C greater than or equal to 130 mg/dL without ASCVD

**OR**

**3.2 BOTH of the following:**

**3.2.1** Submission of medical records (e.g., laboratory values) confirming ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days:

- LDL-C between 55 mg/dL and 99 mg/dL with ASCVD
- LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

**AND**

**3.2.2** Submission of medical records (e.g., chart notes, laboratory values) confirming ONE of the following [prescription claims history may be used in conjunction as confirmation of medication use, dose, and duration]:

**3.2.2.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**3.2.2.2** Patient has a history of contraindication, or intolerance to ezetimibe

Product Name:Nexletol, Nexlizet	
Diagnosis	Hyperlipidemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of a positive clinical response to therapy	

**AND**

**2** - Patient continues to receive statin at maximally tolerated dose (unless patient has documented inability to take statins)

## 2 . Revision History

Date	Notes
8/27/2024	Updated indications to include established and high risk for CVD based on updated labeling. Lowered LDL-C threshold for initiation of therapy. Updated background.

Ninlaro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151702
<b>Guideline Name</b>	Ninlaro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Ninlaro	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple myeloma</p>	

Product Name:Ninlaro	
Diagnosis	Systemic Light Chain Amyloidosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of relapsed or refractory systemic light chain amyloidosis</p>	

Product Name:Ninlaro	
Diagnosis	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used in combination with rituximab and dexamethasone</p>	

Product Name:Ninlaro	
Diagnosis	Multiple Myeloma, Systemic Light Chain Amyloidosis, Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Ninlaro therapy

Product Name:Ninlaro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Ninlaro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ninlaro therapy</p>	

**2 . Revision History**

Date	Notes
------	-------

8/13/2024	Simplified criteria for multiple myeloma to only require diagnosis check.
-----------	---

Nityr



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146591
<b>Guideline Name</b>	Nityr
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nityr	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary tyrosinemia type 1</p>	

Nocdurna



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146371
<b>Guideline Name</b>	Nocdurna
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nocdurna	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nocturia due to nocturnal polyuria (as defined by nighttime urine production that exceeds one-third of the 24-hour urine production)</p>	

**AND**

**2** - Patient wakes at least twice per night on a reoccurring basis to void

**AND**

**3** - Documented serum sodium level is currently within normal limits of the normal laboratory reference range and has been within normal limits over the previous six months

**AND**

**4** - The patient has been evaluated for other medical causes and has either not responded to, tolerated, or has a contraindication to treatments for identifiable medical causes [e.g., overactive bladder, benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), elevated post-void residual urine, and heart failure]

**AND**

**5** - Prescriber attests that the risks have been assessed and benefits outweigh the risks

Product Name:Nocdurna	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Nocdurna therapy

**AND**

**2** - Patient has routine monitoring for serum sodium levels

**AND**

**3** - Prescriber attests that the risks of hyponatremia have been assessed and benefits outweigh the risks

Non-Preferred Drugs



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146833
<b>Guideline Name</b>	Non-Preferred Drugs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Non-Preferred Drugs	
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - If the requested medication is a behavioral health medication, ONE of the following:</p> <p>1.1 The patient has been receiving treatment with the requested non-preferred behavioral health medication and is new to the plan (enrollment effective date within the past 90 days)</p>	

**OR**

**1.2** The patient is currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge

**OR**

**2** - ALL of the following:

**2.1** One of the following:

**2.1.1** Both of the following:

**2.1.1.1** One of the following:

- History of failure to at least THREE preferred alternatives as confirmed by claims history or submission of medical records.\* NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure to all of the preferred products.
- History of contraindication or intolerance to THREE preferred alternatives (please specify contraindication or intolerance).\* NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of contraindication or intolerance to all of the preferred products.

**AND**

**2.1.1.2** One of the following:

**2.1.1.2.1** If the request is for a multi-source brand medication, OR a branded medication with an authorized generic, one of the following:

- The brand is being requested because of an adverse reaction, allergy or sensitivity to a generic/authorized generic equivalent (specify the adverse reaction, allergy, or sensitivity)
- The brand is being requested due to an incomplete response with a generic/authorized generic equivalent, as documented by submission of medical records
- The brand is being requested because transition to a generic/authorized generic equivalent could result in destabilization of the patient.

- Special clinical circumstances exist that preclude the use of a generic/authorized generic equivalent of the brand medication for the patient (document special clinical circumstances)

**OR**

**2.1.1.2.2** If the request is for a generic when there is a brand available and the brand is the preferred formulation, one of the following:

- The generic is being requested because of an adverse reaction, allergy or sensitivity to the brand (specify the adverse reaction, allergy, or sensitivity).
- The generic is being requested due to an incomplete response with the brand, as documented by submission of medical records.
- The generic is being requested because transition to the brand could result in destabilization of the patient.
- Special clinical circumstances exist that preclude the use of the brand equivalent of the generic medication for the patient (document special clinical circumstances).

**OR**

**2.1.2** There are no preferred formulary alternatives for the requested drug.

**AND**

**2.2** One of the following:

**2.2.1** The requested drug must be used for an FDA-approved indication

**OR**

**2.2.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopeia-National Formulary (USP-NF )

**AND**

**2.3** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program.

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a> Prior trials of formulary/PDL alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request.
-------	--

**2 . Revision History**

Date	Notes
4/30/2024	Removed PDL links for CORE markets in background section and added PDL link for NM in notes section.

Northera



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148221
<b>Guideline Name</b>	Northera
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Northera, generic droxidopa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) as defined by ONE of the following when an upright position is assumed or when using a head-up tilt-table testing at an angle of at least 60 degrees:</p> <ul style="list-style-type: none"> <li>At least a 20 millimeters of mercury (mm Hg) fall in systolic pressure</li> </ul>	

- At least a 10 mm Hg fall in diastolic pressure

**AND**

**2** - nOH caused by ONE of the following:

- Primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, and pure autonomic failure)
- Dopamine beta-hydroxylase deficiency
- Non-diabetic autonomic neuropathy

**AND**

**3** - Diagnostic evaluation has excluded other causes associated with orthostatic hypotension (e.g., congestive heart failure, fluid restriction, malignancy)

**AND**

**4** - The patient has tried at least TWO of the following non-pharmacologic interventions:

- Discontinuation of drugs which can cause orthostatic hypotension [e.g., diuretics, antihypertensive medications (primarily sympathetic blockers), anti-anginal drugs (nitrates), alpha-adrenergic antagonists, and antidepressants]
- Raising the head of the bed 10 to 20 degrees
- Compression garments to the lower extremities or abdomen
- Physical maneuvers to improve venous return (e.g., regular modest-intensity exercise)
- Increased salt and water intake, if appropriate
- Avoiding precipitating factors (e.g., overexertion in hot weather, arising too quickly from supine to sitting or standing)

**AND**

**5** - No previous diagnosis of supine hypertension

**AND**

**6** - Prescribed by or in consultation with ONE of the following specialists:

- Cardiologist

- Neurologist
- Nephrologist

**AND**

**7 - ONE of the following:**

**7.1 Failure (after a trial of at least 30 days) of BOTH of the following confirmed by claims history or submitted medical records:**

- fludrocortisone (generic Florinef)
- midodrine (generic ProAmatine)

**OR**

**7.2 History of contraindication or intolerance to BOTH of the following:**

- fludrocortisone (generic Florinef)
- midodrine (generic ProAmatine)

Product Name: Brand Northera, generic droxidopa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Documentation of positive clinical response to the requested therapy</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Physiological countermeasures for neurogenic orthostatic hypotension (nOH) continue to be employed</b></p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
6/6/2024	Updated initial authorization duration to 12 months.

Nourianz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164688
<b>Guideline Name</b>	Nourianz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Nourianz	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of Parkinson's disease

**AND**

2 - Used as adjunctive treatment to levodopa/carbidopa in patients experiencing "off" episodes

**AND**

3 - ONE of the following:

3.1 Failure to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes) as confirmed by claims history or submission of medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

**OR**

3.2 History of contraindication or intolerance to ALL anti-Parkinson's disease therapy from the following adjunctive pharmacotherapy classes (trial must be from all classes) (please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Product Name:Nourianz	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Nourianz therapy

**AND**

2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

**2 . Revision History**

Date	Notes
2/4/2025	Updated formularies. Updated initial auth duration

Nourianz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164688
<b>Guideline Name</b>	Nourianz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Nourianz	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of Parkinson's disease

**AND**

2 - Used as adjunctive treatment to levodopa/carbidopa in patients experiencing "off" episodes

**AND**

3 - ONE of the following:

3.1 Failure to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes) as confirmed by claims history or submission of medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

**OR**

3.2 History of contraindication or intolerance to ALL anti-Parkinson's disease therapy from the following adjunctive pharmacotherapy classes (trial must be from all classes) (please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Product Name:Nourianz	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Nourianz therapy

**AND**

2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

**2 . Revision History**

Date	Notes
2/4/2025	Updated formularies. Updated initial auth duration

Nubeqa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146593
<b>Guideline Name</b>	Nubeqa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nubeqa	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Disease is non-metastatic

**AND**

**2.1.2** Disease is castration-resistant or recurrent

**OR**

**2.2** ALL of the following:

**2.2.1** Disease is metastatic

**AND**

**2.2.2** Disease is hormone-sensitive

**AND**

**2.2.3** Nubeqa will be used in combination with docetaxel

**AND**

**3** - ONE of the following:

**3.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**3.2 Patient has had bilateral orchiectomy**

Product Name:Nubeqa	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Nubeqa therapy</p>	

Product Name:Nubeqa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Nubeqa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Documentation of positive clinical response to Nubeqa therapy

Nucala



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155049
<b>Guideline Name</b>	Nucala
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of EGPA</p>	

**AND**

**2** - Documentation of positive clinical response to Nucala therapy as demonstrated by at least ONE of the following

- Reduction in the frequency and/or severity of relapses
- Reduction or discontinuation of doses of corticosteroids and/or immunosuppressant
- Disease remission
- Reduction in severity or frequency of EGPA-related symptoms

**AND**

**3** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by one of the following

- Allergist
- Immunologist
- Pulmonologist
- Rheumatologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization – Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - Diagnosis of relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) as defined by ALL of the following:**

**1.1 Diagnosis of EGPA**

**AND**

**1.2 Past medical history or presence of asthma**

**AND**

**1.3 Presence of at least TWO of the following characteristics typical of EGPA:**

**1.3.1 Histopathological evidence of ALL of the following:**

- Eosinophilic vasculitis
- Perivascular eosinophilic infiltration
- Eosinophil-rich granulomatous inflammation

**OR**

**1.3.2 Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)**

**OR**

**1.3.3 Pulmonary infiltrates, non-fixed**

**OR**

**1.3.4 Sino-nasal abnormality**

**OR**

**1.3.5 Cardiomyopathy [established by echocardiography or magnetic resonance imaging (MRI)]**

**OR**

**1.3.6** Glomerulonephritis (hematuria, red cell casts, proteinuria)

**OR**

**1.3.7** Alveolar hemorrhage

**OR**

**1.3.8** Palpable purpura

**OR**

**1.3.9** Anti-neutrophil cytoplasmic antibody (ANCA) positive

**AND**

**1.4** History of relapsing or refractory disease defined as ONE of the following:

**1.4.1** Relapsing disease as defined as a past history (within the past 2 years) of at least one EGPA relapse (requiring additional or dose escalation of corticosteroids or immunosuppressant, or hospitalization)

**OR**

**1.4.2** Refractory disease as defined as failure to attain remission within the prior 6 months following induction treatment with standard therapy regimens

**AND**

**2** - Patient is currently taking standard therapy [i.e., systemic glucocorticoids (e.g., prednisone, methylprednisolone)] with or without immunosuppressive therapy (e.g., cyclophosphamide, rituximab) as supported by claims history or submitted medical records

**AND**

**3** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist
- Rheumatologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Nucala therapy as demonstrated by at least ONE of the following:</p> <p><b>1.1</b> Reduction in the frequency and/or severity of relapses</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Reduction or discontinuation of doses of corticosteroids and/or immunosuppressant</p>	

**OR**

**1.3** Disease remission

**OR**

**1.4** Reduction in severity or frequency of eosinophilic granulomatosis with polyangiitis (EGPA)-related symptoms

**AND**

**2** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of severe asthma</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Documentation of positive clinical response to Nucala therapy as demonstrated by at least ONE of the following

- Reduction in the frequency of exacerbations
- Decreased utilization of rescue medications
- Increase in percent predicted FEV1 from pretreatment baseline
- Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- Reduction in oral corticosteroid requirements

**AND**

**3** - Nucala is being used in combination with an inhaled corticosteroid (ICS) containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**4** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization – Not transitioning from UHC medical benefits

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of severe asthma</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Classification of asthma as uncontrolled or inadequately controlled as defined by at least ONE of the following:</b></p> <p><b>2.1</b> Poor symptom control [e.g., Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20]</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.3</b> Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.4</b> Airflow limitation [e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second (FEV1) less than 80% predicted (in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal)]</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.5</b> Patient is currently dependent on oral corticosteroids for the treatment of asthma</p>	

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming asthma is an eosinophilic phenotype as defined by a baseline (pre-treatment) peripheral blood eosinophil level greater than or equal to 150 cells per microliter

**AND**

**4** - Nucala will be used in combination with ONE of the following:

**4.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**OR**

**4.2** Combination therapy including BOTH of the following:

**4.2.1** ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]

**AND**

**4.2.2** ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist - montelukast (Singulair); theophylline]

**AND**

**5** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**6** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

**AND**

**7** - ONE of the following:

- Failure to a 4 month trial of Fasentra (benralizumab) as confirmed by claims history or submitted medical records
- History of contraindication or intolerance to Fasentra (benralizumab) (please specify intolerance or contraindication)

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Nucala therapy as demonstrated by at least ONE of the following:</p> <p><b>1.1</b> Reduction in the frequency of exacerbations</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Decreased utilization of rescue medications</p>	

**OR**

**1.3** Increase in percent predicted forced expiratory volume in 1 second (FEV1) from pretreatment baseline

**OR**

**1.4** Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

**OR**

**1.5** Reduction in oral corticosteroid requirements

**AND**

**2** - Nucala is being used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**3** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Hypereosinophilic Syndrome (HES)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of hypereosinophilic syndrome (HES).</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Documentation of positive clinical response to Nucala therapy as demonstrated by at least one of the following</p> <ul style="list-style-type: none"> <li>• Reduction in frequency of HES flares</li> <li>• Maintenance or reduction in background HES therapy requirements</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is not receiving Nucala in combination with ONE of the following</p> <ul style="list-style-type: none"> <li>• Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]</li> <li>• Anti-IgE therapy [e.g., Xolair (omalizumab)]</li> <li>• Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]</li> <li>• Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Allergist</li> <li>• Cardiologist</li> <li>• Hematologist</li> <li>• Immunologist</li> <li>• Pulmonologist</li> </ul>	

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Hypereosinophilic Syndrome (HES)
Approval Length	12 month(s)

Therapy Stage	Initial Authorization – Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Hypereosinophilic Syndrome (HES) greater than or equal to 6 months ago</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Both of the following:</p> <p>    <b>2.1</b> There is no identifiable non-hematologic secondary cause of the patient’s HES [e.g., drug hypersensitivity, parasitic helminth infection, HIV (human immunodeficiency virus) infection, non-hematologic malignancy]</p> <p style="text-align: center;"><b>AND</b></p> <p>    <b>2.2</b> HES is not FIP1L1-PDGFR alpha (gene) kinase-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting both of the following:</p> <p>    <b>3.1</b> Baseline [pre-Nucala (mepolizumab) treatment] blood eosinophil level greater than or equal to 1000 cells/microliter within the past 4 weeks</p> <p style="text-align: center;"><b>AND</b></p> <p>    <b>3.2</b> Patient is currently receiving a stable dose of background HES therapy (e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is not receiving Nucala in combination with ONE of the following</p>	

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Allergist
- Cardiologist
- Hematologist
- Immunologist
- Pulmonologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Hypereosinophilic Syndrome (HES)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Nucala therapy as demonstrated by at least ONE of the following:</p> <p><b>1.1</b> Reduction in the frequency of Hypereosinophilic Syndrome (HES) flares</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Maintenance or reduction in background HES therapy requirements</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Nucala in combination with ONE of the following</p>	

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Documentation of positive clinical response to Nucala therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient will continue to receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is not receiving Nucala in combination with ONE of the following</p> <ul style="list-style-type: none"> <li>• Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]</li> <li>• Anti-IgE therapy [e.g., Xolair (omalizumab)]</li> <li>• Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]</li> </ul>	

- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

**AND**

**5** - Prescribed by ONE of the following

- Allergist
- Immunologist
- Otolaryngologist
- Pulmonologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization – Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) defined by ALL of the following:</p> <p><b>1.1</b> Two or more of the following symptoms for longer than 12 weeks duration:</p> <ul style="list-style-type: none"> <li>• Nasal mucopurulent discharge</li> <li>• Nasal obstruction, blockage, or congestion</li> <li>• Facial pain, pressure, and/or fullness</li> <li>• Reduction or loss of sense of smell</li> </ul> <p><b>AND</b></p> <p><b>1.2</b> One of the following findings using nasal endoscopy and/or sinus computed tomography (CT):</p> <ul style="list-style-type: none"> <li>• Purulent mucus or edema in the middle meatus or ethmoid regions</li> <li>• Polyps in the nasal cavity or the middle meatus</li> </ul>	

- Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of paranasal sinuses

**AND**

**1.3 ONE of the following:**

- Presence of bilateral nasal polyposis
- Patient has previously required surgical removal of bilateral nasal polyps

**AND**

**1.4 ONE of the following:**

**1.4.1** Patient has required prior sinus surgery

**OR**

**1.4.2** Patient has required systemic corticosteroids (e.g., prednisone, methylprednisolone) for CRSwNP in the previous 2 years

**OR**

**1.4.3** Patient has been unable to obtain symptom relief after trial of TWO of the following classes of agents:

- Nasal saline irrigations
- Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)
- Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)

**AND**

**2** - Patient will receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone).

**AND**

**3** - Patient is not receiving Nucala in combination with ONE of the following

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Otolaryngologist
- Pulmonologist

Product Name:Nucala auto-injector and pre-filled syringe	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Nucala therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient will continue to receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is not receiving Nucala in combination with ONE of the following</p>	

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

## 2 . Revision History

Date	Notes
9/17/2024	Specified existing prior authorization for under the medical benefit.

Nuedexta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146375
<b>Guideline Name</b>	Nuedexta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nuedexta	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pseudobulbar affect (PBA)</p>	

Nuplazid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146376
<b>Guideline Name</b>	Nuplazid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nuplazid	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is currently experiencing hallucinations and delusions associated with Parkinson's disease psychosis (i.e., hallucination and delusion symptoms started after Parkinson's disease diagnosis)

Product Name:Nuplazid	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Nuplazid therapy</p>	

Nurtec, Qulipta, Ubrelvy, Zavzpret



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206564
<b>Guideline Name</b>	Nurtec, Qulipta, Ubrelvy, Zavzpret
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Nurtec ODT	
Diagnosis	Acute Treatment of Migraine
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Used for acute treatment of migraine

**AND**

2 - One of the following:

2.1 Failure (after at least 3 migraine episodes and a minimum of a 30-day trial) to TWO of the following as confirmed by claims history or submission of medical records:

- eletriptan (generic Relpax)
- naratriptan (generic Amerge)
- rizatriptan (generic Maxalt/Maxalt MLT)
- sumatriptan (generic Imitrex)
- zolmitriptan (generic Zomig)

**OR**

2.2 History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- eletriptan (generic Relpax)
- naratriptan (generic Amerge)
- rizatriptan (generic Maxalt/Maxalt MLT)
- sumatriptan (generic Imitrex)
- zolmitriptan (generic Zomig)

**AND**

3 - One of the following:

3.1 Patient is currently treated with ONE of the following prophylactic therapies or classes as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]

- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** Patient has less than 4 migraine days per month

**OR**

**3.3** Patient has greater than or equal to 4 migraine days per month and has contraindication or intolerance to TWO of the following prophylactic therapies or classes (please specify contraindication or intolerance):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepi\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4** - Medication will not be used in combination with another acute calcitonin gene-related peptide receptor (CGRP) antagonists (e.g., Ubrelvy, Zavzpret)

Notes	<p>* Timolol, candesartan, Ajovy and Qulipta are non-preferred and should not be included in denial to provider</p> <p>**Vyepi, OnabotulinumtoxinA are medical benefits and should not be included in denial to provider.</p> <p>***CGRP antagonists for preventive treatment of migraines require a prior authorization.</p>
-------	---

Product Name:Nurtec ODT	
Diagnosis	Preventive Treatment of Episodic Migraine
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of episodic migraines with greater than or equal to 4 migraine days per month</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Used for preventive treatment of migraines</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - One of the following:</b></p> <p><b>3.1 Failure (after a trial of at least two months), to TWO of the following prophylactic therapies as confirmed by claims history or submission of medical records:</b></p> <ul style="list-style-type: none"> <li>• A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol*)</li> <li>• Candesartan* (generic Atacand)</li> <li>• Divalproex sodium (generic Depakote/Depakote ER)</li> <li>• Topiramate (generic Topamax)</li> <li>• A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]</li> <li>• A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2 History of contraindication or intolerance to TWO of the following prophylactic therapies (please specify contraindication or intolerance):</b></p> <ul style="list-style-type: none"> <li>• A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol*)</li> <li>• Candesartan* (generic Atacand)</li> <li>• Divalproex sodium (generic Depakote/Depakote ER)</li> <li>• Topiramate (generic Topamax)</li> <li>• A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]</li> <li>• A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]</li> </ul>	

<b>AND</b>	
4 - Medication will not be used in combination with another CGRP (calcitonin gene-related peptide) antagonist or inhibitor used for the preventive treatment of migraines (e.g. Aimovig, Ajovy, Emgality, Vyepti)	
Notes	* Timolol and candesartan are non-preferred and should not be included in denial to provider

Product Name:Nurtec ODT	
Diagnosis	Acute Treatment of Migraine, Preventive Treatment of Episodic Migraine
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Medication will not be used in combination with another acute calcitonin gene-related peptide receptor (CGRP) antagonist (e.g., Ubrelvy, Zavzpret)</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines (e.g. Aimovig, Ajovy, Emgality, Vyepti)</p>	

Product Name:Zavzpret	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Used for acute treatment of migraine</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - One of the following:</p> <p><b>2.1</b> Failure (after at least 3 migraine episodes and a minimum of a 30-day trial) to BOTH of the following as confirmed by claims history or submission of medical records:</p> <p><b>2.1.1</b> TWO preferred 5-HT1 receptor agonist (triptan) alternatives (e.g., sumatriptan, rizatriptan, or naratriptan), one of which must be sumatriptan nasal spray</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.1.2</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Nurtec ODT</li> <li>• Ubrelvy</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):</p> <ul style="list-style-type: none"> <li>• TWO preferred 5-HT1 receptor agonist (triptan) alternatives (e.g., sumatriptan, rizatriptan, or naratriptan), one of which must be sumatriptan nasal spray</li> <li>• Nurtec ODT</li> <li>• Ubrelvy</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - One of the following:</p>	

**3.1** Patient is currently treated with ONE of the following prophylactic therapies or classes as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** Patient has less than 4 migraine days per month

**OR**

**3.3** Patient has greater than or equal to 4 migraine days per month and has contraindication or intolerance to TWO of the following prophylactic therapies or classes (please specify contraindication or intolerance):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4** - Medication will not be used in combination with another acute calcitonin gene-related peptide receptor (CGRP) antagonists (e.g., Nurtec ODT, Ubrelvy)

Notes

\* Timolol, candesartan, Ajovy and Qulipta are non-preferred and should not be included in denial to provider

\*\*Vyepti, OnabotulinumtoxinA are medical benefits and should not be i

	<p>ncluded in denial to provider.                  ***CGRP antagonists for preventive treatment of migraines require a p                  rior authorization.</p>
--	---

Product Name: Ubrelvy	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Used for acute treatment of migraine</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - One of the following:</p> <p><b>2.1</b> Failure (after at least 3 migraine episodes and a minimum of a 30-day trial) to TWO of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• eletriptan (generic Relpax)</li> <li>• naratriptan (generic Amerge)</li> <li>• rizatriptan (generic Maxalt/Maxalt MLT)</li> <li>• sumatriptan (generic Imitrex)</li> <li>• zolmitriptan (generic Zomig)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance)</p> <ul style="list-style-type: none"> <li>• eletriptan (generic Relpax)</li> <li>• naratriptan (generic Amerge)</li> <li>• rizatriptan (generic Maxalt/Maxalt MLT)</li> <li>• sumatriptan (generic Imitrex)</li> <li>• zolmitriptan (generic Zomig)</li> </ul>	

**AND**

**3** - One of the following:

**3.1** Patient is currently treated with ONE of the following prophylactic therapies or classes as confirmed by claims or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** Patient has less than 4 migraine days per month

**OR**

**3.3** Patient has greater than or equal to 4 migraine days per month and has contraindication or intolerance to TWO of the following prophylactic therapies or classes (please specify contraindication or intolerance):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*] \*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

<b>4 - Medication will not be used in combination with another acute calcitonin gene-related peptide receptor (CGRP) antagonists (e.g., Nurtec ODT, Zavzpret)</b>	
Notes	<p>* Timolol, Ajoyv, Qulipta and candesartan are non-preferred and should not be included in denial to provider</p> <p>**Vyepi, OnabotulinumtoxinA are medical benefit and should not be included in denial to provider.</p> <p>***CGRP antagonists for preventive treatment of migraines require a prior authorization.</p>

<b>Product Name:Ubrelvy, Zavzpret</b>	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Medication will not be used in combination with another acute calcitonin gene-related peptide receptor (CGRP) antagonist (e.g., Nurtec ODT)</p>	

<b>Product Name:Qulipta</b>	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of migraine consistent with The International Classification of Headache Disorders, 3rd edition</p>	

**AND**

**2** - ONE of the following:

**2.1** Patient has 4 to 7 migraine days per month and at least ONE of the following:

**2.1.1** Less than 15 headache days per month

**OR**

**2.1.2** Provider attests this is the member's predominant headache diagnosis (i.e., primary driver of headaches is not different, non-migrainous condition)

**OR**

**2.2** Greater than or equal to 8 migraine days per month

**AND**

**3** - One of the following:

**3.1** Failure (after a trial of at least two months) to TWO of the following prophylactic therapies as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan\* (Atacand)
- Divalproex sodium (Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**3.2** History of contraindication or intolerance to TWO of the following prophylactic therapies (please specify contraindication or intolerance):

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan\* (Atacand)
- Divalproex sodium (Depakote/Depakote ER)
- OnabotulinumtoxinA\*\* (generic Botox)
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**4** - One of the following:

**4.1** Failure (after a trial of at least three months) to Nurtec ODT as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to Nurtec ODT (please specify contraindication or intolerance)

**AND**

**5** - Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines (e.g. Aimovig, Ajovy, Emgality, Nurtec ODT, Vyepti)

Notes	* Timolol, candesartan are non-preferred and should not be included in denial to provider **OnabotulinumtoxinA is a medical benefit and should not be included in denial to provider.
-------	--

Product Name: Qulipta	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Documentation of positive clinical response to therapy

**AND**

2 - Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy, Emgality, Nurtec ODT, Vyepti)

## 2 . Background

### Benefit/Coverage/Program Information

#### PDL Links:

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

## 3 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
3/3/2025	Updated formularies. Added eletriptan and zolmitriptan as step therapy option. Updated prophylactic therapy requirement contraindication/intolerance count from all to two. Updated PDL links

Nuzyra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146378
<b>Guideline Name</b>	Nuzyra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Nuzyra tablets	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p>	

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

**3.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Nuzyra

**AND**

**3.3** ONE of the following:

**3.3.1** Failure to THREE of the following antibiotics or antibiotic regimens, as confirmed by claims history or submitted medical records:

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

**OR**

**3.3.2** History of intolerance or contraindication to ALL of the following antibiotics or antibiotic regimens (please specify intolerance or contraindication):

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

**OR**

**4** - ALL of the following:

**4.1** ONE of the following diagnoses:

**4.1.1** BOTH of the following:

**4.1.1.1** Acute bacterial skin and skin structure infections

**AND**

**4.1.1.2** Infection caused by methicillin-resistant Staphylococcus aureus (MRSA) documented by culture and sensitivity report

**OR**

**4.1.2** BOTH of the following:

**4.1.2.1** Empirical treatment of a patient with acute bacterial skin and skin structure infections

**AND**

**4.1.2.2** Presence of MRSA infection is likely

**AND**

**4.2** ONE of the following:

**4.2.1** Failure to linezolid (generic Zyvox) as confirmed by claims history or submitted medical records

**OR**

**4.2.2** History of intolerance or contraindication to linezolid (generic Zyvox) (please specify intolerance or contraindication)

**AND**

**4.3 ONE of the following:**

**4.3.1** Failure to ONE of the following antibiotics as confirmed by claims history or submitted medical records:

- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- A tetracycline
- Clindamycin

**OR**

**4.3.2** History of intolerance or contraindication to ALL of the following antibiotics (please specify intolerance or contraindication):

- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- A tetracycline
- Clindamycin

**OR**

**5 - ALL of the following:**

**5.1** Diagnosis of acute bacterial skin and skin structure infections

**AND**

**5.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Nuzyra

**AND**

**5.3 ONE of the following:**

**5.3.1** Failure to THREE of the following antibiotics confirmed by claims history or submitted medical records:

- A penicillin
- A cephalosporin
- A tetracycline
- Sulfamethoxazole-trimethoprim (SMZ-TMP)

- Clindamycin

**OR**

**5.3.2** History of intolerance or contraindication to ALL of the following antibiotics (please specify intolerance or contraindication):

- A penicillin
- A cephalosporin
- A tetracycline
- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- Clindamycin

**OR**

**6** - The drug has been recognized for treatment of the indication by the Infectious Diseases Society of America (IDSA)

Notes

Authorization duration for CABP and acute bacterial skin and skin structure infections will be issued for up to 14 days. For all IDSA recognized indications, authorization duration is based on provider and IDSA recommended treatment durations, up to 6 months.

OAB Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149508
<b>Guideline Name</b>	OAB Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/3/2024
-----------------	----------

### 1 . Criteria

Product Name:generic tolterodine IR	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Failure to treatment with oxybutynin immediate release as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - History of contraindication or intolerance to oxybutynin immediate release (please specify contraindication or intolerance)

Product Name:generic tolterodine ER

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Step Therapy
----------------	--------------

**Approval Criteria**

**1** - Failure to treatment with oxybutynin extended-release as confirmed by claims history or submission of medical records

**OR**

**2** - History of contraindication or intolerance to oxybutynin extended-release (please specify contraindication or intolerance)

Product Name:Brand Detrol LA, Brand Ditropan XL, darifenacin ER, Gelnique, Gemtesa, trospium ER, Brand Vesicare

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Failure to a trial of THREE of the following confirmed by claims history or submission of medical records:

- oxybutynin extended-release tablet (generic Ditropan XL)
- tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

**OR**

**2** - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oxybutynin extended-release tablet (generic Ditropan XL)
- tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

Product Name: Oxytrol (Rx)

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Failure to a trial of THREE of the following, confirmed by claims history or submission of medical records:

- Oxytrol for Women (oxybutynin OTC) patch
- tolterodine immediate release (generic Detrol) or tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

**OR**

**2** - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Oxytrol for Women (oxybutynin OTC) patch
- tolterodine immediate release (generic Detrol) or tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

Product Name: flavoxate, oxybutynin oral solution, Brand Detrol

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Failure to a trial of ALL of the following, confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• oxybutynin syrup or tablet</li> <li>• tolterodine tablet (generic Detrol)</li> <li>• trospium tablet</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):</p> <ul style="list-style-type: none"> <li>• oxybutynin syrup or tablet</li> <li>• tolterodine tablet (generic Detrol)</li> <li>• trospium tablet</li> </ul>	

Product Name: Vesicare LS	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of neurogenic detrusor overactivity (NDO) (neurogenic bladder)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> Failure to a trial of ONE of the following, as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• oxybutynin syrup</li> </ul>	

- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oxybutynin syrup
- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

Product Name: Brand Myrbetriq tabs, generic mirabegron tabs, generic fesoterodine ER, Brand Toviaz

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - BOTH of the following:

**1.1** Diagnosis of overactive bladder (OAB)

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to a trial of THREE of the following confirmed by claims history or submission of medical records:

- oxybutynin extended-release tablet (generic Ditropan XL)
- tolterodine immediate release (generic Detrol) or tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

**OR**

**1.2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oxybutynin extended-release tablet (generic Ditropan XL)
- tolterodine immediate release (generic Detrol) or tolterodine extended-release capsule (generic Detrol LA)
- trospium tablet
- solifenacin tablet (generic Vesicare)

**OR**

**2** - BOTH of the following:

**2.1** Diagnosis of neurogenic detrusor overactivity (NDO) (neurogenic bladder)

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to a trial of ONE of the following, as confirmed by claims history or submission of medical records:

- oxybutynin syrup
- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

**OR**

**2.2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oxybutynin syrup
- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

Product Name: Myrbetriq granules	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of neurogenic detrusor overactivity (NDO) (neurogenic bladder)

**AND**

**2** - ONE of the following:

**2.1** Failure to a trial of ONE of the following, as confirmed by claims history or submission of medical records:

- oxybutynin syrup
- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oxybutynin syrup
- oxybutynin tablet
- oxybutynin extended release tablet (generic Ditropan XL)

**AND**

**3** - ONE of the following:

**3.1** Patient is 3 years of age to (including) 17 years of age

**OR**

**3.2** BOTH of the following:

**3.2.1** Physician has provided rationale for needing to use this medication in an unapproved age range

**AND**

**3.2.2** The use of this medication for a patient outside the FDA (Food and Drug Administration) approved age range is supported by information from ONE of the following appropriate compendia:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia - National Formulary (USP-NF)

## 2 . Revision History

Date	Notes
7/3/2024	Copy core

Ocaliva



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164691
<b>Guideline Name</b>	Ocaliva
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Ocaliva	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of primary biliary cholangitis

**AND**

**2** - ONE of the following:

- Patient does not have cirrhosis
- Patient has compensated cirrhosis without evidence of portal hypertension

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

- Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)
- Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal after at least 12 consecutive months of treatment with ursodeoxycholic acid (e.g., Urso, ursodiol)

**OR**

**3.2** History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso, ursodiol)  
(please specify contraindication or intolerance)

**AND**

**4** - Patient is not receiving Ocaliva in combination with Iqirvo (elafibranor) or Livdelzi (seladelpar)

**AND**

**5** - Prescribed by ONE of the following:

- Hepatologist
- Gastroenterologist

Product Name:Ocaliva

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Submission of medical records (e.g., laboratory values) documenting a reduction in alkaline phosphatase (ALP) level from pre-treatment baseline (i.e., prior to Ocaliva therapy)

**AND**

**2** - ONE of the following:

- Patient does not have cirrhosis
- Patient has compensated cirrhosis without evidence of portal hypertension

**AND**

**3** - Patient is not receiving Ocaliva in combination with Iqirvo (elafibranor) or Livdelzi (seladelpar)

**AND**

**4** - Prescribed by ONE of the following:

- Hepatologist
- Gastroenterologist

## 2 . Revision History

Date	Notes
2/4/2025	Updated formularies. Minor formatting changes. Added concurrent use criteria

Odomzo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160623
<b>Guideline Name</b>	Odomzo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Odomzo	
Diagnosis	Basal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nodal metastatic basal cell carcinoma (BCC)</p>	

**OR**

**2** - Diagnosis of diffuse basal cell carcinoma (BCC) formation (e.g., Gorlin syndrome, other genetic forms of multiple BCC)

**OR**

**3** - BOTH of the following:

**3.1** Diagnosis of locally advanced basal cell carcinoma

**AND**

**3.2** ONE of the following:

- Cancer has recurred following surgery
- Cancer has recurred following radiation
- Patient is not a candidate for surgery
- Patient is not a candidate for radiation

Product Name: Odomzo	
Diagnosis	Basal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Odomzo therapy</p>	

Product Name: Odomzo	
Diagnosis	NCCN Recommended Regimens

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Odomzo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Odomzo therapy</p>	

## 2 . Revision History

Date	Notes
11/13/2024	Updated criteria per NCCN recommendations to reflect that Odomzo is recommended for basal cell carcinoma with nodal metastases but not with distant metastases

Ogsiveo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-186193
<b>Guideline Name</b>	Ogsiveo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Ogsiveo	
Diagnosis	Desmoid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of desmoid tumor</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is progressive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient requires systemic treatment</p>	

Product Name:Ogsiveo	
Diagnosis	Desmoid Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Ogsiveo therapy</p>	

Product Name:Ogsiveo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Ogsiveo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ogsiveo therapy</p>	

**2 . Revision History**

Date	Notes
2/21/2025	Combined formularies. Added new GPIs for Ogsiveo (IN previously al ready had new GPIs included). No changes to clinical criteria.

Ohtuvayre



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158298
<b>Guideline Name</b>	Ohtuvayre
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Ohtuvayre	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic obstructive pulmonary disease (COPD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Submission of medical records (e.g., chart notes) documenting both of the following:

**2.1** Post-bronchodilator forced expiratory volume (FEV1) / forced vital capacity (FVC) ratio less than 0.7

**AND**

**2.2** Post-bronchodilator FEV1 % predicted greater than or equal to 30% and less than 80%

**AND**

**3** - Both of the following:

**3.1** One of the following:

**3.1.1** FEV1 is less than 80% of predicted but greater than or equal to 50% of predicted

**OR**

**3.1.2** All of the following:

**3.1.2.1** FEV1 less than 50% of predicted

**AND**

**3.1.2.2** History of chronic bronchitis

**AND**

**3.1.2.3** One of the following:

- Failure to a selective phosphodiesterase 4 (PDE4) inhibitor [i.e., roflumilast (Daliresp)] as confirmed by claims history or submission of medical record
- History of contraindication or intolerance to a selective phosphodiesterase 4 (PDE4) inhibitor [i.e., roflumilast (Daliresp)] (please specify contraindication or intolerance)

**AND**

**3.2** One of the following:

**3.2.1** Patient is on a stabilized dose and receiving concomitant therapy with one of the following as confirmed by claims history or submission of medical records:

- A long-acting beta-agonist [LABA (e.g., Serevent Diskus)]
- A long-acting antimuscarinic agent [LAMA (e.g., Spiriva Respimat/HandiHaler)]
- A LABA/LAMA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat)
- An ISC/LABA/LAMA (i.e., Breztri Aerosphere, Trelegy Ellipta)

**OR**

**3.2.2** Patient has a failure to all of the following as confirmed by claims history or submission of medical records:

- A long-acting beta-agonist [LABA (e.g., Serevent Diskus)]
- A long-acting antimuscarinic agent [LAMA (e.g., Spiriva Respimat/HandiHaler)]
- A LABA/LAMA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat)
- An ISC/LABA/LAMA (i.e., Breztri Aerosphere, Trelegy Ellipta)

**OR**

**3.2.3** Patient has a contraindication or intolerance to all of the following (please specify contraindication or intolerance):

- A long-acting beta-agonist [LABA (e.g., Serevent Diskus)]
- A long-acting antimuscarinic agent [LAMA (e.g., Spiriva Respimat/HandiHaler)]
- A LABA/LAMA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat)
- An ISC/LABA/LAMA (i.e., Breztri Aerosphere, Trelegy Ellipta)

**OR**

**3.2.4** Both of the following:

**3.2.4.1** Patient is unable to use a metered-dose, dry powder or slow mist inhaler (e.g. Spiriva Respimat) to control their COPD due to one of the following:

- Cognitive or physical impairment limiting coordination of handheld devices (e.g., cognitive decline, arthritis in the hands) (Document impairment)

- Patient is unable to generate adequate inspiratory force (e.g., peak inspiratory flow rate (PIFR) resistance is less than 60 liters per minute))

**AND**

**3.2.4.2** Patient requires the use of both of the following as confirmed by claims history or submission of medical records:

- A nebulized LABA [i.e., arformoterol (generic Brovana), formoterol (generic Perforomist)]
- A nebulized long-acting antimuscarinic agent [LAMA (i.e., Yupelri)]

**AND**

**4** - Patient experiences dyspnea during everyday activities (e.g., short of breath when walking up a slight hill)

**AND**

**5** - Prescribed by or in consultation with a Pulmonologist

Product Name: Ohtuvayre	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Ohtuvayre therapy demonstrated by both of the following:</p> <p><b>1.1</b> Improved COPD (chronic obstructive pulmonary disease) symptoms (e.g., dyspnea)</p> <p><b>AND</b></p>	

**1.2** Improved FEV1 (forced expiratory volume)

## **2 . Revision History**

Date	Notes
10/30/2024	New guideline.

Ojemda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151313
<b>Guideline Name</b>	Ojemda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Ojemda	
Diagnosis	Pediatric Low-Grade Glioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pediatric low-grade glioma</p>	

<b>AND</b>
<p><b>2</b> - Disease is relapsed or refractory</p>
<b>AND</b>
<p><b>3</b> - Presence of one of the following genetic mutations:</p> <ul style="list-style-type: none"> <li>• BRAF fusion or rearrangement</li> <li>• BRAF V600 mutation</li> </ul>

<b>Product Name:Ojemda</b>	
Diagnosis	Pediatric Low-Grade Glioma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Ojemda therapy</p>	

<b>Product Name:Ojemda</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Ojemda will be approved for uses not outlined above if supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium.

Product Name:Ojemda	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ojemda therapy</p>	

## 2 . Revision History

Date	Notes
8/12/2024	New guideline

Ojjaara



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164109
<b>Guideline Name</b>	Ojjaara
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Ojjaara	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of symptomatic lower-risk myelofibrosis</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - All of the following:

**2.1** Diagnosis of higher-risk myelofibrosis

**AND**

**2.2** Presence of symptomatic splenomegaly and/or constitutional symptoms

**AND**

**2.3** One of the following:

- Used as continued therapy near the start of conditioning therapy in a transplant candidate
- Patient is not a transplant candidate or transplant not currently feasible

**OR**

**3** - Diagnosis of myelofibrosis-associated anemia

**OR**

**4** - Both of the following:

**4.1** Diagnosis of accelerated/blast phase myeloproliferative neoplasm

**AND**

**4.2** One of the following:

- Used for the improvement of splenomegaly or other disease-related symptoms
- Continued treatment as a single agent near to the start of conditioning therapy in transplant candidates for the improvement of splenomegaly and other disease-related symptoms

Product Name:Ojjaara	
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation that patient has evidence of symptom improvement or reduction in spleen volume while on Ojjaara*</p>	
Notes	*If documentation does not provide evidence of symptom improvement or reduction in spleen volume while on Ojjaara, authorization will be issued for 2 months to allow for dose titration with discontinuation of therapy.

Product Name:Ojjaara	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Ojjaara	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Documentation of positive clinical response to Ojjaara therapy

Olumiant



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164719
<b>Guideline Name</b>	Olumiant
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Olumiant	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of moderately to severely active rheumatoid arthritis (RA)**

**AND**

**2 - Patient is not receiving Olumiant in combination with any of the following:**

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**3 - Prescribed by or in consultation with a rheumatologist**

**AND**

**4 - ONE of the following:**

**4.1 Patient is currently on Olumiant therapy as confirmed by claims history or submission of medical records**

**OR**

**4.2 BOTH of the following:**

**4.2.1 ONE of the following:**

- Failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to ONE non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify contraindication or intolerance)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi

(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**4.2.2 ONE of the following:**

- Failure to at least ONE TNF (tumor necrosis factor) antagonist therapy as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to at least ONE TNF antagonist therapy (please specify intolerance or contraindication)
- Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

Product Name:Olumiant	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Olumiant therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Olumiant in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine or cyclosporine)</li> </ul>	

Product Name:Olumiant
-----------------------

Diagnosis	Alopecia Areata
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of severe alopecia areata

**AND**

2 - Other causes of hair loss have been ruled out (e.g., androgenetic alopecia, cicatricial alopecia, secondary syphilis, tinea capitis, triangular alopecia, and trichotillomania)

**AND**

3 - Patient has a current episode of alopecia areata lasting more than 6 months and at least 50% scalp hair loss

**AND**

4 - Patient is not receiving Olumiant in combination with any of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib), Litfulo (ritlecitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

5 - Prescribed by or in consultation with a dermatologist

Product Name: Olumiant	
Diagnosis	Alopecia Areata

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Olumiant therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Olumiant in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib), Litfulo (ritlecitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine or cyclosporine)</li> </ul>	

## 2 . Revision History

Date	Notes
2/4/2025	Updated guideline name and formularies. Updated safety language. Minor formatting changes

Omega



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146380
<b>Guideline Name</b>	Omega
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Lovaza, generic omega-3-acid ethyl esters, Brand Vascepa, generic icosapent ethyl	
Diagnosis	Severe Hypertriglyceridemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe hypertriglyceridemia [pre-treatment triglyceride level of greater than or equal to 500 milligrams/deciliter (mg/dL)]</p>	

**AND**

**2** - Patient is on an appropriate lipid-lowering diet and exercise regimen

**AND**

**3** - ONE of the following:

**3.1** Failure to at least 90 days of a fibric acid derivative, as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to a fibric acid derivative (please specify contraindication or intolerance)

**AND**

**4** - If the request is for a non-preferred\* product, ONE of the following:

**4.1** Failure to omega-3-acid ethyl esters (generic Lovaza), as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to omega-3-acid ethyl esters (generic Lovaza) (please specify contraindication or intolerance)

Notes

\*Omega 3-acid esters (generic Lovaza) is preferred. Other omega-3 acid derivatives are non-preferred.

Product Name: Brand Lovaza, generic omega-3-acid ethyl esters, Brand Vascepa, generic icosapent ethyl

Diagnosis Severe Hypertriglyceridemia

Approval Length 12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is on an appropriate lipid-lowering diet and exercise regimen</p>	

Product Name: Brand Vascepa, generic icosapent ethyl	
Diagnosis	Cardiovascular Risk Reduction
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hypertriglyceridemia [pre-treatment triglyceride level greater than or equal to 150 milligrams/deciliter (mg/dL)]</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient currently has or is considered high or very high risk for cardiovascular disease (CVD) as evidenced by ONE of the following:</p> <p>2.1 BOTH of the following:</p> <p>2.1.1 At least 45 years of age</p> <p style="text-align: center;"><b>AND</b></p>	

**2.1.2** Established CVD confirmed by ONE of the following:

- Acute coronary syndrome
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease

**OR**

**2.2** ALL of the following:

**2.2.1** Diagnosis of Type 2 diabetes

**AND**

**2.2.2** TWO of the following risk factors for developing cardiovascular disease:

- Men at least 55 years and women at least 65 years
- Cigarette smoker or stopped smoking within the past 3 months
- Hypertension [pretreatment blood pressure greater than or equal to 140 millimeters of mercury (mmHg) systolic or greater than or equal to 90 mmHg diastolic]
- HDL-C (high-density lipoprotein cholesterol) less than or equal to 40 mg/dL for men or less than or equal to 50 mg/dL for women
- High-sensitivity C-reactive protein greater than 3.0 mg/L (liter)
- Creatinine clearance greater than 30 and less than 60 milliliters/minute (mL/min)
- Retinopathy
- Micro- or macro-albuminuria
- Ankle-brachial index (ABI) less than 0.9 without symptoms of intermittent claudication

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**3.1** Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy (i.e., atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and will continue to receive a high-intensity statin at maximally tolerated dose

**OR**

**3.2** BOTH of the following:

**3.2.1** Patient is unable to tolerate high-intensity statin as evidenced by ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms:

- Myalgia [muscle symptoms without creatine kinase (CK) elevations]
- Myositis [muscle symptoms with CK elevations less than 10 times upper limit of normal (ULN)]

**AND**

**3.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity or moderate-intensity statin therapy [i.e., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 10 mg, pravastatin greater than or equal to 10 mg, lovastatin 20-40 mg, fluvastatin XL 80 mg, fluvastatin 20-40 mg up to 40 mg twice daily, or Livalo (pitavastatin) greater than or equal to 1 mg] and will continue to receive a low-intensity or moderate-intensity statin at maximally tolerated dose

**AND**

**4** - Submission of medical record (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**4.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (generic Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**4.2** History of contraindication or intolerance to ezetimibe (please specify contraindication or intolerance)

**OR**

**4.3** Patient has an LDL-C (low density lipoprotein cholesterol) less than 100 mg/dL while on maximally tolerated statin therapy

**AND**

**5** - Used as an adjunct to a low-fat diet and exercise

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

Product Name: Brand Vascepa, generic icosapent ethyl	
Diagnosis	Cardiovascular Risk Reduction
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is on an appropriate low-fat diet and exercise regimen</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is receiving maximally tolerated statin therapy</p>	

Omnipod 5



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164200
<b>Guideline Name</b>	Omnipod 5
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Omnipod 5	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of diabetes</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ALL of the following:**

**2.1 Patient has done ONE of the following for at least 8 weeks:**

- Regularly tests blood glucose at least 4 times/day
- Utilizes a continuous glucose monitor (CGM)

**AND**

**2.2 Patient has completed a diabetes management program**

**AND**

**2.3 Patient injects insulin at least 3 times/day**

**AND**

**3 - ONE of the following:**

- Unexplained, nocturnal, or severe hypoglycemia
- Hypoglycemia unawareness
- Dawn phenomenon blood glucose greater than 200 mg/dL (milligrams/deciliter)
- Wide and unpredictable (erratic) swings in blood glucose levels
- Glycemic targets within individualized range but lifestyle requires increased flexibility of insulin pump use
- HbA1C greater than 7% or outside individualized targets

**AND**

**4 - BOTH of the following:**

**4.1 Patient or caregiver is motivated to assume responsibility for self-care and insulin management**

**AND**

**4.2 Patient or caregiver demonstrates knowledge of importance of nutrition including carbohydrate counting and meal planning**

<b>AND</b>	
<b>5</b> - Prescriber attests that there is a reason or special circumstance the patient cannot use external insulin pumps obtained on the medical benefit	
Notes	If patient meets criteria, approve using NDC List OMNIPOD5

Product Name:Omnipod 5	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response	
Notes	If patient meets criteria, approve using NDC List OMNIPOD5

Product Name:Omnipod 5 pods	
Approval Length	12 month(s)
Guideline Type	Quantity Limit
<b>Approval Criteria</b>	
1 - Physician confirmation that the patient requires a greater quantity	
Notes	Authorization for quantity limit overrides should be entered at the NDC level for the requested Omnipod 5 pods, for the requested quantity.

## 2 . Revision History

Date	Notes
------	-------

1/23/2025	Updated GPs. Updated product name and note of QL section.
-----------	---

OmvoH



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-204189
<b>Guideline Name</b>	OmvoH
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:OmvoH SC	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active ulcerative colitis

**AND**

**2** - ONE of the following:

**2.1** Patient has been established on therapy with Omvoh under an active UnitedHealthcare medical benefit prior authorization for the treatment of moderately to severely active ulcerative colitis

**OR**

**2.2** Patient is currently on Omvoh for subcutaneous use therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Omvoh in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia (ozanimod)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Product Name:Omvoh SC	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Omvoh therapy

**AND**

2 - Patient is NOT receiving Omvoh in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia (ozanimod)]

**2 . Revision History**

Date	Notes
2/27/2025	Updated formularies. Updated GPIs. Reworded criteria for established therapy through a medical prior authorization for clarity. Updated safety language.

Onureg



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164740
<b>Guideline Name</b>	Onureg
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Onureg	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not able to complete intensive curative therapy (e.g., transplant-ineligible)</p>	

Product Name: Onureg	
Diagnosis	Peripheral T-cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of one of the following T-cell lymphomas:</p> <ul style="list-style-type: none"> <li>• Angioimmunoblastic T-cell lymphoma (AITL)</li> <li>• Nodal peripheral T-cell lymphoma with TFH phenotype (PTCL, TFH)</li> <li>• Follicular T-cell lymphoma (FTCL)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - One of the following:</p>	

- Used as initial palliative intent therapy
- Used as second-line and subsequent therapy

Product Name:Onureg	
Diagnosis	Acute Myeloid Leukemia, Peripheral T-cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Onureg therapy</p>	

Product Name:Onureg	
Diagnosis	NCCN Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Onureg	
Diagnosis	NCCN Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - There is documentation of positive clinical response to Onureg therapy

**2 . Revision History**

Date	Notes
2/5/2025	Updated formularies. Added criteria for Peripheral T-cell Lymphoma

Opfolda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146603
<b>Guideline Name</b>	Opfolda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Opfolda	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of late-onset Pompe disease as confirmed by ONE of the following:</p> <p>1.1 Absence or deficiency (less than 40% of the lab specific normal mean) of acid alpha-glucosidase (GAA) activity in lymphocytes, fibroblasts or muscle</p>	

**OR**

**1.2** Molecular genetic testing for deletion or mutations in the GAA gene

**AND**

**2** - Presence of clinical signs and symptoms of the disease (e.g., cardiac hypertrophy, respiratory distress, skeletal muscle weakness, etc.)

**AND**

**3** - Provider attests that the patient is not improving on their current enzyme replacement therapy (ERT) (e.g., Lumizyme, Nexviazyme) for the treatment of late-onset Pompe disease and this therapy will be stopped

**AND**

**4** - Patient weighs at least 40kg

**AND**

**5** - Opfolda will be prescribed in combination with Pombiliti (cipaglucosidase alfa-atga)

Product Name:Opfolda	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Documentation of positive clinical response to Opfolda plus Pombiliti	

**AND**

**2** - Opfolda continues to be prescribed in combination with Pombiliti

Ophthalmic Antihistamine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146382
<b>Guideline Name</b>	Ophthalmic Antihistamine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:azelastine ophth soln	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Failure to Pataday OTC (over-the-counter), as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - History of contraindication or intolerance to Pataday OTC (please specify contraindication or intolerance)

Product Name: olopatadine ophth soln (Rx formulation)

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** Failure to Pataday OTC (over-the-counter), as confirmed by claims history or submission of medical records

**OR**

**1.2** History of contraindication or intolerance to Pataday OTC (please specify contraindication or intolerance)

**AND**

**2** - ONE of the following:

**2.1** Failure to ONE of the following, as confirmed by claims history or submission of medical records:

- Azelastine ophthalmic solution
- Ketotifen
- Cromolyn

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Azelastine ophthalmic solution
- Ketotifen

- Cromolyn

Opzelura - CO, MD, NJ, NM, PA CHIP, WA



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164749
<b>Guideline Name</b>	Opzelura - CO, MD, NJ, NM, PA CHIP, WA
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Opzelura	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of mild to moderate atopic dermatitis**

**AND**

**2 - ONE of the following:**

**2.1** Patient is currently on Opzelura therapy as confirmed by claims history or submission of medical records

**OR**

**2.2** For mild atopic dermatitis:

**2.2.1** Failure to TWO of the following topical therapeutic classes as confirmed by claims history or submission of medical records:

- A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**OR**

**2.2.2** History of intolerance or contraindication to ALL of the following topical therapeutic classes (please specify intolerance or contraindication):

- A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**OR**

**2.3** For moderate atopic dermatitis:

**2.3.1** Failure to TWO of the following topical therapeutic classes as confirmed by claims history or submission of medical records:

- A topical corticosteroid of at least a medium- to high-potency topical corticosteroid [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

- Eucrisa (crisaborole)

**OR**

**2.3.2** History of intolerance or contraindication to ALL of the following topical therapeutic classes (please specify intolerance or contraindication):

- A topical corticosteroid of at least a medium- to high-potency topical corticosteroid [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**AND**

**3** - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] nor JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**4** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)

Product Name:Opzelura	
Diagnosis	Nonsegmental Vitiligo
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of nonsegmental vitiligo	

**AND**

**2** - Other causes of depigmentation have been ruled out [e.g., nevus depigmentosus, pityriasis alba, idiopathic guttate hypomelanosis, tinea (pityriasis) versicolor, halo nevus, piebaldism, progressive macular hypomelanosis, lichen sclerosus, chemical leukoderma, drug-induced leukoderma, hypopigmented mycosis fungoides]

**AND**

**3** - Affected areas do not exceed 10% body surface area

**AND**

**4** - ONE of the following:

**4.1** Failure to a previous nonsegmental vitiligo treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to one previous nonsegmental vitiligo treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors) (please specify intolerance or contraindication)

**AND**

**5** - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**6** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)

Product Name:Opzelura	
Diagnosis	Atopic Dermatitis, Nonsegmental Vitiligo
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] nor JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Updated guideline name. Updated T/F language of Atopic Dermatitis. Updated vitiligo initial authorization to 12 months.

Opzelura - CO, MD, NJ, NM, PA CHIP, WA



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164749
<b>Guideline Name</b>	Opzelura - CO, MD, NJ, NM, PA CHIP, WA
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Opzelura	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of mild to moderate atopic dermatitis**

**AND**

**2 - ONE of the following:**

**2.1 Patient is currently on Opzelura therapy as confirmed by claims history or submission of medical records**

**OR**

**2.2 For mild atopic dermatitis:**

**2.2.1 Failure to TWO of the following topical therapeutic classes as confirmed by claims history or submission of medical records:**

- A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**OR**

**2.2.2 History of intolerance or contraindication to ALL of the following topical therapeutic classes (please specify intolerance or contraindication):**

- A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**OR**

**2.3 For moderate atopic dermatitis:**

**2.3.1 Failure to TWO of the following topical therapeutic classes as confirmed by claims history or submission of medical records:**

- A topical corticosteroid of at least a medium- to high-potency topical corticosteroid [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

- Eucrisa (crisaborole)

**OR**

**2.3.2** History of intolerance or contraindication to ALL of the following topical therapeutic classes (please specify intolerance or contraindication):

- A topical corticosteroid of at least a medium- to high-potency topical corticosteroid [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**AND**

**3** - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] nor JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**4** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)

Product Name:Opzelura	
Diagnosis	Nonsegmental Vitiligo
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of nonsegmental vitiligo	

**AND**

**2** - Other causes of depigmentation have been ruled out [e.g., nevus depigmentosus, pityriasis alba, idiopathic guttate hypomelanosis, tinea (pityriasis) versicolor, halo nevus, piebaldism, progressive macular hypomelanosis, lichen sclerosus, chemical leukoderma, drug-induced leukoderma, hypopigmented mycosis fungoides]

**AND**

**3** - Affected areas do not exceed 10% body surface area

**AND**

**4** - ONE of the following:

**4.1** Failure to a previous nonsegmental vitiligo treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to one previous nonsegmental vitiligo treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors) (please specify intolerance or contraindication)

**AND**

**5** - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**6** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)

Product Name:Opzelura	
Diagnosis	Atopic Dermatitis, Nonsegmental Vitiligo
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Opzelura in combination with another biologic medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] nor JAK inhibitor [e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant medication (e.g., azathioprine, cyclosporine)</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Updated guideline name. Updated T/F language of Atopic Dermatitis. Updated vitiligo initial authorization to 12 months.

Orencia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206565
<b>Guideline Name</b>	Orencia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Orencia	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of moderately to severely active rheumatoid arthritis

**AND**

1.2 One of the following:

1.2.1 Failure to a 3 month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses as confirmed by claims history or submitted medical records

**OR**

1.2.2 History of intolerance or contraindication to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

1.3 Patient is NOT receiving Orenzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

1.4 ONE of the following:

**1.4.1** BOTH of the following:

**1.4.1.1** Failure of one of the preferred adalimumab products\*, confirmed by claims history or submitted medical records

**AND**

**1.4.1.2** Failure of TWO of the following confirmed by claims history or submitted medical records:

- Enbrel (etanercept)
- Olumiant (baricitinib)
- Tyenne (tocilizumab-aazg)

**OR**

**1.4.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Olumiant (baricitinib)
- Tyenne (tocilizumab-aazg)

**AND**

**1.5** Prescribed by, or in consultation with, a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Orencia therapy as confirmed by claims history or submitted medical records

**AND**

**2.2** Diagnosis of moderately to severely active rheumatoid arthritis

**AND**

**2.3** Patient is NOT receiving Orenzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by, or in consultation with, a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Orenzia	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> ONE of the following:</p> <p><b>1.2.1</b> Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab-rzaa)]

**AND**

**1.3** Patient is NOT receiving Orenzia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.4** BOTH of the following:

**1.4.1** ONE of the following:

**1.4.1.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**1.4.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

- One of the preferred ustekinumab products\*

**AND**

**1.4.2** ONE of the following:

**1.4.2.1** Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records

**OR**

**1.4.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**AND**

**1.5** Prescribed by, or in consultation with, ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Orencia therapy as confirmed by claims history or submitted medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Orencia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz

(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes

\*See PDL links in Background

Product Name: Oencia

Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)
-----------	--

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis

**AND**

**2** - Patient is NOT receiving Oencia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - ONE of the following:

**3.1** Failure to ALL of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*

- Enbrel (etanercept)
- Tyenne (tocilizumab-aazg)

**OR**

**3.2** History of contraindication or intolerance to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Tyenne (tocilizumab-aazg)

**OR**

**3.3** Patient is currently on Orenzia therapy as confirmed by claims history or submitted medical records

**AND**

**4** - Prescribed by, or in consultation with, a rheumatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Orenzia	
Diagnosis	Rheumatoid Arthritis (RA), Psoriatic Arthritis, Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Orenzia therapy</p> <p><b>AND</b></p>	

2 - Patient is NOT receiving Orencia in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\*

Notes

\*Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

### Benefit/Coverage/Program Information

#### PDL Links

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
3/4/2025	Added ustekinumab as a step therapy option in PsA. Changed "Stelara" to "ustekinumab" .

Orfadin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146605
<b>Guideline Name</b>	Orfadin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Orfadin, generic nitisinone	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary tyrosinemia type 1</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Special clinical circumstances exist that precludes the use of Nityr (nitisinone) tablets for the patient (document special clinical circumstance)

Product Name: Brand Orfadin, generic nitisinone	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient shows evidence of positive clinical response (e.g., decrease in urinary/plasma succinylacetone and alpha-1-microglobulin levels) while on Orfadin therapy</p>	

Orgovyx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146606
<b>Guideline Name</b>	Orgovyx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Orgovyx	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced prostate cancer</p>	

**AND**

**2** - Patient is a candidate for at least one year of continuous androgen-deprivation therapy

**AND**

**3** - ONE of the following:

- Evidence of biochemical [PSA (prostate-specific antigen)] or clinical relapse after local primary intervention with curative intent
- Newly diagnosed hormone-sensitive metastatic disease
- Advanced localized disease unlikely to be cured by local primary intervention with curative intent

**AND**

**4** - Patient has been without any major adverse cardiovascular events within 6 months before initiation (e.g., myocardial infarction, stroke)

Product Name:Orgovyx	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on therapy	

Product Name:Orgovyx	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Orgovyx	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Orgovyx therapy</p>	

Oriahnn\_MyFembree



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146385
<b>Guideline Name</b>	Oriahnn_MyFembree
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Oriahnn, MyFembree	
Diagnosis	Uterine Fibroids
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of uterine fibroids (leiomyomas)</p>	

**AND**

**2** - Used for the management of heavy menstrual bleeding

**AND**

**3** - ONE of the following:

**3.1** Failure after a three-month trial to ONE of the following as confirmed by claims history or submission of medical records:

- Estrogen/progestin contraceptive (e.g., Loestrin FE)
- Progestin-releasing intrauterine devices (IUDs) (e.g., Mirena)\*
- Progestin-only contraceptive [e.g., norethindrone (generic Aygestin)]

**OR**

**3.2** Contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Estrogen/progestin contraceptive (e.g., Loestrin FE)
- Progestin-releasing intrauterine devices (IUDs) (e.g., Mirena)\*
- Progestin-only contraceptive [e.g., norethindrone (generic Aygestin)]

**AND**

**4** - ONE of the following:

**4.1** Failure after a three-month trial of tranexamic acid (e.g., Lysteda) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to tranexamic acid (e.g., Lysteda) (please specify contraindication or intolerance)

<b>AND</b>	
<p><b>5</b> - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Obstetrics/Gynecologist (OB/GYN)</li> <li>• Reproductive endocrinologist</li> </ul>	
Notes	*This is a medical benefit, should not be included in denial to provider.

Product Name: Oriahnn, MyFembree	
Diagnosis	Uterine Fibroids
Approval Length	12 months*
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Impact to bone mineral density has been considered</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Treatment duration has not exceeded a total of 24 months*</p>	
Notes	*Authorization will be issued for 12 months up to a maximum treatment duration of 24 months. Oriahnn and MyFembree are indicated for a maximum treatment duration of 24 months.

Product Name: MyFembree	
Diagnosis	Pain Associated with Endometriosis

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate to severe pain associated with endometriosis

**AND**

2 - ONE of the following:

2.1 Failure (e.g., inadequate pain relief) to a three-month trial of TWO analgesics (e.g., ibuprofen, meloxicam, naproxen) as confirmed by claims history or submission of medical records

**OR**

2.2 History of contraindication or intolerance to TWO analgesics (e.g., ibuprofen, meloxicam, naproxen) (please specify contraindication or intolerance)

**AND**

3 - ONE of the following:

3.1 Failure to a three-month trial of ONE of the following, as confirmed by claims history or submission of medical records:

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**OR**

3.2 History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Hormonal contraceptives

<ul style="list-style-type: none"> <li>• Progestins [e.g., norethindrone (generic Aygestin)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Obstetrics/Gynecologist (OB/GYN)</li> <li>• Reproductive endocrinologist</li> </ul>	
Notes	*This is a medical benefit, should not be included in denial to provider.

Product Name: MyFembree	
Diagnosis	Pain Associated with Endometriosis
Approval Length	12 months*
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Impact to bone mineral density has been considered</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Treatment duration has not exceeded a total of 24 months*</p>	
Notes	*Authorization will be issued for 12 months up to a maximum treatment duration of 24 months. MyFembree are indicated for a maximum treatment duration of 24 months.

Orilissa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146387
<b>Guideline Name</b>	Orilissa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Orilissa 150 mg	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe pain associated with endometriosis</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure (e.g., inadequate pain relief) to a three month trial of TWO analgesics (e.g., ibuprofen, meloxicam, naproxen) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to TWO analgesics (e.g., ibuprofen, meloxicam, naproxen) (please specify contraindication or intolerance)

**AND**

**3 - ONE of the following:**

**3.1** Failure to a three month trial to ONE of the following as confirmed by claims history or submission of medical records:

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**OR**

**3.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance)

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**AND**

**4 - Treatment duration of Orilissa 150 mg once daily has not exceeded a total of 24 months, as confirmed by claims history or submission of medical records**

**AND**

**5 - Prescribed by or in consultation with ONE of the following:**

- Obstetrics/Gynecologist (OB/GYN)
- Reproductive endocrinologist

Product Name:Orilissa 150 mg	
Approval Length	12 months up to a maximum treatment duration of 24 months
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Impact to bone mineral density has been considered</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Treatment duration has not exceeded a total of 24 months, as confirmed by claims history or submission of medical records</p>	

Product Name:Orilissa 200 mg	
Approval Length	Up to a maximum of 6 months
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe pain associated with endometriosis</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure (e.g., inadequate pain relief) to a three month trial of TWO analgesics (e.g., ibuprofen, meloxicam, naproxen), as confirmed by claims history or submission of medical records

**OR**

**2.2** History of intolerance or contraindication to TWO analgesics (e.g., ibuprofen, meloxicam, naproxen) (please specify intolerance or contraindication)

**AND**

**3 - ONE of the following:**

**3.1** Failure after a three month trial to ONE of the following as confirmed by claims history or submission of medical records:

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**OR**

**3.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**AND**

**4 - Treatment duration of Orilissa 200 mg twice daily has not exceeded a total of 6 months, as confirmed by claims history or submission of medical records**

**AND**

**5 - Prescribed by or in consultation with ONE of the following:**

- Obstetrics/Gynecologist (OB/GYN)
- Reproductive endocrinologist

Orkambi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151772
<b>Guideline Name</b>	Orkambi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Orkambi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Submission of laboratory results confirming that patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

**AND**

**3** - The patient is greater than or equal to 1 years of age

**AND**

**4** - Prescribed by, or in consultation with, a provider who specializes in the treatment of CF

Product Name:Orkambi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Orkambi therapy (e.g., improved lung function, stable lung function)</p>	

## 2 . Revision History

Date	Notes
8/14/2024	Removed prescriber requirement from reauthorization criteria

Orladeyo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147208
<b>Guideline Name</b>	Orladeyo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Orladeyo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p>1.1 C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-converting enzyme 1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosaminase 3-O-sulfotransferase 6
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - ALL of the following:

**2.1** Prescribed for the prophylaxis of HAE attacks

**AND**

**2.2** Not used in combination with other approved products indicated for prophylaxis against HAE attacks (i.e., Cinryze, Haegarda, Takhzyro)

**AND**

**2.3** Prescriber attests that patient has experienced attacks of a severity and/or frequency such that they would clinically benefit from prophylactic therapy with Orladeyo

**AND**

**3** - Prescribed by ONE of the following:

- Immunologist
- Allergist

**AND**

**4 - ONE of the following:**

**4.1** Failure to Haegarda as confirmed by history or submission of medical records

**OR**

**4.2** History of contraindication, or intolerance to Haegarda (please specify a contraindication or intolerance)

**OR**

**4.3** Patient is unable to self-inject Haegarda due to ONE of the following:

- Physical impairment
- Visual impairment
- Lipohypertrophy
- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure [refer to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) for specific phobia diagnostic criteria]

**OR**

**4.4** Patient is currently on Orladeyo therapy, as confirmed by claims history or submission of medical records

Product Name:Orladeyo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Orladeyo therapy	

**AND**

**2** - Reduction in the utilization of on-demand therapies used for acute attacks (e.g., Berinert, Firazyr, Ruconest), as confirmed by claims history or submission of medical records, while on Orladeyo therapy

**AND**

**3** - BOTH of the following:

**3.1** Prescribed for the prophylaxis of HAE attacks

**AND**

**3.2** Not used in combination with other products indicated for prophylaxis against HAE attacks (i.e., Cinryze, Haegarda, Takhzyro)

**AND**

**4** - Prescribed by ONE of the following:

- Immunologist
- Allergist

## 2 . Revision History

Date	Notes
5/9/2024	Update to diagnostic criteria for HAE with normal C1 inhibitor levels. Updated and simplified reauthorization criteria.

Orserdu



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147251
<b>Guideline Name</b>	Orserdu
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Orserdu	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - ONE of the following:

- Advanced
- Metastatic

**AND**

**3** - Disease is estrogen receptor (ER)-positive

**AND**

**4** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**5** - Presence of an ESR1 gene mutation

**AND**

**6** - Patient is ONE of the following:

- Postmenopausal woman
- Male
- Premenopausal woman treated with ovarian ablation/suppression

**AND**

**7** - Disease has progressed following at least one line of endocrine therapy

Product Name: Orserdu

Diagnosis

Breast Cancer

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Orserdu therapy</p>	

Product Name:Orserdu	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Orserdu	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Orserdu therapy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
5/10/2024	Specified postmenopausal "woman" and added premenopausal woman treated with ovarian ablation/suppression to coverage criteria per NCCN.

Osphena



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146849
<b>Guideline Name</b>	Osphena
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Osphena	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause*</p>	

**AND**

**2 - ONE of the following:**

**2.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- Estradiol vaginal cream
- Estradiol vaginal tablet

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Estradiol vaginal cream
- Estradiol vaginal tablet

Notes

\*Treatment of dyspareunia is a benefit exclusion.

Product Name: Osphena	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

## 2 . Revision History

Date	Notes
4/30/2024	Removed reference to other states in GL name



Otezla



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-205230
<b>Guideline Name</b>	Otezla
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Otezla	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - All of the following:

1.1 Diagnosis of active psoriatic arthritis

**AND**

1.2 One of the following:

1.2.1 Failure to a 3 month trial of methotrexate at the maximally indicated dose, as confirmed by claims history or submission of medical records

**OR**

1.2.2 History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Skyrizi (risankizumab-rzaa)]

**AND**

1.3 Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

1.4 Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Otezla therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name:Otezla	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - All of the following:

1.1 Diagnosis of plaque psoriasis in those who are candidates for phototherapy or systemic therapy

**AND**

1.2 One of the following:

1.2.1 All of the following:

1.2.1.1 Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

1.2.1.2 One of the following:

1.2.1.2.1 Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

1.2.1.2.2 History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication)

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin

- Coal tar

**AND**

**1.2.1.3** One of the following:

**1.2.1.3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records

**OR**

**1.2.1.3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**1.3** Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.4** Prescribed by or in consultation with a dermatologist

**OR**

**2** - All of the following:

**2.1** Patient is currently on Otezla therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of plaque psoriasis in those who are candidates for phototherapy or systemic therapy

**AND**

**2.3** Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a dermatologist

<b>Product Name:Otezla</b>	
Diagnosis	Behcet's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - All of the following:</p> <p>1.1 Diagnosis of Behcet's Disease</p> <p><b>AND</b></p>	

**1.2** Patient has active oral ulcers attributed to Behcet's Disease

**AND**

**1.3** One of the following:

**1.3.1** Failure to one non-biologic (e.g., corticosteroids, colchicine) used for treating Behcet's Disease, as confirmed by claims history or submission of medical records

**OR**

**1.3.2** History of contraindication or intolerance to one non-biologic (e.g., corticosteroids, colchicine) used for treating Behcet's Disease (please specify contraindication or intolerance)

**OR**

**1.3.3** Patient has been previously treated with a targeted immunomodulator used for the treatment of Behcet's Disease as confirmed by claims history or submission of medical records [e.g., Remicade (infliximab), adalimumab, Enbrel (etanercept)]

**AND**

**1.4** Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2 - All of the following:**

**2.1** Patient is currently on Otezla therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of Behcet's Disease

**AND**

**2.3** Patient has active oral ulcers attributed to Behcet's Disease

**AND**

**2.4** Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name:Otezla	
Diagnosis	Psoriatic Arthritis, Behcet's Disease, Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Otezla therapy

**AND**

2 - Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**2 . Revision History**

Date	Notes
3/3/2025	Added NM to formulary list. Replaced Stelara with ustekinumab and updated language to state "targeted immunomodulator"

Oxbryta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146611
<b>Guideline Name</b>	Oxbryta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Oxbryta	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of sickle cell disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is at least 4 years of age

**AND**

**3** - ONE of the following:

**3.1** Patient is currently receiving hydroxyurea therapy

**OR**

**3.2** Failure to hydroxyurea therapy as confirmed by claims history or submission of medical records

**OR**

**3.3** History of contraindication or intolerance to hydroxyurea therapy (please specify contraindication or intolerance)

**AND**

**4** - Patient has previously experienced 1 or more sickle cell-related vaso-occlusive crises within the previous 12 months

**AND**

**5** - Baseline hemoglobin (Hb) is less than or equal to 10.5 g/dL (grams/deciliter)

**AND**

**6** - Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy

**AND**

**7** - Patient is not to receive Oxbryta in combination with Adakveo (crizanlizumab-tmca)

**AND**

**8** - Prescribed by, or in consultation with, a hematologist or other specialist with expertise in the diagnosis and management of sickle cell disease

Product Name:Oxbryta	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Oxbryta therapy as demonstrated by at least ONE of the following:</p> <p><b>1.1</b> Increase in hemoglobin (Hb) by greater than or equal to 1 g/dL (gram/deciliter) from baseline</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Decrease in indirect bilirubin from baseline</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.3</b> Decrease in percent reticulocyte count from baseline</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.4</b> Patient has experienced a reduction in sickle cell-related vaso-occlusive crises</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is not receiving Oxbryta in combination with Adakveo (crizanlizumab-tmca)

**AND**

**3** - Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy

**AND**

**4** - Prescribed by, or in consultation with a hematologist, or other specialist with expertise in the diagnosis and management of sickle cell disease

Oxervate



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146612
<b>Guideline Name</b>	Oxervate
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Oxervate	
Diagnosis	Neurotrophic keratitis
Approval Length	8 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Stage 2 or 3 neurotrophic keratitis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Failure to at least ONE OTC (over the counter) ocular artificial tear product (e.g., Systane Ultra, Akwa Tears, Refresh Optive, Soothe XP) as confirmed by claims history or submission of medical records

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Ophthalmologist
- Optometrist

PAH



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206558
<b>Guideline Name</b>	PAH
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Adempas, Brand Letairis, generic ambrisentan, Opsumit, generic sildenafil 20 mg, Brand Revatio tabs/susp, generic sildenafil susp, Tracleer, generic bosentan, Brand Adcirca, Alyq, generic tadalafil (PAH, generic of Adcirca)	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of pulmonary arterial hypertension (PAH)

Product Name:Liqrev, Tadliq	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Pulmonary arterial hypertension is symptomatic</li> <li>• Diagnosis of pulmonary arterial hypertension that is confirmed by right heart catheterization</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2 Patient is currently on any therapy for the diagnosis of pulmonary arterial hypertension</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Failure to BOTH of the following as confirmed by claims history or submission of medical records:</p> <p>2.1.1 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Adempas</li> </ul>	

- Sildenafil citrate oral suspension (generic Revatio)

**AND**

**2.1.2** An ERA (endothelin receptor antagonist) [e.g., ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer)]

**OR**

**2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

**2.2.1** ONE of the following:

- Adempas
- Sildenafil citrate oral suspension (generic Revatio)

**AND**

**2.2.2** An ERA [e.g., ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer)]

Product Name:Opsynvi	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - One of the following:</p> <p><b>1.1</b> Both of the following:</p> <ul style="list-style-type: none"> <li>• Pulmonary arterial hypertension is symptomatic</li> <li>• Diagnosis of pulmonary arterial hypertension that is confirmed by right heart catheterization</li> </ul>	

**OR**

**1.2** Patient is currently on any therapy for the diagnosis of pulmonary arterial hypertension

**AND**

**2** - Failure to BOTH of the following taken together as confirmed by claims history or submission of medical records:

- A PDE-5 inhibitor [e.g., sildenafil citrate (generic Revatio), tadalafil (generic Adcirca)]
- A preferred ERA [e.g., ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer)]

Product Name: Orenitram, Tyvaso DPI, Uptravi titration pack, Uptravi tabs	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> As continuation of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Patient is not taking the requested medication in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> Prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist</p>	

**OR**

**2** - ALL of the following:

**2.1** ONE of the following:

**2.1.1** BOTH of the following:

- Pulmonary arterial hypertension is symptomatic
- Diagnosis of pulmonary arterial hypertension that is confirmed by right heart catheterization

**OR**

**2.1.2** Patient is currently on any therapy for the diagnosis of pulmonary arterial hypertension

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

**2.2.1.1** ONE of the following:

- Adempas
- A PDE-5 inhibitor [e.g., sildenafil citrate (generic Revatio), tadalafil (generic Adcirca)]

**AND**

**2.2.1.2** An ERA (endothelin receptor antagonist) [e.g., ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer)]

**OR**

**2.2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

**2.2.2.1 ONE of the following:**

- Adempas
- A PDE-5 inhibitor [e.g., sildenafil citrate (generic Revatio), tadalafil (generic Adcirca)]

**AND**

**2.2.2.2 An ERA [e.g., ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer)]**

**AND**

**2.3 Patient is not taking the requested medication in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil) as long-term concomitant therapy\***

Notes	*Concomitant use will be allowable for patients to transition from one of these agents to the other.
-------	--

Product Name:Tadliq, Liqrev, Opsynvi	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation the patient is receiving clinical benefit to therapy</p>	

Product Name:Orenitram, Tyvaso DPI, Upravi titration pack, Upravi tabs	
Diagnosis	Pulmonary Arterial Hypertension (PAH)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation the patient is receiving clinical benefit to therapy

**AND**

2 - Patient is not taking the requested medication in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil)

Product Name:Adempas	
Diagnosis	Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH)</p>	

Product Name:Tyvaso DPI	
Diagnosis	Pulmonary Hypertension Associated with Interstitial Lung Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of pulmonary hypertension associated with interstitial lung disease [WHO (World Health Organization) group 3] confirmed by right heart catheterization</p>	

<b>AND</b>
<b>1.2</b> Interstitial lung disease is diagnosed based on evidence of diffuse parenchymal lung disease on computed tomography of the chest
<b>AND</b>
<b>1.3</b> Pulmonary hypertension is symptomatic
<b>AND</b>
<b>2</b> - Prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist

Product Name: Tyvaso DPI	
Diagnosis	Pulmonary Hypertension Associated with Interstitial Lung Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to the requested therapy (e.g., improved exercise ability)	

## 2 . Revision History

Date	Notes
3/3/2025	Updated criteria to add generic Adcirca as step therapy option for applicable drugs.

Palforzia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146614
<b>Guideline Name</b>	Palforzia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Palforzia	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis and clinical history of peanut allergy as documented by BOTH of the following:</p> <p>1.1 A serum peanut-specific IgE (immunoglobulin E) level of greater than or equal to 0.35 kUA/L (kilounits of allergen/liter)</p>	

**AND**

**1.2** A mean wheal diameter that is at least 3 mm (millimeters) larger than the negative control on skin-prick testing for peanut

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

- Patient is 4 to 17 years of age
- Patient is in the initial dose escalation phase of therapy

**OR**

**2.2** BOTH of the following:

- Patient is 4 years of age and older
- Patient is in the up-dosing or maintenance phase of therapy

**AND**

**3** - Used in conjunction with a peanut-avoidant diet

**AND**

**4** - Patient does not have any of the following:

- History of eosinophilic esophagitis (EoE) or eosinophilic gastrointestinal disease
- History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock within the past 2 months
- Severe or poorly controlled asthma

**AND**

**5** - Prescribed by or in consultation with an allergist/immunologist

**AND**

**6** - Prescriber is certified/enrolled in the Palforzia REMS (Risk Evaluation and Mitigation Strategy) Program

Product Name: Palforzia

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response to Palforzia therapy

**AND**

**2** - Used in conjunction with a peanut-avoidant diet

**AND**

**3** - Prescribed by or in consultation with an allergist/immunologist

**AND**

**4** - Prescriber is certified/enrolled in the Palforzia REMS (Risk Evaluation and Mitigation Strategy) Program

Palynziq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155065
<b>Guideline Name</b>	Palynziq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Palynziq	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of phenylketonuria (PKU)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is actively on a phenylalanine-restricted diet

**AND**

**3** - ONE of the following:

**3.1** Failure to a one- to four-week trial of sapropterin as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to sapropterin therapy (please specify contraindication or intolerance)

**AND**

**4** - Physician attestation that the patient will not be receiving Palynziq in combination with sapropterin dihydrochloride

**AND**

**5** - Submission of medical records (e.g., chart notes, laboratory values) documenting that the patient has a blood phenylalanine concentration greater than 600 micromoles/liter

Product Name: Palynziq	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient is actively on a phenylalanine-restricted diet	

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records (e.g., chart notes, laboratory values) documenting that the patient has a blood phenylalanine concentration less than 600 micromoles/liter

**OR**

**2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting that the patient has achieved a 20% reduction in blood phenylalanine concentration from pre-treatment baseline

**OR**

**2.3** Patient is in initial titration/maintenance phase of dosing regimen and dose is being titrated based on blood phenylalanine concentration response up to maximum labeled dosage of 60 milligrams once daily

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting that the patient is not receiving Palynziq in combination with sapropterin dihydrochloride (Prescription claim history that does not show any concomitant sapropterin dihydrochloride claim within 60 days of reauthorization request may be used as documentation)

## 2 . Revision History

Date	Notes
9/17/2024	Updated authorization durations to 12 months

Panretin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164747
<b>Guideline Name</b>	Panretin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Indiana</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Panretin	
Diagnosis	Kaposi's Sarcoma
Approval Length	12 month(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of AIDS (acquired immunodeficiency syndrome)-related Kaposi's Sarcoma (KS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving systemic anti-KS treatment</p>	

Product Name:Panretin	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Panretin	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Panretin therapy</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Added IN formulary. No change to clinical criteria.

Pemazyre



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160650
<b>Guideline Name</b>	Pemazyre
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Pemazyre	
Diagnosis	Cholangiocarcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cholangiocarcinoma</p>	

**AND**

**2** - Disease is ONE of the following:

- Unresectable locally advanced
- Resected gross residual (R2)
- Metastatic

**AND**

**3** - Disease has presence of a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement

**AND**

**4** - Patient has been previously treated

Product Name:Pemazyre	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of myeloid/lymphoid/mixed lineage neoplasms with eosinophilia</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease has presence of a fibroblast growth factor receptor 1 (FGFR1) rearrangement</p>	

Product Name:Pemazyre
-----------------------

Diagnosis	Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Pemazyre therapy</p>	

Product Name: Pemazyre	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Pemazyre will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Pemazyre	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Pemazyre therapy</p>	

## 2 . Revision History

Date	Notes
11/14/2024	Updated criteria for cholangiocarcinoma

Piqray



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147150
<b>Guideline Name</b>	Piqray
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Piqray	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - ONE of the following:

- Advanced
- Metastatic

**AND**

**3** - Disease is hormone receptor (HR)-positive

**AND**

**4** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**5** - Presence of one or more PIK3CA mutations

**AND**

**6** - Used in combination with fulvestrant

**AND**

**7** - Disease has progressed on or after an endocrine-based regimen

Product Name:Piqray	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Piqray therapy

Product Name:Piqray	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Piqray	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Piqray therapy</p>	

**2 . Revision History**

Date	Notes
5/7/2024	Removed requirement for postmenopausal, premenopausal with ovarian ablation/suppression, or male under BC initial auth section; Mino

	r verbiage update to NCCN Recommended Regimens initial auth section (with no changes to clinical intent).
--	---

Pomalyst



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150857
<b>Guideline Name</b>	Pomalyst
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/2/2024
-----------------	----------

### 1 . Criteria

Product Name:Pomalyst	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple myeloma</p>	

**AND**

**2** - ONE of the following:

**2.1** Failure of ONE of the following, confirmed by claims history or submitted medical records:

- Immunomodulatory agent [e.g., Revlimid (lenalidomide)]
- Proteasome inhibitor [e.g., Velcade (bortezomib)]

**OR**

**2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Immunomodulatory agent [e.g., Revlimid (lenalidomide)]
- Proteasome inhibitor [e.g., Velcade (bortezomib)]

**OR**

**2.3** Induction therapy for the management of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome

Product Name:Pomalyst	
Diagnosis	Systemic Light Chain Amyloidosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of systemic light chain amyloidosis</p> <p style="text-align: center;"><b>AND</b></p>	

2 - Used in combination with dexamethasone

Product Name:Pomalyst	
Diagnosis	Kaposi Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of HIV (human immunodeficiency virus)-negative Kaposi Sarcoma</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p> <p>2.1 Diagnosis of AIDS (acquired immunodeficiency syndrome)-related Kaposi Sarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2 Patient is currently being treated with antiretroviral therapy (ART), confirmed by claims history or submitted medical records</p>	

Product Name:Pomalyst	
Diagnosis	Primary CNS Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Diagnosis of primary central nervous system (CNS) lymphoma

**AND**

2 - Used as second-line or subsequent therapy

Product Name:Pomalyst

Diagnosis	Multiple Myeloma, Systemic Light Chain Amyloidosis, Kaposi Sarcoma, Primary CNS Lymphoma
-----------	--

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Pomalyst therapy

Product Name:Pomalyst

Diagnosis	NCCN Recommended Regimen
-----------	--------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Pomalyst

Diagnosis	NCCN Recommended Regimen
-----------	--------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Pomalyst therapy</p>	

## 2 . Revision History

Date	Notes
8/2/2024	Annual review. Updated criteria for multiple myeloma and Kaposi sarcoma. Updated background and references.

PPI (Proton Pump Inhibitors)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161219
<b>Guideline Name</b>	PPI (Proton Pump Inhibitors)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic lansoprazole ODT, generic esomeprazole magnesium susp packets	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient is less than 2 years of age</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ONE of the following:</p>	

**2.1** Failure to BOTH of the following, as confirmed by claims history or submission of medical records

- Lansoprazole DR capsule as sprinkle administration (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium) as sprinkle administration

**OR**

**2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance)

- Lansoprazole DR capsule as sprinkle administration (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium) as sprinkle administration

Product Name: Prilosec OTC, omeprazole tabs, Brand Protonix tabs, Brand Prevacid, Prevacid 24HR, Brand Aciphex, generic rabeprazole tabs, Brand Dexilant, generic dexlansoprazole, Brand Nexium caps, Brand Nexium 24HR

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Failure to at least a 30 day trial of THREE of the following as confirmed by claims history or submission of medical records:

- Omeprazole capsule (generic Prilosec)
- Pantoprazole tablet (generic Protonix)
- Lansoprazole delayed release (DR) capsule (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium)

**OR**

**2** - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Omeprazole capsule (generic Prilosec)
- Pantoprazole tablet (generic Protonix)
- Lansoprazole DR capsule (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium)

Product Name:Prilosec susp packets, Brand Protonix susp packets, Brand Prevacid Solutab, Brand Nexium susp packets, generic pantoprazole susp packets, Rabeprazole Sprinkle

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Failure to at least a 30 day trial to THREE of the following products as confirmed by claims history or submission of medical records:

- Lansoprazole DR capsule as sprinkle administration (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium) as sprinkle administration
- Lansoprazole oral disintegrating tablet (generic Prevacid Solutab) (Prior authorization required)
- Esomeprazole magnesium granule suspension (generic Nexium granule suspension) (Prior authorization required)

**OR**

**2** - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Lansoprazole DR capsule as sprinkle administration (generic Prevacid)
- Esomeprazole magnesium OTC capsule (generic Nexium capsule 24 HR OTC) or esomeprazole magnesium capsule (generic Nexium) as sprinkle administration
- Lansoprazole oral disintegrating tablet (generic Prevacid Solutab)
- Esomeprazole magnesium granule suspension (generic Nexium granule suspension)

Product Name:omeprazole caps, Prilosec, Prilosec OTC, omeprazole tabs, generic pantoprazole tabs/susp packets, Brand Protonix tabs/susp packets, generic lansoprazole,

Brand Prevacid, Prevacid 24HR, generic lansoprazole ODT, Brand Prevacid Solutab, generic esomeprazole magnesium caps, Nexium, Brand Aciphex, generic rabeprazole, Brand Dexilant, generic esomeprazole magnesium susp packets, generic dexlansoprazole, Brand Nexium, Brand Nexium 24HR, Rabeprazole Sprinkle, generic esomeprazole magnesium tabs (OTC)	
Therapy Stage	Initial Authorization
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p>1 - The patient did not exhibit an adequate response to treatment within the quantity limit*</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - The patient has documented erosive disease*</p> <p style="text-align: center;"><b>OR</b></p> <p>3 - The patient has documented symptoms of complicated disease (e.g., dysphagia, bleeding, weight loss, choking, chest pain)*</p> <p style="text-align: center;"><b>OR</b></p> <p>4 - The patient has a pathological hypersecretory condition such as Zollinger-Ellison syndrome, Barrett's Esophagus, multiple endocrine adenomas, or systemic mastocytosis**</p>	
Notes	<p>Authorization will be issued based on circumstance.</p> <p>*Authorization will be issued for 8 weeks.</p> <p>**Authorization of therapy will be issued for 12 months.</p>

Product Name:omeprazole caps, Prilosec, Prilosec OTC, omeprazole tabs, generic pantoprazole tabs/susp packets, Brand Protonix tabs/susp packets, generic lansoprazole, Brand Prevacid, Prevacid 24HR, generic lansoprazole ODT, Brand Prevacid Solutab, generic esomeprazole magnesium caps, Nexium, Brand Aciphex, generic rabeprazole, Brand Dexilant, generic esomeprazole magnesium susp packets, generic dexlansoprazole, Brand Nexium, Brand Nexium 24HR, Rabeprazole Sprinkle, generic esomeprazole magnesium tabs (OTC)	
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p>1 - The patient is continuing therapy for a pathological hypersecretory condition such as Zollinger-Ellison syndrome, Barrett's Esophagus, multiple adenomas, or systemic mastocytosis</p>	

## 2 . Revision History

Date	Notes
11/25/2024	Copy core

Praluent



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146834
<b>Guideline Name</b>	Praluent
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Praluent (all labelers)	
Diagnosis	Primary Hyperlipidemia (Including Heterozygous Familial Hypercholesterolemia (HeFH) and Atherosclerotic Cardiovascular Disease (ASCVD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p>	

**1.1** Heterozygous familial hypercholesterolemia (HeFH) as confirmed by ONE of the following:

**1.1.1** BOTH of the following:

**1.1.1.1** Pre-treatment low density lipoprotein cholesterol (LDL-C) of ONE of the following:

- Greater than or equal to 190 milligrams/deciliter (mg/dL)
- Greater than or equal to 155 mg/dL if less than 16 years of age

**AND**

**1.1.1.2** ONE of the following:

- Family history of myocardial infarction in first-degree relative less than 60 years of age
- Family history of myocardial infarction in second-degree relative less than 50 years of age
- Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative
- Family history of heterozygous or homozygous familial hypercholesterolemia in first- or second-degree relative
- Family history of tendinous xanthomata and/or arcus cornealis in first- or second degree relative

**OR**

**1.1.2** BOTH of the following:

**1.1.2.1** Pre-treatment LDL-C of ONE of the following:

- Greater than or equal to 190 mg/dL
- Greater than or equal to 155 mg/dL if less than 16 years of age

**AND**

**1.1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

- Functional mutation in LDL (low density lipoprotein), apoB (apolipoprotein B), or PCSK9 (proprotein convertase subtilisin/kexin type 9) gene
- Tendinous xanthomata
- Arcus cornealis before age 45

**OR**

**1.2** Atherosclerotic cardiovascular disease (ASCVD) as confirmed by ONE of the following:

- Acute coronary syndromes
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

**OR**

**1.3** Primary hyperlipidemia with pre-treatment LDL-C greater than or equal to 190 mg/dL

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**2.1** Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy [i.e., atorvastatin 40-80 milligrams (mg), rosuvastatin 20-40 mg] and will continue to receive high intensity statin at maximally tolerated dose

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms:

- Myalgia [muscle symptoms without creatine kinase (CK) elevations]
- Myositis [muscle symptoms with CK elevations less than 10 times upper limit of normal (ULN)]

**AND**

**2.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity or moderate-intensity statin therapy [i.e., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 10 mg, pravastatin greater than or equal to 10 mg, lovastatin 20-40 mg, fluvastatin XL 80 mg, fluvastatin 20-40 mg up to 40 mg twice daily, or Livalo (pitavastatin) greater than or equal to 1 mg] and will continue to receive a low-intensity or moderate-intensity statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low- or moderate-, and high-intensity statins as evidenced by ONE of the following:

**2.3.1** ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms for low or moderate-, and high-intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times ULN)

**OR**

**2.3.2** Patient has a labeled contraindication to all statins as documented in medical records

**OR**

**2.3.3** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days or 120 days prior to starting PCSK9 inhibitor therapy:

- LDL-C greater than or equal to 100 mg/dL with ASCVD
- LDL-C greater than or equal to 130 mg/dL without ASCVD

**OR**

**3.2 BOTH** of the following:

**3.2.1** Submission of medical records (e.g., laboratory values) documenting **ONE** of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days or 120 days prior to starting PCSK9 inhibitor therapy:

- LDL-C between 55 mg/dL and 99 mg/dL with ASCVD
- LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

**AND**

**3.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting **ONE** of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**3.2.2.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**3.2.2.2** Patient has a history of contraindication or intolerance to ezetimibe (please specify intolerance or contraindication)

**AND**

**4** - Patient has received comprehensive counseling regarding appropriate diet

**AND**

**5** - Prescribed by **ONE** of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**6** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolcumab)]

**AND**

**7** - Not used in combination with Leqvio (inclisiran)

**Product Name: Praluent (all labelers)**

Diagnosis	Primary Hyperlipidemia (Including Heterozygous Familial Hypercholesterolemia (HeFH) and Atherosclerotic Cardiovascular Disease (ASCVD))
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting low density lipoprotein cholesterol (LDL-C) reduction while on Praluent therapy

**AND**

**3** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolcumab)]

**AND**

**4** - Not used in combination with Leqvio (inclisiran)

Product Name: Praluent (all labelers)	
Diagnosis	Homozygous Familial Hypercholesterolemia (HoFH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:</p> <p><b>1.1</b> Submission of medical records (e.g., chart notes, laboratory values) confirming genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> BOTH of the following:</p> <p><b>1.2.1</b> Pre-treatment low density lipoprotein cholesterol (LDL-C) greater than 400 milligrams/deciliter (mg/dL)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2</b> ONE of the following:</p> <p><b>1.2.2.1</b> Xanthoma before 10 years of age</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2.2.2** Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

**AND**

**2** - Patient has received comprehensive counseling regarding appropriate diets

**AND**

**3** - Patient is receiving other lipid-lowering therapy confirmed by claims history or submitted medical records (e.g., statin, ezetimibe, LDL apheresis)

**AND**

**4** - Prescribed by one of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolcumab)]

**AND**

**6** - Not used in combination with Juxtapid (lomitapide)

Product Name: Praluent (all labelers)	
Diagnosis	Homozygous Familial Hypercholesterolemia (HoFH)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

2 - Submission of medical records (e.g., chart notes, laboratory values) documenting low density lipoprotein cholesterol (LDL-C) reduction while on Praluent therapy

**AND**

3 - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]

**AND**

4 - Not used in combination with Juxtapid (lomitapide)

Product Name:Praluent (Non-72733 labelers)	
Diagnosis	Non-Preferred*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - History of failure to at least THREE preferred alternatives as confirmed by claims history or submission of medical records.* NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure to all of the preferred products.</p>	

**OR**

**2** - History of contraindication or intolerance to THREE preferred alternatives (please specify contraindication or intolerance).\* NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of contraindication or intolerance to all of the preferred products.

Notes	*Reference Non-Preferred Drugs policy. Prior trials of formulary/PDL alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request. PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	---

## 2 . Revision History

Date	Notes
4/30/2024	Updated PDL link

Preferred Non-Solid Dosage Forms



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146840
<b>Guideline Name</b>	Preferred Non-Solid Dosage Forms
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Diagnosis	Requests for Non-Solid Dosage Forms
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Requested drug must be used for an FDA (Food and Drug Administration)-approved indication</p>	

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopeia-National Formulary (USP-NF)

**AND**

**2** - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** The patient is able to swallow a solid dosage form

**AND**

**3.1.2** ONE of the following:

**3.1.2.1** History of failure, contraindication, or intolerance to at least THREE preferred\* solid oral dosage forms (Prior trials of formulary/PDL (preferred drug list) alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request. NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure, contraindication, or intolerance to ALL of the preferred products.)

**OR**

**3.1.2.2** There are no preferred formulary alternatives for the requested drug

**OR**

**3.2** Patient is unable to swallow a solid dosage form

**OR**

**3.3** Patient utilizes a feeding tube for medication administration

**OR**

**3.4** Request is for a nebulized formulation of an inhaled medication for a patient who has an inability to effectively utilize an agent in an inhaler formulation due to neuromuscular or cognitive disability, or other evidence of lack of response to the inhaled formulation supported by clinical documentation

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

## 2 . Revision History

Date	Notes
4/30/2024	Updated PDL link

Pretomanid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146395
<b>Guideline Name</b>	Pretomanid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Pretomanid	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 Diagnosis of pulmonary extensively drug resistant (XDR) tuberculosis (TB)</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2** Treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)

**AND**

**2** - Pretomanid will be used in combination with bedaquiline and linezolid

Prevymis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146619
<b>Guideline Name</b>	Prevymis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Prevymis tabs	
Diagnosis	Cytomegalovirus Prophylaxis
Approval Length	9 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Patient is a recipient of an allogeneic hematopoietic stem cell transplant</p>	

**AND**

**1.2** Patient is cytomegalovirus (CMV)-seropositive

**AND**

**1.3** Provider attests that Prevymsis will be initiated between Day 0 and Day 28 post-transplantation (before or after engraftment) and is being prescribed as prophylaxis and not treatment of CMV infection

**OR**

**2** - ALL of the following:

**2.1** Patient is a recipient of a kidney transplant

**AND**

**2.2** Patient is CMV-seronegative

**AND**

**2.3** Donor is CMV-seropositive

**AND**

**2.4** Provider attests that Prevymsis will be initiated between Day 0 and Day 7 post-transplantation (before or after engraftment) and is being prescribed as prophylaxis and not treatment of CMV infection

Procysbi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146620
<b>Guideline Name</b>	Procysbi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Procysbi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nephropathic cystinosis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is 1 year of age or older

**AND**

**3** - ONE of the following\*:

**3.1** Failure to immediate-release cysteamine bitartrate (generic Cystagon), as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to immediate-release cysteamine bitartrate (generic Cystagon) (please specify intolerance or contraindication)

Notes

\*UHC generally does not consider frequency of dosing and/or lack of compliance to dosing regimens, an indication of medical necessity.

Product Name: Procysbi

Approval Length | 12 month(s)

Therapy Stage | Reauthorization

Guideline Type | Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Procysbi therapy

Progesterone - Non-Oral



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146396
<b>Guideline Name</b>	Progesterone - Non-Oral
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Crinone, Endometrin	
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Treatment is for non-infertility use (e.g., secondary amenorrhea, reduce the risk of recurrent spontaneous preterm birth)</p>	

Progesterone - Oral



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146397
<b>Guideline Name</b>	Progesterone - Oral
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Prometrium, generic progesterone caps	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Amenorrhea</li> <li>Endometrial hyperplasia or prevention of endometrial hyperplasia</li> <li>Abnormal uterine or vaginal bleeding</li> <li>History of preterm birth</li> </ul>	

- Prevention of preterm delivery for current pregnancy

Promacta, Alvaiz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160751
<b>Guideline Name</b>	Promacta, Alvaiz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Promacta, Alvaiz	
Diagnosis	Chronic Immune Thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)</p>	

**AND**

**2** - ONE of the following:

**2.1** Failure to at least ONE of the following as confirmed by claims history or submission of medical records:

- Corticosteroids
- Immunoglobulins
- Splenectomy

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify intolerance or contraindication):

- Corticosteroids
- Immunoglobulins
- Splenectomy

**AND**

**3** - If the request is for Alvaiz, one of the following:

**3.1** Failure to Promacta as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to Promacta (please specify intolerance or contraindication)

**AND**

**4** - If the request is for Promacta powder for oral suspension, ONE of the following:

**4.1** Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following:

- Age
- oral/motor difficulties
- dysphagia

**OR**

**4.2 Patient utilizes a feeding tube for medication administration**

Product Name:Promacta, Alvaiz	
Diagnosis	Chronic Immune Thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Promacta or Alvaiz therapy</p>	

Product Name:Promacta, Alvaiz	
Diagnosis	Chronic Hepatitis C-Associated Thrombocytopenia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C-associated thrombocytopenia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

- Planning to initiate and maintain interferon-based treatment
- Currently receiving interferon-based treatment

**AND**

**3** - If the request is for Alvaiz, one of the following:

**3.1** Failure to Promacta as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to Promacta (please specify intolerance or contraindication)

**AND**

**4** - If the request is for Promacta powder for oral suspension, one of the following:

**4.1** Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following:

- Age
- oral/motor difficulties
- dysphagia

**OR**

**4.2** Patient utilizes a feeding tube for medication administration

Product Name:Promacta, Alvaiz	
Diagnosis	Chronic Hepatitis C-Associated Thrombocytopenia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Promacta or Alvaiz therapy

**AND**

2 - Patient is currently on antiviral interferon therapy for treatment of chronic hepatitis C

Product Name: Promacta, Alvaiz	
Diagnosis	Aplastic Anemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe aplastic anemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Used in combination with standard immunosuppressive therapy [e.g., Atgam (antithymocyte globulin equine), Thymoglobulin (antithymocyte globulin rabbit), cyclosporine]</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of failure, contraindication, or intolerance to at least one course of immunosuppressive therapy [e.g., Atgam (antithymocyte globulin equine), Thymoglobulin (antithymocyte globulin rabbit), cyclosporine]</p>	

**AND**

**3** - If the request is for Alvaiz, one of the following:

**3.1** Failure to Promacta as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to Promacta (please specify intolerance or contraindication)

**AND**

**4** - If the request is for Promacta powder for oral suspension, one of the following:

**4.1** Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following:

- Age
- oral/motor difficulties
- dysphagia

**OR**

**4.2** Patient utilizes a feeding tube for medication administration

Product Name:Promacta, Alvaiz	
Diagnosis	Aplastic Anemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Documentation of positive clinical response to Promacta or Alvaiz therapy

## 2 . Revision History

Date	Notes
11/18/2024	Added non-solid dosage form questions for Promacta packets

Provigil, Nuvigil



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146398
<b>Guideline Name</b>	Provigil, Nuvigil
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Provigil, generic modafinil, Brand Nuvigil, generic armodafinil	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>Narcolepsy</li> <li>Excessive sleepiness due to obstructive sleep apnea</li> <li>Excessive sleepiness due to shift work disorder (circadian rhythm sleep disorder, shift work type)</li> <li>Idiopathic hypersomnia</li> </ul>	

- Diagnosis of multiple sclerosis (MS)
- Diagnosis of major depressive disorder or bipolar depression

Pulmozyme



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146622
<b>Guideline Name</b>	Pulmozyme
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Pulmozyme	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis</p>	

Pyrukynd



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150405
<b>Guideline Name</b>	Pyrukynd
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Pyrukynd Taper Pack, Pyrukynd	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pyruvate kinase (PK) deficiency based on ALL of the following:</p> <p>1.1 Presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 is a missense variant</p>	

**AND**

**1.2** Patient is not homozygous for the c.1436G > A (p.R479H) variant

**AND**

**1.3** Patient does not have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene

**AND**

**2** - Used for the treatment of hemolytic anemia

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** Baseline hemoglobin less than or equal to 10 grams/deciliter (g/dL)

**AND**

**3.1.2** Patient has had no more than 4 transfusions in the previous 52 weeks and no transfusions in the preceding 3-month period

**OR**

**3.2** Patient has had a minimum of 6 transfusion episodes in the preceding 52 weeks

**AND**

**4** - Prescribed by a nephrologist or hematologist

Product Name:Pyrukynd Taper Pack, Pyrukynd	
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following*:</p> <p>1.1 Documentation of positive clinical response to Pyrukynd therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Prescribed by, or in consultation with, a nephrologist or hematologist</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Documentation does not provide evidence of positive clinical response to Pyrukynd therapy, allow for dose titration with discontinuation of therapy**</p>	
Notes	<p>*If criteria is met under step 1, authorization length is 12 months.                  **If criteria is met under step 2, authorization length is 4 weeks.</p>

## 2 . Revision History

Date	Notes
7/24/2024	Updated initial approval duration from 6 months to 12 months. Simplified reauthorization criteria.

Qbrexza



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146399
<b>Guideline Name</b>	Qbrexza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Qbrexza	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary axillary hyperhidrosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

**2.1** Failure to Xerac-AC as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to Xerac-AC (please specify contraindication or intolerance)

Qinlock



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154753
<b>Guideline Name</b>	Qinlock
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Qinlock	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of gastrointestinal stromal tumor (GIST)</p>	

**AND**

**2 - ONE of the following:**

- Gross residual disease (R2 resection)
- Unresectable primary disease
- Tumor rupture
- Recurrent/Metastatic

**AND**

**3 - ONE of the following:**

**3.1** History of failure to ALL of the following as confirmed by claims history or submission of medical records:

- imatinib (generic Gleevec)
- sunitinib (generic Sutent)
- regorafenib (generic Stivarga)

**OR**

**3.2** ALL of the following:

**3.2.1** Performance status 0-2

**AND**

**3.2.2** History of progression on imatinib (Gleevec) as confirmed by claims history or submission of medical records

**AND**

**3.2.3** History of intolerance to sunitinib (Sutent) (please specify intolerance) as confirmed by claims history or submission of medical records

**OR**

**3.3** ALL of the following:

**3.3.1** PDGFRA exon 18 mutations that are insensitive to imatinib (Gleevec) (including PDGFRA D842V)

**AND**

**3.3.2** History of progression on avapritinib (Ayvakit) as confirmed by claims history or submission of medical records

**AND**

**3.3.3** History of progression on dasatinib (Sprycel) as confirmed by claims history or submission of medical records

Product Name:Qinlock	
Diagnosis	Cutaneous Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cutaneous melanoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is unresectable or metastatic</p>	

<b>AND</b>
<b>3</b> - Disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy
<b>AND</b>
<b>4</b> - Positive for activating mutations of KIT

Product Name:Qinlock	
Diagnosis	Gastrointestinal Stromal Tumor (GIST), Cutaneous Melanoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Qinlock therapy</p>	

Product Name:Qinlock	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Qinlock	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Qinlock therapy</p>	

Qlosi, Vuity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208219
<b>Guideline Name</b>	Qlosi, Vuity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vuity	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of presbyopia

**AND**

2 - Patient is between the ages of 40 to 55

**AND**

3 - Patient is unable to use corrective lenses (e.g., glasses, contacts) (document medical rationale why patient is unable to use corrective lenses)

**AND**

4 - Prescribed by ONE of the following:

- Optometrist
- Ophthalmologist

Product Name:Vuity	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p>	

2 - Age less than 55

**AND**

3 - Prescribed by ONE of the following:

- Optometrist
- Ophthalmologist

Product Name: Qlosi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of presbyopia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is between the ages of 45 to 64</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is unable to use corrective lenses (e.g., glasses, contacts) (document medical rationale why patient is unable to use corrective lenses)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Optometrist</li> </ul>	

- Ophthalmologist

Product Name:Qlosi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Age less than 64</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Optometrist</li> <li>• Ophthalmologist</li> </ul>	

## 2 . Revision History

Date	Notes
3/5/2025	Updated formularies. Updated GPIs

Quantity Limits



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146401
<b>Guideline Name</b>	Quantity Limits
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Quantity Limit, Prescription Limit	
Diagnosis	Quantity limit review (General)
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 The requested drug must be used for an FDA (Food and Drug Administration)-approved indication</p>	

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**2** - ONE of the following:

**2.1** The drug is being prescribed within the manufacturer's published dosing guidelines

**OR**

**2.2** The request falls within dosing guidelines found in ONE of the following compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**3** - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation.

**AND**

**4** - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program.

Product Name:Quantity Limit, Prescription Limit	
Diagnosis	Quantity limit review for the treatment of gender dysphoria*
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p><b>1</b> - The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:</p> <ul style="list-style-type: none"> <li>• American Hospital Formulary Service Drug Information</li> <li>• National Comprehensive Cancer Network Drugs and Biologics Compendium</li> <li>• Thomson Micromedex DrugDex</li> <li>• Clinical pharmacology</li> <li>• United States Pharmacopoeia-National Formulary (USP-NF)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The drug is being prescribed for an indication that is recognized as a covered benefit by the applicable health plans' program.</p>	
Notes	* If the above criteria are not met, then refer for clinical review by an appropriate trained professional (physician or pharmacist) based on the applicable regulatory requirement.

Product Name:Quantity Limit, Prescription Limit	
Diagnosis	Monthly prescription limit review for migraine therapy, benzodiazepines, or muscle relaxants
Approval Length	1 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p><b>1</b> - Medical necessity rationale provided for why the member requires 5 or more fills of the same drug or drug class within a month.</p>	
Notes	*If deemed medically necessary, longer authorization duration is permitted

Product Name:Quantity Limit, Prescription Limit	
Diagnosis	Topical products exceeding the allowable package size per fill OR the allowable quantity per month
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - The physician attests that a larger quantity is needed for treatment of a larger surface area.</p>	

Radicava ORS



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155393
<b>Guideline Name</b>	Radicava ORS
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Radicava ORS	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p><b>1.1</b> Patient has been established on therapy with Radicava for amyotrophic lateral sclerosis (ALS) under an active UnitedHealthcare medical benefit prior authorization</p>	

**AND**

**1.2** ALL of the following:

**1.2.1** Diagnosis of “definite” or “probable” ALS per the El Escorial/revised Airlie House diagnostic criteria

**AND**

**1.2.2** Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis of ALS

**AND**

**1.2.3** Patient is currently receiving Radicava therapy

**AND**

**1.2.4** Patient is not dependent on invasive ventilation or tracheostomy

**OR**

**2** - ALL of the following:

**2.1** Submission of medical records (e.g., chart notes, previous medical history, diagnostic testing including: imaging, nerve conduction studies, laboratory values) to support the diagnosis of “definite” or “probable” ALS per the El Escorial/revised Airlie House diagnostic criteria

**AND**

**2.2** Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis of ALS

**AND**

**2.3** Submission of the most recent ALS Functional Rating Scale-Revised (ALSFRS-R) score confirming that the patient has scores greater than or equal to 2 in all items of the ALSFRS-R criteria at the start of treatment

**AND**

**2.4** Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a % forced vital capacity (%FVC) greater than or equal to 80% at the start of treatment

Product Name:Radicava ORS	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of “definite” or “probable” amyotrophic lateral sclerosis (ALS) per the El Escorial/revised Airlie House diagnostic criteria</p> <p><b>AND</b></p> <p><b>2</b> - Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis of ALS</p> <p><b>AND</b></p> <p><b>3</b> - Patient is currently receiving Radicava ORS therapy</p> <p><b>AND</b></p> <p><b>4</b> - Patient is not dependent on invasive ventilation or tracheostomy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
9/20/2024	Clarified criteria for existing prior authorization to be under the medical benefit. Updated initial and reauth durations to 12 months.

Ravicti



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146626
<b>Guideline Name</b>	Ravicti
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Ravicti	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of urea cycle disorders (UCDs)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Inadequate response to ONE of the following:

- Dietary protein restriction
- Amino acid supplementation

**AND**

**3** - Will be used concomitantly with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements)

**AND**

**4** - ONE of the following:

**4.1** Failure to sodium phenylbutyrate (Buphenyl) as confirmed by claims history or submission of medical records\*

**OR**

**4.2** History of intolerance or contraindication to sodium phenylbutyrate (Buphenyl) (please specify contraindication or intolerance)\*

Notes	*UHC generally does not consider frequency of dosing and/or lack of compliance to dosing regimens an indication of medical necessity
-------	--

Product Name: Ravicti	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Ravicti therapy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is actively on dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements)

Rayos



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146402
<b>Guideline Name</b>	Rayos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Rayos	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Rayos must be used for a Food and Drug Administration (FDA)-approved indication</p> <p style="text-align: center;"><b>OR</b></p>	

**1.2** The intended use of Rayos is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**2** - Rayos is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting an intolerance to generic prednisone tablets which is unable to be resolved with attempts to minimize the adverse effects where appropriate

**AND**

**4** - ONE of the following:

**4.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- Dexamethasone tablet/oral solution
- Hydrocortisone tablet
- Methylprednisolone tablet
- Prednisolone tablet/oral solution

**OR**

**4.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Dexamethasone tablet/oral solution
- Hydrocortisone tablet
- Methylprednisolone tablet

- Prednisolone tablet/oral solution

Rectiv



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161192
<b>Guideline Name</b>	Rectiv
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Rectiv ointment, generic nitroglycerin ointment	
Diagnosis	Pain Associated with Chronic Anal Fissures
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe pain associated with chronic anal fissures</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
11/22/2024	Added generic Nitroglycerin ointment.

Regranex



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146404
<b>Guideline Name</b>	Regranex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Regranex	
Approval Length	6 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a lower extremity diabetic neuropathic ulcer</p>	

Relistor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146405
<b>Guideline Name</b>	Relistor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Relistor Injection	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation (e.g. chart notes) demonstrating a diagnosis of opioid induced constipation in a patient with advanced illness receiving palliative care</p>	

**OR**

**2** - Documentation (e.g. chart notes) demonstrating BOTH of the following:

**2.1** ONE of the following:

**2.1.1** Diagnosis of opioid induced constipation with chronic, non-cancer pain

**OR**

**2.1.2** Diagnosis of opioid induced constipation in patients with chronic pain related to prior cancer diagnosis or cancer treatment who do not require frequent (e.g., weekly) opioid dosage escalation

**AND**

**2.2** ONE of the following:

**2.2.1** The patient is not able to swallow oral medications

**OR**

**2.2.2** ALL of the following:

**2.2.2.1** ONE of the following:

**2.2.2.1.1** Failure to ONE of the following as confirmed by claims history or submitted medical records

- Lactulose
- Polyethylene glycol (Miralex)

**OR**

**2.2.2.1.2** History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication)

- Lactulose

- Polyethylene glycol (Miralex)

**AND**

**2.2.2.2** ONE of the following:

**2.2.2.2.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**2.2.2.2.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**AND**

**2.2.2.3** ONE of the following:

**2.2.2.3.1** Failure to Movantik as confirmed by claims history or submitted medical records

**OR**

**2.2.2.3.2** History of contraindication or intolerance to Movantik (please specify intolerance or contraindication)

Product Name:Relistor Injection	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Relistor Injection therapy	

Product Name:Relistor tablet	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Diagnosis of opioid induced constipation with chronic, non-cancer pain</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 Diagnosis of opioid induced constipation in patients with chronic pain related to prior cancer diagnosis or cancer treatment who do not require frequent (e.g., weekly) opioid dosage escalation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ALL of the following:</p> <p>2.1 ONE of the following:</p> <p>2.1.1 Failure to ONE of the following as confirmed by claims history or submitted medical records</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralex)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.1.2 History of contraindication or intolerance to BOTH of the following (please specify intolerance or contraindication)</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralex)</li> </ul>	

**AND**

**2.2** ONE of the following:

**2.2.1** Failure to lubiprostone (generic of Amitiza) as confirmed by claims history or submission of medical records

**OR**

**2.2.2** History of intolerance or contraindication to lubiprostone (generic of Amitiza) (please specify intolerance or contraindication)

**AND**

**2.3** ONE of the following:

**2.3.1** Failure to Movantik as confirmed by claims history or submitted medical records

**OR**

**2.3.2** History of contraindication or intolerance to Movantik (please specify intolerance or contraindication)

Product Name:Relistor tablet	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Relistor Tablet therapy	

Relyvrio



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-210215
<b>Guideline Name</b>	Relyvrio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Relyvrio	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, previous medical history, diagnostic testing including: imaging, nerve conduction studies, laboratory values) to support the diagnosis of amyotrophic lateral sclerosis (ALS)

**AND**

2 - Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis of ALS

**AND**

3 - Provider attestation that the patient's baseline functional ability has been documented prior to initiating treatment (e.g., speech, walking, climbing stairs, etc.)

**AND**

4 - Patient is not dependent on invasive ventilation or tracheostomy

Product Name:Relyvrio	
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of amyotrophic lateral sclerosis (ALS)

**AND**

2 - Prescribed by, or in consultation with, a neurologist with expertise in the diagnosis of ALS

**AND**

**3** - Patient is currently receiving Relyvrio therapy

**AND**

**4** - Provider attestation that the patient has slowed disease progression from baseline

**AND**

**5** - Patient is not dependent on invasive ventilation or tracheostomy

## 2 . Revision History

Date	Notes
3/6/2025	Removing PA CAID for 4/1/25, no replacement, set to default. No change to clinical criteria.

Repatha



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146407
<b>Guideline Name</b>	Repatha
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Repatha	
Diagnosis	Primary Hyperlipidemia (including heterozygous familial hypercholesterolemia) and ASCVD
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p>	

**1.1** Heterozygous familial hypercholesterolemia (HeFH) as confirmed by ONE of the following:

**1.1.1** BOTH of the following:

**1.1.1.1** Pre-treatment LDL-C (low-density lipoprotein cholesterol) is ONE of the following:

- Greater than or equal to 190 milligrams/deciliter (mg/dL)
- Greater than or equal to 155 mg/dL if less than 16 years of age

**AND**

**1.1.1.2** ONE of the following:

- Family history of myocardial infarction in first-degree relative less than 60 years of age
- Family history of myocardial infarction in second-degree relative less than 50 years of age
- Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative
- Family history of heterozygous or homozygous familial hypercholesterolemia in first- or second-degree relative
- Family history of tendinous xanthomata and/or arcus cornealis in first- or second-degree relative

**OR**

**1.1.2** BOTH of the following:

**1.1.2.1** Pre-treatment LDL-C is ONE of the following:

- Greater than or equal to 190 mg/dL
- Greater than or equal to 155 mg/dL if less than 16 years of age

**AND**

**1.1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

- Functional mutation in LDL (low-density lipoprotein), apoB (Apolipoprotein B), or PCSK9 (Proprotein convertase subtilisin/kexin type 9) gene
- Tendinous xanthomata
- Arcus cornealis before age 45

**OR**

**1.2** Atherosclerotic cardiovascular disease (ASCVD) as confirmed by ONE of the following:

- Acute coronary syndromes
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

**OR**

**1.3** Primary hyperlipidemia with pre-treatment LDL-C greater than or equal to 190 mg/dL

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**2.1** Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy (i.e., atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and will continue to receive high-intensity statin at maximally tolerated dose

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms:

- Myalgia [muscle symptoms without creatine kinase (CK) elevations]
- Myositis [muscle symptoms with CK elevations less than 10 times upper limit of normal (ULN)]

**AND**

**2.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity or moderate-intensity statin therapy [i.e., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 10 mg, pravastatin greater than or equal to 10 mg, lovastatin 20-40 mg, fluvastatin XL 80 mg, fluvastatin 20-40 mg up to 40 mg twice daily or Livalo (pitavastatin) greater than or equal to 1 mg] and will continue to receive a low-intensity or moderate-intensity statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low- or moderate-, and high-intensity statins as evidenced by ONE of the following:

**2.3.1** ONE of the following intolerable and persistent (i.e., more than 2 weeks) symptoms for low- or moderate-, and high-intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis [muscle symptoms with CK elevations less than 10 times upper limit of normal (ULN)]

**OR**

**2.3.2** Patient has a labeled contraindication to all statins as confirmed by medical records

**OR**

**2.3.3** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days or 120 days prior to starting PCSK9 inhibitor therapy:

- LDL-C greater than or equal to 100 mg/dL with ASCVD
- LDL-C greater than or equal to 130 mg/dL without ASCVD

**OR**

**3.2 BOTH** of the following:

**3.2.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days or 120 days prior to starting PCSK9 inhibitor therapy:

- LDL-C between 55 mg/dL and 99 mg/dL with ASCVD
- LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

**AND**

**3.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**3.2.2.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**3.2.2.2** Patient has a history of contraindication or intolerance to ezetimibe (please specify intolerance or contraindication)

**AND**

**4** - Patient has received comprehensive counseling regarding appropriate diet

**AND**

**5** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**6** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab)]

**AND**

**7** - Not used in combination with Leqvio (inclisiran)

Product Name: Repatha	
Diagnosis	Primary Hyperlipidemia (including heterozygous familial hypercholesterolemia) and ASCVD
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Cardiologist</li> <li>• Endocrinologist</li> <li>• Lipid specialist</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Submission of medical records (e.g. chart notes, laboratory values) documenting LDL-C (low-density lipoprotein cholesterol) reduction while on Repatha therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab)]</p>	

**AND**

**4** - Not used in combination with Leqvio (inclisiran)

Product Name: Repatha	
Diagnosis	Homozygous Familial Hypercholesterolemia (HoFH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:</p> <p><b>1.1</b> Genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> BOTH of the following:</p> <p><b>1.2.1</b> Pre-treatment LDL-C (low-density lipoprotein cholesterol) greater than 400 mg/dL (milligrams/deciliter)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Xanthoma before 10 years of age</li> <li>• Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has received comprehensive counseling regarding appropriate diet

**AND**

**3** - Patient is receiving other lipid-lowering therapy confirmed by claims history or submitted medical records (e.g., statin, ezetimibe, LDL apheresis)

**AND**

**4** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab)]

**AND**

**6** - Not used in combination with Juxtapid (lomitapide)

Product Name: Repatha	
Diagnosis	Homozygous Familial Hypercholesterolemia (HoFH)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Submission of medical records (e.g., chart notes, laboratory values) documenting LDL-C (low-density lipoprotein cholesterol) reduction while on Repatha therapy	

**AND**

**2** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid Specialist

**AND**

**3** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Praluent (alirocumab)]

**AND**

**4** - Not used in combination with Juxtapid (lomitapide)

Repository Corticotropins



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146628
<b>Guideline Name</b>	Repository Corticotropins
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Acthar, Cortrophin	
Diagnosis	Infantile spasm (i.e., West Syndrome)*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of infantile spasms (i.e., West Syndrome)*</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is less than 2 years old

**AND**

**3** - Both of following:

**3.1** Initial dose: 75 U/m<sup>2</sup> (units/square meters) intramuscular (IM) twice daily for 2 weeks

**AND**

**3.2** After 2 weeks, dose should be tapered according to the following schedule: 30 U/m<sup>2</sup> IM in the morning for 3 days; 15 U/m<sup>2</sup> IM in the morning for 3 days; 10 U/m<sup>2</sup> IM in the morning for 3 days; 10 U/m<sup>2</sup> IM every other morning for 6 days (3 doses)

Notes	*Acthar gel and Cortrophin gel are not medically necessary for treatment of acute exacerbations of multiple sclerosis. See Background for more information.
-------	---

Product Name: Acthar, Cortrophin	
Diagnosis	Opsoclonus-myooclonus syndrome (i.e., OMS, Kinsbourne Syndrome)*
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of opsoclonus-myooclonus syndrome (i.e., OMS, Kinsbourne Syndrome)*</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for Acthar gel, provider submits documentation of reason or special circumstance patient cannot use Cortrophin Gel</p>	
Notes	*Acthar gel and Cortrophin gel are not medically necessary for treatment of acute exacerbations of multiple sclerosis. See Background for more information.

## 2 . Background

### Benefit/Coverage/Program Information

#### More Information:

The Acthar Gel and Purified Cortrophin Gel package inserts have listed other conditions in which it may be used. UHCP has determined that use of Acthar Gel and Purified Cortrophin Gel is not medically necessary for treatment of the following disorders and diseases: multiple sclerosis; rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.

Retevmo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164069
<b>Guideline Name</b>	Retevmo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Retevmo	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is ONE of the following:

- Recurrent
- Advanced
- Metastatic

**AND**

**3** - Presence of RET gene fusion-positive or RET rearrangement positive tumors

Product Name:Retevmo	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - All of the following:</p> <p><b>1.1</b> Diagnosis of medullary thyroid cancer (MTC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Advanced</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>AND</b></p>	

**1.3** Disease has presence of RET gene mutation

**AND**

**1.4** Disease requires treatment with systemic therapy

**OR**

**2** - All of the following:

**2.1** Diagnosis of thyroid cancer

**AND**

**2.2** Disease is one of the following:

- Advanced
- Metastatic

**AND**

**2.3** Disease is RET gene fusion-positive

**AND**

**2.4** Disease requires treatment with systemic therapy

**AND**

**2.5** One of the following:

- Patient is radioactive iodine-refractory
- Treatment with radioactive iodine is not appropriate

Product Name:Retevmo	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following histiocytic neoplasms:</p> <ul style="list-style-type: none"> <li>• Langerhans Cell Histiocytosis</li> <li>• Erdheim-Chester disease</li> <li>• Rosai-Dorfman disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used for RET fusion target as a single agent</p>	

Product Name:Retevmo	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Presence of RET gene fusion-positive solid tumor</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is one of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent</li> <li>• Advanced</li> </ul>	

- Metastatic

Product Name:Retevmo	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Histiocytic Neoplasms, Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Retevmo therapy</p>	

Product Name:Retevmo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Retevmo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Retevmo therapy

Revlimid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151139
<b>Guideline Name</b>	Revlimid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/7/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Revlimid, generic lenalidomide	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of multiple myeloma</p>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Myelodysplastic Syndromes (MDS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of symptomatic anemia due to myelodysplastic syndrome (MDS) associated with a deletion 5q</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p> <p>2.1 Patient has a diagnosis of symptomatic anemia due to myelodysplastic syndrome (MDS) WITHOUT deletion 5q</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2 ONE of the following:</p> <p>2.2.1 ALL of the following:</p> <p>2.2.1.1 Serum erythropoietin levels less than or equal to 500 mU/mL</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2.1.2 One of the following:</p> <ul style="list-style-type: none"> <li>• Ring sideroblasts &lt; 15%</li> <li>• Ring sideroblasts &lt; 5% with an SF3B1 mutation</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2.2.1.3 History of failure, contraindication or intolerance to one of the following:</p>	

- Erythropoietin stimulating agent (ESA) [e.g., Epogen, Procrit, Retacrit (epoetin alfa)] or darbepoetin alfa
- Reblozyl (luspatercept-aamt)

**AND**

**2.2.1.4** Used in combination with an erythropoietin stimulating agent (ESA) [e.g., Epogen, Procrit, Retacrit (epoetin alfa)] or darbepoetin alfa

**OR**

**2.2.2** ALL of the following:

**2.2.2.1** Serum erythropoietin levels less than or equal to 500 mU/mL

**AND**

**2.2.2.2** One of the following:

- Ring sideroblasts  $\geq$  15%
- Ring sideroblasts  $\geq$  5% with an SF3B1 mutation

**AND**

**2.2.2.3** History of failure, contraindication or intolerance to both of the following:

- Erythropoietin stimulating agent (ESA) [e.g., Epogen, Procrit, Retacrit (epoetin alfa)] or darbepoetin alfa
- Reblozyl (luspatercept-aamt)

**OR**

**2.2.3** All of the following:

**2.2.3.1** Serum erythropoietin levels  $>$  500 mU/mL

**AND**

**2.2.3.2** One of the following:

- Ring sideroblasts < 15%
- Ring sideroblasts < 5% with an SF3B1 mutation

**AND**

**2.2.3.3** One of the following:

- Poor probability to respond to immunosuppressive therapy (e.g., azacitidine, decitabine)
- History of failure, contraindication, or intolerance to immunosuppressive therapy (e.g., azacitidine, decitabine)

**OR**

**2.2.4** All of the following:

**2.2.4.1** Serum erythropoetin levels > 500 mU/mL

**AND**

**2.2.4.2** One of the following:

- Ring sideroblasts ≥ 15%
- Ring sideroblasts ≥ 5% with an SF3B1 mutation

**AND**

**2.2.4.3** History of failure, contraindication or intolerance to Reblozyl (luspatercept-aamt)

**OR**

**3 - BOTH of the following:**

**3.1** Diagnosis of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) overlap neoplasm

**AND**

**3.2** One of the following:

- Patient has SF3B1 mutation and thrombocytosis
- Patient has ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	B-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Mantle cell lymphoma (MCL)</li> <li>• Extranodal marginal zone lymphoma of nongastric sites (noncutaneous)</li> <li>• Extranodal marginal zone lymphoma (EMZL) of the stomach</li> <li>• Classic follicular lymphoma</li> <li>• Nodal marginal zone lymphoma</li> <li>• Splenic marginal zone lymphoma</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2 - BOTH of the following:</b></p> <p><b>2.1 ONE of the following diagnoses:</b></p> <ul style="list-style-type: none"> <li>• HIV-related B-cell lymphoma</li> <li>• Diffuse large B-cell lymphoma</li> </ul>	

- High-grade B-cell lymphoma
- Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma
- Post-transplant lymphoproliferative disorders

**AND**

**2.2** Used as second line or subsequent therapy

Product Name:Brand Revlimid, generic lenalidomide	
Diagnosis	Hodgkin Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of Hodgkin lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is refractory to at least 3 prior lines of therapy</p>	

Product Name:Brand Revlimid, generic lenalidomide	
Diagnosis	Systemic Light Chain Amyloidosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of systemic light chain amyloidosis</p>	

**AND**

**2** - Used in combination with ONE of the following:

- Dexamethasone
- Dexamethasone and cyclophosphamide
- Dexamethasone and Ninlaro® (ixazomib)

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has a diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is relapsed or refractory</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Used after prior therapy with Bruton Tyrosine Kinase (BTK) inhibitor and venetoclax-based regimens</p>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	T-Cell Lymphomas
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Peripheral T-cell lymphoma</li> <li>• T-cell leukemia/lymphoma</li> <li>• Hepatosplenic gamma-delta T-cell lymphoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as second-line or subsequent therapy</p>	

Product Name:Brand Revlimid, generic lenalidomide	
Diagnosis	Primary CNS Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of primary central nervous system lymphoma</p>	

Product Name:Brand Revlimid, generic lenalidomide	
Diagnosis	Kaposi Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - BOTH of the following:

1.1 ONE of the following:

1.1.1 Patient has a diagnosis of human immunodeficiency virus (HIV)-negative Kaposi Sarcoma

**OR**

1.1.2 BOTH of the following:

1.1.2.1 Diagnosis of HIV-related Kaposi Sarcoma

**AND**

1.1.2.2 Patient is currently being treated with antiretroviral therapy (ART) confirmed by claims history or submission of medical records

**AND**

1.2 Disease has progressed or not responded to two different systemic first-line systemic therapies (e.g., liposomal doxorubicin, sirolimus, paclitaxel)

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Langerhans Cell Histiocytosis, Rosai-Dorfman disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Langerhans cell histiocytosis</li> </ul>	

- Rosai-Dorfman disease

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Multicentric Castleman Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of multicentric castleman disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - One of the following:</p> <ul style="list-style-type: none"> <li>• Progressed following treatment of relapsed/refractory disease</li> <li>• Considered progressive disease</li> </ul>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	*
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Revlimid therapy</p>	
Notes	*Multiple Myeloma, Myelodysplastic Syndromes (MDS), B-Cell Lymphomas, Hodgkin Lymphoma, Systemic Light Chain Amyloidosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, T-Cell Lymphomas, Primary CNS Lymphomas, Kaposi Sarcoma, Langerhans Cell

	Histiocytosis, Rosai-Dorfman disease, Multicentric Castleman Disease
--	--

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Myelofibrosis-Associated Anemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of myelofibrosis-associated anemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Presence of del(5q) mutation</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - No symptomatic splenomegaly and/or constitutional symptoms</p>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	Myelofibrosis-Associated Anemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response while on Revlimid</p>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Revlimid will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Brand Revlimid, generic lenalidomide	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Revlimid therapy</p>	

Revuforj



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-202195
<b>Guideline Name</b>	Revuforj
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Revuforj	
Diagnosis	Acute Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is relapsed or refractory</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Positive for lysine methyltransferase 2A gene (KMT2A) translocation</p>	

Product Name: Revuforj	
Diagnosis	Acute Leukemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Revuforj therapy</p>	

Product Name: Revuforj	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Revuforj	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Revuforj therapy</p>	

**2 . Revision History**

Date	Notes
2/26/2025	New program.

Reyvow



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206577
<b>Guideline Name</b>	Reyvow
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Reyvow	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Used for acute treatment of migraine

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - ONE of the following:

**3.1** Failure (after at least 3 migraine episodes and a minimum of a 30-day trial), to BOTH of the following as confirmed by claims history or submission of medical records:

**3.1.1** TWO of the following:

- eletriptan (generic Relpax)
- naratriptan (generic Amerge)
- rizatriptan (generic Maxalt/Maxalt MLT)
- sumatriptan (generic Imitrex)
- zolmitriptan (generic Zomig)

**AND**

**3.1.2** ONE of the following:

- Nurtec ODT
- Ubrelvy

**OR**

**3.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- eletriptan (generic Relpax)
- naratriptan (generic Amerge)
- rizatriptan (generic Maxalt/Maxalt MLT)
- sumatriptan (generic Imitrex)
- zolmitriptan (generic Zomig)
- Nurtec ODT

- Ubrelvy

**AND**

**4** - Prescribed by or in consultation with ONE of the following specialists with expertise in the acute treatment of migraine:

- Neurologist
- Pain Specialist
- Headache Specialist [Headache specialists are physicians certified by the United Council for Neurologic Subspecialties (UCNS)]

**AND**

**5** - Prescriber attests to BOTH of the following:

**5.1** Patient has been informed the use of Reyvow may result in significant CNS (central nervous system) impairment, and may impact the patient's ability to drive or operate machinery for 8 hours after each dose

**AND**

**5.2** If used concurrently with a benzodiazepine or other drugs that could potentially cause CNS depression, the prescriber has acknowledged that they have completed an assessment of increased risk for sedation and other cognitive and/or neuropsychiatric adverse events

**AND**

**6** - ONE of the following:

**6.1** Patient is currently treated with ONE of the following prophylactic therapies:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan (generic Atacand)\*
- A calcitonin gene-related peptide receptor (CGRP) antagonist for preventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy (fremanezumab)\*, Emgality (galcanezumab), Nurtec ODT, Qulipta\*, Vyepti (eptinezumab-jjmr)\*\*]\*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]

- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**OR**

**6.2** Patient has less than 4 migraine days per month

**OR**

**6.3** Patient has greater than or equal to 4 migraine days per month and has contraindication or intolerance to TWO of the following prophylactic therapies:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan (generic Atacand)\*
- A calcitonin gene-related peptide receptor (CGRP) antagonist for preventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy (fremanezumab)\*, Emgality (galcanezumab), Nurtec ODT, Qulipta\*, Vyepti (eptinezumab-jjmr)\*\*]\*\*\*
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

Notes	<p>*Timolol, candesartan, Ajovy, and Qulipta are non-preferred and should not be included in denial to provider.</p> <p>**Vyepti and OnabotulinumtoxinA (generic Botox) are medical benefit, should not be included in denial to provider.</p> <p>***CGRP antagonists for preventive treatment of migraines require a prior authorization.</p>
-------	--

Product Name:Reyvow	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

## 2 . Revision History

Date	Notes
3/4/2025	Updated formularies. Added eletriptan and zolmitriptan as step therapy option. Updated prophylactic therapy requirements

Rezdiffra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-195187
<b>Guideline Name</b>	Rezdiffra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Rezdiffra	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) [formerly known as nonalcoholic steatohepatitis (NASH)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is fibrosis stage F2 or F3 as confirmed by ONE of the following:</p> <p><b>2.1</b> Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) (e.g., FibroScan)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> LSM by magnetic resonance elastography (MRE)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.3</b> Liver biopsy within the past 12 months</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has received comprehensive counseling regarding lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by or in consultation with a gastroenterologist or hepatologist</p>	

Product Name: Rezdifra	
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rezdiffra therapy (e.g., improvement in or stabilization of fibrosis)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has NOT progressed to cirrhosis</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a gastroenterologist or hepatologist</p>	

## 2 . Revision History

Date	Notes
2/24/2025	Combined formularies. Revised initial auth criteria for confirming fibrosis stage F2 or F3. Added criterion to reauth section that patient has not progressed to cirrhosis.

Rezlidhia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146631
<b>Guideline Name</b>	Rezlidhia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Rezlidhia	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia (AML)</p>	

<b>AND</b>
<b>2</b> - Positive for a susceptible isocitrate dehydrogenase-1 (IDH1) mutation (e.g., R132C, R132H, R132G, R132S, R132L)
<b>AND</b>
<b>3</b> - Disease is relapsed or refractory

<b>Product Name:Rezlidhia</b>	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Rezlidhia therapy	

<b>Product Name:Rezlidhia</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

Product Name:Rezlidhia	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rezlidhia therapy</p>	

Rezurock



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157766
<b>Guideline Name</b>	Rezurock
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Rezurock	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic graft-versus-host disease (chronic GVHD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - History of failure of at least TWO prior lines of systemic therapy (e.g., corticosteroids, mycophenolate, tacrolimus, etc.) confirmed by claims history or submitted medical records

Product Name:Rezurock	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rezurock therapy</p>	

## 2 . Revision History

Date	Notes
10/21/2024	Removed age requirement in initial auth section.

Rinvoq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206574
<b>Guideline Name</b>	Rinvoq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Rinvoq	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

2 - ONE of the following:

2.1 ALL of the following:

2.1.1 ONE of the following:

2.1.1.1 Failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses as confirmed by claims history or submission of medical records

**OR**

2.1.1.2 History of intolerance or contraindication to ONE non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) (please specify intolerance or contraindication)

**OR**

2.1.1.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Orencia (abatacept), Olumiant (baricitinib), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

2.1.2 ONE of the following:

2.1.2.1 Failure to ALL of the following as confirmed by claims history or submission of medical records:

- Enbrel (etanercept)

- One of the preferred adalimumab products\*
- Tyenne (tocilizumab-aazg)

**OR**

**2.1.2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Enbrel (etanercept)
- One of the preferred adalimumab products\*
- Tyenne (tocilizumab-aazg)

**OR**

**2.1.2.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**2.1.3** ONE of the following:

**2.1.3.1** Failure to Olumiant as confirmed by claims history or submission of medical records

**OR**

**2.1.3.2** History of contraindication or intolerance to Olumiant (please specify contraindication or intolerance)

**OR**

**2.2** Patient is currently on Rinvoq therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

Notes

\*See Table 2 in Background for PDL links.

Product Name: Rinvoq, Rinvoq LQ

Diagnosis Psoriatic Arthritis (PsA)

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of active psoriatic arthritis

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** ONE of the following:

**2.1.1.1** Failure to a 3 month trial of methotrexate at maximally indicated dose as confirmed by claims history or submission of medical records

**OR**

**2.1.1.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**2.1.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Cosentyx (secukinumab), Taltz (ixekizumab), Olumiant (baricitinib), Otezla (apremilast), Skyrizi (risankizumab-rzaa)]

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** BOTH of the following:

**2.1.2.1.1** ONE of the following:

**2.1.2.1.1.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**2.1.2.1.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**2.1.2.1.2** ONE of the following:

**2.1.2.1.2.1** Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records

**OR**

**2.1.2.1.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**OR**

**2.1.2.2** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**OR**

**2.2** Patient is currently on Rinvoq or Rinvoq LQ therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Rinvoq or Rinvoq LQ in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Rheumatologist

<ul style="list-style-type: none"> <li>• Dermatologist</li> </ul>	
Notes	*See Table 2 in Background for PDL links.

Product Name: Rinvoq	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate-to-severe chronic atopic dermatitis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 BOTH of the following:</p> <p>2.1.1 ONE of the following:</p> <p>2.1.1.1 Failure to TWO of the following therapeutic classes of topical therapies, as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• One medium to very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)</li> <li>• One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]</li> <li>• Eucrisa (crisaborole)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.1.1.2 History of intolerance or contraindication to ALL of the following therapeutic classes of topical therapies (please specify intolerance or contraindication):</p>	

- One medium to very-high potency topical corticosteroid [e.g., mometasone furoate (generic Elocon), fluocinolone acetonide (generic Synalar), fluocinonide (generic Lidex)] (see Table 1 in Background)
- One topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]
- Eucrisa (crisaborole)

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** BOTH of the following:

**2.1.2.1.1** Submission of medical records (e.g., chart notes, laboratory values) documenting a 3 month trial of a systemic drug product for the treatment of atopic dermatitis [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab), cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, etc.]

**AND**

**2.1.2.1.2** Physician attests that the patient was not adequately controlled with the documented systemic drug product

**OR**

**2.1.2.2** Physician attests that systemic treatment with BOTH of the following FDA (Food and Drug Administration)-approved atopic dermatitis therapy is inadvisable (document drug and contraindication rationale):

- Adbry (tralokinumab-ldrm)
- Dupixent (dupilumab)

**OR**

**2.1.2.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure [refer to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-V-TR) 300.29 for specific phobia diagnostic criteria]

**OR**

**2.2** Patient is currently on Rinvoq therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Cibinqo (abrocitinib), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura (topical ruxolitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist
- Immunologist

Product Name:Rinvoq	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of moderately to severely active ulcerative colitis (UC)	

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** ONE of the following:

**2.1.1.1** Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine)

**OR**

**2.1.1.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), ustekinumab, Xeljanz/XR (tofacitinib)]

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**2.1.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication)

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**2.1.2.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**OR**

**2.2** Patient is currently on Rinvoq therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), ustekinumab, Skyrizi (risankizumab)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Notes	*See Table 2 in Background for PDL links.
-------	---

Product Name:Rinvoq	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> Diagnosis of active ankylosing spondylitis</p>	

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records

**OR**

**1.2.2** History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**1.3** ONE of the following:

**1.3.1** BOTH of the following:

**1.3.1.1** ONE of the following:

**1.3.1.1.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

**OR**

**1.3.1.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

**AND**

**1.3.1.2** ONE of the following:

**1.3.1.2.1** Failure to Cosentyx (secukinumab), as confirmed by claims history or submission of medical records

**OR**

**1.3.1.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**OR**

**1.3.2** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.4** Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Rinvoq therapy, as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active ankylosing spondylitis

**AND**

**2.3** Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See Table 2 in Background for PDL links.
-------	---

Product Name: Rinvoq	
Diagnosis	Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of non-radiographic axial spondyloarthritis	

**AND**

**2** - ONE of the following:

**2.1** ALL of the following:

**2.1.1** ONE of the following:

**2.1.1.1** Failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records

**OR**

**2.1.1.2** History of intolerance or contraindication to TWO NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**2.1.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of non-radiographic axial spondyloarthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), Cosentyx (secukinumab)]

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** ONE of the following:

**2.1.2.1.1** Failure to Cosentyx (secukinumab), as confirmed by claims history or submission of medical records

**OR**

**2.1.2.1.2** History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

**OR**

**2.1.2.2** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**OR**

**2.2** Patient is currently on Rinvoq therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

Product Name:Rinvoq	
Diagnosis	Crohn's Disease (CD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Diagnosis of moderately to severely active Crohn's Disease	

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** ONE of the following:

**2.1.1.1** Failure to ONE of the following conventional therapy drugs or classes at maximally indicated dose confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Methotrexate (Rheumatrex, Trexall)

**OR**

**2.1.1.2** History of intolerance or contraindication to ALL of the following conventional therapy drugs or classes (please specify intolerance or contraindication)

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Methotrexate (Rheumatrex, Trexall)

**OR**

**2.1.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of Crohn's disease as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab]

**AND**

**2.1.2** ONE of the following:

**2.1.2.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*

<ul style="list-style-type: none"> <li>• One of the preferred ustekinumab products*</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.1.2.2</b> History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• One of the preferred adalimumab products*</li> <li>• One of the preferred ustekinumab products*</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Patient is currently on Rinvoq therapy for moderately to severely active Crohn's disease as confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is NOT receiving Rinvoq in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), ustekinumab, Skyrizi (risankizumab)]</li> <li>• Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by or in consultation with a gastroenterologist</p>	
Notes	*See Table 2 in Background for PDL links.

Product Name:Rinvoq, Rinvoq LQ	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of active polyarticular juvenile idiopathic arthritis

**AND**

2 - One of the following:

2.1 One of the following:

2.1.1 Failure to ALL of the following as confirmed by claims history or submission of medical records

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Tyenne (tocilizumab-aazg)

**OR**

2.1.2 History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Tyenne (tocilizumab-aazg)

**OR**

2.2 Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria<sup>5</sup>)

**OR**

2.3 Patient is currently on Rinvoq or Rinvoq LQ therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib), Xeljanz (tofacitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

Notes

\*See Table 2 in Background for PDL links.

Product Name:Rinvoq

Diagnosis

Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease (CD)

Approval Length

12 month(s)

Therapy Stage

Reauthorization

Guideline Type

Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Rinvoq therapy

**AND**

**2** - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]\*

<ul style="list-style-type: none"> <li>Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)*</li> </ul>	
Notes	* Examples of drug(s) may not be applicable based on the requested indication.

Product Name: Rinvoq, Rinvoq LQ	
Diagnosis	Psoriatic Arthritis (PsA), Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rinvoq or Rinvoq LQ therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Rinvoq or Rinvoq LQ in combination with either of the following:</p> <ul style="list-style-type: none"> <li>Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]*</li> <li>Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)*</li> </ul>	
Notes	* Examples of drug(s) may not be applicable based on the requested indication.

Product Name: Rinvoq	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Rinvoq therapy

**AND**

2 - Patient is NOT receiving Rinvoq in combination with either of the following:

- Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Cibinqo (abrocitinib), Xeljanz/XR (tofacitinib), Olumiant (baricitinib), Opzelura (topical ruxolitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist
- Immunologist

**2 . Background**

Benefit/Coverage/Program Information			
<b>Table 1: Relative potencies of topical corticosteroids</b>			
<u>Class</u>	<u>Drug</u>	<u>Dosage Form</u>	<u>Strength (%)</u>
<u>Very high potency</u>	<u>Augmented betamethasone dipropionate</u>	<u>Ointment, gel</u>	<u>0.05</u>
	<u>Clobetasol propionate</u>	<u>Cream, foam, ointment</u>	<u>0.05</u>
	<u>Diflorasone diacetate</u>	<u>Ointment</u>	<u>0.05</u>

	<u>Halobetasol propionate</u>	<u>Cream, ointment</u>	<u>0.05</u>	
	<u>Amcinonide</u>	<u>Cream, lotion, ointment</u>	<u>0.1</u>	
	<u>Augmented betamethasone dipropionate</u>	<u>Cream, lotion</u>	<u>0.05</u>	
	<u>Betamethasone dipropionate</u>	<u>Cream, foam, ointment, solution</u>	<u>0.05</u>	
<u>High Potency</u>	<u>Desoximetasone</u>	<u>Cream, ointment</u>	<u>0.25</u>	
	<u>Desoximetasone</u>	<u>Gel</u>	<u>0.05</u>	
	<u>Diflorasone diacetate</u>	<u>Cream</u>	<u>0.05</u>	
	<u>Fluocinonide</u>	<u>Cream, gel, ointment, solution</u>	<u>0.05</u>	
	<u>Halcinonide</u>	<u>Cream, ointment</u>	<u>0.1</u>	
	<u>Mometasone furoate</u>	<u>Ointment</u>	<u>0.1</u>	
	<u>Triamcinolone acetonide</u>	<u>Cream, ointment</u>	<u>0.5</u>	
		<u>Betamethasone valerate</u>	<u>Cream, foam, lotion, ointment</u>	<u>0.1</u>
		<u>Clocortolone pivalate</u>	<u>Cream</u>	<u>0.1</u>
<u>Medium potency</u>	<u>Desoximetasone</u>	<u>Cream</u>	<u>0.05</u>	
	<u>Fluocinolone acetonide</u>	<u>Cream, ointment</u>	<u>0.025</u>	
	<u>Flurandrenolide</u>	<u>Cream, ointment, lotion</u>	<u>0.05</u>	
	<u>Fluticasone propionate</u>	<u>Cream</u>	<u>0.05</u>	
	<u>Fluticasone propionate</u>	<u>Ointment</u>	<u>0.005</u>	
	<u>Mometasone furoate</u>	<u>Cream, lotion</u>	<u>0.1</u>	
	<u>Triamcinolone acetonide</u>	<u>Cream, ointment, lotion</u>	<u>0.1</u>	
		<u>Hydrocortisone butyrate</u>	<u>Cream, ointment, solution</u>	<u>0.1</u>
<u>Lower-medium potency</u>	<u>Hydrocortisone probutate</u>	<u>Cream</u>	<u>0.1</u>	
	<u>Hydrocortisone valerate</u>	<u>Cream, ointment</u>	<u>0.2</u>	
	<u>Prednicarbate</u>	<u>Cream</u>	<u>0.1</u>	

<u>Low potency</u>	<u>Alclometasone dipropionate</u>	<u>Cream, ointment</u>	<u>0.05</u>
	<u>Desonide</u>	<u>Cream, gel, foam, ointment</u>	<u>0.05</u>
	<u>Fluocinolone acetonide</u>	<u>Cream, solution</u>	<u>0.01</u>
<u>Lowest potency</u>	<u>Dexamethasone</u>	<u>Cream</u>	<u>0.1</u>
	<u>Hydrocortisone</u>	<u>Cream, lotion, ointment, solution</u>	<u>0.25, 0.5, 1</u>
	<u>Hydrocortisone acetate</u>	<u>Cream, ointment</u>	<u>0.5-1</u>

**Table 2: PDL links**

<b>Colorado</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a>
<b>Hawaii</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a>
<b>Maryland</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a>
<b>New Jersey</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a>
<b>New York</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a>
<b>Rhode Island</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a>
<b>Pennsylvania CHIP</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a>
<b>New Mexico</b>	<a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

### 3 . Revision History

Date	Notes
------	-------

3/4/2025	Added NM to scope. Added ustekinumab as a step therapy option in CD, UC and PsA. Changed "Stelara" to "ustekinumab" .
----------	---

Rivfloza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149311
<b>Guideline Name</b>	Rivfloza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/2/2024
-----------------	----------

### 1 . Criteria

Product Name:Rivfloza	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p><b>1.1</b> Patient has been established on therapy with Rivfloza under an active UnitedHealthcare medical benefit prior authorization for the treatment of primary hyperoxaluria type 1 (PH1)</p>	

**AND**

**1.2** Submission of medical records (e.g., chart notes, laboratory values) documenting a positive clinical response to therapy from pre-treatment baseline (e.g., decreased urinary oxalate concentrations, decreased urinary oxalate: creatinine ratio, decreased plasma oxalate concentrations)

**AND**

**1.3** Patient has NOT received a liver transplant

**AND**

**1.4** Patient has relatively preserved kidney function (e.g., eGFR [estimated glomerular filtration rate] greater than or equal to 30 mL/min/1.73 m<sup>2</sup>)

**AND**

**1.5** Patient is NOT receiving Rivfloza in combination with Oxlumo (lumasiran)

**AND**

**1.6** Prescribed by, or in consultation with, a specialist (e.g., geneticist, nephrologist, urologist) with expertise in the treatment of PH1

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of primary hyperoxaluria type 1 (PH1)

**AND**

**2.2** Confirmation of diagnosis based on BOTH of the following:

**2.2.1** Metabolic testing demonstrating ONE of the following:

**2.2.1.1** Increased urinary oxalate excretion (e.g., greater than 1 mmol/1.73 m<sup>2</sup> per day [90 mg/1.73 m<sup>2</sup> per day], increased urinary oxalate: creatinine ratio relative to normative values for age)

**OR**

**2.2.1.2** Increased plasma oxalate and glyoxylate concentrations

**AND**

**2.2.2** Genetic testing has confirmed a mutation in the alanine: glyoxylate aminotransferase (AGT or AGXT) gene

**AND**

**2.3** Patient has NOT received a liver transplant

**AND**

**2.4** Patient is at least 9 years of age or older

**AND**

**2.5** Patient has relatively preserved kidney function (e.g., eGFR [estimated glomerular filtration rate] greater than or equal to 30 mL/min/1.73 m<sup>2</sup>)

**AND**

**2.6** Patient is NOT receiving Rivfloza in combination with Oxlumio (lumasiran)

**AND**

**2.7** Prescribed by, or in consultation with, a specialist (e.g., geneticist, nephrologist, urologist) with expertise in the treatment of PH1

Product Name: Rivfloza	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting a positive clinical response to therapy from pre-treatment baseline (e.g., decreased urinary oxalate concentrations, decreased urinary oxalate: creatinine ratio, decreased plasma oxalate concentrations)

**AND**

**2** - Patient has NOT received a liver transplant

**AND**

**3** - Patient has relatively preserved kidney function (e.g., eGFR [estimated glomerular filtration rate] greater than or equal to 30 mL/min/1.73 m<sup>2</sup>)

**AND**

**4** - Patient is NOT receiving Rivfloza in combination with Oxlumo (lumasiran)

**AND**

**5** - Prescribed by, or in consultation with, a specialist (e.g., geneticist, nephrologist, urologist) with expertise in the treatment of PH1

## 2 . Revision History

Date	Notes
7/2/2024	New program.

Rozerem



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146409
<b>Guideline Name</b>	Rozerem
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Rozerem, generic ramelteon	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Failure of at least 2 weeks to ALL of the following sedative-hypnotic alternatives confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>Zolpidem or zolpidem ER (generic Ambien, generic Ambien CR)</li> <li>Zaleplon (generic Sonata)</li> <li>Eszopiclone (generic Lunesta)</li> </ul>	

**OR**

**2** - History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Zolpidem or zolpidem ER (generic Ambien, generic Ambien CR)
- Zaleplon (generic Sonata)
- Eszopiclone (generic Lunesta)

**OR**

**3** - History of or potential for a substance abuse disorder

Rozlytrek



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-183188
<b>Guideline Name</b>	Rozlytrek
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Rozlytrek	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of metastatic non-small cell lung cancer (NSCLC)

**AND**

2 - Disease is ROS1 (gene)-positive

Product Name:Rozlytrek	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Presence of solid tumors [e.g., sarcoma, non-small cell lung cancer (NSCLC), salivary, breast, thyroid, colorectal, neuroendocrine, pancreatic, gynecological, cholangiocarcinoma, etc.]</p> <p><b>AND</b></p> <p>2 - Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion [e.g., ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.]</p> <p><b>AND</b></p> <p>3 - Disease is without a known acquired resistance mutation [e.g., TRKA G595R substitution, TRKA G667C substitution, or other recurrent kinase domain (solvent front and xDFG) mutations]</p>	

**AND**

**4** - Disease is ONE of the following:

- Metastatic
- Unresectable

Product Name:Rozlytrek	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Rozlytrek therapy</p>	

Product Name:Rozlytrek	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Rozlytrek	
Diagnosis	NCCN Recommended Regimens

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rozlytrek therapy</p>	

## 2 . Revision History

Date	Notes
2/20/2025	Combined formularies. Minor update to dx check criterion in NSCLC i nitial auth section, with no changes to clinical intent. Minor cosmetic updates.

Rubraca



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146635
<b>Guideline Name</b>	Rubraca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Rubraca	
Diagnosis	Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Epithelial ovarian cancer</li> </ul>	

- Fallopian tube cancer
- Primary peritoneal cancer

**AND**

**2** - BOTH of the following:

**2.1** Cancer has a deleterious BRCA mutation

**AND**

**2.2** To be used as maintenance therapy in individuals who are in complete or partial response to platinum-based chemotherapy

Product Name: Rubraca	
Diagnosis	Prostate cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of metastatic, castration-resistant prostate cancer</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Cancer has a deleterious BRCA mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <p><b>3.1</b> Failure to androgen receptor-directed therapy [e.g., Zytiga (abiraterone), Xtandi (enzalutamide), Erleada (apalutamide)] as confirmed by claims history or submission of medical records</p>	

**OR**

**3.2** Contraindication or intolerance to androgen receptor-directed therapy [e.g., Zytiga (abiraterone), Xtandi (enzalutamide), Erleada (apalutamide)] (please specify intolerance or contraindication)

**AND**

**4** - History of failure, contraindication, or intolerance to taxane-based chemotherapy (e.g., docetaxel, Jevtana (cabazitaxel))

**AND**

**5** - ONE of the following:

**5.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**5.2** Patient has had bilateral orchiectomy

Product Name: Rubraca	
Diagnosis	Uterine cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of BRCA altered uterine leiomyosarcoma (uLMS)	

**AND**

**2** - Disease has progressed following prior treatment with ONE of the following:

- Gemcitabine plus docetaxel
- Doxorubicin

Product Name: Rubraca	
Diagnosis	Pancreatic cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of pancreatic adenocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Presence of ONE of the following:</p> <p><b>3.1</b> Deleterious or suspected deleterious germline or somatic BRCA1/2 mutation</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> Deleterious or suspected deleterious germline or somatic PALB2 mutation</p>	

**AND**

**4** - Disease has NOT progressed while receiving at least 16 weeks of a first-line platinum-based chemotherapy regimen

Product Name: Rubraca	
Diagnosis	Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, Prostate cancer, Uterine cancer, Pancreatic cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does NOT show evidence of progressive disease while on Rubraca therapy</p>	

Product Name: Rubraca	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Rubraca	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Rubraca therapy	

Ruconest



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148152
<b>Guideline Name</b>	Ruconest
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Ruconest	
Diagnosis	Hereditary Angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p><b>1.1</b> C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p>	

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-sulfotransferase 6
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - Prescribed for the acute treatment of HAE attacks

**AND**

**3** - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)

**AND**

**4** - Prescribed by ONE of the following:

- Immunologist
- Allergist

Product Name: Ruconest	
Diagnosis	Hereditary Angioedema (HAE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Ruconest therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed for the acute treatment of HAE attacks</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Immunologist</li> <li>• Allergist</li> </ul>	

## 2 . Revision History

Date	Notes
6/5/2024	Update to types of genetic variant(s) and diagnostic criteria with normal C1 inhibitor levels in initial auth section and minor language update in reauth section; Minor cosmetic updates.

Rukobia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-202202
<b>Guideline Name</b>	Rukobia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Rukobia	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been diagnosed with multidrug-resistant HIV-1 (human immunodeficiency virus type 1) infection</p>	

**AND**

**2** - Patient is currently taking or will be prescribed an optimized background antiretroviral regimen

## 2 . Revision History

Date	Notes
2/27/2025	Minor update to definition of HIV-1 in criteria, with no changes to clinical intent. Removed NY and NY EPP from markets in scope as Rukobia moving to open access for these markets.

Rydapt



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146637
<b>Guideline Name</b>	Rydapt
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Rydapt	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia (AML)</p>	

<b>AND</b>
<b>2</b> - AML is FLT3 mutation-positive
<b>AND</b>
<b>3</b> - Rydapt will be used in combination with standard induction and consolidation therapy

Product Name:Rydapt	
Diagnosis	Systemic Mastocytosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Aggressive systemic mastocytosis (ASM)</li> <li>• Systemic mastocytosis with associated hematologic neoplasm (SM-AHN)</li> <li>• Mast cell leukemia (MCL)</li> </ul>	

Product Name:Rydapt	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia

**AND**

2 - ONE of the following:

- Patient has a FGFR1 rearrangement
- Patient has a FLT3 rearrangement

Product Name: Rydapt

Diagnosis	Acute Myeloid Leukemia (AML), Systemic Mastocytosis, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Rydapt therapy

Product Name: Rydapt

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Rydapt	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Rydapt therapy</p>	

Samsca



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146638
<b>Guideline Name</b>	Samsca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Samsca, generic tolvaptan	
Approval Length	30 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <ul style="list-style-type: none"> <li>Diagnosis of clinically significant euvolemic hyponatremia</li> <li>Diagnosis of clinically significant hypervolemic hyponatremia</li> </ul>	

**AND**

**2** - Patient has not responded to fluid restriction

**AND**

**3** - Treatment has been initiated or re-initiated in a hospital setting prior to discharge

Sandostatin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146639
<b>Guideline Name</b>	Sandostatin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Acromegaly
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acromegaly</p>	

**AND**

**2** - ONE of the following:

**2.1** Inadequate response to ONE of the following:

- Surgery
- Radiotherapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**OR**

**2.2** NOT a candidate for any of the following:

- Surgery
- Radiotherapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Meningioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of meningioma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is surgically inaccessible</p>	

**AND**

**3 - ONE of the following:**

- Disease is recurrent
- Disease is progressive

**AND**

**4 - Additional radiation is not possible**

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Neuroendocrine and Adrenal Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - Patient has neuroendocrine tumors [e.g., carcinoid tumors, Islet cell tumors, gastrinomas, glucagonomas, insulinomas, lung tumors, somatostatinomas, tumors of the pancreas, GI (gastrointestinal) tract, lung and thymus, adrenal glands, and vasoactive intestinal polypeptidomas (VIPomas)]**

**OR**

**2 - ALL of the following:**

- Diagnosis of Pheochromocytoma or Paraganglioma
- Disease is locally unresectable or distant metastases
- Disease is somatostatin receptor positive
- Presence of symptomatic disease

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Neuroendocrine and Adrenal Tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on the requested therapy</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Documentation of positive clinical response (e.g., suppression of severe diarrhea, flushing, etc.) to the requested therapy</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Thymoma or Thymic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of thymoma or thymic carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Used as a second-line therapy for ONE of the following:</p> <p>2.1.1 Unresectable disease following first-line chemotherapy for potentially resectable locally advanced disease, solitary metastasis, or ipsilateral pleural metastasis</p>	

**OR**

**2.1.2** Extrathoracic metastatic disease

**OR**

**2.2** BOTH of the following:

**2.2.1** Used as first line therapy for ONE of the following:

- Unresectable locally advanced disease in combination with radiation therapy
- Potentially resectable locally advanced disease
- Potentially resectable solitary metastasis or ipsilateral pleural metastasis
- Consideration following surgery for solitary metastasis or ipsilateral pleural metastasis
- Medically inoperable/unresectable solitary metastasis or ipsilateral pleural metastasis
- Extrathoracic metastatic disease
- Postoperative treatment for thymoma after R2 resection

**AND**

**2.2.2** Patient is unable to tolerate first-line combination regimens

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Meningioma, Thymoma or Thymic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on the requested therapy	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Malignant Bowel Obstruction

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of malignant bowel obstruction</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Gut function cannot be maintained</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Chemotherapy- and/or Radiation-Induced Diarrhea
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of diarrhea due to concurrent cancer chemotherapy and/or radiation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Presence of Grade 3 or 4 severe diarrhea</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Patient is in palliative or end of life care</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	HIV/AIDS-Related Diarrhea
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of HIV (human immunodeficiency virus)/AIDS (acquired immunodeficiency syndrome)-related diarrhea</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Bleeding Gastroesophageal Varices
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of bleeding gastroesophageal varices associated with liver disease</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Brand Sandostatin, generic octreotide	
Diagnosis	Acromegaly, Malignant Bowel Obstruction, Chemotherapy- and/or Radiation-Induced Diarrhea, HIV/AIDS-Related Diarrhea, Bleeding Gastroesophageal Varices, NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to the requested therapy</p>	

Savaysa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-205208
<b>Guideline Name</b>	Savaysa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Savaysa	
Diagnosis	Therapy upon hospital discharge
Approval Length	35 Day(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Medication is being used as continuation of therapy upon hospital discharge

Product Name:Savaysa	
Diagnosis	Stroke & Systemic Embolism Prevention in Adult Patients with Non-Valvular Atrial Fibrillation
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of atrial fibrillation (AF)

**AND**

2 - Patient does not have an artificial heart valve

**AND**

3 - One of the following:

3.1 Failure to Eliquis as confirmed by claims history or submission of medical records

**OR**

3.2 History of contraindication or intolerance to Eliquis (please specify contraindication or intolerance)

**OR**

3.3 Continuation of prior Savaysa therapy

Product Name:Savaysa	
Diagnosis	Deep Vein Thrombosis or Pulmonary Embolism Treatment in Adult Patients
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of one of the following:</p> <ul style="list-style-type: none"> <li>• Deep vein thrombosis (DVT)</li> <li>• Pulmonary embolism (PE)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient does not have an artificial heart valve</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - One of the following:</p> <p><b>3.1</b> Failure to Eliquis as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> History of contraindication or intolerance to Eliquis (please specify contraindication or intolerance)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.3</b> Continuation of prior Savaysa therapy</p>	

**2 . Revision History**

Date	Notes
2/28/2025	New

Scemblix



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164748
<b>Guideline Name</b>	Scemblix
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Scemblix	
Diagnosis	Chronic Myeloid Leukemia (CML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic myeloid leukemia (CML)

**AND**

2 - Disease is Philadelphia chromosome (Ph+) or BCR::ABL1-positive

**AND**

3 - ONE of the following:

- Used in newly diagnosed chronic phase CML (CP-CML)
- Used in previously treated chronic phase CML (CP-CML)
- Used in chronic phase CML (CP-CML) positive for a T315I mutation
- Used in accelerated phase CML as primary treatment as a single agent

Product Name:Scemblix	
Diagnosis	Myeloid/Lymphoid Neoplasms with Eosinophilia and ABL1 Gene Rearrangement
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and ABL1 rearrangement</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is in chronic or blast phase</p>	

Product Name:Scemblix	
Diagnosis	Chronic Myeloid Leukemia (CML), Myeloid/Lymphoid Neoplasms with Eosinophilia and ABL1 Gene Rearrangement
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Scemblix therapy</p>	

Product Name:Scemblix	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Scemblix	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Scemblix therapy</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Updated formularies. Updated GPIs. Updated initial auth criteria.

Sensipar



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146411
<b>Guideline Name</b>	Sensipar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Sensipar, generic cinacalcet	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Prescribed by or in consultation with an oncologist, endocrinologist, or nephrologist</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Diagnosis of hypercalcemia with parathyroid carcinoma

**OR**

**2.2** ALL of the following:

**2.2.1** Diagnosis of primary hyperparathyroidism (HPT)

**AND**

**2.2.2** Severe hypercalcemia [serum calcium level greater than 12.5 mg/dL (milligrams/deciliter)] due to primary HPT

**AND**

**2.2.3** Patient is unable to undergo parathyroidectomy

**OR**

**2.3** ALL of the following:

**2.3.1** Diagnosis of secondary hyperparathyroidism with chronic kidney disease

**AND**

**2.3.2** Patient is on dialysis

**AND**

**2.3.3** BOTH of the following:

**2.3.3.1** ONE of the following:

- Patient has therapeutic failure to ONE phosphate binder (e.g., PhosLo, Fosrenol, Renvela, Renagel, etc.) confirmed by claims history or submitted medical records
- Patient has intolerance or contraindication to ONE phosphate binders (e.g., PhosLo, Fosrenol, Renvela, Renagel, etc.) (please specify intolerance or contraindication)

**AND**

**2.3.3.2 ONE of the following:**

- Patient has therapeutic failure to ONE vitamin D analog (e.g., calcitriol, Hectorol, Zemplar, etc.) confirmed by claims history or submitted medical records
- Patient has intolerance or contraindication to ONE vitamin D analogs (e.g., calcitriol, Hectorol, Zemplar, etc.) (please specify intolerance or contraindication)

Product Name: Brand Sensipar, generic cinacalcet	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has experienced a reduction in serum calcium from baseline</p>	

Sevelamer carbonate



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146412
<b>Guideline Name</b>	Sevelamer carbonate
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Generic sevelamer carbonate tablets	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - The patient did not exhibit an adequate response to treatment with at least an 8-week trial of calcium acetate as supported by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - The patient experienced an intolerance/adverse reaction to previous therapy with calcium acetate (please indicate intolerance/adverse reaction)

**OR**

**3** - The patient has a documented contraindication to treatment with calcium acetate (please indicate contraindication)

SGLT2 Inhibitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-197208
<b>Guideline Name</b>	SGLT2 Inhibitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Steglatro, Segluromet	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values

- A1C greater than or equal to 6.5%
- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**2** - For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

Product Name: Jardiance	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - For diagnosis of type 2 diabetes mellitus, BOTH of the following:</p> <p><b>1.1</b> ONE of the following:</p> <p><b>1.1.1</b> Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p>	

**1.1.2** For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to ONE of the following therapies for 90 days confirmed by claims history or submission of medical records:

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

**OR**

**1.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

**OR**

**2** - For diagnosis of heart failure (NYHA class II-IV), ONE of the following:

- Failure to dapagliflozin (Farxiga authorized generic) as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to dapagliflozin (Farxiga authorized generic) (please specify intolerance or contraindication)

**OR**

**3** - For diagnosis of chronic kidney disease (CKD) at risk of progression, BOTH of the following:

**3.1** ONE of the following:

- Patient is currently taking an ACE inhibitor or ARB, confirmed by claims history or submission of medical records

- History of intolerance or contraindication to ACE inhibitor or ARB (please specify intolerance or contraindication)

**AND**

**3.2 ONE of the following:**

- Failure to dapagliflozin (Farxiga authorized generic) as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to dapagliflozin (Farxiga authorized generic) (please specify intolerance or contraindication)

Product Name: Jardiance	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name: Invokana	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p><b>1.1</b> Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> </ul>	

- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**1.2** For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**2** - ONE of the following:

**2.1** ONE of the following:

**2.1.1** Failure to ONE of the following therapies for 90 days confirmed by claims history or submission of medical records:

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

**OR**

**2.1.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

**OR**

**2.2** Documented history of diabetic nephropathy with albuminuria

Product Name: Invokana

Approval Length

12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name:Dapagliflozin (Farxiga authorized generic)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For diagnosis of type 2 diabetes mellitus, ONE of the following:</p> <p>1.1 Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2 For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - Diagnosis of heart failure (NYHA class II-IV)</p>	

**OR**

**3 - Diagnosis of chronic kidney disease**

Product Name:Farxiga	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 For diagnosis of type 2 diabetes mellitus, ONE of the following:</p> <p>1.1.1 Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values</p> <ul style="list-style-type: none"> <li>• A1C greater than or equal to 6.5%</li> <li>• Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL</li> <li>• 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test</li> <li>• Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.1.2 For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 Diagnosis of heart failure (NYHA class II-IV)</p>	

<b>OR</b>
<b>1.3</b> Diagnosis of chronic kidney disease
<b>AND</b>
<b>2</b> - The prescriber has given a clinical reason or special circumstance why the patient is unable to use dapagliflozin (Farxiga authorized generic) (please document reason/special circumstance)

Product Name:Farxiga	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - The prescriber has given a clinical reason or special circumstance why the patient is unable to use dapagliflozin (Farxiga authorized generic) (please document reason/special circumstance)</p>	

Product Name:Brenzavvy, Bexagliflozin, Synjardy, Synjardy XR, Invokamet, Invokamet XR, Xigduo XR, Dapagliflozin/Metformin ER	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - ONE of the following:**

**1.1** Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by ONE of the following laboratory values

- A1C greater than or equal to 6.5%
- Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
- 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose tolerance test
- Random plasma glucose greater than or equal to 200 mg/dL in patient with classic symptoms of hyperglycemia or hyperglycemic crisis

**OR**

**1.2** For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed greater than 2 years ago), submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes mellitus

**AND**

**2 - ONE of the following:**

**2.1** Failure to ONE of the following therapies for 90 days confirmed by claims history or submission of medical records:

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Steglatro (ertugliflozin) OR Segluromet (ertugliflozin/metformin)
- Dapagliflozin (Farxiga authorized generic)

Product Name: Brenzavvy, Bexagliflozin, Synjardy, Synjardy XR, Invokamet, Invokamet XR, Xigduo XR, Dapagliflozin/Metformin ER	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Product Name: Inpefa	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 The patient has a diagnosis of heart failure</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 ALL of the following:</p> <p>1.2.1 Diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2.2 Diagnosis of chronic kidney disease</p> <p style="text-align: center;"><b>AND</b></p>	

**1.2.3** At least ONE additional cardiovascular risk factor such as:

- History of heart failure
- Obesity
- Dyslipidemia
- Hypertension
- Elevated cardiac and inflammatory biomarkers

**AND**

**2** - ONE of the following:

- Failure to dapagliflozin (Farxiga authorized generic) confirmed by claims history or submission of medical records
- History of contraindication or intolerance to dapagliflozin (Farxiga authorized generic) (please specify contraindication or intolerance)

Product Name: Inpefa	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	

## 2 . Revision History

Date	Notes
2/26/2025	Updated formularies. Removed step through metformin throughout. Added reauth criteria. Updated diabetes diagnosis check. Separated Farxiga and AG Farxiga

Short-Acting Opioid Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161924
<b>Guideline Name</b>	Short-Acting Opioid Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

<p>Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs, oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglentis, Brand Roxybond, Brand Oxycodone</p>	
Diagnosis	DUR: Non-cough and cold Opioid Naïve (Not having filled an opioid in the past 60 days) exceeding the 7 day supply limit and/or 50-90MME limit*

Guideline Type	Prior Authorization
	<p><b>Approval Criteria</b></p> <p><b>1</b> - Opioid naïve patients (defined as not having filled an opioid in the past 60 days) may receive greater than the 7 day supply limit and/or greater than 50 morphine milligram equivalents (MME) based on ALL of the following:</p> <p><b>1.1</b> If the request is for greater than the 7 day supply limit, ONE of the following:</p> <p><b>1.1.1</b> Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.2</b> End of life care, including hospice care</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.3</b> Palliative care</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.4</b> Sickle cell anemia</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.1.5</b> BOTH of the following:</p> <p><b>1.1.5.1</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Traumatic injury</li> <li>• Post-surgical procedures, excluding dental procedures</li> <li>• Prescriber attests that the patient has received an opioid within the past 60 days</li> </ul>

**AND**

**1.1.5.2** Prescriber attests if requested for traumatic injury or post-surgical procedure, that based on injury or surgical procedure performed the patient requires greater than a 7 day supply of short-acting opioid to adequately control pain

**AND**

**1.2** If the request is for 50 MME to 90 MME, ONE of the following (NOTE: If the request exceeds 90 MME please skip this section and proceed to the MME Reviews section):

**1.2.1** Diagnosis of ONE of the following:

- Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)
- End of life pain (including hospice care)
- Palliative care
- Sickle cell anemia

**OR**

**1.2.2** Patient is currently exceeding 50 MME and prescriber attests patient has been on opioids in the past 60 days

**OR**

**1.2.3** Document ALL of the following:

- The diagnosis is associated with the need for pain management with opioids
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression
- The prescriber has acknowledged that they have completed an addiction risk and risk of overdose assessment
- Prescriber attests the patient requires more than 50 MME per day to adequately control pain

Notes	<p>*This section does NOT apply to cough and cold products.                  **Approval length for cancer-related pain, end of life, palliative care, or sickle cell pain will be issued for 12 months. All other approvals will be issued for the requested duration, not to exceed one month.</p>
-------	---

Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs, oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglentis, Brand Roxybond, Brand Oxycodone

Diagnosis	Non-Preferred Reviews*
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 If the request is for tramadol 100 mg (milligram) tablets, the physician has provided rationale for needing to use the 100 mg tramadol tablet instead of two 50 mg tramadol tablets

**OR**

1.2 If the request is for tramadol 25 mg tablets, the physician has provided rationale why the patient is unable to use half of a 50 mg tramadol tablet

**OR**

1.3 If the request is for Qdolo (tramadol soln), ONE of the following:

1.3.1 Failure of tramadol 50mg tablets as confirmed by claims history or submission of medical records

**OR**

**1.3.2** History of intolerance or contraindication to tramadol 50mg tablets (please specify intolerance or contraindication)

**OR**

**1.3.3** Patient is unable to swallow a solid dosage form

**OR**

**1.3.4** Patient utilizes a feeding tube for medication administration

**OR**

**1.4** If the request is for another non-preferred medication\*\*, then ONE of the following:

**1.4.1** Failure of at least three unique active ingredients from the preferred short-acting opioids list as confirmed by claims history or submission of medical records

**OR**

**1.4.2** History of intolerance or contraindication to three unique active ingredients from the preferred short-acting opioids list (please specify intolerance or contraindication)

Notes	<p>*This section does NOT apply to cough and cold products.                  **PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>
-------	--

Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs,

oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglantis, Brand Roxybond, Brand Oxycodone	
Diagnosis	Cancer-related pain/Hospice/End of Life/Sickle Cell Anemia Related Pain Exceeding the 90 MME Cumulative Threshold*
Guideline Type	Morphine Milligram Equivalents (MME) Reviews**
<p><b>Approval Criteria</b></p> <p>1 - Patient has ONE of the following:</p> <ul style="list-style-type: none"> <li>• Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</li> <li>• End of life diagnosis (hospice care)</li> <li>• Sickle cell anemia related pain</li> </ul>	
Notes	<p>*This section does NOT apply to cough and cold products.</p> <p>**Approval length will be issued for up to the requested amount for 12 months for cancer-related pain/hospice/end of life/sickle cell anemia related pain. The authorization should be entered for an MME of 9999 so as to prevent future disruptions in therapy if the patient's dose is increased.</p>

Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs, oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglantis, Brand Roxybond, Brand Oxycodone	
Diagnosis	Non-cancer-related pain/non-hospice/non-end of life/non-sickle cell anemia related pain Exceeding the 90 MME Cumulative Threshold *
Therapy Stage	Initial Authorization

Guideline Type	Morphine Milligram Equivalents (MME)**
<p><b>Approval Criteria</b></p> <p>1 - Prescriber attests the patient has been screened for substance abuse/opioid dependence</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Treatment goals are defined and include estimated duration of treatment (must document treatment goals)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - BOTH of the following:</p> <p>3.1 Patient has been screened for underlying depression and/or anxiety</p> <p style="text-align: center;"><b>AND</b></p> <p>3.2 If applicable, any underlying conditions have been or will be addressed</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Patient has tried and failed non-opioid pain medication (document drug name and date of trial)</li> <li>• Opioid medication doses of less than 90 morphine milligram equivalents (MME) have been tried and did not adequately control pain (document drug regimen or MME and dates of therapy)***</li> </ul>	
Notes	<p>*This section does NOT apply to cough and cold products.</p> <p>**Approval length will be issued for 6 months for non-cancer-related pain/non-hospice/non-end of life/non-sickle cell anemia related pain up to the current requested MME plus 90 MME</p> <p>***If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 60-</p>

	day authorization may be authorized one time for the requested MME dose.
--	--

Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs, oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglentis, Brand Roxybond, Brand Oxycodone

Diagnosis	Non-cancer-related pain/non-hospice/non-end of life/non-sickle cell anemia related pain Exceeding the 90 MME Cumulative Threshold*
Therapy Stage	Reauthorization
Guideline Type	Morphine Milligram Equivalents (MME)**

**Approval Criteria**

**1** - Prescriber attests the patient has been screened for substance abuse/opioid dependence

**AND**

**2** - Documented rationale for not tapering or discontinuing opioid if treatment goals are not met

**AND**

**3** - Documented meaningful improvement in pain and function when assessed against treatment goals (Document improvement in function or pain score improvement)\*\*\*

Notes	<p>*This section does NOT apply to cough and cold products.</p> <p>**Approval length will be issued for 6 months for non-cancer-related pain/non-hospice/non-end of life/non-sickle cell anemia related pain up to the current requested MME plus 90 MME</p> <p>***If the patient has been established on the requested MME dose for</p>
-------	--

	at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested MME dose.
--	---

Product Name:butorphanol nasal sol, codeine, acetaminophen w/codeine soln and tabs, Brand Fioricet/codeine, generic butalbital/acetaminophen/caffeine w/codeine, Ascomp/codeine, generic butalbital/aspirin/caffeine w/codeine, morphine supp, tabs and soln, Brand Lortab, hydrocodone/acetaminophen soln, Brand Xodol, generic hydrocodone/acetaminophen tabs, hydrocodone/ibuprofen, Brand Dilaudid, generic hydromorphone, oxycodone caps, soln and conc, Brand Roxicodone, Oxaydo, generic oxycodone tabs, Brand Percocet, Prolate tabs and soln, Nalocet, Endocet, Oxycodone-acetaminophen soln and tabs, generic oxycodone/acetaminophen soln and tabs, oxymorphone, pentazocine w/naloxone, Brand Ultram, Synapryn, generic tramadol, Qdolo, Tramadol soln, Brand Ultracet, generic tramadol/acetaminophen, Nucynta, meperidine, levorphanol, Brand Trezix, generic acetaminophen/caffeine/dihydrocodeine, generic belladonna alkaloids/opium, opium, Apadaz, Benzhydrocodone/acetaminophen, Seglentis, Brand Roxybond, Brand Oxycodone

Diagnosis	Criteria for Quantity Limit Reviews*
-----------	--------------------------------------

Guideline Type	Quantity Limit
----------------	----------------

**Approval Criteria**

1 - The requested dose cannot be achieved by a higher strength formulary product

**AND**

2 - The requested dose is within FDA (Food and Drug Administration) maximum dose per day, where an FDA maximum dose per day exists\*\*

Notes	<p>*This section does NOT apply to cough and cold products.</p> <p>**Authorization will be issued for:</p> <ul style="list-style-type: none"> <li>• 12 months for cancer-related pain/hospice/sickle cell anemia related pain/end of life related pain</li> <li>• 6 months for non-cancer-related pain/non-hospice/non-sickle cell anemia related pain/non-end of life related pain</li> </ul>
-------	--

Product Name:Brand Hycodan tab and syrup, generic hydrocodone/homatropine tabs and syrup, Hydromet syrup, Tuzistra XR, hydrocodone polst-chlorphen polst ER, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss CD, promethazine-codeine syrup, promethazine-phenylephrine-codeine syrup (promethazine VC-codeine syrup), Rydex,

Mar-Cof BP, Mar-Cof CG, Ninjacof-XG, Coditussin AC, M-Clear WC, codeine/guaifenesin soln (Virtussin AC/ALC, Virtussin A/C, Maxi-Tuss AC, Guaiatussin AC, G Tussin AC, Guaifenesin AC), Tusnel C, Virtussin DAC, Tuxarin ER, Coditussin DAC	
Diagnosis	DUR: Cough and Cold Opioid Naïve (Not having filled an opioid in the past 60 days) exceeding the 7 day supply limit*
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Cancer-related pain (i.e., patients undergoing active cancer treatment; or cancer survivors with chronic pain who have completed cancer treatment, are in clinical remission, or are under cancer surveillance)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 End of life care, including hospice care</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 Palliative care</p> <p style="text-align: center;"><b>OR</b></p> <p>1.4 Sickle cell anemia</p> <p style="text-align: center;"><b>OR</b></p> <p>1.5 BOTH of the following:</p> <p>1.5.1 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Traumatic injury</li> <li>• Post-surgical procedures, excluding dental procedures</li> <li>• Prescriber attests that the patient has received an opioid within the past 60 days</li> </ul>	

**AND**

**1.5.2** Prescriber attests if requested for traumatic injury or post-surgical procedure, that based on injury or surgical procedure performed the patient requires greater than a 7 day supply of short-acting opioid to adequately control pain

Notes	*Approval length for cancer-related pain, end of life, palliative care, or sickle cell pain will be issued for 12 months. All other approvals will be issued for the requested duration, not to exceed one month.
-------	---

Product Name:Brand Hycodan tab and syrup, generic hydrocodone/homatropine tabs and syrup, Hydromet syrup, Tuzistra XR, hydrocodone polst-chlorphen polst ER, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss CD, promethazine-codeine syrup, promethazine-phenylephrine-codeine syrup (promethazine VC-codeine syrup), Rydex, Mar-Cof BP, Mar-Cof CG, Ninjacof-XG, Coditussin AC, M-Clear WC, codeine/guaifenesin soln (Virtussin AC/ALC, Virtussin A/C, Maxi-Tuss AC, Guaiatussin AC, G Tussin AC, Guaifenesin AC), Tusnel C, Virtussin DAC, Tuxarin ER, Coditussin DAC

Diagnosis	Cough and Cold Products Exceeding the 90 MME Cumulative Threshold
-----------	---

Guideline Type	Morphine Milligram Equivalents (MME)*
----------------	---------------------------------------

**Approval Criteria**

1 - The prescriber attests they are aware of patient's current opioid therapy and morphine milligram equivalents (MME) dose and feels the treatment with the requested product is medically necessary

Notes	*Approval length will be issued for up to 30 days for cough and cold related treatment. The authorization should be entered for the MME requested.
-------	--

Product Name:Brand Hycodan tab and syrup, generic hydrocodone/homatropine tabs and syrup, Hydromet syrup, Tuzistra XR, hydrocodone polst-chlorphen polst ER, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss CD, promethazine-codeine syrup, promethazine-phenylephrine-codeine syrup (promethazine VC-codeine syrup), Rydex, Mar-Cof BP, Mar-Cof CG, Ninjacof-XG, Coditussin AC, M-Clear WC, codeine/guaifenesin soln (Virtussin AC/ALC, Virtussin A/C, Maxi-Tuss AC, Guaiatussin AC, G Tussin AC, Guaifenesin AC), Tusnel C, Virtussin DAC, Tuxarin ER, Coditussin DAC

Diagnosis	Under the Age of 18 Years for Cough and Cold Products
-----------	---

Approval Length	30 Day(s)
-----------------	-----------

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Prescriber attests they are aware of Food and Drug Administration (FDA) labeled contraindications regarding use of opioid containing cough and cold products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (Document rationale for use)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient does not have a comorbid condition that may impact respiratory depression (e.g., asthma or other chronic lung disease, sleep apnea, body mass index &gt; 30)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has tried and failed at least one non-opioid containing cough and cold remedy</p>	

<p>Product Name: Brand Hycodan tab and syrup, generic hydrocodone/homatropine tabs and syrup, Hydromet syrup, Tuzistra XR, hydrocodone polst-chlorphen polst ER, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss CD, promethazine-codeine syrup, promethazine-phenylephrine-codeine syrup (promethazine VC-codeine syrup), Rydex, Mar-Cof BP, Mar-Cof CG, Ninjacof-XG, Coditussin AC, M-Clear WC, codeine/guaifenesin soln (Virtussin AC/ALC, Virtussin A/C, Maxi-Tuss AC, Guaiatussin AC, G Tussin AC, Guaifenesin AC), Tusnel C, Virtussin DAC, Tuxarin ER, Coditussin DAC</p>	
Diagnosis	Cough and Cold Products Exceeding 120mL per fill and/or 360mL per 30 days*
Approval Length	30 days**
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p><b>1</b> - Prescriber attests that a larger quantity is medically necessary</p> <p style="text-align: center;"><b>AND</b></p>	

<b>2 - The requested dose is within the Food and Drug Administration (FDA) maximum dose per day, where an FDA maximum dose per day exists</b>	
Notes	<p>*Quantity Limit Rules in place:</p> <ul style="list-style-type: none"> <li>• 120mL/fill</li> <li>• 360mL/30 days</li> </ul> <p>**Authorization will be issued for up to 30 days. The authorization should be entered for the quantity requested.</p>

<p>Product Name: Brand Hycodan tab and syrup, generic hydrocodone/homatropine tabs and syrup, Hydromet syrup, Tuzistra XR, hydrocodone polst-chlorphen polst ER, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss CD, promethazine-codeine syrup, promethazine-phenylephrine-codeine syrup (promethazine VC-codeine syrup), Rydex, Mar-Cof BP, Mar-Cof CG, Ninjacof-XG, Coditussin AC, M-Clear WC, codeine/guaifenesin soln (Virtussin AC/ALC, Virtussin A/C, Maxi-Tuss AC, Guaiatussin AC, G Tussin AC, Guaifenesin AC), Tusnel C, Virtussin DAC, Tuxarin ER, Coditussin DAC</p>	
Diagnosis	Non-Preferred Cough and Cold Products
Approval Length	30 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - If the request is for a non-preferred* medication, then ONE of the following:</p> <p>1.1 Failure of at least three unique active ingredients from the preferred cough and cold products list as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 History of intolerance or contraindication to at least three unique active ingredients from the preferred cough and cold products list (please specify intolerance or contraindication)</p>	
Notes	**PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

## 2 . Revision History

Date	Notes
------	-------

12/11/2024	Added hydrocodone/apap 10/325 soln, tramadol 75mg and hydrocodone/apap 2.5/325. removed apap/caffeine/dihydrocodeine 325-30-16 mg. Updated Roxybond GPls and added Brand oxycodone abuse deterrent GPls. Updated cancer language.
------------	---

Signifor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146641
<b>Guideline Name</b>	Signifor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Signifor	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endogenous Cushing’s disease (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)</p>	

**AND**

**2** - One of the following:

- Pituitary surgery has not been curative for the patient
- Patient is not a candidate for pituitary surgery

Product Name: Signifor

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Signifor therapy

Siliq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208187
<b>Guideline Name</b>	Siliq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Siliq	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

2 - Patient is not receiving Siliq in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**AND**

4 - One of the following:

4.1 Patient is currently on Siliq therapy as confirmed by claims history or submitted medical records

**OR**

4.2 All of the following:

4.2.1 One of the following:

4.2.1.1 All of the following:

4.2.1.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

4.2.1.1.2 One of the following:

- Failure of ONE of the following topical therapy classes as confirmed by claims history or submitted medical records: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar
- History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication): Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar

**AND**

**4.2.1.1.3** One of the following:

- Failure of a 3 month trial of methotrexate, at maximally indicated dose, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**4.2.1.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**4.2.2** One of the following:

**4.2.2.1** Failure to TWO of the following preferred products, confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**4.2.3** One of the following:

**4.2.3.1** Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records

**OR**

**4.2.3.2** History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

Notes	*See PDL links in Background
-------	------------------------------

Product Name:Siliq	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Siliq therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Siliq in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL Links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p> <p>NY/NY EPP: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a></p> <p>PA CHIP: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p>RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a></p>

## 3 . Revision History

Date	Notes
3/4/2025	Updated formularies. Removed reference to brand Stelara throughout. Removed Ilumya step in PsO section and added preferred ustekinumab as step therapy option. Updated note to reference PDL links in background. Added NM to PDL links in background.

Simponi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208189
<b>Guideline Name</b>	Simponi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Simponi	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

**2** - Patient is NOT receiving Simponi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Simponi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** BOTH of the following:

**4.2.1** ONE of the following:

**4.2.1.1** Failure to a 3 month trial of ONE non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses, confirmed by claims history or submitted medical records

**OR**

**4.2.1.2** History of intolerance or contraindication to ONE non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) (please specify intolerance or contraindication)

**OR**

**4.2.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib)]

**AND**

**4.2.2** ONE of the following:

- Failure to THREE of the following as confirmed by claims history or submitted medical records: One of the preferred adalimumab products\*, Enbrel (etanercept), Olumiant (baricitinib), Tyenne (tocilizumab-aazg)
- History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication): One of the preferred adalimumab products\*, Enbrel (etanercept), Olumiant (baricitinib), Tyenne (tocilizumab-aazg)

Notes	*See PDL links in Background
-------	------------------------------

<b>Product Name: Simponi</b>	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Simponi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz</p>	

(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with **ONE** of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - **ONE** of the following:

**4.1** Patient is currently on Simponi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** **BOTH** of the following:

**4.2.1** **ONE** of the following:

**4.2.1.1** Failure to a 3 month trial of methotrexate at maximally indicated dose, confirmed by claims history or submitted medical records

**OR**

**4.2.1.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**4.2.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Rinvoq (upadacitinib)]

**AND**

**4.2.2** BOTH of the following:

**4.2.2.1** ONE of the following:

- Failure to TWO of the following as confirmed by claims history or submitted medical records: One of the preferred adalimumab products\*, Enbrel (etanercept), One of the preferred ustekinumab products\*
- History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication): One of the preferred adalimumab products\*, Enbrel (etanercept), One of the preferred ustekinumab products\*

**AND**

**4.2.2.2** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

Notes	*See PDL links in Background
-------	------------------------------

<b>Product Name: Simponi</b>	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active ankylosing spondylitis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is NOT receiving Simponi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Simponi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** BOTH of the following:

**4.2.1** ONE of the following:

**4.2.1.1** Failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks confirmed by claims history or submitted medical records

**OR**

**4.2.1.2** History of intolerance or contraindication to TWO NSAIDs (please specify intolerance or contraindication)

**OR**

**4.2.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Xeljanz/Xeljanz XR (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**4.2.2** BOTH of the following:

**4.2.2.1** ONE of the following:

- Failure to BOTH of the following as confirmed by claims history or submitted medical records: One of the preferred adalimumab products\*, Enbrel (etanercept)
- History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication): One of the preferred adalimumab products\*, Enbrel (etanercept)

**AND**

**4.2.2.2** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

Notes	*See PDL links in Background
-------	------------------------------

<b>Product Name: Simponi</b>	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active ulcerative colitis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is NOT receiving Simponi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Simponi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** BOTH of the following:

**4.2.1** ONE of the following:

**4.2.1.1** Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine) as confirmed by claims history or submitted medical records

**OR**

**4.2.1.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., adalimumab, ustekinumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**4.2.2** ONE of the following:

- Failure to one of the following as confirmed by claims history or submitted medical records: One of the preferred adalimumab products\*, One of the preferred ustekinumab products\*

<ul style="list-style-type: none"> <li>History of intolerance or contraindication to both of the following (please specify intolerance or contraindication): One of the preferred adalimumab products*, One of the preferred ustekinumab products*</li> </ul>	
Notes	*See PDL links in Background

<b>Product Name: Simponi</b>	
Diagnosis	Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Simponi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Simponi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]*</p>	
Notes	* Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

<b>Benefit/Coverage/Program Information</b>
<b>PDL Links</b>

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
3/4/2025	Updated formularies. Added ustekinumab as a step therapy option in PsA and UC. Replaced Stelara with ustekinumab throughout. Added NM to PDL links in background.

Sivextro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155233
<b>Guideline Name</b>	Sivextro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Sivextro tablets	
Diagnosis	Skin and Skin Structure Infections
Approval Length	6 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of acute bacterial skin and skin structure infection (including diabetic foot infections)

**AND**

**3.2** ONE of the following:

**3.2.1** Infection is caused by methicillin-resistant *Staphylococcus aureus* (MRSA) documented by culture and sensitivity report

**OR**

**3.2.2** Presence of MRSA infection is likely and empiric treatment is warranted

**AND**

**3.3** ONE of the following:

**3.3.1** Failure of linezolid (generic Zyvox) confirmed by claims history or submitted medical records

**OR**

**3.3.2** History of intolerance or contraindication to linezolid (generic Zyvox) (please specify intolerance or contraindication)

**AND**

**3.4** ONE of the following:

**3.4.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A tetracycline
- Clindamycin

**OR**

**3.4.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A tetracycline
- Clindamycin

**OR**

**4** - ALL of the following:

**4.1** Diagnosis of acute bacterial skin and skin structure infection (including diabetic foot infections)

**AND**

**4.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Sivextro

**AND**

**4.3** ONE of the following:

**4.3.1** Failure of linezolid (generic Zyvox) confirmed by claims history or submitted medical records

**OR**

**4.3.2** History of intolerance or contraindication to linezolid (generic Zyvox) (please specify intolerance or contraindication)

**AND**

**4.4** ONE of the following:

**4.4.1** Failure of TWO of the following confirmed by claims history or submitted medical records:

- A penicillin
- A cephalosporin
- A tetracycline
- Clindamycin
- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A fluoroquinolone

**OR**

**4.4.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- A Penicillin
- A cephalosporin
- A tetracycline
- Clindamycin
- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A fluoroquinolone

Product Name:Sivextro tablets	
Diagnosis	Off-Label Uses
Approval Length	Based on provider and IDSA recommended treatment durations, up to 6 months.
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - For continuation of therapy upon hospital discharge

**OR**

**2** - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**3** - BOTH of the following:

**3.1** The drug has been recognized for treatment of the indication by the Infectious Diseases Society of America (IDSA)

**AND**

**3.2** ONE of the following:

**3.2.1** Failure of linezolid (generic Zyvox) confirmed by claims history or submitted medical records, if susceptibility is confirmed by culture

**OR**

**3.2.2** History of intolerance or contraindication to linezolid (generic Zyvox), if susceptibility is confirmed by culture (please specify intolerance or contraindication)

## 2 . Revision History

Date	Notes
9/18/2024	Added "tablets" to product name to clarify that the policy is specific to oral tablets not IV form

Skyclarys



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146644
<b>Guideline Name</b>	Skyclarys
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Skyclarys	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Friedreich's ataxia</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Confirmed presence of a mutation in the frataxin (FXN) gene

**AND**

**3** - Prescribed by, or in consultation with, one of the following:

- Neurologist
- Neurogeneticist
- Physical Medicine and Rehabilitation physician (i.e., physiatrist)

Product Name:Skyclarys

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response to Skyclarys therapy

**AND**

**2** - Prescribed by, or in consultation with, one of the following:

- Neurologist
- Neurogeneticist
- Physical Medicine and Rehabilitation physician (i.e., physiatrist)

Skyrizi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208191
<b>Guideline Name</b>	Skyrizi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Skyrizi	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderate to severe plaque psoriasis

**AND**

**2** - Patient is NOT receiving Skyrizi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

**AND**

**4** - One of the following:

**4.1** Patient is currently on Skyrizi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ALL of the following:

**4.2.1** One of the following:

**4.2.1.1** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, ustekinumab, Tremfya (guselkumab)]

**OR**

**4.2.1.2** All of the following:

**4.2.1.2.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**4.2.1.2.2** One of the following:

- Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar
- History of intolerance or contraindication to ALL of the following topical therapies classes (please specify intolerance or contraindication): Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar

**AND**

**4.2.1.2.3** One of the following:

- Failure to a 3 month trial of methotrexate at maximally indicated dose confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**AND**

**4.2.2** One of the following:

**4.2.2.1** Failure to TWO of the following preferred products, confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**4.2.3** One of the following:

- Failure to Cosentyx (secukinumab) confirmed by claims history or submission of medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

Notes

\*See PDL links in Background

Product Name:Skyrizi	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Skyrizi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

**AND**

**3** - Prescribed by or in consultation with **ONE** of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - One of the following:

**4.1** Patient is currently on Skyrizi therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** BOTH of the following:

**4.2.1** One of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., adalimumab, Cimzia (certolizumab), Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Rinvoq (upadacitinib)]

**AND**

**4.2.2** Both of the following:

**4.2.2.1** One of the following:

- Failure to **TWO** of the following as confirmed by claims history or submission of medical records: One of the preferred adalimumab products\*, Enbrel (etanercept), One of the preferred ustekinumab products\*

<ul style="list-style-type: none"> <li>History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication): One of the preferred adalimumab products*, Enbrel (etanercept), One of the preferred ustekinumab products*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4.2.2.2</b> One of the following:</p> <ul style="list-style-type: none"> <li>Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records</li> <li>History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)</li> </ul>	
Notes	*See PDL links in Background

Product Name:Skyrizi	
Diagnosis	Crohn's Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active Crohn's disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - One of the following:</p> <p><b>2.1</b> Patient has been established on therapy with Skyrizi under an active UnitedHealthcare prior authorization for the treatment of moderately to severely active Crohn's disease</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Patient is currently on Skyrizi therapy for moderately to severely active Crohn's disease as confirmed by claims history or submission of medical records</p>	

**AND**

**3** - Patient is NOT receiving Skyrizi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Product Name:Skyrizi	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active ulcerative colitis

**AND**

**2** - One of the following:

**2.1** Patient has been established on therapy with Skyrizi under an active UnitedHealthcare medical benefit prior authorization for the treatment of moderately to severely active ulcerative colitis

**OR**

**2.2** Patient is currently on Skyrizi therapy for moderately to severely active ulcerative colitis as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Skyrizi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Product Name:Skyrizi	
Diagnosis	Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Skyrizi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Skyrizi in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]*</p>	
Notes	* Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

Benefit/Coverage/Program Information	
<b>PDL Links</b>	
CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a>	
HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a>	
MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a>	
NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a>	
NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>	
NY: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a>	
PA: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a>	
RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a>	

### 3 . Revision History

Date	Notes

3/4/2025	Updated formularies. Removed reference to brand Stelara throughout. Removed Ilumya step in PsO section and added preferred ustekinumab as step therapy option. Added ustekinumab as ST option in PsA. Added NM to PDL links in background.
----------	--

Sohonos



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146646
<b>Guideline Name</b>	Sohonos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Sohonos	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of fibrodysplasia ossificans progressiva (FOP)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Diagnosis has been confirmed by the presence of a mutation in the activin receptor IA (ACVR1) gene

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

- Patient is female
- Patient is 8 years of age or older

**OR**

**3.2** BOTH of the following:

- Patient is male
- Patient is 10 years of age or older

**AND**

**4** - Sohonos is being used to reduce the volume of new heterotopic ossification (HO)

**AND**

**5** - Prescribed by or in consultation with an FOP expert (e.g., endocrinologist, geneticist, pediatric orthopedist, pediatric rheumatologist)

Product Name:Sohonos	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Documentation of positive clinical response [e.g., reduction in new HO (heterotopic ossification) volume, improved CAJIS (Cumulative Analogue Joint Involvement Scale) and FOP-PFQ (Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire) scores, improved quality of life]

**AND**

**2** - Prescribed by or in consultation with an FOP expert (e.g., endocrinologist, geneticist, pediatric orthopedist, pediatric rheumatologist)

Somavert



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146647
<b>Guideline Name</b>	Somavert
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Somavert	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of acromegaly confirmed by ONE of the following:</p>	

**1.1.1** Serum GH (growth hormone) level greater than 1 ng/mL (nanogram/milliliter) after a 2 hour oral glucose tolerance test (OGTT) at time of diagnosis

**OR**

**1.1.2** Elevated serum IGF-1 (insulin-like growth factor-1) levels (above the age and gender adjusted normal range as provided by the physician's lab) at time of diagnosis

**AND**

**1.2** ONE of the following:

**1.2.1** Inadequate response to ONE of the following:

- Surgery
- Radiation therapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**OR**

**1.2.2** NOT a candidate for any of the following:

- Surgery
- Radiation therapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**AND**

**1.3** Inadequate response, intolerance, or contraindication to a long-acting somatostatin analog [e.g., Sandostatin LAR (octreotide), Somatuline Depot (lanreotide)]

**OR**

**2** - Patient is currently on Somavert therapy for acromegaly

Product Name: Somavert

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>  1 - Documentation of positive clinical response to Somavert therapy (e.g., age-normalized serum IGF-1 level)	

Soriatane



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146417
<b>Guideline Name</b>	Soriatane
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:acitretin	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe psoriasis</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Prescribed by or in consultation with a dermatologist

**AND**

**3** - ONE of the following:

**3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose, as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**AND**

**4** - ONE of the following:

- Greater than or equal to 10% body surface area involvement
- Palmoplantar, facial, or genital involvement
- Severe scalp psoriasis

Product Name:acitretin	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to the requested therapy</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Prescribed by or in consultation with a dermatologist

Sotyktu



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208193
<b>Guideline Name</b>	Sotyktu
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Sotyktu	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate to severe plaque psoriasis

**AND**

2 - ONE of the following:

2.1 ALL of the following:

2.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

2.1.2 ONE of the following:

2.1.2.1 Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

2.1.2.2 History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**2.1.3** ONE of the following:

**2.1.3.1** Failure to a 3 month trial of methotrexate at the maximally indicated dose confirmed by claims history or submission of medical records

**OR**

**2.1.3.2** History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**3** - ONE of the following:

**3.1** Patient is currently on Sotyktu therapy as confirmed by claims history or submission of medical records

**OR**

**3.2** BOTH of the following:

**3.2.1** ONE of the following:

**3.2.1.1** Failure to ALL of the following preferred products confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**3.2.1.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Failure to Cosentyx (secukinumab) confirmed by claims history or submission of medical records

**OR**

**3.2.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**AND**

**4** - Patient is NOT receiving Sotyktu in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**5** - Prescribed by or in consultation with a dermatologist

Notes	*See PDL links in Background
-------	------------------------------

Product Name: Sotyktu	
Diagnosis	Plaque Psoriasis

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Sotyktu therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Sotyktu in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL Links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
3/4/2025	Updated formularies. Removed reference to brand Stelara throughout. Removed Ilumya step in PsO section and added preferred ustekinumab as step therapy option. Added bypass language to patients currently taking Sotyktu. Added NM to PDL links in background.

Spevigo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151142
<b>Guideline Name</b>	Spevigo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/8/2024
-----------------	----------

### 1 . Criteria

Product Name:Spevigo SC	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of generalized pustular psoriasis (GPP) based on BOTH of the following:</p> <p>1.1 Presence of primary, sterile, macroscopically visible pustules on non-acral skin</p>	

**AND**

**1.2** Pustulation is NOT restricted to psoriatic plaques

**AND**

**2** - BOTH of the following:

- Used to prevent GPP flares
- Patient is NOT currently experiencing a GPP flare

**AND**

**3** - ONE of the following:

**3.1** Patient has been established on therapy with Spevigo for GPP under an active UnitedHealthcare medical benefit prior authorization

**OR**

**3.2** Patient is currently on Spevigo therapy for GPP as documented by claims history or submission of medical records (Document date and duration of therapy)

**AND**

**4** - Patient is NOT receiving Spevigo in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]

**AND**

**5** - Prescribed by a dermatologist

Product Name:Spevigo SC	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy (e.g., reduction in the rate and/or number of GPP flares)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Reduction in the utilization of therapy (e.g., intravenous Spevigo) used for GPP flares</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving Spevigo in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by a dermatologist</p>	

## 2 . Revision History

Date	Notes
8/7/2024	New program.

Spravato



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150655
<b>Guideline Name</b>	Spravato
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Spravato	
Diagnosis	Major Depressive Disorder (Treatment-Resistant)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of major depressive disorder (treatment-resistant), according to the current Diagnostic and Statistical Manual of Mental Disorders (DSM) (i.e., DSM-5-TR) criteria, by a mental health professional</p>	

**AND**

**2** - Prescribed by or in consultation with a psychiatrist

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting baseline scoring (prior to starting Spravato) on at least ONE of the following clinical assessments has been completed:

- Baseline score on the 17-item Hamilton Rating Scale for Depression (HAM-D17)
- Baseline score on the 16-item Quick Inventory of Depressive Symptomatology (QIDS-C16)
- Baseline score on the 10-item Montgomery-Asberg Depression Rating Scale (MADRS)
- Baseline score on the 9-item Patient Health Questionnaire (PHQ-9)

**AND**

**4** - ONE of the following:

**4.1** Failure of THREE different antidepressant medications or treatment regimens at the maximally tolerated dose(s) for at least 8 weeks in the current depressive episode, confirmed by claims history or submitted medical records. An antidepressant or treatment regimen would include any of the following classes or combinations:

- Selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, paroxetine, sertraline)
- Serotonin norepinephrine reuptake inhibitors (e.g., duloxetine, venlafaxine, etc.)
- Bupropion
- Tricyclic antidepressants (e.g., amitriptyline, clomipramine, nortriptyline, etc.)
- Mirtazapine
- Monoamine oxidase inhibitors (e.g., selegiline, tranylcypromine, etc.)
- Serotonin modulators (e.g., nefazodone, trazodone, etc.)
- Augmentation with lithium, Cytomel (liothyronine), antipsychotics, or anticonvulsants

**OR**

**4.2** History of intolerance or contraindication to THREE of the following antidepressant medications or treatment regimens (please specify intolerance or contraindication). An

antidepressant or treatment regimen would include any of the following classes or combinations:

- Selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, paroxetine, sertraline)
- Serotonin norepinephrine reuptake inhibitors (e.g., duloxetine, venlafaxine, etc.)
- Bupropion
- Tricyclic antidepressants (e.g., amitriptyline, clomipramine, nortriptyline, etc.)
- Mirtazapine
- Monoamine oxidase inhibitors (e.g., selegiline, tranylcypromine, etc.)
- Serotonin modulators (e.g., nefazodone, trazodone, etc.)
- Augmentation with lithium, Cytomel (liothyronine), antipsychotics, or anticonvulsants

**AND**

**5** - Spravato will be used in combination with an oral antidepressant (one that the patient has not previously failed)

**AND**

**6** - Provider and/or the provider's healthcare setting is certified in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program

Product Name: Spravato	
Diagnosis	Major Depressive Disorder (Treatment-Resistant)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of remission or a positive clinical response to Spravato therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Spravato will be used in combination with an oral antidepressant (confirmed by claims history or submitted medical records)</p>	

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting baseline and recent (within the last month) scoring on at least ONE of the following assessments demonstrating remission or clinical response (e.g., score reduction from baseline) as defined by:

- Hamilton Rating Scale for Depression (HAM-D17; remission defined as a score of less than or equal to 7)
- Quick Inventory of Depressive Symptomatology (QIDS-C16; remission defined as a score of less than or equal to 5)
- Montgomery-Asberg Depression Rating Scale (MADRS; remission defined as a score of less than or equal to 12)
- Baseline score on the 9-item Patient Health Questionnaire (PHQ-9)

**AND**

**4** - Provider and/or the provider's healthcare setting is certified in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program

**AND**

**5** - Prescribed by or in consultation with a psychiatrist

Product Name: Spravato*	
Diagnosis	Depressive symptoms in an adult with major depressive disorder (MDD) with acute suicidal ideation or behavior
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of major depressive disorder according to the current Diagnostic and Statistical Manual of Mental Disorders (DSM) (i.e., DSM-5-TR) criteria, by a mental health professional	

<b>AND</b>	
2 - Patient is experiencing an acute suicidal ideation or behavior	
<b>AND</b>	
3 - Spravato will be used in combination with a newly initiated or optimized oral antidepressant	
<b>AND</b>	
4 - Provider and/or the provider's healthcare setting is certified in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program	
Notes	*Spravato is hard-coded with a quantity of 0.29 per day for the 56mg strength and 0.43 per day for the 84mg strength. If criteria are met, enter one GPI-12 authorization with an MDD override of 1 and a PQE of 24 per 28 days.

Product Name: Spravato*	
Diagnosis	Depressive symptoms in an adult with major depressive disorder (MDD) with acute suicidal ideation or behavior
Approval Length	12 month(s)
Guideline Type	Quantity Limit
<b>Approval Criteria</b>	
1 - The requested drug is prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in the compendia of current literature	
Notes	*Spravato is hard-coded with a quantity of 0.29 per day for the 56mg strength and 0.43 per day for the 84mg strength. If criteria are met, enter one GPI-12 authorization with an MDD override of 1 and a PQE of 24 per 28 days.

Sprycel



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161083
<b>Guideline Name</b>	Sprycel
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Brand Sprycel, generic dasatinib	
Diagnosis	Philadelphia Chromosome-Positive or BCR-ABL1-Positive Chronic Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Philadelphia chromosome-positive or BCR-ABL1-positive chronic myeloid leukemia</p>	

**AND**

**2** - ONE of the following:

**2.1** Patient is not a candidate for imatinib as attested by physician

**OR**

**2.2** Patient is currently on Sprycel therapy

Product Name: Brand Sprycel, generic dasatinib	
Diagnosis	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)</p>	

Product Name: Brand Sprycel, generic dasatinib	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutations</p>	

Product Name:Brand Sprycel, generic dasatinib	
Diagnosis	Chondrosarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic chondrosarcoma</p>	

Product Name:Brand Sprycel, generic dasatinib	
Diagnosis	Chordoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent chordoma</p>	

Product Name:Brand Sprycel, generic dasatinib	
Diagnosis	Myeloid/Lymphoid Neoplasms with Eosinophilia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia</p>	

<b>AND</b>
<b>2</b> - Patient has an ABL1 (gene) rearrangement

Product Name: Brand Sprycel, generic dasatinib	
Diagnosis	Cutaneous Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of cutaneous melanoma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Tumors are metastatic or unresectable</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Contains activating mutations of KIT</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Used as second-line or subsequent therapy for disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy</p>	

Product Name: Brand Sprycel, generic dasatinib	
Diagnosis	Philadelphia Chromosome-Positive or BCR-ABL1-Positive Chronic Myeloid Leukemia, Ph+ALL, GIST, Chondrosarcoma, Chordoma, Myeloid/Lymphoid Neoplasms with Eosinophilia, Cutaneous Melanoma

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Sprycel therapy</p>	

Product Name:Brand Sprycel, generic dasatinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brand Sprycel, generic dasatinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Sprycel therapy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
11/20/2024	Updated GPs and product list to add generic. Updated criteria for GI ST

Stivarga



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152509
<b>Guideline Name</b>	Stivarga
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Stivarga	
Diagnosis	Colorectal Cancer (CRC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced or metastatic colorectal cancer</p>	

**AND**

**2** - History of failure, contraindication, or intolerance to treatment with ALL of the following:

- Oxaliplatin-based chemotherapy
- Irinotecan-based chemotherapy
- Fluoropyrimidine-based chemotherapy
- Anti-VEGF therapy-based chemotherapy

**AND**

**3** - ONE of the following:

**3.1** Tumor is RAS mutant-type

**OR**

**3.2** BOTH of the following:

**3.2.1** Tumor is RAS wild-type

**AND**

**3.2.2** History of failure, contraindication, or intolerance to anti-EGFR therapy [e.g., Erbitux (cetuximab), Vectibix (panitumumab)]

Product Name: Stivarga	
Diagnosis	Soft Tissue Sarcoma (STS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Diagnosis of soft tissue sarcoma (STS)

**AND**

2 - ONE of the following:

2.1 Extremity/superficial trunk or head/neck that is non-adipocytic with advanced/metastatic disease with disseminated metastases

**OR**

2.2 Retroperitoneal/intra-abdominal that is non-adipocytic with recurrent unresectable or stage IV disease

**OR**

2.3 Advanced/metastatic pleomorphic rhabdomyosarcoma

**OR**

2.4 Angiosarcoma

Product Name:Stivarga	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of gastrointestinal stromal tumor (GIST)	

**AND**

**2** - Disease is one of the following:

- Gross residual (R2 resection)
- Unresectable primary
- Tumor rupture
- Recurrent/metastatic

**AND**

**3** - One of the following:

**3.1** SDH-deficient GIST

**OR**

**3.2** One of the following

**3.2.1** Failure to both of the following as confirmed by claims history or submission of medical records:

- imatinib mesylate (generic Gleevec)
- sunitinib malate) (generic Sutent)

**OR**

**3.2.2** History of contraindication or intolerance to both of the following (please specify intolerance or contraindication):

- imatinib mesylate (generic Gleevec)
- sunitinib malate) (generic Sutent)

Product Name:Stivarga	
Diagnosis	Hepatobiliary Cancers
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Both of the following:</p> <p>1.1 Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Gallbladder cancer</li> <li>• Extrahepatic cholangiocarcinoma</li> <li>• Intrahepatic cholangiocarcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable</li> <li>• Resected gross residual (R2)</li> <li>• Metastatic</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p> <p>2.1 Diagnosis of hepatocellular carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2.2 Used as subsequent-line therapy for disease progression</p>	

Product Name: Stivarga	
Diagnosis	Bone Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Osteosarcoma
- Dedifferentiated chondrosarcoma
- High grade undifferentiated pleomorphic sarcoma (UPS)
- Ewing Sarcoma

**AND**

2 - Disease is ONE of the following:

- Relapsed/refractory
- Metastatic

**AND**

3 - Used as second-line therapy

Product Name:Stivarga	
Diagnosis	Glioblastoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent or progressive glioblastoma</p>	

Product Name:Stivarga
-----------------------

Diagnosis	Colorectal Cancer (CRC), Soft Tissue Sarcoma (STS), Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Cancer, Bone Cancer, Glioblastoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Stivarga therapy</p>	

Product Name:Stivarga	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Stivarga	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Stivarga therapy</p>	

Strensiq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146652
<b>Guideline Name</b>	Strensiq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Strensiq	
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia based on ALL of the following:</p> <p>1.1 ONE of the following:</p>	

**1.1.1** Onset of clinical signs and symptoms of hypophosphatasia prior to age 18 years (e.g., respiratory insufficiency, vitamin B6 responsive seizures, hypotonia, failure to thrive, delayed walking, waddling gait, dental abnormalities, low trauma fractures)

**OR**

**1.1.2** Radiographic evidence supporting the diagnosis of hypophosphatasia at the age of onset prior to age 18 years (e.g., craniosynostosis, infantile rickets, non-traumatic fractures)

**AND**

**1.2** ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** Patient has low level activity of serum alkaline phosphatase (ALP) evidenced by an ALP level below the age and gender-adjusted normal range

**AND**

**1.2.1.2** Patient has an elevated level of tissue non-specific alkaline phosphatase (TNSALP) substrate [e.g., serum pyridoxal 5'-phosphate (PLP) level, serum or urine phosphoethanolamine (PEA) level, urinary inorganic pyrophosphate (PPi level)]

**OR**

**1.2.2** Confirmation of tissue-nonspecific alkaline phosphatase (TNSALP) gene mutation by ALPL genomic DNA (deoxyribonucleic acid) testing\*

**AND**

**2** - Prescribed by ONE of the following:

- Endocrinologist
- A specialist experienced in the treatment of metabolic bone disorders

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** Diagnosis of perinatal/infantile-onset hypophosphatasia

**AND**

**3.1.2** Request does not exceed a maximum supply limit of 9 mg/kg/week (milligrams/kilogram/week)

**OR**

**3.2** BOTH of the following:

**3.2.1** Diagnosis of juvenile-onset hypophosphatasia

**AND**

**3.2.2** Request does not exceed a maximum supply limit of 6 mg/kg/week

**AND**

**4** - ONE of the following:

**4.1** Patient is prescribed Strensiq 18 mg/0.45 mL (milliliter), Strensiq 28 mg/0.7 mL, or Strensiq 40 mg/mL vials

**OR**

**4.2** BOTH of the following:

**4.2.1** Patient is prescribed Strensiq 80 mg/0.8 mL vial

**AND**

**4.2.2** Patient's weight is greater than or equal to 40 kg

Notes	*Results of prior genetic testing can be submitted as confirmation of diagnosis of HPP, however please note that the provider should confirm coverage status of any new genetic testing under the patient's United Healthcare plan prior to ordering.
-------	---

Product Name: Strensiq	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Strensiq therapy (e.g., improvement in clinical symptoms, improvement in Radiographic Global Impression of Change)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Clinically relevant decrease from baseline in tissue non-specific alkaline phosphatase (TNSALP) substrate [e.g., serum pyridoxal 5'-phosphate (PLP) level, serum or urine phosphoethanolamine (PEA) level, urinary inorganic pyrophosphate (PPi level)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Endocrinologist</li> <li>• A specialist experienced in the treatment of metabolic bone diseases</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - ONE of the following:</p>	

**4.1** BOTH of the following:

**4.1.1** Diagnosis of perinatal/infantile-onset hypophosphatasia

**AND**

**4.1.2** Request does not exceed a maximum supply limit of 9 mg/kg/week  
(milligrams/kilogram/week)

**OR**

**4.2** BOTH of the following:

**4.2.1** Diagnosis of juvenile-onset hypophosphatasia

**AND**

**4.2.2** Request does not exceed a maximum supply limit of 6 mg/kg/week

**AND**

**5** - ONE of the following:

**5.1** Patient is prescribed Strensiq 18 mg/0.45 mL (milliliter), Strensiq 28 mg/0.7 mL, or Strensiq 40 mg/mL vials

**OR**

**5.2** BOTH of the following:

**5.2.1** Patient is prescribed Strensiq 80 mg/0.8 mL vials

**AND**

**5.2.2** Patient's weight is greater than or equal to 40 kg

Stromectol



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146418
<b>Guideline Name</b>	Stromectol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Stromectol, generic ivermectin tabs	
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Onchocerciasis due to nematode parasite</li> <li>Pediculosis</li> <li>Strongyloidiasis</li> <li>Ascariasis</li> <li>Scabies (including crusted scabies)</li> </ul>	

- Cutaneous larva migrans (hook worm disease)
- Enterobiasis
- Filariasis
- Trichuriasis
- Gnathostomiasis

Sublingual Immunotherapy (SLIT)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146419
<b>Guideline Name</b>	Sublingual Immunotherapy (SLIT)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Grastek	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by symptoms severe enough to interfere with quality of life (e.g., sleep disturbances; impairment of daily, sport, or leisure activities; impairment of school or work performance)</p>	

**AND**

**2** - Diagnosis confirmed by ONE of the following:

**2.1** Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)

**OR**

**2.2** In vitro testing for pollen-specific IgE (immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)

**AND**

**3** - Treatment is started or will be started at least 12 weeks before the beginning of the grass pollen season

**AND**

**4** - ONE of the following:

**4.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**OR**

**4.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]

<ul style="list-style-type: none"> <li>leukotriene inhibitor [e.g., montelukast (Singulair)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Oralair)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - Patient does not have unstable and/or uncontrolled asthma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>7</b> - Prescribed by or in consultation with a specialist in allergy and immunology</p>
---

Product Name:Grastek	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Grastek therapy</p>	

Product Name:Oralair	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by symptoms severe enough to interfere with quality of life (e.g., sleep disturbances; impairment of daily, sport, or leisure activities; impairment of school or work performance)

**AND**

**2** - Diagnosis confirmed by ONE of the following:

**2.1** Positive skin test to any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]

**OR**

**2.2** In vitro testing for pollen-specific IgE (immunoglobulin E) antibodies for any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]

**AND**

**3** - Treatment is started or will be started at least 4 months before the beginning of the grass pollen season

**AND**

**4** - ONE of the following:

**4.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**OR**

**4.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**5** - Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Grastek)

**AND**

**6** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**7** - Prescribed by or in consultation with a specialist in allergy and immunology

Product Name:Oralair	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Oralair therapy	

Product Name:Ragwitek	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of moderate to severe short ragweed pollen-induced allergic rhinitis defined by symptoms severe enough to interfere with quality of life (e.g., sleep disturbances; impairment of daily, sport, or leisure activities; impairment of school or work performance)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Diagnosis confirmed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Positive skin test to short ragweed pollen</li> <li>• In vitro testing for pollen-specific IgE (immunoglobulin E) antibodies for short ragweed pollen</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Treatment is started or will be started at least 12 weeks before the beginning of the short ragweed pollen season</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - ONE of the following:</p> <p><b>4.1</b> Failure to TWO of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• oral antihistamine [e.g., cetirizine (Zyrtec)]</li> <li>• intranasal antihistamine [e.g., azelastine (Astelin)]</li> <li>• intranasal corticosteroid [e.g., fluticasone (Flonase)]</li> <li>• leukotriene inhibitor [e.g., montelukast (Singulair)]</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>4.2</b> History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):</p>	

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**5** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**6** - Prescribed by or in consultation with a specialist in allergy and immunology

Product Name:Ragwitek	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Ragwitek therapy	

Product Name:Odactra	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of house dust mite (HDM)-induced allergic rhinitis	

**AND**

**2** - Diagnosis confirmed by ONE of the following:

- Positive skin test to licensed house dust mite allergen extracts
- In vitro testing for IgE (immunoglobulin E) antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites

**AND**

**3** - ONE of the following:

**3.1** Failure to TWO of the following as confirmed by claims history or submission of medical records:

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**OR**

**3.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- oral antihistamine [e.g., cetirizine (Zyrtec)]
- intranasal antihistamine [e.g., azelastine (Astelin)]
- intranasal corticosteroid [e.g., fluticasone (Flonase)]
- leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**4** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**5** - Prescribed by or in consultation with a specialist in allergy and immunology

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Product Name:Odactra	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Odactra therapy	

Sucraid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206584
<b>Guideline Name</b>	Sucraid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Sucraid	
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Submission of medical records documenting a diagnosis of congenital sucrase-isomaltase deficiency (CSID)

**AND**

2 - Submission of medical records documenting diagnosis has been confirmed by one of the following:

2.1 Endoscopic biopsy of the small bowel indicating ALL of the following:

2.1.1 Normal small bowel morphology

**AND**

2.1.2 Absent or markedly reduced sucrase activity

**AND**

2.1.3 Isomaltase activity varying from 0 to full activity

**AND**

2.1.4 Reduced maltase activity

**AND**

2.1.5 ONE of the following:

2.1.5.1 Normal lactase activity

**OR**

**2.1.5.2 BOTH of the following:**

- Reduced lactase
- Sucrase:lactase ratio of less than 1.0

**OR**

**2.2** Molecular genetic testing of the sucrase-isomaltase (SI) gene indicating a pathogenic isomaltase gene variant

**OR**

**2.3** Carbon-13 sucrose breath test (13C SBT) indicating a cumulative [13C] CO2 exhalation over 90 minutes below 10th percentile (i.e., less than 3.9% for men and less than 5.2% for women)

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist or rare disease specialist

**AND**

**4** - Will be used with a sucrose-free, low starch diet

Product Name: Sucraid	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Sucraid therapy [e.g., reduced symptoms (e.g., abdominal pain, bloating, gas, vomiting), reduced number of stools per day, reduced number of symptomatic days]</p>	

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist or rare disease specialist

**AND**

**3** - Will be used with a sucrose-free, low starch diet

## 2 . Revision History

Date	Notes
3/5/2025	Updated formularies. Added requirement for submission of medical records documenting diagnosis and confirmation of diagnosis

Sunosi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146421
<b>Guideline Name</b>	Sunosi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Sunosi	
Diagnosis	Narcolepsy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of narcolepsy with BOTH of the following:</p>	

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a multiple sleep latency test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT.

**AND**

**2** - Physician attestation that other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - ONE of the following:

**3.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

**3.1.1** ONE of the following:

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant

**AND**

**3.1.2** ONE of the following:

- Modafinil (generic Provigil)
- Armodafinil (generic Nuvigil)

**OR**

**3.2** History of contraindication or intolerance to ALL of the following drugs or classes (please specify contraindication or intolerance):

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant
- Modafinil (generic Provigil)
- Armodafinil (generic Nuvigil)

**AND**

**4** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist
- Pulmonologist

Product Name:Sunosi	
Diagnosis	Narcolepsy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy	

Product Name:Sunosi	
Diagnosis	Obstructive Sleep Apnea
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of obstructive sleep apnea with ONE of the following:

**1.1** Fifteen or more obstructive respiratory events per hour of sleep confirmed by a sleep study

**OR**

**1.2** BOTH of the following:

**1.2.1** Five or more obstructive respiratory events per hour of sleep confirmed by a sleep study

**AND**

**1.2.2** ONE or more of the following signs/symptoms are present:

- Daytime sleepiness
- Nonrestorative sleep
- Fatigue
- Insomnia
- Waking up with breath holding, gasping, or choking
- Habitual snoring noted by bed partner or other observer
- Observed apnea

**AND**

**2** - BOTH of the following:

**2.1** Standard treatments for the underlying airway obstruction [e.g., continuous positive airway pressure (CPAP), bi-level positive airway pressure (BiPAP)] have been used for one month or longer

**AND**

**2.2** Patient is fully compliant with ongoing treatment(s) for the underlying airway obstruction

**AND**

**3 - ONE of the following:**

**3.1** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- Modafinil (generic Provigil)
- Armodafinil (generic Nuvigil)

**OR**

**3.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Modafinil (generic Provigil)
- Armodafinil (generic Nuvigil)

**AND**

**4 - Prescribed by ONE of the following:**

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist
- Pulmonologist

Product Name: Sunosi	
Diagnosis	Obstructive Sleep Apnea
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy

**AND**

**2** - Patient continues to be fully compliant with ongoing treatment(s) for the underlying airway obstruction (e.g., CPAP, BiPAP)

Sutent



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147812
<b>Guideline Name</b>	Sutent
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of gastrointestinal stromal tumor (GIST)</p>	

**AND**

**2 - ONE of the following:**

**2.1** Disease progression on ONE of the following as confirmed by claims history or submission of medical records:

- imatinib (generic Gleevec)
- Stivarga (regorafenib)
- Standard dose Qinlock (ripretinib)\*

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- imatinib (generic Gleevec)
- Stivarga (regorafenib)

**OR**

**2.3** SDH (succinate dehydrogenase)-deficient GIST

Notes	*Qinlock is non-preferred and should not be included in denial to provider.
-------	---

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Renal Cell Carcinoma (RCC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of renal cell carcinoma (RCC)	

<b>AND</b>
<b>2 - ONE of the following:</b>
<b>2.1</b> Disease has relapsed
<b>OR</b>
<b>2.2</b> Disease is advanced
<b>OR</b>
<b>2.3 BOTH of the following:</b>
<b>2.3.1</b> Used in adjuvant setting
<b>AND</b>
<b>2.3.2</b> Patient has a high risk of recurrence following nephrectomy

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Neuroendocrine and Adrenal Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Progressive pancreatic neuroendocrine tumors (pNET)	

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Soft Tissue Sarcoma

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Alveolar soft part sarcoma (ASPS)</li> <li>• Angiosarcoma</li> <li>• Solitary fibrous tumor/hemangiopericytoma</li> </ul>	

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Follicular carcinoma</li> <li>• Oncocytic carcinoma</li> <li>• Papillary carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable locoregional recurrent disease</li> <li>• Persistent disease</li> <li>• Metastatic disease</li> </ul>	

**AND**

**1.3 ONE of the following:**

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**1.4 Disease is refractory to radioactive iodine treatment**

**OR**

**2 - ALL of the following:**

**2.1 Diagnosis of medullary thyroid carcinoma**

**AND**

**2.2 ONE of the following:**

- Patient has progressive disease
- Patient has symptomatic metastatic disease

**AND**

**2.3 ONE of the following:**

**2.3.1 Clinical trials or preferred systemic therapy options are not available or appropriate [e.g., Caprelsa (vandetanib), Cometriq (cabozantinib)]**

**OR**

**2.3.2 There is progression on preferred systemic therapy options [e.g., Caprelsa (vandetanib), Cometriq (cabozantinib)]**

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Chordoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent chordoma</p>	

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Central Nervous System Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of surgically inaccessible meningiomas</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Disease is recurrent</li> <li>• Disease is progressive</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Further radiation is not possible</p>	

Product Name: Brand Sutent, generic sunitinib
---

Diagnosis	Thymic Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of thymic carcinoma</p>	

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has an FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic or blast phase</p>	

Product Name: Brand Sutent, generic sunitinib	
Diagnosis	GIST, RCC, Neuroendocrine and Adrenal Tumors, Soft Tissue Sarcoma, Thyroid Carcinoma, Chordoma, Central Nervous System Cancer, Thymic Carcinoma, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name:Brand Sutent, generic sunitinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brand Sutent, generic sunitinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

**2 . Revision History**

Date	Notes
------	-------

5/28/2024	Updated criteria for GIST, neuroendocrine/adrenal tumors, and thyroid carcinoma per NCCN recommendations.
-----------	---

Symdeko



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151686
<b>Guideline Name</b>	Symdeko
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Symdeko	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Submission of laboratory result documenting ONE of the following:

**2.1** The patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

**OR**

**2.2** The patient has at least ONE mutation in the CFTR gene that is responsive to Symdeko (See Table in Background Section)

**AND**

**3** - Prescribed by, or in consultation with, a provider who specializes in the treatment of CF

Product Name: Symdeko	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Symdeko therapy (e.g., improved lung function, stable lung function)</p>	

## 2 . Background

Benefit/Coverage/Program Information					
Table 1 CFTR Gene Mutations					
546insCTA	E92K	G576A	L346P	R117G	S589N

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

711+3A→G*	E116K	G576A;R668C †	L967S	R117H	S737F
2789+5G→A*	E193K	G622D	L997F	R117L	S912L
3272-26A→G*	E403D	G970D	L1324P	R117P	S945L *
3849+10kbC→T *	E588V	G1069R	L1335P	R170H	S977F*
A120T	E822K	G1244E	L1480P	R258G	S1159F
A234D	E831X	G1249R	M152V	R334L	S1159P
A349V	F191V	G1349D	M265R	R334Q	S1251N
A455E *	F311del	H939R	M952I	R347H *	S1255P
A554E	F311L	H1054D	M952T	R347L	T338I
A1006E	F508C	H1375P	P5L	R347P	T1036N
A1067T	F508C; S1251N †	I148T	P67L *	R352Q *	T1053I
D110E	F508del ‡	I175V	P205S	R352W	V201M
D110H *	F575Y	I336K	Q98R	R553Q	V232D
D192G	F1016S	I601F	Q237E	R668C	V562I
D443Y	F1052V	I618T	Q237H	R751L	V754M
D443Y; G576A; R668C †	F1074L	I807M	Q359R	R792G	V1153E
D579G *	F1099L	I980K	Q1291R	R933G	V1240G

D614G	G126D	I1027T	R31L	R1066H	V1293G
D836Y	G178E	I1139V	R74Q	R1070Q	W1282R
D924N	G178R	I1269N	R74W	R1070W *	Y109N
D979V	G194R	I1366N	R74W; D1270N †	R1162L	Y161S
D1152H *	G194V	K1060T	R74W; V201M †	R1283M	Y1014C
D1270N	G314E	L15P	R74W; V201M; D1270N †	R1283S	Y1032C
E56K	G551D	L206W *	R75Q	S549N	
E60K	G551S	L320V	R117C *	S549R	

\* Clinical data for these mutations in Clinical Studies.

^ A patient must have two copies of the F508del mutation or at least one copy of a responsive mutation presented in the table to be indicated.

† Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.

### 3 . Revision History

Date	Notes
8/13/2024	Simplified reauthorization criteria

Synagis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157006
<b>Guideline Name</b>	Synagis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Synagis*	
Diagnosis	Prematurity
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Patient is an infant born before 29 weeks, 0 days gestation</p> <p style="text-align: center;"><b>AND</b></p>	

**1.2** Patient is less than 12 months of age at the start of RSV “season”

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV “season”\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV “season”

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children

<ul style="list-style-type: none"> <li>Synagis prophylaxis for prevention of nosocomial disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>7 - The request is NOT for one of the following:</p> <ul style="list-style-type: none"> <li>Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab</li> <li>Treatment of symptomatic RSV disease</li> </ul>	
Notes	<p>*Approval for up to 5 doses per single RSV "season."                  **Information regarding RSV season may be found at:                  • Centers for Disease and Prevention (CDC) surveillance reports: <a href="http://www.cdc.gov/nrevss/php/dashboard/index.html">http://www.cdc.gov/nrevss/php/dashboard/index.html</a>                  ***Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV "season," fewer than 5 monthly doses may be needed.</p>

Product Name: Synagis*	
Diagnosis	Chronic Lung Disease (CLD)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 ALL of the following for patients age 0 to less than 12 months:</p> <p>1.1.1 The patient is a preterm infant defined as gestational age less than 32 weeks, 0 days</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Patient has developed chronic lung disease (CLD) of prematurity</p>	

**AND**

**1.1.3** There was a requirement for greater than 21% oxygen for at least the first 28 days after birth

**OR**

**1.2** ALL of the following for patients age greater than or equal to 12 months to less than 24 months:

**1.2.1** The patient was born at less than 32 weeks, 0 days gestation

**AND**

**1.2.2** The patient required at least 28 days of oxygen after birth

**AND**

**1.2.3** The patient continues to require supplemental oxygen, diuretics, or chronic systemic corticosteroid therapy within 6 months of the start of the second RSV "season"

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV "season"\*\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV “season”

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease

**AND**

**7** - The request is NOT for one of the following:

- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Treatment of symptomatic RSV disease

Notes

\*Approval for up to 5 doses per single RSV “season.”  
\*\*Information regarding RSV season may be found at:  
• Centers for Disease and Prevention (CDC) surveillance reports: <https://www.cdc.gov/nrevss/php/dashboard/index.html>  
\*\*\*Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 doses

	eries for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.
--	--

Product Name: Synagis*	
Diagnosis	Congenital Heart Disease (CHD)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 ONE of the following for patients age 0 to less than 12 months:</p> <p>1.1.1 Patient has hemodynamically significant congenital heart disease (CHD) including ONE of the following:</p> <ul style="list-style-type: none"> <li>• Acyanotic heart disease and receiving medication to control congestive heart failure and will require cardiac surgical procedures</li> <li>• Moderate to severe pulmonary hypertension</li> <li>• Documentation that decisions regarding prophylaxis for infants with cyanotic heart defects were made in consultation with a pediatric cardiologist</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.1.2 The patient is undergoing cardiac transplantation during the RSV “season”</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 BOTH of the following:</p> <p>1.2.1 The patient is greater than or equal to 12 months to less than 24 months of age</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2.2 ONE of the following:</p>	

- After cardiac bypass
- At the conclusion of extracorporeal membrane oxygenation
- The patient is undergoing cardiac transplantation during the RSV “season”

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV “season”\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV “season”

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)

- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease

**AND**

7 - The request is NOT for one of the following:

- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Treatment of symptomatic RSV disease

Notes	<p>*Approval for up to 5 doses per single RSV “season.”</p> <p>**Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>• Centers for Disease and Prevention (CDC) surveillance reports: <a href="http://www.cdc.gov/nrevss/php/dashboard/index.html">http://www.cdc.gov/nrevss/php/dashboard/index.html</a></li> </ul> <p>***Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
-------	--

Product Name:Synagis*	
Diagnosis	Congenital abnormalities of the airway or neuromuscular disease
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Patient is age 0 to less than 12 months</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Patient has ONE of the following:</p>	

- Neuromuscular disease
- A congenital anomaly that impairs the ability to clear secretions from the lower airway because of ineffective cough

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV "season"\*\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV "season"

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)

- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease

**AND**

7 - The request is NOT for one of the following:

- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Treatment of symptomatic RSV disease

Notes	<p>*Approval for up to 5 doses per single RSV “season.”</p> <p>**Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>• Centers for Disease and Prevention (CDC) surveillance reports: <a href="https://www.cdc.gov/nrevss/php/dashboard/index.html">https://www.cdc.gov/nrevss/php/dashboard/index.html</a></li> </ul> <p>***Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
-------	--

Product Name:Synagis*	
Diagnosis	Immunocompromised children less than 24 months of age
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Patient is less than 24 months of age</p> <p style="text-align: center;"><b>AND</b></p>	

**1.2** The patient is immunocompromised (e.g. receiving cancer chemotherapy, undergoing hematopoietic stem cell transplantation, or solid organ transplantation)

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV "season"\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV "season"

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children

- Synagis prophylaxis for prevention of nosocomial disease

**AND**

7 - The request is NOT for one of the following:

- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Treatment of symptomatic RSV disease

Notes

\*Approval for up to 5 doses per single RSV "season."  
 \*\*Information regarding RSV season may be found at:  
 • Centers for Disease and Prevention (CDC) surveillance reports: <http://www.cdc.gov/nrevss/php/dashboard/index.html>  
 \*\*\*Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV "season," fewer than 5 monthly doses may be needed.

Product Name: Synagis*	
Diagnosis	Cystic fibrosis (CF)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following for patients age 0 to less than 12 months:</p> <p>1.1.1 Patient has cystic fibrosis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Patient has clinical evidence of at least ONE of the following:</p>	

- Chronic lung disease (CLD)
- Nutritional compromise
- Failure to thrive defined as weight for length less than the 10th percentile on a pediatric growth chart

**OR**

**1.2 BOTH** of the following:

**1.2.1** Patient is greater than or equal to 12 months to less than 24 months of age

**AND**

**1.2.2** Patient has manifestations of severe lung disease including **ONE** of the following:

- Previous hospitalization for pulmonary exacerbation in the first year of life
- Abnormalities on chest radiography or chest computed tomography that persists when stable
- Weight for length less than the 10th percentile on a pediatric growth chart

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Dosage of Synagis does not exceed 5 monthly doses per single RSV "season"\*\*\*

**AND**

**5** - Patient has not previously received treatment with Beyfortus (nirsevimab-alip) during or entering the current RSV "season"

**AND**

**6** - Synagis is not being requested for any of the following situations alone:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease

**AND**

**7** - The request is NOT for one of the following:

- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Treatment of symptomatic RSV disease

Notes	<p>*Approval for up to 5 doses per single RSV “season.”</p> <p>**Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>• Centers for Disease and Prevention (CDC) surveillance reports: <a href="http://www.cdc.gov/nrevss/php/dashboard/index.html">http://www.cdc.gov/nrevss/php/dashboard/index.html</a></li> </ul> <p>***Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. Any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
-------	--

## 2 . Background

Benefit/Coverage/Program Information
<p><b>Additional Information</b></p> <p>In most of North America, peak RSV activity typically occurs between November and March, usually beginning in November or December, peaking in January or February, and ending by the end of March or sometime in April. Communities in the southern United States, particularly some communities in the state of Florida, tend to experience the earliest onset of RSV. Data from the Centers for Disease Control and Prevention (CDC) have identified variations in the onset and offset of the RSV “season” in the state of Florida that could affect the timing of Synagis administration.</p> <ul style="list-style-type: none"> <li>• Despite varied onsets, the RSV “season” is of the same duration (5 months) in the different regions of Florida.</li> <li>• On the basis of the epidemiology of RSV in Alaska, particularly in remote regions where the burden of RSV disease is significantly greater than the general US population, the selection of Alaska Native infants eligible for prophylaxis may differ from the remainder of the United States. Clinicians may wish to use RSV surveillance data generated by the state of Alaska to assist in determining onset and end of the RSV season for qualifying infants.</li> <li>• Limited information is available concerning the burden of RSV disease among Native American populations. However, special consideration may be prudent for Navajo and White Mountain Apache infants in the first year of life.</li> </ul> <p>For analysis of National Respiratory and Enteric Virus Surveillance System (NREVSS) reports in the CDC Morbidity and Mortality Weekly Report, season onset is defined as the first of 2 consecutive weeks during which the mean percentage of specimens testing positive for RSV antigen is <math>\geq 10\%</math> or the mean percentage of specimens testing positive for RSV by PCR is <math>\geq 3\%</math>, whichever occurs first. RSV “season” offset is defined as the last week during which the mean percentage of positive specimens is <math>\geq 10\%</math>, or the mean percentage of positive specimens by PCR is <math>\geq 3\%</math>, whichever occurs last. Use of specimens to determine the start of the RSV “season” requires that the number of specimens tested be statistically significant.</p>

## 3 . Revision History

Date	Notes
10/3/2024	Updated CDC website. Removed old sharepoint link.



Tabrecta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146658
<b>Guideline Name</b>	Tabrecta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Tabrecta	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - ONE of the following:

**2.1** Presence of mesenchymal-epithelial transition (MET) exon 14 skipping positive tumors

**OR**

**2.2** High level MET amplification in lung cancer

<b>Product Name:Tabrecta</b>	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Tabrecta therapy	

<b>Product Name:Tabrecta</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

Product Name:Tabrecta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tabrecta therapy</p>	

Tafinlar



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151115
<b>Guideline Name</b>	Tafinlar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/7/2024
-----------------	----------

## 1 . Criteria

Product Name:Tafinlar	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Unresectable melanoma</p>	

<b>OR</b>
<b>1.2</b> Metastatic melanoma
<b>OR</b>
<b>1.3</b> BOTH of the following:
<b>1.3.1</b> Prescribed as adjuvant therapy for melanoma involving the lymph node(s)
<b>AND</b>
<b>1.3.2</b> Used in combination with Mekinist (trametinib)
<b>AND</b>
<b>2</b> - Cancer is positive for BRAF V600 mutation
<b>AND</b>
<b>3</b> - If the request is for Tafenlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafenlar capsules (document reason or special circumstance)

<b>Product Name: Tafenlar</b>	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - ONE of the following:

**1.1** BOTH of the following:

**1.1.1** Patient has metastatic brain lesions

**AND**

**1.1.2** Tafinlar is active against primary tumor (melanoma)

**OR**

**1.2** Patient has a glioma

**AND**

**2** - Cancer is positive for BRAF V600E mutation

**AND**

**3** - Used in combination with Mekinist (trametinib)

**AND**

**4** - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

Product Name:Tafinlar	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of non-small cell lung cancer (NSCLC)

**AND**

**2** - Disease is ONE of the following:

- Metastatic
- Advanced
- Recurrent

**AND**

**3** - Cancer is positive for BRAF V600E mutation

**AND**

**4** - ONE of the following:

- Used in combination with Mekinist (trametinib)
- Used as a single agent if the combination of Mekinist and Tafinlar is not tolerated

**AND**

**5** - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

Product Name:Tafinlar	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of anaplastic thyroid cancer (ATC)

**AND**

1.2 Cancer is positive for BRAF V600E mutation

**AND**

1.3 Used in combination with Mekinist (trametinib)

**AND**

1.4 ONE of the following:

1.4.1 Disease is ONE of the following:

- Metastatic
- Locally advanced
- Unresectable

**OR**

1.4.2 Prescribed as adjuvant therapy following resection

**AND**

1.5 If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

**OR**

**2** - ALL of the following:

**2.1** ONE of the following diagnoses:

- Follicular carcinoma
- Oncocytic carcinoma
- Papillary carcinoma

**AND**

**2.2** ONE of the following:

- Unresectable locoregional recurrent disease
- Persistent disease
- Metastatic disease

**AND**

**2.3** ONE of the following:

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**2.4** Disease is refractory to radioactive iodine treatment

**AND**

**2.5** Cancer is positive for BRAF V600 mutation

**AND**

**2.6** If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

<b>Product Name:</b> Tafinlar	
Diagnosis	Hepatobiliary Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Gallbladder cancer</li> <li>• Extrahepatic Cholangiocarcinoma</li> <li>• Intrahepatic Cholangiocarcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as subsequent treatment after progression on or after systemic treatment</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is unresectable or metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Cancer is positive for BRAF V600E mutation</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Used in combination with Mekinist (trametinib)</p>	

**AND**

**6** - If the request is for Tafenlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafenlar capsules (document reason or special circumstance)

Product Name:Tafenlar	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Langerhans Cell Histiocytosis</li> <li>• Erdheim-Chester Disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Cancer is positive for BRAF V600E mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - If the request is for Tafenlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafenlar capsules (document reason or special circumstance)</p>	

Product Name:Tafenlar	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Presence of solid tumor</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used as subsequent treatment after progression on or after systemic treatment</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Disease is unresectable or metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Cancer is positive for BRAF V600E mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Used in combination with Mekinist (trametinib)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)</p>	

Product Name:Tafinlar	
Diagnosis	Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Epithelial Ovarian Cancer</li> <li>• Fallopian Tube Cancer</li> <li>• Primary Peritoneal Cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Persistent disease</li> <li>• Recurrence in BRAF V600E positive tumors</li> <li>• Recurrence of low-grade serous carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Used in combination with Mekinist (trametinib)</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)</b></p>	

Product Name:Tafinlar	
Diagnosis	Pancreatic Cancer / Ampullary Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of ONE of the following:

- Pancreatic adenocarcinoma
- Ampullary adenocarcinoma

**AND**

**2** - Disease is ONE of the following:

- Metastatic
- Locally advanced
- Unresectable

**AND**

**3** - Cancer is positive for BRAF V600E mutation

**AND**

**4** - Used in combination with Mekinist (trametinib)

**AND**

**5** - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

Product Name:Tafinlar	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of hairy cell leukemia

**AND**

2 - Used in combination with Mekinist (trametinib)

**AND**

3 - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

Product Name:Tafinlar	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of salivary gland tumor

**AND**

2 - Disease is ONE of the following:

- Recurrent and unresectable
- Metastatic

**AND**

**3** - Cancer is positive for BRAF V600E mutation

**AND**

**4** - Used in combination with Mekinist (trametinib)

**AND**

**5** - If the request is for Tafinlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafinlar capsules (document reason or special circumstance)

Product Name:Tafinlar	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of BRAF V600E-mutated gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Gross residual disease (R2 resection)</li> <li>• Unresectable primary disease</li> <li>• Tumor rupture</li> <li>• Progressive</li> <li>• Recurrent</li> <li>• Metastatic</li> </ul>	

**AND**

**3** - Used in combination with Mekinist (trametinib)

**AND**

**4** - If the request is for Tafenlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafenlar capsules (document reason or special circumstance)

Product Name:Tafenlar	
Diagnosis	All Indications except NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Tafenlar therapy	

Product Name:Tafenlar	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

**AND**

**2** - If the request is for Tafenlar tablets for oral solution, there is a reason or special circumstance why the patient is unable to use Tafenlar capsules (document reason or special circumstance)

Product Name:Tafenlar	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tafenlar therapy</p>	

## 2 . Revision History

Date	Notes
8/6/2024	Added new criteria for hairy cell leukemia, salivary gland tumor, and GIST.

Tagrisso



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164122
<b>Guideline Name</b>	Tagrisso
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Tagrisso	
Diagnosis	Central Nervous System (CNS) Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of brain metastases from EGFR mutation-positive non-small cell lung cancer (NSCLC)</p>	

**OR**

**2** - Diagnosis of leptomeningeal metastases from EGFR mutation-positive NSCLC

Product Name: Tagrisso	
Diagnosis	Central Nervous System (CNS) Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Tagrisso therapy</p>	

Product Name: Tagrisso	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is positive for at least ONE of the following EGFR mutations:</p> <ul style="list-style-type: none"> <li>• Exon 19</li> <li>• Exon 21 L858R</li> <li>• S767I</li> </ul>	

- L861Q
- G719X
- T790M

**AND**

**3** - One of the following:

**3.1** All of the following:

- disease is stage IB, II, IIIA, or IIIB (T3, N2)
- Patient has undergone complete resection
- Patient has received previous adjuvant chemotherapy or ineligible to receive platinum-based chemotherapy

**OR**

**3.2** All of the following:

- Disease is stage II-III
- Disease is locally advanced or unresectable
- No disease progression during or following concurrent or sequential chemoradiation

**OR**

**3.3** Disease is recurrent, advanced, or metastatic

Product Name:Tagrisso	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Tagrisso therapy	

Product Name:Tagrisso	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Tagrisso	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tagrisso therapy</p>	

Takhzyro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147196
<b>Guideline Name</b>	Takhzyro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Takhzyro	
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hereditary angioedema (HAE) as confirmed by ONE of the following:</p> <p>1.1 C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):</p> <ul style="list-style-type: none"> <li>C1-INH antigenic level below the lower limit of normal</li> </ul>	

- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

**1.2.1** Confirmed presence variant(s) in the gene(s) for factor XII, angiotensin-1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosamine 3-O-sulfotransferase 6

**OR**

**1.2.2** Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema

**OR**

**1.2.3** Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

**AND**

**2** - BOTH of the following:

**2.1** For prophylaxis against HAE attacks

**AND**

**2.2** Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Haegarda, Orladeyo)

**AND**

**3** - BOTH of the following:

**3.1** Prescriber attests that patient has experienced attacks of a severity and/or frequency such that they would clinically benefit from prophylactic therapy with Takhzyro

**AND**

**3.2** Documentation of baseline HAE attack rate is greater than or equal to one attack per 4 weeks

**AND**

**4** - Prescribed by ONE of the following:

- Immunologist
- Allergist

**AND**

**5** - ONE of the following:

**5.1** Failure to Haegarda confirmed by claims history or submitted medical records

**OR**

**5.2** History of contraindication or intolerance to Haegarda (please specify intolerance or contraindication)

**OR**

**5.3** Patient is currently on Takhzyro therapy confirmed by claims history or submitted medical records

**AND**

**6** - ONE of the following:

**6.1** For adult and pediatric patients 12 years and older, Takhzyro 300 mg (milligrams) is given every 2 weeks\*

**OR**

**6.2** For pediatric patients 6 to less than 12 years of age, Takhzyro 150 mg is given every 2 weeks\*

**OR**

**6.3** For pediatric patients less than 6 years of age, Takhzyro 150 mg is given every 4 weeks\*\*

Notes

\*Adult and pediatric patients 6 years of age and older approval length: 8 months.  
 \*\*Pediatric patients less than 6 years of age approval length: 12 months.

Product Name: Takhzyro

Therapy Stage

Reauthorization

Guideline Type

Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response while on Takhzyro therapy

**AND**

**2** - Reduction in the utilization of on-demand therapies used for acute attacks (e.g., Berinert, Ruconest, Firazyr, Kalbitor) as determined by claims information, while on Takhzyro therapy

**AND**

**3** - Prescribed by ONE of the following:

- Immunologist
- Allergist

**AND**

**4 - BOTH** of the following:

**4.1** For prophylaxis against hereditary angioedema (HAE) attacks

**AND**

**4.2** Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Haegarda, Orladeyo)

**AND**

**5 - ONE** of the following:

**5.1** Patient is less than 6 years of age and Takhzyro 150 mg (milligrams) is given every 4 weeks\*

**OR**

**5.2** Patient is at least 6 years of age, and **BOTH** of the following:

**5.2.1** Documentation of the number of acute HAE attacks in the previous 6 months, while on Takhzyro therapy

**AND**

**5.2.2** **ONE** of the following:

**5.2.2.1** If the patient experienced no (zero) acute HAE attacks in the previous 6 months, **ONE** of the following\*:

- For adult and pediatric patients 12 years of age and older, Takhzyro 300 mg is given every 4 weeks\*\*
- For pediatric patients 6 to less than 12 years of age, Takhzyro 150 mg is given every 4 weeks\*\*

**OR**

**5.2.2.2** If the patient experienced one or more HAE attacks in the previous 6 months, ONE of the following\*\*\*:

- For adult and pediatric patients 12 years of age and older, Takhzyro 300 mg is given every 2 weeks
- For pediatric patients 6 to less than 12 years of age, Takhzyro 150 mg is given every 2 weeks

Notes	<p>*Patient experienced no acute HAE attacks in the previous 6 months, or is less than 6 years of age approval length: 12 months.</p> <p>**Patients experiencing unexpected breakthrough HAE attacks once switched to every 4 week dosing will require additional review to allow for 2 weeks dosing.</p> <p>***Patient experienced 1 or more HAE attacks in the previous 6 months approval length: 6 months.</p>
-------	---

## 2 . Revision History

Date	Notes
5/9/2024	Update to diagnostic criteria for HAE with normal C1 inhibitor levels. Updated and simplified reauthorization criteria.

Taltz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206586
<b>Guideline Name</b>	Taltz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Taltz	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

1.2 ONE of the following:

1.2.1 ALL of the following:

1.2.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

1.2.1.2 One of the following:

1.2.1.2.1 Failure to ONE of the following topical therapy classes as confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

1.2.1.2.2 History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication)

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin

- Coal tar

**AND**

**1.2.1.3** ONE of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya (guselkumab)]

**AND**

**1.3** One of the following:

**1.3.1** Failure to TWO of the following preferred products, as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products^
- Enbrel (etanercept)
- One of the preferred ustekinumab products^

**OR**

**1.3.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products^
- Enbrel (etanercept)
- One of the preferred ustekinumab products^

**AND**

**1.4 ONE of the following:**

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

**AND**

**1.5** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.6** Prescribed by or in consultation with a dermatologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Taltz therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**2.3** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

<b>AND</b>	
<b>2.4</b> Prescribed by or in consultation with a dermatologist	
Notes	^See Table 1 for PDL Links

Product Name:Taltz	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of active psoriatic arthritis

**AND**

1.2 ONE of the following:

1.2.1 Failure to a 3 month trial of methotrexate at the maximally indicated dose as confirmed by claims history or submission of medical records

**OR**

1.2.2 History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical

records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi (risankizumab)]

**AND**

**1.3** One of the following:

**1.3.1** Failure to TWO of the following preferred products as confirmed by claims history or submission of medical records

- One of the preferred adalimumab products^
- Enbrel (etanercept)
- One of the preferred ustekinumab products^

**OR**

**1.3.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication)

- One of the preferred adalimumab products^
- Enbrel (etanercept)
- One of the preferred ustekinumab products^

**AND**

**1.4** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

**AND**

**1.5** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.6** Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Taltz therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist

Notes

^See Table 1 for PDL Links

Product Name:Taltz

Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of active ankylosing spondylitis

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records

**OR**

**1.2.2** History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab)].

**AND**

**1.3** One of the following:

**1.3.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products^
- Enbrel (etanercept)

**OR**

**1.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication)

- One of the preferred adalimumab products^
- Enbrel (etanercept)

**AND**

**1.4** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

**AND**

**1.5** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.6** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Taltz therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active ankylosing spondylitis

**AND**

**2.3** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	^See Table 1 for PDL Links
-------	----------------------------

Product Name:Taltz	
Diagnosis	Non-Radiographic Axial Spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> Diagnosis of active non-radiographic axial spondyloarthritis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> ONE of the following:</p> <p><b>1.2.1</b> Failure to two NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen,</p>	

naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records

**OR**

**1.2.2** History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of non-radiographic axial spondyloarthritis as confirmed by claims history or submission of medical records [e.g. Cimzia (certolizumab), Cosentyx (secukinumab)]

**AND**

**1.3** ONE of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Cosentyx (secukinumab) (please specify contraindication or intolerance)

**AND**

**1.4** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Taltz therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active non-radiographic axial spondyloarthritis

**AND**

**2.3** Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Product Name:Taltz	
Diagnosis	Plaque Psoriasis, Psoriatic Arthritis (PsA), Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Taltz therapy</p> <p><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx</p>	

(secukinumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]*	
Notes	*Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

Benefit/Coverage/Program Information
<p><b>Table 1: PDL Links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NY/NY EPP: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a></p> <p>PA CHIP: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p>RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>

## 3 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
3/5/2025	Added NM to formulary. Criteria updates. Changed "Stelara" to "uste kinumab" .

Talzenna



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146663
<b>Guideline Name</b>	Talzenna
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Talzenna	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - Disease is ONE of the following:

- Locally advanced
- Metastatic

**AND**

**3** - Presence of a germline BRCA (breast cancer)-mutation

**AND**

**4** - ONE of the following:

**4.1** Patient is currently on Talzenna therapy as confirmed by claims history or submitted medical records

**OR**

**4.2** History of intolerance or contraindication to Lynparza (please specify intolerance or contraindication)

**OR**

**4.3** Provider attests that the patient is not an appropriate candidate for Lynparza

Product Name:Talzenna	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of metastatic castration-resistant prostate cancer

**AND**

2 - Presence of homologous recombination repair (HRR) gene mutations

**AND**

3 - Used in combination with Xtandi (enzalutamide)

**AND**

4 - ONE of the following:

4.1 Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

4.2 Patient has had bilateral orchiectomy

Product Name: Talzenna	
Diagnosis	Breast Cancer, Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Patient does not show evidence of progressive disease while on Talzenna therapy

Product Name:Talzenna	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Talzenna	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Talzenna therapy</p>	

Tarceva



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164100
<b>Guideline Name</b>	Tarceva
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Tarceva, generic erlotinib	
Diagnosis	Pancreatic Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pancreatic cancer</p>	

**AND**

**2** - Disease is ONE of the following:

- Locally advanced
- Unresectable
- Metastatic

**AND**

**3** - Used in combination with gemcitabine

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of non-small cell lung cancer (NSCLC)

**AND**

**2** - Disease is ONE of the following:

- Metastatic
- Recurrent
- Advanced

**AND**

**3** - ONE of the following:

- Tumors are positive for epidermal growth factor receptor (EGFR)exon 19 deletions
- Tumors are positive for exon 21 (L858R) substitution mutations
- Tumors are positive for a known sensitizing EGFR mutation (e.g., S768I, L861Q, G719X)

Product Name:Brand Tarceva, generic erlotinib	
Diagnosis	Chordoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chordoma</p>	

Product Name:Brand Tarceva, generic erlotinib	
Diagnosis	Kidney Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of kidney cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is stage IV or relapsed</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Disease is of non-clear cell histology

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of brain, leptomeningeal, or spine metastases from non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions</li> <li>• Tumors are positive for exon 21 (L858R) substitution mutations</li> <li>• Tumors are positive for a known sensitizing EGFR mutation (e.g., S768I, L861Q, G719X)</li> </ul>	

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	Vulvar cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of vulvar cancer</p>	

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Chordoma, Kidney Cancer, Central Nervous System (CNS) Cancers, Vulvar Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Tarceva therapy</p>	

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Brand Tarceva, generic erlotinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tarceva therapy</p>	



Targretin (bexarotene)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146665
<b>Guideline Name</b>	Targretin (bexarotene)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Targretin, generic bexarotene	
Diagnosis	Cutaneous T-Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cutaneous T-cell lymphoma (CTCL)</p>	

**AND**

**2 - ONE of the following:**

**2.1** Failure to at least one prior therapy (including skin-directed therapies [e.g., corticosteroids (clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate), phototherapy, or systemic therapies [e.g., interferons]) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to at least one prior therapy (including skin-directed therapies [e.g., corticosteroids (clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate), phototherapy, or systemic therapies [e.g., interferons]) (please specify contraindication or intolerance)

Product Name:Brand Targretin, generic bexarotene	
Diagnosis	Cutaneous T-Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient has not had disease progression while on therapy	

Product Name:Brand Targretin, generic bexarotene	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Brand Targretin, generic bexarotene	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Tarpeyo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146666
<b>Guideline Name</b>	Tarpeyo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Tarpeyo	
Approval Length	9 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal biopsy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is at risk for disease progression</p>	

**AND**

**3** - Used to reduce the loss of kidney function

**AND**

**4** - Estimated glomerular filtration rate (eGFR) greater than or equal to 35 mL/min/1.73 m<sup>2</sup> (milliliters/minute/1.73 square meters)

**AND**

**5** - ONE of the following:

**5.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following, as confirmed by claims history or submitted medical records:

- Maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Maximally tolerated angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**OR**

**5.2** Patient has an allergy, contraindication, or intolerance to ACE inhibitors and ARBs (please specify allergy, contraindication, or intolerance)

**AND**

**6** - ONE of the following:

**6.1** Failure of ONE 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) confirmed by claims history or submitted medical records

**OR**

**6.2** History of intolerance or contraindication to ONE glucocorticoid (please specify intolerance or contraindication)

**AND**

**7** - Prescribed by or in consultation with a nephrologist

Tasigna



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146667
<b>Guideline Name</b>	Tasigna
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Tasigna	
Diagnosis	Chronic Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic myeloid leukemia</p>	

**AND**

**2** - ONE of the following:

**2.1** Patient is not a candidate for imatinib (Gleevec) as attested by physician

**OR**

**2.2** Patient is currently on Tassigna therapy

Product Name:Tassigna	
Diagnosis	Gastrointestinal Stromal Tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of progressive gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> Failure to ALL of the following, as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Imatinib (generic Gleevec)</li> <li>• Sunitinib (generic Sutent)</li> <li>• Stivarga (regorafenib)</li> <li>• Qinlock (ripretinib)</li> </ul> <p style="text-align: center;"><b>OR</b></p>	

**2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Imatinib (generic Gleevec)
- Sunitinib (generic Sutent)
- Stivarga (regorafenib)
- Qinlock (ripretinib)

Product Name:Tasigna	
Diagnosis	Acute Lymphoblastic Leukemia (Ph+B-ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+B-ALL)</p>	

Product Name:Tasigna	
Diagnosis	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of myeloid, lymphoid or mixed lineage neoplasms with eosinophilia and ABL1 (gene) rearrangement</p> <p style="text-align: center;"><b>AND</b></p>	

2 - Neoplasm is in blast or chronic phase

Product Name:Tasigna	
Diagnosis	Melanoma: Cutaneous
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic or unresectable melanoma cutaneous tumors with activating mutations of KIT</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as second-line or subsequent therapy for disease progression, intolerance, and or projected risk of progression with BRAF-targeted therapy</p>	

Product Name:Tasigna	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor</p>	

Product Name:Tasigna	
Diagnosis	Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor (GIST), Acute Lymphoblastic Leukemia (Ph+B-ALL), Myeloid/Lymphoid

	Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes, Melanoma: Cutaneous, Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Tasigna therapy</p>	

Product Name:Tasigna	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Tasigna will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Tasigna	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tasigna therapy</p>	

Tasmar



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146422
<b>Guideline Name</b>	Tasmar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic tolcapone, Brand Tasmar	
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**3** - ONE of the following:

**3.1** Failure to TWO of the following anti-Parkinson's disease adjunctive pharmacotherapy classes (trial must be from TWO different classes) as confirmed by claims history or submission of medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

**OR**

**3.2** History of intolerance or contraindication to ALL of the following anti-Parkinson's disease adjunctive pharmacotherapy classes (please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

**AND**

**4** - Patient has received baseline liver function tests to rule out the presence of underlying liver disease

**AND**

**5** - Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**6** - Prescriber attests they have had complete discussion with the patient about the risks and benefits of Tasmar (tolcapone) use, including the risk of liver failure

Product Name:generic tolcapone, Brand Tasmar	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Tasmar (tolcapone) therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has received periodic evaluation of liver function tests to rule out liver failure associated with Tasmar (tolcapone) use</p>	

Tavalisse



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208220
<b>Guideline Name</b>	Tavalisse
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Tavalisse	
Diagnosis	Chronic immune thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic immune thrombocytopenia (ITP)

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 ONE of the following:

2.1.1.1 Failure to at least ONE of the following classes confirmed by claims history or submitted medical records:

- Corticosteroids
- Immunoglobulins

**OR**

2.1.1.2 History of contraindication or intolerance to BOTH of the following classes (please specify intolerance or contraindication):

- Corticosteroids
- Immunoglobulins

**AND**

2.1.2 ONE of the following:

2.1.2.1 Failure to Promacta (eltrombopag) confirmed by claims history or submitted medical records

**OR**

2.1.2.2 History of contraindication or intolerance to Promacta (eltrombopag) (please specify intolerance or contraindication)

**OR**

**2.2** Patient is currently on Tavalisse therapy

Product Name:Tavalisse	
Diagnosis	Chronic immune thrombocytopenia (ITP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tavalisse therapy</p>	

## 2 . Revision History

Date	Notes
3/6/2025	Updated formularies

Tavneos



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-183190
<b>Guideline Name</b>	Tavneos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Tavneos	
Diagnosis	ANCA (Anti-Neutrophil Cytoplasmic Autoantibody)-Associated Vasculitis
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of severe active ANCA (anti-neutrophil cytoplasmic autoantibody)-associated vasculitis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting the disease is <b>ONE</b> of the following types:</p> <p><b>2.1</b> Granulomatosis with polyangiitis (GPA)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Microscopic polyangiitis (MPA)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is being treated with an initial immunosuppressive regimen to induce remission (i.e., rituximab, cyclophosphamide)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Tavneos is being prescribed as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed by <b>ONE</b> of the following:</p> <ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Nephrologist</li> <li>• Pulmonologist</li> </ul>	

- Vascular Medicine Specialist

Product Name:Tavneos	
Diagnosis	ANCA (Anti-Neutrophil Cytoplasmic Autoantibody)-Associated Vasculitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Tavneos therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tavneos is being prescribed as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Nephrologist</li> <li>• Pulmonologist</li> <li>• Vascular Medicine Specialist</li> </ul>	

**2 . Revision History**

Date	Notes
2/20/2025	Combined formularies. No changes to clinical criteria.

Tazverik



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147187
<b>Guideline Name</b>	Tazverik
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Tazverik	
Diagnosis	Epithelioid Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of epithelioid sarcoma</p>	

**AND**

**2** - Disease is ONE of the following:

- Metastatic
- Locally advanced

**AND**

**3** - Disease is not eligible for complete resection

Product Name:Tazverik	
Diagnosis	Follicular Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of relapsed or refractory follicular lymphoma

**AND**

**2** - ONE of the following:

**2.1** Subsequent therapy in EZH2 (gene) mutation positive disease after 2 prior therapies

**OR**

**2.2** Second-line therapy irrespective of EZH2 mutation status for older or infirm patients with indications for treatment (i.e., other therapy options are not expected to be tolerable)

**OR**

**2.3** Third-line and/or subsequent therapy (if not previously given) irrespective of EZH2 mutation status in patients with indications for treatment

Product Name:Tazverik	
Diagnosis	Epithelioid Sarcoma, Follicular Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Tazverik therapy</p>	

Product Name:Tazverik	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Tazverik	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tazverik therapy</p>	

## 2 . Revision History

Date	Notes
5/8/2024	New guideline

Tegsedi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146671
<b>Guideline Name</b>	Tegsedi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Tegsedi	
Diagnosis	Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p>	

- Diagnosis of Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
- Documentation that the patient has a pathogenic transthyretin (TTR) mutation (e.g., V30M)

**AND**

**2** - Prescribed by or in consultation with a neurologist

**AND**

**3** - Documentation of ONE of the following:

- Patient has a baseline polyneuropathy disability (PND) score less than or equal to IIIb
- Patient has a baseline familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
- Patient has a baseline neuropathy impairment (NIS) score greater than or equal to 10 and less than or equal to 130

**AND**

**4** - Patient has not had a liver transplant

**AND**

**5** - Presence of clinical signs and symptoms of the disease (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.)

**AND**

**6** - Patient is not receiving Tegsedi in combination with ONE of the following:

- Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran)]
- Tafamidis (e.g., Vyndaqel, Vyndamax)

Product Name:Tegsedi

Diagnosis	Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation that the patient has experienced a positive clinical response to Tegsedi therapy (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Tegsedi in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran)]</li> <li>• Tafamidis (e.g., Vyndaqel, Vyndamax)</li> </ul>	

Temodar



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-165047
<b>Guideline Name</b>	Temodar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Temodar, generic temozolomide	
Diagnosis	Central Nervous Systems (CNS) Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following types of central nervous system tumors:

- Intracranial and Spinal Ependymoma (excluding Subependymoma)
- World Health Organization (WHO) Grade 2, 3, or 4 isocitrate dehydrogenase (IDH)-mutation Astrocytoma
- WHO Grade 2 or 3 IDH-mutant, 1p19q Codeleted Oligodendroglioma
- Medulloblastoma
- Circumscribed Gliomas
- Glioblastoma
- Limited or extensive brain metastases
- Primary CNS (central nervous system) lymphoma

Product Name:Brand Temodar, generic temozolomide	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following types of melanoma:</p> <ul style="list-style-type: none"> <li>• Metastatic or unresectable cutaneous melanoma</li> <li>• Metastatic or unresectable uveal melanoma</li> <li>• Mucosal melanoma</li> </ul>	

Product Name:Brand Temodar, generic temozolomide	
Diagnosis	Neuroendocrine and Adrenal Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following types of neuroendocrine tumors:

- Bronchopulmonary/thymic disease
- Poorly controlled carcinoid syndrome in gastrointestinal tract, lung or thymus
- Pancreas
- Pheochromocytoma/paraganglioma
- Poorly differentiated (High Grade)/ large or small cell
- Well differentiated grade 3 neuroendocrine tumors

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Primary Cutaneous Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following types of primary cutaneous lymphomas:</p> <ul style="list-style-type: none"> <li>• Mycosis fungoides (MF)</li> <li>• Sézary syndrome (SS)</li> </ul>	

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1 - ONE of the following:**

- Diagnosis of recurrent unresectable or stage IV retroperitoneal/intra-abdominal soft tissue sarcoma
- Diagnosis of rhabdomyosarcoma
- Undifferentiated pleomorphic sarcoma
- Diagnosis of solitary fibrous tumor/hemangiopericytoma

**OR**

**2 - BOTH of the following:**

**2.1** Diagnosis of soft tissue sarcoma of the extremity/body wall, head/neck

**AND**

**2.2** ONE of the following:

- Disease is stage IV
- Disease has disseminated metastases

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Bone Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Ewing's sarcoma family of tumors</li> <li>• Mesenchymal chondrosarcoma</li> </ul>	

**AND**

**2** - ONE of the following:

- Disease has relapsed
- Disease is progressive following primary treatment
- Used as second-line therapy for metastatic disease

**AND**

**3** - Used in combination with Camptosar (irinotecan)

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of recurrent or metastatic uterine sarcoma</p>	

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Small Cell Lung Cancer (SCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of small cell lung cancer (SCLC)</p>	

**AND**

**2** - ONE of the following:

**2.1** Relapse following complete or partial response or stable disease with primary treatment

**OR**

**2.2** Primary progressive disease

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	Central Nervous Systems (CNS) Tumor, Melanoma, Neuroendocrine and Adrenal Tumors, Primary Cutaneous Lymphomas, Soft Tissue Sarcoma, Bone Cancer, Uterine Sarcoma, Small Cell Lung Cancer (SCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Temodar therapy</p>	

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Temodar will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Brand Temodar, generic temozolomide	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Temodar therapy</p>	

## 2 . Revision History

Date	Notes
2/12/2025	Combined formularies. Corrected spelling of Camptosar.

Tepmetko



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146673
<b>Guideline Name</b>	Tepmetko
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Tepmetko	
Diagnosis	Non-Small Cell Lung Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer</p>	

<b>AND</b>
<b>2</b> - Disease is recurrent, advanced, or metastatic
<b>AND</b>
<b>3</b> - Tumor is MET exon 14 skipping mutation positive

<b>Product Name:</b> Tepmetko	
Diagnosis	Non-Small Cell Lung Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Patient does not show evidence of progressive disease while on Tepmetko therapy	

<b>Product Name:</b> Tepmetko	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

<b>Product Name:</b> Tepmetko
-------------------------------

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Tepmetko therapy	

Test Strips



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146425
<b>Guideline Name</b>	Test Strips
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Non-preferred Test Strips	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Failure of both of the following confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>OneTouch Ultra Test Strips</li> <li>OneTouch Verio Test Strips</li> </ul>	

**OR**

**1.2** History of intolerance or contraindication to both of the following (please specify intolerance or contraindication):

- OneTouch Ultra Test Strips
- OneTouch Verio Test Strips

**OR**

**2** - Patient is on an insulin pump

Product Name:All Test Strips	
Approval Length	12 month(s)
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p><b>1</b> - If the patient is insulin dependent or pregnant, the physician must confirm the patient requires a greater quantity because of more frequent blood glucose testing (e.g., patients on intravenous insulin infusions)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - If the patient is not insulin dependent nor pregnant, <b>ONE</b> the following:</p> <p><b>2.1</b> The patient is experiencing or is prone to hypoglycemia or hyperglycemia and requires additional testing to achieve glycemic control</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> The patient's physician is adjusting medications and the patient requires additional blood glucose testing during this time</p>	

**OR**

**2.3** The patient's physician is adjusting MNT (medical nutrition therapy) and the patient requires additional blood glucose testing during this time

**OR**

**2.4** The patient requires additional testing due to fluctuations in blood glucose due to physical activity/exercise

**OR**

**2.5** Other circumstances where prescribing physician confirms that the patient requires a greater quantity because of more frequent blood glucose testing (clinical review required by UnitedHealthcare reviewing pharmacist and/or medical director)

Notes

The quantity limit for insulin-dependent and pregnant patients is 6 test strips/day. The quantity limit for non-insulin dependent and non-pregnant patients is 2 test strips/day.

Testosterone



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-163813
<b>Guideline Name</b>	Testosterone
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Androderm, generic testosterone gel, Brand Androgel, generic testosterone gel pump, Brand Androgel Pump, testosterone soln, Brand Fortesta, generic testosterone TD gel, Natesto, Brand Testim, Brand Vogelxo, Brand Vogelxo Pump, Xyosted, Jatenzo, Kyzatrex, Tlando, Brand Depo-Testosterone, generic testosterone cypionate, testosterone enanthate, Undecatrex	
Diagnosis	Hypogonadism
Approval Length	12 month(s)
Therapy Stage	Initial Authorization*
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - ONE of the following:**

**1.1** TWO pre-treatment serum total testosterone levels less than 300 ng/dL (nanograms/deciliter) [less than 10.4 nmol/L (nanomoles/liter)] or less than the reference range for the lab, taken at separate times (This may require treatment to be temporarily held. Document lab value and date for both levels)

**OR**

**1.2** BOTH of the following:

**1.2.1** Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) [e.g., thyroid disorder, HIV (human immunodeficiency virus) disease, liver disorder, diabetes, obesity]

**AND**

**1.2.2** ONE pre-treatment calculated free or bioavailable testosterone level less than 50 pg/mL (picograms/milliliter) (< 5 ng/dL or < 0.17 nmol/L) or less than the reference range for the lab (This may require treatment to be temporarily held. Document lab value and date)

**OR**

**1.3** Patient has a history of ONE of the following:

- Bilateral orchiectomy
- Panhypopituitarism
- A genetic disorder known to cause hypogonadism (e.g., congenital anorchia, Klinefelter's syndrome)

**AND**

**2 - Patient is NOT taking any of the following growth hormones, unless diagnosed with panhypopituitarism:**

- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope

- Saizen

**AND**

**3** - Patient is NOT taking any aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]

**AND**

**4** - Patient was male at birth

**AND**

**5** - Diagnosis of hypogonadism

**AND**

**6** - ONE of the following:

- Significant reduction in weight (less than 90% ideal body weight) [e.g., AIDS (acquired immunodeficiency syndrome) wasting syndrome]
- Osteopenia
- Osteoporosis
- Decreased bone density
- Decreased libido
- Organic cause of testosterone deficiency (e.g., injury, tumor, infection, or genetic defects)

**AND**

**7** - ONE of the following:

**7.1** If the request is for a non-preferred\*\* topical testosterone (gel, solution) or testosterone transdermal systems (patches), ONE of the following:

**7.1.1** Failure to ONE of the following, confirmed by claims history or submitted medical records

- generic testosterone 1% topical gel

- testosterone 1.62% pump (generic Androgel 1.62% pump)

**OR**

**7.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- generic testosterone 1% topical gel
- testosterone 1.62% pump (generic Androgel 1.62% pump)

**OR**

**7.2** If the request is for Xyosted, BOTH of the following:

**7.2.1** ONE of the following:

**7.2.1.1** Failure to testosterone cypionate injection (generic Depo-Testosterone), confirmed by claims history or submitted medical records

**OR**

**7.2.1.2** History of intolerance or contraindication to testosterone cypionate injection (generic Depo-Testosterone) (please specify intolerance or contraindication)

**AND**

**7.2.2** ONE of the following:

**7.2.2.1** Failure to intramuscular testosterone enanthate injection, confirmed by claims history or submitted medical records

**OR**

**7.2.2.2** History of intolerance or contraindication to intramuscular testosterone enanthate injection (please specify intolerance or contraindication)

**OR**

**7.3** If the request is for Jatenzo, Kyzatrex, Tlando, or Undecatrex, ONE of the following:

**7.3.1** Failure to ALL of the following:

- testosterone cypionate vials
- testosterone enanthate vials
- testosterone gel - tube, pack, or pump bottle, or testosterone 1.62% pump (generic Androgel 1.62% pump)

**OR**

**7.3.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- testosterone cypionate vials
- testosterone enanthate vials
- testosterone gel - tube, pack, or pump bottle or testosterone 1.62% pump (generic Androgel 1.62% pump)

Notes

\*Patients that have previously received injectable testosterone open access should be reviewed using reauthorization criteria  
 \*\*PDL Link: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

Product Name: Androderm, generic testosterone gel, Brand Androgel, generic testosterone gel pump, Brand Androgel Pump, testosterone soln, Brand Fortesta, generic testosterone TD gel, Natesto, Brand Testim, Brand Vogelxo, Brand Vogelxo Pump, Xyosted, Jatenzo, Kyzatrex, Tlando, Brand Depo-Testosterone, generic testosterone cypionate, testosterone enanthate, Undecatrex

Diagnosis	Gender Dysphoria
Approval Length	12 month(s)
Therapy Stage	Initial Authorization*
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient is using hormones to change physical characteristics

**AND**

**2** - Patient must be diagnosed with gender dysphoria, as defined by the current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)

**AND**

**3** - Patient is NOT taking any of the following growth hormones, unless diagnosed with panhypopituitarism:

- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope
- Saizen

**AND**

**4** - Patient is NOT taking any aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]

**AND**

**5** - ONE of the following:

**5.1** If the request is for a non-preferred\*\* topical testosterone (gel, solution) or testosterone transdermal systems (patches), ONE of the following:

**5.1.1** Failure to ONE of the following, confirmed by claims history or submitted medical records:

- generic testosterone 1% topical gel
- testosterone 1.62% pump (generic AndroGel 1.62% pump)

**OR**

**5.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- generic testosterone 1% topical gel
- testosterone 1.62% pump (generic AndroGel 1.62% pump)

**OR**

**5.2** If the request is for Xyosted, BOTH of the following:

**5.2.1** ONE of the following:

**5.2.1.1** Failure to testosterone cypionate injection (generic Depo-Testosterone), confirmed by claims history or submitted medical records

**OR**

**5.2.1.2** History of intolerance or contraindication to testosterone cypionate injection (generic Depo-Testosterone) (please specify intolerance or contraindication)

**AND**

**5.2.2** ONE of the following:

**5.2.2.1** Failure to intramuscular testosterone enanthate injection, confirmed by claims history or submitted medical records

**OR**

**5.2.2.2** History of intolerance or contraindication to intramuscular testosterone enanthate injection (please specify intolerance or contraindication)

**OR**

**5.3** If the request is for Jatenzo, Kyzatrex, Tlando, or Undecatrex, ONE of the following:

**5.3.1** Failure to ALL of the following:

- testosterone cypionate vials
- testosterone enanthate vials
- testosterone gel - tube, pack, or pump bottle or testosterone 1.62% pump (generic Androgel 1.62% pump)

**OR**

**5.3.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- testosterone cypionate vials
- testosterone enanthate vials
- testosterone gel - tube, pack, or pump bottle or testosterone 1.62% pump (generic Androgel 1.62% pump)

Notes	<p>*Patients that have previously received injectable testosterone open access should be reviewed using reauthorization criteria                  **PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>
-------	---

Product Name: Androderm, generic testosterone gel, Brand Androgel, generic testosterone gel pump, Brand Androgel Pump, testosterone soln, Brand Fortesta, generic testosterone TD gel, Natesto, Brand Testim, Brand Vogelxo, Brand Vogelxo Pump, Xyosted, Jatenzo, Kyzatrex, Tlando, Brand Depo-Testosterone, generic testosterone cypionate, testosterone enanthate, Undecatrex

Diagnosis	Hypogonadism, Gender Dysphoria
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 Patient has a history of ONE of the following:

- Bilateral orchiectomy
- Panhypopituitarism

- A genetic disorder known to cause hypogonadism (e.g., congenital anorchia, Klinefelter's syndrome)

**OR**

**1.2 BOTH of the following:**

**1.2.1 Patient has a diagnosis of ONE of the following:**

- Hypogonadism
- Gender dysphoria, as defined by the current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)

**AND**

**1.2.2 ONE of the following:**

**1.2.2.1** Follow-up total serum testosterone level drawn within the past 12 months is within or below the normal male limits of the reporting lab (document value and date)

**OR**

**1.2.2.2** Follow-up total serum testosterone level drawn within the past 12 months is outside of upper male limits of normal for the reporting lab and the dose is adjusted (document value and date)

**OR**

**1.2.2.3 BOTH of the following:**

**1.2.2.3.1** Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) [e.g., thyroid disorder, HIV (human immunodeficiency virus) disease, liver disorder, diabetes, obesity]

**AND**

**1.2.2.3.2 ONE of the following:**

- Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is within or below the normal male limits of the reporting lab (document lab value and date)
- Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is outside of upper male limits of normal for the reporting lab and the dose is adjusted (document value and date)

**AND**

**2** - Patient is NOT taking any of the following growth hormones, unless diagnosed with panhypopituitarism:

- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope
- Saizen

**AND**

**3** - Patient is NOT taking any aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]

## 2 . Revision History

Date	Notes
1/15/2025	Updated GPs. Added Undecatrex

Tezspire



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155266
<b>Guideline Name</b>	Tezspire
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Tezspire auto-injector pen	
Diagnosis	Severe Asthma
Approval Length	6 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Tezspire under an active UnitedHealthcare medical benefit prior authorization for the treatment of severe asthma</p>	

**AND**

**2** - Documentation of positive clinical response to Tezspire therapy as demonstrated by at least ONE of the following:

**2.1** Reduction in the frequency of exacerbations

**OR**

**2.2** Decreased utilization of rescue medications

**OR**

**2.3** Increase in percent predicted FEV1 (forced expiratory volume in 1 second) from pretreatment baseline

**OR**

**2.4** Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

**AND**

**3** - Tezspire is being used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**AND**

**4** - Patient is NOT receiving Tezspire in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE-therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name: Tezspire auto-injector pen	
Diagnosis	Severe Asthma
Approval Length	6 month(s)
Therapy Stage	Initial Authorization - Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of severe asthma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Classification of asthma as uncontrolled or inadequately controlled as defined by at least ONE of the following:</p> <p><b>2.1</b> Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control test [ACT] score consistently less than 20)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months</p> <p style="text-align: center;"><b>OR</b></p>	

**2.3** Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)

**OR**

**2.4** Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal])

**OR**

**2.5** Patient is currently dependent on oral corticosteroids for the treatment of asthma

**AND**

**3** - Tezspire will be used in combination with ONE of the following:

**3.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) product [e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**OR**

**3.2** Combination therapy including BOTH of the following:

**3.2.1** ONE maximally-dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]

**AND**

**3.2.2** ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist – montelukast (Singulair); theophylline]

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Tezspire will be used to treat eosinophilic asthma

**AND**

**4.1.2** BOTH of the following:

**4.1.2.1** ONE of the following

- Failure to a 4-month trial of an anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Fasenra (benralizumab)] as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to an anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Fasenra (benralizumab)] (please specify contraindication or intolerance)

**AND**

**4.1.2.2** ONE of the following:

- Failure to a 4-month trial of Dupixent (dupilumab) as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Dupixent (dupilumab) (please specify contraindication or intolerance)

**OR**

**4.2** BOTH of the following:

**4.2.1** Tezspire will be used to treat persistent allergic asthma

**AND**

**4.2.2** ONE of the following:

- Failure to a 4-month trial of Xolair (omalizumab) as confirmed by claims history or submission of medical records

- History of intolerance or contraindication to Xolair (omalizumab) (please specify contraindication or intolerance)

**OR**

**4.3 BOTH** of the following:

**4.3.1** Tezspire will be used to treat oral corticosteroid dependent asthma

**AND**

**4.3.2 ONE** of the following:

- Failure to a 4-month trial of Dupixent (dupilumab) as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to Dupixent (dupilumab) (please specify contraindication or intolerance)

**OR**

**4.4** Patient's asthma is not of the eosinophilic, allergic, or oral corticosteroid dependent phenotype

**AND**

**5 -** Patient is NOT receiving Tezspire in combination with any of the following:

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]

**AND**

**6 -** Prescribed by ONE of the following:

- Allergist
- Immunologist

- Pulmonologist

Product Name: Tezspire auto-injector pen	
Diagnosis	Severe Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Tezspire therapy as demonstrated by at least ONE of the following:

- Reduction in the frequency of exacerbations
- Decreased utilization of rescue medications
- Increase in percent predicted FEV1 (forced expiratory volume in 1 second) from pretreatment baseline
- Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

**AND**

**2** - Tezspire is being used in combination with an ICS-containing maintenance medication [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

**AND**

**3** - Patient is NOT receiving Tezspire in combination with any of the following:

- Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab), Nucala (mepolizumab)]
- Anti-IgE therapy [e.g., Xolair (omalizumab)]
- Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]

## 2 . Revision History

Date	Notes
9/19/2024	Modified wording for existing prior authorization for under the medical benefit.

Thalomid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150980
<b>Guideline Name</b>	Thalomid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/5/2024
-----------------	----------

### 1 . Criteria

Product Name:Thalomid	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple myeloma</p>	

Product Name:Thalomid	
Diagnosis	Erythema Nodosum Leprosum (ENL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe erythema nodosum leprosum (ENL)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Used for acute treatment</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Used as maintenance therapy for prevention and suppression of cutaneous manifestations of ENL recurrence</p>	

Product Name:Thalomid	
Diagnosis	Castleman Disease (CD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Castleman Disease (CD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1 NOT used as first line therapy**

**OR**

**2.2 ALL of the following:**

**2.2.1 Therapy is for active idiopathic multicentric CD with no evidence of organ failure**

**AND**

**2.2.2 Used in combination with cyclophosphamide and prednisone**

**AND**

**2.2.3 Patient is human immunodeficiency virus (HIV)-negative**

**AND**

**2.2.4 Patient is human herpesvirus-8 (HHV8)-negative**

<b>Product Name:Thalomid</b>	
<b>Diagnosis</b>	Kaposi Sarcoma
<b>Approval Length</b>	12 month(s)
<b>Therapy Stage</b>	Initial Authorization
<b>Guideline Type</b>	Prior Authorization
<b>Approval Criteria</b>	
<b>1 - ONE of the following:</b>	
<b>1.1 Diagnosis of HIV (human immunodeficiency virus)-negative Kaposi Sarcoma</b>	

**OR**

**1.2** BOTH of the following:

**1.2.1** Diagnosis of AIDS-related Kaposi Sarcoma

**AND**

**1.2.2** Patient is currently being treated with antiretroviral therapy (ART) as confirmed by claims history or submission of medical records

**AND**

**2** - NOT used as first line therapy

**AND**

**3** - Patient has immune reconstitution inflammatory syndrome (IRIS)

<b>Product Name:</b> Thalomid	
Diagnosis	Langerhans Cell Histiocytosis, Rosai-Dorfman Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of Langerhans cell histiocytosis	
<b>OR</b>	

**2 - Diagnosis of Rosai-Dorfman Disease**

Product Name:Thalomid	
Diagnosis	Multiple Myeloma, Castleman Disease (CD), Kaposi Sarcoma, Langerhans Cell Histiocytosis, Rosai-Dorfman Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Thalomid therapy</p>	

Product Name:Thalomid	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Thalomid	
Diagnosis	Erythema Nodosum Leprosum (ENL), NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Thalomid therapy

**2 . Revision History**

Date	Notes
8/5/2024	Removed criteria for myelofibrosis-associated anemia. Renamed diagnosis header from B-Cell Lymphomas to Castleman Disease (CD). Updated criteria for Kaposi sarcoma per NCCN guidance.

Therapeutic Duplication (Subtype A)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-216248
<b>Guideline Name</b>	Therapeutic Duplication (Subtype A)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State Kansas</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State North Carolina</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Texas</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Generic arformoterol nebulizer solution, Brand Brovana nebulizer, generic formoterol nebulizer solution, Brand Perforomist nebulizer, Striverdi Respimat, Serevent Diskus, Incruse Ellipta, Brand Spiriva Handihaler, generic tiotropium, Spiriva Respimat, Tudorza Pressair, generic ipratropium inhalation solution, Atrovent HFA, Anoro Ellipta, Stiolto Respimat, Bevespi Aerosphere, Duaklir Pressair, Breztri Aerosphere, Glyxambi, Steglujan,

Qtern, Trijardy XR, Brand Pulmicort suspension, generic budesonide suspension, Victoza, Adlyxin, Trulicity, Bydureon BCise, Byetta, Ozempic, Rybelsus, Januvia, Janumet, Janumet XR, Brand Onglyza, generic saxagliptin, Brand Kombiglyze XR, generic saxagliptin/metformin ER, Tradjenta, Jentadueto, Jentadueto XR, Nesina, alogliptin, Kazano, alogliptin/metformin, Oseni, alogliptin/pioglitazone, Mounjaro, Xultophy, Soliqua, Invokana, brand Farxiga, generic dapagliflozin, Jardiance, Invokamet, Invokamet XR, brand Xigduo XR, generic dapagliflozin/metformin ER, Synjardy, Synjardy XR, Steglatro, Segluromet, Zituvio, Brand Flovent HFA, Fluticasone propionate HFA, Flovent Diskus, Brand Fluticasone propionate Diskus, Brand Pulmicort Flexhaler, Alvesco, ArmonAir Digihaler, Asmanex Twisthaler, Asmanex HFA, Arnuity Ellipta, Qvar RediHaler, Lonhala Magnair, Trelegy Ellipta, Brand Advair Diskus, generic fluticasone propionate/salmeterol diskus (generic Advair Diskus), generic Wixela Inhub (generic Advair Diskus), AirDuo Respiclick, fluticasone/salmeterol (authorized generic of AirDuo), Brand Advair HFA, Brand Fluticasone/salmeterol HFA, Brand Symbicort, generic budesonide/formoterol, Breyna, AirDuo Digihaler, Dulera, Breo Ellipta, Brand fluticasone/vilanterol Ellipta, Basaglar Tempo pen, Basaglar Kwikpen, Insulin Glargine Solostar, Lantus Solostar, Toujeo Solostar, Toujeo Max Solostar, Semglee Pen Injector, Insulin Glargine-YFGN pen, Lantus vial, Insulin Glargine vial, Semglee vial, Insulin Glargine-YFGN vial, Levemir vial, Levemir Flextouch, Levemir Flexpen, Tresiba vial, Insulin Degludec vial, Tresiba Flextouch, Insulin Degludec Flextouch, Rezvoglar, Baclofen tabs, generic baclofen suspension, Brand Fleqsuvy, Brand Ozobax DS, brand Ozobax, Brand Baclofen solution, brand Lioresal intrathecal, generic baclofen intrathecal, brand Gablofen intrathecal, baclofen intrathecal solution, Lyvispah, generic carisoprodol tab, brand Soma, brand Vanadom tab, generic chlorzoxazone, brand Lorzone, generic cyclobenzaprine, brand Fexmid, generic cyclobenzaprine ER, brand Amrix, metaxalone, methocarbamol, orphenadrine CR/ER, generic tizanidine caps/tabs, brand Zanaflex caps/tabs, brand Dantrium, generic dantrolene, brand Norgesic, generic orphenadrine/aspirin/caffeine, norgesic forte, orphengesic forte, Brand Neurontin caps/tabs/soln, generic gabapentin caps/tabs/soln, gabapentin tinytabs, brand Lyrica caps/soln, generic pregabalin caps/soln, brand Gralise, brand Lyrica CR, generic pregabalin ER, Horizant, Zorvolex, brand Zipsor, generic diclofenac caps, brand Lofena, generic diclofenac tabs, diclofenac DR/ER, brand Cambia, generic diclofenac packet (migraine), etodolac cap, brand Lodine, generic etodolac tab, etodolac ER, brand Nalfon caps/tabs, generic fenoprofen caps/tabs, flurbiprofen, ibuprofen caps/tabs/chewable (includes All Manufactures), Brand Advil, ibuprofen suspension (40 mg/ml & 100 mg/5ml), indomethacin caps, indomethacin ER/SR caps, indocin susp, indocin suppository, indomethacin suppository, ketoprofen cap, ketoprofen ER cap, ketorolac tabs, meclofenamate cap, mefenamic acid, meloxicam cap/tab, brand Relafen DS, generic nabumetone, generic naproxen tab/susp/caps (includes All Manufactures), brand naprosyn tab/susp, brand Aleve, brand Anaprox DS, brand EC-Naprosyn, generic naproxen DR, generic EC-naproxen, brand Naprelan, generic naproxen CR/ER, Brand Daypro, generic oxaprozin, brand Feldene, generic piroxicam, sulindac, tolmetin, brand Celebrex, generic celecoxib, Elyxyb, brand Arthrotec, generic diclofenac sodium/misoprostol, brand Duexis, generic ibuprofen/famotidine, brand Vimovo, generic naproxen/esomeprazole, brand Advil PM, generic ibuprofen/diphenhydramine, brand Aleve PM, generic naproxen/diphenhydramine, hydrocodone/ibuprofen, brand Treximet, generic sumatriptan/naproxen, Motrin Dual Action/Tylenol, Advil Dual Action/acetaminophen, acetaminophen/ibuprofen, Naproxen/capsaicin cream (Naprotin), Inpefa, Saxenda, Wegovy, Brand Brenzavvy, Brand Bexagliflozin, Zepbound, Coxanto, Jantoven, warfarin tabs, Pradaxa, generic dabigatran, Eliquis, Savaysa, Xarelto, Brand Lunesta, generic eszopiclone, zaleplon, Zolpidem, Brand Ambien, generic zolpidem, Brand Ambien CR, generic zolpidem CR. Edluar, Zolpimist, Brand Rozerem, generic ramelteon, Brand Silenor, generic doxepin (sleep) 3mg

and 6 mg tabs, Belsomra, Dayvigo, Quviviq, Brand Precedex, generic dexmedetomidine, Dexmedetomidine, Igalmi, Brand Hetlioz, generic tasimelteon, Hetlioz LQ, Brand Restoril, generic temazepam, Brand Halcion, generic triazolam, Brand Doral, generic quazepam, flurazepam, estazolam, Zituvimet, Sitagliptin/metformin, Brand Tanlor, Dolobid, generic diflunisal, Zituvimet XR, Tresni, Fenopron, Gabarone, Addaprin

Diagnosis	DUR: Therapeutic Duplication
Approval Length	12 month(s)
Guideline Type	Administrative

**Approval Criteria**

1 - The requested medication will be used exclusively, and the previously prescribed medication will be discontinued

**OR**

2 - All of the following:

2.1 The requested medication combination is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

2.2 The drug combination is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program

**AND**

2.3 The provider attests that they are aware that the patient is using duplicate therapy

**AND**

**2.4** Special clinical circumstances exist that necessitate the need for duplicate therapy (document special circumstances)

**AND**

**2.5** Provider attests that the necessity for continued concomitant therapy and safety will be periodically assessed

## 2 . Revision History

Date	Notes
3/18/2025	Updated product list. Combined formularies. Changed to Admin GL type. Removed GPIs.

Therapeutic Duplication (Subtype B)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-216246
<b>Guideline Name</b>	Therapeutic Duplication (Subtype B)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State Washington</li> <li>• Medicaid - Community &amp; State Kansas</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State North Carolina</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:(All formulations/packaging, except for Entyvio) Entyvio Pen, Stelara, Cimzia, Abrilada, Humira, Amjevita, Idacio, Hulio, Cyltezo, Yusimry, Yuflyma, Hadlima, Hyrimoz, adalimumab (adalimumab-AATY, adalimumab-RYVK, adalimumab-ADB, adalimumab-AACF, adalimumab-ADAZ, adalimumab-FKJP), Simponi, Enbrel, Actemra, Cosentyx, Ilaris, Kineret, Kevzara, Taltz, Tremfya, Orencia, Xeljanz, Xeljanz XR, Xeljanz Solution, Siliq, Otezla, Olumiant, Ilumya, Skyrizi, Rinvoq, Sotyktu, Cibinqo, Adbry, Dupixent, brand Copaxone, generic glatiramer acetate, generic glatopa, Mavenclad, Rebif, Avonex, Betaseron, Extavia, brand Aubagio, generic teriflunomide, Plegridy, Lemtrada, Tysabri, Ocrevus, brand Tecfidera, generic dimethyl fumarate, Vumerity, brand Gilenya, generic fingolimod, Tascenso ODT, Zeposia, Mayzent, Bafiertam, Kesimpta, Ponvory, Xolair, Fasenra, Nucala, Cinqair, Tezspire, Velsipity, Bimzelx, Omvoh, Zymfentra, Simlandi, Spevigo, Tyenne, Rinvoq LQ, Nemluvio, Ebglyss, Wezlana, Steqeyma, Yesintek, Pyzchiva, Otulfi, Selarsdi	
Diagnosis	DUR: Therapeutic Duplication
Approval Length	12 month(s)
Guideline Type	Administrative
<p><b>Approval Criteria</b></p> <p>1 - The requested medication will be used exclusively, and the previously prescribed medication will be discontinued</p>	

## 2 . Revision History

Date	Notes
3/17/2025	Updated to Admin GL type.

Tibsovo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208199
<b>Guideline Name</b>	Tibsovo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Tibsovo	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of acute myeloid leukemia (AML)

**AND**

2 - AML is IDH1 (isocitrate dehydrogenase 1) mutation-positive

**AND**

3 - ONE of the following:

3.1 Disease is relapsed or refractory

**OR**

3.2 BOTH of the following:

3.2.1 New diagnosis of AML

**AND**

3.2.2 ONE of the following:

- Patient is 75 years of age or older
- Patient has comorbidities that preclude the use of intensive induction chemotherapy
- Patient is 60 years of age or older AND not a candidate for or declines intensive induction therapy
- Patient is 60 years of age or older AND receiving post-induction therapy following response to previous lower intensity therapy

Product Name: Tibsovo	
Diagnosis	Bone Cancer
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chondrosarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Susceptible IDH1 (isocitrate dehydrogenase 1) mutation-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Conventional (grades 1-3)</li> <li>• Dedifferentiated</li> </ul>	

Product Name:Tibsovo	
Diagnosis	Biliary Tract Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cholangiocarcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Susceptible IDH1 (isocitrate dehydrogenase 1) mutation-positive</p>	

**AND**

**3** - Disease is ONE of the following:

- Locally advanced
- Unresectable
- Metastatic

**AND**

**4** - Disease has progressed on or after systemic treatment

Product Name: Tibsovo	
Diagnosis	Oligodendroglioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of oligodendroglioma

**AND**

**2** - Disease is recurrent or progressive

**AND**

**3** - Presence of BOTH of the following:

- IDH1 mutation
- 1p19q codeletion

<b>AND</b>
<b>4 - Disease is WHO grade 2 or 3</b>

Product Name:Tibsovo	
Diagnosis	Astrocytoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of astrocytoma</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Disease is recurrent or progressive</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Presence of IDH1 mutation</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Disease is WHO grade 2, 3, or 4</b></p>	

Product Name:Tibsovo	
Diagnosis	Myelodysplastic Syndrome (MDS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of myelodysplastic syndrome (MDS)

**AND**

2 - Disease is relapsed or refractory

**AND**

3 - Presence of IDH1 mutation

**Product Name: Tibsovo**

Diagnosis	Acute Myeloid Leukemia (AML), Bone Cancer, Biliary Tract Cancer, Oligodendroglioma, Astrocytoma, Myelodysplastic syndrome (MDS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Tibsovo therapy

**Product Name: Tibsovo**

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Tibsovo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tibsovo therapy</p>	

**2 . Revision History**

Date	Notes
3/5/2025	Updated formularies. Updated criteria for oligodendroglioma and astr ocytoma

Tobramycin Inhalation



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146678
<b>Guideline Name</b>	Tobramycin Inhalation
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:generic tobramycin 300 mg/4mL nebu soln (generic Bethkis)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - BOTH of the following:</p>	

**2.1** Diagnosis of noncystic fibrosis bronchiectasis

**AND**

**2.2** ONE of the following:

**2.2.1** Three or more exacerbations per year

**OR**

**2.2.2** Two or more exacerbations requiring hospitalization per year

Product Name: Kitabis Pak, Brand Tobi nebu soln, generic tobramycin 300 mg/5mL nebu soln, Brand Tobramycin 300mg/5mL nebu soln, Tobi Podhaler, Brand Bethkis

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - ONE of the following:

**1.1** Diagnosis of cystic fibrosis (CF)

**OR**

**1.2** BOTH of the following:

**1.2.1** Diagnosis of noncystic fibrosis bronchiectasis

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Three or more exacerbations per year

**OR**

**1.2.2.2** Two or more exacerbations requiring hospitalization per year

**AND**

**2** - Lung infection with positive culture demonstrating *Pseudomonas aeruginosa* infection

**AND**

**3** - ONE of the following:

**3.1** Failure to generic tobramycin 300 mg/4mL (milligrams/milliliter) solution for inhalation (generic Bethkis) as confirmed by claims history or submission of medical records

**OR**

**3.2** History of contraindication or intolerance to generic tobramycin 300 mg/4mL solution for inhalation (generic Bethkis) (please specify contraindication or intolerance)

Product Name: Kitabis Pak, Brand Tobi nebu soln, generic tobramycin 300 mg/5mL nebu soln, Brand Tobramycin 300mg/5mL nebu soln, Tobi Podhaler, Brand Bethkis

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

Tocilizumab



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155299
<b>Guideline Name</b>	Tocilizumab
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Actemra subcutaneous, Tyenne subcutaneous	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)</p>	

**AND**

**1.2** ONE of the following:

**1.2.1** Failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses confirmed by claims history or submitted medical records

**OR**

**1.2.2** History of intolerance or contraindication to ONE non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a biologic or targeted synthetic DMARD FDA (Food and Drug Administration)-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]

**AND**

**1.3** ONE of the following:

**1.3.1** Failure of ONE of the preferred adalimumab products\* confirmed by claims history or submitted medical records

**OR**

**1.3.2** History of intolerance or contraindication to ALL preferred adalimumab products\* (please specify intolerance or contraindication)

**AND**

**1.4** If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products (please document reason/special circumstances)\*\*

**AND**

**1.5** Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**1.6** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on tocilizumab therapy as confirmed by claims history or submitted medical records

**AND**

**2.2** Diagnosis of moderately to severely active RA

**AND**

**2.3** Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**2.4** If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products (please document reason/special circumstances)\*\*

**AND**

**2.5 Prescribed by or in consultation with a rheumatologist**

Notes	<p>*For a list of preferred adalimumab products please reference drug coverage tools.                  **For a list of preferred tocilizumab products please reference drug coverage tools.</p>
-------	---

Product Name:Actemra subcutaneous, Tyenne subcutaneous	
Diagnosis	Giant Cell Arteritis (GCA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of giant cell arteritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure to ONE glucocorticoid (e.g., prednisone) confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of intolerance or contraindication to ALL glucocorticoids (e.g., prednisone) (please specify intolerance or contraindication)</p> <p style="text-align: center;"><b>OR</b></p>	

**2.3** Patient is currently on tocilizumab therapy as confirmed by claims history or submitted medical records

**AND**

**3** - If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products (please document reason/special circumstances)\*\*

**AND**

**4** - Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**5** - Prescribed by or in consultation with a rheumatologist

Notes

\*\*For a list of preferred tocilizumab products please reference drug coverage tools.

Product Name: Actemra subcutaneous, Tyenne subcutaneous

Diagnosis Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA)

**AND**

**2 - ONE of the following:**

**2.1** Failure to ONE of the preferred adalimumab products\* confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to ALL of the preferred adalimumab products\* (please specify intolerance or contraindication)

**OR**

**2.3** Patient is currently on tocilizumab therapy as confirmed by claims history or submitted medical records

**AND**

**3 -** If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products\*\* (please document reason/special circumstances)

**AND**

**4 -** Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**5 -** Prescribed by or in consultation with a rheumatologist

Notes	*For a list of preferred adalimumab products please reference drug coverage tools. **For a list of preferred tocilizumab products please reference drug coverage tools.
-------	--

Product Name:Actemra subcutaneous, Tyenne subcutaneous	
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active systemic juvenile idiopathic arthritis (SJIA)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products** (please document reason/special circumstances)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by or in consultation with a rheumatologist</p>	
Notes	**For a list of preferred tocilizumab products please reference drug coverage tools.

Product Name:Actemra subcutaneous, Tyenne subcutaneous	
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) as documented by ALL of the following:

**1.1** ONE of the following:

**1.1.1** Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints

**OR**

**1.1.2** At least TWO of the following:

- Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of the fingers)
- Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)
- Telangiectasia
- Abnormal nailfold capillaries
- Pulmonary arterial hypertension
- Raynaud's phenomenon
- SSc-related autoantibodies (e.g., anticentromere, anti-topoisomerase I, anti-RNA polymerase III)

**AND**

**1.2** Presence of interstitial lung disease as determined by finding evidence of pulmonary fibrosis on HRCT (high-resolution computed tomography), involving at least 10% of the lungs

**AND**

**2** - Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

**3** - If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical

reason or special circumstance why the patient is unable to use the preferred tocilizumab products** (please document reason/special circumstances)	
<b>AND</b>	
<b>4 - Prescribed by or in consultation with a pulmonologist</b>	
Notes	**For a list of preferred tocilizumab products please reference drug coverage tools.

Product Name:Actemra subcutaneous, Tyenne subcutaneous	
Diagnosis	RA, GCA, PJIA, SJIA, SSc-ILD
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Documentation of positive clinical response to tocilizumab therapy</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Patient is NOT receiving tocilizumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]*</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - If the request is for a non-preferred tocilizumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred tocilizumab products** (please document reason/special circumstances)</b></p>	
Notes	<p>* Examples of drug(s) may not be applicable based on the requested indication.</p> <p>**For a list of preferred tocilizumab products please reference drug coverage tools.</p>

## 2 . Background

Benefit/Coverage/Program Information
<b>PDL Link</b> NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

## 3 . Revision History

Date	Notes
9/19/2024	Updated safety language. Added Tyenne and renamed policy to Tocili zumab. Updated step through agents where appropriate.

Topical NSAIDs



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146920
<b>Guideline Name</b>	Topical NSAIDs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand diclofenac epolamine patch, Brand Flector	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute pain due to minor strains, sprains, or contusions</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - The patient did not receive adequate pain relief when treated with at least TWO preferred*</p>	

non-steroidal anti-inflammatory drugs (NSAIDs), one of which must be celecoxib (generic for Celebrex), as confirmed by claims history or submitted medical records. An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy

**AND**

**3** - ONE of the following:

**3.1** Failure to ONE of the following, as confirmed by claims history or submission of medical records:

- diclofenac topical gel 1% [Rx (prescription) formulation]
- diclofenac topical gel 1% [OTC (over-the-counter) formulation]

**OR**

**3.2** History of intolerance or contraindication to BOTH of the following (please provide intolerance or contraindication):

- diclofenac topical gel 1% (Rx formulation)
- diclofenac topical gel 1% (OTC formulation)

Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>
-------	--

Product Name: Brand Pennsaid, generic diclofenac sodium soln 2%, diclofenac sodium soln 1.5%	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of pain due to osteoarthritis of the knee(s)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - The patient did not receive adequate pain relief when treated with at least TWO preferred\* non-steroidal anti-inflammatory drugs (NSAIDs), one of which must be celecoxib (generic for Celebrex), as confirmed by claims history or submitted medical records. An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy

**AND**

**3** - ONE of the following:

**3.1** If the request is for Pennsaid (diclofenac sodium soln 2%), ONE of the following:

**3.1.1** Failure of BOTH of the following, as confirmed by claims history or submitted medical records:

- diclofenac topical gel 1% [Rx (prescription) or OTC (over the counter) formulation] (generic for Voltaren)
- diclofenac 1.5% topical solution

**OR**

**3.1.2** History of intolerance or contraindication to BOTH of the following (please provide intolerance or contraindication):

- diclofenac topical gel 1% (Rx or OTC formulation) (generic for Voltaren)
- diclofenac 1.5% topical solution

**OR**

**3.2** If the request is for diclofenac topical solution 1.5%, ONE of the following:

**3.2.1** Failure of ONE of the following, as confirmed by claims history or submitted medical records:

- diclofenac topical gel 1% (Rx formulation) (generic for Voltaren)
- diclofenac topical gel 1% (OTC formulation) (generic for Voltaren)

**OR**

<p><b>3.2.2</b> History of intolerance or contraindication to BOTH of the following (please provide intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>diclofenac topical gel 1% (Rx formulation) (generic for Voltaren)</li> <li>diclofenac topical gel 1% (OTC formulation) (generic for Voltaren)</li> </ul>	
Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

Product Name: Voltaren (Rx and OTC formulations)	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient has a diagnosis of pain due to osteoarthritis of joints amenable to topical treatment, including but not limited to the hands, knees, ankles, elbows, feet, and wrists</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> If the request is for the Rx (prescription) formulation, BOTH of the following:</p> <p><b>2.1.1</b> The patient did not receive adequate pain relief when treated with at least TWO preferred* non-steroidal anti-inflammatory drugs (NSAIDs), one of which must be celecoxib (generic for Celebrex), as confirmed by claims history or submitted medical records. An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.1.2</b> ONE of the following:</p> <p><b>2.1.2.1</b> Failure to BOTH of the following, as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>diclofenac topical gel 1% [Rx or OTC (over-the-counter) formulation] (generic Voltaren)</li> </ul>	

<ul style="list-style-type: none"> <li>Brand Voltaren topical gel 1% (OTC formulation)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.1.2.2</b> History of intolerance or contraindication to BOTH of the following (please provide intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>diclofenac topical gel 1% (Rx or OTC formulation) (generic Voltaren)</li> <li>Brand Voltaren topical gel 1% (OTC formulation)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> If the request is for the OTC formulation, ONE of the following:</p> <p><b>2.2.1</b> Failure to ONE of the following, as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>diclofenac topical gel 1% (Rx formulation) (generic Voltaren)</li> <li>diclofenac topical gel 1% (OTC formulation) (generic Voltaren)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2.2</b> History of intolerance or contraindication to BOTH of the following (please provide intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>diclofenac topical gel 1% (Rx formulation) (generic Voltaren)</li> <li>diclofenac topical gel 1% (OTC formulation) (generic Voltaren)</li> </ul>	
Notes	*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a>

## 2 . Revision History

Date	Notes
5/1/2024	Added NM PDL Link

Topical Retinoid Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161609
<b>Guideline Name</b>	Topical Retinoid Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:generic tretinoin microsphere, Retin-A Micro, Brand Differin cream, generic adapalene cream, Differin gel (Rx only)/lotion, adapalene gel/soln/pads, Fabior, tazarotene foam, Tazorac, generic tazarotene, adapalene/benzoyl peroxide, Brand Epiduo, Brand Epiduo Forte, Brand Atralin, generic tretinoin gel, Avita, Brand Retin-A, Altreno, Akliel, Arazlo	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - The patient has a non-cosmetic medical condition (e.g., acne vulgaris, psoriasis, precancerous skin lesions) (See Table 1 in Background for additional list of non-cosmetic medical conditions)</p>	

**AND**

**2** - Medication is not being requested solely for cosmetic purposes (e.g., photo-aging, wrinkling, hyperpigmentation, sun damage, melasma) (See Table 1 in Background for additional list of non-cosmetic medical conditions)

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** Patient has a diagnosis of acne vulgaris

**AND**

**3.1.2** ONE of the following:

**3.1.2.1** Failure to a trial of BOTH of the following as confirmed by claims history or submission of medical records:

- Differin OTC (over the counter)
- Tretinoin cream (generic Retin-A cream)

**OR**

**3.1.2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Differin OTC
- Tretinoin cream (generic Retin-A cream)

**OR**

**3.2** BOTH of the following:

**3.2.1** Patient does NOT have a diagnosis of acne vulgaris

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Failure to a trial of at least THREE preferred\* products as confirmed by claims history or submission of medical records

**OR**

**3.2.2.2** History of intolerance or contraindication to ALL preferred\* products (please specify intolerance or contraindication)

Notes	<p>*Step therapy is not limited to topical retinoids. In instances where there are fewer than three preferred alternatives, the patient must have a history of failure, contraindication, or intolerance to ALL of the preferred products.</p> <p>*PDL Link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p>
-------	--

Product Name:generic tretinoin cream	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient is less than 18 years old</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - ALL of the following:</p> <p><b>2.1</b> Patient is 18 years of age or older</p> <p style="text-align: center;"><b>AND</b></p>	

**2.2** Patient has a non-cosmetic medical condition (e.g., acne vulgaris, psoriasis, precancerous skin lesions) (See Table 1 in Background for additional list of non-cosmetic medical conditions)

**AND**

**2.3** Medication is not being requested solely for cosmetic purposes (e.g., photo-aging, wrinkling, hyperpigmentation, sun damage, melasma) (See Table 1 in Background for additional list of non-cosmetic medical conditions)

## 2 . Background

### Benefit/Coverage/Program Information

**Table 1: Examples of non-cosmetic medical conditions include, but are not limited to, the following:**

Acanthosis nigricans	Keratoderma
Acne	Keratoderma palmaris et plantaris
Acne keloidalis nuchae	Keratosis rubra figurata
Acne rosacea	Kyrle's disease
Acne vulgaris	Lamellar ichthyosis
Actinic cheilitis	Leukoplakia
Actinic dermatitis	Lichen planus
Actinic keratosis	Mal de Meleda
	Malignancy
Basal cell carcinoma	Mendes da Costa syndrome
Bowen's disease	Molluscum contagiosum
Cystic acne	Non-bullous congenital ichthyosis

Darier's disease	Papillon-Lefevre syndrome
Darier-White Disease	Porokeratosis
Dermal mucinosis	Pseudofollicular barbae
Discoid lupus erythematosus	Pseudoacanthosis nigricans
Epidermoid cysts	Psoriasis
Epidermolytic hyperkeratosis	Psoriasis erythrodermic, palmoplantar
Erythrokeratoderma variabilis	Psoriasis pustular
Favre Racouchot disease	Psoriatic arthritis
Flat warts	Rosacea
Folliculitis	Sebaceous cysts
Fox Fordyce disease	Senile keratosis
Grover's disease	Solar keratosis
Hidradenitis suppurativa	Squamous cell carcinoma
Hyperkeratosis	Systematized epidermal nevus
Hyperkeratosis follicularis	Transient acantholytic dermatosis
Hyperkeratotic eczema	Tylotic eczema
Ichthyoses	X-linked ichthyosis
Ichthyosis vulgaris	Verruca plana
Keloid scar	Von Zumbusch pustular
Keratoacanthoma	Warts
Keratosis follicularis	Wound healing (mild)

### 3 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
12/3/2024	Updated GPs

Trelegy Ellipta, Breztri



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146429
<b>Guideline Name</b>	Trelegy Ellipta, Breztri
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Trelegy Ellipta, Breztri Aerosphere	
Diagnosis	Chronic Obstructive Pulmonary Disease (COPD)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema</p>	

**AND**

**2 - ONE of the following:**

**2.1** Failure to a 30 day trial of ONE of the following combinations as confirmed by claims history or submission of medical records:

**2.1.1** ONE of the following long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA)

- Anoro Ellipta (umeclidinium/vilanterol)
- Stiolto Respimat (tiotropium/olodaterol)

**OR**

**2.1.2** ONE of the following inhaled corticosteroid (ICS) plus long-acting beta2-agonist (LABA)

- fluticasone/salmeterol (authorized generic of AirDuo)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify intolerance or contraindication):

- Anoro Ellipta (umeclidinium/vilanterol)
- Stiolto Respimat (tiotropium/olodaterol)
- fluticasone/salmeterol (authorized generic of AirDuo)
- fluticasone propionate/salmeterol diskus (generic Advair Diskus)
- Wixela Inhub (generic Advair Diskus)

**OR**

**2.3** Eosinophil count greater than or equal to 300 cells/microliter as confirmed by submission of medical records

Product Name: Trelegy Ellipta, Breztri Aerosphere	
Diagnosis	Asthma
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of asthma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Failure to treatment with at least a 30-day trial of ONE of the following, confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• fluticasone/salmeterol (authorized generic of AirDuo)</li> <li>• fluticasone propionate/salmeterol diskus (generic Advair Diskus)</li> <li>• Wixela Inhub (generic Advair Diskus)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> History of contraindication or intolerance to ALL of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• fluticasone/salmeterol (authorized generic of AirDuo)</li> <li>• fluticasone propionate/salmeterol diskus (generic Advair Diskus)</li> <li>• Wixela Inhub (generic Advair Diskus)</li> </ul>	

Tremfya



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-206588
<b>Guideline Name</b>	Tremfya
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Tremfya	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**2** - Patient is NOT receiving Tremfya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

**AND**

**4** - One of the following:

**4.1** Patient is currently on Tremfya therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** All of the following:

**4.2.1** One of the following:

**4.2.1.1** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), ustekinumab]

**OR**

**4.2.1.2** All of the following:

**4.2.1.2.1** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**4.2.1.2.2** One of the following:

- Failure to ONE of the following topical therapy classes confirmed by claims history or submission of medical records: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar
- History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication): Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar

**AND**

**4.2.1.2.3** One of the following:

- Failure to a 3 month trial of methotrexate at maximally indicated dose confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**AND**

**4.2.2** One of the following:

**4.2.2.1** Failure to TWO of the following preferred products as confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following preferred products (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**4.2.3** One of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

Notes

\*See PDL links in Background

Product Name: Tremfya

Diagnosis	Psoriatic Arthritis (PsA)
-----------	---------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Diagnosis of active psoriatic arthritis

**AND**

**2** - Patient is NOT receiving Tremfya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - One of the following:

**4.1** Patient is currently on Tremfya therapy as confirmed by claims history or submission of medical records

**OR**

**4.2** ALL of the following:

**4.2.1** One of the following:

- Failure to a 3 month trial of methotrexate at the maximally indicated dose, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), ustekinumab, Xeljanz/XR (tofacitinib), Otezla (apremilast), Rinvoq (upadacitinib)]

**AND**

**4.2.2** One of the following:

**4.2.2.1** Failure to TWO of the following preferred products as confirmed by claims history or submitted medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**4.2.2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication)

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**4.2.3** One of the following:

- Failure to Cosentyx (secukinumab) as confirmed by claims history or submitted medical records
- History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

Notes

\*See PDL links in Background

Product Name:Tremfya	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of moderately to severely active ulcerative colitis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - One of the following:</p> <p><b>2.1</b> Patient has been established on therapy with Tremfya under an active UnitedHealthcare</p>	

medical benefit prior authorization for the treatment of moderately to severely active ulcerative colitis

**OR**

**2.2** Patient is currently on Tremfya therapy for moderately to severely active ulcerative colitis as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Tremfya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi (risankizumab)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Product Name:Tremfya	
Diagnosis	Plaque Psoriasis, Psoriatic Arthritis (PsA), Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Tremfya therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Tremfya in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Cosentyx (secukinumab), Taltz</p>	

(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]*	
Notes	*Examples of drug(s) may not be applicable based on the requested indication.

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL Links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NY: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a></p> <p>PA: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p>RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a></p>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
3/6/2025	Added NM to formulary. Changed "Stelara" to "ustekinumab". Criteria updates for PsO and PsA dx.

Trikafta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151756
<b>Guideline Name</b>	Trikafta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Trikafta	
Diagnosis	Cystic Fibrosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p>	

**AND**

**2** - Submission of laboratory results documenting that the patient has at least ONE of the following mutations in the CFTR gene:

- F508del mutation
- A mutation that is responsive based on in vitro data (see chart in Table 1 of background section)

**AND**

**3** - The patient is greater than or equal to 2 years of age

**AND**

**4** - Prescribed by, or in consultation with, a provider who specializes in the treatment of CF

<b>Product Name: Trikafta</b>	
Diagnosis	Cystic Fibrosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Trikafta therapy (e.g., improved lung function, stable lung function)	

## 2 . Background

<b>Benefit/Coverage/Program Information</b>
---

**Table 1**

List of <i>CFTR</i> gene mutations that are responsive to Trikafta					
<i>3141del9</i>	<i>E822K</i>	<i>G1069R</i>	<i>L967S</i>	<i>R117L</i>	<i>S912L</i>
<i>546insCTA</i>	<i>F191V</i>	<i>G1244E</i>	<i>L997F</i>	<i>R117P</i>	<i>S945L</i>
<i>A46D</i>	<i>F311del</i>	<i>G1249R</i>	<i>L1077P</i>	<i>R170H</i>	<i>S977F</i>
<i>A120T</i>	<i>F311L</i>	<i>G1349D</i>	<i>L1324P</i>	<i>R258G</i>	<i>S1159F</i>
<i>A234D</i>	<i>F508C</i>	<i>H139R</i>	<i>L1335P</i>	<i>R334L</i>	<i>S1159P</i>
<i>A349V</i>	<i>F508C;S1251N</i> †	<i>H199Y</i>	<i>L1480P</i>	<i>R334Q</i>	<i>S1251N</i>
<i>A455E</i>	<i>F508del *</i>	<i>H939R</i>	<i>M152V</i>	<i>R347H</i>	<i>S1255P</i>
<i>A554E</i>	<i>F575Y</i>	<i>H1054D</i>	<i>M265R</i>	<i>R347L</i>	<i>T338I</i>
<i>A1006E</i>	<i>F1016S</i>	<i>H1085P</i>	<i>M952I</i>	<i>R347P</i>	<i>T1036N</i>
<i>A1067T</i>	<i>F1052V</i>	<i>H1085R</i>	<i>M952T</i>	<i>R352Q</i>	<i>T1053I</i>
<i>D110E</i>	<i>F1074L</i>	<i>H1375P</i>	<i>M1101K</i>	<i>R352W</i>	<i>V201M</i>
<i>D110H</i>	<i>F1099L</i>	<i>I148T</i>	<i>P5L</i>	<i>R553Q</i>	<i>V232D</i>
<i>D192G</i>	<i>G27R</i>	<i>I175V</i>	<i>P67L</i>	<i>R668C</i>	<i>V456A</i>
<i>D443Y</i>	<i>G85E</i>	<i>I336K</i>	<i>P205S</i>	<i>R751L</i>	<i>V456F</i>
<i>D443Y;G576A;R668C</i> †	<i>G126D</i>	<i>I502T</i>	<i>P574H</i>	<i>R792G</i>	<i>V562I</i>
<i>D579G</i>	<i>G178E</i>	<i>I601F</i>	<i>Q98R</i>	<i>R933G</i>	<i>V754M</i>
<i>D614G</i>	<i>G178R</i>	<i>I618T</i>	<i>Q237E</i>	<i>R1066H</i>	<i>V1153E</i>
<i>D836Y</i>	<i>G194R</i>	<i>I807M</i>	<i>Q237H</i>	<i>R1070Q</i>	<i>V1240G</i>
<i>D924N</i>	<i>G194V</i>	<i>I980K</i>	<i>Q359R</i>	<i>R1070W</i>	<i>V1293G</i>
<i>D979V</i>	<i>G314E</i>	<i>I1027T</i>	<i>Q1291R</i>	<i>R1162L</i>	<i>W361R</i>
<i>D1152H</i>	<i>G463V</i>	<i>I1139V</i>	<i>R31L</i>	<i>R1283M</i>	<i>W1098C</i>
<i>D1270N</i>	<i>G480C</i>	<i>I1269N</i>	<i>R74Q</i>	<i>R1283S</i>	<i>W1282R</i>
<i>E56K</i>	<i>G551D</i>	<i>I1366N</i>	<i>R74W</i>	<i>S13F</i>	<i>Y109N</i>

<i>E60K</i>	<i>G551S</i>	<i>K1060T</i>	<i>R74W;D1270N</i> †	<i>S341P</i>	<i>Y161D</i>
<i>E92K</i>	<i>G576A</i>	<i>L15P</i>	<i>R74W;V201M</i> †	<i>S364P</i>	<i>Y161S</i>
<i>E116K</i>	<i>G576A;R668C</i> †	<i>L165S</i>	<i>R74W;V201M;</i> <i>D1270N</i> †	<i>S492F</i>	<i>Y563N</i>
<i>E193K</i>	<i>G622D</i>	<i>L206W</i>	<i>R75Q</i>	<i>S549N</i>	<i>Y1014C</i>
<i>E403D</i>	<i>G628R</i>	<i>L320V</i>	<i>R117C</i>	<i>S549R</i>	<i>Y1032C</i>
<i>E474K</i>	<i>G970D</i>	<i>L346P</i>	<i>R117G</i>	<i>S589N</i>	
<i>E588V</i>	<i>G1061R</i>	<i>L453S</i>	<i>R117H</i>	<i>S737F</i>	
<p>* <i>F508del</i> is a responsive <i>CFTR</i> mutation based on both clinical and <i>in vitro</i> data.</p> <p>† Complex/compound mutations where a single allele of the <i>CFTR</i> gene has multiple mutations; these exist independent of the presence of mutations on the other allele.</p>					

### 3 . Revision History

Date	Notes
8/14/2024	Removed prescriber requirement from reauthorization criteria. Increased initial authorization approval duration to 12 months.

Triptans



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208201
<b>Guideline Name</b>	Triptans
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:almotriptan, generic eletriptan, Brand Relpax, generic frovatriptan, Brand Frova, Onzetra XSail, generic rizatriptan, Brand Maxalt, generic rizatriptan ODT, Brand Maxalt-MLT, Imitrex Statdose System, sumatriptan auto-inj, Brand Imitrex nasal spr/tabs, generic sumatriptan nasal spr/tabs/inj, Brand Imitrex Statdose Refill, generic sumatriptan refill, generic sumatriptan/naproxen, Brand Treximet, Zembrace Symtouch, generic zolmitriptan tabs/nasal spr, Brand Zomig tabs/nasal spr, Brand Zolmitriptan nasal spr, zolmitriptan ODT, Tosymra	
Diagnosis	Non-Preferred Products*
Approval Length	12 month(s)

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - If the requested medication is non-preferred*, <b>BOTH</b> of the following:</p> <p><b>1.1</b> Diagnosis of migraine headaches with or without aura</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> ONE of the following:</p> <p><b>1.2.1</b> Patient has failure to <b>THREE</b> of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• Eletriptan (generic Relpax)</li> <li>• Naratriptan</li> <li>• Rizatriptan</li> <li>• One of the following sumatriptan formulations: tablets, nasal spray, 4 mg injection, or 6 mg injection</li> <li>• Zolmitriptan (generic Zomig)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2.2</b> Patient has a history of contraindication or intolerance to <b>ALL</b> of the following (please specify intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>• Eletriptan (generic Relpax)</li> <li>• Naratriptan</li> <li>• Rizatriptan</li> <li>• One of the following sumatriptan formulations: tablets, nasal spray, 4 mg injection, or 6 mg injection</li> <li>• Zolmitriptan (generic Zomig)</li> </ul>	
Notes	*PDL links in Background.

<p>Product Name: Imitrex Statdose System, sumatriptan auto-inj, sumatriptan inj, Brand Imitrex Statdose Refill, generic sumatriptan refill</p>	
Diagnosis	Migraine Headaches

Approval Length	12 month(s)
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of migraine headaches with or without aura</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Currently receiving prophylactic therapy with at least ONE of the following as confirmed by claims history or submission of medical records:</b></p> <ul style="list-style-type: none"> <li>• A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol*)</li> <li>• Candesartan* (generic Atacand)</li> <li>• A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine*** [i.e., Aimovig, Ajovy*, Emgality, Qulipta*, Vyepiti**]</li> <li>• Divalproex sodium (generic Depakote/Depakote ER)</li> <li>• OnabotulinumtoxinA (generic Botox)**</li> <li>• A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]</li> <li>• Topiramate (generic Topamax)</li> <li>• A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - ONE of the following:</b></p> <p><b>3.1 Higher dose or quantity is supported in the dosage and administration section of the manufacturer’s prescribing information</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2 Higher dose or quantity is supported by one of the following compendia:</b></p> <ul style="list-style-type: none"> <li>• American Hospital Formulary Service Drug Information</li> <li>• Thomson Micromedex DrugDex</li> <li>• Clinical pharmacology</li> <li>• United States Pharmacopoeia-National Formulary (USP-NF)</li> </ul>	

<b>OR</b>	
<p><b>3.3</b> Provider provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the FDA for the diagnosis indicated</p>	
<b>AND</b>	
<p><b>4</b> - Provider acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity</p>	
Notes	<p>See Table 1 in Background.                      *This is non-preferred and should not be included in denial to provider                      .                      **This is a medical benefit and should not be included in denial to provider.                      ***Requires prior authorization</p>

Product Name: Imitrex Statdose System, sumatriptan auto-inj, sumatriptan inj, Brand Imitrex Statdose Refill, generic sumatriptan refill	
Diagnosis	Cluster Headaches
Approval Length	12 month(s)
Guideline Type	Quantity Limit
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of cluster headaches</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p>	

**3.1** Higher dose or quantity is supported in the dosage and administration section of the manufacturer’s prescribing information

**OR**

**3.2** Higher dose or quantity is supported by one of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**3.3** Provider provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the FDA for the diagnosis indicated

**AND**

**4** - Provider acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes	See Table 1 in Background.
-------	----------------------------

Product Name:almotriptan, generic eletriptan, Brand Relpax, generic frovatriptan, Brand Frova, Onzetra XSail, generic rizatriptan, Brand Maxalt, generic rizatriptan ODT, Brand Maxalt-MLT, Brand Imitrex nasal spr/tabs, generic sumatriptan nasal spr/tabs, generic sumatriptan/naproxen, Brand Treximet, Zembrace Symtouch, generic zolmitriptan tabs/nasal spr, Brand Zomig tabs/nasal spr, Brand Zolmitriptan nasal spr, zolmitriptan ODT, Tosymra, generic naratriptan

Approval Length	12 month(s)
Guideline Type	Quantity Limit

**Approval Criteria**

**1** - Diagnosis of migraine headaches with or without aura

**AND**

**2** - Currently receiving prophylactic therapy with at least ONE of the following as confirmed by claims history or submission of medical records:

- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol\*)
- Candesartan\* (generic Atacand)
- A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for preventive treatment of migraine\*\*\* [i.e., Aimovig, Ajovy\*, Emgality, Qulipta\*, Vyepti\*\*]
- Divalproex sodium (generic Depakote/Depakote ER)
- OnabotulinumtoxinA (generic Botox)\*\*
- A serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta), venlafaxine (Effexor/Effexor XR)]
- Topiramate (generic Topamax)
- A tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]

**AND**

**3** - ONE of the following:

**3.1** Higher dose or quantity is supported in the dosage and administration section of the manufacturer's prescribing information

**OR**

**3.2** Higher dose or quantity is supported by one of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**3.3** Provider provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the FDA for the diagnosis indicated

**AND**

4 - Provider acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes	See Table 1 in Background. *This is non-preferred and should not be included in denial to provider. **This is a medical benefit and should not be included in denial to provider. ***Requires prior authorization
-------	--

**2 . Background**

Benefit/Coverage/Program Information		
<b>Table 1. Quantity Limits</b>		
Drug Name	Strength	Quantity Limit
Brand Amerge generic naratriptan	1mg, 2.5mg	9 tabs/month
Brand Frova Generic frovatriptan	2.5mg	9 tabs/month
Brand Imitrex tablets Generic sumatriptan tablets	25mg, 50mg, 100mg	9 tabs/month
Brand Maxalt Generic rizatriptan	5mg, 10mg	9 tabs/month

Brand Maxalt MLT Generic rizatriptan ODT	5mg, 10mg	9 tabs/month
Generic almotriptan	6.25mg, 12.5mg	6 tabs/month
Relpax Generic eletriptan	20mg, 40mg	6 tabs/month
Brand Zomig Generic zolmitriptan	2.5mg, 5mg	6 tabs/month
Brand Zomig ZMT Generic zolmitriptan ODT	2.5mg, 5mg	6 tabs/month
Brand Imitrex nasal spray Generic sumatriptan nasal spray	5mg, 20mg	6 spray devices/month
Zomig nasal spray	2.5mg, 5mg	6 spray devices/month
Treximet Generic sumatriptan/naproxen	85mg/500 mg, 10mg/60mg	9 tabs/month
Onzetra Xsail	11mg	1 box (8 units)/month
Zembrace SymTouch	3mg/ <u>0.5mL</u>	<u>2 boxes (8 units)/month</u>
<u>Brand Imitrex</u> <u>Generic Sumatriptan</u> <u>Autoinjector/Cartridge Refills</u>	<u>4mg/0.5mL</u> <u>6mg/0.5mL</u>	<u>8 autoinjectors or</u> <u>cartridge refills/month</u> <u>(4 boxes/month)</u>
<u>Brand Imitrex</u> <u>Generic Sumatriptan</u> <u>Vials</u>	<u>6mg/0.5mL</u>	<u>10 vials/month (2</u> <u>boxes/month)</u>

<a href="#"><u>Generic Sumatriptan Pre-filled Syringe</u></a>	<a href="#"><u>6mg/0.5mL</u></a>	<a href="#"><u>8 prefilled syringes (4 boxes/month)</u></a>
<a href="#"><u>Tosymra nasal spray</u></a>	<a href="#"><u>10mg</u></a>	<a href="#"><u>6 units per month</u></a>

**PDL links**

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

**3 . Revision History**

Date	Notes
3/5/2025	Updated formularies. Removed naratriptan step therapy section. Added eletriptan and zolmitriptan as options in the non-preferred section. Updated prophylactic therapies list and notes



Truqap



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-202194
<b>Guideline Name</b>	Truqap
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Truqap	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of breast cancer

**AND**

**2** - Disease is ONE of the following:

- Locally advanced
- Recurrent unresectable (local or regional)
- Metastatic

**AND**

**3** - Disease is hormone receptor (HR)-positive

**AND**

**4** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**5** - Presence of one or more PIK3CA/AKT1/PTEN-alterations

**AND**

**6** - ONE of the following:

**6.1** Has progressed on at least one endocrine-based regimen in the metastatic setting (e.g., anastrozole, letrozole, exemestane, tamoxifen)

**OR**

**6.2** Recurrence on or within 12 months of completing adjuvant therapy

**AND**

**7** - Used in combination with fulvestrant

Product Name:Truqap	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Truqap therapy</p> <p><b>AND</b></p> <p><b>2</b> - Used in combination with fulvestrant</p>	

Product Name:Truqap	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Truqap	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Truqap therapy</p>	

## 2 . Revision History

Date	Notes
2/25/2025	Combined formularies. Added new GPIs for Truqap therapy packs. F or BC initial auth section, added "recurrent unresectable (local or regional)" as an option for disease type.

Tryvio



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154415
<b>Guideline Name</b>	Tryvio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/5/2024
-----------------	----------

### 1 . Criteria

Product Name: Tryvio	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of resistant hypertension</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - One of the following:**

**2.1** Systolic blood pressure greater than or equal to 130 mm Hg (millimeters of mercury) on two consecutive measurements

**OR**

**2.2** Diastolic blood pressure greater than or equal to 80 mm Hg on two consecutive measurements

**AND**

**3 - Patient is receiving concomitant therapy with all of the following confirmed by claims history or submitted medical records:**

**3.1** Maximally tolerated blocker of the renin-angiotensin system [angiotensin-converting enzyme (ACE) inhibitor (e.g., enalapril, lisinopril) or angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)]

**AND**

**3.2** Maximally tolerated calcium channel blocker (e.g., amlodipine, diltiazem, verapamil)

**AND**

**3.3** Maximally tolerated diuretics (e.g., hydrochlorothiazide)

**AND**

**4 - One of the following:**

**4.1** Patient is receiving concomitant therapy with a mineralocorticoid receptor antagonist [MRA (e.g., spironolactone, eplerenone)] confirmed by claims history or submitted medical records

**OR**

**4.2** Patient has a contraindication, or intolerance to mineralocorticoid receptor antagonist [MRA (e.g., spironolactone, eplerenone)] (please specify intolerance or contraindication)

**AND**

**5** - One of the following:

**5.1** Patient is receiving concomitant therapy with a beta-blocker (e.g., labetalol, carvedilol) confirmed by claims history or submitted medical records

**OR**

**5.2** Patient has a contraindication, or intolerance to beta-blockers (e.g., labetalol, carvedilol) (please specify intolerance or contraindication)

**AND**

**6** - Prescribed by or in consultation with a cardiologist

Product Name: Tryvio

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation the patient is receiving clinical benefit to Tryvio therapy

**AND**

**2** - Patient is receiving concomitant therapy with all of the following confirmed by claims history or submitted medical records:

**2.1** Maximally tolerated blocker of the renin-angiotensin system [angiotensin-converting

enzyme (ACE) inhibitor (e.g., enalapril, lisinopril) or angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)]

**AND**

**2.2** Maximally tolerated calcium channel blocker (e.g., amlodipine, diltiazem, verapamil)

**AND**

**2.3** Maximally tolerated diuretics (e.g., hydrochlorothiazide)

## 2 . Revision History

Date	Notes
9/5/2024	New guideline.

Tukysa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146682
<b>Guideline Name</b>	Tukysa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Tukysa	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - Disease is ONE of the following:

- Advanced unresectable
- Metastatic

**AND**

**3** - Disease is human epidermal growth factor receptor 2 (HER2)-positive

**AND**

**4** - Patient has been previously treated with an anti-HER2-based regimen in the metastatic setting [e.g., trastuzumab (Herceptin, Kanjinti), pertuzumab (Perjeta), ado-trastuzumab emtansine (T-DM1)]

**AND**

**5** - Used in combination with trastuzumab (e.g., Herceptin, Kanjinti, Ontruzant) and capecitabine (Xeloda)

Product Name:Tukysa	
Diagnosis	CNS Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of brain metastases with HER2 (human epidermal growth factor receptor 2) positive breast cancer</p>	

**AND**

**2** - Patient has been previously treated with an anti-HER2-based regimen [e.g., trastuzumab (Herceptin, Kanjinti), pertuzumab (Perjeta), ado-trastuzumab emtansine (T-DM1)]

**AND**

**3** - Used in combination with trastuzumab (e.g., Herceptin, Kanjinti, Ontruzant) and capecitabine (Xeloda)

Product Name:Tukysa	
Diagnosis	Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of unresectable, advanced, or metastatic colorectal cancer [HER2-amplified and RAS (gene) and BRAF (gene) wild-type]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease is human epidermal growth factor receptor 2 (HER2)-positive</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - ONE of the following:</p> <p><b>3.1</b> Patient has previously been treated with ONE of the following regimens:</p> <ul style="list-style-type: none"> <li>• Fluoropyrimidine-based chemotherapy</li> <li>• Oxaliplatin-based chemotherapy</li> </ul>	

<ul style="list-style-type: none"> <li>Irinotecan-based chemotherapy</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> Patient is not appropriate for intensive therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Used in combination with trastuzumab (e.g., Herceptin, Kanjinti)</p>
--

Product Name:Tukysa	
Diagnosis	Breast Cancer, CNS Cancers, Colorectal Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Tukysa therapy</p>	

Product Name:Tukysa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Tukysa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tukysa therapy</p>	

Turalio



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161274
<b>Guideline Name</b>	Turalio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Turalio	
Diagnosis	Tenosynovial Giant Cell Tumor (TGCT)/Pigmented Villonodular Synovitis (PVNS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has a diagnosis of tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS)</p>	

Product Name:Turalio	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Langerhans Cell Histiocytosis</li> <li>• Erdheim-Chester Disease</li> <li>• Rosai-Dorfman Disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Colony stimulating factor 1 receptor (CSF1R) mutation positive</p>	

Product Name:Turalio	
Diagnosis	Tenosynovial Giant Cell Tumor (TGCT)/Pigmented Villonodular Synovitis (PVNS), Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Turalio therapy</p>	

Product Name:Turalio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Turalio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Turalio therapy</p>	

## 2 . Revision History

Date	Notes
11/26/2024	Updated GPIs

Tykerb



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-161480
<b>Guideline Name</b>	Tykerb
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Brand Tykerb, generic lapatinib	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of recurrent unresectable (local or regional) or stage IV breast cancer</p>	

**AND**

**1.2** Disease is hormone receptor positive and human epidermal growth factor receptor 2-positive (HER2+)

**AND**

**1.3** Used in combination with an aromatase inhibitor [e.g., Aromasin (exemestane), Femara (letrozole), Arimidex (anastrozole)]

**OR**

**2** - ALL of the following:

**2.1** ONE of the following:

- Diagnosis of recurrent unresectable (local or regional) or stage IV breast cancer
- Breast cancer that is unresponsive to preoperative systemic therapy

**AND**

**2.2** Disease is HER2+

**AND**

**2.3** Used as fourth line therapy and beyond in combination with ONE of the following:

- Herceptin (trastuzumab)
- Xeloda (capecitabine)

Product Name: Brand Tykerb, generic lapatinib	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - ALL of the following:</b></p> <p><b>1.1</b> Diagnosis of recurrent, central nervous system (CNS) cancer with metastatic lesions</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Tykerb is active against primary (breast) tumor</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> Used in combination with Xeloda (capecitabine)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2 - ALL of the following:</b></p> <p><b>2.1</b> Diagnosis of progressive or recurrent intracranial or spinal ependymoma (excluding subependymoma)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2</b> Patient has received previous radiation therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.3 ONE of the following:</b></p> <ul style="list-style-type: none"> <li>• Patient has received gross total or subtotal resection with negative cerebrospinal fluid (CSF) cytology</li> <li>• Patient has received subtotal resection and evidence of metastasis (brain, spine, or CSF)</li> </ul>	

- Patient has unresectable disease

**AND**

**2.4** Used in combination with Temodar (temozolomide)

Product Name: Brand Tykerb, generic lapatinib	
Diagnosis	Chordoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent conventional or chondroid chordoma</p> <p><b>AND</b></p> <p>2 - Disease is epidermal growth factor receptor (EGFR)-positive</p>	

Product Name: Brand Tykerb, generic lapatinib	
Diagnosis	Colon Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of colon cancer</p>	

**AND**

**2** - Disease is human epidermal growth factor receptor 2 (HER2)-amplified and RAS and BRAF wild type

**AND**

**3** - ONE of the following:

**3.1** Disease is proficient mismatch repair/microsatellite-stable (pMMR/MSS)

**OR**

**3.2** BOTH of the following:

**3.2.1** Disease is positive for deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) or polymerase epsilon/delta (POLE/POLD1) mutation

**AND**

**3.2.2** ONE of the following:

- Patient is ineligible for or progressed on checkpoint inhibitor immunotherapy [e.g., Opdivo (nivolumab), Keytruda (pembrolizumab), Jemperli (dostarlimab-gxly)]
- Patient has a contraindication to checkpoint inhibitor immunotherapy

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

- Used as initial therapy for unresectable metachronous metastases
- Previous therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12 months

**OR**

**4.2** Intensive chemotherapy with one of the following is not recommended:

- Oxaliplatin
- Irinotecan
- Capecitabine

**OR**

**4.3** Used as second-line and subsequent therapy for progression of advanced or metastatic disease

**AND**

**5** - Used in combination with trastuzumab

**AND**

**6** - Patient has not previously been treated with a HER2 inhibitor [e.g., trastuzumab, Perjeta (pertuzumab), Nerlynx (neratinib)]

Product Name: Brand Tykerb, generic lapatinib	
Diagnosis	Rectal Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of rectal cancer</p>	

**AND**

**2** - Disease is human epidermal growth factor receptor 2 (HER2)-amplified and RAS and BRAF wild type

**AND**

**3** - ONE of the following:

**3.1** Disease is proficient mismatch repair/microsatellite-stable (pMMR/MSS)

**OR**

**3.2** BOTH of the following:

**3.2.1** Disease is positive for deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) or polymerase epsilon/delta (POLE/POLD1) mutation

**AND**

**3.2.2** ONE of the following:

- Patient is ineligible for or progressed on checkpoint inhibitor immunotherapy [e.g., Opdivo (nivolumab), Keytruda (pembrolizumab), Jemperli (dostarlimab-gxly)]
- Patient has a contraindication to checkpoint inhibitor immunotherapy

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

- Used as initial therapy for unresectable metachronous metastases
- Previous therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12 months

**OR**

**4.2** Intensive chemotherapy with one of the following is not recommended:

- Oxaliplatin
- Irinotecan
- Capecitabine

**OR**

**4.3** Used as second-line and subsequent therapy for progression of advanced or metastatic disease

**AND**

**5** - Used in combination with trastuzumab

**AND**

**6** - Patient has not previously been treated with a HER2 inhibitor [e.g., trastuzumab, Perjeta (pertuzumab), Nerlynx (neratinib)]

Product Name: Brand Tykerb, generic lapatinib	
Diagnosis	Breast Cancer, Central Nervous System (CNS) Cancers, Chordoma, Colon Cancer, Rectal Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Tykerb therapy	

Product Name:Brand Tykerb, generic lapatinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brand Tykerb, generic lapatinib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Tykerb therapy</p>	

## 2 . Revision History

Date	Notes
12/2/2024	Updated coverage criteria for breast cancer, central nervous system cancers, chordoma, colon cancer, and rectal cancer

Tymlos



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146685
<b>Guideline Name</b>	Tymlos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Tymlos	
Approval Length	24 Months*
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 BOTH of the following:</p> <ul style="list-style-type: none"> <li>Patient is female</li> <li>Diagnosis of postmenopausal osteoporosis</li> </ul>	

**OR**

**1.2 BOTH** of the following:

- Patient is male
- Diagnosis of osteoporosis

**AND**

**2 - ONE** of the following:

**2.1** Patient is at high risk of fracture [e.g., recent fracture (e.g., within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids), very low T-score (e.g., less than -3.0), high risk for falls or history of injurious falls, and very high fracture probability by FRAX (fracture risk assessment tool) (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%)]

**OR**

**2.2** Patient has a history of failure, intolerance, or contraindication to other available osteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate)

**AND**

**3 - Treatment duration** has not exceeded a total of 24 months\* of cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos) during the patient's lifetime

Notes

\*Duration of coverage will be limited to 24 months of cumulative parathyroid hormone analog therapy (e.g., Teriparatide Injection, Forteo, Tymlos) in the patient's lifetime.

Upneeq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208217
<b>Guideline Name</b>	Upneeq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Upneeq	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acquired blepharoptosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has a functional impairment related to the position of the eyelid</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Marginal reflex distance-1 (MRD-1) is less than or equal to 2 millimeters (mm) in primary gaze</li> <li>• Marginal reflex distance-1 (MRD-1) is less than or equal to 2 mm in down gaze</li> <li>• Superior visual field loss of at least 12 degrees or 24 percent</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Other treatable causes of blepharoptosis have been ruled out (e.g., recent botulinum toxin injections, myasthenia gravis)</p>	

Product Name:Upneeq	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of a positive clinical response to therapy</p>	

## 2 . Revision History

Date	Notes
3/5/2025	Added PA-CAID for 4/1 go-live. No change to criteria.

Ustekinumab



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-207324
<b>Guideline Name</b>	Ustekinumab
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/5/2025
-----------------	----------

## 1 . Criteria

Product Name:All subcutaneous formulations of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

1.2 ONE of the following:

1.2.1 ALL of the following:

1.2.1.1 Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

1.2.1.2 ONE of the following:

1.2.1.2.1 Failure to ONE of the following topical therapy classes, confirmed by claims history or submitted medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

1.2.1.2.2 History of intolerance or contraindication to ALL of the following topical therapy classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin

- Coal tar

**AND**

**1.2.1.3 ONE of the following:**

- Failure to a 3 month trial of methotrexate at maximally indicated dose, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

**1.2.2** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of plaque psoriasis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)]

**AND**

**1.3 ONE of the following:**

- Failure to one of the preferred adalimumab products confirmed by claims history or submitted medical records
- History of intolerance or contraindication to one of the preferred adalimumab products (please specify intolerance or contraindication)

**AND**

**1.4** Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.5 ONE of the following:**

**1.5.1** Requested medication is ustekinumab 45 mg (milligrams)/0.5 mL (milliliters)

**OR**

**1.5.2** BOTH of the following:

- Requested medication is ustekinumab 90 mg/1 mL
- Patient's weight is greater than 100 kilograms (220 pounds)

**AND**

**1.6** Prescribed by or in consultation with a dermatologist

**AND**

**1.7** If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**1.8** If the request is for Brand Stelara, ONE of the following:

**1.8.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**1.8.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on ustekinumab therapy as confirmed by claims history or submitted medical records

**AND**

**2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**2.3** Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a dermatologist

**AND**

**2.5** If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**2.6** If the request is for Brand Stelara, ONE of the following:

**2.6.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**2.6.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

Notes

\*See PDL links in Background

Product Name: All subcutaneous formulations of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek

Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 ONE of the following:

1.1.1 BOTH of the following:

- Requested medication is ustekinumab 45 mg (milligrams)/0.5 mL (milliliters)
- Diagnosis of active psoriatic arthritis

**OR**

1.1.2 ALL of the following:

- Requested medication is ustekinumab 90 mg/1 mL

- Patient's weight is greater than 100 kilograms (220 pounds)
- Diagnosis of active psoriatic arthritis
- Diagnosis of co-existent moderate to severe plaque psoriasis

**AND**

**1.2** Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**1.3** ONE of the following:

- Failure to a 3 month trial of methotrexate at maximally indicated dose, confirmed by claims history or submitted medical records
- History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)
- Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab), Tremfya (guselkumab) Xeljanz (tofacitinib), Otezla (apremilast), Rinvoq (upadacitinib)]

**AND**

**1.4** ONE of the following:

- Failure to one of the preferred adalimumab products confirmed by claims history or submitted medical records
- History of intolerance or contraindication to one of the preferred adalimumab products (please specify intolerance or contraindication)

**AND**

**1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**AND**

**1.6** If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**1.7** If the request is for Brand Stelara, ONE of the following:

**1.7.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**1.7.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on ustekinumab therapy as confirmed by claims history or submitted medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving ustekinumab in combination with another targeted

immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**AND**

**2.5** If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**2.6** If the request is for Brand Stelara, ONE of the following:

**2.6.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**2.6.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

Notes

\*See PDL links in Background

Product Name: All subcutaneous formulations of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek

Diagnosis	Plaque Psoriasis, Psoriatic Arthritis
Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to ustekinumab therapy

**AND**

2 - Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\*

**AND**

3 - If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*\*

**AND**

4 - If the request is for Brand Stelara, ONE of the following:

4.1 Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*\*

**OR**

4.2 BOTH of the following:

<ul style="list-style-type: none"> <li>• Submission of medical records confirming patient has previously been successfully treated with brand Stelara</li> <li>• Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness**</li> </ul>	
Notes	<p>*Examples of drug(s) may not be applicable based on the requested indication.</p> <p>**See PDL links in Background</p>

Product Name: 90 mg/mL subcutaneous formulation of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek	
Diagnosis	Crohn's Disease (CD)
Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active Crohn's disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 BOTH of the following:</p> <p>2.1.1 ONE of the following:</p> <p>2.1.1.1 Failure to ONE of the following conventional therapy drugs or classes at maximally indicated dose, confirmed by claims history or submitted medical records:</p> <ul style="list-style-type: none"> <li>• Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)</li> <li>• 6-mercaptopurine (Purinethol)</li> <li>• Azathioprine (Imuran)</li> <li>• Methotrexate (Rheumatrex, Trexall)</li> </ul>	

**OR**

**2.1.1.2** History of intolerance or contraindication to ALL of the following conventional therapy drugs or classes (please specify intolerance or contraindication):

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Methotrexate (Rheumatrex, Trexall)

**OR**

**2.1.1.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of Crohn's disease as confirmed by claims history or submission of medical records [e.g., Cimzia (certolizumab), adalimumab]

**AND**

**2.1.2** ONE of the following:

- Failure to one of the preferred adalimumab products, as confirmed by claims history or submitted medical records
- History of intolerance or contraindication to one of the preferred adalimumab products (please specify intolerance or contraindication)

**OR**

**2.2** Patient is currently on ustekinumab therapy for moderately to severely active Crohn's disease as confirmed by claims history or submitted medical records

**OR**

**2.3** Patient has been established on therapy with ustekinumab under an active UnitedHealthcare medical benefit prior authorization for treatment of moderately to severely active Crohn's disease

**AND**

**3** - Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi (risankizumab)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

**AND**

**5** - If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**6** - If the request is for Brand Stelara, ONE of the following:

**6.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**6.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

Notes

\*See PDL links in Background

Product Name: 90 mg/mL subcutaneous formulation of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek

Diagnosis

Ulcerative Colitis

Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active ulcerative colitis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 BOTH of the following:</p> <p>2.1.1 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine), as confirmed by claims history or submitted medical records</li> <li>• Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), Xeljanz (tofacitinib)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2.1.2 ONE of the following:</p> <ul style="list-style-type: none"> <li>• Failure to one of the preferred adalimumab products, confirmed by claims history or submitted medical records</li> <li>• History of intolerance or contraindication to one of the preferred adalimumab products (please specify intolerance or contraindication)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Patient is currently on ustekinumab therapy for moderately to severely active ulcerative colitis as confirmed by claims history or submitted medical records</p>	

**OR**

**2.3** Patient has been established on therapy with ustekinumab under an active UnitedHealthcare medical benefit prior authorization for treatment of moderately to severely active ulcerative colitis

**AND**

**3** - Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi (risankizumab)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

**AND**

**5** - If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)\*

**AND**

**6** - If the request is for Brand Stelara, ONE of the following:

**6.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**6.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara

<ul style="list-style-type: none"> <li>Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness*</li> </ul>	
Notes	*See PDL links in Background

Product Name: 90 mg/mL subcutaneous formulation of the following: Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek	
Diagnosis	Crohn's Disease (CD), Ulcerative Colitis
Approval Length	12 month(s) NOTE: If approving a non-preferred ustekinumab, please enter: 1) The group authorization CSPREFUSTE and 2) An authorization for the non-preferred ustekinumab at GPI-12 level
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to ustekinumab therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving ustekinumab in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi (risankizumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is for a non-preferred ustekinumab product, the prescriber has given a clinical reason or special circumstance why the patient is unable to use the preferred ustekinumab products (please document reason/special circumstances)*</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - If the request is for Brand Stelara, ONE of the following:</p>	

**4.1** Submission of medical records confirming patient allergy or intolerance to at least two preferred ustekinumab biosimilars' inactive ingredients\*

**OR**

**4.2** BOTH of the following:

- Submission of medical records confirming patient has previously been successfully treated with brand Stelara
- Submission of medical records confirming patient has tried at least two preferred ustekinumab biosimilars for 6-8 weeks per product and saw a decrease in effectiveness\*

Notes

\*See PDL links in Background

## 2 . Background

### Benefit/Coverage/Program Information

#### PDL Links

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

### 3 . Revision History

Date	Notes
3/5/2025	Changed effective date to 3/5/2025.

Vafseo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158251
<b>Guideline Name</b>	Vafseo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Vafseo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of anemia due to chronic kidney disease (CKD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has been receiving dialysis for at least three months

**AND**

**3** - Both of the following:

- Ferritin greater than 100 mcg/L
- Transferrin saturation (TSAT) greater than 20%

**AND**

**4** - Hemoglobin level less than 11 g/dL

**AND**

**5** - One of the following:

**5.1** Failure to an erythropoietin stimulating agent (ESA) [e.g., Aranesp (darbepoetin), Epogen (epoetin alfa), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)] as confirmed by claims history or submission of medical records

**OR**

**5.2** History of contraindication or intolerance to an erythropoietin stimulating agent (ESA) [e.g., Aranesp (darbepoetin), Epogen (epoetin alfa), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)] (please specify contraindication or intolerance)

**AND**

**6** - Prescribed by or in consultation with one of the following:

- Hematologist
- Nephrologist

Product Name:Vafseo

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vafseo therapy (e.g., clinically meaningful increase in hemoglobin level)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Adequate iron stores confirmed by both of the following:</p> <ul style="list-style-type: none"> <li>• Ferritin greater than 100 mcg/L</li> <li>• Transferrin saturation (TSAT) greater than 20%</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Hemoglobin level does not exceed 12 g/dL</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is not on concurrent treatment with an erythropoietin stimulating agent (ESA) [e.g., Aranesp (darbepoetin), Epogen (epoetin alfa), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)]</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - Prescribed by or in consultation with one of the following:</p> <ul style="list-style-type: none"> <li>• Hematologist</li> <li>• Nephrologist</li> </ul>	

**2 . Revision History**

Date	Notes
10/30/2024	New

Valchlor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146686
<b>Guideline Name</b>	Valchlor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Valchlor	
Diagnosis	Primary Cutaneous Lymphomas
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Chronic or smoldering T-cell leukemia/lymphoma</li> <li>Primary cutaneous marginal zone or follicle center B-cell lymphoma</li> </ul>	

- Lymphomatoid papulosis (LyP) with extensive lesions
- Mycosis fungoides (MF)/Sezary syndrome (SS)

Product Name:Valchlor	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Langerhans Cell Histiocytosis (LCH)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Skin disease is unifocal and isolated</p>	

Product Name:Valchlor	
Diagnosis	Primary Cutaneous Lymphomas, Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Valchlor</p>	

Product Name:Valchlor	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Valchlor	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Valchlor therapy</p>	

Vanflyta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158192
<b>Guideline Name</b>	Vanflyta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Vanflyta	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia (AML)</p>	

**AND**

**2** - Disease is FLT3 internal tandem duplication (ITD) positive

**AND**

**3** - ONE of the following:

**3.1** Vanflyta will be used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy

**OR**

**3.2** Vanflyta will be used for patients with relapsed/refractory disease as a component of repeating the initial successful induction regimen or as a single agent

Product Name:Vanflyta	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Vanflyta therapy	

Product Name:Vanflyta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Vanflyta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vanflyta therapy</p>	

**2 . Revision History**

Date	Notes
10/29/2024	For AML, added "Initial Authorization" therapy stage and added allowance for relapsed/refractory disease per NCCN recommendations.

Vecamyl



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146688
<b>Guideline Name</b>	Vecamyl
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Vecamyl	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately severe to severe essential hypertension</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - Diagnosis of uncomplicated malignant hypertension

Product Name:Vecamyl

Approval Length 12 month(s)

Therapy Stage Reauthorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Documentation of a positive clinical response to Vecamyl therapy

Velsipity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208196
<b>Guideline Name</b>	Velsipity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Velsipity	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of moderately to severely active ulcerative colitis (UC)

**AND**

**2** - ONE of the following:

**2.1** Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine)

**OR**

**2.2** Patient has been previously treated with a targeted immunomodulator FDA (Food and Drug Administration)-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), ustekinumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]

**AND**

**3** - ONE of the following:

**3.1** Patient is currently on Velsipity therapy as confirmed by claims history or submission of medical records

**OR**

**3.2** Failure to ONE of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**3.3** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*

<ul style="list-style-type: none"> <li>• One of the preferred ustekinumab products*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is NOT receiving Velsipity in combination with a targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed by or in consultation with a gastroenterologist</p>	
Notes	*For a list of preferred adalimumab products please reference drug coverage tools.

Product Name:Velsipity	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Velsipity therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Velsipity in combination with a targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]</p>	

## 2 . Background

Benefit/Coverage/Program Information
<p><b>PDL links:</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p> <p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p> <p>NY: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a></p> <p>PA CHIP: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p>RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a></p>

### 3 . Revision History

Date	Notes
3/5/2025	Updated formularies. Updated safety check language. Replaced Stelara with ustekinumab throughout. Added ustekinumab as a step option in UC. Added NM PDL link to background.

Vemlidy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146689
<b>Guideline Name</b>	Vemlidy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Vemlidy	
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Failure to entecavir (generic Baraclude) as confirmed by claims history or submission of medical records</p>	

**OR**

**1.2** History of contraindication or intolerance to entecavir (generic Baraclude) (please specify contraindication or intolerance)

**OR**

**1.3** Patient is not a suitable candidate for entecavir (generic Baraclude)

**AND**

**2** - ONE of the following:

**2.1** Failure to tenofovir disoproxil fumarate (generic Viread) as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to tenofovir disoproxil fumarate (generic Viread) (please specify contraindication or intolerance)

**OR**

**2.3** Patient has an estimated glomerular filtration rate below 90 mL/min (milliliters/minute)

**OR**

**2.4** Patient has a diagnosis of osteopenia as defined by a BMD (bone mineral density) T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from one of the following with evidence of progressive bone loss on serial DEXA (dual-energy X-ray absorptiometry) scan [Provider must submit patient specific BMD T-scores]:

- Lumbar spine (at least two vertebral bodies)
- Hip (femoral neck, total hip)

- Radius (one-third radius site)

**OR**

**2.5** Patient has a diagnosis of osteoporosis as defined by a BMD T-score less than or equal to -2.5 based on BMD measurements from one of the following [Provider must submit patient specific BMD T-score]:

- Lumbar spine (at least two vertebral bodies)
- Hip (femoral neck, total hip)
- Radius (one-third radius site)

**OR**

**2.6** Patient has a prior low-trauma or non-traumatic fracture

**OR**

**2.7** Patient is less than 20 years of age

Venclexta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149599
<b>Guideline Name</b>	Venclexta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/5/2024
-----------------	----------

### 1 . Criteria

Product Name:Venclexta	
Diagnosis	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</p>	

Product Name:Venclexta	
Diagnosis	Mantle Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of mantle cell lymphoma (MCL)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Not used as first line therapy</p>	

Product Name:Venclexta	
Diagnosis	Acute Myeloid Leukemia (AML)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of newly-diagnosed acute myeloid leukemia (AML)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Used as treatment induction in candidates for intensive induction therapy</p>	

**OR**

**1.2.2** Used as treatment induction in candidates for lower-intensity induction therapy

**OR**

**1.2.3** Used as follow-up after induction therapy following response to previous lower intensity therapy with the same regimen

**OR**

**1.2.4** Used as consolidation therapy as continuation of lower-intensity regimen used for induction

**AND**

**1.3** Used in combination with decitabine, azacitidine, or low-dose cytarabine

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of relapsed/refractory acute myeloid leukemia (AML)

**AND**

**2.2** Used as a component of repeating the initial successful induction regimen

**AND**

**2.3** Greater than or equal to 12 months since induction regimen if not administered continuously

**AND**

**2.4** Therapy was not stopped due to development of clinical resistance

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) - acute myeloid leukemia (AML)

**AND**

**3.2** Considered systemic disease and therapy is given as palliative intent

**AND**

**3.3** Patient has low performance and/or nutritional status (i.e., serum albumin less than 3.2 g/dL [grams/deciliter]; not a candidate for intensive remission therapy or Elzonris)

**AND**

**3.4** Venclexta therapy to be given in combination with azacitidine, decitabine, or low-dose cytarabine

Product Name:Venclexta	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of relapsed or progressive multiple myeloma which has been previously treated

**AND**

2 - Patient has t(11;14) translocation

**AND**

3 - Venclexta therapy to be given in combination with dexamethasone

Product Name:Venclexta	
Diagnosis	Acute Lymphoblastic Leukemia (ALL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Venclexta therapy to be given in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Decitabine</li> <li>• Hyper-CVAD</li> <li>• Nelarabine</li> <li>• Mini hyper-CVD</li> </ul>	

Product Name:Venclexta	
Diagnosis	Chronic Myelomonocytic Leukemia (CMML)

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic myelomonocytic leukemia (CMML)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Classified as CMML-2 (less than 20% bone marrow blasts or blast equivalents)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Venclexta therapy to be given in combination with azacitidine or decitabine</p>	

Product Name:Venclexta	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of hairy cell leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is progressive after relapsed/refractory therapy</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Disease is resistant to BRAF inhibitor therapy (i.e., Zelboraf, Tafinlar)

Product Name:Venclexta

Diagnosis	Accelerated/Blast Phase Myeloproliferative Neoplasm
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of accelerated/blast phase myeloproliferative neoplasm

**AND**

2 - Used for management of disease progression of myeloproliferative neoplasm

**AND**

3 - Venclexta therapy to be given in combination with azacitidine or decitabine

Product Name:Venclexta

Diagnosis	Systemic Light Chain Amyloidosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of relapsed/refractory systemic light chain amyloidosis

**AND**

**2** - Patient has t(11;14) translocation

Product Name:Venclexta	
Diagnosis	Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma which has been previously treated</p>	

Product Name:Venclexta	
Diagnosis	All Indications except NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Venclexta therapy</p>	

Product Name:Venclexta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Venclexta	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Venclexta therapy</p>	

**2 . Revision History**

Date	Notes
7/5/2024	Updated criteria for ALL and AML based on NCCN recommendations . Updated verbiage for MM and NCCN Recommended Regimens. Ad ded criteria for CMML, hairy cell leukemia, and accelerated/blast pha se myeloproliferative neoplasms based on NCCN recommendations.

Veozah



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163787
<b>Guideline Name</b>	Veozah
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Veozah	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe vasomotor symptoms due to menopause</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - One of the following:

**2.1** Failure (after a 30-day trial) to ONE of the following as confirmed by claims history or submission of medical records:

- Hormonal therapy (e.g., estradiol, Premarin, Prempro)
- Non-hormonal therapy [e.g., clonidine, gabapentin, selective serotonin inhibitors (e.g., paroxetine), serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine)]

**OR**

**2.2** History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):

- Hormonal therapy (e.g., estradiol, Premarin, Prempro)
- Non-hormonal therapy [e.g., clonidine, gabapentin, selective serotonin inhibitors (e.g., paroxetine), serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine)]

**AND**

**3** - Patient has received baseline hepatic laboratory tests to rule out the presence of underlying liver disease

Product Name: Veozah	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy (e.g., decrease in frequency and severity of vasomotor symptoms from baseline)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Patient has received periodic evaluation of hepatic laboratory tests to rule out liver injury associated with Veozah use

## 2 . Revision History

Date	Notes
1/14/2025	Added criteria for hepatic laboratory tests

Verkazia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146434
<b>Guideline Name</b>	Verkazia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Verkazia, Cyclosporine in Klarity	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe vernal keratoconjunctivitis</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure to TWO of the following categories as confirmed by claims history or submission of medical records:

- Ophthalmic antihistamines (e.g., azelastine, olopatadine)
- Ophthalmic mast cell stabilizers (e.g., cromolyn sodium)
- Ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following categories (please specify intolerance or contraindication):

- Ophthalmic antihistamines (e.g., azelastine, olopatadine)
- Ophthalmic mast cell stabilizers (e.g., cromolyn sodium)
- Ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone)

Product Name: Verkazia, Cyclosporine in Klarity	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response</p>	

Verquvo



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146436
<b>Guideline Name</b>	Verquvo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Verquvo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of heart failure</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Ejection fraction is less than 45 percent

**AND**

**3** - Heart failure is classified as ONE of the following:

- New York Heart Association Class II
- New York Heart Association Class III
- New York Heart Association Class IV

**AND**

**4** - ONE of the following:

**4.1** Hospitalization for heart failure within the past six months

**OR**

**4.2** Outpatient IV (intravenous) diuretics for heart failure within the past three months

**AND**

**5** - ONE of the following:

**5.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated beta-blocker (e.g., bisoprolol, carvedilol, metoprolol) confirmed by claims history or submission of medical records

**OR**

**5.2** Patient has a contraindication or intolerance to beta-blocker therapy (please specify intolerance or contraindication)

**AND**

**6** - ONE of the following:

**6.1** Patient is on a stabilized dose and receiving concomitant therapy with one of the following confirmed by claims history or submission of medical records:

- Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Angiotensin II receptor blocker (ARB) (e.g., losartan)
- Angiotensin receptor-neprilysin inhibitor (ARNI) (e.g., Entresto)

**OR**

**6.2** Patient has an allergy, contraindication, or intolerance to ACE inhibitors, ARBs, and ARNIs (please specify intolerance or contraindication)

**AND**

**7** - ONE of the following:

**7.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated aldosterone antagonist (e.g., spironolactone) confirmed by claims history or submission of medical records

**OR**

**7.2** Patient has a contraindication or intolerance to aldosterone antagonist therapy (please specify intolerance or contraindication)

**AND**

**8** - ONE of the following:

**8.1** Patient is on a stabilized dose and receiving concomitant therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated for heart failure (e.g., Farxiga) confirmed by claims history or submission of medical records

**OR**

**8.2** Patient has a contraindication or intolerance to SGLT2 inhibitor therapy (please specify intolerance or contraindication)

**AND**

**9** - Verquvo is prescribed by or in consultation with a cardiologist

Product Name:Verquvo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to therapy	

Verzenio



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-151148
<b>Guideline Name</b>	Verzenio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	8/8/2024
-----------------	----------

### 1 . Criteria

Product Name:Verzenio	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - Disease is hormone-receptor (HR)-positive

**AND**

**3** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Disease is advanced, recurrent, or metastatic

**AND**

**4.1.2** ONE of the following:

**4.1.2.1** Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) or Faslodex (fulvestrant)

**OR**

**4.1.2.2** ALL of the following:

- Used as monotherapy
- Patient has disease progression following endocrine therapy
- Patient has already received at least one prior chemotherapy regimen

**OR**

**4.2** BOTH of the following:

**4.2.1** Disease is early breast cancer at high risk of recurrence (i.e., greater than or equal to 4

positive lymph nodes, or 1-3 positive lymph nodes with one or both of the following: Grade 3 disease, tumor size greater than or equal to 5 centimeters)

**AND**

**4.2.2** Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) or tamoxifen

Product Name:Verzenio	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Verzenio therapy</p>	

Product Name:Verzenio	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent or metastatic endometrial cancer</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tumor is estrogen receptor (ER)-positive</p>	

**AND**

**3** - Used in combination with letrozole

Product Name:Verzenio	
Diagnosis	Endometrial Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Verzenio therapy</p>	

Product Name:Verzenio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Verzenio will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Verzenio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Verzenio therapy

**2 . Revision History**

Date	Notes
8/7/2024	Annual review. Updated background and added clinical criteria for endometrial carcinoma per NCCN. Updated references.

Verzenio



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146691
<b>Guideline Name</b>	Verzenio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Verzenio	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of breast cancer</p>	

**AND**

**2** - Disease is hormone-receptor (HR)-positive

**AND**

**3** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Disease is advanced, recurrent, or metastatic

**AND**

**4.1.2** ONE of the following:

**4.1.2.1** Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) or Faslodex (fulvestrant)

**OR**

**4.1.2.2** ALL of the following:

- Used as monotherapy
- Patient has disease progression following endocrine therapy
- Patient has already received at least one prior chemotherapy regimen

**OR**

**4.2** BOTH of the following:

**4.2.1** Disease is early breast cancer at high risk of recurrence (i.e., greater than or equal to 4

positive lymph nodes, or 1-3 positive lymph nodes with one or both of the following: Grade 3 disease, tumor size greater than or equal to 5 centimeters)

**AND**

**4.2.2** Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) or tamoxifen

Product Name:Verzenio	
Diagnosis	Breast Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Verzenio therapy	

Product Name:Verzenio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Verzenio will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

Product Name:Verzenio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Verzenio therapy	

Vijoice



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152575
<b>Guideline Name</b>	Vijoice
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Vijoice tablets, Vijoice granules	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - ONE of the following:

**2.1** Confirmed presence of a mutation in the PIK3CA gene

**OR**

**2.2** ONE of the following:

**2.2.1** TWO or more of the following spectrum features:

- Overgrowth: adipose, muscle, nerve, skeletal
- Vascular malformations: capillary, venous, arteriovenous, lymphatic
- Epidermal nevus

**OR**

**2.2.2** ONE or more of the following isolated features:

- Large isolated lymphatic malformation
- Isolated macrodactyly or overgrown splayed feet/ hands with overgrown limbs
- Truncal adipose overgrowth
- Hemimegalencephaly (bilateral) / dysplastic megalencephaly / focal cortical dysplasia
- Epidermal nevus
- Seborrhic keratoses
- Benign lichenoid keratoses

**AND**

**3** - Patient is 2 years of age or older

**AND**

**4** - Patient has severe manifestations of PROS requiring systemic therapy

**AND**

**5** - Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has specialized expertise in the management of PROS manifestations

Product Name:Vijoice tablets, Vijoice granules	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vijoice therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has specialized expertise in the management of PIK3CA-Related Overgrowth Spectrum (PROS) manifestations</p>	

## 2 . Revision History

Date	Notes
8/23/2024	Added new GPI for Vijoice granules formulation. Updated product name list and GPI table accordingly. Updated initial authorization criteria. a. Updated initial authorization duration to 12 months.

Vitrakvi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208221
<b>Guideline Name</b>	Vitrakvi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vitrakvi	
Diagnosis	Solid Tumors
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Presence of a solid tumor

**AND**

2 - Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion (e.g., ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)

**AND**

3 - Disease is without a known acquired resistance mutation (e.g., TRKA G595R, G623R, G696A, F617L)

**AND**

4 - Disease is ONE of the following:

- Metastatic
- Unresectable

Product Name:Vitrakvi	
Diagnosis	Solid tumors
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Vitrakvi therapy</p>	

Product Name:Vitrakvi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Vitrakvi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vitrakvi therapy</p>	

## 2 . Revision History

Date	Notes
3/6/2025	Updated formularies

Vivjoa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146437
<b>Guideline Name</b>	Vivjoa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Vivjoa	
Approval Length	4 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of recurrent vulvovaginal candidiasis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not of reproductive potential (i.e., persons who are biological females who are</p>	

postmenopausal or have another reason for permanent infertility [(e.g., tubal ligation, hysterectomy, salpingo-oophorectomy)]

**AND**

**3** - BOTH of the following:

**3.1** Other causes (including but not limited to bacterial vaginosis or trichomoniasis) have been ruled out

**AND**

**3.2** Failure of a maintenance course of oral fluconazole defined as 100-mg, 150-mg, or 200-mg taken weekly for 6 months confirmed by claims history or submission of medical records.

**AND**

**4** - Prescribed by, or in consultation with, one of the following:

- Infectious disease physician
- Obstetrician/Gynecologist

Vizimpro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146694
<b>Guideline Name</b>	Vizimpro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Vizimpro	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - Disease is recurrent, advanced, or metastatic

**AND**

**3** - Disease is positive for ONE of the following EGFR (epidermal growth factor receptor) mutations:

- Exon 19 deletion
- Exon 21 L858R substitution
- S768I
- L861Q
- G719X

Product Name:Vizimpro	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Patient does not show evidence of progressive disease while on Vizimpro therapy	

Product Name:Vizimpro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Vizimpro	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vizimpro therapy</p>	

Vonjo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-154898
<b>Guideline Name</b>	Vonjo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Vonjo	
Diagnosis	Myelofibrosis (MF)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>Primary myelofibrosis</li> <li>Post-polycythemia vera myelofibrosis</li> </ul>	

- Post-essential thrombocythemia myelofibrosis
- Accelerated/blast phase myeloproliferative neoplasm

**AND**

**2** - One of the following:

**2.1** BOTH of the following:

**2.1.1** Patient has symptomatic lower-risk myelofibrosis

**AND**

**2.1.2** Patient has a platelet count less than  $50 \times 10^9/L$

**OR**

**2.2** All of the following:

**2.2.1** Patient has higher-risk myelofibrosis

**AND**

**2.2.2** Patient is not a transplant candidate or transplant not currently feasible

**AND**

**2.2.3** One of the following:

**2.2.3.1** Patient has a platelet count less than  $50 \times 10^9/L$

**OR**

**2.2.3.2** Both of the following:

**2.2.3.2.1** Patient has symptomatic splenomegaly and/or constitutional symptoms

**AND**

**2.2.3.2.2** Patient has a platelet count greater than or equal to  $50 \times 10^9/L$

**OR**

**2.3** Used for treatment of myelofibrosis-associated anemia

**OR**

**2.4** Used for splenomegaly and other disease-related symptoms in one of the following:

**2.4.1** Continued near the start of conditioning therapy of transplant candidates

**OR**

**2.4.2** Palliation in combination with hypomethylating agents (azacitidine or decitabine) as bridging therapy prior to transplant, or if not a candidate for transplant

Product Name: Vonjo	
Diagnosis	Myelofibrosis (MF)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation that patient has evidence of symptom improvement or reduction in spleen volume while on Vonjo	

Product Name: Vonjo	
Diagnosis	NCCN Recommended Regimens

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Vonjo will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Vonjo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vonjo therapy</p>	

Voranigo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164769
<b>Guideline Name</b>	Voranigo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Voranigo	
Diagnosis	Astrocytoma/Oligodendroglioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - One of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Astrocytoma</li> <li>• Oligodendroglioma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Presence of IDH1 or IDH2 mutation</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - History of one of the following:</p> <ul style="list-style-type: none"> <li>• Biopsy</li> <li>• Sub-total resection</li> <li>• Gross total resection</li> </ul>	

Product Name: Voranigo	
Diagnosis	Astrocytoma/Oligodendroglioma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Voranigo therapy</p>	

Product Name: Voranigo	
Diagnosis	NCCN Recommended Regimens

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Voranigo	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Voranigo therapy</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Updated formularies. Removed Grade 2 disease requirement

Votrient



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163957
<b>Guideline Name</b>	Votrient
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Renal Cell Carcinoma (RCC)/Kidney Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following</p> <p>1.1 Diagnosis of renal cell carcinoma (RCC)</p>	

**AND**

**1.2 ONE of the following:**

- Disease has relapsed
- Stage IV disease
- Disease is advanced

**OR**

**2 - Diagnosis of von Hippel-Lindau (VHL)-associated renal cell carcinoma**

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Soft Tissue Sarcoma (STS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Angiosarcoma</li> <li>• Alveolar soft part sarcoma</li> <li>• Pleomorphic rhabdomyosarcoma</li> <li>• Retroperitoneal/intra-abdominal disease that is unresectable, stage IV, or postoperative treatment for residual disease</li> <li>• Soft tissue sarcoma of the extremity/superficial trunk or head/neck with disease that is stage IV or recurrent and has disseminated metastases</li> <li>• Solitary fibrous tumor/hemangiopericytoma</li> <li>• Desmoid tumors (aggressive fibromatosis)</li> <li>• Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Transformation</li> <li>• Dedifferentiated Chordoma</li> <li>• Epithelioid hemangioendothelioma</li> <li>• Extraskeletal myxoid chondrosarcoma</li> </ul>	

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - All of the following:</p> <p>1.1 Diagnosis of one of the following:</p> <ul style="list-style-type: none"> <li>• Follicular carcinoma</li> <li>• Oncocytic carcinoma</li> <li>• Papillary carcinoma</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.2 One of the following:</p> <ul style="list-style-type: none"> <li>• Unresectable locoregional recurrent disease</li> <li>• Persistent disease</li> <li>• Metastatic disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.3 One of the following:</p> <ul style="list-style-type: none"> <li>• Patient has symptomatic disease</li> <li>• Patient has progressive disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.4 One of the following:</p> <ul style="list-style-type: none"> <li>• Disease is refractory to radioactive iodine treatment</li> <li>• Distant metastatic disease not amenable to radioactive iodine treatment</li> </ul>	

**OR**

**2** - All of the following:

**2.1** Diagnosis of medullary carcinoma

**AND**

**2.2** One of the following:

- Disease is progressive
- Disease is symptomatic with distant metastases

**AND**

**2.3** One of the following:

**2.3.1** Failure to ONE of the following, as confirmed by claims history or submission of medical records:

- Caprelsa (vandetanib)
- Cometriq (cabozantinib)

**OR**

**2.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Caprelsa (vandetanib)
- Cometriq (cabozantinib)

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of uterine sarcoma

**AND**

2 - One of the following:

- Disease is advanced
- Disease is recurrent/metastatic
- Disease is inoperable

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Ovarian Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer

**AND**

2 - ONE of the following:

- Disease is persistent
- Disease is recurrent

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Chondrosarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chondrosarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is metastatic and widespread</p>	

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Gastrointestinal Stromal Tumors (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Gastrointestinal Stromal Tumors (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is unresectable, progressive, or metastatic</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - One of the following:</p>	

**3.1** Used as first-line therapy in SDH-deficient GIST

**OR**

**3.2** Used after progression on ALL of the following:

- Imatinib (generic Gleevac)
- Sunitinib (generic Sutent)
- Stivarga (regorafenib)
- Standard dose Qinlock (ripretinib)

Product Name: Brand Votrient, generic pazopanib	
Diagnosis	Merkel Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Merkel Cell Carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is M1 disseminated</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - One of the following:</p> <p>3.1 Anti-PD-L1 or anti-PD-1 therapy is contraindicated</p> <p style="text-align: center;"><b>OR</b></p>	

**3.2** Disease has progressed on anti-PD-L1 or anti-PD-1 therapy

Product Name:Brand Votrient, generic pazopanib	
Diagnosis	Renal Cell Carcinoma (RCC)/Kidney Cancer, Soft Tissue Sarcoma (STS), Thyroid Carcinoma, Uterine Sarcoma, Ovarian Cancer, Chondrosarcoma, Gastrointestinal Stromal Tumors (GIST), Merkel Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Votrient therapy</p>	

Product Name:Brand Votrient, generic pazopanib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Votrient will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Brand Votrient, generic pazopanib	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Votrient therapy

**2 . Revision History**

Date	Notes
1/16/2025	copy core

Vowst



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164987
<b>Guideline Name</b>	Vowst
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vowst	
Approval Length	1 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of recurrent *Clostridioides difficile* infection (rCDI) as defined by BOTH of the following:

**1.1** Presence of diarrhea defined as a passage of 3 or more loose bowel movements within a 24-hour period for 2 consecutive days

**AND**

**1.2** A positive stool test for *Clostridioides difficile* toxin

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - Patient has had one or more recurrences of CDI following an initial episode of CDI

**AND**

**4** - Patient has completed at least 10 days of ONE of the following antibiotic therapies for rCDI 2 to 4 days prior to initiating Vowst as confirmed by claims history or submission of medical records:

- Oral vancomycin
- Dificid (fidaxomicin)

**AND**

**5** - Previous episode of CDI is under control [e.g., less than 3 unformed/loose (i.e., Bristol Stool Scale type 6-7) stools/day for 2 consecutive days]

**AND**

**6** - Patient will drink magnesium citrate on the day before and at least 8 hours prior to taking the first dose of Vowst

**AND**

**7** - Prescribed by or in consultation with one of the following:

- Gastroenterologist
- Infectious disease specialist

## 2 . Revision History

Date	Notes
2/11/2025	Updated formularies. No changes to clinical criteria.

Voxzogo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-210193
<b>Guideline Name</b>	Voxzogo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Voxzogo	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient is less than 18 years of age

**AND**

2 - Diagnosis of achondroplasia as confirmed by ONE of the following:

2.1 Submission of medical records documenting BOTH of the following:

2.1.1 Patient has clinical manifestations characteristic of achondroplasia (e.g., macrocephaly, frontal bossing, midface retrusion, disproportionate short stature with rhizomelic shortening of the arms and the legs, brachydactyly, trident configuration of the hands, thoracolumbar kyphosis, and accentuated lumbar lordosis)

**AND**

2.1.2 Patient has radiographic findings characteristic of achondroplasia (e.g., large calvaria and narrowing of the foramen magnum region, undertubulated, shortened long bones with metaphyseal abnormalities, narrowing of the interpedicular distance of the caudal spine, square ilia and horizontal acetabula, small sacrosciatic notches, proximal scooping of the femoral metaphyses, and short and narrow chest)

**OR**

2.2 Submission of medical records documenting molecular genetic testing confirmed c.1138G > A or c.1138G > C variant (i.e., p.Gly380Arg mutation) in the fibroblast growth factor receptor-3 (FGFR3) gene

**AND**

3 - Patient has open epiphyses

**AND**

4 - BOTH of the following:

**4.1** Patient has not had limb-lengthening surgery in the previous 18 months

**AND**

**4.2** Patient does not plan to have limb-lengthening surgery while on Voxzogo

**AND**

**5** - Prescribed by ONE of the following:

- Clinical geneticist
- Endocrinologist
- A practitioner who has specialized expertise in the management of achondroplasia

Product Name:Voxzogo	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Voxzogo therapy [e.g., improvement in annualized growth velocity (AGV) compared to baseline]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has open epiphyses</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient does not plan to have limb-lengthening surgery while on Voxzogo</p>	

**AND**

**4** - Prescribed by or in consultation with **ONE** of the following:

- Clinical geneticist
- Endocrinologist
- A practitioner who has specialized expertise in the management of achondroplasia

## **2 . Revision History**

Date	Notes
3/6/2025	Added PA-CAID for 4/1 go-live. No change to criteria.

Voydeya



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150928
<b>Guideline Name</b>	Voydeya
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/5/2024
-----------------	----------

## 1 . Criteria

Product Name:Voydeya	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as confirmed by both of the following:</p> <p>1.1 Flow cytometry analysis confirming presence of PNH clones</p>	

**AND**

**1.2** Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia, unexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease, pulmonary hypertension, etc.)

**AND**

**2** - All of the following:

**2.1** Patient is currently receiving complement protein C5 inhibitor Soliris (eculizumab) or Ultomiris (ravulizumab)

**AND**

**2.2** Patient is experiencing extravascular hemolysis (EVH) while on complement protein C5 inhibitor Soliris (eculizumab) or Ultomiris (ravulizumab)

**AND**

**2.3** Patient will continue to receive complement protein C5 inhibitor Soliris (eculizumab) or Ultomiris (ravulizumab)

**AND**

**3** - Patient is not receiving Voydeya in combination with a complement protein C3 inhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g., Fabhalta (iptacopan)] used for the treatment of PNH

**AND**

**4** - Prescribed by, or in consultation with one of the following:

- Hematologist
- Oncologist

Product Name:Voydeya	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Voydeya therapy [e.g., decrease in extravascular hemolysis (EVH), increased or stabilization of hemoglobin levels, reduction in transfusions, improvement in hemolysis, etc.)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient continues to receive Voydeya in combination with complement protein C5 inhibitor Soliris (eculizumab) or Ultomiris (ravulizumab) for PNH</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is not receiving Voydeya in combination with a complement protein C3 inhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g., Fabhalta (iptacopan)] used for the treatment of PNH</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by, or in consultation with one of the following:</p> <ul style="list-style-type: none"> <li>• Hematologist</li> <li>• Oncologist</li> </ul>	

Vtama



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-207211
<b>Guideline Name</b>	Vtama
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vtama	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of plaque psoriasis

**AND**

**2** - ONE of the following:

**2.1** Failure to a minimum duration of a 4-week trial to TWO of the following topical therapies as confirmed by claims history or submission of medical records:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

**2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**OR**

**2.3** Patient is currently on Vtama therapy as confirmed by claims history or submission of medical records

**AND**

**3** - Patient is NOT receiving Vtama in combination with a targeted immunomodulator [e.g.,

Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

Product Name:Vtama	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Vtama in combination with a targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

## 2 . Revision History

Date	Notes
2/28/2025	Added ST bypass for current users in initial auth section. Removed r eference to Stelara in examples of targeted immunomodulators due t o ustekinumab biosimilar availability. Minor cosmetic updates.

Vyalev



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-164784
<b>Guideline Name</b>	Vyalev
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2025
-----------------	----------

**1 . Criteria**

Product Name:Vyalev	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has inadequately controlled motor fluctuations despite being treated with optimized oral therapies (e.g. levodopa)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a neurologist</p>	

Product Name:Vyalev	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vyalev therapy demonstrated by an increase in “on” time without troublesome dyskinesia</p>	

## 2 . Revision History

Date	Notes
2/5/2025	New guideline

Vyalev



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164784
<b>Guideline Name</b>	Vyalev
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vyalev	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of advanced Parkinson's disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has inadequately controlled motor fluctuations despite being treated with optimized oral therapies (e.g. levodopa)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a neurologist</p>	

Product Name:Vyalev	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Vyalev therapy demonstrated by an increase in “on” time without troublesome dyskinesia</p>	

## 2 . Revision History

Date	Notes
2/5/2025	New guideline

Vyndaqel and Vyndamax



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208204
<b>Guideline Name</b>	Vyndaqel and Vyndamax
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Michigan</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Vyndaqel, Vyndamax	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)

**AND**

**2** - ONE of the following:

**2.1** Documentation that the patient has a pathogenic transthyretin (TTR) mutation (e.g., V30M)

**OR**

**2.2** Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of ATTR amyloid deposits

**OR**

**2.3** ALL of the following

**2.3.1** Echocardiogram or cardiac magnetic resonance imaging suggestive of amyloidosis

**AND**

**2.3.2** Radionuclide imaging (99mTc-DPD, 99mTc-PYP, or 99m Tc-HMDP) showing grade 2 or 3 cardiac uptake\*

**AND**

**2.3.3** Absence of light chain amyloidosis

**AND**

**3** - Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure

**AND**

**4** - Physician attests that the patient has an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level that, when combined with signs and symptoms, is considered definitive for a diagnosis of ATTR-CM

**AND**

**5** - ONE of the following:

- History of heart failure, with at least one prior hospitalization for heart failure
- Presence of clinical signs and symptoms of heart failure (e.g., dyspnea, edema)

**AND**

**6** - Prescribed by, or in consultation, with a cardiologist

**AND**

**7** - Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis), Onpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]

Notes	*May require prior authorization and notification
-------	---

Product Name:Vyndaqel, Vyndamax	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation that the patient has experienced a positive clinical response to Vyndaqel or Vyndamax (e.g., improved symptoms, quality of life, slowing of disease progression, decreased hospitalizations, etc.)</p>	

**AND**

**2** - Documentation that patient continues to have New York Heart Association (NYHA) Functional Class I, II, or III heart failure

**AND**

**3** - Prescribed by or in consultation with a cardiologist

**AND**

**4** - Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis), Onpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]

## 2 . Revision History

Date	Notes
3/5/2025	Updated formularies. Updated initial auth criteria. Removed criteria allowing for temporary combination therapy. Added examples of RNA-targeted therapy

Wainua



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146700
<b>Guideline Name</b>	Wainua
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Wainua	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Diagnosis of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy</p>	

**AND**

**1.2** Documentation that the patient has a pathogenic transthyretin (TTR) mutation (e.g., V30M)

**AND**

**2** - Prescribed by or in consultation with a neurologist

**AND**

**3** - Documentation of ONE of the following:

- Patient has a baseline polyneuropathy disability (PND) score less than or equal to IIIb
- Patient has a baseline familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
- Patient has a baseline neuropathy impairment (NIS) score greater than or equal to 10 and less than or equal to 130

**AND**

**4** - Patient has NOT had a liver transplant

**AND**

**5** - Presence of clinical signs and symptoms of the disease (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.)

**AND**

**6** - Patient is NOT receiving Wainua in combination with ONE of the following:

- Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran), Tegsedi (inotersen)]
- Tafamidis (e.g., Vyndaqel, Vyndamax)

Product Name:Wainua	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation that the patient has experienced a positive clinical response to Wainua therapy (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Wainua in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran), Tegsedi (inotersen)]</li> <li>• Tafamidis (e.g., Vyndaqel, Vyndamax)</li> </ul>	

Wakix



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146701
<b>Guideline Name</b>	Wakix
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Wakix	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of narcolepsy with BOTH of the following:</p>	

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a MSLT (Multiple Sleep Latency Test) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation that other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - One of the following:

**3.1** Failure to ALL of the following, as confirmed by claims history or submission of medical records:

- An amphetamine-based stimulant (e.g., amphetamine, dextroamphetamine) OR a methylphenidate-based stimulant
- Armodafinil (generic Nuvigil) OR modafinil (generic Provigil)
- Sunosi (solriamfetol)

**OR**

**3.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- An amphetamine-based stimulant (e.g., amphetamine, dextroamphetamine) OR a methylphenidate-based stimulant
- Armodafinil (generic Nuvigil) OR modafinil (generic Provigil)
- Sunosi (solriamfetol)

**OR**

**3.3** Patient has a history of or potential for a substance abuse disorder

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist
- Pulmonologist
- Sleep Medicine Specialist

Product Name:Wakix	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Reduction in symptoms of excessive daytime sleepiness associated with Wakix therapy	

Product Name:Wakix	
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1** - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of narcolepsy with cataplexy (i.e., Narcolepsy Type 1) with BOTH of the following:

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a MSLT (Multiple Sleep Latency Test) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Patient has experienced cataplexy defined as more than one episode of sudden loss of muscle tone with retained consciousness

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist
- Pulmonologist
- Sleep Medicine Specialist

Product Name:Wakix

Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Reduction in frequency of cataplexy attacks associated with therapy

**OR**

2 - Reduction in symptoms of excessive daytime sleepiness associated with therapy

Wegovy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152718
<b>Guideline Name</b>	Wegovy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Wegovy	
Diagnosis	Reduction of risk of major adverse cardiovascular events
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Treatment is being requested to reduce the risk of major adverse cardiovascular events</p>	

**AND**

**2** - Patient is 45 years of age or older

**AND**

**3** - Submission of medical records documenting all the following:

**3.1** BMI (body mass index) greater than or equal to 27 kg/m<sup>2</sup> (kilograms per square meter)

**AND**

**3.2** Established cardiovascular disease as evidenced by one of the following:

**3.2.1** Prior myocardial infarction (MI)

**OR**

**3.2.2** Prior ischemic or hemorrhagic stroke

**OR**

**3.2.3** Symptomatic peripheral arterial disease (PAD) evidenced by one of the following:

- Intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest)
- Peripheral arterial revascularization procedure
- Amputation due to atherosclerotic disease

**AND**

**4** - Used in combination with a reduced calorie diet and increased physical activity

**AND**

**5** - One of the following:

**5.1** For patients with history of MI, one of the following:

**5.1.1** Patient is on therapy from each of the following classes (as confirmed by claims history or submission of medical records):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Beta blocker (i.e., carvedilol, metoprolol, or bisoprolol)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**OR**

**5.1.2** Patient has a history of intolerance or contraindication to all of the following therapeutic classes (please specify intolerance or contraindication):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Beta blocker (i.e., carvedilol, metoprolol, or bisoprolol)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**OR**

**5.2** For patients with history of ischemic or hemorrhagic stroke, or symptomatic PAD, one of the following:

**5.2.1** Patient is on therapy from each of the following classes (as confirmed by claims history or submission of medical records):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**OR**

**5.2.2** Patient has a history of intolerance or contraindication to all of the following therapeutic classes (please specify intolerance or contraindication):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**AND**

**6** - Patient does NOT have diagnosis of diabetes or HgA1c greater than or equal to 6.5%

**AND**

**7** - Patient does NOT have New York Heart Association class IV heart failure

Product Name:Wegovy	
Diagnosis	Reduction of risk of major adverse cardiovascular events
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - BMI (body mass index) greater than or equal to 27 kg/m<sup>2</sup> (kilograms per square meter)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Used in combination with a reduced calorie diet and increased physical activity</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient does NOT have diagnosis of diabetes or HgA1c greater than or equal to 6.5%</p>	

**AND**

**4** - Patient does NOT have New York Heart Association class IV heart failure

Product Name:Wegovy	
Diagnosis	Weight Loss
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Wegovy when used solely for the treatment of weight loss is excluded and is to be denied as a benefit exclusion</p>	

## 2 . Revision History

Date	Notes
8/27/2024	New guideline

Welireg



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155269
<b>Guideline Name</b>	Welireg
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Welireg	
Diagnosis	Von Hippel-Lindau (VHL) Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of von Hippel-Lindau (VHL) disease</p>	

**AND**

**2** - Patient requires therapy for ONE of the following:

- Renal cell carcinoma (RCC)
- Central nervous system (CNS) hemangioblastoma
- Pancreatic neuroendocrine tumor (pNET)

**AND**

**3** - Patient does not require immediate surgery

Product Name: Welireg	
Diagnosis	Advanced Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of advanced renal cell carcinoma (RCC)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Disease has progressed after treatment with BOTH of the following:</p> <p><b>2.1</b> Programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) checkpoint inhibitor [e.g., Keytruda (pembrolizumab), Opdivo (nivolumab)]</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2</b> Vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) [e.g., Cabometyx (cabozantinib), Inlyta (axitinib), Lenvima (lenvatinib)]</p>	

Product Name: Welireg	
Diagnosis	Von Hippel-Lindau (VHL) Disease, Advanced Renal Cell Carcinoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of disease progression while on Welireg</p>	

Product Name: Welireg	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name: Welireg	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Welireg therapy</p>	

## 2 . Revision History

Date	Notes
9/19/2024	Updated examples of PD-L1 checkpoint inhibitors and VEGF-TKIs within advanced RCC criteria.

Winrevair



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152475
<b>Guideline Name</b>	Winrevair
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Winrevair	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 All of the following:</p> <p>1.1.1 Diagnosis of pulmonary arterial hypertension (PAH)</p>	

**AND**

**1.1.2** PAH has been confirmed by right heart catheterization

**AND**

**1.1.3** Prescriber attestation that other types of pulmonary hypertension (PH) are excluded as a diagnosis

**AND**

**1.1.4** Pulmonary arterial hypertension is symptomatic

**OR**

**1.2** Both of the following:

**1.2.1** Diagnosis of pulmonary arterial hypertension

**AND**

**1.2.2** Patient is currently on Winrevair therapy as documented by claims history or submission of medical records

**AND**

**2** - One of the following:

**2.1** Both of the following:

**2.1.1** Patient has a cardiopulmonary comorbidity (e.g., obesity, hypertension, diabetes mellitus, coronary heart disease)

**AND**

**2.1.2** Patient is currently taking at least ONE of the following oral therapies:

- Endothelin receptor antagonist (ERA) [e.g., ambrisentan, bosentan, Opsumit (macitentan)]
- Phosphodiesterase-5 inhibitor (PDE5i) (e.g., sildenafil, tadalafil)

**OR**

**2.2** Both of the following:

**2.2.1** Patient does not have a cardiopulmonary comorbidity (e.g., obesity, hypertension, diabetes mellitus, coronary heart disease)

**AND**

**2.2.2** Patient is currently taking oral combination therapy with BOTH of the following:

**2.2.2.1** Endothelin receptor antagonist (ERA) [e.g., ambrisentan, bosentan, Opsumit (macitentan)]

**AND**

**2.2.2.2** One of the following:

- Phosphodiesterase-5 inhibitor (PDE5i) (e.g., sildenafil, tadalafil)
- Soluble guanylate cyclase stimulator (sGC) [e.g., Adempas (riociguat)]

**AND**

**3** - Prescribed by, or in consultation with, a cardiologist, pulmonologist, or rheumatologist

Product Name: Winrevair	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of a positive clinical response to Winrevair therapy [e.g., improvement in symptoms of right heart failure, exercise tolerance, six-minute walk distance (6MWD), resting and ambulatory oximetry]

**AND**

2 - Prescribed by, or in consultation with, a cardiologist, pulmonologist, or rheumatologist

**2 . Revision History**

Date	Notes
8/21/2024	Copy core

Xalkori



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146703
<b>Guideline Name</b>	Xalkori
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Xalkori	
Diagnosis	Inflammatory Myofibroblastic Tumor (IMT)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of inflammatory myofibroblastic tumor (IMT) with anaplastic lymphoma kinase (ALK) translocation</p>	

Product Name:Xalkori	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ONE of the following:</p> <ul style="list-style-type: none"> <li>• Metastatic</li> <li>• Recurrent</li> <li>• Advanced</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Tumor is anaplastic lymphoma kinase (ALK)-positive</li> <li>• Tumor is ROS1-positive</li> <li>• Tumor is positive for mesenchymal-epithelial transition (MET) amplification</li> <li>• Tumor is positive for MET exon 14 skipping mutation</li> </ul>	

Product Name:Xalkori	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of metastatic brain cancer from non-small cell lung cancer (NSCLC)

**AND**

2 - ONE of the following:

- Tumor is anaplastic lymphoma kinase (ALK)-positive
- Tumor is ROS1-positive

Product Name:Xalkori	
Diagnosis	Anaplastic Large Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of anaplastic large cell lymphoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tumor is anaplastic lymphoma kinase (ALK)-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Disease is relapsed or refractory</p>	

Product Name:Xalkori	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Langerhans Cell Histiocytosis</li> <li>• Erdheim-Chester Disease</li> <li>• Rosai-Dorfman Disease</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is positive for anaplastic lymphoma kinase (ALK) rearrangement</p>	

Product Name: Xalkori	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic or unresectable cutaneous melanoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is ROS1 gene fusion-positive</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Used as second-line or subsequent therapy for disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy</p>	

Product Name:Xalkori	
Diagnosis	Inflammatory Myofibroblastic Tumor (IMT), Non-Small Cell Lung Cancer (NSCLC), Central Nervous System (CNS) Cancers, Anaplastic Large Cell Lymphoma, Histiocytic Neoplasms, Melanoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Xalkori therapy</p>	

Product Name:Xalkori	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Xalkori	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

1 - Documentation of positive clinical response to Xalkori therapy

Xarelto



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208213
<b>Guideline Name</b>	Xarelto
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Continuation of Therapy Upon Hospital Discharge
Approval Length	35 Day(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Xarelto will be approved as continuation of therapy upon hospital discharge

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban

Diagnosis	Stroke and Systemic Embolism Prevention in Adult Patients with Non-Valvular Atrial Fibrillation (AF)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of atrial fibrillation (AF)

**AND**

2 - Patient does not have an artificial heart valve

**AND**

3 - ONE of the following:

- Failure to Eliquis as confirmed by claims history or submission of medical records
- History of contraindication or intolerance to Eliquis (please specify contraindication or intolerance)
- Continuation of prior Xarelto therapy

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban

Diagnosis	Prophylaxis of Venous Thromboembolism (VTE) after Orthopedic Surgery (Hip Replacement or Knee Replacement) in Adult Patients
Approval Length	35 Day(s)
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ONE of the following:

1.1 Patient has or is scheduled to have total knee replacement surgery

**OR**

1.2 Patient has or is scheduled to have total hip replacement surgery

**AND**

2 - Patient does not have an artificial heart valve

**AND**

3 - ONE of the following:

3.1 Xarelto is being prescribed as continuation of therapy following hospitalization after orthopedic surgery

**OR**

3.2 Provider provides reason or special circumstance why the patient is unable to use Eliquis

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) in Adult Patients
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - Diagnosis of ONE of the following:**

- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)

**AND**

**2 - Patient does not have an artificial heart valve**

**AND**

**3 - ONE of the following:**

- Failure to Eliquis as confirmed by claims history or submission of medical records
- History on intolerance or contraindication to Eliquis (please specify intolerance or contraindication)
- Continuation of prior Xarelto therapy

**Product Name:**Xarelto tablets, Xarelto oral suspension, generic rivaroxaban

Diagnosis	Reduction in the Risk of Recurrence of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Adult Patients
Approval Length	12 month(s)
Guideline Type	Prior Authorization

**Approval Criteria**

**1 - Previous diagnosis of ONE of the following:**

- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)

**AND**

**2 - Patient does not have an artificial heart valve**

**AND**

**3** - Patient must have been treated with an anticoagulant [e.g., warfarin, Eliquis (apixaban)] for at least 6 months prior to request as confirmed by claims history or submission of medical records

**AND**

**4** - ONE of the following:

**4.1** Failure to Eliquis as confirmed by claims history or submission of medical records

**OR**

**4.2** History of intolerance or contraindication to Eliquis (please specify intolerance or contraindication)

**OR**

**4.3** Continuation of prior Xarelto therapy

Product Name:Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Reduction in the Risk of Major Cardiovascular Events [Cardiovascular (CV) Death, Myocardial Infarction (MI) and Stroke] in Adult Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>Chronic coronary artery disease (CAD)</li> </ul>	

<ul style="list-style-type: none"> <li>Peripheral artery disease (PAD)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient does not have an artificial heart valve</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is on concurrent aspirin therapy</p>
--

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Prophylaxis of Venous Thromboembolism (VTE) in Acutely Ill Medical Adult Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding
Approval Length	2 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient was admitted to the hospital for an acute medical illness</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient does not have an artificial heart valve</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is at risk of thromboembolic complications due to moderate or severe restricted mobility</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is not at high risk of bleeding</p>	

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Thromboprophylaxis in Pediatric Patients with Congenital Heart Disease After the Fontan Procedure
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of congenital heart disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient does not have an artificial heart valve</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is at risk of thromboembolic complications due to Fontan procedure</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is 2 years to 17 years of age</p>	

Product Name: Xarelto tablets, Xarelto oral suspension, generic rivaroxaban	
Diagnosis	Treatment of VTE and Reduction in the Risk of Recurrent VTE in Pediatric Patients
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - The requested medication is being used for the treatment of venous thromboembolism (VTE) or the reduction in the risk of recurrent VTE

**AND**

**2** - Patient does not have an artificial heart valve

**AND**

**3** - Patient has received at least 5 days of initial parenteral anticoagulant treatment

**AND**

**4** - Patient is 0 years to 17 years of age

## 2 . Revision History

Date	Notes
3/5/2025	Updated formularies. Added generic rixaroxaban. Removed step through Savaysa throughout

Xdemvy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146441
<b>Guideline Name</b>	Xdemvy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xdemvy	
Approval Length	6 Week(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Demodex blepharitis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient demonstrates ONE of the following signs of Demodex infestation:</p>	

- Cylindrical cuff at the root of the eyelashes
- Lid margin erythema
- Eyelash anomalies (e.g., eyelash misdirection, eyelash loss)

**AND**

**3** - Patient demonstrates TWO of the following symptoms of Demodex infestation:

- Itching/Burning
- Foreign body sensation
- Crusting/matted lashes
- Blurry vision
- Discomfort/irritation
- Tearing/lacrimation
- Dryness
- Purulence/discharge

**AND**

**4** - Patient is practicing good eye-lid hygiene (e.g., non-prescription tree-tea oil)

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Ophthalmologist
- Optometrist

Xeljanz, Xeljanz XR, Xeljanz Oral Solution



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208200
<b>Guideline Name</b>	Xeljanz, Xeljanz XR, Xeljanz Oral Solution
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Xeljanz tabs, Xeljanz XR	
Diagnosis	Rheumatoid Arthritis (RA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

1.2 One of the following:

1.2.1 Failure to a 3 month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses as confirmed by claims history or submission of medical records

**OR**

1.2.2 History of intolerance or contraindication to one non-biologic DMARD [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of rheumatoid arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Orencia (abatacept), Olumiant (baricitinib), Rinvoq (upadacitinib)]

**AND**

1.3 BOTH of the following:

1.3.1 ONE of the following:

1.3.1.1 Failure to ALL of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

- Tyenne (tocilizumab-aazg)

**OR**

**1.3.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- Tyenne (tocilizumab-aazg)

**OR**

**1.3.1.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.3.2** One of the following:

**1.3.2.1** Failure to Olumiant (baricitinib) as confirmed by claims history or submission of medical records

**OR**

**1.3.2.2** History of intolerance or contraindication to Olumiant (baricitinib) (please specify intolerance or contraindication)

**AND**

**1.4** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Diagnosis of moderately to severely active RA

**AND**

**2.2** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**2.3** Patient is currently on Xeljanz/Xeljanz XR therapy as confirmed by claims history or submission of medical records

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See Table 1 in Background for PDL Links
-------	--

Product Name: Xeljanz tabs, Xeljanz XR	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of active psoriatic arthritis

**AND**

1.2 ONE of the following:

1.2.1 Failure to a 3 month trial of methotrexate at the maximally indicated dose as confirmed by claims history or submission of medical records

**OR**

1.2.2 History of intolerance or contraindication to methotrexate (please specify intolerance or contraindication)

**OR**

1.2.3 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of psoriatic arthritis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

1.3 ONE of the following:

1.3.1 BOTH of the following:

1.3.1.1 One of the following:

1.3.1.1.1 Failure to TWO of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**OR**

**1.3.1.1.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)
- One of the preferred ustekinumab products\*

**AND**

**1.3.1.2** One of the following:

**1.3.1.2.1** Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records

**OR**

**1.3.1.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**OR**

**1.3.2** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.4** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab),

Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant (baricitinib), Otezla (apremilast)]

- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Xeljanz/Xeljanz XR therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant (baricitinib), Otezla (apremilast)]
- Potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	*See Table 1 in Background for PDL Links
-------	--

Product Name: Xeljanz tabs, Xeljanz XR	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of moderately to severely active ulcerative colitis (UC)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine) as confirmed by claims history or submitted medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., Simponi (golimumab), ustekinumab, Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 ONE of the following:</p> <p>1.3.1 Failure to ONE of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>• One of the preferred adalimumab products*</li> </ul>	

- One of the preferred ustekinumab products\*

**OR**

**1.3.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- One of the preferred ustekinumab products\*

**OR**

**1.3.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.4** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib), ustekinumab, Skyrizi (risankizumab)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**1.5** Prescribed by or in consultation with a gastroenterologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Xeljanz/Xeljanz XR therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active UC

**AND**

**2.3** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib), ustekinumab, Skyrizi (risankizumab)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**2.4** Prescribed by or in consultation with a gastroenterologist

Notes	*See Table 1 in Background for PDL Links
-------	--

Product Name: Xeljanz tabs, Xeljanz XR	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ALL of the following:</p> <p><b>1.1</b> Diagnosis of active ankylosing spondylitis</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> One of the following:</p> <p><b>1.2.1</b> Failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, as confirmed by claims history or submission of medical records</p>	

**OR**

**1.2.2** History of intolerance or contraindication to two NSAIDs (e.g., ibuprofen, naproxen) (please specify intolerance or contraindication)

**OR**

**1.2.3** Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ankylosing spondylitis as confirmed by claims history or submission of medical records [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab, Simponi (golimumab), Rinvoq (upadacitinib)]

**AND**

**1.3** ONE of the following:

**1.3.1** BOTH of the following:

**1.3.1.1** One of the following:

**1.3.1.1.1** Failure to BOTH of the following as confirmed by claims history or submission of medical records:

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

**OR**

**1.3.1.1.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- One of the preferred adalimumab products\*
- Enbrel (etanercept)

**AND**

**1.3.1.2** ONE of the following:

**1.3.1.2.1** Failure to Cosentyx (secukinumab) as confirmed by claims history or submission of medical records

**OR**

**1.3.1.2.2** History of intolerance or contraindication to Cosentyx (secukinumab) (please specify intolerance or contraindication)

**OR**

**1.3.2** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.4** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Xeljanz/Xeljanz XR therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active ankylosing spondylitis

**AND**

**2.3** Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq (upadacitinib), Olumiant (baricitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*See Table 1 in Background for PDL Links
-------	--

Product Name: Xeljanz tabs, Xeljanz XR	
Diagnosis	Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ulcerative Colitis (UC), Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Xeljanz/Xeljanz XR therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is NOT receiving Xeljanz/Xeljanz XR in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant (baricitinib), Otezla (apremilast)]*</li> </ul>	

<ul style="list-style-type: none"> <li>Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)*</li> </ul>	
Notes	* Examples of drug(s) may not be applicable based on the requested indication.

Product Name: Xeljanz tabs/oral soln	
Diagnosis	Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of active polyarticular course juvenile idiopathic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Failure to ALL of the following as confirmed by claims history or submission of medical records:</p> <ul style="list-style-type: none"> <li>One of the preferred adalimumab products*</li> <li>Enbrel (etanercept)</li> <li>Tyenne (tocilizumab-aazg)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of intolerance or contraindication to ALL of the following (please specific intolerance or contraindication):</p> <ul style="list-style-type: none"> <li>One of the preferred adalimumab products*</li> <li>Enbrel (etanercept)</li> <li>Tyenne (tocilizumab-aazg)</li> </ul>	

**OR**

**1.2.3** Patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29 for specific phobia diagnostic criteria)

**AND**

**1.3** Patient is NOT receiving Xeljanz/Xeljanz oral solution in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib), Rinvoq (upadacitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**1.4** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Xeljanz/Xeljanz Oral Solution as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of active polyarticular course juvenile idiopathic arthritis

**AND**

**2.3** Patient is NOT receiving Xeljanz/Xeljanz Oral Solution in combination with either of the following:

- Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib), Rinvoq (upadacitinib)]
- Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)

**AND**

**2.4 Prescribed by or in consultation with a rheumatologist**

Notes	*See Table 1 in Background for PDL Links
-------	--

Product Name: Xeljanz tabs/oral soln	
Diagnosis	Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xeljanz or Xeljanz oral solution therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Xeljanz or Xeljanz oral solution in combination with either of the following:</p> <ul style="list-style-type: none"> <li>• Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib), Rinvoq (upadacitinib)]</li> <li>• Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate mofetil)</li> </ul>	

**2 . Background**

**Benefit/Coverage/Program Information**

**Table 1. PDL Links**

CO: <https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html>

HI: <https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html>

MD: <https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html>

NM: <https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html>

NJ: <https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html>

NY: <https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html>

PA CHIP: <https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP>

RI: <https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html>

**3 . Revision History**

Date	Notes
3/5/2025	Updated formularies. Added ustekinumab as a step therapy option in PsA and UC. Replaced Stelara with ustekinumab throughout. Added NM to PDL links in background.

Xenazine



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146705
<b>Guideline Name</b>	Xenazine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Xenazine, generic tetrabenazine	
Diagnosis	Chorea associated with Huntington’s Disease
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chorea in patients with Huntington’s disease</p>	

Product Name:Brand Xenazine, generic tetrabenazine
--

Diagnosis	Tardive Dyskinesia (Off-Label)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of tardive dyskinesia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>2.1 Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication</p> <p style="text-align: center;"><b>OR</b></p> <p>2.2 Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Psychiatrist</li> </ul>	

Product Name: Brand Xenazine, generic tetrabenazine	
Diagnosis	Tourette's Syndrome (Off-Label)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient has tics associated with Tourette's syndrome

**AND**

2 - ONE of the following:

2.1 Failure of haloperidol confirmed by claims history or submitted medical records

**OR**

2.2 History of intolerance or contraindication to haloperidol (please specify intolerance or contraindication)

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Psychiatrist

Product Name: Brand Xenazine, generic tetrabenazine	
Diagnosis	Tardive Dyskinesia (Off-Label), Tourette's Syndrome (Off-Label)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>	

Xenleta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146442
<b>Guideline Name</b>	Xenleta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xenleta	
Diagnosis	Community-acquired bacterial pneumonia
Approval Length	7 Day(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 For continuation of therapy upon hospital discharge</p>	

**OR**

**1.2** As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**1.3** All of the following:

**1.3.1** Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

**1.3.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Xenleta

**AND**

**1.3.3** One of the following:

**1.3.3.1** Failure to three of the following antibiotics or antibiotic regimens confirmed by claims history or submitted medical records:

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

**OR**

**1.3.3.2** History of contraindication or intolerance to all of the following antibiotics or antibiotic regimens (please specify intolerance or contraindication):

- Amoxicillin
- A macrolide
- Doxycycline

- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

Product Name: Xenleta	
Diagnosis	Off-Label Uses
Approval Length	Based on provider and IDSA recommended treatment durations, not to exceed 6 months
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 The drug has been recognized for treatment of the indication by the Infectious Diseases Society of America (IDSA)</p>	

Xermelo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151737
<b>Guideline Name</b>	Xermelo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xermelo	
Diagnosis	Carcinoid Syndrome Diarrhea
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of carcinoid syndrome diarrhea</p>	

**AND**

**2** - Diarrhea is inadequately controlled with somatostatin analog therapy (e.g., octreotide, Sandostatin LAR, Somatuline Depot, Lanreotide), as confirmed by claims history or submission of medical records

**AND**

**3** - Used in combination with somatostatin analog therapy (e.g., octreotide, Sandostatin LAR, Somatuline Depot, Lanreotide)

Product Name:Xermelo	
Diagnosis	Carcinoid Syndrome Diarrhea
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Xermelo</p>	

## 2 . Revision History

Date	Notes
8/14/2024	Updated initial authorization duration to 12 months.

Xifaxan



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148288
<b>Guideline Name</b>	Xifaxan
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xifaxan 200mg	
Diagnosis	Travelers' Diarrhea
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of travelers' diarrhea</p> <p style="text-align: center;"><b>AND</b></p>	

**2 - ONE of the following:**

**2.1** Failure of ONE of the following confirmed by claims history or submitted medical records:

- Azithromycin (generic Zithromax)
- Ciprofloxacin (generic Cipro)
- Levofloxacin (generic Levaquin)
- Ofloxacin (generic Floxin)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following (please specify intolerance or contraindication):

- Azithromycin (generic Zithromax)
- Ciprofloxacin (generic Cipro)
- Levofloxacin (generic Levaquin)
- Ofloxacin (generic Floxin)

Product Name: Xifaxan 550mg	
Diagnosis	Hepatic Encephalopathy (HE)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Used for prophylaxis of hepatic encephalopathy (HE) recurrence</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - ONE of the following:</b></p> <p><b>2.1 BOTH of the following:</b></p> <ul style="list-style-type: none"> <li>• Used as add-on therapy to lactulose, confirmed by claims history or submitted medical records</li> </ul>	

- Patient is unable to achieve an optimal clinical response with lactulose monotherapy, confirmed by claims history or submitted medical records

**OR**

**2.2** History of contraindication or intolerance to lactulose (please specify intolerance or contraindication)

Product Name: Xifaxan 550mg	
Diagnosis	Hepatic Encephalopathy (HE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xifaxan therapy</p>	

Product Name: Xifaxan 550mg	
Diagnosis	Irritable Bowel Syndrome with Diarrhea (IBS-D)
Approval Length	1 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of irritable bowel syndrome with diarrhea (IBS-D)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p>	

**2.1** Failure of ONE tricyclic antidepressant (e.g. amitriptyline) confirmed by claims history or submitted medical records

**OR**

**2.2** History of intolerance or contraindication to tricyclic antidepressants (e.g. amitriptyline) (please specify intolerance or contraindication)

Product Name: Xifaxan 550mg

Diagnosis	Irritable Bowel Syndrome with Diarrhea (IBS-D)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Patient continues to need Xifaxan and has experienced positive results with prior use

Product Name: Xifaxan 200mg

Diagnosis	Inflammatory Bowel Disease (e.g. Crohn's Disease, Ulcerative Colitis, Diverticulitis) (Off-label)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of inflammatory bowel disease

**AND**

**2 - ONE of the following:**

**2.1** Failure of BOTH of the following confirmed by claims history or submitted medical records:

- Ciprofloxacin (generic Cipro)
- Metronidazole (generic Flagyl)

**OR**

**2.2** History of intolerance or contraindication to BOTH of the following (please specify intolerance or contraindication):

- Ciprofloxacin (generic Cipro)
- Metronidazole (generic Flagyl)

Product Name: Xifaxan 200mg	
Diagnosis	Inflammatory Bowel Disease (e.g. Crohn's Disease, Ulcerative Colitis, Diverticulitis) (Off-label)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Xifaxan therapy	

## 2 . Revision History

Date	Notes
6/7/2024	Updated language from "Diagnosis of hepatic encephalopathy" to "Used for prophylaxis of hepatic encephalopathy (HE) recurrence" to align with PI; Minor cosmetic updates.

Xolair



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150979
<b>Guideline Name</b>	Xolair
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	8/6/2024
-----------------	----------

## 1 . Criteria

Product Name:Xolair	
Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Xolair for moderate to severe persistent asthma under an active UnitedHealthcare medical benefit prior authorization</p>	

**AND**

**2** - Documentation of positive clinical response to Xolair therapy as demonstrated by at least ONE of the following

**2.1** Reduction in the frequency of exacerbations

**OR**

**2.2** Decreased utilization of rescue medications

**OR**

**2.3** Increase in percent predicted forced expiratory volume (FEV1) from pretreatment baseline

**OR**

**2.4** Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

**AND**

**3** - Xolair is being used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**4** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenna (benralizumab)]

- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Product Name: Xolair	
Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of moderate or severe asthma

**AND**

2 - Classification of asthma as uncontrolled or inadequately controlled as defined by at least ONE of the following:

2.1 Poor symptom control [e.g., Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20]

**OR**

2.2 Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months

**OR**

2.3 Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)

**OR**

2.4 Airflow limitation [e.g., after appropriate bronchodilator withhold forced expiratory volume

in 1 second (FEV1) less than 80% predicted (in the face of reduced FEV1-forced vital capacity [FVC] defined as less than the lower limit of normal)]

**OR**

**2.5** Patient is currently dependent on oral corticosteroids for the treatment of asthma

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting a baseline (pre-omalizumab treatment) serum total IgE (immunoglobulin E) level greater than or equal to 30 IU/mL (international units/milliliter) and less than or equal to 1300 IU/mL

**AND**

**4** - Positive skin test or in vitro reactivity to a perennial aeroallergen

**AND**

**5** - Used in combination with ONE of the following:

**5.1** ONE maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)-long-acting beta2-agonist (LABA) product [e.g., fluticasone propionate-salmeterol (AirDuo, Advair), budesonide-formoterol (Symbicort)]

**OR**

**5.2** Combination therapy including BOTH of the following:

**5.2.1** One maximally-dosed (appropriately adjusted for age) ICS (inhaled corticosteroid) product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]

**AND**

**5.2.2** One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist - montelukast (Singulair); theophylline]

**AND**

**6** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**7** - Prescribed by ONE of the following:

- Allergist
- Immunologist
- Pulmonologist

Product Name:Xolair	
Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response as demonstrated by at least ONE of the following:</p> <ul style="list-style-type: none"> <li>• Reduction in frequency of exacerbations</li> <li>• Decreased utilization of rescue medications</li> <li>• Increase in percent predicted FEV1 (forced expiratory volume in 1 second) from pretreatment baseline</li> <li>• Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing)</li> </ul>	

**AND**

**2** - Used in combination with an ICS (inhaled corticosteroid)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)]

**AND**

**3** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Product Name:Xolair	
Diagnosis	Chronic Urticaria
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has been established on therapy with Xolair for chronic urticaria under an active UnitedHealthcare medical benefit prior authorization</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Documentation of positive clinical response to Xolair therapy (e.g., reduction in exacerbations, itch severity, hives)</p> <p style="text-align: center;"><b>AND</b></p>	

**3** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Product Name:Xolair	
Diagnosis	Chronic Urticaria
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic urticaria</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p><b>2.1</b> Patient remains symptomatic despite at least a 2-week trial and failure of two H1-antihistamines [e.g., Allegra (fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine)]* (confirmed by claims history or submitted medical records)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Patient remains symptomatic despite at least a 2-week trial and failure of BOTH of the following taken in combination (confirmed by claims history or submitted medical records):</p> <p><b>2.2.1</b> Second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]</p> <p style="text-align: center;"><b>AND</b></p>	

**2.2.2** ONE of the following:

- Different second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]
- First generation H1-antihistamine [e.g., Benadryl (diphenhydramine), Chlor-Trimeton (chlorpheniramine), Vistaril (hydroxyzine)]\*
- H2-antihistamine [e.g., Pepcid (famotidine), Tagamet HB (cimetidine), Zantac (ranitidine)]
- Leukotriene modifier [e.g., Singulair (montelukast)]

**OR**

**2.3** History of contraindication or intolerance to ONE of the following (please specify contraindication or intolerance):

**2.3.1** Two H1-antihistamines [e.g., Allegra (fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine)]\*

**OR**

**2.3.2** BOTH of the following taken in combination:

**2.3.2.1** Second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]

**AND**

**2.3.2.2** ONE of the following:

- Different second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]
- First generation H1-antihistamine [e.g., Benadryl (diphenhydramine), Chlor-Trimeton (chlorpheniramine), Vistaril (hydroxyzine)]\*
- H2-antihistamine [e.g., Pepcid (famotidine), Tagamet HB (cimetidine), Zantac (ranitidine)]
- Leukotriene modifier [e.g., Singulair (montelukast)]

**AND**

**3** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**4** - Prescribed by one of the following:

- Allergist
- Dermatologist
- Immunologist

Notes

\*Patients 65 years of age and older in whom first generation H1-antihistamines are considered high risk medications to be avoided (e.g., Beers criteria, HEDIS) should be directed to try alternatives that are not considered high risk.

Product Name: Xolair

Diagnosis Chronic Urticaria

Approval Length 12 month(s)

Therapy Stage Reauthorization

Guideline Type Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response (e.g., reduction in exacerbations, itch severity, hives)

**AND**

**2** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]

- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

Product Name:Xolair	
Diagnosis	Nasal Polyps
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Xolair for nasal polyps under an active UnitedHealthcare medical benefit prior authorization</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Xolair therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient will continue to receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Patient is not receiving Xolair in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)]</li> <li>• Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]</li> <li>• Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]</li> </ul>	

Product Name:Xolair

Diagnosis	Nasal Polyps
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nasal polyps</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - TWO or more of the following symptoms for longer than 12 weeks duration:</p> <ul style="list-style-type: none"> <li>• Nasal mucopurulent discharge</li> <li>• Nasal obstruction, blockage, or congestion</li> <li>• Facial pain, pressure, and/or fullness</li> <li>• Reduction or loss of sense of smell</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following findings using nasal endoscopy and/or sinus computed tomography (CT):</p> <ul style="list-style-type: none"> <li>• Purulent mucus or edema in the middle meatus or ethmoid regions</li> <li>• Polyps in the nasal cavity or the middle meatus</li> <li>• Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of paranasal sinuses</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - ONE of the following:</p> <p>4.1 Patient has required prior sinus surgery</p> <p style="text-align: center;"><b>OR</b></p>	

**4.2** Patient has required systemic corticosteroids (e.g., prednisone, methylprednisolone) for nasal polyps in the previous 2 years

**OR**

**4.3** Patient has been unable to obtain symptom relief after trial of BOTH of the following confirmed by claims history or submitted medical records:

- Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)
- One other therapy used in management of nasal polyps [i.e., nasal saline irrigations, antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)]

**AND**

**5** - Patient will receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)

**AND**

**6** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab)]
- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**7** - Prescribed by one of the following:

- Allergist
- Immunologist
- Otolaryngologist
- Pulmonologist

Product Name: Xolair

Diagnosis

Nasal Polyps

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xolair therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient will continue to receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not receiving Xolair in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab), Nucala (mepolizumab)]</li> <li>• Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]</li> <li>• Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]</li> </ul>	

Product Name: Xolair	
Diagnosis	IgE-Mediated Food Allergy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Transitioning from UHC medical benefits
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient has been established on therapy with Xolair for IgE-Mediated food allergy under an active UnitedHealthcare medical benefit prior authorization</p>	

**AND**

**2** - Documentation of positive clinical response to Xolair therapy (e.g., reduction in type I allergic reactions)

**AND**

**3** - Xolair will be used in conjunction with food allergen avoidance

**AND**

**4** - Patient access to epinephrine

**AND**

**5** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**6** - Prescribed by an allergist or immunologist

Product Name:Xolair	
Diagnosis	IgE-Mediated Food Allergy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization - Not transitioning from UHC medical benefits
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of IgE-mediated food allergy to one or more foods

**AND**

2 - Patient is at least 1 year of age

**AND**

3 - IgE-mediated food allergy to specific food(s) has been confirmed by both of the following:

3.1 History of type I allergic reactions (e.g., nausea, vomiting, cramping, diarrhea, flushing, pruritus, urticaria, swelling of the lips, face or throat, wheezing, lightheadedness, syncope)

**AND**

3.2 One of the following:

- Food specific skin prick testing (SPT)
- IgE antibody in vitro testing
- Oral food challenge (OFC)

**AND**

4 - Xolair will be used in conjunction with food allergen avoidance

**AND**

5 - Patient has access to epinephrine

**AND**

**6** - Patient is not receiving Xolair in combination with any of the following:

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**7** - Prescribed by allergist or immunologist

Product Name:Xolair	
Diagnosis	IgE-Mediated Food Allergy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Xolair therapy (e.g., reduction in type I allergic reactions)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Xolair will be used in conjunction with food allergen avoidance</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient has access to epinephrine</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient is not receiving Xolair in combination with any of the following:</p>	

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]
- Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**AND**

**5** - Prescribed by an allergist or immunologist

## 2 . Revision History

Date	Notes
8/5/2024	Expanded coverage of Xolair for IgE-mediated food allergy to all food s. Updated references.

Xolremdi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-156895
<b>Guideline Name</b>	Xolremdi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name:Xolremdi	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome</p>	

**AND**

**2** - Patient has a genotype-confirmed mutation of chemokine (C-X-C motif) receptor 4 (CXCR4) consistent with WHIM phenotype

**AND**

**3** - Patient has an absolute neutrophil count (ANC) less than or equal to 500 cells per microliter

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Geneticist
- Hematologist
- Immunologist

Product Name: Xolremdi	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response [e.g., improvement in absolute neutrophil counts (ANC), improvement in absolute lymphocyte counts (ALC), reduction in infections] to Xolremdi therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with ONE of the following:</p>	

- Allergist
- Geneticist
- Hematologist
- Immunologist

## 2 . Revision History

Date	Notes
10/2/2024	New program

Xopenex Respules



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146444
<b>Guideline Name</b>	Xopenex Respules
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Xopenex inhalation soln, generic levalbuterol inhalation soln	
Approval Length	12 month(s)
Guideline Type	Step Therapy
<p><b>Approval Criteria</b></p> <p>1 - Failure to treatment with albuterol inhalation solution, as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p>	

**2** - History of contraindication or intolerance to albuterol inhalation solution (please specify contraindication or intolerance)

Xospata



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146708
<b>Guideline Name</b>	Xospata
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xospata	
Diagnosis	Acute Myeloid Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of acute myeloid leukemia (AML)</p>	

**AND**

**2** - AML is FMS-like tyrosine kinase 3 (FLT3) mutation-positive

**AND**

**3** - ONE of the following:

- Used in combination with azacitidine as low-intensity treatment induction when not a candidate for intensive induction therapy
- Follow-up after induction therapy with response to previous lower intensity therapy with the same regimen
- Post-allogeneic hematopoietic cell transplantation and in remission
- Disease is relapsed or refractory

Product Name:Xospata	
Diagnosis	Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> Patient has an FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic phase</p> <p style="text-align: center;"><b>OR</b></p>	

**2.2 Patient has an FMS-like tyrosine kinase 3 (FLT3) rearrangement in blast phase**

<b>Product Name:Xospata</b>	
Diagnosis	Acute Myeloid Leukemia, Myeloid/Lymphoid Neoplasms
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Xospata therapy</p>	

<b>Product Name:Xospata</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Xospata will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

<b>Product Name:Xospata</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**Approval Criteria**

1 - Documentation of positive clinical response to Xospata therapy

Xphozah



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-199196
<b>Guideline Name</b>	Xphozah
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Xphozah	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of chronic kidney disease (CKD)

**AND**

2 - Patient is receiving dialysis

**AND**

3 - Serum phosphorus is greater than 6.5 mg/dL (milligrams per deciliter)

**AND**

4 - Patient has had an inadequate response to at least a 4-week maximally tolerated dose of BOTH of the following phosphate binders as confirmed by claims history or submission of medical records:

4.1 calcium acetate (generic PhosLo)

**AND**

4.2 sevelamer carbonate (generic Renvela)

**AND**

5 - Xphozah will be used as add-on therapy

**AND**

6 - Prescribed by or in consultation with a nephrologist

Product Name: Xphozah	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xphozah therapy [e.g., reduction of serum phosphorus towards the normal range (3.5 to 5.5 milligrams per deciliter)]</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a nephrologist</p>	

## 2 . Revision History

Date	Notes
2/26/2025	Combined formularies. No changes to clinical criteria. Minor cosmetic update.

Xpovio



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-211192
<b>Guideline Name</b>	Xpovio
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Xpovio	
Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of relapsed or refractory multiple myeloma (RRMM)

**AND**

1.2 Patient has received at least four prior therapies

**AND**

1.3 Disease is refractory to ALL of the following:

- Two proteasome inhibitors
- Two immunomodulatory agents
- An anti-CD38 monoclonal antibody

**AND**

1.4 Used in combination with dexamethasone

**OR**

2 - ALL of the following:

2.1 Diagnosis of multiple myeloma

**AND**

2.2 Patient has received at least one prior therapy

**AND**

**2.3** Used in combination with ONE of the following:

- Velcade (bortezomib) and dexamethasone
- Darzalex (daratumumab) and dexamethasone
- Kyprolis (carfilzomib) and dexamethasone

**OR**

**3** - ALL of the following:

**3.1** Diagnosis of multiple myeloma

**AND**

**3.2** Patient has received at least 2 prior therapies, including an immunomodulatory agent (e.g., lenalidomide, thalidomide) and a proteasome inhibitor (e.g., bortezomib, carfilzomib)

**AND**

**3.3** Patient has demonstrated progression on or within 60 days of completion of the last therapy

**AND**

**3.4** Used in combination with Pomalyst (pomalidomide) and dexamethasone

Product Name: Xpovio	
Diagnosis	Diffuse Large B-cell Lymphoma (DLBCL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

**1 - ONE of the following:**

**1.1** Diagnosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (including histologic transformation of indolent lymphomas to DLBCL)

**OR**

**1.2** Diagnosis of relapsed or refractory HIV (human immunodeficiency virus)-related diffuse large B-cell lymphoma, primary effusion lymphoma, or HHV8-positive diffuse large B-cell lymphoma

**OR**

**1.3** Diagnosis of relapsed or refractory monomorphic B-Cell type post-transplant lymphoproliferative disorder

**AND**

**2 - Patient has received at least 2 lines of systemic therapies**

<b>Product Name:Xpovio</b>	
Diagnosis	Multiple Myeloma, Diffuse Large B-cell Lymphoma (DLBCL)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Xpovio therapy	

<b>Product Name:Xpovio</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Xpovio	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xpovio therapy</p>	

## 2 . Revision History

Date	Notes
3/6/2025	Updated formularies

Xtandi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152523
<b>Guideline Name</b>	Xtandi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xtandi	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2** - ONE of the following:

**2.1** Both of the following:

**2.1.1** Disease is castration-resistant

**AND**

**2.1.2** One of the following:

- Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]
- Patient has had bilateral orchiectomy

**OR**

**2.2** Both of the following:

**2.2.1** Disease is metastatic castration-sensitive

**AND**

**2.2.2** One of the following:

- Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]
- Patient has had bilateral orchiectomy

**OR**

**2.3** Disease is non-metastatic castration-sensitive with biochemical recurrence at high risk for metastasis

**AND**

**3 - ONE of the following:**

**3.1 BOTH of the following:**

**3.1.1 Disease is castration-resistant**

**AND**

**3.1.2 ONE of the following:**

**3.1.2.1 Failure to BOTH of the following as confirmed by claims history or submission of medical records:**

- Erleada (apalutamide)
- Nubeqa (darolutamide)

**OR**

**3.1.2.2 History of contraindication or intolerance to BOTH of the following (please specify contraindication or intolerance):**

- Erleada (apalutamide)
- Nubeqa (darolutamide)

**OR**

**3.1.2.3 Continuation of ongoing Xtandi therapy**

**OR**

**3.2 BOTH of the following:**

**3.2.1 Disease is BOTH of the following:**

- Metastatic

- Castration-sensitive

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Failure to ALL of the following as confirmed by claims history or submission of medical records:

- abiraterone (generic Zytiga)
- Erleada (apalutamide)
- Nubeqa (darolutamide)

**OR**

**3.2.2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- abiraterone (generic Zytiga)
- Erleada (apalutamide)
- Nubeqa (darolutamide)

**OR**

**3.2.2.3** Continuation of ongoing Xtandi therapy

**OR**

**3.3** BOTH of the following:

**3.3.1** Disease is ALL of the following:

- Non-metastatic
- Castration-sensitive
- Recurrent
- High risk for metastasis

**AND**

**3.3.2 ONE of the following:**

**3.3.2.1** Failure to abiraterone (generic Zytiga) as confirmed by claims history or submission of medical records

**OR**

**3.3.2.2** History of contraindication or intolerance to abiraterone (generic Zytiga) (please specify contraindication or intolerance)

**OR**

**3.3.2.3** Continuation of ongoing Xtandi therapy

Product Name:Xtandi	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Xtandi therapy	

Product Name:Xtandi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Xtandi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xtandi therapy</p>	

## 2 . Revision History

Date	Notes
8/22/2024	Copy core

Xuriden



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146711
<b>Guideline Name</b>	Xuriden
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Xuriden	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of a hereditary orotic aciduria</p>	

Product Name:Xuriden
----------------------

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Xuriden therapy	

Xyrem, Xywav, Lumryz



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158013
<b>Guideline Name</b>	Xyrem, Xywav, Lumryz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name:Xyrem, Sodium Oxybate, Xywav, Lumryz	
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, laboratory values) documenting a diagnosis of narcolepsy with cataplexy (i.e., Narcolepsy Type 1) with BOTH of the following:</p>	

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) on a Multiple Sleep Latency Test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Patient has experienced cataplexy defined as more than one episode of sudden loss of muscle tone with retained consciousness

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications, or other sleep disorders)

**AND**

**3** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist
- Pulmonologist

**AND**

**4** - ONE of the following:

**4.1** Failure to Wakix (pitolisant) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to Wakix (pitolisant) (please specify intolerance or contraindication)

Product Name: Xyrem, Sodium Oxybate, Xywav, Lumryz	
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation demonstrating a reduction in frequency of cataplexy attacks associated with therapy</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2</b> - Documentation demonstrating reduction in symptoms of excessive daytime sleepiness associated with therapy</p>	

Product Name: Xyrem, Sodium Oxybate, Xywav, Lumryz	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p>	

**1** - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of narcolepsy without cataplexy (i.e., Narcolepsy Type 2) with BOTH of the following:

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a Multiple Sleep Latency Test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Cataplexy is absent

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - ONE of the following:

**3.1** Failure of BOTH of the following confirmed by claims history or submission of medical records:

**3.1.1** ONE of the following:

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant

**AND**

**3.1.2** ONE of the following:

- Modafinil (Provigil)
- Armodafinil (Nuvigil)

**OR**

**3.2** History of contraindication or intolerance of ALL of the following (please specify intolerance or contraindication):

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant
- Modafinil (Provigil)
- Armodafinil (Nuvigil)

**AND**

**4** - ONE of the following:

**4.1** Failure to Sunosi (solriamfetol) as confirmed by claims history or submission of medical records

**OR**

**4.2** History of contraindication or intolerance to Sunosi (solriamfetol) (please specify intolerance or contraindication)

**AND**

**5** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist
- Pulmonologist

Product Name: Xyrem, Sodium Oxybate, Xywav, Lumryz	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation demonstrating reduction in symptoms of excessive daytime sleepiness associated with therapy</p>	

Product Name: Xywav	
Diagnosis	Idiopathic Hypersomnia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab values) documenting a diagnosis of idiopathic hypersomnia with both of the following:</p> <p>1.1 The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 A mean sleep latency of &lt; 8 minutes and fewer than two REM (rapid eye movement) periods (SOREMPs) are found on a MSLT (multiple sleep latency test) performed according to standard techniques following a normal overnight polysomnogram, or no SOREMPs if the REM sleep latency on the preceding polysomnogram was &lt; 15 minutes</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Physician attestation that other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - ONE of the following:

**3.1** Failure of BOTH of the following confirmed by claims history or submission of medical records:

**3.1.1** ONE of the following:

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant

**AND**

**3.1.2** ONE of the following:

- Modafinil (Provigil)
- Armodafinil (Nuvigil)

**OR**

**3.2** History of contraindication or intolerance of ALL of the following (please specify intolerance or contraindication):

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant
- Modafinil (Provigil)
- Armodafinil (Nuvigil)

**AND**

**4** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist

- Sleep medicine specialist
- Pulmonologist

Product Name: Xywav	
Diagnosis	Idiopathic Hypersomnia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation demonstrating reduction in symptoms of excessive daytime sleepiness associated with therapy</p>	

## 2 . Revision History

Date	Notes
10/25/2024	Added new Lumryz GPI. Removed * from Narcolepsy Type 1 Reauth . Updated initial auth length for idiopathic Hypersomnia.

Yonsa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146714
<b>Guideline Name</b>	Yonsa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Yonsa	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2** - ONE of the following:

**2.1** Disease is metastatic

**OR**

**2.2** Disease is regional node positive (e.g., N1)

**OR**

**2.3** Patient is in a very-high-risk group receiving external beam radiation therapy (EBRT)

**AND**

**3** - Used in combination with methylprednisolone

**AND**

**4** - ONE of the following:

**4.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Firmagon (degarelix)]

**OR**

**4.2** Patient has had bilateral orchiectomy

**AND**

**5** - ONE of the following:

**5.1** Prescriber provides a reason or special circumstance the patient cannot take abiraterone (generic Zytiga)

**OR**

**5.2** Patient is currently on Yonsa therapy

Product Name:Yonsa	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Patient does not show evidence of progressive disease while on Yonsa therapy	

Product Name:Yonsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

Product Name:Yonsa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Yonsa therapy	

Yorvipath



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-205218
<b>Guideline Name</b>	Yorvipath
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Yorvipath	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of hypoparathyroidism</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Confirmation of initial diagnosis by both of the following:</b></p> <p><b>2.1</b> Pretreatment low albumin-corrected serum calcium (i.e., less than or equal to 8.5 milligrams per deciliter) confirmed on at least two occasions separated by at least 2 weeks</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2</b> Pretreatment undetectable or inappropriately low intact PTH concentration (i.e., less than 20 picograms per milliliter), by second- or third-generation immunoassay, on at least two occasions</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Yorvipath is not being used to treat acute post-surgical hypoparathyroidism</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Patient is currently on adequate supplemental calcium and active vitamin D (e.g., calcitriol) therapy as evidenced by both of the following:</b></p> <p><b>4.1</b> Albumin-corrected serum calcium 7.8–10.6 micrograms per deciliter</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4.2</b> Serum 25(OH) vitamin D 20–80 nanograms per milliliter</p>	

**AND**

**5** - Prescribed by one of the following:

- Endocrinologist
- Nephrologist

Product Name:Yorvipath

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

**1** - Documentation of positive clinical response [e.g., albumin-corrected serum calcium level in normal range (approximately 8.3-10.6 milligrams per deciliter), independence from conventional therapy (e.g., requiring no active vitamin D, less than or equal to 600 milligrams per day of calcium)]

**AND**

**2** - Prescribed by one of the following:

- Endocrinologist
- Nephrologist

**2 . Revision History**

Date	Notes
2/28/2025	Added PA-CAID for 4/1 go-live. No change to criteria.

Zejula



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164847
<b>Guideline Name</b>	Zejula
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Zejula	
Diagnosis	Ovarian Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Epithelial ovarian cancer</li> <li>• Fallopian tube cancer</li> <li>• Primary peritoneal cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is stage II-IV</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <p>3.1 Maintenance therapy for those who are in complete or partial response to a platinum-based chemotherapy</p> <p style="text-align: center;"><b>OR</b></p> <p>3.2 Recurrence therapy for platinum-sensitive disease in combination with bevacizumab</p>	

Product Name:Zejula	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of castration-resistant distant metastatic (M1) prostate cancer</p>	

**AND**

**2** - Patient is positive for pathogenic BRCA1 or BRCA2 mutation

**AND**

**3** - Patient has not had treatment since disease progression to metastatic castration-resistant prostate cancer (mCRPC)

**AND**

**4** - ONE of the following:

- Patient has not received prior docetaxel and prior novel hormone therapy
- Patient had progression on prior docetaxel therapy and has not received prior novel hormone therapy
- Patient had progression on prior novel hormone therapy and has not received prior docetaxel therapy

**AND**

**5** - Used in combination with Yonsa (fine-particle abiraterone) and methylprednisolone

Product Name:Zejula	
Diagnosis	Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of BRCA-2 (breast cancer) altered uterine leiomyosarcoma (LMS)	

<b>AND</b>
<b>2</b> - Disease is advanced, recurrent/metastatic, or inoperable
<b>AND</b>
<b>3</b> - Used as second-line or subsequent therapy

<b>Product Name:Zejula</b>	
Diagnosis	Ovarian Cancer, Prostate Cancer, Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Patient does not show evidence of progressive disease while on Zejula therapy	

<b>Product Name:Zejula</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

<b>Product Name:Zejula</b>
----------------------------

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zejula therapy</p>	

## 2 . Revision History

Date	Notes
2/6/2025	Updated criteria for Ovarian cancer per NCCN guidelines and consolidated sections for maintenance therapy and treatment. Added new criteria for prostate cancer per NCCN guidelines. Updated Uterine Sarcoma section per NCCN guidelines.

Zejula



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164847
<b>Guideline Name</b>	Zejula
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> <li>• Medicaid - Community &amp; State Washington</li> </ul>

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Zejula	
Diagnosis	Ovarian Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Epithelial ovarian cancer</li> <li>• Fallopian tube cancer</li> <li>• Primary peritoneal cancer</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is stage II-IV</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - ONE of the following:</p> <p>3.1 Maintenance therapy for those who are in complete or partial response to a platinum-based chemotherapy</p> <p style="text-align: center;"><b>OR</b></p> <p>3.2 Recurrence therapy for platinum-sensitive disease in combination with bevacizumab</p>	

Product Name:Zejula	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of castration-resistant distant metastatic (M1) prostate cancer</p>	

**AND**

**2** - Patient is positive for pathogenic BRCA1 or BRCA2 mutation

**AND**

**3** - Patient has not had treatment since disease progression to metastatic castration-resistant prostate cancer (mCRPC)

**AND**

**4** - ONE of the following:

- Patient has not received prior docetaxel and prior novel hormone therapy
- Patient had progression on prior docetaxel therapy and has not received prior novel hormone therapy
- Patient had progression on prior novel hormone therapy and has not received prior docetaxel therapy

**AND**

**5** - Used in combination with Yonsa (fine-particle abiraterone) and methylprednisolone

Product Name:Zejula	
Diagnosis	Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of BRCA-2 (breast cancer) altered uterine leiomyosarcoma (LMS)	

<b>AND</b>
<b>2</b> - Disease is advanced, recurrent/metastatic, or inoperable
<b>AND</b>
<b>3</b> - Used as second-line or subsequent therapy

<b>Product Name:Zejula</b>	
Diagnosis	Ovarian Cancer, Prostate Cancer, Uterine Sarcoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Patient does not show evidence of progressive disease while on Zejula therapy	

<b>Product Name:Zejula</b>	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
<b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium	

<b>Product Name:Zejula</b>
----------------------------

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zejula therapy</p>	

## 2 . Revision History

Date	Notes
2/6/2025	Updated criteria for Ovarian cancer per NCCN guidelines and consolidated sections for maintenance therapy and treatment. Added new criteria for prostate cancer per NCCN guidelines. Updated Uterine Sarcoma section per NCCN guidelines.

Zelboraf



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147406
<b>Guideline Name</b>	Zelboraf
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name:Zelboraf	
Diagnosis	Melanoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>Unresectable melanoma</li> </ul>	

- Metastatic melanoma

**AND**

**2** - Patient is positive for BRAF V600 mutation

Product Name:Zelboraf	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - ONE of the following:</p> <p><b>1.1</b> BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Patient has metastatic brain lesions</li> <li>• Zelboraf is active against primary tumor (melanoma)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> BOTH of the following:</p> <p><b>1.2.1</b> Diagnosis of glioma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2</b> ONE of the following:</p> <ul style="list-style-type: none"> <li>• Incomplete resection, biopsy, or surgically inaccessible location</li> <li>• Disease is recurrent or progressive</li> </ul>	

<b>AND</b>
<b>2</b> - Cancer is positive for BRAF V600E mutation
<b>AND</b>
<b>3</b> - Used in combination with Cotellic (cobimetinib)

<b>Product Name:Zelboraf</b>	
Diagnosis	Hairy Cell Leukemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of hairy cell leukemia	

<b>Product Name:Zelboraf</b>	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Diagnosis of non-small cell lung cancer (NSCLC)	
<b>AND</b>	

**2** - Disease is ONE of the following:

- Metastatic
- Advanced
- Recurrent

**AND**

**3** - Cancer is positive for BRAF V600E mutation

Product Name:Zelboraf	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of ONE of the following:</p> <ul style="list-style-type: none"> <li>• Erdheim-Chester Disease</li> <li>• Langerhans Cell Histiocytosis</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Cancer is positive for BRAF V600 mutation</p>	

Product Name:Zelboraf	
Diagnosis	Thyroid Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Follicular carcinoma
- Oncocytic carcinoma
- Papillary carcinoma

**AND**

2 - ONE of the following:

- Unresectable locoregional recurrent disease
- Metastatic disease
- Persistent disease

**AND**

3 - ONE of the following:

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

4 - Disease is refractory to radioactive iodine

**AND**

5 - Cancer is positive for BRAF V600 mutation

Product Name:Zelboraf	
Diagnosis	Melanoma, CNS Cancers, Hairy Cell Leukemia, NSCLC, Histiocytic Neoplasms, Thyroid Cancer
Approval Length	12 month(s)

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Zelboraf therapy</p>	

Product Name:Zelboraf	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Zelboraf	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zelboraf therapy</p>	

## 2 . Revision History

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Date	Notes
5/14/2024	Under thyroid cancer initial criteria section, updated diagnosis option from Hurthle cell carcinoma to oncocytic carcinoma.

Zepbound



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208212
<b>Guideline Name</b>	Zepbound
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Zepbound	
Diagnosis	Obstructive Sleep Apnea
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	

1 - Treatment is being requested for obstructive sleep apnea (OSA)

**AND**

2 - Patient is greater than or equal to 18 years of age

**AND**

3 - Submission of medical records confirming all of the following:

3.1 Moderate-to-severe obstructive sleep apnea evidenced by both of the following:

3.1.1 Sleep study

**AND**

3.1.2 One of the following:

- Apnea Hypopnea Index (AHI) greater than or equal to 15
- Respiratory Disturbance Index (RDI) greater than or equal to 15
- Respiratory Event Index (REI) greater than or equal to 15

**AND**

3.2 BMI (body mass index) greater than or equal to 30 kg/m<sup>2</sup> (kilograms per square meter) in the past 6 months

**AND**

3.3 At least one previous unsuccessful dietary effort to lose weight

**AND**

3.4 One of the following:

3.4.1 Both of the following:

- Patient is currently on positive airway pressure (PAP) therapy for at least 3 consecutive months
- Patient is adherent to PAP therapy, defined as greater than or equal to 4 hours of use per night for greater than or equal to 70 percent of nights

**OR**

**3.4.2** Patient is not a candidate for, or is intolerant to, PAP therapy (e.g., upper airway anatomic abnormalities, etc.)

**AND**

**4** - Used in combination with a reduced calorie diet and increased physical activity

**AND**

**5** - Provider attests to both of the following:

- Patient counseled on appropriate positional therapy
- Patient counseled on avoidance of alcohol and/or sedatives before bedtime

**AND**

**6** - Patient does NOT have a diagnosis of diabetes or HgA1c (hemoglobin A1c) greater than 6.5%

**AND**

**7** - Prescriber attests the patient does NOT have any one of the following:

- Planned surgery for sleep apnea or obesity
- Significant craniofacial abnormalities
- A diagnosis of central or mixed sleep apnea

**AND**

**8** - Prescribed by, or in consultation with, a sleep specialist

Product Name: Zepbound	
Diagnosis	Obstructive Sleep Apnea
Approval Length	For patients who have been on Zepbound therapy for fewer than 52 weeks of consecutive therapy, authorization of 6 months; OR for patients who have been on Zepbound therapy for greater than or equal to 52 weeks of consecutive therapy, authorization of 12 months
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - One of the following:</p> <p><b>1.1</b> If patient has been on Zepbound for less than 52 weeks of consecutive therapy, submission of medical records confirming a decrease from baseline in one of the following:</p> <ul style="list-style-type: none"> <li>• Apnea Hypopnea Index (AHI)</li> <li>• Respiratory Disturbance Index (RDI)</li> <li>• Respiratory Event Index (REI)</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> If patient has been on Zepbound for greater than or equal to 52 weeks of consecutive therapy, submission of medical records confirming a 50% decrease from baseline in one of the following:</p> <ul style="list-style-type: none"> <li>• Apnea Hypopnea Index (AHI)</li> <li>• Respiratory Disturbance Index (RDI)</li> <li>• Respiratory Event Index (REI)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has had a weight loss of greater than or equal to 10% of baseline body weight</p>	

<p><b>AND</b></p> <p><b>3</b> - Used in combination with a reduced calorie diet and increased physical activity</p> <p><b>AND</b></p> <p><b>4</b> - Patient does NOT have a diagnosis of diabetes or HgA1c (hemoglobin A1c) greater than 6.5%</p> <p><b>AND</b></p> <p><b>5</b> - Patient continues to require treatment for obstructive sleep apnea</p>
--

Product Name: Zepbound	
Diagnosis	Weight Loss
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Zepbound when used solely for the treatment of weight loss is excluded and is to be denied as a benefit exclusion</p>	

## 2 . Revision History

Date	Notes
3/5/2025	New guideline

Zeposia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208215
<b>Guideline Name</b>	Zeposia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Zeposia	
Diagnosis	Multiple Sclerosis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of multiple sclerosis (MS)

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 Failure to a trial of a preferred\* dimethyl fumarate product, as confirmed by claims history or submission of medical records

**AND**

2.1.2 Failure to a trial of at least ONE additional preferred\* alternative, as confirmed by claims history or submission of medical records

**OR**

2.2 History of intolerance or contraindication to ALL preferred\* alternatives (please specify intolerance or contraindication)

**OR**

2.3 Patient is currently on Zeposia therapy as confirmed by claims history or submission of medical records

Notes	*PDL links are in Table 1 of Background.
-------	--

Product Name:Zeposia	
Diagnosis	Multiple Sclerosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Zeposia therapy

Product Name:Zeposia	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Diagnosis of moderately to severely active ulcerative colitis (UC)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Patient has had prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants (e.g., azathioprine, 6-mercaptopurine) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 Patient has been previously treated with a targeted immunomodulator FDA-approved for the treatment of ulcerative colitis as confirmed by claims history or submission of medical records [e.g., adalimumab, Simponi (golimumab), ustekinumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)]</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 Patient is not receiving Zeposia in combination with a targeted immunomodulator [e.g.,</p>	

adalimumab, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]

**AND**

**1.4 ONE of the following:**

**1.4.1** Failure to ONE of the preferred adalimumab products\* as confirmed by claims history or submission of medical records

**OR**

**1.4.2** History of intolerance or contraindication to ONE of the preferred adalimumab products\* (please specify intolerance or contraindication)

**AND**

**1.5** Prescribed by or in consultation with a gastroenterologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Zeposia therapy as confirmed by claims history or submission of medical records

**AND**

**2.2** Diagnosis of moderately to severely active ulcerative colitis

**AND**

**2.3** Patient is not receiving Zeposia in combination with a targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]

**AND**

**2.4** Prescribed by or in consultation with a gastroenterologist

Notes	*PDL links are in Table 1 of Background.
-------	--

<b>Product Name:Zeposia</b>	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zeposia therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Zeposia in combination with a targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]</p>	

## 2 . Background

<b>Benefit/Coverage/Program Information</b>
<p><b>Table 1. PDL links</b></p> <p>CO: <a href="https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/colorado-health-plans/co-comm-plan-home/co-cp-pharmacy.html</a></p>

<p>HI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/hawaii-health-plans/hi-comm-plan-home/hi-cp-pharmacy.html</a></p> <p>MD: <a href="https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/maryland-health-plans/md-comm-plan-home/md-cp-pharmacy.html</a></p> <p>NJ: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-jersey-health-plans/nj-comm-plan-home/nj-cp-pharmacy.html</a></p> <p>NM: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-mexico-health-plans/nm-comm-plan-home/nm-cp-pharmacy.html</a></p> <p>NY: <a href="https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/new-york-health-plans/ny-comm-plan-home/ny-cp-pharmacy.html</a></p> <p>PA: <a href="https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/pennsylvania-health-plans/pa-comm-plan-home/pa-cp-pharmacy.html?rfid=UHCCP</a></p> <p>RI: <a href="https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html">https://www.uhcprovider.com/en/health-plans-by-state/rhode-island-health-plans/ri-comm-plan-home/ri-cp-pharmacy.html</a></p>
--

### 3 . Revision History

Date	Notes
3/5/2025	Updated formularies. Replaced Stelara with ustekinumab throughout. Updated safety check language

Zilbrysq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-208209
<b>Guideline Name</b>	Zilbrysq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>• Medicaid - Community &amp; State Arizona</li> <li>• Medicaid - Community &amp; State Colorado</li> <li>• Medicaid - Community &amp; State Hawaii</li> <li>• Medicaid - Community &amp; State Indiana</li> <li>• Medicaid - Community &amp; State Maryland</li> <li>• Medicaid - Community &amp; State Nebraska</li> <li>• Medicaid - Community &amp; State New Jersey</li> <li>• Medicaid - Community &amp; State New Mexico</li> <li>• Medicaid - Community &amp; State New York</li> <li>• Medicaid - Community &amp; State New York EPP</li> <li>• Medicaid - Community &amp; State Pennsylvania</li> <li>• Medicaid - Community &amp; State Pennsylvania CHIP</li> <li>• Medicaid - Community &amp; State Rhode Island</li> <li>• Medicaid - Community &amp; State Virginia</li> </ul>

### Guideline Note:

Effective Date:	4/1/2025
-----------------	----------

### 1 . Criteria

Product Name:Zilbrysq	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming ALL of the following:</p> <p><b>1.1</b> Diagnosis of generalized myasthenia gravis (gMG)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Positive serologic test for anti-AChR antibodies</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.4</b> Patient has a Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score greater than or equal to 6 at initiation of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.) as confirmed by claims history or submission of medical records</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Patient has a history of failure of at least one immunosuppressive therapy (as confirmed by claims history or submission of medical records) and has required four or more courses of</p>	

plasmapheresis/ plasma exchanges and/or intravenous immune globulin over the course of at least 12 months without symptom control

**OR**

**2.3** Contraindication or intolerance to at least two immunosuppressive agents (please specify contraindication or intolerance)

**AND**

**3** - Patient is not receiving Zilbrysq in combination with another complement inhibitor [e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]

**AND**

**4** - Prescribed by, or in consultation with, a neurologist

Product Name:Zilbrysq	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes, laboratory tests) to demonstrate a positive clinical response from baseline as demonstrated by at least ALL of the following:</p> <p><b>1.1</b> Improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline</p> <p><b>AND</b></p> <p><b>1.2</b> Reduction in signs and symptoms of myasthenia gravis</p>	

**AND**

**1.3** Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Zilbrysq\*

**AND**

**2** - Patient is not receiving Zilbrysq in combination with another complement inhibitor [e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]

**AND**

**3** - Prescribed by, or in consultation with, a neurologist

Notes	*Add on, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Zilbrysq therapy will be considered as treatment failure
-------	--

## 2 . Revision History

Date	Notes
3/5/2025	Combined formularies. Updated listing of examples of complement inhibitors and neonatal Fc receptor blockers.

Zokinvy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146719
<b>Guideline Name</b>	Zokinvy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zokinvy	
Diagnosis	Hutchinson-Gilford Progeria Syndrome
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Hutchinson-Gilford Progeria Syndrome</p>	

Product Name:Zokinvy
----------------------

Diagnosis	Progeroid Laminopathies
Approval Length	12 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of processing deficient Progeroid Laminopathies</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of ONE of the following:</p> <ul style="list-style-type: none"><li>• Heterozygous LMNA (gene) mutation with progerin-like protein accumulation</li><li>• Homozygous or compound heterozygous ZMPSTE24 (gene) mutations</li></ul>	

Zolanza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146720
<b>Guideline Name</b>	Zolanza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State New Mexico</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zolanza	
Diagnosis	Cutaneous T-Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cutaneous T-cell lymphoma (CTCL)</p>	

**AND**

**2** - Patient has progressive, persistent, or recurrent disease on or following two systemic therapies [e.g., Adcetris (brentuximab vedotin), bexarotene, interferon alfa-db, interferon gamma-1b, methotrexate, Poteligeo (mogamulizumab), romidepsin]

Product Name:Zolinza	
Diagnosis	Cutaneous T-Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Zolinza therapy</p>	

Product Name:Zolinza	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Zolinza	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b> 1 - Documentation of positive clinical response to Zolanza therapy	

Zoryve



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-164689
<b>Guideline Name</b>	Zoryve
<b>Formulary</b>	Medicaid - Community & State Colorado Medicaid - Community & State Hawaii Medicaid - Community & State Maryland Medicaid - Community & State New Jersey Medicaid - Community & State New Mexico Medicaid - Community & State New York Medicaid - Community & State New York EPP Medicaid - Community & State Pennsylvania CHIP Medicaid - Community & State Rhode Island

### Guideline Note:

Effective Date:	3/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Zoryve 0.3% cream	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Diagnosis of plaque psoriasis

**AND**

2 - ONE of the following:

**2.1** Submission of medical records or claims history confirming failure to a minimum duration of a 4-week trial to TWO of the following topical therapies:

Corticosteroids (e.g., betamethasone, clobetasol, desonide)

Vitamin D analogs (e.g., calcitriol, calcipotriene)

Tazarotene

Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

Anthralin

Coal tar

**OR**

**2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

Corticosteroids (e.g., betamethasone, clobetasol, desonide)

Vitamin D analogs (e.g., calcitriol, calcipotriene)

Tazarotene

Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

Anthralin

Coal tar

**AND**

**3** - Patient is not receiving Zoryve 0.3% cream in combination with a Targeted Immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]

**AND**

**4** - Prescribed by, or in consultation with, a dermatologist

Product Name:Zoryve 0.3% cream	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p><b>AND</b></p> <p><b>2</b> - Patient is not receiving Zoryve 0.3% cream in combination with a Targeted Immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orenzia (abatacept), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]</p>	

Product Name:Zoryve foam	
Diagnosis	Seborrheic dermatitis

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of seborrheic dermatitis

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records or claims history confirming failure to a minimum duration of a 4-week trial to TWO of the following topical therapies:

Topical corticosteroids (e.g., betamethasone, hydrocortisone)

Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox, itraconazole)

Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

Topical corticosteroids (e.g., betamethasone, hydrocortisone)

Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox, itraconazole)

Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

**AND**

**3** - Patient is not receiving Zoryve foam in combination with either of the following:

Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry (tralokinumab-ldrm)]

Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

Product Name: Zoryve foam	
Diagnosis	Seborrheic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Zoryve foam in combination with either of the following:</p> <p style="padding-left: 40px;">Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry (tralokinumab-ldrm)]</p> <p style="padding-left: 40px;">Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]</p>	

Product Name: Zoryve 0.15% cream	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of mild to moderate atopic dermatitis</p>	

**AND**

**2** - ONE of the following:

**2.1** For mild atopic dermatitis:

**2.1.1** Submission of medical records or claims history confirming failure to TWO of the following topical therapeutic classes:

A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)

One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

Eucrisa (crisaborole)

**OR**

**2.1.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

A topical corticosteroid [e.g., DesOwen (desonide), hydrocortisone] (any potency)

One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

Eucrisa (crisaborole)

**OR**

**2.2** For moderate atopic dermatitis:

**2.2.1** Submission of medical records or claims history confirming failure to TWO of the following topical therapeutic classes:

A topical corticosteroid of at least a medium- to high-potency [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]

One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

Eucrisa (crisaborole)

**OR**

**2.2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

A topical corticosteroid of at least a medium- to high-potency [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]

One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]

Eucrisa (crisaborole)

**AND**

**3** - Patient is not receiving Zoryve 0.15% cream in combination with a targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab), Rinvoq (upadacitinib)]

Product Name:Zoryve 0.15% cream	
Diagnosis	Atopic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Zoryve 0.15% cream in combination with a targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab), Rinvoq (upadacitinib)]</p>	

## 2 . Revision History

Date	Notes
2/5/2025	Updated cream product names to specify strengths. Updated all authorizations to 12 months. Updated targeted immunomodulator language. Removed prescriber requirements for Zoryve foam initial auth. Added criteria for Zoryve 0.15% cream for atopic dermatitis.

Zoryve



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146446
<b>Guideline Name</b>	Zoryve
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zoryve cream	
Diagnosis	Plaque Psoriasis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of plaque psoriasis</p>	

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records or claims history confirming failure to a minimum duration of a 4-week trial to TWO of the following topical therapies:

Corticosteroids (e.g., betamethasone, clobetasol, desonide)

Vitamin D analogs (e.g., calcitriol, calcipotriene)

Tazarotene

Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

Anthralin

Coal tar

**OR**

**2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

Corticosteroids (e.g., betamethasone, clobetasol, desonide)

Vitamin D analogs (e.g., calcitriol, calcipotriene)

Tazarotene

Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

Anthralin

Coal tar

**AND**

**3** - Patient is not receiving Zoryve cream in combination with ONE of the following:

Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (Secukinumab), Stelara (Ustekinumab), Orencia (abatacept)]

Janus kinase inhibitor [e.g., Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by, or in consultation with, a dermatologist

Product Name: Zoryve cream	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Zoryve cream in combination with ONE of the following:</p> <p>Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (Secukinumab), Stelara (Ustekinumab), Orencia (abatacept)]</p> <p>Janus kinase inhibitor [e.g., Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]</p> <p>Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]</p>	

Product Name: Zoryve foam

Diagnosis	Seborrheic dermatitis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Diagnosis of seborrheic dermatitis

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records or claims history confirming failure to a minimum duration of a 4-week trial to TWO of the following topical therapies:

Topical corticosteroids (e.g., betamethasone, hydrocortisone)

Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox, itraconazole)

Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

**OR**

**2.2** History of intolerance or contraindication to ALL of the following topical therapies (please specify intolerance or contraindication):

Topical corticosteroids (e.g., betamethasone, hydrocortisone)

Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox, itraconazole)

Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

**AND**

**3** - Patient is not receiving Zoryve foam in combination with ONE of the following:

Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry (tralokinumab-ldrm)]

Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by, or in consultation with, one of the following:

Dermatologist

Allergist

Immunologist

Product Name: Zoryve foam

Diagnosis	Seborrheic Dermatitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

**AND**

**2** - Patient is not receiving Zoryve foam in combination with ONE of the following:

Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry (tralokinumab-ldrm)]

Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]

Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

Zurzuvae



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-146447
<b>Guideline Name</b>	Zurzuvae
<b>Formulary</b>	Medicaid - Community & State New Mexico

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zurzuvae	
Approval Length	1 month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of postpartum depression (PPD)</p> <p style="text-align: center;"><b>AND</b></p>	

**2** - Onset of current depressive episode was during the third trimester or within 4 weeks postpartum

Zydelig



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146721
<b>Guideline Name</b>	Zydelig
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zydelig	
Diagnosis	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)</p>	

**AND**

**2** - ONE of the following:

Disease has relapsed

Disease is refractory

Product Name:Zydelig

Diagnosis	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Patient does not show evidence of progressive disease while on Zydelig therapy

Product Name:Zydelig

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name:Zydelig

UnitedHealthcare Community Plan of New Mexico - Clinical Pharmacy Guidelines

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<b>Approval Criteria</b>	
1 - Documentation of positive clinical response to Zydelig therapy	

Zykadia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146722
<b>Guideline Name</b>	Zykadia
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Zykadia	
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-small cell lung cancer (NSCLC)</p>	

**AND**

**2** - ONE of the following:

Disease is metastatic

Disease is recurrent

Disease is advanced

**AND**

**3** - ONE of the following:

Tumor is ALK (anaplastic lymphoma kinase)-positive

Tumor is ROS-1 (gene) positive

Product Name:Zykadia	
Diagnosis	Soft Tissue Sarcoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of inflammatory myofibroblastic tumor (IMT) with anaplastic lymphoma kinase (ALK) translocation</p>	

Product Name:Zykadia	
Diagnosis	Central Nervous System (CNS) Cancers
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of metastatic brain cancer from non-small cell lung cancer (NSCLC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Tumor is anaplastic lymphoma kinase (ALK)-positive</p>	

Product Name:Zykadia	
Diagnosis	Histiocytic Neoplasms
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Erdheim-Chester Disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Disease is positive for anaplastic lymphoma kinase (ALK) rearrangement</p>	

Product Name:Zykadia	
Diagnosis	Inflammatory Myofibroblastic Tumor (IMT)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p> </p>	

**Approval Criteria**

1 - Diagnosis of advanced, recurrent, metastatic, or inoperable inflammatory myofibroblastic tumor (IMT)

**AND**

2 - Disease is positive for anaplastic lymphoma kinase (ALK) translocation

Product Name:Zykadia

Diagnosis	Anaplastic Large Cell Lymphoma
-----------	--------------------------------

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

**Approval Criteria**

1 - Diagnosis of anaplastic large cell lymphoma

**AND**

2 - Tumor is anaplastic lymphoma kinase (ALK)-positive

**AND**

3 - Disease is relapsed or refractory

**AND**

4 - Used as palliative intent therapy or second-line and subsequent therapy

Product Name:Zykadia

Diagnosis	Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, Central Nervous System (CNS) Cancers, Histiocytic Neoplasms, Inflammatory Myofibroblastic Tumor (IMT), Anaplastic Large Cell Lymphoma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Zykadia therapy</p>	

Product Name:Zykadia	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

Product Name:Zykadia	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zykadia therapy</p>	

Zymfentra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-163906
<b>Guideline Name</b>	Zymfentra
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	2/1/2025
-----------------	----------

## 1 . Criteria

Product Name:Zymfentra	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records documenting clinical rationale for need of subcutaneous infliximab (Zymfentra) in place of infliximab administered intravenously (covered under the medical benefit)</p>	

**AND**

**2** - Diagnosis of moderately to severely active ulcerative colitis (UC)

**AND**

**3** - One of the following:

**3.1** Patient has been established on therapy with an infliximab product under an active UnitedHealthcare prior authorization for the treatment of moderately to severely active ulcerative colitis

**OR**

**3.2** Patient is currently on Zymfentra therapy for moderately to severely active ulcerative colitis as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is not receiving Zymfentra in combination with a targeted immunomodulator [e.g., adalimumab, Entyvio (vedolizumab), Olumiant (baricitinib), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]

**AND**

**5** - Prescribed by or in consultation with a gastroenterologist

Product Name:Zymfentra	
Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

1 - Documentation of positive clinical response to Zymfentra therapy

**AND**

2 - Patient is not receiving Zymfentra in combination with a targeted immunomodulator [e.g., adalimumab, Entyvio (vedolizumab), Olumiant (baricitinib), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]

Product Name:Zymfentra	
Diagnosis	Crohn's disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records documenting clinical rationale for need of subcutaneous infliximab (Zymfentra) in place of infliximab administered intravenously (covered under the medical benefit)</p> <p><b>AND</b></p> <p>2 - Diagnosis of moderately to severely active Crohn's disease (CD)</p> <p><b>AND</b></p> <p>3 - One of the following:</p> <p><b>3.1</b> Patient has been established on therapy with an infliximab product under an active UnitedHealthcare prior authorization for the treatment of moderately to severely active crohn's disease</p>	

**OR**

**3.2** Patient is currently on Zymfentra therapy for moderately to severely active crohn's disease as confirmed by claims history or submission of medical records

**AND**

**4** - Patient is not receiving Zymfentra in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orenzia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]

**AND**

**5** - Prescribed by or in consultation with a gastroenterologist

Product Name:Zymfentra	
Diagnosis	Crohn's disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to Zymfentra therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is not receiving Zymfentra in combination with a targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orenzia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]</p>	

## 2 . Revision History

Date	Notes
1/16/2025	Added requirement for justification of subq infliximab vs IV

Zytiga



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150964
<b>Guideline Name</b>	Zytiga
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	8/5/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2 - ONE of the following:**

**2.1** Disease is metastatic

**OR**

**2.2** Disease is regional node positive (Any T, N1, M0)

**OR**

**2.3** Patient is in a very-high-risk group receiving external beam radiation therapy (EBRT)

**OR**

**2.4** Positive pelvic persistence/recurrence after prostatectomy

**AND**

**3 - Used in combination with prednisone or dexamethasone**

**AND**

**4 - ONE of the following:**

**4.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**4.2** Patient has had bilateral orchiectomy

**AND**

**5** - If the request is for the 500 mg (milligram) tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on the requested therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg</p>	

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of salivary gland tumor</p>	

<b>AND</b>
<b>2</b> - Used in combination with prednisone
<b>AND</b>
<b>3</b> - Androgen receptor positive recurrent disease
<b>AND</b>
<b>4</b> - If the request is for the 500mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250mg

Product Name: Brand Zytiga, generic abiraterone	
Diagnosis	Salivary Gland Tumor
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on Zytiga therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for the 500mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250mg</p>	

Product Name: Brand Zytiga, generic abiraterone	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg</p>	

Product Name: Brand Zytiga, generic abiraterone	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Zytiga therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg</p>	

Zytiga



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146723
<b>Guideline Name</b>	Zytiga
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of prostate cancer</p>	

**AND**

**2 - ONE of the following:**

**2.1** Disease is metastatic

**OR**

**2.2** Disease is regional node positive (Any T, N1, M0)

**OR**

**2.3** Patient is in a very-high-risk group receiving external beam radiation therapy (EBRT)

**OR**

**2.4** Positive pelvic persistence/recurrence after prostatectomy

**AND**

**3 - Used in combination with prednisone or dexamethasone**

**AND**

**4 - ONE of the following:**

**4.1** Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]

**OR**

**4.2** Patient has had bilateral orchiectomy

**AND**

**5** - If the request is for the 500 mg (milligram) tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	Prostate Cancer
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient does not show evidence of progressive disease while on the requested therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg</p>	

Product Name:Brand Zytiga, generic abiraterone	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>	

**AND**

**2** - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg

Product Name: Brand Zytiga, generic abiraterone	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

**Approval Criteria**

**1** - Documentation of positive clinical response to Zytiga therapy

**AND**

**2** - If the request is for the 500 mg tablet, the prescriber provides a reason or special circumstance the patient cannot take abiraterone 250 mg

Zyvox



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-146448
<b>Guideline Name</b>	Zyvox
<b>Formulary</b>	Medicaid - Community & State New Mexico

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Zyvox, generic linezolid	
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p>	

**OR**

**3** - ONE of the following diagnoses:

Nosocomial pneumonia

Community-acquired pneumonia

Skin and skin structure infections (complicated and uncomplicated)

**OR**

**4** - Invasive infection caused by or likely to be caused by vancomycin-resistant *Enterococcus faecium* (VRE)

**OR**

**5** - The drug has been recognized for treatment of the indication by the Infectious Diseases Society of America (IDSA)

Notes	Approval Duration: For vancomycin-resistant <i>Enterococcus faecium</i> , a uthorization will be issued for 28 days. For osteomyelitis, authorization will be issued for the requested duration, not to exceed 6 weeks. All o ther approvals are for 14 days.
-------	---